

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
17 May 2001 (17.05.2001)

PCT

(10) International Publication Number  
**WO 01/34629 A1**

(51) International Patent Classification<sup>7</sup>: **C07H 21/04**,  
21/02, C07K 5/00, 14/00, C12Q 1/68, C12N 1/21, 15/63,  
15/85, 15/86

Redwing Road, Bethesda, MD, 20817 (US). **BAKER, Kevin, P.** [GB/US]; 14006 Indian Run Drive, Darnestown, MD 20878 (US).

(21) International Application Number: PCT/US00/30654

(74) Agents: **HOOVER, Kenley, K.** et al.; c/o Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850 (US).

(22) International Filing Date:

8 November 2000 (08.11.2000)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/164,835 12 November 1999 (12.11.1999) US

60/221,142 27 July 2000 (27.07.2000) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **HUMAN GENOME SCIENCES, INC.** [US/US]; 9410 Key West Avenue, Rockville, MD 20850 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **RUBEN, Steven, M.** [US/US]; 18528 Heritage Hills Drive, Olney, MD 20832 (US). **KOMATSOUKIS, George, A.** [US/US]; 9518 Garwood Steet, Silver Spring, MD 20901 (US). **WEI, Ping** [CN/US]; 19100 Baltimore Road, Brookeville, MD 20833 (US). **FISCELLA, Michele** [US/US]; 6308

Published:

— With international search report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: 21 HUMAN SECRETED PROTEINS

(57) Abstract: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

WO 01/34629 A1

## 21 Human Secreted Proteins

### *Field of the Invention*

This invention relates to newly identified polynucleotides, polypeptides encoded by these polynucleotides, antibodies that bind these polypeptides, uses of  
5 such polynucleotides, polypeptides, and antibodies, and their production.

### *Background of the Invention*

Unlike bacterium, which exist as a single compartment surrounded by a membrane, human cells and other eucaryotes are subdivided by membranes into many functionally distinct compartments. Each membrane-bounded compartment, or  
10 organelle, contains different proteins essential for the function of the organelle. The cell uses "sorting signals," which are amino acid motifs located within the protein, to target proteins to particular cellular organelles.

One type of sorting signal, called a signal sequence, a signal peptide, or a leader sequence, directs a class of proteins to an organelle called the endoplasmic  
15 reticulum (ER). The ER separates the membrane-bounded proteins from all other types of proteins. Once localized to the ER, both groups of proteins can be further directed to another organelle called the Golgi apparatus. Here, the Golgi distributes the proteins to vesicles, including secretory vesicles, the cell membrane, lysosomes, and the other organelles.

20 Proteins targeted to the ER by a signal sequence can be released into the extracellular space as a secreted protein. For example, vesicles containing secreted proteins can fuse with the cell membrane and release their contents into the extracellular space - a process called exocytosis. Exocytosis can occur constitutively or after receipt of a triggering signal. In the latter case, the proteins are stored in  
25 secretory vesicles (or secretory granules) until exocytosis is triggered. Similarly, proteins residing on the cell membrane can also be secreted into the extracellular space by proteolytic cleavage of a "linker" holding the protein to the membrane.

Despite the great progress made in recent years, only a small number of genes encoding human secreted proteins have been identified. These secreted proteins  
30 include the commercially valuable human insulin, interferon, Factor VIII, human growth hormone, tissue plasminogen activator, and erythropoietin. Thus, in light of

the pervasive role of secreted proteins in human physiology, a need exists for identifying and characterizing novel human secreted proteins and the genes that encode them. This knowledge will allow one to detect, to treat, and to prevent medical diseases, disorders, and/or conditions by using secreted proteins or the genes that encode them.

### ***Summary of the Invention***

The present invention relates to novel polynucleotides and the encoded polypeptides. Moreover, the present invention relates to vectors, host cells, antibodies, and recombinant and synthetic methods for producing the polypeptides and polynucleotides. Also provided are diagnostic methods for detecting diseases, disorders, and/or conditions related to the polypeptides and polynucleotides, and therapeutic methods for treating such diseases, disorders, and/or conditions. The invention further relates to screening methods for identifying binding partners of the polypeptides.

### ***Detailed Description***

#### **Definitions**

The following definitions are provided to facilitate understanding of certain terms used throughout this specification.

In the present invention, "isolated" refers to material removed from its original environment (e.g., the natural environment if it is naturally occurring), and thus is altered "by the hand of man" from its natural state. For example, an isolated polynucleotide could be part of a vector or a composition of matter, or could be contained within a cell, and still be "isolated" because that vector, composition of matter, or particular cell is not the original environment of the polynucleotide. The term "isolated" does not refer to genomic or cDNA libraries, whole cell total or mRNA preparations, genomic DNA preparations (including those separated by electrophoresis and transferred onto blots), sheared whole cell genomic DNA preparations or other compositions where the art demonstrates no distinguishing features of the polynucleotide/sequences of the present invention.

In the present invention, a "secreted" protein refers to those proteins capable of being directed to the ER, secretory vesicles, or the extracellular space as a result of a signal sequence, as well as those proteins released into the extracellular space without necessarily containing a signal sequence. If the secreted protein is released  
5 into the extracellular space, the secreted protein can undergo extracellular processing to produce a "mature" protein. Release into the extracellular space can occur by many mechanisms, including exocytosis and proteolytic cleavage.

In specific embodiments, the polynucleotides of the invention are at least 15,  
10 at least 30, at least 50, at least 100, at least 125, at least 500, or at least 1000 continuous nucleotides but are less than or equal to 300 kb, 200 kb, 100 kb, 50 kb, 15 kb, 10 kb, 7.5 kb, 5 kb, 2.5 kb, 2.0 kb, or 1 kb, in length. In a further embodiment, polynucleotides of the invention comprise a portion of the coding sequences, as disclosed herein, but do not comprise all or a portion of any intron. In another  
15 embodiment, the polynucleotides comprising coding sequences do not contain coding sequences of a genomic flanking gene (i.e., 5' or 3' to the gene of interest in the genome). In other embodiments, the polynucleotides of the invention do not contain the coding sequence of more than 1000, 500, 250, 100, 50, 25, 20, 15, 10, 5, 4, 3, 2, or 1 genomic flanking gene(s).

20 As used herein, a "polynucleotide" refers to a molecule having a nucleic acid sequence contained in SEQ ID NO:X or the cDNA contained within the clone deposited with the ATCC. For example, the polynucleotide can contain the nucleotide sequence of the full length cDNA sequence, including the 5' and 3' untranslated sequences, the coding region, with or without the signal sequence, the  
25 secreted protein coding region, as well as fragments, epitopes, domains, and variants of the nucleic acid sequence. Moreover, as used herein, a "polypeptide" refers to a molecule having the translated amino acid sequence generated from the polynucleotide as broadly defined.

In the present invention, the full length sequence identified as SEQ ID NO:X  
30 was often generated by overlapping sequences contained in multiple clones (contig analysis). A representative clone containing all or most of the sequence for SEQ ID NO:X was deposited with the American Type Culture Collection ("ATCC"). As



shown in Table 1, each clone is identified by a cDNA Clone ID (Identifier) and the ATCC Deposit Number. The ATCC is located at 10801 University Boulevard, Manassas, Virginia 20110-2209, USA. The ATCC deposit was made pursuant to the terms of the Budapest Treaty on the international recognition of the deposit of  
5 microorganisms for purposes of patent procedure.

A "polynucleotide" of the present invention also includes those polynucleotides capable of hybridizing, under stringent hybridization conditions, to sequences contained in SEQ ID NO:X, the complement thereof, or the cDNA within the clone deposited with the ATCC. "Stringent hybridization conditions" refers to an  
10 overnight incubation at 42 degree C in a solution comprising 50% formamide, 5x SSC (750 mM NaCl, 75 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 µg/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1x SSC at about 65 degree C.

Also contemplated are nucleic acid molecules that hybridize to the  
15 polynucleotides of the present invention at lower stringency hybridization conditions. Changes in the stringency of hybridization and signal detection are primarily accomplished through the manipulation of formamide concentration (lower percentages of formamide result in lowered stringency); salt conditions, or temperature. For example, lower stringency conditions include an overnight  
20 incubation at 37 degree C in a solution comprising 6X SSPE (20X SSPE = 3M NaCl; 0.2M NaH<sub>2</sub>PO<sub>4</sub>; 0.02M EDTA, pH 7.4), 0.5% SDS, 30% formamide, 100 ug/ml salmon sperm blocking DNA; followed by washes at 50 degree C with 1XSSPE, 0.1% SDS. In addition, to achieve even lower stringency, washes performed following stringent hybridization can be done at higher salt concentrations (e.g. 5X  
25 SSC).

Note that variations in the above conditions may be accomplished through the inclusion and/or substitution of alternate blocking reagents used to suppress background in hybridization experiments. Typical blocking reagents include Denhardt's reagent, BLOTTO, heparin, denatured salmon sperm DNA, and  
30 commercially available proprietary formulations. The inclusion of specific blocking reagents may require modification of the hybridization conditions described above, due to problems with compatibility.

Of course, a polynucleotide which hybridizes only to polyA<sup>+</sup> sequences (such as any 3' terminal polyA<sup>+</sup> tract of a cDNA shown in the sequence listing), or to a complementary stretch of T (or U) residues, would not be included in the definition of "polynucleotide," since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-stranded cDNA clone generated using oligo dT as a primer).

The polynucleotide of the present invention can be composed of any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. For example, polynucleotides can be composed of single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, the polynucleotide can be composed of triple-stranded regions comprising RNA or DNA or both RNA and DNA. A polynucleotide may also contain one or more modified bases or DNA or RNA backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications can be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically, or metabolically modified forms.

The polypeptide of the present invention can be composed of amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres, and may contain amino acids other than the 20 gene-encoded amino acids. The polypeptides may be modified by either natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched, for example, as a result of

ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched, and branched cyclic polypeptides may result from posttranslation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. (See, for instance, PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York (1993); POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York, pgs. 1-12 (1983); Seifter et al., Meth Enzymol 182:626-646 (1990); Rattan et al., Ann NY Acad Sci 663:48-62 (1992).)

"SEQ ID NO:X" refers to a polynucleotide sequence while "SEQ ID NO:Y" refers to a polypeptide sequence, both sequences identified by an integer specified in Table 1.

"A polypeptide having biological activity" refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of a polypeptide of the present invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. In the case where dose dependency does exist, it need not be identical to that of the polypeptide, but rather substantially similar to the dose-dependence in a given activity as compared to the polypeptide of the present invention (i.e., the candidate polypeptide will exhibit greater activity or not more than about 25-fold less and, preferably, not more than about tenfold less activity, and most preferably, not more than about three-fold less activity relative to the polypeptide of the present invention.)

Many proteins (and translated DNA sequences) contain regions where the amino acid composition is highly biased toward a small subset of the available

residues. For example, membrane spanning domains and signal peptides (which are also membrane spanning) typically contain long stretches where Leucine (L), Valine (V), Alanine (A), and Isoleucine (I) predominate. Poly-Adenosine tracts (polyA) at the end of cDNAs appear in forward translations as poly-Lysine (poly-K) and poly-  
5 Phenylalanine (poly-F) when the reverse complement is translated. These regions are often referred to as “low complexity” regions.

Such regions can cause database similarity search programs such as BLAST to find high-scoring sequence matches that do not imply true homology. The problem is exacerbated by the fact that most weight matrices (used to score the alignments  
10 generated by BLAST) give a match between any of a group of hydrophobic amino acids (L,V and I) that are commonly found in certain low complexity regions almost as high a score as for exact matches.

In order to compensate for this, BLASTX.2 (version 2.0a5MP-WashU) employs two filters (“seg” and “xnu”) which “mask” the low complexity regions in a  
15 particular sequence. These filters parse the sequence for such regions, and create a new sequence in which the amino acids in the low complexity region have been replaced with the character “X”. This is then used as the input sequence (sometimes referred to herein as “Query” and/or “Q”) to the BLASTX program. While this regime helps to ensure that high-scoring matches represent true homology, there is a  
20 negative consequence in that the BLASTX program uses the query sequence that has been masked by the filters to draw alignments.

Thus, a stretch of “X”s in an alignment shown in the following application does not necessarily indicate that either the underlying DNA sequence or the translated protein sequence is unknown or uncertain. Nor is the presence of such  
25 stretches meant to indicate that the sequence is identical or not identical to the sequence disclosed in the alignment of the present invention. Such stretches may simply indicate that the BLASTX program masked amino acids in that region due to the detection of a low complexity region, as defined above. In all cases, the reference sequence(s) (sometimes referred to herein as “Subject”, “Sbjct”, and/or “S”) indicated  
30 in the specification, sequence table (Table 1), and/or the deposited clone is (are) the definitive embodiment(s) of the present invention, and should not be construed as

limiting the present invention to the partial sequence shown in an alignment, unless specifically noted otherwise herein.

### Polynucleotides and Polypeptides of the Invention

5

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 1**

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no.

10 gb|AAD33892.1|AF142780\_1 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "(AF142780) butyrophilin-like protein [Mus musculus]" A partial alignment demonstrating the observed homology is shown immediately below.

```

15  >gb|AAD33892.1|AF142780_1 (AF142780) butyrophilin-like protein [Mus musculus]
      >gb|AAD33892.1|AF142780_1 (AF142780) butyrophilin-like protein [Mus
      musculus] >sp|AAD33892|AAD33892 Butyrophilin-like protein.
      Length = 247

20  Plus Strand HSPs:

      Score = 835 (293.9 bits), Expect = 1.5e-82, P = 1.5e-82
      Identities = 159/233 (68%), Positives = 183/233 (78%), Frame = +1

25  Q:   313 HQIAALFTVTVPKELYIIHGSNVTLECNFDTGSHVNLGAITASLQKVENDTSPHRERAT 492
      H +AALFTVT PKE+Y ++ GS+V+LEC+FD L I ASLQKVENDTS ERAT
      S:   15 HPVAALFTVTAPKEVYTVDVGSSVSLECDFDRRECTELEGRASLQKVENDTSLQSERAT 74

30  Q:   493 LLEEQLPLGKASFHIPQVQVRDEGQYQCIIYGVAWDYKYLTLKVKASYRKINTHILKVP 672
      LLEEQLPLGKA FHIP VQVRD GQY+C++I G AWDYKYLTKVKASY +I+T IL+VP
      S:   75 LLEEQLPLGKALFHIPSVQVRDSGQYRCLVICGAAWDYKYLTKVKASYMRIDTRILEVP 134

      Q:   673 ETDEVELTCQATGYPLAEVSWPNVSVANTSHSRTPEGLYQVTSVLRLKPPPGRNFSCVF 852
      T EV+LTCQA GYPLAEVSW NVSVANTSH RTPEGLYQVTSVLRLKP P RNFSC+F
35  S:   135 GTGEVQLTCQARGYPLAEVSWQNVSVANTSHIRTPEGLYQVTSVLRLKPQPSRNFSCMF 194

      Q:   853 WNTHVRELTLASIDLQSQMEPRTHPTWLLHIFIPSCXXXXXXXXXTVIALRKQL 1011
      WN H++ELT A ID S+MEP+ TW LH+FIP+C VI RK++
40  S:   195 WNAHMKELTSIIDPLSRMEPKVPRTWPLHVFIPACTIALIFLAIVIIQRKRI 247

```

The segment of gb|AAD33892.1|AF142780\_1 that is shown as "S" above is set out in the sequence listing as SEQ ID NO: Based on the structural similarity these homologous polypeptides are expected to share at least some biological activities.

Such activities are known in the art, some of which are described elsewhere herein.

45 Assays for determining such activities are also known in the art, some of which have

been described elsewhere herein. Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO: which corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

5           This gene is expressed primarily in the following tissues/cDNA libraries: Soares\_pregnant\_uterus\_NbHPU and to a lesser extent in Primary Dendritic Cells, lib 1; Thymus; Human Adult Spleen; Aorta endothelial cells + TNF- $\alpha$ ; Human T-cell lymphoma, re-excision; Primary Dendritic cells, frac 2 and Soares\_testis\_NHT.

          Polynucleotides and polypeptides of the invention are useful as reagents for  
10   differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: immune system diseases and/or disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of  
15   the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene  
20   expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

          Based upon the tissue distribution and homology to butyrophilin, polynucleotides, translation products and antibodies corresponding to this gene may be useful in the diagnosis and/or treatment of a variety of disorders. Elevated  
25   expression in uterus suggests utility for the study diagnosis and/or treatment of reproductive disorders. The homology to butyrophilin suggests that polynucleotides, translation products and antibodies corresponding to this gene may be useful in dairy products, vaccines, and assays for susceptibility to multiple sclerosis. The tissue distribution indicates also an enrichment in hematopoietic/immune tissues.  
30   Furthermore, this gene product shares homology to B7-H1, a novel member of the B7 family of T-cell costimulatory molecules. Thus, this gene product may be useful in the treatment and/or diagnosis of immune disorders.

## FEATURES OF PROTEIN ENCODED BY GENE NO: 2

5 Translation products corresponding to this gene share sequence homology with the murine Gremlin protein (See, e.g., Genbank Accession AAC40111), which is thought to play a role in the inhibition of Bone Morphogenic Proteins.

This gene is expressed primarily in the following tissues/cDNA libraries: Osteoblasts and to a lesser extent in Soares\_senescent\_fibroblasts\_NbHSF; Jia bone marrow stroma; Human Osteoblasts II; Human Thymus Stromal Cells; Soares melanocyte 2NbHM; HSA 172 Cells; Human Osteoclastoma; Stromal cell TF274; Stratagene fibroblast (#937212); Human endometrial stromal cells-treated with progesterone; Human endometrial stromal cells-treated with estradiol; Human adult (K.Okubo); Human endometrial stromal cells; NCI\_CGAP\_Gas4; Human Gall  
15 Bladder; Colon Tumor; Human 8 Week Whole Embryo; Colon Tumor II; Human Bone Marrow Stromal Fibroblast; HUMAN SCHWANOMA; Crohn's Disease; Pharynx Carcinoma; Human Normal Cartilage Fraction IV; Human Pre-Differentiated Adipocytes; HSC172 cells; NCI\_CGAP\_Co12; human corpus colosum; NCI\_CGAP\_Co9; Synovial hypoxia-RSF subtracted; Human Stomach, re-excision;  
20 Human Colon, re-excision; NCI\_CGAP\_Alvi; Gessler Wilms tumor; Monocyte activated, re-excision; 12 Week Old Early Stage Human, II; Human Pancreas Tumor, Reexcision; Synovial Fibroblasts (control); Bone Marrow Stromal Cell, untreated; NCI\_CGAP\_Co3; CHME Cell Line, untreated; Colon Carcinoma; NCI\_CGAP\_Co8; Human Placenta; Pancreas normal PCA4 No; Monocyte activated; Pancreas Tumor  
25 PCA4 Tu; Neutrophils IL-1 and LPS induced; H. Frontal cortex, epileptic, re-excision and NCI\_CGAP\_Lu5.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to:  
30 diseases and/or disorders of the musculoskeletal system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of

disorders of the above tissues or cells, particularly of the musculoskeletal system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., musculoskeletal, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The homology of translation products corresponding to this gene to the murine gremlin protein indicates that polynucleotides, translation products and antibodies corresponding to this gene may be useful for the inhibition of members of the TGF-beta family of growth factors. Elevated levels of expression of this gene product in osteoblasts and osteoclastoma tissue suggests that polynucleotides, translation products and antibodies corresponding to this gene may play a role in the survival, proliferation, and/or growth of osteoclasts. Therefore, it may be useful in influencing bone mass in such conditions as osteoporosis.

The secreted protein can also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, and as nutritional supplements. It may also have a very wide range of biological activities. Representative uses are described in the "Chemotaxis" and "Binding Activity" sections below, in Examples 11, 12, 13, 14, 15, 16, 18, 19, and 20, and elsewhere herein. Briefly, the protein may possess the following activities: cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines; immunostimulating /immunosuppressant activities (e.g. for treating human immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation of hematopoiesis (e.g. for treating anemia or as adjunct to chemotherapy); stimulation or growth of bone, cartilage, tendons, ligaments and/or nerves (e.g. for treating wounds, stimulation of follicle stimulating hormone (for control of fertility); chemotactic and chemokinetic activities (e.g. for treating infections, tumors); hemostatic or thrombolytic activity (e.g. for treating hemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g. for treating septic shock, Crohn's disease); as antimicrobials; for treating psoriasis or other hyperproliferative



diseases; for regulation of metabolism, and behavior. Also contemplated is the use of the corresponding nucleic acid in gene therapy procedures.

The tissue distribution in immune tissue (e.g., neutrophils, bone marrow) indicates the protein product of this clone would be useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. Involvement in the regulation of cytokine production, antigen presentation, or other processes suggests a usefulness for treatment of cancer (e.g. by boosting immune responses). Expression in cells of lymphoid origin, indicates the natural gene product would be involved in immune functions. Therefore it would also be useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, and scleroderma.

Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. The tissue distribution (e.g., osteoblasts) suggests that the protein product of this clone is useful for the diagnosis and/or treatment of bone disorders. The tissue distribution in tumors of colon, pancreas, and pharynx origins suggests that the protein product of this clone is useful for the diagnosis and intervention of these tumors, in addition to other tumors where expression has been indicated. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate

ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

5

### **FEATURES OF PROTEIN ENCODED BY GENE NO: 3**

Translation products corresponding to this gene share sequence homology with the murine MPS-1 protein and rat MPG-1 protein (See Genbank Accession numbers AAA73957 and AAD38417, respectively). The MPS-1 protein is a macrophage specific protein having evolutionary conservation to the lytic family of perforin proteins. Based upon the homology, it is thought that translation products corresponding to this gene may function in a lytic capacity, causing cellular death.

This gene is expressed primarily in the following tissues/cDNA libraries:

15 Human Bone Marrow, treated and to a lesser extent in Human rejected kidney; Human T-cell lymphoma, re-excision; Human Adult Small Intestine; Human Osteoblasts II; Ulcerative Colitis; Human Placenta; human tonsils; Hodgkin's Lymphoma II and Primary Dendritic Cells, lib 1.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: diseases and/or disorders of the immune system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

20

25

30

This gene is the human ortholog of mouse and rat Macrophage specific gene 1. The mouse gene was identified by differential cDNA analysis and showed macrophage lineage and differentiation stage-specific expression with high level in mature macrophages and moderate level in certain myelomonocytic cell lines.

5 The tissue distribution in human Bone Marrow and other hematopoietic cell types indicates the gene and its protein product is useful for the diagnosis and treatment of human immune system disorders, osteoblastoma, arthritis and other cancers. Translation products corresponding to this gene may function as a lytic protein involved in cellular death.

10 Alternatively, translation products corresponding to this gene may participate in immune function and immune surveillance. Additionally, translation products corresponding to this gene, as well as antibodies directed against these translation products, may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

15

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 4**

This gene is expressed primarily in the following tissues/cDNA libraries:

20 Soares fetal liver spleen 1NFLS and to a lesser extent in NCI\_CGAP\_GCB1; Human Pituitary, subt IX; Soares\_NFL\_T\_GBC\_S1; Soares\_NhHMPu\_S1; Human Pituitary, subtracted; Soares adult brain N2b4HB55Y; Rejected Kidney, lib 4; H. Frontal cortex,epileptic,re-excision; Soares melanocyte 2NbHM; Human Cerebellum; Activated T-Cells, 12 hrs, subtracted; Human Colon, subtraction; Pancreatic Islet;

25 NCI\_CGAP\_Ut4; Stratagene NT2 neuronal precursor 937230; NCI\_CGAP\_Kid6; Stratagene pancreas (#937208); Stratagene HeLa cell s3 937216; Stratagene endothelial cell 937223; NCI\_CGAP\_Co3; Stratagene colon (#937204); Early Stage Human Brain; Human Fetal Kidney, Reexcision; Human Fetal Heart; human tonsils; NCI\_CGAP\_GC6; NCI\_CGAP\_Kid5; HUMAN B CELL LYMPHOMA; Soares

30 ovary tumor NbHOT; Hodgkin's Lymphoma II; Soares\_testis\_NHT; H.Leukocytes, normalized cot 50A3; PRMIX; Namalwa Cells; HL-60, RA 4h, Subtracted; NCI\_CGAP\_Pr8; NCI\_CGAP\_Pr9; Human Pituitary, re-excision; Human Fetal

Brain; stomach cancer (human); Human Colon; Human retina cDNA Tsp509I-cleaved sublibrary; NCI\_CGAP\_Lip2; Human Fetal Spleen; Smooth muscle, control, re-excision; H. Epididymus, caput & corpus; H. cerebellum, Enzyme subtracted; Human Lung; H. Epididymus, cauda; Human Lung Cancer, re-excision; Healing  
 5 groin wound - zero hr post-incision (control); Human Epididymus; STROMAL - OSTEOCLASTOMA; Synovial IL-1/TNF stimulated; Hepatocellular Tumor; pBMC stimulated w/ poly I/C; Smooth muscle, IL1b induced; Stratagene schizo brain S11; Synovial hypoxia-RSF subtracted; NCI\_CGAP\_Co14; B-cells (unstimulated); LNCAP prostate cell line; Jurkat T-Cell, S phase; H. Lymph node breast Cancer;  
 10 Human Adult Small Intestine; Breast, Normal: (4005522B2); Stratagene lung carcinoma 937218; Human Prostate; B-Cells; Human Brain, Striatum; Monocyte activated, re-excision; Human Fetal Kidney; Human Uterine Cancer; NCI\_CGAP\_Gas4; Human Pancreas Tumor, Reexcision; Ovary, Cancer (9809C332): Poorly differentiated adenocarcinoma; Ovary, Cancer: (4004576 A8); Human  
 15 Chondrosarcoma; Bone Marrow Stromal Cell, untreated; Human Thymus Stromal Cells; Soares breast 2NbHBst; Human Adrenal Gland Tumor; Human Gall Bladder; Smooth muscle, serum induced, re-exc; Smooth muscle, serum treated; breast lymph node CDNA library; Human Placenta; H Macrophage (GM-CSF treated), re-excision; Normal colon; NCI\_CGAP\_GC4; Human Synovial Sarcoma; Pancreas normal PCA4  
 20 No; 12 Week Early Stage Human II, Reexcision; NCI\_CGAP\_Brn23; Monocyte activated; Soares\_placenta\_8to9weeks\_2NbHP8to9W; Human Testes; Bone Marrow Cell Line (RS4,11); NCI\_CGAP\_Lu5; Keratinocyte; Colon Normal III; Soares\_fetal\_heart\_NbHH19W and Primary Dendritic Cells, lib 1.

Polynucleotides and polypeptides of the invention are useful as reagents for  
 25 differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: diseases and/or disorders of the immune system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of  
 30 disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids

(e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

- 5           The observed tissue distribution suggests that this gene product may be useful in the diagnosis and/or treatment of a variety of disorders. Enriched expression in fetal liver and spleen suggests a possible role in hematopoiesis and in the survival, proliferation, differentiation, and/or activation of blood cell lineages. Thus, the gene product may be involved in immune system dysfunction, susceptibility to infection,
- 10   autoimmunity, leukemia/lymphoma, inflammation, and immune modulation. Additionally, translation products corresponding to this gene, as well as antibodies directed against these translation products, may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

## 15   **FEATURES OF PROTEIN ENCODED BY GENE NO: 5**

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no.

20   gb|AAC17217.1| (all information available through the recited accession number is incorporated herein by reference) which is described therein as "| (AF016032) guanosine-diphosphatase like protein [Homo sapiens]" A partial alignment demonstrating the observed homology is shown immediately below.

25           >gb|AAC17217.1| (AF016032) guanosine-diphosphatase like protein [Homo sapiens]  
               >sp|O15092|O15092 GUANOSINE-DIPHOSPHATASE LIKE PROTEIN (KIAA0392).  
               >dbj|BAA21575.1| (AB002390) KIAA0392 [Homo sapiens] {SUB 60-609}  
               Length = 609

30           Plus Strand HSPs:

              Score = 829 (291.8 bits), Expect = 6.1e-82, P = 6.1e-82  
               Identities = 168/283 (59%), Positives = 199/283 (70%), Frame = +3

35           Q:     219 MARISFSYLCPASWYFTV-PTVSPF-----LRQRVAXXXXXXXXXXXXXXXXXXDFRHWSA 380  
                   M RI   S L PASW+F++ P   P       LRQ +                   R+  
               S:     1 MGRIGISCLFPASWHFSISPVGCPRI LNTNL RQIMVISVLA AAAVSLLYFSVVIIRNKYG 60

40           Q:     381 SLPRDRQYERYLARVGELEATDTEPNLNYGLXVDCGSSGSRIFXYFWPRHNGNPHDLLD 560  
                   L RD++++RYLARV ++EATDT +PN+NYG+ VDCGSSGSR+F Y WPRHNGNPHDLLD  
               S:     61 RLTRDKKFQRYLARVTDIEATDTNNPNVNYGIVVDCGSSGSRV FVYC WPRHNGNPHDLLD 120

5  
10

```

Q: 561 IKQMRDRNSQPVVKKIKPGISAMADTPEHASDYLRPLLSFAAAHVPVKKHKETPLYILCT 740
      I+QMRD+N +PVV KIKPGIS A +PE SDY+ PLL+FAA HVP KHKETPLYILCT
S: 121 IRQMRDKNRKPVVMKIKPGISEFATSPEKVS DYISPLLNFAAEHVPRAKHKETPLYILCT 180

Q: 741 AGMRLLPKQQLAILADLVKDLPLEFDFLFSQSQA EVISGKQEGVYAWIGINFVLXRFDH 920
      AGMR+LPE +Q AIL DL+ D+P+ FDFLFS S AEVISGKQEGVYAWIGINFVL RF+H
S: 181 AGMRILPESQKKAILEDLLTDIPVHFDFLFS DSHA EVISGKQEGVYAWIGINFVLGRFEH 240

Q: 921 EDESDAEATQEL-----AAGRRTVGILDMGGAXXQIAYE 1025
      ++ D EA E+ A R+RT GILDMGG QIAYE
S: 241 IEDDD-EAVVEVNI PGSESSEAIVRKRTAGILDMGGVSTQIAYE 283

```

The segment of gb|AAC17217.1| that is shown as "S" above is set out in the  
 15 sequence listing as SEQ ID NO: . Based on the structural similarity these  
 homologous polypeptides are expected to share at least some biological activities.  
 Such activities are known in the art, some of which are described elsewhere herein.  
 Assays for determining such activities are also known in the art, some of which have  
 been described elsewhere herein. Preferred polypeptides of the invention comprise a  
 20 polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID  
 NO: which corresponds to the "Q" sequence in the alignment shown above (gaps  
 introduced in a sequence by the computer are, of course, removed).

This gene is expressed primarily in the following tissues/cDNA libraries:  
 Soares infant brain 1NIB and to a lesser extent in Messangial cell, frac 1; Human  
 25 Umbilical Vein Endothelial cells, frac B, re-excision; Adipocytes, re-excision; Fetal  
 Heart, re-excision; Smooth muscle, IL1b induced; Human Osteosarcoma; human  
 ovarian cancer; NCI\_CGAP\_CLL1; PC3 Prostate cell line; Soares melanocyte  
 2NbHM and Primary Dendritic Cells, lib 1.

Polynucleotides and polypeptides of the invention are useful as reagents for  
 30 differential identification of the tissue(s) or cell type(s) present in a biological sample  
 and for diagnosis of diseases and conditions which include but are not limited to:  
 disorders of the immune system. Similarly, polypeptides and antibodies directed to  
 these polypeptides are useful in providing immunological probes for differential  
 identification of the tissue(s) or cell type(s). For a number of disorders of the above  
 35 tissues or cells, particularly of the immune system, expression of this gene at  
 significantly higher or lower levels may be routinely detected in certain tissues or cell  
 types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma,  
 urine, synovial fluid and spinal fluid) or another tissue or sample taken from an  
 individual having such a disorder, relative to the standard gene expression level, i.e.,

the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Based on its homology to apyrase, diphosphatase and CD39, which are thought to be involved in cell-cell interactions and aggregation, this protein may have similar roles in cell-cell interactions. Based on its expression in infant brain, the gene and its products may be involved in the formation of the correct neural interactions which are required for cognitive, learning and other higher neural functions such as memory. Thus this gene may be useful for the diagnosis and treatment of such disorders as well as other neurodegenerative disorders such as Alzheimer's, Parkinson's, ALS and multiple sclerosis. In addition the proteins may be useful in the treatment of nerve injuries including spinal cord injuries, where nerve regeneration would be advantageous. Additionally, translation products corresponding to this gene, as well as antibodies directed against these translation products, may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

15

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 6**

Translation products corresponding to this gene share sequence homology with the human HER2 receptor protein (See, e.g., Genbank Accession AAA75493). This gene is expressed primarily in the following tissues/cDNA libraries: NCI\_CGAP\_Pr28 and to a lesser extent in NCI\_CGAP\_Pr23; Hodgkin's Lymphoma I; Healing groin wound - zero hr post-incision (control); Healing groin wound, 6.5 hours post incision; NCI\_CGAP\_Ut2; NCI\_CGAP\_Pr2; NCI\_CGAP\_Kid6; Soares adult brain N2b5HB55Y; Hodgkin's Lymphoma II; Soares\_fetal\_heart\_NbHH19W and Soares infant brain 1NIB.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: diseases and/or disorders of the immune system and cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of

30

disorders of the above tissues or cells, particularly of the immune system and cancerous tissues, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The homology to the human Her2 receptor, and the tissue distribution mainly in human prostate tumor and Hodgkin's Lymphoma I tissues, indicates the gene and its protein product is useful for the diagnosis and treatment of human prostate cancer, Hodgkin's lymphoma, and other immune system disorders.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 7

15

Translation products corresponding to this gene share sequence homology with the human Steerin-1 protein (See, e.g., Genbank Accession AJ251973), and the extensin-like protein.

In specific embodiments, polypeptides of the invention comprise, or alternatively consists of, the following amino acid sequence:

MSDNAPASLESGSSSTPTNCSTSSAIPQGAATKPWRSKSLSVKHSATVSMLS  
 VKPPGPEAPRPTPEAMKPAPNNQKSMLEKLKLFNSKGGSKAGEGPGSRDTSC  
 ERLETLPSEEESELEAASRMLTTVGPASSSPKIALKGIAQRTFSRALTNKKSSL  
 KGNEKEKEKQREKDKEKSKDLAKRASVTERLDLKEEPKEDPSGAAVPEMP  
 KKSSKIASFIPKGGKLNSAKKEPMAPSHSGIPKPGMKSMGKSPSAPAPSKEG  
 ERSRSGKLSSGLPQQKPQLDGRHSSSSSLASSEGKGPGGTTLNHSISSQTVSG  
 SVGTTQTTGSNTVSVQLPQPQQQYNHPNTATVAPFLYRSQTDTEGNXTXESS  
 STGVSVEPXHFPRLDSELLWKNSLGKILRLGGCGQ SNPHATMTQQGRRGREF  
 (SEQ ID NO: 146). Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the



polynucleotide encoding these polypeptides ) are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

5           This gene is expressed primarily in the following tissues/cDNA libraries: Soares\_pregnant\_uterus\_NbHPU and to a lesser extent in 7TM-PNMIX; Human Osteoblasts II; Human Fetal Kidney, Reexcision and Soares melanocyte 2NbHM.

          Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample  
10   and for diagnosis of diseases and conditions which include but are not limited to: reproductive diseases and/or disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive system, expression of this  
15   gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., reproductive, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily  
20   fluid from an individual not having the disorder.

          The homology to human Steerin-1 protein and to extensin-like protein as well as to Zn-finger transcription factor suggests it plays role in gene expression, regulation and development. The tissue distribution in human pregnant uterus and osteoblast indicates the gene and its protein product is useful for the diagnosis and  
25   treatment of female reproductive disorders and abnormal embryonic development. Additionally, translation products corresponding to this gene, as well as antibodies directed against these translation products, may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

30

## **FEATURES OF PROTEIN ENCODED BY GENE NO: 8**

This gene is expressed primarily in pooled Dendritic cells and Human Thymus Stromal Cells.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: 5 diseases and/or disorders of the immune system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression 10 of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an 15 individual not having the disorder.

The tissue distribution in human dendritic and thymus stromal cells indicates the gene and its protein product is useful for the diagnosis and treatment of human immune system disorders. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a 20 usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency 25 diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Additionally, translation products corresponding to this gene, as well as antibodies directed against 30 these translation products, may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 9**

The gene encoding the disclosed cDNA is thought to reside on chromosome  
5 12. Accordingly, polynucleotides related to this invention have uses, such as, for  
example, as a marker in linkage analysis for chromosome 12.

This gene is expressed primarily in the following tissues/cDNA libraries:  
Soares\_fetal\_heart\_NbHH19W and to a lesser extent in Human Liver, normal; Early  
Stage Human Brain; H. hypothalamus, frac A; Activated T-cells; Human Tonsils, Lib  
10 2; human corpus colosum; Stratagene lung carcinoma 937218; Stratagene fetal spleen  
(#937205); Human umbilical vein endothelial cells, IL-4 induced; Macrophage (GM-  
CSF treated); Stratagene liver (#937224); Bone marrow; Endothelial-induced; Human  
Amygdala; Stratagene lung (#937210); Spleen, Chronic lymphocytic leukemia;  
Human Bone Marrow, treated; Soares\_NhHMPu\_S1; Primary Dendritic Cells, lib 1  
15 and Soares infant brain 1NIB.

Polynucleotides and polypeptides of the invention are useful as reagents for  
differential identification of the tissue(s) or cell type(s) present in a biological sample  
and for diagnosis of diseases and conditions which include but are not limited to:  
developmental and immune system disorders. Similarly, polypeptides and antibodies  
20 directed to these polypeptides are useful in providing immunological probes for  
differential identification of the tissue(s) or cell type(s). For a number of disorders of  
the above tissues or cells, particularly of the immune and developing systems,  
expression of this gene at significantly higher or lower levels may be routinely  
detected in certain tissues or cell types (e.g., immune, developing, cancerous and  
25 wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid  
and spinal fluid) or another tissue or sample taken from an individual having such a  
disorder, relative to the standard gene expression level, i.e., the expression level in  
healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in human fetal tissues indicates the gene and its protein  
30 product are useful for the diagnosis and treatment of developmental disorders and  
adult immune disorders and cancers. This gene product may be involved in the  
regulation of cytokine production, antigen presentation, or other processes that may

also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be  
5 also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell  
10 types. Additionally, translation products corresponding to this gene, as well as antibodies directed against these translation products, may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

#### 15 **FEATURES OF PROTEIN ENCODED BY GENE NO: 10**

The gene encoding the disclosed cDNA is believed to reside on chromosome 19. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 19.

20 This gene is expressed primarily in T-cell helper and testis, and to a lesser extent ubiquitously.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to:  
25 diseases and/or disorders of the testis and the immune system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the testis and the immune system, expression of this gene at significantly higher or lower levels may be  
30 routinely detected in certain tissues or cell types (e.g., testis, immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a

disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The observed tissue distribution suggests that this gene product may be useful in the diagnosis and/or treatment of a variety of disorders. Based upon the tissue  
5 distribution in T-cell helper this gene product may be useful for diagnosis and/or treatment of immune system dysfunctions, leukemias/lymphomas, susceptibility to infections, and circulatory disorders. Similarly, elevated expression in testis suggests a possible role in male fertility and a possible application of this gene product as a male contraceptive. The secreted protein can also be used to determine biological  
10 activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions and as nutritional supplements. It may also have a very wide range of biological activities. Typical of these are cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines; immunostimulating/immunosuppressant activities (e.g. for treating human  
15 immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation of hematopoiesis (e.g. for treating anemia or as adjunct to chemotherapy); stimulation or growth of bone, cartilage, tendons, ligaments and/or nerves (e.g. for treating wounds, stimulation of follicle stimulating hormone (for control of fertility); chemotactic and chemokinetic activities (e.g. for treating infections, tumors);  
20 hemostatic or thrombolytic activity (e.g. for treating hemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g. for treating septic shock, Crohn's disease); as antimicrobials; for treating psoriasis or other hyperproliferative diseases; for regulation of metabolism, and behavior. Also contemplated is the use of the corresponding nucleic acid in gene therapy procedures. Additionally, translation  
25 products corresponding to this gene, as well as antibodies directed against these translation products, may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

30 **FEATURES OF PROTEIN ENCODED BY GENE NO: 11**

This gene is expressed primarily in the following tissues/cDNA libraries: prostate, Dendritic cells, pooled; Soares\_fetal\_lung\_NbHL19W and to a lesser extent in Human Pineal Gland; L428 and Activated T-Cell (12hs)/Thiouridine labelledEco.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: diseases and/or disorders of the immune system and cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system and cancerous tissues, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in human prostate and hematopoietic cell lineage indicates the gene and its protein product is useful for the diagnosis and treatment of human prostate cancer and immune system disorders. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Additionally, translation products corresponding to this gene, as well as antibodies directed against these translation products, may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 12**

- 5           This gene is expressed primarily in the following tissues/cDNA libraries:  
Human Whole Brain #2 - Oligo dT > 1.5Kb; Keratinocyte and to a lesser extent in  
Bone Marrow Cell Line (RS4,11); T cell helper II; Testis 1; Human 8 Week Whole  
Embryo, subtracted; Human retina cDNA Tsp509I-cleaved sublibrary; Stratagene  
schizo brain S11; Human Umbilical Vein, Endo. remake; Human Stomach, re-  
10   excision; H. Lymph node breast Cancer; Human Infant Brain; Breast Cancer Cell line,  
angiogenic; Human Activated T-Cells; T-Cell PHA 24 hrs; Stratagene hNT neuron  
(#937233); Human Testes Tumor; Primary Dendritic cells, frac 2; Human Adult  
Pulmonary, re-excision; Human 8 Week Whole Embryo;  
Soares\_fetal\_lung\_NbHL19W and Primary Dendritic Cells, lib 1.
- 15           Polynucleotides and polypeptides of the invention are useful as reagents for  
differential identification of the tissue(s) or cell type(s) present in a biological sample  
and for diagnosis of diseases and conditions which include but are not limited to:  
diseases and/or disorders of the neural and immune systems. Similarly, polypeptides  
and antibodies directed to these polypeptides are useful in providing immunological  
20   probes for differential identification of the tissue(s) or cell type(s). For a number of  
disorders of the above tissues or cells, particularly of the neural and immune systems,  
expression of this gene at significantly higher or lower levels may be routinely  
detected in certain tissues or cell types (e.g., neural, immune, cancerous and wounded  
tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal  
25   fluid) or another tissue or sample taken from an individual having such a disorder,  
relative to the standard gene expression level, i.e., the expression level in healthy  
tissue or bodily fluid from an individual not having the disorder.

The observed tissue distribution suggests that this clone could be useful in the  
diagnosis and/or treatment of neurodevelopmental, neurodegenerative, hemopoietic  
30   and immune disorders and neoplasms. This gene product may be involved in the  
regulation of cytokine production, antigen presentation, or other processes that may  
also suggest a usefulness in the treatment of cancer (e.g. by boosting immune

responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Additionally, translation products corresponding to this gene, as well as antibodies directed against these translation products, may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 13**

15

When tested against U937 Myeloid cell lines, supernatants removed from cells containing this gene activated the GAS assay. Thus, it is likely that this gene activates myeloid cells through the Jak-STAT signal transduction pathway. The gamma activating sequence (GAS) is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

25

This gene is ubiquitously expressed with some enrichment in neural/sensory tissues, as well as in primary dendritic cells.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: diseases and/or disorders of the neural and immune systems. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of

30



disorders of the above tissues or cells, particularly of the neural and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., neural, immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The observed tissue distribution suggests utility for the study diagnosis and/or treatment of a variety of diseases. The enriched expression in neural/sensory tissues indicates that this gene may be useful for the treatment, detection, and/or diagnosis of neurodegenerative disorders and behavioral disorders such as Alzheimer's Disease, Parkinson's Disease, learning disabilities. Alternatively, the expression in dendritic cells and the observed biological activity suggests utility for the study, diagnosis, and/or treatment of immune system diseases and/or disorders and infectious diseases. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Additionally, translation products corresponding to this gene, as well as antibodies directed against these translation products, may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 14**

This gene is expressed primarily in cells of the immune/hematopoietic system, notably monocytes and dendritic cells as well as fetal liver and spleen which is known to have hematopoietic function.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: diseases and/or disorders of the immune system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Based on its expression in fetal liver and spleen which is known to have hematopoietic functions as well as expression in dendritic cells, this gene and its encoded polypeptides may be useful for the diagnosis and treatment of disorders associated with immune function such as over activity of the immune system as observed in autoimmunity syndromes including systemic lupus erythematosus (SLE) and rheumatoid arthritis or in the treatment of disorders associated with poor immune function such as specific immune cell cytopenias. The gene products may also be useful for the modulation of the immune response in organ transplantation, and allergies. The gene may be useful for the treatment of immune disorders or for the priming of immune based therapies against tumors. Additionally, translation products corresponding to this gene, as well as antibodies directed against these translation products, may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 15**

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no.

- 5 gb|AAB57679.1| (all information available through the recited accession number is incorporated herein by reference in its entirety) which is described therein as "transmembrane receptor UNC5H2 [Rattus norvegicus]" A partial alignment demonstrating the observed homology is shown immediately below.

```

10  >gb|AAB57679.1| transmembrane receptor UNC5H2 [Rattus norvegicus]
    >sp|O08722|O08722 TRANSMEMBRANE RECEPTOR UNC5H2.
    Length = 945

    Plus Strand HSPs:
15  Score = 638 (224.6 bits), Expect = 2.3e-61, P = 2.3e-61
    Identities = 122/130 (93%), Positives = 124/130 (95%), Frame = +3

    Q:      3  EGEQIFQLHTTLAETPAGSLDTLCSAPGXTVTTQLGPFYAFKIPLSIRQKICNSLDAPNS 182
    EGEQIFQLHTTLAETPAGSLD LCSAPG  TTQLGPFYAFKIPLSIRQKICNSLDAPNS
20  S:     816  EGEQIFQLHTTLAETPAGSLDALCSAPGNAATTQLGPFYAFKIPLSIRQKICNSLDAPNS 875

    Q:     183  RGNDWRMLAQKLSMDRYLNYFATKASPTGVILDLWEALQQDDGDLNSLASALEEMGKSEM 362
    RGNDWR+LAQKLSMDRYLNYFATKASPTGVILDLWEA  QQDDGDLNSLASALEEMGKSEM
25  S:     876  RGNDWRLLAQKLSMDRYLNYFATKASPTGVILDLWEARQQDDGDLNSLASALEEMGKSEM 935

    Q:     363  LVAVATDGDC 392
    LVA+  TDGDC
    S:     936  LVAMTTDGDC 945
30

```

- The segment of gb|AAB57679.1| that is shown as "S" above is set out in the sequence listing as SEQ ID NO: Based on the structural similarity these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein. Assays for
- 35 determining such activities are also known in the art, some of which have been described elsewhere herein. Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO: which corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

- 40 The translation product of this gene shares sequence homology with netrin receptors which are thought to be important in the developing nervous system. The netrins are a family of phylogenetically conserved guidance cues that can function as diffusible attractants and repellents for different classes of cells and axons. In

vertebrates, insects and nematodes, members of the DCC subfamily of the immunoglobulin superfamily have been implicated as receptors that are involved in migration towards netrin sources. Based on the sequence similarity of his human gene product to rat netrin receptor, the translation product of this clone is expected to share  
 5 at least some biological activities with netrin receptor proteins. Such activities are known in the art, some of which are described elsewhere herein.

In specific embodiments, polypeptides of the invention comprise, or alternatively consists of, the following amino acid sequence:  
 EGEGQIFQLHTTLAETPAGSLDTLCSAPGXTVTTQLGPYAFKIPLSIRQKICNSL  
 10 DAPNSRGNDWRMLAQKLSMDRYLNYFATKASPTGVILDLWEALQQDDGDL  
 NSLASALEEMGKSEMLVAVATDGDC (SEQ ID NO: 152). Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which  
 15 hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides ) are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in the following tissues/cDNA libraries:  
 20 normalized infant brain cDNA and to a lesser extent in Smooth muscle, serum treated; NCI\_CGAP\_Kid5; Soares\_multiple\_sclerosis\_2NbHMSP; Soares ovary tumor NbHOT; Soares\_pregnant\_uterus\_NbHPU; H. Epididymus, cauda; Smooth Muscle-HASTE normalized; Human Synovium; Gessler Wilms tumor; Human Chondrosarcoma; Human Thymus Stromal Cells; NCI\_CGAP\_Pan1; Fetal Heart;  
 25 NCI\_CGAP\_GC4; Osteoblasts; Human Cerebellum; Soares\_NFL\_T\_GBC\_S1; Soares\_NhHMPu\_S1; Soares infant brain 1NIB; Human Astrocyte; Sinus piniformis Tumour; Human OB MG63 treated (10 nM E2) fraction I; Barstead spleen HPLRB2; Normal Human Trabecular Bone Cells; Adipocytes, re-excision; Smooth Muscle Serum Treated, Norm; Smooth muscle-ILb induced; Human Normal Breast;  
 30 NCI\_CGAP\_AA1; Palate normal; Human adult (K.Okubo); H. Kidney Cortex, subtracted; Human Osteosarcoma; Prostate BPH; Spinal Cord, re-excision; Breast Cancer Cell line, angiogenic; 12 Week Old Early Stage Human, II; Human

Osteoblasts II; Human Pancreas Tumor; Stromal cell TF274; Human Pancreas Tumor, Reexcision; Ovary, Cancer (9809C332); Poorly differentiated adenocarcinoma; Hemangiopericytoma; Soares breast 2NbHBst; Human Adrenal Gland Tumor; Smooth muscle, serum induced, re-exc; Pancreas Islet Cell Tumor;  
 5 Colon Normal II; Adipocytes; NCI\_CGAP\_Co8; Human Fetal Kidney, Reexcision; NCI\_CGAP\_Kid3; Human Bone Marrow, treated; Hodgkin's Lymphoma II; Keratinocyte; Soares\_fetal\_lung\_NbHL19W and Colon Tumor II.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample  
 10 and for diagnosis of diseases and conditions which include but are not limited to: diseases and/or disorders of the neural system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the neural system, expression of this gene at  
 15 significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., neural, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an  
 20 individual not having the disorder.

The tissue distribution in brain and sequence homology to transmembrane receptor UNC5H2 [*Rattus norvegicus*] indicates the protein product of this clone would be useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses  
 25 are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma,  
 30 congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism,

and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition,

5 homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or

10 immunotherapy targets for the above listed tissues.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 16**

15 This gene is expressed primarily in the following tissues/cDNA libraries:  
Dendritic cells, pooled; human tonsils.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to:

20 immune system diseases and/or disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or

25 cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

30 Based on its expression in tonsil and dendritic cells, this gene and its encoded polypeptides may be useful for the diagnosis and treatment of disorders associated with immune function such as those associated with over activity of the immune

system as observed in autoimmunity syndromes including systemic lupus erythematosus (SLE) and rheumatoid arthritis or in the treatment of disorders associated with poor immune function such as specific immune cell cytopenias. The gene products may also be useful for the modulation of the immune response in organ  
5 transplantation, and allergies.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 17**

10 Preferred polypeptides of the invention comprise, or alternatively consist of, a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO: 148. Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by  
15 the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides ) are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in the following tissues/cDNA libraries:  
20 KMH2; Human Adrenal Gland Tumor; Dendritic cells, pooled; Bone Marrow Cell Line (RS4,11).

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to:  
25 diseases and/or disorders of the immune system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain  
30 tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene

expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Based on expression in bone marrow and dendritic cells this gene and its encoded gene products may be useful for the diagnosis and treatment of diseases of the immune system, including autoimmune syndromes such as systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, diabetes mellitus as well as immune deficiency syndromes. The gene may also be used to regulate the immune response in such conditions as organ transplantation or allergies. Additionally, translation products corresponding to this gene, as well as antibodies directed against these translation products, may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 18**

15

This gene is expressed primarily in two distinct types of tissues- e.g., cells of immune/hematopoietic function and in testes as exemplified by the following tissues/cDNA libraries: Human Eosinophils; Human Testes, Reexcision; NCI\_CGAP\_Pr3; Early Stage Human Brain; Endothelial-induced; Activated T-cell(12h)/Thiouridine-re-excision; T cell helper II; Soares\_fetal\_heart\_NbHH19W; Primary Dendritic Cells, lib 1; HSC172 cells; H. Epididymus, caput & corpus; Smooth Muscle- HASTE normalized; Amniotic Cells - Primary Culture; NCI\_CGAP\_Pr22; Soares\_pineal\_gland\_N3HPG; NCI\_CGAP\_Pr28; NCI\_CGAP\_CLL1; Resting T-Cell Library,II; Stratagene colon (#937204); Dendritic cells, pooled; Soares\_pregnant\_uterus\_NbHPU; Soares\_NhHMPu\_S1; NCI\_CGAP\_Co1; Chromosome 7 HeLa cDNA Library; Atrium cDNA library Human heart; Chromosome 7 Fetal Brain cDNA Library; Human OB MG63 control fraction I; Cem cells cyclohexamide treated; Stomach cancer (human),re-excision; Human endometrial stromal cells-treated with estradiol; Smooth muscle, IL1b induced; Synovial hypoxia-RSF subtracted; Human Whole Brain #2 - Oligo dT > 1.5Kb; HL-60, PMA 4H, re-excision; LNCAP prostate cell line; Synovial hypoxia; Jurkat T-cell G1 phase; Brain Frontal Cortex, re-excision; Stratagene neuroepithelium



(#937231); Human Umbilical Vein, Reexcision; Gessler Wilms tumor; HUMAN JURKAT MEMBRANE BOUND POLYSOMES; Human Fetal Dura Mater; Human Activated T-Cells; Human Hypothalamus, Schizophrenia; NCI\_CGAP\_Br2; Human Rhabdomyosarcoma; Human adult testis, large inserts; Pancreas Islet Cell Tumor; Colon Carcinoma; breast lymph node CDNA library; Adipocytes; CD34 depleted Buffy Coat (Cord Blood), re-excision; Human Microvascular Endothelial Cells, fract. A; Monocyte activated; HUMAN B CELL LYMPHOMA; Spleen, Chronic lymphocytic leukemia; Human Bone Marrow, treated; Human Testes; Soares\_fetal\_liver\_spleen\_1NFLS\_S1 and Soares fetal liver spleen 1NFLS.

10 Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: immune system diseases and/or disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for  
15 differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or  
20 sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Based on its expression in various sources associated with immune function such as eosinophils, lymph node, T-cells, and dendritic cells this gene and its encoded  
25 polypeptides may be useful for the diagnosis and treatment of disorders associated with immune function such as those where over activity of the immune system is pathologic, as observed in autoimmunity syndromes including systemic lupus erythematosus (SLE) and rheumatoid arthritis or in the treatment of disorders associated with poor immune function such as specific immune cell cytopenias. The  
30 gene products may also be useful for the modulation of the immune response in organ transplantation, and allergies. Additionally, translation products corresponding to this

gene, as well as antibodies directed against these translation products, may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

## 5 FEATURES OF PROTEIN ENCODED BY GENE NO: 19

This gene is expressed primarily in the following tissues/cDNA libraries:  
Human Fetal Brain; pBMC stimulated w/ poly I/C.

Polynucleotides and polypeptides of the invention are useful as reagents for  
10 differential identification of the tissue(s) or cell type(s) present in a biological sample  
and for diagnosis of diseases and conditions which include but are not limited to:  
neural system diseases and/or disorders. Similarly, polypeptides and antibodies  
directed to these polypeptides are useful in providing immunological probes for  
differential identification of the tissue(s) or cell type(s). For a number of disorders of  
15 the above tissues or cells, particularly of the neural system, expression of this gene at  
significantly higher or lower levels may be routinely detected in certain tissues or cell  
types (e.g., neural, cancerous and wounded tissues) or bodily fluids (e.g., lymph,  
serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample  
taken from an individual having such a disorder, relative to the standard gene  
20 expression level, i.e., the expression level in healthy tissue or bodily fluid from an  
individual not having the disorder.

Due to its expression in the developing brain, this gene and its encoded  
polypeptides may be useful for the diagnosis and treatment of neurological disorders,  
including stroke, Alzheimer's disease, multiple sclerosis, ALS, and other disorders  
25 associated with loss of cognitive and learning functions. The protein may also be  
useful for treatment of spinal cord and other nerve injuries in which regeneration and  
regrowth on neural cells is required. Additionally, translation products corresponding  
to this gene, as well as antibodies directed against these translation products, may  
show utility as a tumor marker and/or immunotherapy targets for the above listed  
30 tissues.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 20**

This gene is expressed primarily in the following tissues/cDNA libraries:

Soares\_pregnant\_uterus\_NbHPU and to a lesser extent in Human endometrial stromal  
 5 cells-treated with progesterone; NCI\_CGAP\_Pr28; Human endometrial stromal cells;  
 Keratinocyte; Human Whole Brain #2 - Oligo dT > 1.5Kb; Soares\_NhHMPu\_S1;  
 NCI\_CGAP\_GCB1; Human endometrial stromal cells-treated with estradiol;  
 NCI\_CGAP\_Co10; NCI\_CGAP\_Ut2; NCI\_CGAP\_Gas4; NCI\_CGAP\_Pan1;  
 NCI\_CGAP\_GC4; NCI\_CGAP\_GC6; Soares ovary tumor NbHOT; Bone Marrow  
 10 Cell Line (RS4,11); Hodgkin's Lymphoma II; Human 8 Week Whole Embryo;  
 Soares\_fetal\_lung\_NbHL19W; T cell helper II; Soares\_NFL\_T\_GBC\_S1; Healing  
 Abdomen Wound, 15 days post incision; NCI\_CGAP\_Ov35; Testis 1; Human 8 Week  
 Whole Embryo, subtracted; Human retina cDNA Tsp509I-cleaved sublibrary;  
 NCI\_CGAP\_Ov23; Activated T-cells; H. Epididymus, cauda; Stratagene schizo  
 15 brain S11; NCI\_CGAP\_Co9; Human Umbilical Vein, Endo. remake; Ovary, Cancer:  
 (15799A1F) Poorly differentiated carcinoma; Human Stomach, re-excision; wilm's  
 tumor; Human Manic Depression Tissue; H. Lymph node breast Cancer; Human  
 Infant Brain; Breast Cancer Cell line, angiogenic; NCI\_CGAP\_Ut1;  
 NCI\_CGAP\_Kid6; Human Fetal Dura Mater; Human Activated T-Cells; T-Cell PHA  
 20 24 hrs; NCI\_CGAP\_CLL1; Human Thymus Stromal Cells; CHME Cell Line, treated  
 5 hrs; Stratagene hNT neuron (#937233); Human T-Cell Lymphoma; Colon  
 Carcinoma; Human Placenta; NCI\_CGAP\_Kid11; Human Testes Tumor; Primary  
 Dendritic cells, frac 2; Pancreas normal PCA4 No; Human Adult Pulmonary, re-  
 excision; Human Bone Marrow, treated; Soares\_parathyroid\_tumor\_NbHPA; Soares  
 25 melanocyte 2NbHM; Colon Tumor II; Soares\_fetal\_heart\_NbHH19W and Primary  
 Dendritic Cells, lib 1.

Polynucleotides and polypeptides of the invention are useful as reagents for  
 differential identification of the tissue(s) or cell type(s) present in a biological sample  
 and for diagnosis of diseases and conditions which include but are not limited to:  
 30 diseases and/or disorders of the reproductive, immune, and hemopoietic systems.  
 Similarly, polypeptides and antibodies directed to these polypeptides are useful in  
 providing immunological probes for differential identification of the tissue(s) or cell

type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive, immune, and hemapoietic systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., reproductive, immune, hemapoietic, cancerous and wounded tissues) or  
5 bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The observed tissue distribution suggests that this gene product may be useful  
10 for the diagnosis and/or treatment of diseases of the reproductive system, neoplasms and other proliferative disorders. Similarly, expression in hemapoietic cells may indicate roles in the proliferation, survival, differentiation, and/or activation of a variety of blood cell lineages, and implicate this gene product in immune system dysfunction, autoimmunity, leukemias/lymphomas, susceptibility to infections, and  
15 circulatory disorders. Additionally, translation products corresponding to this gene, as well as antibodies directed against these translation products, may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

## 20 **FEATURES OF PROTEIN ENCODED BY GENE NO: 21**

Preferred polypeptides of the invention comprise, or alternatively consist of, a polypeptide having the amino acid sequence: 157) set out in the sequence listing as SEQ ID NO: SEQ ID NO: and/or SEQ ID NO:156. Moreover, fragments and  
25 variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides ) are encompassed by the invention. Antibodies that bind polypeptides of the invention are  
30 also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

Translation products corresponding to this gene share sequence homology with the human dermatan/chondroitin sulfate 2-sulfotransferase (See, e.g., Genbank Accession AB020316).

This gene is expressed primarily in the following tissues/cDNA libraries:

- 5 STROMAL -OSTEOCLASTOMA; Dendritic cells, pooled; Smooth muscle, control; Nine Week Old Early Stage Human.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to:

10 diseases and/or disorders of musculoskeletal tissues. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the musculoskeletal tissues, expression of this gene at significantly higher or lower levels may be routinely

15 detected in certain tissues or cell types (e.g., musculoskeletal, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

20 The secreted protein can also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, and as nutritional supplements. It may also have a very wide range of biological activities. Representative uses are described in the "Chemotaxis" and "Binding Activity" sections below, in Examples 11, 12, 13, 14, 15,

25 16, 18, 19, and 20, and elsewhere herein. Briefly, the protein may possess the following activities: cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines; immunostimulating/immunosuppressant activities (e.g. for treating human immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation of hematopoiesis (e.g. for treating anemia or as adjunct to

30 chemotherapy); stimulation or growth of bone, cartilage, tendons, ligaments and/or nerves (e.g. for treating wounds, stimulation of follicle stimulating hormone (for control of fertility); chemotactic and chemokinetic activities (e.g. for treating

infections, tumors); hemostatic or thrombolytic activity (e.g. for treating hemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g. for treating septic shock, Crohn's disease); as antimicrobials; for treating psoriasis or other hyperproliferative diseases; for regulation of metabolism, and behavior. Also contemplated is the use of

5 the corresponding nucleic acid in gene therapy procedures. Elevated levels of expression of this gene product in osteoclastoma suggests that it may play a role in the survival, proliferation, and/or growth of osteoclasts. Therefore, it may be useful in influencing bone mass in such conditions as osteoporosis. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue

10 markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Table 1

Gene No.	cDNA Clone ID	ATCC Deposit No.:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
1	HDPPA04	PTA-867 10/26/99	pCMVSPORT 3.0	11	2406	1	2406	271	271	74	1	19	20	283
1	HDPPA04	PTA-867 10/26/99	pCMVSPORT 3.0	32	1675	1	1613		1003	95	1	18	19	23
1	HDPPA04	PTA-867 10/26/99	pCMVSPORT 3.0	33	786	1	786	261	261	96	1	19	20	93
2	HOHBY44	PTA-867 10/26/99	pCMVSPORT 2.0	12	3369	1	3369	170	170	75	1	24	25	184
2	HOHBY44	PTA-867 10/26/99	pCMVSPORT 2.0	34	1063	533	1063		2	97	1	1	2	77
2	HOHBY44	PTA-867 10/26/99	pCMVSPORT 2.0	35	1178	1	1178		1125	98	1	1	2	84
3	HOHBL42	PTA-867 10/26/99	pCMVSPORT 2.0	13	3258	1	1690	61	61	76	1	17	18	716
3	HOHBL42	PTA-867 10/26/99	pCMVSPORT 2.0	36	790	1	790	82	82	99	1	15	16	61
3	HOHBL42	PTA-867 10/26/99	pCMVSPORT 2.0	37	1203	1	1203		809	100	1			11
3	HOHBL42	PTA-867 10/26/99	pCMVSPORT 2.0	38	804	1	804		590	101	1	1	2	66

Gene No.	cDNA Clone ID	ATCC Deposit No.:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
4	HRABV43	PTA-867 10/26/99	pCMVSPORT 3.0	14	3077	1	3077	99	99	77	1	22	23	617
4	HRABV43	PTA-867 10/26/99	pCMVSPORT 3.0	39	1602	1	1602	88	88	102	1	22	23	505
4	HRABV43	PTA-867 10/26/99	pCMVSPORT 3.0	40	1789	209	1775	63	63	103	1	22	23	191
5	HDP RH52	PTA-867 10/26/99	pCMVSPORT 3.0	15	1082	64	1082	219	219	78	1	21	22	288
5	HDP RH52	PTA-867 10/26/99	pCMVSPORT 3.0	41	2102	1	2102		1711	104	1	19	20	33
6	HDTEK44	PTA-867 10/26/99	pCMVSPORT 2.0	16	2070	20	2070		691	79	1	14	15	83
6	HDTEK44	PTA-867 10/26/99	pCMVSPORT 2.0	42	1005	1	1005	175	175	105	1	17	18	67
6	HDTEK44	PTA-867 10/26/99	pCMVSPORT 2.0	43	2988	1	2988	116	116	106	1	17	18	67
6	HDTEK44	PTA-867 10/26/99	pCMVSPORT 2.0	44	2052	2	2052		673	107	1	14	15	83
7	HOHBP82	PTA-867 10/26/99	pCMVSPORT 2.0	17	2055	1	2055	369	369	80	1	27	28	39
7	HOHBP82	PTA-867 10/26/99	pCMVSPORT 2.0	45	617	1	617	396	396	108	1	27	28	63



Gene No.	cDNA Clone ID	ATCC Deposit No:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
7	HOHBP82	PTA-867 10/26/99	pCMVSPORT 2.0	46	558	1	558		63	109	1			9
7	HOHBP82	PTA-867 10/26/99	pCMVSPORT 2.0	47	1454	411	1454		1040	110	1	12	13	94
8	HWBAD01	PTA-867 10/26/99	pCMVSPORT 3.0	18	829	1	829	125	125	81	1	21	22	41
8	HWBAD01	PTA-867 10/26/99	pCMVSPORT 3.0	48	835	1	835		541	111	1	13	14	77
8	HWBAD01	PTA-867 10/26/99	pCMVSPORT 3.0	49	516	1	516		511	112	1	1	2	87
9	HWABE12	PTA-867 10/26/99	pCMVSPORT 3.0	19	1056	1	1056	146	146	82	1	34	35	50
9	HWABE12	PTA-867 10/26/99	pCMVSPORT 3.0	50	534	1	534		532	113	1	1	2	86
9	HWABE12	PTA-867 10/26/99	pCMVSPORT 3.0	51	503	76	184		502	114	1	1	2	53
10	HHEPJ23	PTA-867 10/26/99	pCMVSPORT 3.0	20	3143	1	3143	175	175	83	1	21	22	62
10	HHEPJ23	PTA-867 10/26/99	pCMVSPORT 3.0	52	607	1	607	175	175	115	1	21	22	62
11	HWBAR14	PTA-867 10/26/99	pCMVSPORT 3.0	21	3878	1	3878	152	152	84	1	48	49	371

Gene No.	cDNA Clone ID	ATCC Deposit No:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
11	HWBAR14	PTA-867 10/26/99	pCMVSPORT 3.0	53	432	1	432	287	287	116	1	33	34	48
11	HWBAR14	PTA-867 10/26/99	pCMVSPORT 3.0	54	794	1	794		204	117	1			12
11	HWBAR14	PTA-867 10/26/99	pCMVSPORT 3.0	55	1019	1	1019		528	118	1	1	2	129
12	HDPPN86	PTA-867 10/26/99	pCMVSPORT 3.0	22	6297	1	6297	127	127	85	1	32	33	46
12	HDPPN86	PTA-867 10/26/99	pCMVSPORT 3.0	56	2042	1	2042	117	117	119	1	26	27	46
13	HDPIW06	PTA-867 10/26/99	pCMVSPORT 3.0	23	5257	1	5257	147	147	86	1	25	26	53
13	HDPIW06	PTA-867 10/26/99	pCMVSPORT 3.0	57	584	1	584	174	174	120	1	25	26	53
13	HDPIW06	PTA-867 10/26/99	pCMVSPORT 3.0	58	684	1	684		226	121	1			4
13	HDPIW06	PTA-867 10/26/99	pCMVSPORT 3.0	59	2070	1	2070		2014	122	1			19
13	HDPIW06	PTA-867 10/26/99	pCMVSPORT 3.0	60	427	1	427		153	123	1	1	2	51
14	HWBCH13	PTA-867 10/26/99	pCMVSPORT 3.0	24	464	1	464	82	82	87	1	29	30	73

Gene No.	cDNA Clone ID	ATCC Deposit No.:Z and Date	Vector	NT SEQ ID NO:	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO:	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
14	HWBCH13	PTA-867 10/26/99	pCMVSPORT 3.0	61	341	1	341		193	124	1			5
14	HWBCH13	PTA-867 10/26/99	pCMVSPORT 3.0	62	804	1	804		535	125	1			10
14	HWBCH13	PTA-867 10/26/99	pCMVSPORT 3.0	63	1081	1	1081		772	126	1	1	2	57
15	HOHCJ90	PTA-867 10/26/99	pCMVSPORT 2.0	25	1116	231	1116	307	307	88	1	29	30	80
15	HOHCJ90	PTA-867 10/26/99	pCMVSPORT 2.0	64	2211	1	1170		1275	127	1	1	2	164
16	HWBCM79	PTA-867 10/26/99	pCMVSPORT 3.0	26	1563	1	1563	381	381	89	1	26	27	36
17	HWBDM62	PTA-867 10/26/99	pCMVSPORT 3.0	27	1528	1	1528	101	101	90	1	17	18	40
17	HWBDM62	PTA-867 10/26/99	pCMVSPORT 3.0	65	1236	1	1236		387	128	1			2
17	HWBDM62	PTA-867 10/26/99	pCMVSPORT 3.0	66	797	1	797		309	129	1	17	18	22
17	HWBDM62	PTA-867 10/26/99	pCMVSPORT 3.0	67	534	1	534		179	130	1	1	2	53
18	HWBCV72	PTA-867 10/26/99	pCMVSPORT 3.0	28	235	1	235	46	46	91	1	23	24	63

Gene No.	cDNA Clone ID	ATCC Deposit No:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
18	HWBCV72	PTA-867 10/26/99	pCMVSPORT 3.0	68	1096	1	1096		169	131	1			7
18	HWBCV72	PTA-867 10/26/99	pCMVSPORT 3.0	69	1288	153	1288		493	132	1			8
18	HWBCV72	PTA-867 10/26/99	pCMVSPORT 3.0	70	3319	3125	3305		860	133	1	1	2	352
19	HMTAL77	PTA-867 10/26/99	pCMVSPORT 3.0	29	569	1	569		218	92	1	14	15	86
19	HMTAL77	PTA-867 10/26/99	pCMVSPORT 3.0	71	372	41	372		241	134	1			7
20	HHEPG23	PTA-867 10/26/99	pCMVSPORT 3.0	30	2767	1	2767	421	421	93	1			20
20	HHEPG23	PTA-867 10/26/99	pCMVSPORT 3.0	72	337	23	337	124	124	135	1			20
20	HHEPG23	PTA-867 10/26/99	pCMVSPORT 3.0	73	1415	1	1415		938	136	1			11
21	HWBAR88	PTA-867 10/26/99	pCMVSPORT 3.0	31	1051	1	1051	156	156	94	1	18	19	75

Table 1 summarizes the information corresponding to each "Gene No." described above. The nucleotide sequence identified as "NT SEQ ID NO:X" was assembled from partially homologous ("overlapping") sequences obtained from the "cDNA clone ID" identified in Table 1 and, in some cases, from additional related DNA clones. The overlapping sequences were assembled into a single contiguous sequence of high redundancy (usually three to five overlapping sequences at each nucleotide position), resulting in a final sequence identified as SEQ ID NO:X.

The cDNA Clone ID was deposited on the date and given the corresponding deposit number listed in "ATCC Deposit No:Z and Date." Some of the deposits contain multiple different clones corresponding to the same gene. "Vector" refers to the type of vector contained in the cDNA Clone ID.

"Total NT Seq." refers to the total number of nucleotides in the contig identified by "Gene No." The deposited clone may contain all or most of these sequences, reflected by the nucleotide position indicated as "5' NT of Clone Seq." and the "3' NT of Clone Seq." of SEQ ID NO:X. The nucleotide position of SEQ ID NO:X of the putative start codon (methionine) is identified as "5' NT of Start Codon." Similarly, the nucleotide position of SEQ ID NO:X of the predicted signal sequence is identified as "5' NT of First AA of Signal Pep."

The translated amino acid sequence, beginning with the methionine, is identified as "AA SEQ ID NO:Y," although other reading frames can also be easily translated using known molecular biology techniques. The polypeptides produced by these alternative open reading frames are specifically contemplated by the present invention.

The first and last amino acid position of SEQ ID NO:Y of the predicted signal peptide is identified as "First AA of Sig Pep" and "Last AA of Sig Pep." The predicted first amino acid position of SEQ ID NO:Y of the secreted portion is identified as "Predicted First AA of Secreted Portion." Finally, the amino acid position of SEQ ID NO:Y of the last amino acid in the open reading frame is identified as "Last AA of ORF."

SEQ ID NO:X (where X may be any of the polynucleotide sequences disclosed in the sequence listing) and the translated SEQ ID NO:Y (where Y may be any of the polypeptide sequences disclosed in the sequence listing) are sufficiently

accurate and otherwise suitable for a variety of uses well known in the art and described further below. For instance, SEQ ID NO:X is useful for designing nucleic acid hybridization probes that will detect nucleic acid sequences contained in SEQ ID NO:X or the cDNA contained in the deposited clone. These probes will also  
5 hybridize to nucleic acid molecules in biological samples, thereby enabling a variety of forensic and diagnostic methods of the invention. Similarly, polypeptides identified from SEQ ID NO:Y may be used, for example, to generate antibodies which bind specifically to proteins containing the polypeptides and the secreted proteins encoded by the cDNA clones identified in Table 1.

10 Nevertheless, DNA sequences generated by sequencing reactions can contain sequencing errors. The errors exist as misidentified nucleotides, or as insertions or deletions of nucleotides in the generated DNA sequence. The erroneously inserted or deleted nucleotides cause frame shifts in the reading frames of the predicted amino acid sequence. In these cases, the predicted amino acid sequence diverges from the  
15 actual amino acid sequence, even though the generated DNA sequence may be greater than 99.9% identical to the actual DNA sequence (for example, one base insertion or deletion in an open reading frame of over 1000 bases).

Accordingly, for those applications requiring precision in the nucleotide sequence or the amino acid sequence, the present invention provides not only the  
20 generated nucleotide sequence identified as SEQ ID NO:X and the predicted translated amino acid sequence identified as SEQ ID NO:Y, but also a sample of plasmid DNA containing a human cDNA of the invention deposited with the ATCC, as set forth in Table 1. The nucleotide sequence of each deposited clone can readily be determined by sequencing the deposited clone in accordance with known methods.  
25 The predicted amino acid sequence can then be verified from such deposits. Moreover, the amino acid sequence of the protein encoded by a particular clone can also be directly determined by peptide sequencing or by expressing the protein in a suitable host cell containing the deposited human cDNA, collecting the protein, and determining its sequence.

30 The present invention also relates to the genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, or the deposited clone. The corresponding gene can be isolated in accordance with known methods using the sequence information disclosed

herein. Such methods include preparing probes or primers from the disclosed sequence and identifying or amplifying the corresponding gene from appropriate sources of genomic material.

Also provided in the present invention are allelic variants, orthologs, and/or  
5 species homologs. Procedures known in the art can be used to obtain full-length genes, allelic variants, splice variants, full-length coding portions, orthologs, and/or species homologs of genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, or a deposited clone, using information from the sequences disclosed herein or the clones deposited with the ATCC. For example, allelic variants and/or species homologs may  
10 be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source for allelic variants and/or the desired homologue.

Table 2 provides preferred epitopes contained in certain embodiments of the  
15 invention and polynucleotide sequences that may be disclaimed according to certain embodiments of the invention. The first column refers to each "Gene No." described above in Table 1. The second column provides the sequence identifier, "NT SEQ ID NO:X", for polynucleotide sequences disclosed in Table 1. The third column provides the sequence identifier, "AA SEQ ID NO:Y", for polypeptide sequences disclosed in  
20 Table 1. The fourth column provides a unique integer "ntA" where "ntA" is any integer between 1 and the final nucleotide minus 15 of SEQ ID NO:X, and the fifth column provides a unique integer "ntB" where "ntB" is any integer between 15 and the final nucleotide of SEQ ID NO:X, where both ntA and ntB correspond to the positions of nucleotide residues shown in SEQ ID NO:X, and where ntB is greater  
25 than or equal to a + 14. For each of the polynucleotides shown as SEQ ID NO:X, the uniquely defined integers can be substituted into the general formula of a-b, and used to describe polynucleotides which may be preferably excluded from the invention. Column 6 lists residues comprising predicted epitopes contained in the polypeptides encoded by each of the preferred ORFs (SEQ ID NO:Y). Identification of potential  
30 immunogenic regions was performed according to the method of Jameson and Wolf ((1988) CABIOS, 4; 181-186); specifically, the Genetics Computer Group (GCG) implementation of this algorithm, embodied in the program PEPTIDESTRUCTURE

(Wisconsin Package v10.0, Genetics Computer Group (GCG), Madison, Wisc.). This method returns a measure of the probability that a given residue is found on the surface of the protein. Regions where the antigenic index score is greater than 0.9 over at least 6 amino acids are indicated in Table 2 as "Preferred Epitopes".

- 5 Polypeptides of the invention may possess one, two, three, four, five or more antigenic epitopes comprising residues described in Table 2. It will be appreciated that depending on the analytical criteria used to predict antigenic determinants, the exact address of the determinant may vary slightly.

10 Table 3 summarizes the expression profile of polynucleotides corresponding to the clones disclosed in Table 1. The first column provides a unique clone identifier, "Clone ID", for a cDNA clone related to each contig sequence disclosed in Table 1. Column 2, "Library Codes" shows the expression profile of tissue and/or cell line libraries which express the polynucleotides of the invention. Each Library Code  
15 in column 2 represents a tissue/cell source identifier code corresponding to the Library Code and Library description provided in Table 5. Expression of these polynucleotides was not observed in the other tissues and/or cell libraries tested. One of skill in the art could routinely use this information to identify tissues which show a predominant expression pattern of the corresponding polynucleotide of the invention  
20 or to identify polynucleotides which show predominant and/or specific tissue expression.

Table 4, column 1, provides a nucleotide sequence identifier, "SEQ ID NO:X," that matches a nucleotide SEQ ID NO:X disclosed in Table 1, column 5. Table 4, column 2, provides the chromosomal location, "Cytologic Band or  
25 Chromosome," of polynucleotides corresponding to SEQ ID NO:X. Chromosomal location was determined by finding exact matches to EST and cDNA sequences contained in the NCBI (National Center for Biotechnology Information) UniGene database. Given a presumptive chromosomal location, disease locus association was determined by comparison with the Morbid Map, derived from Online Mendelian  
30 Inheritance in Man (Online Mendelian Inheritance in Man, OMIM™. McKusick-Nathans Institute for Genetic Medicine, Johns Hopkins University (Baltimore, MD) and National Center for Biotechnology Information, National Library of Medicine



(Bethesda, MD) 2000. World Wide Web URL: <http://www.ncbi.nlm.nih.gov/omim/>).

If the putative chromosomal location of the Query overlapped with the chromosomal location of a Morbid Map entry, the OMIM reference identification number of the morbid map entry is provided in Table 4, column 3, labelled "OMIM ID." A key to the OMIM reference identification numbers is provided in Table 6.

Table 5 provides a key to the Library Code disclosed in Table 3. Column 1 provides the Library Code disclosed in Table 3, column 2. Column 2 provides a description of the tissue or cell source from which the corresponding library was derived. Library codes corresponding to diseased Tissues are indicated in column 3 with the word "disease".

Table 6 provides a key to the OMIM reference identification numbers disclosed in Table 4, column 3. OMIM reference identification numbers (Column 1) were derived from Online Mendelian Inheritance in Man (Online Mendelian Inheritance in Man, OMIM. McKusick-Nathans Institute for Genetic Medicine, Johns Hopkins University (Baltimore, MD) and National Center for Biotechnology Information, National Library of Medicine, (Bethesda, MD) 2000. World Wide Web URL: <http://www.ncbi.nlm.nih.gov/omim/>). Column 2 provides diseases associated with the cytologic band disclosed in Table 4, column 2, as determined using the Morbid Map database.

Table 2

Gene #	NT SEQ ID NO: X	AA SEQ ID NO: Y	nt A	nt B	Preferred Epitopes
1	11	74	1 - 2392	15 - 2406	Lys-61 to Arg-72 Arg-95 to Tyr-100 Ala-121 to Ile-126 Asn-163 to Gly-172 Lys-183 to Asn-189 Ser-211 to His-218 Leu-251 to Val-269.
1	32	95	1 - 1661	15 - 1675	Ser-16 to Lys-23.
1	33	96	1 - 772	15 - 786	Lys-61 to Arg-72.
2	12	75	1 - 3355	15 - 3369	Glu-23 to Gln-30 Asn-42 to Gly-65 Thr-84 to Lys-100 Glu-105 to Ser-110 Arg-132 to Phe-138 Pro-159 to Arg-172.
2	34	97	1 - 1049	15 - 1063	
2	35	98	1 - 1164	15 - 1178	Cys-25 to Asn-36.
3	13	76	1 - 3244	15 - 3258	
3	36	99	1 - 776	15 - 790	
3	37	100	1 - 1189	15 - 1203	
3	38	101	1 - 790	15 - 804	
4	14	77	1 - 3063	15 - 3077	Gln-200 to Lys-208 Asn-273 to Glu-283 Trp-319 to Thr-325 Ala-340 to Pro-359 Gln-365 to Pro-370 Pro-395 to Ser-400 Asn-541 to Thr-546 Glu-563 to Ala-571 Pro-574 to Ala-583 Glu-590 to Asp-599 Arg-604 to Glu-612.
4	39	102	1 - 1588	15 - 1602	Gln-200 to Lys-208 Asn-273 to Glu-283 Trp-319 to Thr-325 Ala-340 to Pro-357.
4	40	103	1 - 1775	15 - 1789	
5	15	78	1 - 1068	15 - 1082	Leu-56 to Tyr-62 Glu-73 to Asn-81.
5	41	104	1 - 2088	15 - 2102	
6	16	79	1 - 2056	15 - 2070	Arg-45 to Ser-54 Ser-78 to Ser-83.
6	42	105	1 - 991	15 - 1005	Leu-36 to Gly-41 Lys-51 to Arg-56 Arg-58 to Gly-66.
6	43	106	1 - 2974	15 - 2988	Leu-36 to Gly-41 Lys-51 to Arg-56 Arg-58 to Gly-66.
6	44	107	1 - 2038	15 - 2052	Arg-45 to Ser-54 Ser-78 to Ser-83.
7	17	80	1 - 2041	15 - 2055	Pro-20 to Gln-28.

7	45	108	1 - 603	15 - 617	
7	46	109	1 - 544	15 - 558	
7	47	110	1 - 1440	15 - 1454	Ala-45 to Arg-50.
8	18	81	1 - 815	15 - 829	
8	48	111	1 - 821	15 - 835	Pro-59 to Arg-67.
8	49	112	1 - 502	15 - 516	
9	19	82	1 - 1042	15 - 1056	
9	50	113	1 - 520	15 - 534	
9	51	114	1 - 489	15 - 503	
10	20	83	1 - 3129	15 - 3143	
10	52	115	1 - 593	15 - 607	
11	21	84	1 - 418	15 - 432	
11	53	116	1 - 780	15 - 794	Leu-2 to Leu-10.
11	54	117	1 - 1005	15 - 1019	Phe-13 to Ser-19 Ser-96 to Pro-104.
12	22	85	1 - 6283	15 - 6297	
12	55	118	1 - 2028	15 - 2042	
13	23	86	1 - 5243	15 - 5257	Gln-30 to His-36.
13	56	119	1 - 570	15 - 584	Gln-30 to His-36.
13	57	120	1 - 670	15 - 684	
13	58	121	1 - 2056	15 - 2070	
13	59	122	1 - 413	15 - 427	Leu-24 to Arg-30 Lys-42 to Ala-50.
14	24	87	1 - 450	15 - 464	
14	60	123	1 - 327	15 - 341	
14	61	124	1 - 790	15 - 804	
14	62	125	1 - 1067	15 - 1081	Pro-34 to Gly-41.
15	25	88	1 - 1102	15 - 1116	Pro-10 to Arg-16.
15	63	126	1 - 2197	15 - 2211	
16	26	89	1 - 1549	15 - 1563	
17	27	90	1 - 1514	15 - 1528	
17	64	127	1 - 1222	15 - 1236	
17	65	128	1 - 783	15 - 797	
17	66	129	1 - 520	15 - 534	Arg-21 to Arg-34.
18	28	91	1 - 221	15 - 235	Glu-34 to Lys-40.
18	67	130	1 - 1082	15 - 1096	
18	68	131	1 - 1274	15 - 1288	
18	69	132	1 - 3305	15 - 3319	Ser-108 to Gly-131 Ala-138 to Tyr-145 Lys-160 to Gly-165 Ile-193 to Cys-200 Pro-209 to Arg-215 Thr-220 to Leu-229 Ile-233 to Ile-253 Leu-257 to Lys-263 Pro-273 to Pro-285 Gly-345 to Phe-352.
19	29	92	1 - 555	15 - 569	
19	70	133	1 - 358	15 - 372	
20	30	93	1 - 2753	15 - 2767	
20	71	134	1 - 323	15 - 337	
20	72	135	1 - 1401	15 - 1415	
21	31	94	1 - 1037	15 - 1051	

**Table 3**

Clone ID	Library Codes
HDPPA04	H0004 H0494 H0521 H0522 H0591 H0641 L1290 S0452 T0049
HOHBY44	H0013 H0014 H0031 H0171 H0327 H0489 H0544 H0545 H0551 H0597 H0622 H0628 H0661 H0665 H0667 H0668 L1290 S0002 S0003 S0026 S0053 S0126 S0192 S0212 S0222 S0250 S0276 S0336 S0350 S0360 S0376 S0380 S0420 S0426 T0039 T0040
HOHBL42	H0031 H0036 H0251 H0264 H0306 H0309 H0361 H0402 H0427 H0445 H0486 H0506 H0518 H0521 H0581 H0586 H0587 H0591 H0592 H0644 H0656 H0657 H0677 H0690 L1290 S0116 S0152 S0250 S0358 S0374 S0408
HRABV43	H0012 H0014 H0026 H0032 H0036 H0038 H0050 H0052 H0057 H0059 H0085 H0135 H0150 H0156 H0178 H0213 H0224 H0231 H0251 H0255 H0261 H0264 H0318 H0331 H0341 H0343 H0370 H0424 H0486 H0492 H0494 H0518 H0519 H0521 H0549 H0550 H0551 H0553 H0555 H0587 H0592 H0594 H0599 H0604 H0607 H0619 H0620 H0622 H0624 H0650 H0656 H0658 H0662 H0672 H0673 H0677 H0687 L1290 S0002 S0007 S0011 S0027 S0037 S0049 S0150 S0196 S0212 S0222 S0268 S0276 S0278 S0358 S0374 S0378 S0390 S0426 S3014 T0042
HDPRH52	H0252 H0328 H0433 H0521 H0645 L1290 S0037 S0152 S0208 S0342
HDTEK44	H0485 H0486 H0586 H0592 H0683 H0687 L1290
HOHBP82	S0250
HWBAD01	H0551 H0580
HWABE12	H0327 H0412 H0435 H0445 H0488 H0510 H0521 H0539 H0581 H0638 H0657 L1290 S0007 S0010 S0046 S0116 S0144 S0330 S0358 S0376 S0424 S6014 T0002
HHEPJ23	H0009 H0012 H0014 H0024 H0040 H0041 H0052 H0083 H0087 H0100 H0123 H0125 H0131 H0135 H0136 H0156 H0215 H0252 H0256 H0257 H0261 H0264 H0265 H0266 H0284 H0290 H0295 H0316 H0318 H0328 H0402 H0412 H0415 H0424 H0445 H0484 H0486 H0494 H0520 H0529 H0530 H0542 H0543 H0545 H0547 H0550 H0553 H0555 H0556 H0559 H0560 H0580 H0581 H0586 H0592 H0593 H0618 H0620 H0650 H0652 H0656 H0660 H0665 H0686 H0689 H0698 H0706 L1290 S0049 S0051 S0110 S0144 S0150 S0182 S0210 S0222 S0278 S0358 S0360 S0376 S0420
HWBAR14	H0012 H0265 H0560 H0561 H0580 H0593 H0665 H0687 H0693 H0694 L1290 S0053 S6028 T0006
HDPPN86	H0013 H0056 H0090 H0341 H0423 H0494 H0521 H0522 H0542 H0543 H0546 H0547 H0553 H0575 H0580 L1290 S0038 S0418 S6028 T0002 T0010
HDPIW06	H0008 H0013 H0032 H0039 H0051 H0052 H0165 H0169 H0274 H0373 H0427 H0431 H0445 H0509 H0520 H0521 H0547 H0553 H0575 H0587 H0590 H0624 H0631 H0638 H0647 H0649 H0652 H0658 H0688 H0696 L0022 L1290 S0007 S0015 S0026 S0028 S0031 S0036 S0038 S0040 S0212 S0222 S0242 S0276 S0328 S0354 S0364 S0412 S0438 S0448 S6024 S6028 T0060
HWBCH13	H0486 H0521 S0002
HOHCJ90	H0163 H0251 H0252 H0286 H0292 H0333 H0505 H0521 H0529 H0550 H0551 H0555 H0619 H0620 H0622 H0633 H0658 L0022 S0026 S0027 S0032 S0037 S0040 S0044 S0126 S0206 S0250 S0260 S0282 S0354 S0360 S3012 S3014
HWBCM79	H0264 H0580
HWBDM62	H0156 H0341 H0560 H0580 L0022
HWBCV72	H0038 H0069 H0083 H0123 H0124 H0125 H0253 H0266 H0284 H0295

	H0318 H0402 H0423 H0436 H0445 H0457 H0519 H0521 H0539 H0543 H0546 H0549 H0550 H0551 H0556 H0559 H0580 H0581 H0595 H0599 H0616 H0618 H0623 H0658 H0662 H0687 L0022 S0002 S0007 S0037 S0038 S0040 S0046 S0051 S0150 S0194 S0206 S0276 S0282 S0356 S0358 T0040 T0041
HMTAL77	H0030 H0036 H0050 H0090 H0123 H0124 H0150 H0171 H0333 H0341 H0343 H0351 H0352 H0370 H0412 H0427 H0435 H0436 H0486 H0487 H0518 H0520 H0521 H0522 H0539 H0543 H0547 H0556 H0581 H0591 H0594 H0597 H0599 H0618 H0620 H0628 H0633 H0637 H0641 H0644 H0658 H0659 H0670 L0022 S0007 S0027 S0045 S0051 S0116 S0134 S0150 S0212 S0222 S0330 S0360 S0366 S0418 S0420 S0428 S3014 T0010 T0042 T0109
HHEPG23	H0009 H0013 H0056 H0090 H0341 H0423 H0494 H0521 H0522 H0542 H0543 H0546 H0547 H0553 H0555 H0575 H0580 L0022 S0038 S0116 S0418 S6028 T0002 T0010
HWBAR88	H0144 H0272 H0412 H0580 H0650 S0011 S0428

Table 4

SEQ ID NO: X	Cytologic Band or Chromosome:	OMIM Reference(s):						
14	11q13	102200	106100	131100	133780	147050	153700	
		161015	164009	168461	180721	180840	191181	
		193235	209901	232600	259700	259770	600045	
		600319	600528	601884				

Table 5

Library Code	Library Description	Disease
H0004	Human Adult Spleen	
H0008	Whole 6 Week Old Embryo	
H0009	Human Fetal Brain	
H0012	Human Fetal Kidney	
H0013	Human 8 Week Whole Embryo	
H0014	Human Gall Bladder	
H0024	Human Fetal Lung III	
H0026	Namalwa Cells	
H0030	Human Placenta	
H0031	Human Placenta	
H0032	Human Prostate	
H0036	Human Adult Small Intestine	
H0038	Human Testes	
H0039	Human Pancreas Tumor	disease
H0040	Human Testes Tumor	disease
H0041	Human Fetal Bone	
H0050	Human Fetal Heart	
H0051	Human Hippocampus	
H0052	Human Cerebellum	
H0056	Human Umbilical Vein, Endo. remake	
H0057	Human Fetal Spleen	
H0059	Human Uterine Cancer	disease
H0069	Human Activated T-Cells	
H0083	HUMAN JURKAT MEMBRANE BOUND POLYSOMES	
H0085	Human Colon	
H0087	Human Thymus	
H0090	Human T-Cell Lymphoma	disease
H0100	Human Whole Six Week Old Embryo	
H0123	Human Fetal Dura Mater	
H0124	Human Rhabdomyosarcoma	disease
H0125	Cem cells cyclohexamide treated	
H0131	LNCAP + 0.3nM R1881	
H0135	Human Synovial Sarcoma	
H0136	Supt Cells, cyclohexamide treated	
H0144	Nine Week Old Early Stage Human	
H0150	Human Epididymus	
H0156	Human Adrenal Gland Tumor	disease
H0163	Human Synovium	
H0165	Human Prostate Cancer, Stage B2	disease
H0169	Human Prostate Cancer, Stage C fraction	disease
H0171	12 Week Old Early Stage Human, II	
H0178	Human Fetal Brain	
H0213	Human Pituitary, subtracted	
H0215	Raji cells, cyclohexamide treated, differentially expressed	
H0224	Activated T-Cells, 12 hrs, subtracted	
H0231	Human Colon, subtraction	
H0251	Human Chondrosarcoma	disease
H0252	Human Osteosarcoma	disease
H0253	Human adult testis, large inserts	
H0255	breast lymph node CDNA library	

H0256	HL-60, unstimulated	
H0257	HL-60, PMA 4H	
H0261	H. cerebellum, Enzyme subtracted	
H0264	human tonsils	
H0265	Activated T-Cell (12hs)/Thiouridine labelledEco	
H0266	Human Microvascular Endothelial Cells, fract. A	
H0272	HUMAN TONSILS, FRACTION 2	
H0274	Human Adult Spleen, fractionII	
H0284	Human OB MG63 control fraction I	
H0286	Human OB MG63 treated (10 nM E2) fraction I	
H0290	Human OB HOS treated (1 nM E2) fraction I	
H0292	Human OB HOS treated (10 nM E2) fraction I	
H0295	Amniotic Cells - Primary Culture	
H0306	CD34 depleted Buffy Coat (Cord Blood)	
H0309	Human Chronic Synovitis	disease
H0316	HUMAN STOMACH	
H0318	HUMAN B CELL LYMPHOMA	disease
H0327	human corpus colosum	
H0328	human ovarian cancer	disease
H0331	Hepatocellular Tumor	disease
H0333	Hemangiopericytoma	disease
H0341	Bone Marrow Cell Line (RS4,11)	
H0343	stomach cancer (human)	disease
H0351	Glioblastoma	disease
H0352	wilm's tumor	disease
H0361	Human rejected kidney	disease
H0370	H. Lymph node breast Cancer	disease
H0373	Human Heart	
H0402	CD34 depleted Buffy Coat (Cord Blood), re-excision	
H0412	Human umbilical vein endothelial cells, IL-4 induced	
H0415	H. Ovarian Tumor, II, OV5232	disease
H0423	T-Cell PHA 24 hrs	
H0424	Human Pituitary, subt IX	
H0427	Human Adipose	
H0431	H. Kidney Medulla, re-excision	
H0433	Human Umbilical Vein Endothelial cells, frac B, re-excision	
H0435	Ovarian Tumor 10-3-95	
H0436	Resting T-Cell Library,II	
H0445	Spleen, Chronic lymphocytic leukemia	disease
H0457	Human Eosinophils	
H0484	Breast Cancer Cell line, angiogenic	
H0485	Hodgkin's Lymphoma I	disease
H0486	Hodgkin's Lymphoma II	disease
H0487	Human Tonsils, lib I	
H0488	Human Tonsils, Lib 2	
H0489	Crohn's Disease	disease
H0492	HL-60, RA 4h, Subtracted	
H0494	Keratinocyte	
H0505	Human Astrocyte	
H0506	Ulcerative Colitis	
H0509	Liver, Hepatoma	disease
H0510	Human Liver, normal	
H0518	pBMC stimulated w/ poly I/C	



H0519	NTERA2, control	
H0520	NTERA2 + retinoic acid, 14 days	
H0521	Primary Dendritic Cells, lib 1	
H0522	Primary Dendritic cells,frac 2	
H0529	Myeloid Progenitor Cell Line	
H0530	Human Dermal Endothelial Cells,untreated	
H0539	Pancreas Islet Cell Tumor	disease
H0542	T Cell helper I	
H0543	T cell helper II	
H0544	Human endometrial stromal cells	
H0545	Human endometrial stromal cells-treated with progesterone	
H0546	Human endometrial stromal cells-treated with estradiol	
H0547	NTERA2 teratocarcinoma cell line+retinoic acid (14 days)	
H0549	H. Epididymus, caput & corpus	
H0550	H. Epididymus, cauda	
H0551	Human Thymus Stromal Cells	
H0553	Human Placenta	
H0555	Rejected Kidney, lib 4	disease
H0556	Activated T-cell(12h)/Thiouridine-re-excision	
H0559	HL-60, PMA 4H, re-excision	
H0560	KMH2	
H0561	L428	
H0575	Human Adult Pulmonary,rc-excision	
H0580	Dendritic cells, pooled	
H0581	Human Bone Marrow, treated	
H0586	Healing groin wound, 6.5 hours post incision	disease
H0587	Healing groin wound, 7.5 hours post incision	disease
H0590	Human adult small intestine,rc-excision	
H0591	Human T-cell lymphoma,rc-excision	disease
H0592	Healing groin wound - zero hr post-incision (control)	disease
H0593	Olfactory epithelium,nasalcavity	
H0594	Human Lung Cancer,rc-excision	disease
H0595	Stomach cancer (human),rc-excision	disease
H0597	Human Colon, re-excision	
H0599	Human Adult Heart,rc-excision	
H0604	Human Pituitary, re-excision	
H0607	H.Leukocytes, normalized cot 50A3	
H0616	Human Testes, Reexcision	
H0618	Human Adult Testes, Large Inserts, Reexcision	
H0619	Fetal Heart	
H0620	Human Fetal Kidney, Reexcision	
H0622	Human Pancreas Tumor, Reexcision	disease
H0623	Human Umbilical Vein, Reexcision	
H0624	12 Week Early Stage Human II, Reexcision	
H0628	Human Pre-Differentiated Adipocytes	
H0631	Saos2, Dexamethosome Treated	
H0633	Lung Carcinoma A549 TNFalpha activated	disease
H0637	Dendritic Cells From CD34 Cells	
H0638	CD40 activated monocyte dendritic cells	
H0641	LPS activated derived dendritic cells	
H0644	Human Placenta (re-excision)	
H0645	Fetal Heart, re-excision	
H0647	Lung, Cancer (4005163 B7): Invasive, Poorly Diff. Adenocarcinoma, Metastatic	disease

H0649	Lung, Normal: (4005313 B1)	
H0650	B-Cells	
H0652	Lung, Normal: (4005313 B1)	
H0656	B-cells (unstimulated)	
H0657	B-cells (stimulated)	
H0658	Ovary, Cancer (9809C332): Poorly differentiated adenocarcinoma	disease
H0659	Ovary, Cancer (15395A1F): Grade II Papillary Carcinoma	disease
H0660	Ovary, Cancer: (15799A1F) Poorly differentiated carcinoma	disease
H0661	Breast, Cancer: (4004943 A5)	disease
H0662	Breast, Normal: (4005522B2)	
H0665	Stromal cells 3.88	
H0667	Stromal cells(HBM3.18)	
H0668	stromal cell clone 2.5	
H0670	Ovary, Cancer(4004650 A3): Well-Differentiated Micropapillary Serous Carcinoma	
H0672	Ovary, Cancer: (4004576 A8)	
H0673	Human Prostate Cancer, Stage B2, re-excision	
H0677	TNFR degenerate oligo	
H0683	Ovarian cancer, Serous Papillary Adenocarcinoma	
H0686	Adenocarcinoma of Ovary, Human Cell Line	
H0687	Human normal ovary(#9610G215)	
H0688	Human Ovarian Cancer(#9807G017)	
H0689	Ovarian Cancer	
H0690	Ovarian Cancer, # 9702G001	
H0693	Normal Prostate #ODQ3958EN	
H0694	Prostate cancer (adenocarcinoma)	
H0696	Prostate Adenocarcinoma	
H0698	NK CellsYao20 IL2 treated for 48 hrs	
H0706	Human Adult Skeletal Muscle	
L0022	Stratagene schizo brain S11	
L1290	Human heart cDNA (YNakamura)	
S0002	Monocyte activated	
S0003	Human Osteoclastoma	disease
S0007	Early Stage Human Brain	
S0010	Human Amygdala	
S0011	STROMAL -OSTEOCLASTOMA	disease
S0015	Kidney medulla	
S0026	Stromal cell TF274	
S0027	Smooth muscle, serum treated	
S0028	Smooth muscle,control	
S0031	Spinal cord	
S0032	Smooth muscle-ILb induced	
S0036	Human Substantia Nigra	
S0037	Smooth muscle, IL1b induced	
S0038	Human Whole Brain #2 - Oligo dT > 1.5Kb	
S0040	Adipocytes	
S0044	Prostate BPH	disease
S0045	Endothelial cells-control	
S0046	Endothelial-induced	
S0049	Human Brain, Striatum	
S0051	Human Hypothalamus,Schizophrenia	disease
S0053	Neutrophils IL-1 and LPS induced	
S0110	Brain Amygdala Depression	disease

S0116	Bone marrow	
S0126	Osteoblasts	
S0134	Apoptotic T-cell	
S0144	Macrophage (GM-CSF treated)	
S0150	LNCAP prostate cell line	
S0152	PC3 Prostate cell line	
S0182	Human B Cell 8866	
S0192	Synovial Fibroblasts (control)	
S0194	Synovial hypoxia	
S0196	Synovial IL-1/TNF stimulated	
S0206	Smooth Muscle- HASTE normalized	
S0208	Mesangial cell, frac 1	
S0210	Mesangial cell, frac 2	
S0212	Bone Marrow Stromal Cell, untreated	
S0222	H. Frontal cortex,epileptic,re-excision	disease
S0242	Synovial Fibroblasts (IL1/TNF), subt	
S0250	Human Osteoblasts II	disease
S0260	Spinal Cord, re-excision	
S0268	PRMIX	
S0276	Synovial hypoxia-RSF subtracted	
S0278	H Macrophage (GM-CSF treated), re-excision	
S0282	Brain Frontal Cortex, re-excision	
S0328	Palate carcinoma	disease
S0330	Palate normal	
S0336	Human Normal Cartilage Fraction IV	
S0342	Adipocytes,re-excision	
S0350	Pharynx Carcinoma	disease
S0354	Colon Normal II	
S0356	Colon Carcinoma	disease
S0358	Colon Normal III	
S0360	Colon Tumor II	disease
S0364	Human Quadriceps	
S0366	Human Soleus	
S0374	Normal colon	
S0376	Colon Tumor	disease
S0378	Pancreas normal PCA4 No	
S0380	Pancreas Tumor PCA4 Tu	disease
S0390	Smooth muscle, control, re-excision	
S0408	Colon, normal	
S0412	Temporal cortex-Alzheimer, subtracted	disease
S0418	CHME Cell Line,treated 5 hrs	
S0420	CHME Cell Line,untreated	
S0424	TF-1 Cell Line GM-CSF Treated	
S0426	Monocyte activated, re-excision	
S0428	Neutrophils control, re-excision	
S0438	Liver Normal Met5No	
S0448	Larynx Normal	
S0452	Thymus	
S3012	Smooth Muscle Serum Treated, Norm	
S3014	Smooth muscle, serum induced,re-exc	
S6014	H. hypothalamus, frac A	
S6024	Alzheimers, spongy change	disease
S6028	Human Manic Depression Tissue	disease

T0002	Activated T-cells	
T0006	Human Pineal Gland	
T0010	Human Infant Brain	
T0039	HSA 172 Cells	
T0040	HSC172 cells	
T0041	Jurkat T-cell G1 phase	
T0042	Jurkat T-Cell, S phase	
T0049	Aorta endothelial cells + TNF-a	
T0060	Human White Adipose	
T0109	Human (HCC) cell line liver (mouse) metastasis, remake	

Table 6

OMIM ID	OMIM Description
102200	Somatotrophinoma (2)
106100	Angioedema, hereditary (3)
131100	Carcinoid tumor of lung (3) Multiple endocrine neoplasia I (3) Prolactinoma, hyperparathyroidism, carcinoid syndrome (2)
133780	Vitreoretinopathy, exudative, familial (2)
147050	Atopy (2)
153700	Macular dystrophy, vitelliform type (3)
161015	Mitochondrial complex I deficiency, 252010 (1) (?)
164009	Leukemia, acute promyelocytic, NUPA/RARA type (3)
168461	Centrocytic lymphoma (2) Multiple myeloma, 254250 (2) Parathyroid adenomatosis 1 (2)
180721	Retinitis pigmentosa, digenic (3)
180840	Susceptibility to IDDM (1) (?)
191181	Cervical carcinoma (2)
193235	Vitreoretinopathy, neovascular inflammatory (2)
209901	Bardet-Biedl syndrome 1 (2)
232600	McArdle disease (3)
259700	Osteopetrosis, recessive (2)
259770	Osteoporosis-pseudoglioma syndrome (2)
600045	Xeroderma pigmentosum, group E, subtype 2 (1)
600319	Diabetes mellitus, insulin-dependent, 4 (2)
600528	CPT deficiency, hepatic, type I, 255120 (1)
601884	[High bone mass] (2)

The polypeptides of the invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides  
5 are well understood in the art.

The polypeptides may be in the form of the secreted protein, including the mature form, or may be a part of a larger protein, such as a fusion protein (see below). It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification ,  
10 such as multiple histidine residues, or an additional sequence for stability during recombinant production.

The polypeptides of the present invention are preferably provided in an isolated form, and preferably are substantially purified. A recombinantly produced version of a polypeptide, including the secreted polypeptide, can be substantially  
15 purified using techniques described herein or otherwise known in the art, such as, for example, by the one-step method described in Smith and Johnson, Gene 67:31-40 (1988). Polypeptides of the invention also can be purified from natural, synthetic or recombinant sources using techniques described herein or otherwise known in the art, such as, for example, antibodies of the invention raised against the secreted protein.

20 The present invention provides a polynucleotide comprising, or alternatively consisting of, the nucleic acid sequence of SEQ ID NO:X, and/or a cDNA contained in ATCC deposit Z. The present invention also provides a polypeptide comprising, or alternatively, consisting of, the polypeptide sequence of SEQ ID NO:Y and/or a polypeptide encoded by the cDNA contained in ATCC deposit Z. Polynucleotides  
25 encoding a polypeptide comprising, or alternatively consisting of the polypeptide sequence of SEQ ID NO:Y and/or a polypeptide sequence encoded by the cDNA contained in ATCC deposit Z are also encompassed by the invention.

#### **Signal Sequences**

The present invention also encompasses mature forms of the polypeptide  
30 having the polypeptide sequence of SEQ ID NO:Y and/or the polypeptide sequence encoded by the cDNA in a deposited clone. Polynucleotides encoding the mature forms (such as, for example, the polynucleotide sequence in SEQ ID NO:X and/or the

polynucleotide sequence contained in the cDNA of a deposited clone) are also encompassed by the invention. According to the signal hypothesis, proteins secreted by mammalian cells have a signal or secretary leader sequence which is cleaved from the mature protein once export of the growing protein chain across the rough  
5 endoplasmic reticulum has been initiated. Most mammalian cells and even insect cells cleave secreted proteins with the same specificity. However, in some cases, cleavage of a secreted protein is not entirely uniform, which results in two or more mature species of the protein. Further, it has long been known that cleavage specificity of a secreted protein is ultimately determined by the primary structure of  
10 the complete protein, that is, it is inherent in the amino acid sequence of the polypeptide.

Methods for predicting whether a protein has a signal sequence, as well as the cleavage point for that sequence, are available. For instance, the method of McGeoch, *Virus Res.* 3:271-286 (1985), uses the information from a short N-terminal  
15 charged region and a subsequent uncharged region of the complete (uncleaved) protein. The method of von Heinje, *Nucleic Acids Res.* 14:4683-4690 (1986) uses the information from the residues surrounding the cleavage site, typically residues -13 to +2, where +1 indicates the amino terminus of the secreted protein. The accuracy of predicting the cleavage points of known mammalian secretory proteins for each of  
20 these methods is in the range of 75-80%. (von Heinje, *supra*.) However, the two methods do not always produce the same predicted cleavage point(s) for a given protein.

In the present case, the deduced amino acid sequence of the secreted polypeptide was analyzed by a computer program called SignalP (Henrik Nielsen et  
25 al., *Protein Engineering* 10:1-6 (1997)), which predicts the cellular location of a protein based on the amino acid sequence. As part of this computational prediction of localization, the methods of McGeoch and von Heinje are incorporated. The analysis of the amino acid sequences of the secreted proteins described herein by this program provided the results shown in Table 1.

30 As one of ordinary skill would appreciate, however, cleavage sites sometimes vary from organism to organism and cannot be predicted with absolute certainty. Accordingly, the present invention provides secreted polypeptides having a sequence

shown in SEQ ID NO:Y which have an N-terminus beginning within 5 residues (i.e., + or - 5 residues) of the predicted cleavage point. Similarly, it is also recognized that in some cases, cleavage of the signal sequence from a secreted protein is not entirely uniform, resulting in more than one secreted species. These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

Moreover, the signal sequence identified by the above analysis may not necessarily predict the naturally occurring signal sequence. For example, the naturally occurring signal sequence may be further upstream from the predicted signal sequence. However, it is likely that the predicted signal sequence will be capable of directing the secreted protein to the ER. Nonetheless, the present invention provides the mature protein produced by expression of the polynucleotide sequence of SEQ ID NO:X and/or the polynucleotide sequence contained in the cDNA of a deposited clone, in a mammalian cell (e.g., COS cells, as described below). These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

### **Polynucleotide and Polypeptide Variants**

The present invention is directed to variants of the polynucleotide sequence disclosed in SEQ ID NO:X, the complementary strand thereto, and/or the cDNA sequence contained in a deposited clone.

The present invention also encompasses variants of the polypeptide sequence disclosed in SEQ ID NO:Y and/or encoded by a deposited clone.

"Variant" refers to a polynucleotide or polypeptide differing from the polynucleotide or polypeptide of the present invention, but retaining essential properties thereof. Generally, variants are overall closely similar, and, in many regions, identical to the polynucleotide or polypeptide of the present invention.

The present invention is also directed to nucleic acid molecules which comprise, or alternatively consist of, a nucleotide sequence which is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to, for example, the nucleotide coding sequence in SEQ ID NO:X or the complementary strand thereto, the nucleotide coding sequence contained in a deposited cDNA clone or the



complementary strand thereto, a nucleotide sequence encoding the polypeptide of SEQ ID NO:Y, a nucleotide sequence encoding the polypeptide encoded by the cDNA contained in a deposited clone, and/or polynucleotide fragments of any of these nucleic acid molecules (e.g., those fragments described herein).

- 5 Polynucleotides which hybridize to these nucleic acid molecules under stringent hybridization conditions or lower stringency conditions are also encompassed by the invention, as are polypeptides encoded by these polynucleotides.

The present invention is also directed to polypeptides which comprise, or alternatively consist of, an amino acid sequence which is at least 80%, 85%, 90%,  
10 95%, 96%, 97%, 98%, 99% identical to, for example, the polypeptide sequence shown in SEQ ID NO:Y, the polypeptide sequence encoded by the cDNA contained in a deposited clone, and/or polypeptide fragments of any of these polypeptides (e.g., those fragments described herein).

By a nucleic acid having a nucleotide sequence at least, for example, 95%  
15 "identical" to a reference nucleotide sequence of the present invention, it is intended that the nucleotide sequence of the nucleic acid is identical to the reference sequence except that the nucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence encoding the polypeptide. In other words, to obtain a nucleic acid having a nucleotide sequence at least 95%  
20 identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. The query sequence may be an entire sequence shown in Table 1, the ORF (open reading frame), or any fragment specified  
25 as described herein.

As a practical matter, whether any particular nucleic acid molecule or polypeptide is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to a nucleotide sequence of the present invention can be determined conventionally using known computer programs. A preferred method for determining the best  
30 overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp.

App. Biosci. 6:237-245(1990)). In a sequence alignment the query and subject sequences are both DNA sequences. An RNA sequence can be compared by converting U's to T's. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB alignment of DNA sequences to  
5 calculate percent identity are: Matrix=Unitary, k-tuple=4, Mismatch Penalty=1, Joining Penalty=30, Randomization Group Length=0, Cutoff Score=1, Gap Penalty=5, Gap Size Penalty 0.05, Window Size=500 or the length of the subject nucleotide sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence because of 5' or 3' deletions, not because of internal deletions, a manual correction must be made to the  
10 results. This is because the FASTDB program does not account for 5' and 3' truncations of the subject sequence when calculating percent identity. For subject sequences truncated at the 5' or 3' ends, relative to the query sequence, the percent identity is corrected by calculating the number of bases of the query sequence that are  
15 5' and 3' of the subject sequence, which are not matched/aligned, as a percent of the total bases of the query sequence. Whether a nucleotide is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This corrected  
20 score is what is used for the purposes of the present invention. Only bases outside the 5' and 3' bases of the subject sequence, as displayed by the FASTDB alignment, which are not matched/aligned with the query sequence, are calculated for the purposes of manually adjusting the percent identity score.

For example, a 90 base subject sequence is aligned to a 100 base query  
25 sequence to determine percent identity. The deletions occur at the 5' end of the subject sequence and therefore, the FASTDB alignment does not show a matched/alignment of the first 10 bases at 5' end. The 10 unpaired bases represent 10% of the sequence (number of bases at the 5' and 3' ends not matched/total number of bases in the query sequence) so 10% is subtracted from the percent identity score  
30 calculated by the FASTDB program. If the remaining 90 bases were perfectly matched the final percent identity would be 90%. In another example, a 90 base subject sequence is compared with a 100 base query sequence. This time the

deletions are internal deletions so that there are no bases on the 5' or 3' of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only bases 5' and 3' of the subject sequence which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are to be made for the purposes of the present invention.

By a polypeptide having an amino acid sequence at least, for example, 95% "identical" to a query amino acid sequence of the present invention, it is intended that the amino acid sequence of the subject polypeptide is identical to the query sequence except that the subject polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the query amino acid sequence. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a query amino acid sequence, up to 5% of the amino acid residues in the subject sequence may be inserted, deleted, (indels) or substituted with another amino acid. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

As a practical matter, whether any particular polypeptide is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to, for instance, an amino acid sequences shown in Table 1 (SEQ ID NO:Y) or to the amino acid sequence encoded by cDNA contained in a deposited clone can be determined conventionally using known computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. 6:237-245(1990)). In a sequence alignment the query and subject sequences are either both nucleotide sequences or both amino acid sequences. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB amino acid alignment are: Matrix=PAM 0, k-tuple=2, Mismatch Penalty=1, Joining Penalty=20, Randomization Group Length=0, Cutoff Score=1, Window Size=sequence length, Gap Penalty=5, Gap Size Penalty=0.05, Window

Size=500 or the length of the subject amino acid sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence due to N- or C-terminal deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for N- and C-terminal truncations of the subject sequence when calculating global percent identity. For subject sequences truncated at the N- and C-termini, relative to the query sequence, the percent identity is corrected by calculating the number of residues of the query sequence that are N- and C-terminal of the subject sequence, which are not matched/aligned with a corresponding subject residue, as a percent of the total bases of the query sequence. Whether a residue is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This final percent identity score is what is used for the purposes of the present invention. Only residues to the N- and C-termini of the subject sequence, which are not matched/aligned with the query sequence, are considered for the purposes of manually adjusting the percent identity score. That is, only query residue positions outside the farthest N- and C-terminal residues of the subject sequence.

For example, a 90 amino acid residue subject sequence is aligned with a 100 residue query sequence to determine percent identity. The deletion occurs at the N-terminus of the subject sequence and therefore, the FASTDB alignment does not show a matching/alignment of the first 10 residues at the N-terminus. The 10 unpaired residues represent 10% of the sequence (number of residues at the N- and C-termini not matched/total number of residues in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 residues were perfectly matched the final percent identity would be 90%. In another example, a 90 residue subject sequence is compared with a 100 residue query sequence. This time the deletions are internal deletions so there are no residues at the N- or C-termini of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only residue positions outside the N- and C-terminal ends of the subject sequence, as displayed in the FASTDB alignment, which are not

matched/aligned with the query sequence are manually corrected for. No other manual corrections are to be made for the purposes of the present invention.

The variants may contain alterations in the coding regions, non-coding regions, or both. Especially preferred are polynucleotide variants containing  
5 alterations which produce silent substitutions, additions, or deletions, but do not alter the properties or activities of the encoded polypeptide. Nucleotide variants produced by silent substitutions due to the degeneracy of the genetic code are preferred. Moreover, variants in which 5-10, 1-5, or 1-2 amino acids are substituted, deleted, or added in any combination are also preferred. Polynucleotide variants can be produced  
10 for a variety of reasons, e.g., to optimize codon expression for a particular host (change codons in the human mRNA to those preferred by a bacterial host such as *E. coli*).

Naturally occurring variants are called "allelic variants," and refer to one of several alternate forms of a gene occupying a given locus on a chromosome of an  
15 organism. (Genes II, Lewin, B., ed., John Wiley & Sons, New York (1985).) These allelic variants can vary at either the polynucleotide and/or polypeptide level and are included in the present invention. Alternatively, non-naturally occurring variants may be produced by mutagenesis techniques or by direct synthesis.

Using known methods of protein engineering and recombinant DNA  
20 technology, variants may be generated to improve or alter the characteristics of the polypeptides of the present invention. For instance, one or more amino acids can be deleted from the N-terminus or C-terminus of the secreted protein without substantial loss of biological function. The authors of Ron et al., *J. Biol. Chem.* 268: 2984-2988 (1993), reported variant KGF proteins having heparin binding activity even after  
25 deleting 3, 8, or 27 amino-terminal amino acid residues. Similarly, Interferon gamma exhibited up to ten times higher activity after deleting 8-10 amino acid residues from the carboxy terminus of this protein. (Dobeli et al., *J. Biotechnology* 7:199-216 (1988).)

Moreover, ample evidence demonstrates that variants often retain a biological  
30 activity similar to that of the naturally occurring protein. For example, Gayle and coworkers (*J. Biol. Chem.* 268:22105-22111 (1993)) conducted extensive mutational analysis of human cytokine IL-1a. They used random mutagenesis to generate over

3,500 individual IL-1a mutants that averaged 2.5 amino acid changes per variant over the entire length of the molecule. Multiple mutations were examined at every possible amino acid position. The investigators found that "[m]ost of the molecule could be altered with little effect on either [binding or biological activity]." (See, 5 Abstract.) In fact, only 23 unique amino acid sequences, out of more than 3,500 nucleotide sequences examined, produced a protein that significantly differed in activity from wild-type.

Furthermore, even if deleting one or more amino acids from the N-terminus or C-terminus of a polypeptide results in modification or loss of one or more biological 10 functions, other biological activities may still be retained. For example, the ability of a deletion variant to induce and/or to bind antibodies which recognize the secreted form will likely be retained when less than the majority of the residues of the secreted form are removed from the N-terminus or C-terminus. Whether a particular polypeptide lacking N- or C-terminal residues of a protein retains such immunogenic 15 activities can readily be determined by routine methods described herein and otherwise known in the art.

Thus, the invention further includes polypeptide variants which show substantial biological activity. Such variants include deletions, insertions, inversions, repeats, and substitutions selected according to general rules known in the 20 art so as to have little effect on activity. For example, guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie et al., Science 247:1306-1310 (1990), wherein the authors indicate that there are two main strategies for studying the tolerance of an amino acid sequence to change.

The first strategy exploits the tolerance of amino acid substitutions by natural 25 selection during the process of evolution. By comparing amino acid sequences in different species, conserved amino acids can be identified. These conserved amino acids are likely important for protein function. In contrast, the amino acid positions where substitutions have been tolerated by natural selection indicates that these positions are not critical for protein function. Thus, positions tolerating amino acid 30 substitution could be modified while still maintaining biological activity of the protein.

The second strategy uses genetic engineering to introduce amino acid changes at specific positions of a cloned gene to identify regions critical for protein function. For example, site directed mutagenesis or alanine-scanning mutagenesis (introduction of single alanine mutations at every residue in the molecule) can be used.

- 5 (Cunningham and Wells, Science 244:1081-1085 (1989).) The resulting mutant molecules can then be tested for biological activity.

As the authors state, these two strategies have revealed that proteins are surprisingly tolerant of amino acid substitutions. The authors further indicate which amino acid changes are likely to be permissive at certain amino acid positions in the protein. For example, most buried (within the tertiary structure of the protein) amino acid residues require nonpolar side chains, whereas few features of surface side chains are generally conserved. Moreover, tolerated conservative amino acid substitutions involve replacement of the aliphatic or hydrophobic amino acids Ala, Val, Leu and Ile; replacement of the hydroxyl residues Ser and Thr; replacement of the acidic residues Asp and Glu; replacement of the amide residues Asn and Gln, replacement of the basic residues Lys, Arg, and His; replacement of the aromatic residues Phe, Tyr, and Trp, and replacement of the small-sized amino acids Ala, Ser, Thr, Met, and Gly.

Besides conservative amino acid substitution, variants of the present invention include (i) substitutions with one or more of the non-conserved amino acid residues, where the substituted amino acid residues may or may not be one encoded by the genetic code, or (ii) substitution with one or more of amino acid residues having a substituent group, or (iii) fusion of the mature polypeptide with another compound, such as a compound to increase the stability and/or solubility of the polypeptide (for example, polyethylene glycol), or (iv) fusion of the polypeptide with additional amino acids, such as, for example, an IgG Fc fusion region peptide, or leader or secretory sequence, or a sequence facilitating purification or (v) fusion of the polypeptide with another compound, such as albumin (including, but not limited to, recombinant albumin (see, e.g., U.S. Patent No. 5,876,969, issued March 2, 1999, EP Patent 0 413 622, and U.S. Patent No. 5,766,883, issued June 16, 1998, herein incorporated by reference in their entirety)). Such variant polypeptides are deemed to be within the scope of those skilled in the art from the teachings herein.

For example, polypeptide variants containing amino acid substitutions of charged amino acids with other charged or neutral amino acids may produce proteins with improved characteristics, such as less aggregation. Aggregation of pharmaceutical formulations both reduces activity and increases clearance due to the aggregate's immunogenic activity. (Pinckard et al., Clin. Exp. Immunol. 2:331-340 (1967); Robbins et al., Diabetes 36: 838-845 (1987); Cleland et al., Crit. Rev. Therapeutic Drug Carrier Systems 10:307-377 (1993).)

A further embodiment of the invention relates to a polypeptide which comprises the amino acid sequence of the present invention having an amino acid sequence which contains at least one amino acid substitution, but not more than 50 amino acid substitutions, even more preferably, not more than 40 amino acid substitutions, still more preferably, not more than 30 amino acid substitutions, and still even more preferably, not more than 20 amino acid substitutions. Of course, in order of ever-increasing preference, it is highly preferable for a peptide or polypeptide to have an amino acid sequence which comprises the amino acid sequence of the present invention, which contains at least one, but not more than 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 amino acid substitutions. In specific embodiments, the number of additions, substitutions, and/or deletions in the amino acid sequence of the present invention or fragments thereof (e.g., the mature form and/or other fragments described herein), is 1-5, 5-10, 5-25, 5-50, 10-50 or 50-150, conservative amino acid substitutions are preferable.

### **Polynucleotide and Polypeptide Fragments**

The present invention is also directed to polynucleotide fragments of the polynucleotides of the invention.

In the present invention, a "polynucleotide fragment" refers to a short polynucleotide having a nucleic acid sequence which: is a portion of that contained in a deposited clone, or encoding the polypeptide encoded by the cDNA in a deposited clone; is a portion of that shown in SEQ ID NO:X or the complementary strand thereto, or is a portion of a polynucleotide sequence encoding the polypeptide of SEQ ID NO:Y. The nucleotide fragments of the invention are preferably at least about 15 nt, and more preferably at least about 20 nt, still more preferably at least about 30 nt,



and even more preferably, at least about 40 nt, at least about 50 nt, at least about 75 nt, or at least about 150 nt in length. A fragment "at least 20 nt in length," for example, is intended to include 20 or more contiguous bases from the cDNA sequence contained in a deposited clone or the nucleotide sequence shown in SEQ ID NO:X. In this context "about" includes the particularly recited value, a value larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. These nucleotide fragments have uses that include, but are not limited to, as diagnostic probes and primers as discussed herein. Of course, larger fragments (e.g., 50, 150, 500, 600, 2000 nucleotides) are preferred.

Moreover, representative examples of polynucleotide fragments of the invention, include, for example, fragments comprising, or alternatively consisting of, a sequence from about nucleotide number 1-50, 51-100, 101-150, 151-200, 201-250, 251-300, 301-350, 351-400, 401-450, 451-500, 501-550, 551-600, 651-700, 701-750, 751-800, 800-850, 851-900, 901-950, 951-1000, 1001-1050, 1051-1100, 1101-1150, 1151-1200, 1201-1250, 1251-1300, 1301-1350, 1351-1400, 1401-1450, 1451-1500, 1501-1550, 1551-1600, 1601-1650, 1651-1700, 1701-1750, 1751-1800, 1801-1850, 1851-1900, 1901-1950, 1951-2000, or 2001 to the end of SEQ ID NO:X, or the complementary strand thereto, or the cDNA contained in a deposited clone. In this context "about" includes the particularly recited ranges, and ranges larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. Preferably, these fragments encode a polypeptide which has biological activity. More preferably, these polynucleotides can be used as probes or primers as discussed herein. Polynucleotides which hybridize to these nucleic acid molecules under stringent hybridization conditions or lower stringency conditions are also encompassed by the invention, as are polypeptides encoded by these polynucleotides.

In the present invention, a "polypeptide fragment" refers to an amino acid sequence which is a portion of that contained in SEQ ID NO:Y or encoded by the cDNA contained in a deposited clone. Protein (polypeptide) fragments may be "free-standing," or comprised within a larger polypeptide of which the fragment forms a part or region, most preferably as a single continuous region. Representative examples of polypeptide fragments of the invention, include, for example, fragments comprising, or alternatively consisting of, from about amino acid number 1-20, 21-40,

41-60, 61-80, 81-100, 102-120, 121-140, 141-160, or 161 to the end of the coding region. Moreover, polypeptide fragments can be about 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, or 150 amino acids in length. In this context "about" includes the particularly recited ranges or values, and ranges or values larger or smaller by several (5, 4, 3, 2, or 1) amino acids, at either extreme or at both extremes. Polynucleotides encoding these polypeptides are also encompassed by the invention.

Preferred polypeptide fragments include the secreted protein as well as the mature form. Further preferred polypeptide fragments include the secreted protein or the mature form having a continuous series of deleted residues from the amino or the carboxy terminus, or both. For example, any number of amino acids, ranging from 1-60, can be deleted from the amino terminus of either the secreted polypeptide or the mature form. Similarly, any number of amino acids, ranging from 1-30, can be deleted from the carboxy terminus of the secreted protein or mature form. Furthermore, any combination of the above amino and carboxy terminus deletions are preferred. Similarly, polynucleotides encoding these polypeptide fragments are also preferred.

Also preferred are polypeptide and polynucleotide fragments characterized by structural or functional domains, such as fragments that comprise alpha-helix and alpha-helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic index regions. Polypeptide fragments of SEQ ID NO:Y falling within conserved domains are specifically contemplated by the present invention. Moreover, polynucleotides encoding these domains are also contemplated.

Other preferred polypeptide fragments are biologically active fragments. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide of the present invention. The biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity. Polynucleotides encoding these polypeptide fragments are also encompassed by the invention:

Preferably, the polynucleotide fragments of the invention encode a polypeptide which demonstrates a functional activity. By a polypeptide demonstrating a "functional activity" is meant, a polypeptide capable of displaying one or more known functional activities associated with a full-length (complete) polypeptide of invention protein. Such functional activities include, but are not limited to, biological activity, antigenicity [ability to bind (or compete with a polypeptide of the invention for binding) to an antibody to the polypeptide of the invention], immunogenicity (ability to generate antibody which binds to a polypeptide of the invention), ability to form multimers with polypeptides of the invention, and ability to bind to a receptor or ligand for a polypeptide of the invention.

The functional activity of polypeptides of the invention, and fragments, variants derivatives, and analogs thereof, can be assayed by various methods.

For example, in one embodiment where one is assaying for the ability to bind or compete with full-length polypeptide of the invention for binding to an antibody of the polypeptide of the invention, various immunoassays known in the art can be used, including but not limited to, competitive and non-competitive assay systems using techniques such as radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, immunoradiometric assays, gel diffusion precipitation reactions, immunodiffusion assays, in situ immunoassays (using colloidal gold, enzyme or radioisotope labels, for example), western blots, precipitation reactions, agglutination assays (e.g., gel agglutination assays, hemagglutination assays), complement fixation assays, immunofluorescence assays, protein A assays, and immunoelectrophoresis assays, etc. In one embodiment, antibody binding is detected by detecting a label on the primary antibody. In another embodiment, the primary antibody is detected by detecting binding of a secondary antibody or reagent to the primary antibody. In a further embodiment, the secondary antibody is labeled. Many means are known in the art for detecting binding in an immunoassay and are within the scope of the present invention.

In another embodiment, where a ligand for a polypeptide of the invention identified, or the ability of a polypeptide fragment, variant or derivative of the invention to multimerize is being evaluated, binding can be assayed, e.g., by means well-known in the art, such as, for example, reducing and non-reducing gel

chromatography, protein affinity chromatography, and affinity blotting. See generally, Phizicky, E., et al., 1995, Microbiol. Rev. 59:94-123. In another embodiment, physiological correlates of binding of a polypeptide of the invention to its substrates (signal transduction) can be assayed.

5 In addition, assays described herein (see Examples) and otherwise known in the art may routinely be applied to measure the ability of polypeptides of the invention and fragments, variants derivatives and analogs thereof to elicit related biological activity related to that of the polypeptide of the invention (either in vitro or in vivo). Other methods will be known to the skilled artisan and are within the scope  
10 of the invention.

### **Epitopes and Antibodies**

The present invention encompasses polypeptides comprising, or alternatively consisting of, an epitope of the polypeptide having an amino acid sequence of SEQ ID  
15 NO:Y, or an epitope of the polypeptide sequence encoded by a polynucleotide sequence contained in ATCC deposit No. Z or encoded by a polynucleotide that hybridizes to the complement of the sequence of SEQ ID NO:X or contained in ATCC deposit No. Z under stringent hybridization conditions or lower stringency hybridization conditions as defined supra. The present invention further encompasses  
20 polynucleotide sequences encoding an epitope of a polypeptide sequence of the invention (such as, for example, the sequence disclosed in SEQ ID NO:X), polynucleotide sequences of the complementary strand of a polynucleotide sequence encoding an epitope of the invention, and polynucleotide sequences which hybridize to the complementary strand under stringent hybridization conditions or lower  
25 stringency hybridization conditions defined supra.

The term "epitopes," as used herein, refers to portions of a polypeptide having antigenic or immunogenic activity in an animal, preferably a mammal, and most preferably in a human. In a preferred embodiment, the present invention encompasses a polypeptide comprising an epitope, as well as the polynucleotide  
30 encoding this polypeptide. An "immunogenic epitope," as used herein, is defined as a portion of a protein that elicits an antibody response in an animal, as determined by any method known in the art, for example, by the methods for generating antibodies

described *infra*. (See, for example, Geysen et al., Proc. Natl. Acad. Sci. USA 81:3998-4002 (1983)). The term "antigenic epitope," as used herein, is defined as a portion of a protein to which an antibody can immunospecifically bind its antigen as determined by any method well known in the art, for example, by the immunoassays  
5 described herein. Immunospecific binding excludes non-specific binding but does not necessarily exclude cross-reactivity with other antigens. Antigenic epitopes need not necessarily be immunogenic.

Fragments which function as epitopes may be produced by any conventional means. (See, e.g., Houghten, Proc. Natl. Acad. Sci. USA 82:5131-5135 (1985),  
10 further described in U.S. Patent No. 4,631,211).

In the present invention, antigenic epitopes preferably contain a sequence of at least 4, at least 5, at least 6, at least 7, more preferably at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 20, at least 25, at least 30, at least 40, at least 50, and, most preferably, between about 15 to about 30  
15 amino acids. Preferred polypeptides comprising immunogenic or antigenic epitopes are at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 amino acid residues in length. Additional non-exclusive preferred antigenic epitopes include the antigenic epitopes disclosed herein, as well as portions thereof. Antigenic epitopes are useful, for example, to raise antibodies, including monoclonal antibodies,  
20 that specifically bind the epitope. Preferred antigenic epitopes include the antigenic epitopes disclosed herein, as well as any combination of two, three, four, five or more of these antigenic epitopes. Antigenic epitopes can be used as the target molecules in immunoassays. (See, for instance, Wilson et al., Cell 37:767-778 (1984); Sutcliffe et al., Science 219:660-666 (1983)).

25 Similarly, immunogenic epitopes can be used, for example, to induce antibodies according to methods well known in the art. (See, for instance, Sutcliffe et al., *supra*; Wilson et al., *supra*; Chow et al., Proc. Natl. Acad. Sci. USA 82:910-914; and Bittle et al., J. Gen. Virol. 66:2347-2354 (1985)). Preferred immunogenic epitopes include the immunogenic epitopes disclosed herein, as well as any  
30 combination of two, three, four, five or more of these immunogenic epitopes. The polypeptides comprising one or more immunogenic epitopes may be presented for eliciting an antibody response together with a carrier protein, such as an albumin, to

an animal system (such as rabbit or mouse), or, if the polypeptide is of sufficient length (at least about 25 amino acids), the polypeptide may be presented without a carrier. However, immunogenic epitopes comprising as few as 8 to 10 amino acids have been shown to be sufficient to raise antibodies capable of binding to, at the very least, linear epitopes in a denatured polypeptide (e.g., in Western blotting).

Epitope-bearing polypeptides of the present invention may be used to induce antibodies according to methods well known in the art including, but not limited to, in vivo immunization, in vitro immunization, and phage display methods. See, e.g., Sutcliffe et al., *supra*; Wilson et al., *supra*, and Bittle et al., *J. Gen. Virol.*, 66:2347-2354 (1985). If in vivo immunization is used, animals may be immunized with free peptide; however, anti-peptide antibody titer may be boosted by coupling the peptide to a macromolecular carrier, such as keyhole limpet hemacyanin (KLH) or tetanus toxoid. For instance, peptides containing cysteine residues may be coupled to a carrier using a linker such as maleimidobenzoyl- N-hydroxysuccinimide ester (MBS), while other peptides may be coupled to carriers using a more general linking agent such as glutaraldehyde. Animals such as rabbits, rats and mice are immunized with either free or carrier- coupled peptides, for instance, by intraperitoneal and/or intradermal injection of emulsions containing about 100 µg of peptide or carrier protein and Freund's adjuvant or any other adjuvant known for stimulating an immune response. Several booster injections may be needed, for instance, at intervals of about two weeks, to provide a useful titer of anti-peptide antibody which can be detected, for example, by ELISA assay using free peptide adsorbed to a solid surface. The titer of anti-peptide antibodies in serum from an immunized animal may be increased by selection of anti-peptide antibodies, for instance, by adsorption to the peptide on a solid support and elution of the selected antibodies according to methods well known in the art.

As one of skill in the art will appreciate, and as discussed above, the polypeptides of the present invention comprising an immunogenic or antigenic epitope can be fused to other polypeptide sequences. For example, the polypeptides of the present invention may be fused with the constant domain of immunoglobulins (IgA, IgE, IgG, IgM), or portions thereof (CH1, CH2, CH3, or any combination thereof and portions thereof), or albumin (including but not limited to recombinant

albumin (see, e.g., U.S. Patent No. 5,876,969, issued March 2, 1999, EP Patent 0 413 622, and U.S. Patent No. 5,766,883, issued June 16, 1998, herein incorporated by reference in their entirety)), resulting in chimeric polypeptides. Such fusion proteins may facilitate purification and may increase half-life in vivo. This has been shown for chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. See, e.g., EP 394,827; Traunecker et al., *Nature*, 331:84-86 (1988). Enhanced delivery of an antigen across the epithelial barrier to the immune system has been demonstrated for antigens (e.g., insulin) conjugated to an FcRn binding partner such as IgG or Fc fragments (see, e.g., PCT Publications WO 96/22024 and WO 99/04813). IgG Fusion proteins that have a disulfide-linked dimeric structure due to the IgG portion disulfide bonds have also been found to be more efficient in binding and neutralizing other molecules than monomeric polypeptides or fragments thereof alone. See, e.g., Fountoulakis et al., *J. Biochem.*, 120:3958-3964 (1995). Nucleic acids encoding the above epitopes can also be recombined with a gene of interest as an epitope tag (e.g., the hemagglutinin ("HA") tag or flag tag) to aid in detection and purification of the expressed polypeptide. For example, a system described by Janknecht et al. allows for the ready purification of non-denatured fusion proteins expressed in human cell lines (Janknecht et al., 1991, *Proc. Natl. Acad. Sci. USA* 88:8972- 897). In this system, the gene of interest is subcloned into a vaccinia recombination plasmid such that the open reading frame of the gene is translationally fused to an amino-terminal tag consisting of six histidine residues. The tag serves as a matrix binding domain for the fusion protein. Extracts from cells infected with the recombinant vaccinia virus are loaded onto Ni<sup>2+</sup>-nitriloacetic acid-agarose column and histidine-tagged proteins can be selectively eluted with imidazole-containing buffers.

Additional fusion proteins of the invention may be generated through the techniques of gene-shuffling, motif-shuffling, exon-shuffling, and/or codon-shuffling (collectively referred to as "DNA shuffling"). DNA shuffling may be employed to modulate the activities of polypeptides of the invention, such methods can be used to generate polypeptides with altered activity, as well as agonists and antagonists of the polypeptides. See, generally, U.S. Patent Nos. 5,605,793; 5,811,238; 5,830,721;

5,834,252; and 5,837,458, and Patten et al., Curr. Opinion Biotechnol. 8:724-33 (1997); Harayama, Trends Biotechnol. 16(2):76-82 (1998); Hansson, et al., J. Mol. Biol. 287:265-76 (1999); and Lorenzo and Blasco, Biotechniques 24(2):308- 13 (1998) (each of these patents and publications are hereby incorporated by reference in its entirety). In one embodiment, alteration of polynucleotides corresponding to SEQ ID NO:X and the polypeptides encoded by these polynucleotides may be achieved by DNA shuffling. DNA shuffling involves the assembly of two or more DNA segments by homologous or site-specific recombination to generate variation in the polynucleotide sequence. In another embodiment, polynucleotides of the invention, or the encoded polypeptides, may be altered by being subjected to random mutagenesis by error-prone PCR, random nucleotide insertion or other methods prior to recombination. In another embodiment, one or more components, motifs, sections, parts, domains, fragments, etc., of a polynucleotide encoding a polypeptide of the invention may be recombined with one or more components, motifs, sections, parts, domains, fragments, etc. of one or more heterologous molecules.

### **Antibodies**

Further polypeptides of the invention relate to antibodies and T-cell antigen receptors (TCR) which immunospecifically bind a polypeptide, polypeptide fragment, or variant of SEQ ID NO:Y, and/or an epitope, of the present invention (as determined by immunoassays well known in the art for assaying specific antibody-antigen binding). Antibodies of the invention include, but are not limited to, polyclonal, monoclonal, multispecific, human, humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab') fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies (including, e.g., anti-Id antibodies to antibodies of the invention), and epitope-binding fragments of any of the above. The term "antibody," as used herein, refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site that immunospecifically binds an antigen. The immunoglobulin molecules of the invention can be of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) or subclass of immunoglobulin molecule. In preferred embodiments, the immunoglobulin



molecules of the invention are IgG1. In other preferred embodiments, the immunoglobulin molecules of the invention are IgG4.

Most preferably the antibodies are human antigen-binding antibody fragments of the present invention and include, but are not limited to, Fab, Fab' and F(ab')<sub>2</sub>, Fd, single-chain Fvs (scFv), single-chain antibodies, disulfide-linked Fvs (sdFv) and fragments comprising either a VL or VH domain. Antigen-binding antibody fragments, including single-chain antibodies, may comprise the variable region(s) alone or in combination with the entirety or a portion of the following: hinge region, CH1, CH2, and CH3 domains. Also included in the invention are antigen-binding fragments also comprising any combination of variable region(s) with a hinge region, CH1, CH2, and CH3 domains. The antibodies of the invention may be from any animal origin including birds and mammals. Preferably, the antibodies are human, murine (e.g., mouse and rat), donkey, sheep rabbit, goat, guinea pig, camel, horse, or chicken. As used herein, "human" antibodies include antibodies having the amino acid sequence of a human immunoglobulin and include antibodies isolated from human immunoglobulin libraries or from animals transgenic for one or more human immunoglobulin and that do not express endogenous immunoglobulins, as described infra and, for example in, U.S. Patent No. 5,939,598 by Kucherlapati et al.

The antibodies of the present invention may be monospecific, bispecific, trispecific or of greater multispecificity. Multispecific antibodies may be specific for different epitopes of a polypeptide of the present invention or may be specific for both a polypeptide of the present invention as well as for a heterologous epitope, such as a heterologous polypeptide or solid support material. See, e.g., PCT publications WO 93/17715; WO 92/08802; WO 91/00360; WO 92/05793; Tutt, et al., J. Immunol. 147:60-69 (1991); U.S. Patent Nos. 4,474,893; 4,714,681; 4,925,648; 5,573,920; 5,601,819; Kostelny et al., J. Immunol. 148:1547-1553 (1992).

Antibodies of the present invention may be described or specified in terms of the epitope(s) or portion(s) of a polypeptide of the present invention which they recognize or specifically bind. The epitope(s) or polypeptide portion(s) may be specified as described herein, e.g., by N-terminal and C-terminal positions, by size in contiguous amino acid residues, or listed in the Tables and Figures. Antibodies which specifically bind any epitope or polypeptide of the present invention may also be

excluded. Therefore, the present invention includes antibodies that specifically bind polypeptides of the present invention, and allows for the exclusion of the same.

Antibodies of the present invention may also be described or specified in terms of their cross-reactivity. Antibodies that do not bind any other analog, ortholog, or homolog of a polypeptide of the present invention are included. Antibodies that bind polypeptides with at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 65%, at least 60%, at least 55%, and at least 50% identity (as calculated using methods known in the art and described herein) to a polypeptide of the present invention are also included in the present invention. In specific embodiments, antibodies of the present invention cross-react with murine, rat and/or rabbit homologs of human proteins and the corresponding epitopes thereof. Antibodies that do not bind polypeptides with less than 95%, less than 90%, less than 85%, less than 80%, less than 75%, less than 70%, less than 65%, less than 60%, less than 55%, and less than 50% identity (as calculated using methods known in the art and described herein) to a polypeptide of the present invention are also included in the present invention. In a specific embodiment, the above-described cross-reactivity is with respect to any single specific antigenic or immunogenic polypeptide, or combination(s) of 2, 3, 4, 5, or more of the specific antigenic and/or immunogenic polypeptides disclosed herein. Further included in the present invention are antibodies which bind polypeptides encoded by polynucleotides which hybridize to a polynucleotide of the present invention under stringent hybridization conditions (as described herein). Antibodies of the present invention may also be described or specified in terms of their binding affinity to a polypeptide of the invention. Preferred binding affinities include those with a dissociation constant or  $K_d$  less than  $5 \times 10^{-2}$  M,  $10^{-2}$  M,  $5 \times 10^{-3}$  M,  $10^{-3}$  M,  $5 \times 10^{-4}$  M,  $10^{-4}$  M,  $5 \times 10^{-5}$  M,  $10^{-5}$  M,  $5 \times 10^{-6}$  M,  $10^{-6}$  M,  $5 \times 10^{-7}$  M,  $10^{-7}$  M,  $5 \times 10^{-8}$  M,  $10^{-8}$  M,  $5 \times 10^{-9}$  M,  $10^{-9}$  M,  $5 \times 10^{-10}$  M,  $10^{-10}$  M,  $5 \times 10^{-11}$  M,  $10^{-11}$  M,  $5 \times 10^{-12}$  M,  $10^{-12}$  M,  $5 \times 10^{-13}$  M,  $10^{-13}$  M,  $5 \times 10^{-14}$  M,  $10^{-14}$  M,  $5 \times 10^{-15}$  M, or  $10^{-15}$  M.

The invention also provides antibodies that competitively inhibit binding of an antibody to an epitope of the invention as determined by any method known in the art for determining competitive binding, for example, the immunoassays described herein. In preferred embodiments, the antibody competitively inhibits binding to the

epitope by at least 95%, at least 90%, at least 85 %, at least 80%, at least 75%, at least 70%, at least 60%, or at least 50%.

Antibodies of the present invention may act as agonists or antagonists of the polypeptides of the present invention. For example, the present invention includes  
5 antibodies which disrupt the receptor/ligand interactions with the polypeptides of the invention either partially or fully. Preferably, antibodies of the present invention bind an antigenic epitope disclosed herein, or a portion thereof. The invention features both receptor-specific antibodies and ligand-specific antibodies. The invention also features receptor-specific antibodies which do not prevent ligand  
10 binding but prevent receptor activation. Receptor activation (i.e., signaling) may be determined by techniques described herein or otherwise known in the art. For example, receptor activation can be determined by detecting the phosphorylation (e.g., tyrosine or serine/threonine) of the receptor or its substrate by immunoprecipitation followed by western blot analysis (for example, as described  
15 supra). In specific embodiments, antibodies are provided that inhibit ligand activity or receptor activity by at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 60%, or at least 50% of the activity in absence of the antibody.

The invention also features receptor-specific antibodies which both prevent  
20 ligand binding and receptor activation as well as antibodies that recognize the receptor-ligand complex, and, preferably, do not specifically recognize the unbound receptor or the unbound ligand. Likewise, included in the invention are neutralizing antibodies which bind the ligand and prevent binding of the ligand to the receptor, as well as antibodies which bind the ligand, thereby preventing receptor activation, but  
25 do not prevent the ligand from binding the receptor. Further included in the invention are antibodies which activate the receptor. These antibodies may act as receptor agonists, i.e., potentiate or activate either all or a subset of the biological activities of the ligand-mediated receptor activation, for example, by inducing dimerization of the receptor. The antibodies may be specified as agonists, antagonists or inverse agonists  
30 for biological activities comprising the specific biological activities of the peptides of the invention disclosed herein. The above antibody agonists can be made using methods known in the art. See, e.g., PCT publication WO 96/40281; U.S. Patent No.

5,811,097; Deng et al., Blood 92(6):1981-1988 (1998); Chen et al., Cancer Res. 58(16):3668-3678 (1998); Harrop et al., J. Immunol. 161(4):1786-1794 (1998); Zhu et al., Cancer Res. 58(15):3209-3214 (1998); Yoon et al., J. Immunol. 160(7):3170-3179 (1998); Prat et al., J. Cell. Sci. 111(Pt2):237-247 (1998); Pitard et al., J. Immunol. Methods 205(2):177-190 (1997); Liautard et al., Cytokine 9(4):233-241 (1997); Carlson et al., J. Biol. Chem. 272(17):11295-11301 (1997); Taryman et al., Neuron 14(4):755-762 (1995); Muller et al., Structure 6(9):1153-1167 (1998); Bartunek et al., Cytokine 8(1):14-20 (1996) (which are all incorporated by reference herein in their entireties).

10           Antibodies of the present invention may be used, for example, but not limited to, to purify, detect, and target the polypeptides of the present invention, including both in vitro and in vivo diagnostic and therapeutic methods. For example, the antibodies have use in immunoassays for qualitatively and quantitatively measuring levels of the polypeptides of the present invention in biological samples. See, e.g.,  
15   Harlow et al., Antibodies: A Laboratory Manual, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988) (incorporated by reference herein in its entirety).

          As discussed in more detail below, the antibodies of the present invention may be used either alone or in combination with other compositions. The antibodies may further be recombinantly fused to a heterologous polypeptide at the N- or C-terminus  
20   or chemically conjugated (including covalently and non-covalently conjugations) to polypeptides or other compositions. For example, antibodies of the present invention may be recombinantly fused or conjugated to molecules useful as labels in detection assays and effector molecules such as heterologous polypeptides, drugs, radionuclides, or toxins. See, e.g., PCT publications WO 92/08495; WO 91/14438;  
25   WO 89/12624; U.S. Patent No. 5,314,995; and EP 396,387.

          The antibodies of the invention include derivatives that are modified, i.e., by the covalent attachment of any type of molecule to the antibody such that covalent attachment does not prevent the antibody from generating an anti-idiotypic response. For example, but not by way of limitation, the antibody derivatives include  
30   antibodies that have been modified, e.g., by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to a cellular ligand or other protein, etc. Any of

numerous chemical modifications may be carried out by known techniques, including, but not limited to specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, etc. Additionally, the derivative may contain one or more non-classical amino acids.

5           The antibodies of the present invention may be generated by any suitable method known in the art. Polyclonal antibodies to an antigen-of- interest can be produced by various procedures well known in the art. For example, a polypeptide of the invention can be administered to various host animals including, but not limited to, rabbits, mice, rats, etc. to induce the production of sera containing polyclonal  
10   antibodies specific for the antigen. Various adjuvants may be used to increase the immunological response, depending on the host species, and include but are not limited to, Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and  
15   potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and corynebacterium parvum. Such adjuvants are also well known in the art.

Monoclonal antibodies can be prepared using a wide variety of techniques known in the art including the use of hybridoma, recombinant, and phage display technologies, or a combination thereof. For example, monoclonal antibodies can be  
20   produced using hybridoma techniques including those known in the art and taught, for example, in Harlow et al., *Antibodies: A Laboratory Manual*, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988); Hammerling, et al., in: *Monoclonal Antibodies and T-Cell Hybridomas* 563-681 (Elsevier, N.Y., 1981) (said references incorporated by reference in their entireties). The term "monoclonal antibody" as used herein is not  
25   limited to antibodies produced through hybridoma technology. The term "monoclonal antibody" refers to an antibody that is derived from a single clone, including any eukaryotic, prokaryotic, or phage clone, and not the method by which it is produced.

Methods for producing and screening for specific antibodies using hybridoma  
30   technology are routine and well known in the art and are discussed in detail in the Examples (e.g., Example 16). In a non-limiting example, mice can be immunized with a polypeptide of the invention or a cell expressing such peptide. Once an

immune response is detected, e.g., antibodies specific for the antigen are detected in the mouse serum, the mouse spleen is harvested and splenocytes isolated. The splenocytes are then fused by well known techniques to any suitable myeloma cells, for example cells from cell line SP20 available from the ATCC. Hybridomas are  
5 selected and cloned by limited dilution. The hybridoma clones are then assayed by methods known in the art for cells that secrete antibodies capable of binding a polypeptide of the invention. Ascites fluid, which generally contains high levels of antibodies, can be generated by immunizing mice with positive hybridoma clones.

Accordingly, the present invention provides methods of generating  
10 monoclonal antibodies as well as antibodies produced by the method comprising culturing a hybridoma cell secreting an antibody of the invention wherein, preferably, the hybridoma is generated by fusing splenocytes isolated from a mouse immunized with an antigen of the invention with myeloma cells and then screening the hybridomas resulting from the fusion for hybridoma clones that secrete an antibody  
15 able to bind a polypeptide of the invention.

Antibody fragments which recognize specific epitopes may be generated by known techniques. For example, Fab and F(ab')<sub>2</sub> fragments of the invention may be produced by proteolytic cleavage of immunoglobulin molecules, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')<sub>2</sub> fragments).  
20 F(ab')<sub>2</sub> fragments contain the variable region, the light chain constant region and the CH1 domain of the heavy chain.

For example, the antibodies of the present invention can also be generated using various phage display methods known in the art. In phage display methods, functional antibody domains are displayed on the surface of phage particles which  
25 carry the polynucleotide sequences encoding them. In a particular embodiment, such phage can be utilized to display antigen binding domains expressed from a repertoire or combinatorial antibody library (e.g., human or murine). Phage expressing an antigen binding domain that binds the antigen of interest can be selected or identified with antigen, e.g., using labeled antigen or antigen bound or captured to a solid  
30 surface or bead. Phage used in these methods are typically filamentous phage including fd and M13 binding domains expressed from phage with Fab, Fv or disulfide stabilized Fv antibody domains recombinantly fused to either the phage

gene III or gene VIII protein. Examples of phage display methods that can be used to make the antibodies of the present invention include those disclosed in Brinkman et al., *J. Immunol. Methods* 182:41-50 (1995); Ames et al., *J. Immunol. Methods* 184:177-186 (1995); Kettleborough et al., *Eur. J. Immunol.* 24:952-958 (1994); Persic  
5 et al., *Gene* 187 9-18 (1997); Burton et al., *Advances in Immunology* 57:191-280 (1994); PCT application No. PCT/GB91/01134; PCT publications WO 90/02809; WO 91/10737; WO 92/01047; WO 92/18619; WO 93/11236; WO 95/15982; WO 95/20401; and U.S. Patent Nos. 5,698,426; 5,223,409; 5,403,484; 5,580,717; 5,427,908; 5,750,753; 5,821,047; 5,571,698; 5,427,908; 5,516,637; 5,780,225;  
10 5,658,727; 5,733,743 and 5,969,108; each of which is incorporated herein by reference in its entirety.

As described in the above references, after phage selection, the antibody coding regions from the phage can be isolated and used to generate whole antibodies, including human antibodies, or any other desired antigen binding fragment, and  
15 expressed in any desired host, including mammalian cells, insect cells, plant cells, yeast, and bacteria, e.g., as described in detail below. For example, techniques to recombinantly produce Fab, Fab' and F(ab')<sub>2</sub> fragments can also be employed using methods known in the art such as those disclosed in PCT publication WO 92/22324; Mullinax et al., *BioTechniques* 12(6):864-869 (1992); and Sawai et al., *AJRI* 34:26-  
20 34 (1995); and Better et al., *Science* 240:1041-1043 (1988) (said references incorporated by reference in their entireties).

Examples of techniques which can be used to produce single-chain Fvs and antibodies include those described in U.S. Patents 4,946,778 and 5,258,498; Huston et al., *Methods in Enzymology* 203:46-88 (1991); Shu et al., *PNAS* 90:7995-7999  
25 (1993); and Skerra et al., *Science* 240:1038-1040 (1988). For some uses, including in vivo use of antibodies in humans and in vitro detection assays, it may be preferable to use chimeric, humanized, or human antibodies. A chimeric antibody is a molecule in which different portions of the antibody are derived from different animal species, such as antibodies having a variable region derived from a murine monoclonal  
30 antibody and a human immunoglobulin constant region. Methods for producing chimeric antibodies are known in the art. See e.g., Morrison, *Science* 229:1202 (1985); Oi et al., *BioTechniques* 4:214 (1986); Gillies et al., (1989) *J. Immunol.*

Methods 125:191-202; U.S. Patent Nos. 5,807,715; 4,816,567; and 4,816,397, which are incorporated herein by reference in their entirety. Humanized antibodies are antibody molecules from non-human species antibody that binds the desired antigen having one or more complementarity determining regions (CDRs) from the non-human species and a framework regions from a human immunoglobulin molecule. Often, framework residues in the human framework regions will be substituted with the corresponding residue from the CDR donor antibody to alter, preferably improve, antigen binding. These framework substitutions are identified by methods well known in the art, e.g., by modeling of the interactions of the CDR and framework residues to identify framework residues important for antigen binding and sequence comparison to identify unusual framework residues at particular positions. (See, e.g., Queen et al., U.S. Patent No. 5,585,089; Riechmann et al., Nature 332:323 (1988), which are incorporated herein by reference in their entirety.) Antibodies can be humanized using a variety of techniques known in the art including, for example, CDR-grafting (EP 239,400; PCT publication WO 91/09967; U.S. Patent Nos. 5,225,539; 5,530,101; and 5,585,089), veneering or resurfacing (EP 592,106; EP 519,596; Padlan, Molecular Immunology 28(4/5):489-498 (1991); Studnicka et al., Protein Engineering 7(6):805-814 (1994); Roguska. et al., PNAS 91:969-973 (1994)), and chain shuffling (U.S. Patent No. 5,565,332).

Completely human antibodies are particularly desirable for therapeutic treatment of human patients. Human antibodies can be made by a variety of methods known in the art including phage display methods described above using antibody libraries derived from human immunoglobulin sequences. See also, U.S. Patent Nos. 4,444,887 and 4,716,111; and PCT publications WO 98/46645, WO 98/50433, WO 98/24893, WO 98/16654, WO 96/34096, WO 96/33735, and WO 91/10741; each of which is incorporated herein by reference in its entirety.

Human antibodies can also be produced using transgenic mice which are incapable of expressing functional endogenous immunoglobulins, but which can express human immunoglobulin genes. For example, the human heavy and light chain immunoglobulin gene complexes may be introduced randomly or by homologous recombination into mouse embryonic stem cells. Alternatively, the human variable region, constant region, and diversity region may be introduced into



mouse embryonic stem cells in addition to the human heavy and light chain genes. The mouse heavy and light chain immunoglobulin genes may be rendered non-functional separately or simultaneously with the introduction of human immunoglobulin loci by homologous recombination. In particular, homozygous deletion of the JH region prevents endogenous antibody production. The modified embryonic stem cells are expanded and microinjected into blastocysts to produce chimeric mice. The chimeric mice are then bred to produce homozygous offspring which express human antibodies. The transgenic mice are immunized in the normal fashion with a selected antigen, e.g., all or a portion of a polypeptide of the invention.

Monoclonal antibodies directed against the antigen can be obtained from the immunized, transgenic mice using conventional hybridoma technology. The human immunoglobulin transgenes harbored by the transgenic mice rearrange during B cell differentiation, and subsequently undergo class switching and somatic mutation. Thus, using such a technique, it is possible to produce therapeutically useful IgG, IgA, IgM and IgE antibodies. For an overview of this technology for producing human antibodies, see Lonberg and Huszar, *Int. Rev. Immunol.* 13:65-93 (1995). For a detailed discussion of this technology for producing human antibodies and human monoclonal antibodies and protocols for producing such antibodies, see, e.g., PCT publications WO 98/24893; WO 92/01047; WO 96/34096; WO 96/33735; European Patent No. 0 598 877; U.S. Patent Nos. 5,413,923; 5,625,126; 5,633,425; 5,569,825; 5,661,016; 5,545,806; 5,814,318; 5,885,793; 5,916,771; and 5,939,598, which are incorporated by reference herein in their entirety. In addition, companies such as Abgenix, Inc. (Freemont, CA) and Genpharm (San Jose, CA) can be engaged to provide human antibodies directed against a selected antigen using technology similar to that described above.

Completely human antibodies which recognize a selected epitope can be generated using a technique referred to as "guided selection." In this approach a selected non-human monoclonal antibody, e.g., a mouse antibody, is used to guide the selection of a completely human antibody recognizing the same epitope. (Jespers et al., *Bio/technology* 12:899-903 (1988)).

Further, antibodies to the polypeptides of the invention can, in turn, be utilized to generate anti-idiotypic antibodies that "mimic" polypeptides of the invention using

techniques well known to those skilled in the art. (See, e.g., Greenspan & Bona, FASEB J. 7(5):437-444; (1989) and Nissinoff, J. Immunol. 147(8):2429-2438 (1991)). For example, antibodies which bind to and competitively inhibit polypeptide multimerization and/or binding of a polypeptide of the invention to a ligand can be used to generate anti-idiotypes that "mimic" the polypeptide multimerization and/or binding domain and, as a consequence, bind to and neutralize polypeptide and/or its ligand. Such neutralizing anti-idiotypes or Fab fragments of such anti-idiotypes can be used in therapeutic regimens to neutralize polypeptide ligand. For example, such anti-idiotypic antibodies can be used to bind a polypeptide of the invention and/or to bind its ligands/receptors, and thereby block its biological activity.

#### *Polynucleotides Encoding Antibodies*

The invention further provides polynucleotides comprising a nucleotide sequence encoding an antibody of the invention and fragments thereof. The invention also encompasses polynucleotides that hybridize under stringent or lower stringency hybridization conditions, e.g., as defined supra, to polynucleotides that encode an antibody, preferably, that specifically binds to a polypeptide of the invention, preferably, an antibody that binds to a polypeptide having the amino acid sequence of SEQ ID NO:Y.

The polynucleotides may be obtained, and the nucleotide sequence of the polynucleotides determined, by any method known in the art. For example, if the nucleotide sequence of the antibody is known, a polynucleotide encoding the antibody may be assembled from chemically synthesized oligonucleotides (e.g., as described in Kutmeier et al., BioTechniques 17:242 (1994)), which, briefly, involves the synthesis of overlapping oligonucleotides containing portions of the sequence encoding the antibody, annealing and ligating of those oligonucleotides, and then amplification of the ligated oligonucleotides by PCR.

Alternatively, a polynucleotide encoding an antibody may be generated from nucleic acid from a suitable source. If a clone containing a nucleic acid encoding a particular antibody is not available, but the sequence of the antibody molecule is known, a nucleic acid encoding the immunoglobulin may be chemically synthesized or obtained from a suitable source (e.g., an antibody cDNA library, or a cDNA library

generated from, or nucleic acid, preferably poly A+ RNA, isolated from, any tissue or cells expressing the antibody, such as hybridoma cells selected to express an antibody of the invention) by PCR amplification using synthetic primers hybridizable to the 3' and 5' ends of the sequence or by cloning using an oligonucleotide probe  
5 specific for the particular gene sequence to identify, e.g., a cDNA clone from a cDNA library that encodes the antibody. Amplified nucleic acids generated by PCR may then be cloned into replicable cloning vectors using any method well known in the art.

Once the nucleotide sequence and corresponding amino acid sequence of the  
10 antibody is determined, the nucleotide sequence of the antibody may be manipulated using methods well known in the art for the manipulation of nucleotide sequences, e.g., recombinant DNA techniques, site directed mutagenesis, PCR, etc. (see, for example, the techniques described in Sambrook et al., 1990, Molecular Cloning, A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor,  
15 NY and Ausubel et al., eds., 1998, Current Protocols in Molecular Biology, John Wiley & Sons, NY, which are both incorporated by reference herein in their entireties), to generate antibodies having a different amino acid sequence, for example to create amino acid substitutions, deletions, and/or insertions.

In a specific embodiment, the amino acid sequence of the heavy and/or light  
20 chain variable domains may be inspected to identify the sequences of the complementarity determining regions (CDRs) by methods that are well known in the art, e.g., by comparison to known amino acid sequences of other heavy and light chain variable regions to determine the regions of sequence hypervariability. Using routine recombinant DNA techniques, one or more of the CDRs may be inserted  
25 within framework regions, e.g., into human framework regions to humanize a non-human antibody, as described supra. The framework regions may be naturally occurring or consensus framework regions, and preferably human framework regions (see, e.g., Chothia et al., J. Mol. Biol. 278: 457-479 (1998) for a listing of human framework regions). Preferably, the polynucleotide generated by the combination of  
30 the framework regions and CDRs encodes an antibody that specifically binds a polypeptide of the invention. Preferably, as discussed supra, one or more amino acid substitutions may be made within the framework regions, and, preferably, the amino

acid substitutions improve binding of the antibody to its antigen. Additionally, such methods may be used to make amino acid substitutions or deletions of one or more variable region cysteine residues participating in an intrachain disulfide bond to generate antibody molecules lacking one or more intrachain disulfide bonds. Other alterations to the polynucleotide are encompassed by the present invention and within the skill of the art.

In addition, techniques developed for the production of "chimeric antibodies" (Morrison et al., Proc. Natl. Acad. Sci. 81:851-855 (1984); Neuberger et al., Nature 312:604-608 (1984); Takeda et al., Nature 314:452-454 (1985)) by splicing genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used. As described supra, a chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region, e.g., humanized antibodies.

Alternatively, techniques described for the production of single chain antibodies (U.S. Patent No. 4,946,778; Bird, Science 242:423-42 (1988); Huston et al., Proc. Natl. Acad. Sci. USA 85:5879-5883 (1988); and Ward et al., Nature 334:544-54 (1989)) can be adapted to produce single chain antibodies. Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain polypeptide. Techniques for the assembly of functional Fv fragments in E. coli may also be used (Skerra et al., Science 242:1038-1041 (1988)).

## 25 *Methods of Producing Antibodies*

The antibodies of the invention can be produced by any method known in the art for the synthesis of antibodies, in particular, by chemical synthesis or preferably, by recombinant expression techniques.

Recombinant expression of an antibody of the invention, or fragment, derivative or analog thereof, (e.g., a heavy or light chain of an antibody of the invention or a single chain antibody of the invention), requires construction of an expression vector containing a polynucleotide that encodes the antibody. Once a

polynucleotide encoding an antibody molecule or a heavy or light chain of an antibody, or portion thereof (preferably containing the heavy or light chain variable domain), of the invention has been obtained, the vector for the production of the antibody molecule may be produced by recombinant DNA technology using techniques well known in the art. Thus, methods for preparing a protein by expressing a polynucleotide containing an antibody encoding nucleotide sequence are described herein. Methods which are well known to those skilled in the art can be used to construct expression vectors containing antibody coding sequences and appropriate transcriptional and translational control signals. These methods include, for example, in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. The invention, thus, provides replicable vectors comprising a nucleotide sequence encoding an antibody molecule of the invention, or a heavy or light chain thereof, or a heavy or light chain variable domain, operably linked to a promoter. Such vectors may include the nucleotide sequence encoding the constant region of the antibody molecule (see, e.g., PCT Publication WO 86/05807; PCT Publication WO 89/01036; and U.S. Patent No. 5,122,464) and the variable domain of the antibody may be cloned into such a vector for expression of the entire heavy or light chain.

The expression vector is transferred to a host cell by conventional techniques and the transfected cells are then cultured by conventional techniques to produce an antibody of the invention. Thus, the invention includes host cells containing a polynucleotide encoding an antibody of the invention, or a heavy or light chain thereof, or a single chain antibody of the invention, operably linked to a heterologous promoter. In preferred embodiments for the expression of double-chained antibodies, vectors encoding both the heavy and light chains may be co-expressed in the host cell for expression of the entire immunoglobulin molecule, as detailed below.

A variety of host-expression vector systems may be utilized to express the antibody molecules of the invention. Such host-expression systems represent vehicles by which the coding sequences of interest may be produced and subsequently purified, but also represent cells which may, when transformed or transfected with the appropriate nucleotide coding sequences, express an antibody molecule of the invention in situ. These include but are not limited to microorganisms such as

bacteria (e.g., *E. coli*, *B. subtilis*) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing antibody coding sequences; yeast (e.g., *Saccharomyces*, *Pichia*) transformed with recombinant yeast expression vectors containing antibody coding sequences; insect cell systems  
5 infected with recombinant virus expression vectors (e.g., baculovirus) containing antibody coding sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing antibody coding sequences; or mammalian cell systems (e.g., COS, CHO,  
10 BHK, 293, 3T3 cells) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter). Preferably, bacterial cells such as *Escherichia coli*, and more preferably, eukaryotic cells, especially for the expression of whole  
15 recombinant antibody molecule, are used for the expression of a recombinant antibody molecule. For example, mammalian cells such as Chinese hamster ovary cells (CHO), in conjunction with a vector such as the major intermediate early gene promoter element from human cytomegalovirus is an effective expression system for antibodies (Foecking et al., *Gene* 45:101 (1986); Cockett et al., *Bio/Technology* 8:2  
20 (1990)).

In bacterial systems, a number of expression vectors may be advantageously selected depending upon the use intended for the antibody molecule being expressed. For example, when a large quantity of such a protein is to be produced, for the generation of pharmaceutical compositions of an antibody molecule, vectors which  
25 direct the expression of high levels of fusion protein products that are readily purified may be desirable. Such vectors include, but are not limited, to the *E. coli* expression vector pUR278 (Ruther et al., *EMBO J.* 2:1791 (1983)), in which the antibody coding sequence may be ligated individually into the vector in frame with the lac Z coding region so that a fusion protein is produced; pIN vectors (Inouye & Inouye, *Nucleic  
30 Acids Res.* 13:3101-3109 (1985); Van Heeke & Schuster, *J. Biol. Chem.* 24:5503-5509 (1989)); and the like. pGEX vectors may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such

fusion proteins are soluble and can easily be purified from lysed cells by adsorption and binding to matrix glutathione-agarose beads followed by elution in the presence of free glutathione. The pGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released from the  
5 GST moiety.

In an insect system, *Autographa californica* nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes. The virus grows in *Spodoptera frugiperda* cells. The antibody coding sequence may be cloned individually into non-essential regions (for example the polyhedrin gene) of the virus  
10 and placed under control of an AcNPV promoter (for example the polyhedrin promoter).

In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, the antibody coding sequence of interest may be ligated to an adenovirus transcription/translation  
15 control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by in vitro or in vivo recombination. Insertion in a non-essential region of the viral genome (e.g., region E1 or E3) will result in a recombinant virus that is viable and capable of expressing the antibody molecule in infected hosts. (e.g., see Logan & Shenk, Proc. Natl. Acad.  
20 Sci. USA 81:355-359 (1984)). Specific initiation signals may also be required for efficient translation of inserted antibody coding sequences. These signals include the ATG initiation codon and adjacent sequences. Furthermore, the initiation codon must be in phase with the reading frame of the desired coding sequence to ensure translation of the entire insert. These exogenous translational control signals and  
25 initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators, etc. (see Bittner et al., Methods in Enzymol. 153:51-544 (1987)).

In addition, a host cell strain may be chosen which modulates the expression  
30 of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (e.g., glycosylation) and processing (e.g., cleavage) of protein products may be important for the function of the protein.

Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed. To this end, eukaryotic host cells which possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product may be used. Such mammalian host cells include but are not limited to CHO, VERO, BHK, HeLa, COS, MDCK, 293, 3T3, WI38, and in particular, breast cancer cell lines such as, for example, BT483, Hs578T, HTB2, BT20 and T47D, and normal mammary gland cell line such as, for example, CRL7030 and Hs578Bst.

For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express the antibody molecule may be engineered. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression control elements (e.g., promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. This method may advantageously be used to engineer cell lines which express the antibody molecule. Such engineered cell lines may be particularly useful in screening and evaluation of compounds that interact directly or indirectly with the antibody molecule.

A number of selection systems may be used, including but not limited to the herpes simplex virus thymidine kinase (Wigler et al., Cell 11:223 (1977)), hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, Proc. Natl. Acad. Sci. USA 48:202 (1992)), and adenine phosphoribosyltransferase (Lowy et al., Cell 22:817 (1980)) genes can be employed in tk-, hgp<sup>r</sup>t- or ap<sup>r</sup>t- cells, respectively. Also, antimetabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler et al., Natl. Acad. Sci. USA 77:357 (1980); O'Hare et al., Proc. Natl. Acad. Sci. USA 78:1527 (1981)); gpt,



which confers resistance to mycophenolic acid (Mulligan & Berg, Proc. Natl. Acad. Sci. USA 78:2072 (1981)); neo, which confers resistance to the aminoglycoside G-418 Clinical Pharmacy 12:488-505; Wu and Wu, Biotherapy 3:87-95 (1991); Tolstoshev, Ann. Rev. Pharmacol. Toxicol. 32:573-596 (1993); Mulligan, Science 5 260:926-932 (1993); and Morgan and Anderson, Ann. Rev. Biochem. 62:191-217 (1993); May, 1993, TIB TECH 11(5):155-215); and hygro, which confers resistance to hygromycin (Santerre et al., Gene 30:147 (1984)). Methods commonly known in the art of recombinant DNA technology may be routinely applied to select the desired recombinant clone, and such methods are described, for example, in Ausubel et al. 10 (eds.), Current Protocols in Molecular Biology, John Wiley & Sons, NY (1993); Kriegler, Gene Transfer and Expression, A Laboratory Manual, Stockton Press, NY (1990); and in Chapters 12 and 13, Dracopoli et al. (eds), Current Protocols in Human Genetics, John Wiley & Sons, NY (1994); Colberre-Garapin et al., J. Mol. Biol. 150:1 (1981), which are incorporated by reference herein in their entireties.

15 The expression levels of an antibody molecule can be increased by vector amplification (for a review, see Bebbington and Hentschel, The use of vectors based on gene amplification for the expression of cloned genes in mammalian cells in DNA cloning, Vol.3. (Academic Press, New York, 1987)). When a marker in the vector system expressing antibody is amplifiable, increase in the level of inhibitor present in 20 culture of host cell will increase the number of copies of the marker gene. Since the amplified region is associated with the antibody gene, production of the antibody will also increase (Crouse et al., Mol. Cell. Biol. 3:257 (1983)).

The host cell may be co-transfected with two expression vectors of the invention, the first vector encoding a heavy chain derived polypeptide and the second 25 vector encoding a light chain derived polypeptide. The two vectors may contain identical selectable markers which enable equal expression of heavy and light chain polypeptides. Alternatively, a single vector may be used which encodes, and is capable of expressing, both heavy and light chain polypeptides. In such situations, the light chain should be placed before the heavy chain to avoid an excess of toxic 30 free heavy chain (Proudfoot, Nature 322:52 (1986); Kohler, Proc. Natl. Acad. Sci. USA 77:2197 (1980)). The coding sequences for the heavy and light chains may comprise cDNA or genomic DNA.

Once an antibody molecule of the invention has been produced by an animal, chemically synthesized, or recombinantly expressed, it may be purified by any method known in the art for purification of an immunoglobulin molecule, for example, by chromatography (e.g., ion exchange, affinity, particularly by affinity for the specific antigen after Protein A, and sizing column chromatography),  
5 centrifugation, differential solubility, or by any other standard technique for the purification of proteins. In addition, the antibodies of the present invention or fragments thereof can be fused to heterologous polypeptide sequences described herein or otherwise known in the art, to facilitate purification.

10 The present invention encompasses antibodies recombinantly fused or chemically conjugated (including both covalently and non-covalently conjugations) to a polypeptide (or portion thereof, preferably at least 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino acids of the polypeptide) of the present invention to generate fusion proteins. The fusion does not necessarily need to be direct, but may occur through  
15 linker sequences. The antibodies may be specific for antigens other than polypeptides (or portion thereof, preferably at least 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino acids of the polypeptide) of the present invention. For example, antibodies may be used to target the polypeptides of the present invention to particular cell types, either in vitro or in vivo, by fusing or conjugating the polypeptides of the present invention  
20 to antibodies specific for particular cell surface receptors. Antibodies fused or conjugated to the polypeptides of the present invention may also be used in in vitro immunoassays and purification methods using methods known in the art. See e.g., Harbor et al., supra, and PCT publication WO 93/21232; EP 439,095; Naramura et al., Immunol. Lett. 39:91-99 (1994); U.S. Patent 5,474,981; Gillies et al., PNAS  
25 89:1428-1432 (1992); Fell et al., J. Immunol. 146:2446-2452(1991), which are incorporated by reference in their entirety.

The present invention further includes compositions comprising the polypeptides of the present invention fused or conjugated to antibody domains other than the variable regions. For example, the polypeptides of the present invention may  
30 be fused or conjugated to an antibody Fc region, or portion thereof. The antibody portion fused to a polypeptide of the present invention may comprise the constant region, hinge region, CH1 domain, CH2 domain, and CH3 domain or any

combination of whole domains or portions thereof. The polypeptides may also be fused or conjugated to the above antibody portions to form multimers. For example, Fc portions fused to the polypeptides of the present invention can form dimers through disulfide bonding between the Fc portions. Higher multimeric forms can be made by fusing the polypeptides to portions of IgA and IgM. Methods for fusing or conjugating the polypeptides of the present invention to antibody portions are known in the art. See, e.g., U.S. Patent Nos. 5,336,603; 5,622,929; 5,359,046; 5,349,053; 5,447,851; 5,112,946; EP 307,434; EP 367,166; PCT publications WO 96/04388; WO 91/06570; Ashkenazi et al., Proc. Natl. Acad. Sci. USA 88:10535-10539 (1991); Zheng et al., J. Immunol. 154:5590-5600 (1995); and Vil et al., Proc. Natl. Acad. Sci. USA 89:11337-11341 (1992) (said references incorporated by reference in their entireties).

As discussed, supra, the polypeptides corresponding to a polypeptide, polypeptide fragment, or a variant of SEQ ID NO:Y may be fused or conjugated to the above antibody portions to increase the in vivo half life of the polypeptides or for use in immunoassays using methods known in the art. Further, the polypeptides corresponding to SEQ ID NO:Y may be fused or conjugated to the above antibody portions to facilitate purification. One reported example describes chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. (EP 394,827; Traunecker et al., Nature 331:84-86 (1988)). The polypeptides of the present invention fused or conjugated to an antibody having disulfide-linked dimeric structures (due to the IgG) may also be more efficient in binding and neutralizing other molecules, than the monomeric secreted protein or protein fragment alone. (Fountoulakis et al., J. Biochem. 270:3958-3964 (1995)). In many cases, the Fc part in a fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties. (EP A 232,262). Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified, would be desired. For example, the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for example, human proteins, such as hIL-5, have been fused with Fc portions for the purpose of high-throughput screening assays to

identify antagonists of hIL-5. (See, Bennett et al., J. Molecular Recognition 8:52-58 (1995); Johanson et al., J. Biol. Chem. 270:9459-9471 (1995).

Moreover, the antibodies or fragments thereof of the present invention can be fused to marker sequences, such as a peptide to facilitate purification. In preferred  
5 embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available. As described in Gentz et al., Proc. Natl. Acad. Sci. USA 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Other peptide tags  
10 useful for purification include, but are not limited to, the "HA" tag, which corresponds to an epitope derived from the influenza hemagglutinin protein (Wilson et al., Cell 37:767 (1984)) and the "flag" tag.

The present invention further encompasses antibodies or fragments thereof conjugated to a diagnostic or therapeutic agent. The antibodies can be used  
15 diagnostically to, for example, monitor the development or progression of a tumor as part of a clinical testing procedure to, e.g., determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent  
20 materials, radioactive materials, positron emitting metals using various positron emission tomographies, and nonradioactive paramagnetic metal ions. The detectable substance may be coupled or conjugated either directly to the antibody (or fragment thereof) or indirectly, through an intermediate (such as, for example, a linker known in the art) using techniques known in the art. See, for example, U.S. Patent No.  
25 4,741,900 for metal ions which can be conjugated to antibodies for use as diagnostics according to the present invention. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone,  
30 fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin,

and aequorin; and examples of suitable radioactive material include  $^{125}\text{I}$ ,  $^{131}\text{I}$ ,  $^{111}\text{In}$  or  $^{99}\text{Tc}$ .

Further, an antibody or fragment thereof may be conjugated to a therapeutic moiety such as a cytotoxin, e.g., a cytostatic or cytotoxic agent, a therapeutic agent or a radioactive metal ion, e.g., alpha-emitters such as, for example,  $^{213}\text{Bi}$ . A cytotoxin or cytotoxic agent includes any agent that is detrimental to cells. Examples include paclitaxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, teniposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof. Therapeutic agents include, but are not limited to, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (e.g., mechlorethamine, thioepa chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), and anti-mitotic agents (e.g., vincristine and vinblastine).

The conjugates of the invention can be used for modifying a given biological response, the therapeutic agent or drug moiety is not to be construed as limited to classical chemical therapeutic agents. For example, the drug moiety may be a protein or polypeptide possessing a desired biological activity. Such proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin; a protein such as tumor necrosis factor,  $\alpha$ -interferon,  $\beta$ -interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator, an apoptotic agent, e.g., TNF- $\alpha$ , TNF- $\beta$ , AIM I (See, International Publication No. WO 97/33899), AIM II (See, International Publication No. WO 97/34911), Fas Ligand (Takahashi *et al.*, *Int. Immunol.*, 6:1567-1574 (1994)), VEGI (See, International Publication No. WO 99/23105), a thrombotic agent or an anti-angiogenic agent, e.g., angiostatin or endostatin; or, biological response modifiers such as, for example, lymphokines, interleukin-1 ("IL-1"), interleukin-2 ("IL-2"), interleukin-6 ("IL-6"),

granulocyte macrophage colony stimulating factor ("GM-CSF"), granulocyte colony stimulating factor ("G-CSF"), or other growth factors.

Antibodies may also be attached to solid supports, which are particularly useful for immunoassays or purification of the target antigen. Such solid supports  
5 include, but are not limited to, glass, cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene.

Techniques for conjugating such therapeutic moiety to antibodies are well known, see, e.g., Arnon et al., "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy", in *Monoclonal Antibodies And Cancer Therapy*, Reisfeld  
10 et al. (eds.), pp. 243-56 (Alan R. Liss, Inc. 1985); Hellstrom et al., "Antibodies For Drug Delivery", in *Controlled Drug Delivery* (2nd Ed.), Robinson et al. (eds.), pp. 623-53 (Marcel Dekker, Inc. 1987); Thorpe, "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", in *Monoclonal Antibodies '84: Biological And Clinical Applications*, Pinchera et al. (eds.), pp. 475-506 (1985); "Analysis, Results,  
15 And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy", in *Monoclonal Antibodies For Cancer Detection And Therapy*, Baldwin et al. (eds.), pp. 303-16 (Academic Press 1985), and Thorpe et al., "The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates", *Immunol. Rev.* 62:119-58 (1982).

20 Alternatively, an antibody can be conjugated to a second antibody to form an antibody heteroconjugate as described by Segal in U.S. Patent No. 4,676,980, which is incorporated herein by reference in its entirety.

An antibody, with or without a therapeutic moiety conjugated to it, administered alone or in combination with cytotoxic factor(s) and/or cytokine(s) can  
25 be used as a therapeutic.

### *Immunophenotyping*

The antibodies of the invention may be utilized for immunophenotyping of cell lines and biological samples. The translation product of the gene of the present  
30 invention may be useful as a cell specific marker, or more specifically as a cellular marker that is differentially expressed at various stages of differentiation and/or maturation of particular cell types. Monoclonal antibodies directed against a specific

epitope, or combination of epitopes, will allow for the screening of cellular populations expressing the marker. Various techniques can be utilized using monoclonal antibodies to screen for cellular populations expressing the marker(s), and include magnetic separation using antibody-coated magnetic beads, "panning" with antibody attached to a solid matrix (i.e., plate), and flow cytometry (See, e.g., U.S. Patent 5,985,660; and Morrison *et al.*, *Cell*, 96:737-49 (1999)).

These techniques allow for the screening of particular populations of cells, such as might be found with hematological malignancies (i.e. minimal residual disease (MRD) in acute leukemic patients) and "non-self" cells in transplantations to prevent Graft-versus-Host Disease (GVHD). Alternatively, these techniques allow for the screening of hematopoietic stem and progenitor cells capable of undergoing proliferation and/or differentiation, as might be found in human umbilical cord blood.

#### *Assays For Antibody Binding*

The antibodies of the invention may be assayed for immunospecific binding by any method known in the art. The immunoassays which can be used include but are not limited to competitive and non-competitive assay systems using techniques such as western blots, radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, immunoprecipitation assays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement-fixation assays, immunoradiometric assays, fluorescent immunoassays, protein A immunoassays, to name but a few. Such assays are routine and well known in the art (see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York, which is incorporated by reference herein in its entirety). Exemplary immunoassays are described briefly below (but are not intended by way of limitation).

Immunoprecipitation protocols generally comprise lysing a population of cells in a lysis buffer such as RIPA buffer (1% NP-40 or Triton X- 100, 1% sodium deoxycholate, 0.1% SDS, 0.15 M NaCl, 0.01 M sodium phosphate at pH 7.2, 1% Trasylol) supplemented with protein phosphatase and/or protease inhibitors (e.g., EDTA, PMSF, aprotinin, sodium vanadate), adding the antibody of interest to the cell lysate, incubating for a period of time (e.g., 1-4 hours) at 4° C, adding protein A

and/or protein G sepharose beads to the cell lysate, incubating for about an hour or more at 4° C, washing the beads in lysis buffer and resuspending the beads in SDS/sample buffer. The ability of the antibody of interest to immunoprecipitate a particular antigen can be assessed by, e.g., western blot analysis. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the binding of the antibody to an antigen and decrease the background (e.g., pre-clearing the cell lysate with sepharose beads). For further discussion regarding immunoprecipitation protocols see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 10.16.1.

Western blot analysis generally comprises preparing protein samples, electrophoresis of the protein samples in a polyacrylamide gel (e.g., 8%- 20% SDS-PAGE depending on the molecular weight of the antigen), transferring the protein sample from the polyacrylamide gel to a membrane such as nitrocellulose, PVDF or nylon, blocking the membrane in blocking solution (e.g., PBS with 3% BSA or non-fat milk), washing the membrane in washing buffer (e.g., PBS-Tween 20), blocking the membrane with primary antibody (the antibody of interest) diluted in blocking buffer, washing the membrane in washing buffer, blocking the membrane with a secondary antibody (which recognizes the primary antibody, e.g., an anti-human antibody) conjugated to an enzymatic substrate (e.g., horseradish peroxidase or alkaline phosphatase) or radioactive molecule (e.g., <sup>32</sup>P or <sup>125</sup>I) diluted in blocking buffer, washing the membrane in wash buffer, and detecting the presence of the antigen. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the signal detected and to reduce the background noise. For further discussion regarding western blot protocols see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 10.8.1.

ELISAs comprise preparing antigen, coating the well of a 96 well microtiter plate with the antigen, adding the antibody of interest conjugated to a detectable compound such as an enzymatic substrate (e.g., horseradish peroxidase or alkaline phosphatase) to the well and incubating for a period of time, and detecting the presence of the antigen. In ELISAs the antibody of interest does not have to be conjugated to a detectable compound; instead, a second antibody (which recognizes



the antibody of interest) conjugated to a detectable compound may be added to the well. Further, instead of coating the well with the antigen, the antibody may be coated to the well. In this case, a second antibody conjugated to a detectable compound may be added following the addition of the antigen of interest to the coated well. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the signal detected as well as other variations of ELISAs known in the art. For further discussion regarding ELISAs see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 11.2.1.

10           The binding affinity of an antibody to an antigen and the off-rate of an antibody-antigen interaction can be determined by competitive binding assays. One example of a competitive binding assay is a radioimmunoassay comprising the incubation of labeled antigen (e.g., 3H or 125I) with the antibody of interest in the presence of increasing amounts of unlabeled antigen, and the detection of the antibody bound to the labeled antigen. The affinity of the antibody of interest for a particular antigen and the binding off-rates can be determined from the data by scatchard plot analysis. Competition with a second antibody can also be determined using radioimmunoassays. In this case, the antigen is incubated with antibody of interest conjugated to a labeled compound (e.g., 3H or 125I) in the presence of increasing amounts of an unlabeled second antibody.

### *Therapeutic Uses*

25           The present invention is further directed to antibody-based therapies which involve administering antibodies of the invention to an animal, preferably a mammal, and most preferably a human, patient for treating one or more of the disclosed diseases, disorders, or conditions. Therapeutic compounds of the invention include, but are not limited to, antibodies of the invention (including fragments, analogs and derivatives thereof as described herein) and nucleic acids encoding antibodies of the invention (including fragments, analogs and derivatives thereof and anti-idiotypic antibodies as described herein). The antibodies of the invention can be used to treat, inhibit or prevent diseases, disorders or conditions associated with aberrant expression and/or activity of a polypeptide of the invention, including, but not limited to, any

one or more of the diseases, disorders, or conditions described herein. The treatment and/or prevention of diseases, disorders, or conditions associated with aberrant expression and/or activity of a polypeptide of the invention includes, but is not limited to, alleviating symptoms associated with those diseases, disorders or  
5 conditions. Antibodies of the invention may be provided in pharmaceutically acceptable compositions as known in the art or as described herein.

A summary of the ways in which the antibodies of the present invention may be used therapeutically includes binding polynucleotides or polypeptides of the present invention locally or systemically in the body or by direct cytotoxicity of the  
10 antibody, e.g. as mediated by complement (CDC) or by effector cells (ADCC). Some of these approaches are described in more detail below. Armed with the teachings provided herein, one of ordinary skill in the art will know how to use the antibodies of the present invention for diagnostic, monitoring or therapeutic purposes without undue experimentation.

15 The antibodies of this invention may be advantageously utilized in combination with other monoclonal or chimeric antibodies, or with lymphokines or hematopoietic growth factors (such as, e.g., IL-2, IL-3 and IL-7), for example, which serve to increase the number or activity of effector cells which interact with the antibodies.

20 The antibodies of the invention may be administered alone or in combination with other types of treatments (e.g., radiation therapy, chemotherapy, hormonal therapy, immunotherapy and anti-tumor agents). Generally, administration of products of a species origin or species reactivity (in the case of antibodies) that is the same species as that of the patient is preferred. Thus, in a preferred embodiment,  
25 human antibodies, fragments derivatives, analogs, or nucleic acids, are administered to a human patient for therapy or prophylaxis.

It is preferred to use high affinity and/or potent in vivo inhibiting and/or neutralizing antibodies against polypeptides or polynucleotides of the present invention, fragments or regions thereof, for both immunoassays directed to and  
30 therapy of disorders related to polynucleotides or polypeptides, including fragments thereof, of the present invention. Such antibodies, fragments, or regions, will preferably have an affinity for polynucleotides or polypeptides of the invention,

including fragments thereof. Preferred binding affinities include those with a dissociation constant or  $K_d$  less than  $5 \times 10^{-2}$  M,  $10^{-2}$  M,  $5 \times 10^{-3}$  M,  $10^{-3}$  M,  $5 \times 10^{-4}$  M,  $10^{-4}$  M,  $5 \times 10^{-5}$  M,  $10^{-5}$  M,  $5 \times 10^{-6}$  M,  $10^{-6}$  M,  $5 \times 10^{-7}$  M,  $10^{-7}$  M,  $5 \times 10^{-8}$  M,  $10^{-8}$  M,  $5 \times 10^{-9}$  M,  $10^{-9}$  M,  $5 \times 10^{-10}$  M,  $10^{-10}$  M,  $5 \times 10^{-11}$  M,  $10^{-11}$  M,  $5 \times 10^{-12}$  M,  $10^{-12}$  M,  $5 \times 10^{-13}$  M,  $10^{-13}$  M,  $5 \times 10^{-14}$  M,  $10^{-14}$  M,  $5 \times 10^{-15}$  M, and  $10^{-15}$  M.

### *Gene Therapy*

In a specific embodiment, nucleic acids comprising sequences encoding antibodies or functional derivatives thereof, are administered to treat, inhibit or prevent a disease or disorder associated with aberrant expression and/or activity of a polypeptide of the invention, by way of gene therapy. Gene therapy refers to therapy performed by the administration to a subject of an expressed or expressible nucleic acid. In this embodiment of the invention, the nucleic acids produce their encoded protein that mediates a therapeutic effect.

Any of the methods for gene therapy available in the art can be used according to the present invention. Exemplary methods are described below.

For general reviews of the methods of gene therapy, see Goldspiel et al., *Clinical Pharmacy* 12:488-505 (1993); Wu and Wu, *Biotherapy* 3:87-95 (1991); Tolstoshev, *Ann. Rev. Pharmacol. Toxicol.* 32:573-596 (1993); Mulligan, *Science* 260:926-932 (1993); and Morgan and Anderson, *Ann. Rev. Biochem.* 62:191-217 (1993); May, *TIBTECH* 11(5):155-215 (1993). Methods commonly known in the art of recombinant DNA technology which can be used are described in Ausubel et al. (eds.), *Current Protocols in Molecular Biology*, John Wiley & Sons, NY (1993); and Kriegler, *Gene Transfer and Expression, A Laboratory Manual*, Stockton Press, NY (1990).

In a preferred aspect, the compound comprises nucleic acid sequences encoding an antibody, said nucleic acid sequences being part of expression vectors that express the antibody or fragments or chimeric proteins or heavy or light chains thereof in a suitable host. In particular, such nucleic acid sequences have promoters operably linked to the antibody coding region, said promoter being inducible or constitutive, and, optionally, tissue-specific. In another particular embodiment, nucleic acid molecules are used in which the antibody coding sequences and any other

desired sequences are flanked by regions that promote homologous recombination at a desired site in the genome, thus providing for intrachromosomal expression of the antibody encoding nucleic acids (Koller and Smithies, Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); Zijlstra et al., Nature 342:435-438 (1989). In specific  
5       embodiments, the expressed antibody molecule is a single chain antibody;  
alternatively, the nucleic acid sequences include sequences encoding both the heavy and light chains, or fragments thereof, of the antibody.

Delivery of the nucleic acids into a patient may be either direct, in which case the patient is directly exposed to the nucleic acid or nucleic acid- carrying vectors, or  
10       indirect, in which case, cells are first transformed with the nucleic acids in vitro, then transplanted into the patient. These two approaches are known, respectively, as in vivo or ex vivo gene therapy.

In a specific embodiment, the nucleic acid sequences are directly administered in vivo, where it is expressed to produce the encoded product. This can be  
15       accomplished by any of numerous methods known in the art, e.g., by constructing them as part of an appropriate nucleic acid expression vector and administering it so that they become intracellular, e.g., by infection using defective or attenuated retrovirals or other viral vectors (see U.S. Patent No. 4,980,286), or by direct injection of naked DNA, or by use of microparticle bombardment (e.g., a gene gun;  
20       Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, encapsulation in liposomes, microparticles, or microcapsules, or by administering them in linkage to a peptide which is known to enter the nucleus, by administering it in linkage to a ligand subject to receptor-mediated endocytosis (see, e.g., Wu and Wu, J. Biol. Chem. 262:4429-4432 (1987)) (which can be used to target  
25       cell types specifically expressing the receptors), etc. In another embodiment, nucleic acid-ligand complexes can be formed in which the ligand comprises a fusogenic viral peptide to disrupt endosomes, allowing the nucleic acid to avoid lysosomal degradation. In yet another embodiment, the nucleic acid can be targeted in vivo for cell specific uptake and expression, by targeting a specific receptor (see, e.g., PCT  
30       Publications WO 92/06180; WO 92/22635; WO92/20316; WO93/14188, WO 93/20221). Alternatively, the nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination

(Koller and Smithies, *Proc. Natl. Acad. Sci. USA* 86:8932-8935 (1989); Zijlstra et al., *Nature* 342:435-438 (1989)).

In a specific embodiment, viral vectors that contains nucleic acid sequences encoding an antibody of the invention are used. For example, a retroviral vector can be used (see Miller et al., *Meth. Enzymol.* 217:581-599 (1993)). These retroviral vectors contain the components necessary for the correct packaging of the viral genome and integration into the host cell DNA. The nucleic acid sequences encoding the antibody to be used in gene therapy are cloned into one or more vectors, which facilitates delivery of the gene into a patient. More detail about retroviral vectors can be found in Boesen et al., *Biotherapy* 6:291-302 (1994), which describes the use of a retroviral vector to deliver the *mdr1* gene to hematopoietic stem cells in order to make the stem cells more resistant to chemotherapy. Other references illustrating the use of retroviral vectors in gene therapy are: Clowes et al., *J. Clin. Invest.* 93:644-651 (1994); Kiem et al., *Blood* 83:1467-1473 (1994); Salmons and Gunzberg, *Human Gene Therapy* 4:129-141 (1993); and Grossman and Wilson, *Curr. Opin. in Genetics and Devel.* 3:110-114 (1993).

Adenoviruses are other viral vectors that can be used in gene therapy. Adenoviruses are especially attractive vehicles for delivering genes to respiratory epithelia. Adenoviruses naturally infect respiratory epithelia where they cause a mild disease. Other targets for adenovirus-based delivery systems are liver, the central nervous system, endothelial cells, and muscle. Adenoviruses have the advantage of being capable of infecting non-dividing cells. Kozarsky and Wilson, *Current Opinion in Genetics and Development* 3:499-503 (1993) present a review of adenovirus-based gene therapy. Bout et al., *Human Gene Therapy* 5:3-10 (1994) demonstrated the use of adenovirus vectors to transfer genes to the respiratory epithelia of rhesus monkeys. Other instances of the use of adenoviruses in gene therapy can be found in Rosenfeld et al., *Science* 252:431-434 (1991); Rosenfeld et al., *Cell* 68:143-155 (1992); Mastrangeli et al., *J. Clin. Invest.* 91:225-234 (1993); PCT Publication WO94/12649; and Wang, et al., *Gene Therapy* 2:775-783 (1995). In a preferred embodiment, adenovirus vectors are used.

Adeno-associated virus (AAV) has also been proposed for use in gene therapy (Walsh et al., Proc. Soc. Exp. Biol. Med. 204:289-300 (1993); U.S. Patent No. 5,436,146).

Another approach to gene therapy involves transferring a gene to cells in tissue culture by such methods as electroporation, lipofection, calcium phosphate mediated transfection, or viral infection. Usually, the method of transfer includes the transfer of a selectable marker to the cells. The cells are then placed under selection to isolate those cells that have taken up and are expressing the transferred gene. Those cells are then delivered to a patient.

10 In this embodiment, the nucleic acid is introduced into a cell prior to administration in vivo of the resulting recombinant cell. Such introduction can be carried out by any method known in the art, including but not limited to transfection, electroporation, microinjection, infection with a viral or bacteriophage vector containing the nucleic acid sequences, cell fusion, chromosome-mediated gene transfer, microcell-mediated gene transfer, spheroplast fusion, etc. Numerous techniques are known in the art for the introduction of foreign genes into cells (see, e.g., Loeffler and Behr, Meth. Enzymol. 217:599-618 (1993); Cohen et al., Meth. Enzymol. 217:618-644 (1993); Cline, Pharmac. Ther. 29:69-92m (1985) and may be used in accordance with the present invention, provided that the necessary developmental and physiological functions of the recipient cells are not disrupted. The technique should provide for the stable transfer of the nucleic acid to the cell, so that the nucleic acid is expressible by the cell and preferably heritable and expressible by its cell progeny.

25 The resulting recombinant cells can be delivered to a patient by various methods known in the art. Recombinant blood cells (e.g., hematopoietic stem or progenitor cells) are preferably administered intravenously. The amount of cells envisioned for use depends on the desired effect, patient state, etc., and can be determined by one skilled in the art.

Cells into which a nucleic acid can be introduced for purposes of gene therapy encompass any desired, available cell type, and include but are not limited to epithelial cells, endothelial cells, keratinocytes, fibroblasts, muscle cells, hepatocytes; blood cells such as Tlymphocytes, Blymphocytes, monocytes, macrophages,

neutrophils, eosinophils, megakaryocytes, granulocytes; various stem or progenitor cells, in particular hematopoietic stem or progenitor cells, e.g., as obtained from bone marrow, umbilical cord blood, peripheral blood, fetal liver, etc.

5 In a preferred embodiment, the cell used for gene therapy is autologous to the patient.

In an embodiment in which recombinant cells are used in gene therapy, nucleic acid sequences encoding an antibody are introduced into the cells such that they are expressible by the cells or their progeny, and the recombinant cells are then administered in vivo for therapeutic effect. In a specific embodiment, stem or  
10 progenitor cells are used. Any stem and/or progenitor cells which can be isolated and maintained in vitro can potentially be used in accordance with this embodiment of the present invention (see e.g. PCT Publication WO 94/08598; Stemple and Anderson, Cell 71:973-985 (1992); Rheinwald, Meth. Cell Bio. 21A:229 (1980); and Pittelkow and Scott, Mayo Clinic Proc. 61:771 (1986)).

15 In a specific embodiment, the nucleic acid to be introduced for purposes of gene therapy comprises an inducible promoter operably linked to the coding region, such that expression of the nucleic acid is controllable by controlling the presence or absence of the appropriate inducer of transcription.

#### 20 *Demonstration of Therapeutic or Prophylactic Activity*

The compounds or pharmaceutical compositions of the invention are preferably tested in vitro, and then in vivo for the desired therapeutic or prophylactic activity, prior to use in humans. For example, in vitro assays to demonstrate the therapeutic or prophylactic utility of a compound or pharmaceutical composition  
25 include, the effect of a compound on a cell line or a patient tissue sample. The effect of the compound or composition on the cell line and/or tissue sample can be determined utilizing techniques known to those of skill in the art including, but not limited to, rosette formation assays and cell lysis assays. In accordance with the invention, in vitro assays which can be used to determine whether administration of a  
30 specific compound is indicated, include in vitro cell culture assays in which a patient tissue sample is grown in culture, and exposed to or otherwise administered a compound, and the effect of such compound upon the tissue sample is observed.

*Therapeutic/Prophylactic Administration and Composition*

The invention provides methods of treatment, inhibition and prophylaxis by administration to a subject of an effective amount of a compound or pharmaceutical composition of the invention, preferably an antibody of the invention. In a preferred aspect, the compound is substantially purified (e.g., substantially free from substances that limit its effect or produce undesired side-effects). The subject is preferably an animal, including but not limited to animals such as cows, pigs, horses, chickens, cats, dogs, etc., and is preferably a mammal, and most preferably human.

Formulations and methods of administration that can be employed when the compound comprises a nucleic acid or an immunoglobulin are described above; additional appropriate formulations and routes of administration can be selected from among those described herein below.

Various delivery systems are known and can be used to administer a compound of the invention, e.g., encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the compound, receptor-mediated endocytosis (see, e.g., Wu and Wu, J. Biol. Chem. 262:4429-4432 (1987)), construction of a nucleic acid as part of a retroviral or other vector, etc. Methods of introduction include but are not limited to intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The compounds or compositions may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local. In addition, it may be desirable to introduce the pharmaceutical compounds or compositions of the invention into the central nervous system by any suitable route, including intraventricular and intrathecal injection; intraventricular injection may be facilitated by an intraventricular catheter, for example, attached to a reservoir, such as an Ommaya reservoir. Pulmonary administration can also be employed, e.g., by use of an inhaler or nebulizer, and formulation with an aerosolizing agent.

In a specific embodiment, it may be desirable to administer the pharmaceutical compounds or compositions of the invention locally to the area in need of treatment;



this may be achieved by, for example, and not by way of limitation, local infusion during surgery, topical application, e.g., in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers. Preferably, when  
5 administering a protein, including an antibody, of the invention, care must be taken to use materials to which the protein does not absorb.

In another embodiment, the compound or composition can be delivered in a vesicle, in particular a liposome (see Langer, *Science* 249:1527-1533 (1990); Treat et al., in *Liposomes in the Therapy of Infectious Disease and Cancer*, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353- 365 (1989); Lopez-Berestein, *ibid.*, pp. 317-327; see generally *ibid.*)  
10

In yet another embodiment, the compound or composition can be delivered in a controlled release system. In one embodiment, a pump may be used (see Langer, supra; Sefton, *CRC Crit. Ref. Biomed. Eng.* 14:201 (1987); Buchwald et al., *Surgery* 88:507 (1980); Saudek et al., *N. Engl. J. Med.* 321:574 (1989)). In another embodiment, polymeric materials can be used (see *Medical Applications of Controlled Release*, Langer and Wise (eds.), CRC Pres., Boca Raton, Florida (1974); *Controlled Drug Bioavailability, Drug Product Design and Performance*, Smolen and Ball (eds.), Wiley, New York (1984); Ranger and Peppas, J., *Macromol. Sci. Rev. Macromol. Chem.* 23:61 (1983); see also Levy et al., *Science* 228:190 (1985); During et al., *Ann. Neurol.* 25:351 (1989); Howard et al., *J. Neurosurg.* 71:105 (1989)). In yet another embodiment, a controlled release system can be placed in proximity of the therapeutic target, i.e., the brain, thus requiring only a fraction of the systemic dose  
20 (see, e.g., Goodson, in *Medical Applications of Controlled Release*, supra, vol. 2, pp. 115-138 (1984)).  
25

Other controlled release systems are discussed in the review by Langer (*Science* 249:1527-1533 (1990)).

In a specific embodiment where the compound of the invention is a nucleic acid encoding a protein, the nucleic acid can be administered in vivo to promote  
30 expression of its encoded protein, by constructing it as part of an appropriate nucleic acid expression vector and administering it so that it becomes intracellular, e.g., by

use of a retroviral vector (see U.S. Patent No. 4,980,286), or by direct injection, or by use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, or by administering it in linkage to a homeobox- like peptide which is known to enter the nucleus (see e.g.,  
5 Joliot et al., Proc. Natl. Acad. Sci. USA 88:1864-1868 (1991)), etc. Alternatively, a nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination.

The present invention also provides pharmaceutical compositions. Such compositions comprise a therapeutically effective amount of a compound, and a  
10 pharmaceutically acceptable carrier. In a specific embodiment, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic  
15 is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid  
20 carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering  
25 agents. These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like. The composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides. Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium  
30 saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E.W. Martin. Such compositions will contain a therapeutically effective amount of

the compound, preferably in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the patient. The formulation should suit the mode of administration.

In a preferred embodiment, the composition is formulated in accordance with  
5 routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings. Typically, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the composition may also include a solubilizing agent and a local anesthetic such as lignocaine to ease pain at the site of the injection. Generally, the ingredients are  
10 supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition  
15 is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.

The compounds of the invention can be formulated as neutral or salt forms. Pharmaceutically acceptable salts include those formed with anions such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those  
20 formed with cations such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, etc.

The amount of the compound of the invention which will be effective in the treatment, inhibition and prevention of a disease or disorder associated with aberrant  
25 expression and/or activity of a polypeptide of the invention can be determined by standard clinical techniques. In addition, in vitro assays may optionally be employed to help identify optimal dosage ranges. The precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the  
30 practitioner and each patient's circumstances. Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems.

For antibodies, the dosage administered to a patient is typically 0.1 mg/kg to 100 mg/kg of the patient's body weight. Preferably, the dosage administered to a patient is between 0.1 mg/kg and 20 mg/kg of the patient's body weight, more preferably 1 mg/kg to 10 mg/kg of the patient's body weight. Generally, human  
5 antibodies have a longer half-life within the human body than antibodies from other species due to the immune response to the foreign polypeptides. Thus, lower dosages of human antibodies and less frequent administration is often possible. Further, the dosage and frequency of administration of antibodies of the invention may be reduced by enhancing uptake and tissue penetration (e.g., into the brain) of the  
10 antibodies by modifications such as, for example, lipidation.

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture,  
15 use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.

### *Diagnosis and Imaging*

Labeled antibodies, and derivatives and analogs thereof, which specifically  
20 bind to a polypeptide of interest can be used for diagnostic purposes to detect, diagnose, or monitor diseases, disorders, and/or conditions associated with the aberrant expression and/or activity of a polypeptide of the invention. The invention provides for the detection of aberrant expression of a polypeptide of interest, comprising (a) assaying the expression of the polypeptide of interest in cells or body  
25 fluid of an individual using one or more antibodies specific to the polypeptide interest and (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of aberrant expression.

The invention provides a diagnostic assay for diagnosing a disorder,  
30 comprising (a) assaying the expression of the polypeptide of interest in cells or body fluid of an individual using one or more antibodies specific to the polypeptide interest and (b) comparing the level of gene expression with a standard gene expression level,

whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of a particular disorder. With respect to cancer, the presence of a relatively high amount of transcript in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Antibodies of the invention can be used to assay protein levels in a biological sample using classical immunohistological methods known to those of skill in the art (e.g., see Jalkanen, et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, et al., J. Cell Biol. 105:3087-3096 (1987)). Other antibody-based methods useful for detecting protein gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known in the art and include enzyme labels, such as, glucose oxidase; radioisotopes, such as iodine ( $^{125}\text{I}$ ,  $^{121}\text{I}$ ), carbon ( $^{14}\text{C}$ ), sulfur ( $^{35}\text{S}$ ), tritium ( $^3\text{H}$ ), indium ( $^{112}\text{In}$ ), and technetium ( $^{99}\text{Tc}$ ); luminescent labels, such as luminol; and fluorescent labels, such as fluorescein and rhodamine, and biotin.

One aspect of the invention is the detection and diagnosis of a disease or disorder associated with aberrant expression of a polypeptide of interest in an animal, preferably a mammal and most preferably a human. In one embodiment, diagnosis comprises: a) administering (for example, parenterally, subcutaneously, or intraperitoneally) to a subject an effective amount of a labeled molecule which specifically binds to the polypeptide of interest; b) waiting for a time interval following the administering for permitting the labeled molecule to preferentially concentrate at sites in the subject where the polypeptide is expressed (and for unbound labeled molecule to be cleared to background level); c) determining background level; and d) detecting the labeled molecule in the subject, such that detection of labeled molecule above the background level indicates that the subject has a particular disease or disorder associated with aberrant expression of the polypeptide of interest. Background level can be determined by various methods

including, comparing the amount of labeled molecule detected to a standard value previously determined for a particular system.

It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety needed to produce  
5 diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of <sup>99m</sup>Tc. The labeled antibody or antibody fragment will then preferentially accumulate at the location of cells which contain the specific protein. In vivo tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of  
10 Radiolabeled Antibodies and Their Fragments." (Chapter 13 in Tumor Imaging: The Radiochemical Detection of Cancer, S.W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982).

Depending on several variables, including the type of label used and the mode of administration, the time interval following the administration for permitting the  
15 labeled molecule to preferentially concentrate at sites in the subject and for unbound labeled molecule to be cleared to background level is 6 to 48 hours or 6 to 24 hours or 6 to 12 hours. In another embodiment the time interval following administration is 5 to 20 days or 5 to 10 days.

In an embodiment, monitoring of the disease or disorder is carried out by  
20 repeating the method for diagnosing the disease or disease, for example, one month after initial diagnosis, six months after initial diagnosis, one year after initial diagnosis, etc.

Presence of the labeled molecule can be detected in the patient using methods known in the art for in vivo scanning. These methods depend upon the type of label  
25 used. Skilled artisans will be able to determine the appropriate method for detecting a particular label. Methods and devices that may be used in the diagnostic methods of the invention include, but are not limited to, computed tomography (CT), whole body scan such as position emission tomography (PET), magnetic resonance imaging (MRI), and sonography.

30 In a specific embodiment, the molecule is labeled with a radioisotope and is detected in the patient using a radiation responsive surgical instrument (Thurston et al., U.S. Patent No. 5,441,050). In another embodiment, the molecule is labeled with

a fluorescent compound and is detected in the patient using a fluorescence responsive scanning instrument. In another embodiment, the molecule is labeled with a positron emitting metal and is detected in the patient using positron emission-tomography. In yet another embodiment, the molecule is labeled with a paramagnetic label and is  
5 detected in a patient using magnetic resonance imaging (MRI).

### *Kits*

The present invention provides kits that can be used in the above methods. In one embodiment, a kit comprises an antibody of the invention, preferably a purified  
10 antibody, in one or more containers. In a specific embodiment, the kits of the present invention contain a substantially isolated polypeptide comprising an epitope which is specifically immunoreactive with an antibody included in the kit. Preferably, the kits of the present invention further comprise a control antibody which does not react with the polypeptide of interest. In another specific embodiment, the kits of the present  
15 invention contain a means for detecting the binding of an antibody to a polypeptide of interest (e.g., the antibody may be conjugated to a detectable substrate such as a fluorescent compound, an enzymatic substrate, a radioactive compound or a luminescent compound, or a second antibody which recognizes the first antibody may be conjugated to a detectable substrate).

20 In another specific embodiment of the present invention, the kit is a diagnostic kit for use in screening serum containing antibodies specific against proliferative and/or cancerous polynucleotides and polypeptides. Such a kit may include a control antibody that does not react with the polypeptide of interest. Such a kit may include a substantially isolated polypeptide antigen comprising an epitope which is specifically  
25 immunoreactive with at least one anti-polypeptide antigen antibody. Further, such a kit includes means for detecting the binding of said antibody to the antigen (e.g., the antibody may be conjugated to a fluorescent compound such as fluorescein or rhodamine which can be detected by flow cytometry). In specific embodiments, the kit may include a recombinantly produced or chemically synthesized polypeptide  
30 antigen. The polypeptide antigen of the kit may also be attached to a solid support.

In a more specific embodiment the detecting means of the above-described kit includes a solid support to which said polypeptide antigen is attached. Such a kit may

also include a non-attached reporter-labeled anti-human antibody. In this embodiment, binding of the antibody to the polypeptide antigen can be detected by binding of the said reporter-labeled antibody.

In an additional embodiment, the invention includes a diagnostic kit for use in screening serum containing antigens of the polypeptide of the invention. The diagnostic kit includes a substantially isolated antibody specifically immunoreactive with polypeptide or polynucleotide antigens, and means for detecting the binding of the polynucleotide or polypeptide antigen to the antibody. In one embodiment, the antibody is attached to a solid support. In a specific embodiment, the antibody may be a monoclonal antibody. The detecting means of the kit may include a second, labeled monoclonal antibody. Alternatively, or in addition, the detecting means may include a labeled, competing antigen.

In one diagnostic configuration, test serum is reacted with a solid phase reagent having a surface-bound antigen obtained by the methods of the present invention. After binding with specific antigen antibody to the reagent and removing unbound serum components by washing, the reagent is reacted with reporter-labeled anti-human antibody to bind reporter to the reagent in proportion to the amount of bound anti-antigen antibody on the solid support. The reagent is again washed to remove unbound labeled antibody, and the amount of reporter associated with the reagent is determined. Typically, the reporter is an enzyme which is detected by incubating the solid phase in the presence of a suitable fluorometric, luminescent or colorimetric substrate (Sigma, St. Louis, MO).

The solid surface reagent in the above assay is prepared by known techniques for attaching protein material to solid support material, such as polymeric beads, dip sticks, 96-well plate or filter material. These attachment methods generally include non-specific adsorption of the protein to the support or covalent attachment of the protein, typically through a free amine group, to a chemically reactive group on the solid support, such as an activated carboxyl, hydroxyl, or aldehyde group. Alternatively, streptavidin coated plates can be used in conjunction with biotinylated antigen(s).

Thus, the invention provides an assay system or kit for carrying out this diagnostic method. The kit generally includes a support with surface-bound



recombinant antigens, and a reporter-labeled anti-human antibody for detecting surface-bound anti-antigen antibody.

### **Fusion Proteins**

5 Any polypeptide of the present invention can be used to generate fusion proteins. For example, the polypeptide of the present invention, when fused to a second protein, can be used as an antigenic tag. Antibodies raised against the polypeptide of the present invention can be used to indirectly detect the second protein by binding to the polypeptide. Moreover, because secreted proteins target  
10 cellular locations based on trafficking signals, the polypeptides of the present invention can be used as targeting molecules once fused to other proteins.

Examples of domains that can be fused to polypeptides of the present invention include not only heterologous signal sequences, but also other heterologous functional regions. The fusion does not necessarily need to be direct, but may occur  
15 through linker sequences.

Moreover, fusion proteins may also be engineered to improve characteristics of the polypeptide of the present invention. For instance, a region of additional amino acids, particularly charged amino acids, may be added to the N-terminus of the polypeptide to improve stability and persistence during purification from the host cell  
20 or subsequent handling and storage. Also, peptide moieties may be added to the polypeptide to facilitate purification. Such regions may be removed prior to final preparation of the polypeptide. The addition of peptide moieties to facilitate handling of polypeptides are familiar and routine techniques in the art.

Moreover, polypeptides of the present invention, including fragments, and  
25 specifically epitopes, can be combined with parts of the constant domain of immunoglobulins (IgA, IgE, IgG, IgM) or portions thereof (CH1, CH2, CH3, and any combination thereof, including both entire domains and portions thereof), resulting in chimeric polypeptides. These fusion proteins facilitate purification and show an increased half-life in vivo. One reported example describes chimeric proteins  
30 consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. (EP A 394,827; Traunecker et al., Nature 331:84-86 (1988).)

Fusion proteins having disulfide-linked dimeric structures (due to the IgG) can also be more efficient in binding and neutralizing other molecules, than the monomeric secreted protein or protein fragment alone. (Fountoulakis et al., J. Biochem. 270:3958-3964 (1995).) Polynucleotides comprising or alternatively consisting of  
5 nucleic acids which encode these fusion proteins are also encompassed by the invention.

Similarly, EP-A-O 464 533 (Canadian counterpart 2045869) discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, the Fc part in a  
10 fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties. (EP-A 0232 262.) Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified, would be desired. For example, the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for  
15 example, human proteins, such as hIL-5, have been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5. (See, D. Bennett et al., J. Molecular Recognition 8:52-58 (1995); K. Johanson et al., J. Biol. Chem. 270:9459-9471 (1995).)

Moreover, the polypeptides of the present invention can be fused to marker  
20 sequences, such as a peptide which facilitates purification of the fused polypeptide. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available. As described in Gentz et al., Proc. Natl. Acad. Sci. USA 86:821-824 (1989), for  
25 instance, hexa-histidine provides for convenient purification of the fusion protein. Another peptide tag useful for purification, the "HA" tag, corresponds to an epitope derived from the influenza hemagglutinin protein. (Wilson et al., Cell 37:767 (1984).)

Thus, any of these above fusions can be engineered using the polynucleotides  
30 or the polypeptides of the present invention.

### **Vectors, Host Cells, and Protein Production**

The present invention also relates to vectors containing the polynucleotide of the present invention, host cells, and the production of polypeptides by recombinant techniques. The vector may be, for example, a phage, plasmid, viral, or retroviral vector. Retroviral vectors may be replication competent or replication defective. In the latter case, viral propagation generally will occur only in complementing host cells.

The polynucleotides may be joined to a vector containing a selectable marker for propagation in a host. Generally, a plasmid vector is introduced in a precipitate, such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the vector is a virus, it may be packaged in vitro using an appropriate packaging cell line and then transduced into host cells.

The polynucleotide insert should be operatively linked to an appropriate promoter, such as the phage lambda PL promoter, the *E. coli* lac, trp, phoA and tac promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to name a few. Other suitable promoters will be known to the skilled artisan. The expression constructs will further contain sites for transcription initiation, termination, and, in the transcribed region, a ribosome binding site for translation. The coding portion of the transcripts expressed by the constructs will preferably include a translation initiating codon at the beginning and a termination codon (UAA, UGA or UAG) appropriately positioned at the end of the polypeptide to be translated.

As indicated, the expression vectors will preferably include at least one selectable marker. Such markers include dihydrofolate reductase, G418 or neomycin resistance for eukaryotic cell culture and tetracycline, kanamycin or ampicillin resistance genes for culturing in *E. coli* and other bacteria. Representative examples of appropriate hosts include, but are not limited to, bacterial cells, such as *E. coli*, *Streptomyces* and *Salmonella typhimurium* cells; fungal cells, such as yeast cells (e.g., *Saccharomyces cerevisiae* or *Pichia pastoris* (ATCC Accession No. 201178)); insect cells such as *Drosophila* S2 and *Spodoptera Sf9* cells; animal cells such as CHO, COS, 293, and Bowes melanoma cells; and plant cells. Appropriate culture mediums and conditions for the above-described host cells are known in the art.

Among vectors preferred for use in bacteria include pQE70, pQE60 and pQE-9, available from QIAGEN, Inc.; pBluescript vectors, Phagescript vectors, pNH8A,

pNH16a, pNH18A, pNH46A, available from Stratagene Cloning Systems, Inc.; and ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia Biotech, Inc. Among preferred eukaryotic vectors are pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia. Preferred expression vectors for use in yeast systems include, but are not limited to pYES2, pYD1, pTEF1/Zeo, pYES2/GS, pPICZ, pGAPZ, pGAPZalph, pPIC9, pPIC3.5, pHIL-D2, pHIL-S1, pPIC3.5K, pPIC9K, and PAO815 (all available from Invitrogen, Carlsbad, CA). Other suitable vectors will be readily apparent to the skilled artisan.

Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, or other methods. Such methods are described in many standard laboratory manuals, such as Davis et al., Basic Methods In Molecular Biology (1986). It is specifically contemplated that the polypeptides of the present invention may in fact be expressed by a host cell lacking a recombinant vector.

A polypeptide of this invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography ("HPLC") is employed for purification.

Polypeptides of the present invention, and preferably the secreted form, can also be recovered from: products purified from natural sources, including bodily fluids, tissues and cells, whether directly isolated or cultured; products of chemical synthetic procedures; and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant, insect, and mammalian cells. Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention may be glycosylated or may be non-glycosylated. In addition, polypeptides of the invention may also include an initial modified methionine residue, in some cases as a result of host-

mediated processes. Thus, it is well known in the art that the N-terminal methionine encoded by the translation initiation codon generally is removed with high efficiency from any protein after translation in all eukaryotic cells. While the N-terminal methionine on most proteins also is efficiently removed in most prokaryotes, for some  
5 proteins, this prokaryotic removal process is inefficient, depending on the nature of the amino acid to which the N-terminal methionine is covalently linked.

In one embodiment, the yeast *Pichia pastoris* is used to express the polypeptide of the present invention in a eukaryotic system. *Pichia pastoris* is a methylotrophic yeast which can metabolize methanol as its sole carbon source. A  
10 main step in the methanol metabolization pathway is the oxidation of methanol to formaldehyde using O<sub>2</sub>. This reaction is catalyzed by the enzyme alcohol oxidase. In order to metabolize methanol as its sole carbon source, *Pichia pastoris* must generate high levels of alcohol oxidase due, in part, to the relatively low affinity of alcohol oxidase for O<sub>2</sub>. Consequently, in a growth medium depending on methanol as a main  
15 carbon source, the promoter region of one of the two alcohol oxidase genes (*AOX1*) is highly active. In the presence of methanol, alcohol oxidase produced from the *AOX1* gene comprises up to approximately 30% of the total soluble protein in *Pichia pastoris*. See, Ellis, S.B., *et al.*, *Mol. Cell. Biol.* 5:1111-21 (1985); Koutz, P.J., *et al.*, *Yeast* 5:167-77 (1989); Tschopp, J.F., *et al.*, *Nucl. Acids Res.* 15:3859-76 (1987).  
20 Thus, a heterologous coding sequence, such as, for example, a polynucleotide of the present invention, under the transcriptional regulation of all or part of the *AOX1* regulatory sequence is expressed at exceptionally high levels in *Pichia* yeast grown in the presence of methanol.

In one example, the plasmid vector pPIC9K is used to express DNA encoding  
25 a polypeptide of the invention, as set forth herein, in a *Pichea* yeast system essentially as described in "*Pichia* Protocols: Methods in Molecular Biology," D.R. Higgins and J. Cregg, eds. The Humana Press, Totowa, NJ, 1998. This expression vector allows expression and secretion of a protein of the invention by virtue of the strong *AOX1* promoter linked to the *Pichia pastoris* alkaline phosphatase (PHO) secretory signal  
30 peptide (i.e., leader) located upstream of a multiple cloning site.

Many other yeast vectors could be used in place of pPIC9K, such as, pYES2, pYD1, pTEF1/Zeo, pYES2/GS, pPICZ, pGAPZ, pGAPZalpha, pPIC9, pPIC3.5, pHIL-D2, pHIL-S1, pPIC3.5K, and PAO815, as one skilled in the art would readily appreciate, as long as the proposed expression construct provides appropriately located signals for transcription, translation, secretion (if desired), and the like, including an in-frame AUG as required.

In another embodiment, high-level expression of a heterologous coding sequence, such as, for example, a polynucleotide of the present invention, may be achieved by cloning the heterologous polynucleotide of the invention into an expression vector such as, for example, pGAPZ or pGAPZalpha, and growing the yeast culture in the absence of methanol.

In addition to encompassing host cells containing the vector constructs discussed herein, the invention also encompasses primary, secondary, and immortalized host cells of vertebrate origin, particularly mammalian origin, that have been engineered to delete or replace endogenous genetic material (e.g., coding sequence), and/or to include genetic material (e.g., heterologous polynucleotide sequences) that is operably associated with the polynucleotides of the invention, and which activates, alters, and/or amplifies endogenous polynucleotides. For example, techniques known in the art may be used to operably associate heterologous control regions (e.g., promoter and/or enhancer) and endogenous polynucleotide sequences via homologous recombination, resulting in the formation of a new transcription unit (see, e.g., U.S. Patent No. 5,641,670, issued June 24, 1997; U.S. Patent No. 5,733,761, issued March 31, 1998; International Publication No. WO 96/29411, published September 26, 1996; International Publication No. WO 94/12650, published August 4, 1994; Koller et al., Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); and Zijlstra et al., Nature 342:435-438 (1989), the disclosures of each of which are incorporated by reference in their entireties).

In addition, polypeptides of the invention can be chemically synthesized using techniques known in the art (e.g., see Creighton, 1983, Proteins: Structures and Molecular Principles, W.H. Freeman & Co., N.Y., and Hunkapiller et al., *Nature*, 310:105-111 (1984)). For example, a polypeptide corresponding to a fragment of a

polypeptide sequence of the invention can be synthesized by use of a peptide synthesizer. Furthermore, if desired, nonclassical amino acids or chemical amino acid analogs can be introduced as a substitution or addition into the polypeptide sequence. Non-classical amino acids include, but are not limited to, to the D-isomers of the  
5 common amino acids, 2,4-diaminobutyric acid,  $\alpha$ -amino isobutyric acid, 4-aminobutyric acid, Abu, 2-amino butyric acid,  $\gamma$ -Abu,  $\epsilon$ -Ahx, 6-amino hexanoic acid, Aib, 2-amino isobutyric acid, 3-amino propionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosine, citrulline, homocitrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine,  $\beta$ -alanine, fluoro-  
10 amino acids, designer amino acids such as  $\beta$ -methyl amino acids, Ca-methyl amino acids, Na-methyl amino acids, and amino acid analogs in general. Furthermore, the amino acid can be D (dextrorotary) or L (levorotary).

The invention encompasses polypeptides which are differentially modified during or after translation, *e.g.*, by glycosylation, acetylation, phosphorylation,  
15 amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to an antibody molecule or other cellular ligand, etc. Any of numerous chemical modifications may be carried out by known techniques, including but not limited, to specific chemical cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease,  $\text{NaBH}_4$ ; acetylation, formylation, oxidation, reduction; metabolic  
20 synthesis in the presence of tunicamycin; etc.

Additional post-translational modifications encompassed by the invention include, for example, *e.g.*, N-linked or O-linked carbohydrate chains, processing of N-terminal or C-terminal ends), attachment of chemical moieties to the amino acid backbone, chemical modifications of N-linked or O-linked carbohydrate chains, and  
25 addition or deletion of an N-terminal methionine residue as a result of procaryotic host cell expression. The polypeptides may also be modified with a detectable label, such as an enzymatic, fluorescent, isotopic or affinity label to allow for detection and isolation of the protein.

Also provided by the invention are chemically modified derivatives of the  
30 polypeptides of the invention which may provide additional advantages such as increased solubility, stability and circulating time of the polypeptide, or decreased immunogenicity (see U.S. Patent NO: 4,179,337). The chemical moieties for

derivitization may be selected from water soluble polymers such as polyethylene glycol, ethylene glycol/propylene glycol copolymers, carboxymethylcellulose, dextran, polyvinyl alcohol and the like. The polypeptides may be modified at random positions within the molecule, or at predetermined positions within the molecule and may include one, two, three or more attached chemical moieties.

The polymer may be of any molecular weight, and may be branched or unbranched. For polyethylene glycol, the preferred molecular weight is between about 1 kDa and about 100 kDa (the term "about" indicating that in preparations of polyethylene glycol, some molecules will weigh more, some less, than the stated molecular weight) for ease in handling and manufacturing. Other sizes may be used, depending on the desired therapeutic profile (e.g., the duration of sustained release desired, the effects, if any on biological activity, the ease in handling, the degree or lack of antigenicity and other known effects of the polyethylene glycol to a therapeutic protein or analog). For example, the polyethylene glycol may have an average molecular weight of about 200, 500, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, 7000, 7500, 8000, 8500, 9000, 9500, 10,000, 10,500, 11,000, 11,500, 12,000, 12,500, 13,000, 13,500, 14,000, 14,500, 15,000, 15,500, 16,000, 16,500, 17,000, 17,500, 18,000, 18,500, 19,000, 19,500, 20,000, 25,000, 30,000, 35,000, 40,000, 50,000, 55,000, 60,000, 65,000, 70,000, 75,000, 80,000, 85,000, 90,000, 95,000, or 100,000 kDa.

As noted above, the polyethylene glycol may have a branched structure. Branched polyethylene glycols are described, for example, in U.S. Patent No. 5,643,575; Morpurgo *et al.*, *Appl. Biochem. Biotechnol.* 56:59-72 (1996); Vorobjev *et al.*, *Nucleosides Nucleotides* 18:2745-2750 (1999); and Caliceti *et al.*, *Bioconjug. Chem.* 10:638-646 (1999), the disclosures of each of which are incorporated herein by reference.

The polyethylene glycol molecules (or other chemical moieties) should be attached to the protein with consideration of effects on functional or antigenic domains of the protein. There are a number of attachment methods available to those skilled in the art, e.g., EP 0 401 384, herein incorporated by reference (coupling PEG to G-CSF), see also Malik *et al.*, *Exp. Hematol.* 20:1028-1035 (1992) (reporting pegylation of GM-CSF using tresyl chloride). For example, polyethylene glycol may



be covalently bound through amino acid residues via a reactive group, such as, a free amino or carboxyl group. Reactive groups are those to which an activated polyethylene glycol molecule may be bound. The amino acid residues having a free amino group may include lysine residues and the N-terminal amino acid residues; those having a free carboxyl group may include aspartic acid residues glutamic acid residues and the C-terminal amino acid residue. Sulfhydryl groups may also be used as a reactive group for attaching the polyethylene glycol molecules. Preferred for therapeutic purposes is attachment at an amino group, such as attachment at the N-terminus or lysine group.

As suggested above, polyethylene glycol may be attached to proteins via linkage to any of a number of amino acid residues. For example, polyethylene glycol can be linked to a proteins via covalent bonds to lysine, histidine, aspartic acid, glutamic acid, or cysteine residues. One or more reaction chemistries may be employed to attach polyethylene glycol to specific amino acid residues (e.g., lysine, histidine, aspartic acid, glutamic acid, or cysteine) of the protein or to more than one type of amino acid residue (e.g., lysine, histidine, aspartic acid, glutamic acid, cysteine and combinations thereof) of the protein.

One may specifically desire proteins chemically modified at the N-terminus. Using polyethylene glycol as an illustration of the present composition, one may select from a variety of polyethylene glycol molecules (by molecular weight, branching, etc.), the proportion of polyethylene glycol molecules to protein (polypeptide) molecules in the reaction mix, the type of pegylation reaction to be performed, and the method of obtaining the selected N-terminally pegylated protein. The method of obtaining the N-terminally pegylated preparation (i.e., separating this moiety from other monopegylated moieties if necessary) may be by purification of the N-terminally pegylated material from a population of pegylated protein molecules. Selective proteins chemically modified at the N-terminus modification may be accomplished by reductive alkylation which exploits differential reactivity of different types of primary amino groups (lysine versus the N-terminal) available for derivatization in a particular protein. Under the appropriate reaction conditions, substantially selective derivatization of the protein at the N-terminus with a carbonyl group containing polymer is achieved.

As indicated above, pegylation of the proteins of the invention may be accomplished by any number of means. For example, polyethylene glycol may be attached to the protein either directly or by an intervening linker. Linkerless systems for attaching polyethylene glycol to proteins are described in Delgado *et al.*, *Crit. Rev. Thera. Drug Carrier Sys.* 9:249-304 (1992); Francis *et al.*, *Intern. J. of Hematol.* 68:1-18 (1998); U.S. Patent No. 4,002,531; U.S. Patent No. 5,349,052; WO 95/06058; and WO 98/32466, the disclosures of each of which are incorporated herein by reference.

One system for attaching polyethylene glycol directly to amino acid residues of proteins without an intervening linker employs tresylated MPEG, which is produced by the modification of monmethoxy polyethylene glycol (MPEG) using tresylchloride ( $\text{ClSO}_2\text{CH}_2\text{CF}_3$ ). Upon reaction of protein with tresylated MPEG, polyethylene glycol is directly attached to amine groups of the protein. Thus, the invention includes protein-polyethylene glycol conjugates produced by reacting proteins of the invention with a polyethylene glycol molecule having a 2,2,2-trifluoroethane sulphonyl group.

Polyethylene glycol can also be attached to proteins using a number of different intervening linkers. For example, U.S. Patent No. 5,612,460, the entire disclosure of which is incorporated herein by reference, discloses urethane linkers for connecting polyethylene glycol to proteins. Protein-polyethylene glycol conjugates wherein the polyethylene glycol is attached to the protein by a linker can also be produced by reaction of proteins with compounds such as MPEG-succinimidylsuccinate, MPEG activated with 1,1'-carbonyldiimidazole, MPEG-2,4,5-trichloropenylcarbonate, MPEG-p-nitrophenolcarbonate, and various MPEG-succinate derivatives. A number additional polyethylene glycol derivatives and reaction chemistries for attaching polyethylene glycol to proteins are described in WO 98/32466, the entire disclosure of which is incorporated herein by reference. Pegylated protein products produced using the reaction chemistries set out herein are included within the scope of the invention.

The number of polyethylene glycol moieties attached to each protein of the invention (*i.e.*, the degree of substitution) may also vary. For example, the pegylated proteins of the invention may be linked, on average, to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12,

15, 17, 20, or more polyethylene glycol molecules. Similarly, the average degree of substitution within ranges such as 1-3, 2-4, 3-5, 4-6, 5-7, 6-8, 7-9, 8-10, 9-11, 10-12, 11-13, 12-14, 13-15, 14-16, 15-17, 16-18, 17-19, or 18-20 polyethylene glycol moieties per protein molecule. Methods for determining the degree of substitution are  
5 discussed, for example, in Delgado *et al.*, *Crit. Rev. Thera. Drug Carrier Sys.* 9:249-304 (1992).

The polypeptides of the invention may be in monomers or multimers (i.e., dimers, trimers, tetramers and higher multimers). Accordingly, the present invention relates to monomers and multimers of the polypeptides of the invention, their  
10 preparation, and compositions (preferably, *Therapeutics*) containing them. In specific embodiments, the polypeptides of the invention are monomers, dimers, trimers or tetramers. In additional embodiments, the multimers of the invention are at least dimers, at least trimers, or at least tetramers.

Multimers encompassed by the invention may be homomers or heteromers.  
15 As used herein, the term homomer, refers to a multimer containing only polypeptides corresponding to the amino acid sequence of SEQ ID NO:Y or encoded by the cDNA contained in a deposited clone (including fragments, variants, splice variants, and fusion proteins, corresponding to these polypeptides as described herein). These homomers may contain polypeptides having identical or different amino acid  
20 sequences. In a specific embodiment, a homomer of the invention is a multimer containing only polypeptides having an identical amino acid sequence. In another specific embodiment, a homomer of the invention is a multimer containing polypeptides having different amino acid sequences. In specific embodiments, the multimer of the invention is a homodimer (*e.g.*, containing polypeptides having  
25 identical or different amino acid sequences) or a homotrimer (*e.g.*, containing polypeptides having identical and/or different amino acid sequences). In additional embodiments, the homomeric multimer of the invention is at least a homodimer, at least a homotrimer, or at least a homotetramer.

As used herein, the term heteromer refers to a multimer containing one or  
30 more heterologous polypeptides (*i.e.*, polypeptides of different proteins) in addition to the polypeptides of the invention. In a specific embodiment, the multimer of the invention is a heterodimer, a heterotrimer, or a heterotetramer. In additional

embodiments, the heteromeric multimer of the invention is at least a heterodimer, at least a heterotrimer, or at least a heterotetramer.

Multimers of the invention may be the result of hydrophobic, hydrophilic, ionic and/or covalent associations and/or may be indirectly linked, by for example, liposome formation. Thus, in one embodiment, multimers of the invention, such as, for example, homodimers or homotrimers, are formed when polypeptides of the invention contact one another in solution. In another embodiment, heteromultimers of the invention, such as, for example, heterotrimers or heterotetramers, are formed when polypeptides of the invention contact antibodies to the polypeptides of the invention (including antibodies to the heterologous polypeptide sequence in a fusion protein of the invention) in solution. In other embodiments, multimers of the invention are formed by covalent associations with and/or between the polypeptides of the invention. Such covalent associations may involve one or more amino acid residues contained in the polypeptide sequence ( e.g., that recited in the sequence listing, or contained in the polypeptide encoded by a deposited clone). In one instance, the covalent associations are cross-linking between cysteine residues located within the polypeptide sequences which interact in the native (i.e., naturally occurring) polypeptide. In another instance, the covalent associations are the consequence of chemical or recombinant manipulation. Alternatively, such covalent associations may involve one or more amino acid residues contained in the heterologous polypeptide sequence in a fusion protein of the invention.

In one example, covalent associations are between the heterologous sequence contained in a fusion protein of the invention (see, e.g., US Patent Number 5,478,925). In a specific example, the covalent associations are between the heterologous sequence contained in an Fc fusion protein of the invention (as described herein). In another specific example, covalent associations of fusion proteins of the invention are between heterologous polypeptide sequence from another protein that is capable of forming covalently associated multimers, such as for example, osteoprotegerin (see, e.g., International Publication NO: WO 98/49305, the contents of which are herein incorporated by reference in its entirety). In another embodiment, two or more polypeptides of the invention are joined through peptide linkers. Examples include those peptide linkers described in U.S. Pat. No. 5,073,627

(hereby incorporated by reference). Proteins comprising multiple polypeptides of the invention separated by peptide linkers may be produced using conventional recombinant DNA technology.

Another method for preparing multimer polypeptides of the invention involves  
5 use of polypeptides of the invention fused to a leucine zipper or isoleucine zipper polypeptide sequence. Leucine zipper and isoleucine zipper domains are polypeptides that promote multimerization of the proteins in which they are found. Leucine zippers were originally identified in several DNA-binding proteins (Landschulz et al., Science 240:1759, (1988)), and have since been found in a variety of different  
10 proteins. Among the known leucine zippers are naturally occurring peptides and derivatives thereof that dimerize or trimerize. Examples of leucine zipper domains suitable for producing soluble multimeric proteins of the invention are those described in PCT application WO 94/10308, hereby incorporated by reference. Recombinant fusion proteins comprising a polypeptide of the invention fused to a polypeptide  
15 sequence that dimerizes or trimerizes in solution are expressed in suitable host cells, and the resulting soluble multimeric fusion protein is recovered from the culture supernatant using techniques known in the art.

Trimeric polypeptides of the invention may offer the advantage of enhanced biological activity. Preferred leucine zipper moieties and isoleucine moieties are  
20 those that preferentially form trimers. One example is a leucine zipper derived from lung surfactant protein D (SPD), as described in Hoppe et al. (FEBS Letters 344:191, (1994)) and in U.S. patent application Ser. No. 08/446,922, hereby incorporated by reference. Other peptides derived from naturally occurring trimeric proteins may be employed in preparing trimeric polypeptides of the invention.

25 In another example, proteins of the invention are associated by interactions between Flag® polypeptide sequence contained in fusion proteins of the invention containing Flag® polypeptide sequence. In a further embodiment, associations proteins of the invention are associated by interactions between heterologous polypeptide sequence contained in Flag® fusion proteins of the invention and anti-  
30 Flag® antibody.

The multimers of the invention may be generated using chemical techniques known in the art. For example, polypeptides desired to be contained in the multimers

of the invention may be chemically cross-linked using linker molecules and linker molecule length optimization techniques known in the art (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). Additionally, multimers of the invention may be generated using techniques known in the art to form one or more inter-molecule cross-links between the cysteine residues located within the sequence of the polypeptides desired to be contained in the multimer (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). Further, polypeptides of the invention may be routinely modified by the addition of cysteine or biotin to the C terminus or N-terminus of the polypeptide and techniques known in the art may be applied to generate multimers containing one or more of these modified polypeptides (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). Additionally, techniques known in the art may be applied to generate liposomes containing the polypeptide components desired to be contained in the multimer of the invention (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety).

Alternatively, multimers of the invention may be generated using genetic engineering techniques known in the art. In one embodiment, polypeptides contained in multimers of the invention are produced recombinantly using fusion protein technology described herein or otherwise known in the art (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). In a specific embodiment, polynucleotides coding for a homodimer of the invention are generated by ligating a polynucleotide sequence encoding a polypeptide of the invention to a sequence encoding a linker polypeptide and then further to a synthetic polynucleotide encoding the translated product of the polypeptide in the reverse orientation from the original C-terminus to the N-terminus (lacking the leader sequence) (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). In another embodiment, recombinant techniques described herein or otherwise known in the art are applied to generate recombinant polypeptides of the invention which contain a transmembrane domain (or hydrophobic or signal peptide) and which can be incorporated by membrane reconstitution techniques into

liposomes (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety).

### **Uses of the Polynucleotides**

5           Each of the polynucleotides identified herein can be used in numerous ways as reagents. The following description should be considered exemplary and utilizes known techniques.

          The polynucleotides of the present invention are useful for chromosome identification. There exists an ongoing need to identify new chromosome markers,  
10       since few chromosome marking reagents, based on actual sequence data (repeat polymorphisms), are presently available. Each polynucleotide of the present invention can be used as a chromosome marker.

          Briefly, sequences can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp) from the sequences shown in SEQ ID NO:X. Primers can be  
15       selected using computer analysis so that primers do not span more than one predicted exon in the genomic DNA. These primers are then used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the SEQ ID NO:X will yield an amplified fragment.

20           Similarly, somatic hybrids provide a rapid method of PCR mapping the polynucleotides to particular chromosomes. Three or more clones can be assigned per day using a single thermal cycler. Moreover, sublocalization of the polynucleotides can be achieved with panels of specific chromosome fragments. Other gene mapping strategies that can be used include in situ hybridization, prescreening with labeled  
25       flow-sorted chromosomes, preselection by hybridization to construct chromosome specific-cDNA libraries and computer mapping techniques (See, e.g., Shuler, Trends Biotechnol 16:456-459 (1998) which is hereby incorporated by reference in its entirety)..

          Precise chromosomal location of the polynucleotides can also be achieved  
30       using fluorescence in situ hybridization (FISH) of a metaphase chromosomal spread. This technique uses polynucleotides as short as 500 or 600 bases; however, polynucleotides 2,000-4,000 bp are preferred. For a review of this technique, see

Verma et al., "Human Chromosomes: a Manual of Basic Techniques," Pergamon Press, New York (1988).

For chromosome mapping, the polynucleotides can be used individually (to mark a single chromosome or a single site on that chromosome) or in panels (for marking multiple sites and/or multiple chromosomes).

The polynucleotides of the present invention would likewise be useful for radiation hybrid mapping, HAPPY mapping, and long range restriction mapping. For a review of these techniques and others known in the art, see, e.g., Dear, "Genome Mapping: A Practical Approach," IRL Press at Oxford University Press, London (1997); Aydin, J. Mol. Med. 77:691-694 (1999); Hacia et al., Mol. Psychiatry 3:483-492 (1998); Herrick et al., Chromosome Res. 7:409-423 (1999); Hamilton et al., Methods Cell Biol. 62:265-280 (2000); and/or Ott, J. Hered. 90:68-70 (1999) each of which is hereby incorporated by reference in its entirety.

Once a polynucleotide has been mapped to a precise chromosomal location, the physical position of the polynucleotide can be used in linkage analysis. Linkage analysis establishes coinheritance between a chromosomal location and presentation of a particular disease. (Disease mapping data are found, for example, in V. McKusick, Mendelian Inheritance in Man (available on line through Johns Hopkins University Welch Medical Library) .) Assuming 1 megabase mapping resolution and one gene per 20 kb, a cDNA precisely localized to a chromosomal region associated with the disease could be one of 50-500 potential causative genes.

Thus, once coinheritance is established, differences in the polynucleotide and the corresponding gene between affected and unaffected individuals can be examined. First, visible structural alterations in the chromosomes, such as deletions or translocations, are examined in chromosome spreads or by PCR. If no structural alterations exist, the presence of point mutations are ascertained. Mutations observed in some or all affected individuals, but not in normal individuals, indicates that the mutation may cause the disease. However, complete sequencing of the polypeptide and the corresponding gene from several normal individuals is required to distinguish the mutation from a polymorphism. If a new polymorphism is identified, this polymorphic polypeptide can be used for further linkage analysis.



Furthermore, increased or decreased expression of the gene in affected individuals as compared to unaffected individuals can be assessed using polynucleotides of the present invention. Any of these alterations (altered expression, chromosomal rearrangement, or mutation) can be used as a diagnostic or prognostic marker.

Thus, the invention also provides a diagnostic method useful during diagnosis of a disorder, involving measuring the expression level of polynucleotides of the present invention in cells or body fluid from an individual and comparing the measured gene expression level with a standard level of polynucleotide expression level, whereby an increase or decrease in the gene expression level compared to the standard is indicative of a disorder.

In still another embodiment, the invention includes a kit for analyzing samples for the presence of proliferative and/or cancerous polynucleotides derived from a test subject. In a general embodiment, the kit includes at least one polynucleotide probe containing a nucleotide sequence that will specifically hybridize with a polynucleotide of the present invention and a suitable container. In a specific embodiment, the kit includes two polynucleotide probes defining an internal region of the polynucleotide of the present invention, where each probe has one strand containing a 31'mer-end internal to the region. In a further embodiment, the probes may be useful as primers for polymerase chain reaction amplification.

Where a diagnosis of a disorder, has already been made according to conventional methods, the present invention is useful as a prognostic indicator, whereby patients exhibiting enhanced or depressed polynucleotide of the present invention expression will experience a worse clinical outcome relative to patients expressing the gene at a level nearer the standard level.

By "measuring the expression level of polynucleotide of the present invention" is intended qualitatively or quantitatively measuring or estimating the level of the polypeptide of the present invention or the level of the mRNA encoding the polypeptide in a first biological sample either directly (e.g., by determining or estimating absolute protein level or mRNA level) or relatively (e.g., by comparing to the polypeptide level or mRNA level in a second biological sample). Preferably, the polypeptide level or mRNA level in the first biological sample is measured or

estimated and compared to a standard polypeptide level or mRNA level, the standard being taken from a second biological sample obtained from an individual not having the disorder or being determined by averaging levels from a population of individuals not having a disorder. As will be appreciated in the art, once a standard polypeptide  
5 level or mRNA level is known, it can be used repeatedly as a standard for comparison.

By "biological sample" is intended any biological sample obtained from an individual, body fluid, cell line, tissue culture, or other source which contains the polypeptide of the present invention or mRNA. As indicated, biological samples  
10 include body fluids (such as semen, lymph, sera, plasma, urine, synovial fluid and spinal fluid) which contain the polypeptide of the present invention, and other tissue sources found to express the polypeptide of the present invention. Methods for obtaining tissue biopsies and body fluids from mammals are well known in the art. Where the biological sample is to include mRNA, a tissue biopsy is the preferred  
15 source.

The method(s) provided above may preferably be applied in a diagnostic method and/or kits in which polynucleotides and/or polypeptides are attached to a solid support. In one exemplary method, the support may be a "gene chip" or a "biological chip" as described in US Patents 5,837,832, 5,874,219, and 5,856,174.  
20 Further, such a gene chip with polynucleotides of the present invention attached may be used to identify polymorphisms between the polynucleotide sequences, with polynucleotides isolated from a test subject. The knowledge of such polymorphisms (i.e. their location, as well as, their existence) would be beneficial in identifying disease loci for many disorders, including cancerous diseases and conditions. Such a  
25 method is described in US Patents 5,858,659 and 5,856,104. The US Patents referenced supra are hereby incorporated by reference in their entirety herein.

The present invention encompasses polynucleotides of the present invention that are chemically synthesized, or reproduced as peptide nucleic acids (PNA), or according to other methods known in the art. The use of PNAs would serve as the  
30 preferred form if the polynucleotides are incorporated onto a solid support, or gene chip. For the purposes of the present invention, a peptide nucleic acid (PNA) is a polyamide type of DNA analog and the monomeric units for adenine, guanine,

thymine and cytosine are available commercially (Perceptive Biosystems). Certain components of DNA, such as phosphorus, phosphorus oxides, or deoxyribose derivatives, are not present in PNAs. As disclosed by P. E. Nielsen, M. Egholm, R. H. Berg and O. Buchardt, *Science* 254, 1497 (1991); and M. Egholm, O. Buchardt, L.Christensen, C. Behrens, S. M. Freier, D. A. Driver, R. H. Berg, S. K. Kim, B. Norden, and P. E. Nielsen, *Nature* 365, 666 (1993), PNAs bind specifically and tightly to complementary DNA strands and are not degraded by nucleases. In fact, PNA binds more strongly to DNA than DNA itself does. This is probably because there is no electrostatic repulsion between the two strands, and also the polyamide backbone is more flexible. Because of this, PNA/DNA duplexes bind under a wider range of stringency conditions than DNA/DNA duplexes, making it easier to perform multiplex hybridization. Smaller probes can be used than with DNA due to the strong binding. In addition, it is more likely that single base mismatches can be determined with PNA/DNA hybridization because a single mismatch in a PNA/DNA 15-mer lowers the melting point ( $T_{sub.m}$ ) by 8°-20° C, vs. 4°-16° C for the DNA/DNA 15-mer duplex. Also, the absence of charge groups in PNA means that hybridization can be done at low ionic strengths and reduce possible interference by salt during the analysis.

The present invention is useful for detecting cancer in mammals. In particular the invention is useful during diagnosis of pathological cell proliferative neoplasias which include, but are not limited to: acute myelogenous leukemias including acute monocytic leukemia, acute myeloblastic leukemia, acute promyelocytic leukemia, acute myelomonocytic leukemia, acute erythroleukemia, acute megakaryocytic leukemia, and acute undifferentiated leukemia, etc.; and chronic myelogenous leukemias including chronic myelomonocytic leukemia, chronic granulocytic leukemia, etc. Preferred mammals include monkeys, apes, cats, dogs, cows, pigs, horses, rabbits and humans. Particularly preferred are humans.

Pathological cell proliferative diseases, disorders, and/or conditions are often associated with inappropriate activation of proto-oncogenes. (Germann, E. P. et al., "The Etiology of Acute Leukemia: Molecular Genetics and Viral Oncology," in *Neoplastic Diseases of the Blood*, Vol 1., Wiernik, P. H. et al. eds., 161-182 (1985)). Neoplasias are now believed to result from the qualitative alteration of a normal

cellular gene product, or from the quantitative modification of gene expression by insertion into the chromosome of a viral sequence, by chromosomal translocation of a gene to a more actively transcribed region, or by some other mechanism. (Germann et al., supra) It is likely that mutated or altered expression of specific genes is involved in the pathogenesis of some leukemias, among other tissues and cell types. (Germann et al., supra) Indeed, the human counterparts of the oncogenes involved in some animal neoplasias have been amplified or translocated in some cases of human leukemia and carcinoma. (Germann et al., supra)

For example, c-myc expression is highly amplified in the non-lymphocytic leukemia cell line HL-60. When HL-60 cells are chemically induced to stop proliferation, the level of c-myc is found to be downregulated. (International Publication Number WO 91/15580) However, it has been shown that exposure of HL-60 cells to a DNA construct that is complementary to the 5' end of c-myc or c-myb blocks translation of the corresponding mRNAs which downregulates expression of the c-myc or c-myb proteins and causes arrest of cell proliferation and differentiation of the treated cells. (International Publication Number WO 91/15580; Wickstrom et al., Proc. Natl. Acad. Sci. 85:1028 (1988); Anfossi et al., Proc. Natl. Acad. Sci. 86:3379 (1989)). However, the skilled artisan would appreciate the present invention's usefulness would not be limited to treatment of proliferative diseases, disorders, and/or conditions of hematopoietic cells and tissues, in light of the numerous cells and cell types of varying origins which are known to exhibit proliferative phenotypes.

In addition to the foregoing, a polynucleotide can be used to control gene expression through triple helix formation or antisense DNA or RNA. Antisense techniques are discussed, for example, in Okano, J. Neurochem. 56: 560 (1991); "Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988). Triple helix formation is discussed in, for instance Lee et al., Nucleic Acids Research 6: 3073 (1979); Cooney et al., Science 241: 456 (1988); and Dervan et al., Science 251: 1360 (1991). Both methods rely on binding of the polynucleotide to a complementary DNA or RNA. For these techniques, preferred polynucleotides are usually oligonucleotides 20 to 40 bases in length and complementary to either the region of the gene involved in transcription (triple helix - see Lee et al., Nucl. Acids Res. 6:3073 (1979); Cooney et al., Science 241:456

(1988); and Dervan et al., Science 251:1360 (1991) ) or to the mRNA itself (antisense - Okano, J. Neurochem. 56:560 (1991); Oligodeoxy-nucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988).) Triple helix formation optimally results in a shut-off of RNA transcription from DNA, while  
5 antisense RNA hybridization blocks translation of an mRNA molecule into polypeptide. Both techniques are effective in model systems, and the information disclosed herein can be used to design antisense or triple helix polynucleotides in an effort to treat or prevent disease.

Polynucleotides of the present invention are also useful in gene therapy. One  
10 goal of gene therapy is to insert a normal gene into an organism having a defective gene, in an effort to correct the genetic defect. The polynucleotides disclosed in the present invention offer a means of targeting such genetic defects in a highly accurate manner. Another goal is to insert a new gene that was not present in the host genome, thereby producing a new trait in the host cell.

15 The polynucleotides are also useful for identifying individuals from minute biological samples. The United States military, for example, is considering the use of restriction fragment length polymorphism (RFLP) for identification of its personnel. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for  
20 identifying personnel. This method does not suffer from the current limitations of "Dog Tags" which can be lost, switched, or stolen, making positive identification difficult. The polynucleotides of the present invention can be used as additional DNA markers for RFLP.

The polynucleotides of the present invention can also be used as an alternative  
25 to RFLP, by determining the actual base-by-base DNA sequence of selected portions of an individual's genome. These sequences can be used to prepare PCR primers for amplifying and isolating such selected DNA, which can then be sequenced. Using this technique, individuals can be identified because each individual will have a unique set of DNA sequences. Once an unique ID database is established for an  
30 individual, positive identification of that individual, living or dead, can be made from extremely small tissue samples.

Forensic biology also benefits from using DNA-based identification techniques as disclosed herein. DNA sequences taken from very small biological samples such as tissues, e.g., hair or skin, or body fluids, e.g., blood, saliva, semen, synovial fluid, amniotic fluid, breast milk, lymph, pulmonary sputum or surfactant, urine, fecal matter, etc., can be amplified using PCR. In one prior art technique, gene sequences amplified from polymorphic loci, such as DQa class II HLA gene, are used in forensic biology to identify individuals. (Erlich, H., PCR Technology, Freeman and Co. (1992).) Once these specific polymorphic loci are amplified, they are digested with one or more restriction enzymes, yielding an identifying set of bands on a Southern blot probed with DNA corresponding to the DQa class II HLA gene. Similarly, polynucleotides of the present invention can be used as polymorphic markers for forensic purposes.

There is also a need for reagents capable of identifying the source of a particular tissue. Such need arises, for example, in forensics when presented with tissue of unknown origin. Appropriate reagents can comprise, for example, DNA probes or primers specific to particular tissue prepared from the sequences of the present invention. Panels of such reagents can identify tissue by species and/or by organ type. In a similar fashion, these reagents can be used to screen tissue cultures for contamination.

In the very least, the polynucleotides of the present invention can be used as molecular weight markers on Southern gels, as diagnostic probes for the presence of a specific mRNA in a particular cell type, as a probe to "subtract-out" known sequences in the process of discovering novel polynucleotides, for selecting and making oligomers for attachment to a "gene chip" or other support, to raise anti-DNA antibodies using DNA immunization techniques, and as an antigen to elicit an immune response.

### **Uses of the Polypeptides**

Each of the polypeptides identified herein can be used in numerous ways. The following description should be considered exemplary and utilizes known techniques.

A polypeptide of the present invention can be used to assay protein levels in a biological sample using antibody-based techniques. For example, protein expression

in tissues can be studied with classical immunohistological methods. (Jalkanen, M., et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, M., et al., J. Cell . Biol. 105:3087-3096 (1987).) Other antibody-based methods useful for detecting protein gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known in the art and include enzyme labels, such as, glucose oxidase, and radioisotopes, such as iodine ( $^{125}\text{I}$ ,  $^{121}\text{I}$ ), carbon ( $^{14}\text{C}$ ), sulfur ( $^{35}\text{S}$ ), tritium ( $^3\text{H}$ ), indium ( $^{112}\text{In}$ ), and technetium ( $^{99\text{m}}\text{Tc}$ ), and fluorescent labels, such as fluorescein and rhodamine, and biotin.

10 In addition to assaying secreted protein levels in a biological sample, proteins can also be detected in vivo by imaging. Antibody labels or markers for in vivo imaging of protein include those detectable by X-radiography, NMR or ESR. For X-radiography, suitable labels include radioisotopes such as barium or cesium, which emit detectable radiation but are not overtly harmful to the subject. Suitable markers  
15 for NMR and ESR include those with a detectable characteristic spin, such as deuterium, which may be incorporated into the antibody by labeling of nutrients for the relevant hybridoma.

A protein-specific antibody or antibody fragment which has been labeled with an appropriate detectable imaging moiety, such as a radioisotope (for example,  $^{131}\text{I}$ ,  $^{112}\text{In}$ ,  $^{99\text{m}}\text{Tc}$ ), a radio-opaque substance, or a material detectable by nuclear  
20 magnetic resonance, is introduced (for example, parenterally, subcutaneously, or intraperitoneally) into the mammal. It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety needed to produce diagnostic images. In the case of a radioisotope moiety, for a  
25 human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of  $^{99\text{m}}\text{Tc}$ . The labeled antibody or antibody fragment will then preferentially accumulate at the location of cells which contain the specific protein. In vivo tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments." (Chapter 13 in Tumor Imaging: The Radiochemical Detection of Cancer, S.W. Burchiel and B. A. Rhodes, eds.,  
30 Masson Publishing Inc. (1982).)

Thus, the invention provides a diagnostic method of a disorder, which involves (a) assaying the expression of a polypeptide of the present invention in cells or body fluid of an individual; (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of a disorder. With respect to cancer, the presence of a relatively high amount of transcript in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Moreover, polypeptides of the present invention can be used to treat, prevent, and/or diagnose disease. For example, patients can be administered a polypeptide of the present invention in an effort to replace absent or decreased levels of the polypeptide (e.g., insulin), to supplement absent or decreased levels of a different polypeptide (e.g., hemoglobin S for hemoglobin B, SOD, catalase, DNA repair proteins), to inhibit the activity of a polypeptide (e.g., an oncogene or tumor suppressor), to activate the activity of a polypeptide (e.g., by binding to a receptor), to reduce the activity of a membrane bound receptor by competing with it for free ligand (e.g., soluble TNF receptors used in reducing inflammation), or to bring about a desired response (e.g., blood vessel growth inhibition, enhancement of the immune response to proliferative cells or tissues).

Similarly, antibodies directed to a polypeptide of the present invention can also be used to treat, prevent, and/or diagnose disease. For example, administration of an antibody directed to a polypeptide of the present invention can bind and reduce overproduction of the polypeptide. Similarly, administration of an antibody can activate the polypeptide, such as by binding to a polypeptide bound to a membrane (receptor).

At the very least, the polypeptides of the present invention can be used as molecular weight markers on SDS-PAGE gels or on molecular sieve gel filtration columns using methods well known to those of skill in the art. Polypeptides can also



be used to raise antibodies, which in turn are used to measure protein expression from a recombinant cell, as a way of assessing transformation of the host cell. Moreover, the polypeptides of the present invention can be used to test the following biological activities.

5

### **Gene Therapy Methods**

Another aspect of the present invention is to gene therapy methods for treating or preventing disorders, diseases and conditions. The gene therapy methods relate to the introduction of nucleic acid (DNA, RNA and antisense DNA or RNA) sequences into an animal to achieve expression of a polypeptide of the present invention. This method requires a polynucleotide which codes for a polypeptide of the invention that operatively linked to a promoter and any other genetic elements necessary for the expression of the polypeptide by the target tissue. Such gene therapy and delivery techniques are known in the art, see, for example, WO90/11092, which is herein incorporated by reference.

Thus, for example, cells from a patient may be engineered with a polynucleotide (DNA or RNA) comprising a promoter operably linked to a polynucleotide of the invention *ex vivo*, with the engineered cells then being provided to a patient to be treated with the polypeptide. Such methods are well-known in the art. For example, see Beldegrun et al., J. Natl. Cancer Inst., 85:207-216 (1993); Ferrantini et al., Cancer Research, 53:107-1112 (1993); Ferrantini et al., J. Immunology 153: 4604-4615 (1994); Kaido, T., et al., Int. J. Cancer 60: 221-229 (1995); Ogura et al., Cancer Research 50: 5102-5106 (1990); Santodonato, et al., Human Gene Therapy 7:1-10 (1996); Santodonato, et al., Gene Therapy 4:1246-1255 (1997); and Zhang, et al., Cancer Gene Therapy 3: 31-38 (1996)), which are herein incorporated by reference. In one embodiment, the cells which are engineered are arterial cells. The arterial cells may be reintroduced into the patient through direct injection to the artery, the tissues surrounding the artery, or through catheter injection.

As discussed in more detail below, the polynucleotide constructs can be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver,

and the like). The polynucleotide constructs may be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

In one embodiment, the polynucleotide of the invention is delivered as a naked polynucleotide. The term "naked" polynucleotide, DNA or RNA refers to sequences  
5 that are free from any delivery vehicle that acts to assist, promote or facilitate entry into the cell, including viral sequences, viral particles, liposome formulations, lipofectin or precipitating agents and the like. However, the polynucleotides of the invention can also be delivered in liposome formulations and lipofectin formulations and the like can be prepared by methods well known to those skilled in the art. Such  
10 methods are described, for example, in U.S. Patent Nos. 5,593,972, 5,589,466, and 5,580,859, which are herein incorporated by reference.

The polynucleotide vector constructs of the invention used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Appropriate vectors  
15 include pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; pSVK3, pBPV, pMSG and pSVL available from Pharmacia; and pEF1/V5, pcDNA3.1, and pRc/CMV2 available from Invitrogen. Other suitable vectors will be readily apparent to the skilled artisan.

Any strong promoter known to those skilled in the art can be used for driving  
20 the expression of polynucleotide sequence of the invention. Suitable promoters include adenoviral promoters, such as the adenoviral major late promoter; or heterologous promoters, such as the cytomegalovirus (CMV) promoter; the respiratory syncytial virus (RSV) promoter; inducible promoters, such as the MMT promoter, the metallothionein promoter; heat shock promoters; the albumin promoter;  
25 the ApoAI promoter; human globin promoters; viral thymidine kinase promoters, such as the Herpes Simplex thymidine kinase promoter; retroviral LTRs; the b-actin promoter; and human growth hormone promoters. The promoter also may be the native promoter for the polynucleotides of the invention.

Unlike other gene therapy techniques, one major advantage of introducing  
30 naked nucleic acid sequences into target cells is the transitory nature of the polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA

sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

The polynucleotide construct of the invention can be delivered to the interstitial space of tissues within the an animal, including of muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and connective tissue. Interstitial space of the tissues comprises the intercellular, fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely differentiated cells, such as, for example, stem cells of blood or skin fibroblasts. *In vivo* muscle cells are particularly competent in their ability to take up and express polynucleotides.

For the naked *nucleic acid* sequence injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05 mg/kg body weight to about 50 mg/kg body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence can readily be determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration.

The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation particularly for delivery to lungs or bronchial tissues, throat or mucous membranes of the nose. In addition, naked DNA constructs can be delivered to arteries during angioplasty by the catheter used in the procedure.

The naked polynucleotides are delivered by any method known in the art, including, but not limited to, direct needle injection at the delivery site, intravenous injection, topical administration, catheter infusion, and so-called "gene guns". These delivery methods are known in the art.

5 The constructs may also be delivered with delivery vehicles such as viral sequences, viral particles, liposome formulations, lipofectin, precipitating agents, etc. Such methods of delivery are known in the art.

In certain embodiments, the polynucleotide constructs of the invention are complexed in a liposome preparation. Liposomal preparations for use in the instant  
10 invention include cationic (positively charged), anionic (negatively charged) and neutral preparations. However, cationic liposomes are particularly preferred because a tight charge complex can be formed between the cationic liposome and the polyanionic nucleic acid. Cationic liposomes have been shown to mediate intracellular delivery of plasmid DNA (Felgner et al., Proc. Natl. Acad. Sci. USA ,  
15 84:7413-7416 (1987), which is herein incorporated by reference); mRNA (Malone et al., Proc. Natl. Acad. Sci. USA , 86:6077-6081 (1989), which is herein incorporated by reference); and purified transcription factors (Debs et al., J. Biol. Chem., 265:10189-10192 (1990), which is herein incorporated by reference), in functional form.

20 Cationic liposomes are readily available. For example, N[1-2,3-dioleoyloxy)propyl]-N,N,N-triethylammonium (DOTMA) liposomes are particularly useful and are available under the trademark Lipofectin, from GIBCO BRL, Grand Island, N.Y. (See, also, Felgner et al., Proc. Natl Acad. Sci. USA , 84:7413-7416 (1987), which is herein incorporated by reference). Other commercially  
25 available liposomes include transfectace (DDAB/DOPE) and DOTAP/DOPE (Boehringer).

Other cationic liposomes can be prepared from readily available materials using techniques well known in the art. See, e.g. PCT Publication NO: WO 90/11092 (which is herein incorporated by reference) for a description of the synthesis of  
30 DOTAP (1,2-bis(oleoyloxy)-3-(trimethylammonio)propane) liposomes. Preparation of DOTMA liposomes is explained in the literature, see, e.g., Felgner et al., Proc.

Natl. Acad. Sci. USA, 84:7413-7417, which is herein incorporated by reference. Similar methods can be used to prepare liposomes from other cationic lipid materials.

Similarly, anionic and neutral liposomes are readily available, such as from Avanti Polar Lipids (Birmingham, Ala.), or can be easily prepared using readily available materials. Such materials include phosphatidyl, choline, cholesterol, phosphatidyl ethanolamine, dioleoylphosphatidyl choline (DOPC), dioleoylphosphatidyl glycerol (DOPG), dioleoylphosphatidyl ethanolamine (DOPE), among others. These materials can also be mixed with the DOTMA and DOTAP starting materials in appropriate ratios. Methods for making liposomes using these materials are well known in the art.

For example, commercially dioleoylphosphatidyl choline (DOPC), dioleoylphosphatidyl glycerol (DOPG), and dioleoylphosphatidyl ethanolamine (DOPE) can be used in various combinations to make conventional liposomes, with or without the addition of cholesterol. Thus, for example, DOPG/DOPC vesicles can be prepared by drying 50 mg each of DOPG and DOPC under a stream of nitrogen gas into a sonication vial. The sample is placed under a vacuum pump overnight and is hydrated the following day with deionized water. The sample is then sonicated for 2 hours in a capped vial, using a Heat Systems model 350 sonicator equipped with an inverted cup (bath type) probe at the maximum setting while the bath is circulated at 15EC. Alternatively, negatively charged vesicles can be prepared without sonication to produce multilamellar vesicles or by extrusion through nucleopore membranes to produce unilamellar vesicles of discrete size. Other methods are known and available to those of skill in the art.

The liposomes can comprise multilamellar vesicles (MLVs), small unilamellar vesicles (SUVs), or large unilamellar vesicles (LUVs), with SUVs being preferred. The various liposome-nucleic acid complexes are prepared using methods well known in the art. See, e.g., Straubinger et al., *Methods of Immunology*, 101:512-527 (1983), which is herein incorporated by reference. For example, MLVs containing nucleic acid can be prepared by depositing a thin film of phospholipid on the walls of a glass tube and subsequently hydrating with a solution of the material to be encapsulated. SUVs are prepared by extended sonication of MLVs to produce a homogeneous population of unilamellar liposomes. The material to be entrapped is added to a

suspension of preformed MLVs and then sonicated. When using liposomes containing cationic lipids, the dried lipid film is resuspended in an appropriate solution such as sterile water or an isotonic buffer solution such as 10 mM Tris/NaCl, sonicated, and then the preformed liposomes are mixed directly with the DNA. The liposome and DNA form a very stable complex due to binding of the positively charged liposomes to the cationic DNA. SUVs find use with small nucleic acid fragments. LUVs are prepared by a number of methods, well known in the art. Commonly used methods include  $\text{Ca}^{2+}$ -EDTA chelation (Papahadjopoulos et al., *Biochim. Biophys. Acta*, 394:483 (1975); Wilson et al., *Cell*, 17:77 (1979)); ether injection (Deamer et al., *Biochim. Biophys. Acta*, 443:629 (1976); Ostro et al., *Biochem. Biophys. Res. Commun.*, 76:836 (1977); Fraley et al., *Proc. Natl. Acad. Sci. USA*, 76:3348 (1979)); detergent dialysis (Enoch et al., *Proc. Natl. Acad. Sci. USA*, 76:145 (1979)); and reverse-phase evaporation (REV) (Fraley et al., *J. Biol. Chem.*, 255:10431 (1980); Szoka et al., *Proc. Natl. Acad. Sci. USA*, 75:145 (1978); Schaefer-Ridder et al., *Science*, 215:166 (1982)), which are herein incorporated by reference.

Generally, the ratio of DNA to liposomes will be from about 10:1 to about 1:10. Preferably, the ration will be from about 5:1 to about 1:5. More preferably, the ration will be about 3:1 to about 1:3. Still more preferably, the ratio will be about 1:1.

U.S. Patent NO: 5,676,954 (which is herein incorporated by reference) reports on the injection of genetic material, complexed with cationic liposomes carriers, into mice. U.S. Patent Nos. 4,897,355, 4,946,787, 5,049,386, 5,459,127, 5,589,466, 5,693,622, 5,580,859, 5,703,055, and international publication NO: WO 94/9469 (which are herein incorporated by reference) provide cationic lipids for use in transfecting DNA into cells and mammals. U.S. Patent Nos. 5,589,466, 5,693,622, 5,580,859, 5,703,055, and international publication NO: WO 94/9469 (which are herein incorporated by reference) provide methods for delivering DNA-cationic lipid complexes to mammals.

In certain embodiments, cells are engineered, *ex vivo* or *in vivo*, using a retroviral particle containing RNA which comprises a sequence encoding polypeptides of the invention. Retroviruses from which the retroviral plasmid vectors may be derived include, but are not limited to, Moloney Murine Leukemia Virus, spleen necrosis virus, Rous sarcoma Virus, Harvey Sarcoma Virus, avian leukosis

virus, gibbon ape leukemia virus, human immunodeficiency virus, Myeloproliferative Sarcoma Virus, and mammary tumor virus.

The retroviral plasmid vector is employed to transduce packaging cell lines to form producer cell lines. Examples of packaging cells which may be transfected  
5 include, but are not limited to, the PE501, PA317, R-2, R-AM, PA12, T19-14X, VT-19-17-H2, RCRE, RCRIP, GP+E-86, GP+envAm12, and DAN cell lines as described in Miller, Human Gene Therapy , 1:5-14 (1990), which is incorporated herein by reference in its entirety. The vector may transduce the packaging cells through any means known in the art. Such means include, but are not limited to, electroporation,  
10 the use of liposomes, and CaPO<sub>4</sub> precipitation. In one alternative, the retroviral plasmid vector may be encapsulated into a liposome, or coupled to a lipid, and then administered to a host.

The producer cell line generates infectious retroviral vector particles which include polynucleotide encoding polypeptides of the invention. Such retroviral vector  
15 particles then may be employed, to transduce eukaryotic cells, either *in vitro* or *in vivo*. The transduced eukaryotic cells will express polypeptides of the invention.

In certain other embodiments, cells are engineered, *ex vivo* or *in vivo*, with polynucleotides of the invention contained in an adenovirus vector. Adenovirus can be manipulated such that it encodes and expresses polypeptides of the invention, and  
20 at the same time is inactivated in terms of its ability to replicate in a normal lytic viral life cycle. Adenovirus expression is achieved without integration of the viral DNA into the host cell chromosome, thereby alleviating concerns about insertional mutagenesis. Furthermore, adenoviruses have been used as live enteric vaccines for many years with an excellent safety profile (Schwartz et al., Am. Rev. Respir. Dis.,  
25 109:233-238 (1974)). Finally, adenovirus mediated gene transfer has been demonstrated in a number of instances including transfer of alpha-1-antitrypsin and CFTR to the lungs of cotton rats (Rosenfeld et al., Science , 252:431-434 (1991); Rosenfeld et al., Cell, 68:143-155 (1992)). Furthermore, extensive studies to attempt to establish adenovirus as a causative agent in human cancer were uniformly negative  
30 (Green et al. Proc. Natl. Acad. Sci. USA , 76:6606 (1979)).

Suitable adenoviral vectors useful in the present invention are described, for example, in Kozarsky and Wilson, Curr. Opin. Genet. Devel., 3:499-503 (1993);

Rosenfeld et al., Cell , 68:143-155 (1992); Engelhardt et al., Human Genet. Ther., 4:759-769 (1993); Yang et al., Nature Genet., 7:362-369 (1994); Wilson et al., Nature , 365:691-692 (1993); and U.S. Patent NO: 5,652,224, which are herein incorporated by reference. For example, the adenovirus vector Ad2 is useful and can  
5 be grown in human 293 cells. These cells contain the E1 region of adenovirus and constitutively express E1a and E1b, which complement the defective adenoviruses by providing the products of the genes deleted from the vector. In addition to Ad2, other varieties of adenovirus (e.g., Ad3, Ad5, and Ad7) are also useful in the present invention.

10 Preferably, the adenoviruses used in the present invention are replication deficient. Replication deficient adenoviruses require the aid of a helper virus and/or packaging cell line to form infectious particles. The resulting virus is capable of infecting cells and can express a polynucleotide of interest which is operably linked to a promoter, but cannot replicate in most cells. Replication deficient adenoviruses  
15 may be deleted in one or more of all or a portion of the following genes: E1a, E1b, E3, E4, E2a, or L1 through L5.

In certain other embodiments, the cells are engineered, *ex vivo* or *in vivo*, using an adeno-associated virus (AAV). AAVs are naturally occurring defective viruses that require helper viruses to produce infectious particles (Muzyczka, Curr.  
20 Topics in Microbiol. Immunol., 158:97 (1992)). It is also one of the few viruses that may integrate its DNA into non-dividing cells. Vectors containing as little as 300 base pairs of AAV can be packaged and can integrate, but space for exogenous DNA is limited to about 4.5 kb. Methods for producing and using such AAVs are known in the art. See, for example, U.S. Patent Nos. 5,139,941, 5,173,414, 5,354,678,  
25 5,436,146, 5,474,935, 5,478,745, and 5,589,377.

For example, an appropriate AAV vector for use in the present invention will include all the sequences necessary for DNA replication, encapsidation, and host-cell integration. The polynucleotide construct containing polynucleotides of the invention is inserted into the AAV vector using standard cloning methods, such as those found  
30 in Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press (1989). The recombinant AAV vector is then transfected into packaging cells which are infected with a helper virus, using any standard technique, including



lipofection, electroporation, calcium phosphate precipitation, etc. Appropriate helper viruses include adenoviruses, cytomegaloviruses, vaccinia viruses, or herpes viruses. Once the packaging cells are transfected and infected, they will produce infectious AAV viral particles which contain the polynucleotide construct of the invention.

- 5 These viral particles are then used to transduce eukaryotic cells, either *ex vivo* or *in vivo*. The transduced cells will contain the polynucleotide construct integrated into its genome, and will express the desired gene product.

- Another method of gene therapy involves operably associating heterologous control regions and endogenous polynucleotide sequences (e.g. encoding the
- 10 polypeptide sequence of interest) via homologous recombination (see, e.g., U.S. Patent NO: 5,641,670, issued June 24, 1997; International Publication NO: WO 96/29411, published September 26, 1996; International Publication NO: WO 94/12650, published August 4, 1994; Koller et al., Proc. Natl. Acad. Sci. USA, 86:8932-8935 (1989); and Zijlstra et al., Nature, 342:435-438 (1989). This method
- 15 involves the activation of a gene which is present in the target cells, but which is not normally expressed in the cells, or is expressed at a lower level than desired.

- Polynucleotide constructs are made, using standard techniques known in the art, which contain the promoter with targeting sequences flanking the promoter. Suitable promoters are described herein. The targeting sequence is sufficiently
- 20 complementary to an endogenous sequence to permit homologous recombination of the promoter-targeting sequence with the endogenous sequence. The targeting sequence will be sufficiently near the 5' end of the desired endogenous polynucleotide sequence so the promoter will be operably linked to the endogenous sequence upon homologous recombination.

- 25 The promoter and the targeting sequences can be amplified using PCR. Preferably, the amplified promoter contains distinct restriction enzyme sites on the 5' and 3' ends. Preferably, the 3' end of the first targeting sequence contains the same restriction enzyme site as the 5' end of the amplified promoter and the 5' end of the second targeting sequence contains the same restriction site as the 3' end of the
- 30 amplified promoter. The amplified promoter and targeting sequences are digested and ligated together.

The promoter-targeting sequence construct is delivered to the cells, either as naked polynucleotide, or in conjunction with transfection-facilitating agents, such as liposomes, viral sequences, viral particles, whole viruses, lipofection, precipitating agents, etc., described in more detail above. The P promoter-targeting sequence can  
5 be delivered by any method, included direct needle injection, intravenous injection, topical administration, catheter infusion, particle accelerators, etc. The methods are described in more detail below.

The promoter-targeting sequence construct is taken up by cells. Homologous recombination between the construct and the endogenous sequence takes place, such  
10 that an endogenous sequence is placed under the control of the promoter. The promoter then drives the expression of the endogenous sequence.

The polynucleotides encoding polypeptides of the present invention may be administered along with other polynucleotides encoding other angiogenic proteins. Angiogenic proteins include, but are not limited to, acidic and basic fibroblast growth  
15 factors, VEGF-1, VEGF-2 (VEGF-C), VEGF-3 (VEGF-B), epidermal growth factor alpha and beta, platelet-derived endothelial cell growth factor, platelet-derived growth factor, tumor necrosis factor alpha, hepatocyte growth factor, insulin like growth factor, colony stimulating factor, macrophage colony stimulating factor, granulocyte/macrophage colony stimulating factor, and nitric oxide synthase.

20 Preferably, the polynucleotide encoding a polypeptide of the invention contains a secretory signal sequence that facilitates secretion of the protein. Typically, the signal sequence is positioned in the coding region of the polynucleotide to be expressed towards or at the 5' end of the coding region. The signal sequence may be homologous or heterologous to the polynucleotide of interest and may be  
25 homologous or heterologous to the cells to be transfected. Additionally, the signal sequence may be chemically synthesized using methods known in the art.

Any mode of administration of any of the above-described polynucleotides constructs can be used so long as the mode results in the expression of one or more molecules in an amount sufficient to provide a therapeutic effect. This includes direct  
30 needle injection, systemic injection, catheter infusion, biolistic injectors, particle accelerators (i.e., "gene guns"), gelfoam sponge depots, other commercially available depot materials, osmotic pumps (e.g., Alza minipumps), oral or suppositorial solid

(tablet or pill) pharmaceutical formulations, and decanting or topical applications during surgery. For example, direct injection of naked calcium phosphate-precipitated plasmid into rat liver and rat spleen or a protein-coated plasmid into the portal vein has resulted in gene expression of the foreign gene in the  
5 rat livers. (Kaneda et al., Science, 243:375 (1989)).

A preferred method of local administration is by direct injection. Preferably, a recombinant molecule of the present invention complexed with a delivery vehicle is administered by direct injection into or locally within the area of arteries. Administration of a composition locally within the area of arteries refers to injecting  
10 the composition centimeters and preferably, millimeters within arteries.

Another method of local administration is to contact a polynucleotide construct of the present invention in or around a surgical wound. For example, a patient can undergo surgery and the polynucleotide construct can be coated on the surface of tissue inside the wound or the construct can be injected into areas of tissue  
15 inside the wound.

Therapeutic compositions useful in systemic administration, include recombinant molecules of the present invention complexed to a targeted delivery vehicle of the present invention. Suitable delivery vehicles for use with systemic administration comprise liposomes comprising ligands for targeting the vehicle to a  
20 particular site.

Preferred methods of systemic administration, include intravenous injection, aerosol, oral and percutaneous (topical) delivery. Intravenous injections can be performed using methods standard in the art. Aerosol delivery can also be performed using methods standard in the art (see, for example, Stribling et al., Proc. Natl. Acad.  
25 Sci. USA, 189:11277-11281 (1992), which is incorporated herein by reference). Oral delivery can be performed by complexing a polynucleotide construct of the present invention to a carrier capable of withstanding degradation by digestive enzymes in the gut of an animal. Examples of such carriers, include plastic capsules or tablets, such as those known in the art. Topical delivery can be performed by mixing a  
30 polynucleotide construct of the present invention with a lipophilic reagent (e.g., DMSO) that is capable of passing into the skin.

Determining an effective amount of substance to be delivered can depend upon a number of factors including, for example, the chemical structure and biological activity of the substance, the age and weight of the animal, the precise condition requiring treatment and its severity, and the route of administration. The frequency of treatments depends upon a number of factors, such as the amount of polynucleotide constructs administered per dose, as well as the health and history of the subject. The precise amount, number of doses, and timing of doses will be determined by the attending physician or veterinarian. Therapeutic compositions of the present invention can be administered to any animal, preferably to mammals and birds. Preferred mammals include humans, dogs, cats, mice, rats, rabbits sheep, cattle, horses and pigs, with humans being particularly

### **Biological Activities**

The polynucleotides or polypeptides, or agonists or antagonists of the present invention can be used in assays to test for one or more biological activities. If these polynucleotides and polypeptides do exhibit activity in a particular assay, it is likely that these molecules may be involved in the diseases associated with the biological activity. Thus, the polynucleotides or polypeptides, or agonists or antagonists could be used to treat the associated disease.

### **Immune Activity**

Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing diseases, disorders, and/or conditions of the immune system, by, for example, activating or inhibiting the proliferation, differentiation, or mobilization (chemotaxis) of immune cells. Immune cells develop through a process called hematopoiesis, producing myeloid (platelets, red blood cells, neutrophils, and macrophages) and lymphoid (B and T lymphocytes) cells from pluripotent stem cells. The etiology of these immune diseases, disorders, and/or conditions may be genetic, somatic, such as cancer and some autoimmune diseases, acquired (e.g., by chemotherapy or toxins), or infectious. Moreover, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of

the present invention can be used as a marker or detector of a particular immune system disease or disorder.

Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing diseases, disorders, and/or conditions of hematopoietic cells. Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention could be used to increase differentiation and proliferation of hematopoietic cells, including the pluripotent stem cells, in an effort to treat or prevent those diseases, disorders, and/or conditions associated with a decrease in certain (or many) types hematopoietic cells.

Examples of immunologic deficiency syndromes include, but are not limited to: blood protein diseases, disorders, and/or conditions (e.g., agammaglobulinemia, dysgammaglobulinemia), ataxia telangiectasia, common variable immunodeficiency, Digeorge Syndrome, HIV infection, HTLV-BLV infection, leukocyte adhesion deficiency syndrome, lymphopenia, phagocyte bactericidal dysfunction, severe combined immunodeficiency (SCIDs), Wiskott-Aldrich Disorder, anemia, thrombocytopenia, or hemoglobinuria.

Moreover, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention could also be used to modulate hemostatic (the stopping of bleeding) or thrombolytic activity (clot formation). For example, by increasing hemostatic or thrombolytic activity, polynucleotides or polypeptides, and/or agonists or antagonists of the present invention could be used to treat or prevent blood coagulation diseases, disorders, and/or conditions (e.g., afibrinogenemia, factor deficiencies), blood platelet diseases, disorders, and/or conditions (e.g., thrombocytopenia), or wounds resulting from trauma, surgery, or other causes. Alternatively, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention that can decrease hemostatic or thrombolytic activity could be used to inhibit or dissolve clotting. These molecules could be important in the treatment or prevention of heart attacks (infarction), strokes, or scarring.

The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing autoimmune disorders. Many autoimmune disorders result from inappropriate

recognition of self as foreign material by immune cells. This inappropriate recognition results in an immune response leading to the destruction of the host tissue. Therefore, the administration of polynucleotides and polypeptides of the invention that can inhibit an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing autoimmune disorders.

Autoimmune diseases or disorders that may be treated, prevented, and/or diagnosed by polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention include, but are not limited to, one or more of the following:

10 autoimmune hemolytic anemia, autoimmune neonatal thrombocytopenia, idiopathic thrombocytopenia purpura, autoimmunocytopenia, hemolytic anemia, antiphospholipid syndrome, dermatitis, allergic encephalomyelitis, myocarditis, relapsing polychondritis, rheumatic heart disease, glomerulonephritis (e.g. IgA nephropathy), Multiple Sclerosis, Neuritis, Uveitis Ophthalmia,

15 Polyendocrinopathies, Purpura (e.g., Henloch-Scoenlein purpura), Reiter's Disease, Stiff-Man Syndrome, Autoimmune Pulmonary Inflammation, Autism, Guillain-Barre Syndrome, insulin dependent diabetes mellitus, and autoimmune inflammatory eye, autoimmune thyroiditis, hypothyroidism (i.e., Hashimoto's thyroiditis, systemic lupus erythematosus, Goodpasture's syndrome, Pemphigus, Receptor autoimmunities such

20 as, for example, (a) Graves' Disease, (b) Myasthenia Gravis, and (c) insulin resistance, autoimmune hemolytic anemia, autoimmune thrombocytopenic purpura, rheumatoid arthritis, scleroderma with anti-collagen antibodies, mixed connective tissue disease, polymyositis/dermatomyositis, pernicious anemia, idiopathic Addison's disease, infertility, glomerulonephritis such as primary glomerulonephritis and IgA

25 nephropathy, bullous pemphigoid, Sjogren's syndrome, diabetes mellitus, and adrenergic drug resistance (including adrenergic drug resistance with asthma or cystic fibrosis), chronic active hepatitis, primary biliary cirrhosis, other endocrine gland failure, vitiligo, vasculitis, post-MI, cardiomy syndrome, urticaria, atopic dermatitis, asthma, inflammatory myopathies, and other inflammatory, granulomatous,

30 degenerative, and atrophic disorders.

Additional autoimmune disorders (that are probable) that may be treated, prevented, and/or diagnosed with the compositions of the invention include, but are

not limited to, rheumatoid arthritis (often characterized, e.g., by immune complexes in joints), scleroderma with anti-collagen antibodies (often characterized, e.g., by nucleolar and other nuclear antibodies), mixed connective tissue disease (often characterized, e.g., by antibodies to extractable nuclear antigens (e.g., ribonucleoprotein)), polymyositis (often characterized, e.g., by nonhistone ANA), pernicious anemia (often characterized, e.g., by antiparietal cell, microsomes, and intrinsic factor antibodies), idiopathic Addison's disease (often characterized, e.g., by humoral and cell-mediated adrenal cytotoxicity, infertility (often characterized, e.g., by antispermatozoal antibodies), glomerulonephritis (often characterized, e.g., by glomerular basement membrane antibodies or immune complexes), bullous pemphigoid (often characterized, e.g., by IgG and complement in basement membrane), Sjogren's syndrome (often characterized, e.g., by multiple tissue antibodies, and/or a specific nonhistone ANA (SS-B)), diabetes mellitus (often characterized, e.g., by cell-mediated and humoral islet cell antibodies), and adrenergic drug resistance (including adrenergic drug resistance with asthma or cystic fibrosis) (often characterized, e.g., by beta-adrenergic receptor antibodies).

Additional autoimmune disorders (that are possible) that may be treated, prevented, and/or diagnosed with the compositions of the invention include, but are not limited to, chronic active hepatitis (often characterized, e.g., by smooth muscle antibodies), primary biliary cirrhosis (often characterized, e.g., by mitochondrial antibodies), other endocrine gland failure (often characterized, e.g., by specific tissue antibodies in some cases), vitiligo (often characterized, e.g., by melanocyte antibodies), vasculitis (often characterized, e.g., by Ig and complement in vessel walls and/or low serum complement), post-MI (often characterized, e.g., by myocardial antibodies), cardiomyopathy syndrome (often characterized, e.g., by myocardial antibodies), urticaria (often characterized, e.g., by IgG and IgM antibodies to IgE), atopic dermatitis (often characterized, e.g., by IgG and IgM antibodies to IgE), asthma (often characterized, e.g., by IgG and IgM antibodies to IgE), and many other inflammatory, granulomatous, degenerative, and atrophic disorders.

In a preferred embodiment, the autoimmune diseases and disorders and/or conditions associated with the diseases and disorders recited above are treated,

prevented, and/or diagnosed using for example, antagonists or agonists, polypeptides or polynucleotides, or antibodies of the present invention.

In a preferred embodiment polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention could be used as an agent to boost  
5 immunoresponsiveness among B cell and/or T cell immunodeficient individuals.

B cell immunodeficiencies that may be ameliorated or treated by administering the polypeptides or polynucleotides of the invention, and/or agonists thereof, include, but are not limited to, severe combined immunodeficiency (SCID)-X linked, SCID-autosomal, adenosine deaminase deficiency (ADA deficiency), X-  
10 linked agammaglobulinemia (XLA), Bruton's disease, congenital agammaglobulinemia, X-linked infantile agammaglobulinemia, acquired agammaglobulinemia, adult onset agammaglobulinemia, late-onset agammaglobulinemia, dysgammaglobulinemia, hypogammaglobulinemia, transient hypogammaglobulinemia of infancy, unspecified hypogammaglobulinemia,  
15 agammaglobulinemia, common variable immunodeficiency (CVI) (acquired), Wiskott-Aldrich Syndrome (WAS), X-linked immunodeficiency with hyper IgM, non X-linked immunodeficiency with hyper IgM, selective IgA deficiency, IgG subclass deficiency (with or without IgA deficiency), antibody deficiency with normal or elevated Igs, immunodeficiency with thymoma, Ig heavy chain deletions, kappa  
20 chain deficiency, B cell lymphoproliferative disorder (BLPD), selective IgM immunodeficiency, recessive agammaglobulinemia (Swiss type), reticular dysgenesis, neonatal neutropenia, severe congenital leukopenia, thymic aplasia, aplasia or dysplasia with immunodeficiency, ataxia-telangiectasia, short limbed dwarfism, X-linked lymphoproliferative syndrome (XLP), Nezelof  
25 syndrome-combined immunodeficiency with Igs, purine nucleoside phosphorylase deficiency (PNP), MHC Class II deficiency (Bare Lymphocyte Syndrome) and severe combined immunodeficiency.

T cell deficiencies that may be ameliorated or treated by administering the polypeptides or polynucleotides of the invention, and/or agonists thereof include, but  
30 are not limited to, for example, DiGeorge anomaly, thymic hypoplasia, third and fourth pharyngeal pouch syndrome, 22q11.2 deletion, chronic mucocutaneous candidiasis, natural killer cell deficiency (NK), idiopathic CD4+ T-lymphocytopenia,



immunodeficiency with predominant T cell defect (unspecified), and unspecified immunodeficiency of cell mediated immunity. In specific embodiments, DiGeorge anomaly or conditions associated with DiGeorge anomaly are ameliorated or treated by, for example, administering the polypeptides or polynucleotides of the invention, or antagonists or agonists thereof.

Other immunodeficiencies that may be ameliorated or treated by administering polypeptides or polynucleotides of the invention, and/or agonists thereof, include, but are not limited to, severe combined immunodeficiency (SCID; e.g., X-linked SCID, autosomal SCID, and adenosine deaminase deficiency), ataxia-telangiectasia, Wiskott-Aldrich syndrome, short-limber dwarfism, X-linked lymphoproliferative syndrome (XLP), Nezelof syndrome (e.g., purine nucleoside phosphorylase deficiency), MHC Class II deficiency. In specific embodiments, ataxia-telangiectasia or conditions associated with ataxia-telangiectasia are ameliorated or treated by administering the polypeptides or polynucleotides of the invention, and/or agonists thereof.

In a specific preferred embodiment, rheumatoid arthritis is treated, prevented, and/or diagnosed using polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention. In another specific preferred embodiment, systemic lupus erythematosus is treated, prevented, and/or diagnosed using polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention. In another specific preferred embodiment, idiopathic thrombocytopenia purpura is treated, prevented, and/or diagnosed using polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention. In another specific preferred embodiment IgA nephropathy is treated, prevented, and/or diagnosed using polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention. In a preferred embodiment, the autoimmune diseases and disorders and/or conditions associated with the diseases and disorders recited above are treated, prevented, and/or diagnosed using antibodies against the protein of the invention.

Similarly, allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems, may also be treated, prevented, and/or diagnosed using polypeptides, antibodies, or polynucleotides of the invention, and/or

agonists or antagonists thereof. Moreover, these molecules can be used to treat, prevent, and/or diagnose anaphylaxis, hypersensitivity to an antigenic molecule, or blood group incompatibility.

Moreover, inflammatory conditions may also be treated, diagnosed, and/or prevented with polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention. Such inflammatory conditions include, but are not limited to, for example, respiratory disorders (such as, e.g., asthma and allergy); gastrointestinal disorders (such as, e.g., inflammatory bowel disease); cancers (such as, e.g., gastric, ovarian, lung, bladder, liver, and breast); CNS disorders (such as, e.g., multiple sclerosis, blood-brain barrier permeability, ischemic brain injury and/or stroke, traumatic brain injury, neurodegenerative disorders (such as, e.g., Parkinson's disease and Alzheimer's disease), AIDS-related dementia, and prion disease); cardiovascular disorders (such as, e.g., atherosclerosis, myocarditis, cardiovascular disease, and cardiopulmonary bypass complications); as well as many additional diseases, conditions, and disorders that are characterized by inflammation (such as, e.g., chronic hepatitis (B and C), rheumatoid arthritis, gout, trauma, septic shock, pancreatitis, sarcoidosis, dermatitis, renal ischemia-reperfusion injury, Grave's disease, systemic lupus erythematosus, diabetes mellitus (i.e., type 1 diabetes), and allogenic transplant rejection).

In specific embodiments, polypeptides, antibodies, or polynucleotides of the invention, and/or agonists or antagonists thereof, are useful to treat, diagnose, and/or prevent transplantation rejections, graft-versus-host disease, autoimmune and inflammatory diseases (e.g., immune complex-induced vasculitis, glomerulonephritis, hemolytic anemia, myasthenia gravis, type II collagen-induced arthritis, experimental allergic and hyperacute xenograft rejection, rheumatoid arthritis, and systemic lupus erythematosus (SLE)). Organ rejection occurs by host immune cell destruction of the transplanted tissue through an immune response. Similarly, an immune response is also involved in GVHD, but, in this case, the foreign transplanted immune cells destroy the host tissues. Polypeptides, antibodies, or polynucleotides of the invention, and/or agonists or antagonists thereof, that inhibit an immune response, particularly the activation, proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing organ rejection or GVHD.

Similarly, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may also be used to modulate and/or diagnose inflammation. For example, since polypeptides, antibodies, or polynucleotides of the invention, and/or agonists or antagonists of the invention may inhibit the activation, proliferation and/or differentiation of cells involved in an inflammatory response, these molecules can be used to treat, diagnose, or prognose, inflammatory conditions, both chronic and acute conditions, including, but not limited to, inflammation associated with infection (e.g., septic shock, sepsis, or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine induced lung injury, inflammatory bowel disease, Crohn's disease, and resulting from over production of cytokines (e.g., TNF or IL-1.).

Polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the invention can be used to treat, detect, and/or prevent infectious agents. For example, by increasing the immune response, particularly increasing the proliferation activation and/or differentiation of B and/or T cells, infectious diseases may be treated, detected, and/or prevented. The immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may also directly inhibit the infectious agent (refer to section of application listing infectious agents, etc), without necessarily eliciting an immune response.

Additional preferred embodiments of the invention include, but are not limited to, the use of polypeptides, antibodies, polynucleotides and/or agonists or antagonists in the following applications:

Administration to an animal (e.g., mouse, rat, rabbit, hamster, guinea pig, pigs, micro-pig, chicken, camel, goat, horse, cow, sheep, dog, cat, non-human primate, and human, most preferably human) to boost the immune system to produce increased quantities of one or more antibodies (e.g., IgG, IgA, IgM, and IgE), to induce higher affinity antibody production (e.g., IgG, IgA, IgM, and IgE), and/or to increase an immune response.

Administration to an animal (including, but not limited to, those listed above, and also including transgenic animals) incapable of producing functional endogenous antibody molecules or having an otherwise compromised endogenous immune system, but which is capable of producing human immunoglobulin molecules by means of a reconstituted or partially reconstituted immune system from another animal (see, e.g., published PCT Application Nos. WO98/24893, WO/9634096, WO/9633735, and WO/9110741.

A vaccine adjuvant that enhances immune responsiveness to specific antigen.

An adjuvant to enhance tumor-specific immune responses.

10 An adjuvant to enhance anti-viral immune responses. Anti-viral immune responses that may be enhanced using the compositions of the invention as an adjuvant, include virus and virus associated diseases or symptoms described herein or otherwise known in the art. In specific embodiments, the compositions of the invention are used as an adjuvant to enhance an immune response to a virus, disease, 15 or symptom selected from the group consisting of: AIDS, meningitis, Dengue, EBV, and hepatitis (e.g., hepatitis B). In another specific embodiment, the compositions of the invention are used as an adjuvant to enhance an immune response to a virus, disease, or symptom selected from the group consisting of: HIV/AIDS, Respiratory syncytial virus, Dengue, Rotavirus, Japanese B encephalitis, Influenza A and B, 20 Parainfluenza, Measles, Cytomegalovirus, Rabies, Junin, Chikungunya, Rift Valley fever, Herpes simplex, and yellow fever.

An adjuvant to enhance anti-bacterial or anti-fungal immune responses. Anti-bacterial or anti-fungal immune responses that may be enhanced using the compositions of the invention as an adjuvant, include bacteria or fungus and bacteria 25 or fungus associated diseases or symptoms described herein or otherwise known in the art. In specific embodiments, the compositions of the invention are used as an adjuvant to enhance an immune response to a bacteria or fungus, disease, or symptom selected from the group consisting of: tetanus, Diphtheria, botulism, and meningitis type B. In another specific embodiment, the compositions of the invention are used as 30 an adjuvant to enhance an immune response to a bacteria or fungus, disease, or symptom selected from the group consisting of: *Vibrio cholerae*, *Mycobacterium leprae*, *Salmonella typhi*, *Salmonella paratyphi*, *Meissneria meningitidis*,

*Streptococcus pneumoniae*, Group B streptococcus, *Shigella spp.*, Enterotoxigenic *Escherichia coli*, Enterohemorrhagic *E. coli*, *Borrelia burgdorferi*, and Plasmodium (malaria).

5 An adjuvant to enhance anti-parasitic immune responses. Anti-parasitic immune responses that may be enhanced using the compositions of the invention as an adjuvant, include parasite and parasite associated diseases or symptoms described herein or otherwise known in the art. In specific embodiments, the compositions of the invention are used as an adjuvant to enhance an immune response to a parasite. In another specific embodiment, the compositions of the invention are used as an  
10 adjuvant to enhance an immune response to Plasmodium (malaria).

As a stimulator of B cell responsiveness to pathogens.

As an activator of T cells.

As an agent that elevates the immune status of an individual prior to their receipt of immunosuppressive therapies.

15 As an agent to induce higher affinity antibodies.

As an agent to increase serum immunoglobulin concentrations.

As an agent to accelerate recovery of immunocompromised individuals.

As an agent to boost immunoresponsiveness among aged populations.

As an immune system enhancer prior to, during, or after bone marrow  
20 transplant and/or other transplants (e.g., allogeneic or xenogeneic organ transplantation). With respect to transplantation, compositions of the invention may be administered prior to, concomitant with, and/or after transplantation. In a specific embodiment, compositions of the invention are administered after transplantation, prior to the beginning of recovery of T-cell populations. In another specific  
25 embodiment, compositions of the invention are first administered after transplantation after the beginning of recovery of T cell populations, but prior to full recovery of B cell populations.

As an agent to boost immunoresponsiveness among individuals having an acquired loss of B cell function. Conditions resulting in an acquired loss of B cell  
30 function that may be ameliorated or treated by administering the polypeptides, antibodies, polynucleotides and/or agonists or antagonists thereof, include, but are

not limited to, HIV Infection, AIDS, bone marrow transplant, and B cell chronic lymphocytic leukemia (CLL).

As an agent to boost immunoresponsiveness among individuals having a temporary immune deficiency. Conditions resulting in a temporary immune deficiency that may be ameliorated or treated by administering the polypeptides, antibodies, polynucleotides and/or agonists or antagonists thereof, include, but are not limited to, recovery from viral infections (e.g., influenza), conditions associated with malnutrition, recovery from infectious mononucleosis, or conditions associated with stress, recovery from measles, recovery from blood transfusion, recovery from surgery.

As a regulator of antigen presentation by monocytes, dendritic cells, and/or B-cells. In one embodiment, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention enhance antigen presentation or antagonizes antigen presentation in vitro or in vivo. Moreover, in related embodiments, said enhancement or antagonization of antigen presentation may be useful as an anti-tumor treatment or to modulate the immune system.

As an agent to direct an individuals immune system towards development of a humoral response (i.e. TH2) as opposed to a TH1 cellular response.

As a means to induce tumor proliferation and thus make it more susceptible to anti-neoplastic agents. For example, multiple myeloma is a slowly dividing disease and is thus refractory to virtually all anti-neoplastic regimens. If these cells were forced to proliferate more rapidly their susceptibility profile would likely change.

As a stimulator of B cell production in pathologies such as AIDS, chronic lymphocyte disorder and/or Common Variable Immunodeficiency.

As a therapy for generation and/or regeneration of lymphoid tissues following surgery, trauma or genetic defect.

As a gene-based therapy for genetically inherited disorders resulting in immuno-incompetence such as observed among SCID patients.

As an antigen for the generation of antibodies to inhibit or enhance immune mediated responses against polypeptides of the invention.

As a means of activating T cells.

As a means of activating monocytes/macrophages to defend against parasitic diseases that effect monocytes such as Leshmania.

As pretreatment of bone marrow samples prior to transplant. Such treatment would increase B cell representation and thus accelerate recover.

5 As a means of regulating secreted cytokines that are elicited by polypeptides of the invention.

Additionally, polypeptides or polynucleotides of the invention, and/or agonists thereof, may be used to treat or prevent IgE-mediated allergic reactions. Such allergic reactions include, but are not limited to, asthma, rhinitis, and eczema.

10 All of the above described applications as they may apply to veterinary medicine.

Antagonists of the invention include, for example, binding and/or inhibitory antibodies, antisense nucleic acids, or ribozymes. These would be expected to reverse many of the activities of the ligand described above as well as find clinical or  
15 practical application as:

A means of blocking various aspects of immune responses to foreign agents or self. Examples include autoimmune disorders such as lupus, and arthritis, as well as immunoresponsiveness to skin allergies, inflammation, bowel disease, injury and pathogens.

20 A therapy for preventing the B cell proliferation and Ig secretion associated with autoimmune diseases such as idiopathic thrombocytopenic purpura, systemic lupus erythramatosus and MS.

An inhibitor of B and/or T cell migration in endothelial cells. This activity disrupts tissue architecture or cognate responses and is useful, for example in  
25 disrupting immune responses, and blocking sepsis.

An inhibitor of graft versus-host disease or transplant rejection.

A therapy for B cell and/or T cell malignancies such as ALL, Hodgkins disease, non-Hodgkins lymphoma, Chronic lymphocyte leukemia, plasmacytomas, multiple myeloma, Burkitt's lymphoma, and EBV-transformed diseases.

30 A therapy for chronic hypergammaglobulinemeia evident in such diseases as monoclonalgammopathy of undetermined significance (MGUS), Waldenstrom's disease, related idiopathic monoclonalgammopathies, and plasmacytomas.

A therapy for decreasing cellular proliferation of Large B-cell Lymphomas.

A means of decreasing the involvement of B cells and Ig associated with Chronic Myelogenous Leukemia.

An immunosuppressive agent(s).

5 Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to modulate IgE concentrations in vitro or in vivo.

In another embodiment, administration of polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the invention, may be used to treat or prevent IgE-mediated allergic reactions including, but not limited to, asthma,  
10 rhinitis, and eczema.

The agonists and antagonists may be employed in a composition with a pharmaceutically acceptable carrier, e.g., as described herein.

The agonists or antagonists may be employed for instance to inhibit polypeptide chemotaxis and activation of macrophages and their precursors, and of  
15 neutrophils, basophils, B lymphocytes and some T-cell subsets, e.g., activated and CD8 cytotoxic T cells and natural killer cells, in certain auto-immune and chronic inflammatory and infective diseases. Examples of autoimmune diseases are described herein and include multiple sclerosis, and insulin-dependent diabetes. The antagonists or agonists may also be employed to treat infectious diseases including  
20 silicosis, sarcoidosis, idiopathic pulmonary fibrosis by, for example, preventing the recruitment and activation of mononuclear phagocytes. They may also be employed to treat idiopathic hyper-eosinophilic syndrome by, for example, preventing eosinophil production and migration. The antagonists or agonists or may also be employed for treating atherosclerosis, for example, by preventing monocyte  
25 infiltration in the artery wall.

Antibodies against polypeptides of the invention may be employed to treat ARDS.

Agonists and/or antagonists of the invention also have uses in stimulating wound and tissue repair, stimulating angiogenesis, stimulating the repair of vascular  
30 or lymphatic diseases or disorders. Additionally, agonists and antagonists of the invention may be used to stimulate the regeneration of mucosal surfaces.



In a specific embodiment, polynucleotides or polypeptides, and/or agonists thereof are used to treat or prevent a disorder characterized by primary or acquired immunodeficiency, deficient serum immunoglobulin production, recurrent infections, and/or immune system dysfunction. Moreover, polynucleotides or polypeptides, and/or agonists thereof may be used to treat or prevent infections of the joints, bones, skin, and/or parotid glands, blood-borne infections (e.g., sepsis, meningitis, septic arthritis, and/or osteomyelitis), autoimmune diseases (e.g., those disclosed herein), inflammatory disorders, and malignancies, and/or any disease or disorder or condition associated with these infections, diseases, disorders and/or malignancies) including, but not limited to, CVID, other primary immune deficiencies, HIV disease, CLL, recurrent bronchitis, sinusitis, otitis media, conjunctivitis, pneumonia, hepatitis, meningitis, herpes zoster (e.g., severe herpes zoster), and/or pneumocystis carinii.

In another embodiment, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention are used to treat, and/or diagnose an individual having common variable immunodeficiency disease ("CVID"; also known as "acquired agammaglobulinemia" and "acquired hypogammaglobulinemia") or a subset of this disease.

In a specific embodiment, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to treat, diagnose, and/or prevent (1) cancers or neoplasms and (2) autoimmune cell or tissue-related cancers or neoplasms. In a preferred embodiment, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention conjugated to a toxin or a radioactive isotope, as described herein, may be used to treat, diagnose, and/or prevent acute myelogenous leukemia. In a further preferred embodiment, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention conjugated to a toxin or a radioactive isotope, as described herein, may be used to treat, diagnose, and/or prevent, chronic myelogenous leukemia, multiple myeloma, non-Hodgkins lymphoma, and/or Hodgkins disease.

In another specific embodiment, polynucleotides or polypeptides, and/or agonists or antagonists of the invention may be used to treat, diagnose, prognose, and/or prevent selective IgA deficiency, myeloperoxidase deficiency, C2 deficiency, ataxia-telangiectasia, DiGeorge anomaly, common variable immunodeficiency (CVI),

X-linked agammaglobulinemia, severe combined immunodeficiency (SCID), chronic granulomatous disease (CGD), and Wiskott-Aldrich syndrome.

Examples of autoimmune disorders that can be treated or detected are described above and also include, but are not limited to: Addison's Disease, hemolytic anemia, antiphospholipid syndrome, rheumatoid arthritis, dermatitis, allergic encephalomyelitis, glomerulonephritis, Goodpasture's Syndrome, Graves' Disease, Multiple Sclerosis, Myasthenia Gravis, Neuritis, Ophthalmia, Bullous Pemphigoid, Pemphigus, Polyendocrinopathies, Purpura, Reiter's Disease, Stiff-Man Syndrome, Autoimmune Thyroiditis, Systemic Lupus Erythematosus, Autoimmune Pulmonary Inflammation, Guillain-Barre Syndrome, insulin dependent diabetes mellitus, and autoimmune inflammatory eye disease.

In a preferred embodiment, the autoimmune diseases and disorders and/or conditions associated with the diseases and disorders recited above are treated, prognosed, prevented, and/or diagnosed using antibodies against the polypeptide of the invention.

As an agent to boost immunoresponsiveness among B cell immunodeficient individuals, such as, for example, an individual who has undergone a partial or complete splenectomy.

Additionally, polynucleotides, polypeptides, and/or antagonists of the invention may affect apoptosis, and therefore, would be useful in treating a number of diseases associated with increased cell survival or the inhibition of apoptosis. For example, diseases associated with increased cell survival or the inhibition of apoptosis that could be treated or detected by polynucleotides, polypeptides, and/or antagonists of the invention, include cancers (such as follicular lymphomas, carcinomas with p53 mutations, and hormone-dependent tumors, including, but not limited to colon cancer, cardiac tumors, pancreatic cancer, melanoma, retinoblastoma, glioblastoma, lung cancer, intestinal cancer, testicular cancer, stomach cancer, neuroblastoma, myxoma, myoma, lymphoma, endothelioma, osteoblastoma, osteoclastoma, osteosarcoma, chondrosarcoma, adenoma, breast cancer, prostate cancer, Kaposi's sarcoma and ovarian cancer); autoimmune disorders (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related

glomerulonephritis and rheumatoid arthritis) and viral infections (such as herpes viruses, pox viruses and adenoviruses), inflammation, graft v. host disease, acute graft rejection, and chronic graft rejection. In preferred embodiments, polynucleotides, polypeptides, and/or antagonists of the invention are used to inhibit growth, progression, and/or metastasis of cancers, in particular those listed above.

Additional diseases or conditions associated with increased cell survival that could be treated or detected by polynucleotides, polypeptides, and/or antagonists of the invention, include, but are not limited to, progression, and/or metastases of malignancies and related disorders such as leukemia (including acute leukemias (e.g., acute lymphocytic leukemia, acute myelocytic leukemia (including myeloblastic, promyelocytic, myelomonocytic, monocytic, and erythroleukemia)) and chronic leukemias (e.g., chronic myelocytic (granulocytic) leukemia and chronic lymphocytic leukemia)), polycythemia vera, lymphomas (e.g., Hodgkin's disease and non-Hodgkin's disease), multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease, and solid tumors including, but not limited to, sarcomas and carcinomas such as fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, menangioma, melanoma, neuroblastoma, and retinoblastoma.

Diseases associated with increased apoptosis that could be treated or detected by polynucleotides, polypeptides, and/or antagonists of the invention, include AIDS; neurodegenerative disorders (such as Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, Retinitis pigmentosa, Cerebellar degeneration and

brain tumor or prior associated disease); autoimmune disorders (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) myelodysplastic syndromes (such as aplastic anemia), graft v. host disease, ischemic injury (such as that caused by myocardial infarction, stroke and reperfusion injury), liver injury (e.g., hepatitis related liver injury, ischemia/reperfusion injury, cholestosis (bile duct injury) and liver cancer); toxin-induced liver disease (such as that caused by alcohol), septic shock, cachexia and anorexia.

Hyperproliferative diseases and/or disorders that could be detected and/or treated by polynucleotides, polypeptides, and/or antagonists of the invention, include, but are not limited to neoplasms located in the: liver, abdomen, bone, breast, digestive system, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous (central and peripheral), lymphatic system, pelvic, skin, soft tissue, spleen, thoracic, and urogenital.

Similarly, other hyperproliferative disorders can also be treated or detected by polynucleotides, polypeptides, and/or antagonists of the invention. Examples of such hyperproliferative disorders include, but are not limited to:

hypergammaglobulinemia, lymphoproliferative disorders, paraproteinemias, purpura, sarcoidosis, Sezary Syndrome, Waldenström's Macroglobulinemia, Gaucher's Disease, histiocytosis, and any other hyperproliferative disease, besides neoplasia, located in an organ system listed above.

## **Hyperproliferative Disorders**

A polynucleotides or polypeptides, or agonists or antagonists of the invention can be used to treat, prevent, and/or diagnose hyperproliferative diseases, disorders, and/or conditions, including neoplasms. A polynucleotides or polypeptides, or agonists or antagonists of the present invention may inhibit the proliferation of the disorder through direct or indirect interactions. Alternatively, a polynucleotides or polypeptides, or agonists or antagonists of the present invention may proliferate other cells which can inhibit the hyperproliferative disorder.

For example, by increasing an immune response, particularly increasing antigenic qualities of the hyperproliferative disorder or by proliferating, differentiating, or mobilizing T-cells, hyperproliferative diseases, disorders, and/or conditions can be treated, prevented, and/or diagnosed. This immune response may  
5 be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, decreasing an immune response may also be a method of treating, preventing, and/or diagnosing hyperproliferative diseases, disorders, and/or conditions, such as a chemotherapeutic agent.

Examples of hyperproliferative diseases, disorders, and/or conditions that can  
10 be treated, prevented, and/or diagnosed by polynucleotides or polypeptides, or agonists or antagonists of the present invention include, but are not limited to neoplasms located in the: colon, abdomen, bone, breast, digestive system, liver, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous (central and peripheral),  
15 lymphatic system, pelvic, skin, soft tissue, spleen, thoracic, and urogenital.

Similarly, other hyperproliferative diseases, disorders, and/or conditions can also be treated, prevented, and/or diagnosed by a polynucleotides or polypeptides, or agonists or antagonists of the present invention. Examples of such hyperproliferative diseases, disorders, and/or conditions include, but are not limited to:  
20 hypergammaglobulinemia, lymphoproliferative diseases, disorders, and/or conditions, paraproteinemias, purpura, sarcoidosis, Sezary Syndrome, Waldenström's Macroglobulinemia, Gaucher's Disease, histiocytosis, and any other hyperproliferative disease, besides neoplasia, located in an organ system listed above.

One preferred embodiment utilizes polynucleotides of the present invention to  
25 inhibit aberrant cellular division, by gene therapy using the present invention, and/or protein fusions or fragments thereof.

Thus, the present invention provides a method for treating or preventing cell proliferative diseases, disorders, and/or conditions by inserting into an abnormally proliferating cell a polynucleotide of the present invention, wherein said  
30 polynucleotide represses said expression.

Another embodiment of the present invention provides a method of treating or preventing cell-proliferative diseases, disorders, and/or conditions in individuals

comprising administration of one or more active gene copies of the present invention to an abnormally proliferating cell or cells. In a preferred embodiment, polynucleotides of the present invention is a DNA construct comprising a recombinant expression vector effective in expressing a DNA sequence encoding said polynucleotides. In another preferred embodiment of the present invention, the DNA construct encoding the polynucleotides of the present invention is inserted into cells to be treated utilizing a retrovirus, or more preferably an adenoviral vector (See G J. Nabel, et. al., PNAS 1999 96: 324-326, which is hereby incorporated by reference). In a most preferred embodiment, the viral vector is defective and will not transform non-proliferating cells, only proliferating cells. Moreover, in a preferred embodiment, the polynucleotides of the present invention inserted into proliferating cells either alone, or in combination with or fused to other polynucleotides, can then be modulated via an external stimulus (i.e. magnetic, specific small molecule, chemical, or drug administration, etc.), which acts upon the promoter upstream of said polynucleotides to induce expression of the encoded protein product. As such the beneficial therapeutic affect of the present invention may be expressly modulated (i.e. to increase, decrease, or inhibit expression of the present invention) based upon said external stimulus.

Polynucleotides of the present invention may be useful in repressing expression of oncogenic genes or antigens. By "repressing expression of the oncogenic genes " is intended the suppression of the transcription of the gene, the degradation of the gene transcript (pre-message RNA), the inhibition of splicing, the destruction of the messenger RNA, the prevention of the post-translational modifications of the protein, the destruction of the protein, or the inhibition of the normal function of the protein.

For local administration to abnormally proliferating cells, polynucleotides of the present invention may be administered by any method known to those of skill in the art including, but not limited to transfection, electroporation, microinjection of cells, or in vehicles such as liposomes, lipofectin, or as naked polynucleotides, or any other method described throughout the specification. The polynucleotide of the present invention may be delivered by known gene delivery systems such as, but not limited to, retroviral vectors (Gilboa, J. Virology 44:845 (1982); Hocke, Nature

320:275 (1986); Wilson, et al., Proc. Natl. Acad. Sci. U.S.A. 85:3014), vaccinia virus system (Chakrabarty et al., Mol. Cell Biol. 5:3403 (1985) or other efficient DNA delivery systems (Yates et al., Nature 313:812 (1985)) known to those skilled in the art. These references are exemplary only and are hereby incorporated by reference.

5 In order to specifically deliver or transfect cells which are abnormally proliferating and spare non-dividing cells, it is preferable to utilize a retrovirus, or adenoviral (as described in the art and elsewhere herein) delivery system known to those of skill in the art. Since host DNA replication is required for retroviral DNA to integrate and the retrovirus will be unable to self replicate due to the lack of the retrovirus genes  
10 needed for its life cycle. Utilizing such a retroviral delivery system for polynucleotides of the present invention will target said gene and constructs to abnormally proliferating cells and will spare the non-dividing normal cells.

The polynucleotides of the present invention may be delivered directly to cell proliferative disorder/disease sites in internal organs, body cavities and the like by use  
15 of imaging devices used to guide an injecting needle directly to the disease site. The polynucleotides of the present invention may also be administered to disease sites at the time of surgical intervention.

By "cell proliferative disease" is meant any human or animal disease or disorder, affecting any one or any combination of organs, cavities, or body parts,  
20 which is characterized by single or multiple local abnormal proliferations of cells, groups of cells, or tissues, whether benign or malignant.

Any amount of the polynucleotides of the present invention may be administered as long as it has a biologically inhibiting effect on the proliferation of the treated cells. Moreover, it is possible to administer more than one of the  
25 polynucleotide of the present invention simultaneously to the same site. By "biologically inhibiting" is meant partial or total growth inhibition as well as decreases in the rate of proliferation or growth of the cells. The biologically inhibitory dose may be determined by assessing the effects of the polynucleotides of the present invention on target malignant or abnormally proliferating cell growth in  
30 tissue culture, tumor growth in animals and cell cultures, or any other method known to one of ordinary skill in the art.

The present invention is further directed to antibody-based therapies which involve administering of anti-polypeptides and anti-polynucleotide antibodies to a mammalian, preferably human, patient for treating, preventing, and/or diagnosing one or more of the described diseases, disorders, and/or conditions. Methods for  
5 producing anti-polypeptides and anti-polynucleotide antibodies polyclonal and monoclonal antibodies are described in detail elsewhere herein. Such antibodies may be provided in pharmaceutically acceptable compositions as known in the art or as described herein.

A summary of the ways in which the antibodies of the present invention may  
10 be used therapeutically includes binding polynucleotides or polypeptides of the present invention locally or systemically in the body or by direct cytotoxicity of the antibody, e.g. as mediated by complement (CDC) or by effector cells (ADCC). Some of these approaches are described in more detail below. Armed with the teachings provided herein, one of ordinary skill in the art will know how to use the antibodies of  
15 the present invention for diagnostic, monitoring or therapeutic purposes without undue experimentation.

In particular, the antibodies, fragments and derivatives of the present invention are useful for treating, preventing, and/or diagnosing a subject having or developing cell proliferative and/or differentiation diseases, disorders, and/or conditions as  
20 described herein. Such treatment comprises administering a single or multiple doses of the antibody, or a fragment, derivative, or a conjugate thereof.

The antibodies of this invention may be advantageously utilized in combination with other monoclonal or chimeric antibodies, or with lymphokines or hematopoietic growth factors, for example, which serve to increase the number or  
25 activity of effector cells which interact with the antibodies.

It is preferred to use high affinity and/or potent in vivo inhibiting and/or neutralizing antibodies against polypeptides or polynucleotides of the present invention, fragments or regions thereof, for both immunoassays directed to and therapy of diseases, disorders, and/or conditions related to polynucleotides or  
30 polypeptides, including fragments thereof, of the present invention. Such antibodies, fragments, or regions, will preferably have an affinity for polynucleotides or polypeptides, including fragments thereof. Preferred binding affinities include those



with a dissociation constant or  $K_d$  less than  $5 \times 10^{-6}M$ ,  $10^{-6}M$ ,  $5 \times 10^{-7}M$ ,  $10^{-7}M$ ,  $5 \times 10^{-8}M$ ,  $10^{-8}M$ ,  $5 \times 10^{-9}M$ ,  $10^{-9}M$ ,  $5 \times 10^{-10}M$ ,  $10^{-10}M$ ,  $5 \times 10^{-11}M$ ,  $10^{-11}M$ ,  $5 \times 10^{-12}M$ ,  $10^{-12}M$ ,  $5 \times 10^{-13}M$ ,  $10^{-13}M$ ,  $5 \times 10^{-14}M$ ,  $10^{-14}M$ ,  $5 \times 10^{-15}M$ , and  $10^{-15}M$ .

Moreover, polypeptides of the present invention are useful in inhibiting the  
5 angiogenesis of proliferative cells or tissues, either alone, as a protein fusion, or in  
combination with other polypeptides directly or indirectly, as described elsewhere  
herein. In a most preferred embodiment, said anti-angiogenesis effect may be  
achieved indirectly, for example, through the inhibition of hematopoietic, tumor-  
specific cells, such as tumor-associated macrophages (See Joseph IB, et al. J Natl  
10 Cancer Inst, 90(21):1648-53 (1998), which is hereby incorporated by reference).  
Antibodies directed to polypeptides or polynucleotides of the present invention may  
also result in inhibition of angiogenesis directly, or indirectly (See Witte L, et al.,  
Cancer Metastasis Rev. 17(2):155-61 (1998), which is hereby incorporated by  
reference)).

15 Polypeptides, including protein fusions, of the present invention, or fragments  
thereof may be useful in inhibiting proliferative cells or tissues through the induction  
of apoptosis. Said polypeptides may act either directly, or indirectly to induce  
apoptosis of proliferative cells and tissues, for example in the activation of a death-  
domain receptor, such as tumor necrosis factor (TNF) receptor-1, CD95 (Fas/APO-1),  
20 TNF-receptor-related apoptosis-mediated protein (TRAMP) and TNF-related  
apoptosis-inducing ligand (TRAIL) receptor-1 and -2 (See Schulze-Osthoff K, et.al.,  
Eur J Biochem 254(3):439-59 (1998), which is hereby incorporated by reference).  
Moreover, in another preferred embodiment of the present invention, said  
polypeptides may induce apoptosis through other mechanisms, such as in the  
25 activation of other proteins which will activate apoptosis, or through stimulating the  
expression of said proteins, either alone or in combination with small molecule drugs  
or adjuvants, such as apoptonin, galectins, thioredoxins, antiinflammatory proteins  
(See for example, Mutat Res 400(1-2):447-55 (1998), Med Hypotheses.50(5):423-33  
(1998), Chem Biol Interact. Apr 24;111-112:23-34 (1998), J Mol Med.76(6):402-12  
30 (1998), Int J Tissue React;20(1):3-15 (1998), which are all hereby incorporated by  
reference).

Polypeptides, including protein fusions to, or fragments thereof, of the present invention are useful in inhibiting the metastasis of proliferative cells or tissues. Inhibition may occur as a direct result of administering polypeptides, or antibodies directed to said polypeptides as described elsewhere herein, or indirectly, such as  
5 activating the expression of proteins known to inhibit metastasis, for example alpha 4 integrins, (See, e.g., Curr Top Microbiol Immunol 1998;231:125-41, which is hereby incorporated by reference). Such therapeutic affects of the present invention may be achieved either alone, or in combination with small molecule drugs or adjuvants.

In another embodiment, the invention provides a method of delivering  
10 compositions containing the polypeptides of the invention (e.g., compositions containing polypeptides or polypeptide antibodies associated with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs) to targeted cells expressing the polypeptide of the present invention. Polypeptides or polypeptide antibodies of the invention may be associated with with heterologous polypeptides,  
15 heterologous nucleic acids, toxins, or prodrugs via hydrophobic, hydrophilic, ionic and/or covalent interactions.

Polypeptides, protein fusions to, or fragments thereof, of the present invention are useful in enhancing the immunogenicity and/or antigenicity of proliferating cells or tissues, either directly, such as would occur if the polypeptides of the present  
20 invention 'vaccinated' the immune response to respond to proliferative antigens and immunogens, or indirectly, such as in activating the expression of proteins known to enhance the immune response (e.g. chemokines), to said antigens and immunogens.

### **Cardiovascular Disorders**

25 Polynucleotides or polypeptides, or agonists or antagonists of the invention may be used to treat, prevent, and/or diagnose cardiovascular diseases, disorders, and/or conditions, including peripheral artery disease, such as limb ischemia.

Cardiovascular diseases, disorders, and/or conditions include cardiovascular abnormalities, such as arterio-arterial fistula, arteriovenous fistula, cerebral  
30 arteriovenous malformations, congenital heart defects, pulmonary atresia, and Scimitar Syndrome. Congenital heart defects include aortic coarctation, cor triatriatum, coronary vessel anomalies, crisscross heart, dextrocardia, patent ductus

arteriosus, Ebstein's anomaly, Eisenmenger complex, hypoplastic left heart syndrome, levocardia, tetralogy of fallot, transposition of great vessels, double outlet right ventricle, tricuspid atresia, persistent truncus arteriosus, and heart septal defects, such as aortopulmonary septal defect, endocardial cushion defects, Lutembacher's Syndrome, trilog of Fallot, ventricular heart septal defects.

Cardiovascular diseases, disorders, and/or conditions also include heart disease, such as arrhythmias, carcinoid heart disease, high cardiac output, low cardiac output, cardiac tamponade, endocarditis (including bacterial), heart aneurysm, cardiac arrest, congestive heart failure, congestive cardiomyopathy, paroxysmal dyspnea, cardiac edema, heart hypertrophy, congestive cardiomyopathy, left ventricular hypertrophy, right ventricular hypertrophy, post-infarction heart rupture, ventricular septal rupture, heart valve diseases, myocardial diseases, myocardial ischemia, pericardial effusion, pericarditis (including constrictive and tuberculous), pneumopericardium, postpericardiotomy syndrome, pulmonary heart disease, rheumatic heart disease, ventricular dysfunction, hyperemia, cardiovascular pregnancy complications, Scimitar Syndrome, cardiovascular syphilis, and cardiovascular tuberculosis.

Arrhythmias include sinus arrhythmia, atrial fibrillation, atrial flutter, bradycardia, extrasystole, Adams-Stokes Syndrome, bundle-branch block, sinoatrial block, long QT syndrome, parasystole, Lown-Ganong-Levine Syndrome, Mahaim-type pre-excitation syndrome, Wolff-Parkinson-White syndrome, sick sinus syndrome, tachycardias, and ventricular fibrillation. Tachycardias include paroxysmal tachycardia, supraventricular tachycardia, accelerated idioventricular rhythm, atrioventricular nodal reentry tachycardia, ectopic atrial tachycardia, ectopic junctional tachycardia, sinoatrial nodal reentry tachycardia, sinus tachycardia, Torsades de Pointes, and ventricular tachycardia.

Heart valve disease include aortic valve insufficiency, aortic valve stenosis, hear murmurs, aortic valve prolapse, mitral valve prolapse, tricuspid valve prolapse, mitral valve insufficiency, mitral valve stenosis, pulmonary atresia, pulmonary valve insufficiency, pulmonary valve stenosis, tricuspid atresia, tricuspid valve insufficiency, and tricuspid valve stenosis.

Myocardial diseases include alcoholic cardiomyopathy, congestive cardiomyopathy, hypertrophic cardiomyopathy, aortic subvalvular stenosis, pulmonary subvalvular stenosis, restrictive cardiomyopathy, Chagas cardiomyopathy, endocardial fibroelastosis, endomyocardial fibrosis, Kearns Syndrome, myocardial  
5 reperfusion injury, and myocarditis.

Myocardial ischemias include coronary disease, such as angina pectoris, coronary aneurysm, coronary arteriosclerosis, coronary thrombosis, coronary vasospasm, myocardial infarction and myocardial stunning.

Cardiovascular diseases also include vascular diseases such as aneurysms,  
10 angiodyplasia, angiomatosis, bacillary angiomatosis, Hippel-Lindau Disease, Klippel-Trenaunay-Weber Syndrome, Sturge-Weber Syndrome, angioneurotic edema, aortic diseases, Takayasu's Arteritis, aortitis, Leriche's Syndrome, arterial occlusive diseases, arteritis, enarteritis, polyarteritis nodosa, cerebrovascular diseases, disorders, and/or conditions, diabetic angiopathies, diabetic retinopathy, embolisms, thrombosis,  
15 erythromelalgia, hemorrhoids, hepatic veno-occlusive disease, hypertension, hypotension, ischemia, peripheral vascular diseases, phlebitis, pulmonary veno-occlusive disease, Raynaud's disease, CREST syndrome, retinal vein occlusion, Scimitar syndrome, superior vena cava syndrome, telangiectasia, atacia telangiectasia, hereditary hemorrhagic telangiectasia, varicocele, varicose veins, varicose ulcer,  
20 vasculitis, and venous insufficiency.

Aneurysms include dissecting aneurysms, false aneurysms, infected aneurysms, ruptured aneurysms, aortic aneurysms, cerebral aneurysms, coronary aneurysms, heart aneurysms, and iliac aneurysms.

Arterial occlusive diseases include arteriosclerosis, intermittent claudication,  
25 carotid stenosis, fibromuscular dysplasias, mesenteric vascular occlusion, Moyamoya disease, renal artery obstruction, retinal artery occlusion, and thromboangiitis obliterans.

Cerebrovascular diseases, disorders, and/or conditions include carotid artery diseases, cerebral amyloid angiopathy, cerebral aneurysm, cerebral anoxia, cerebral  
30 arteriosclerosis, cerebral arteriovenous malformation, cerebral artery diseases, cerebral embolism and thrombosis, carotid artery thrombosis, sinus thrombosis, Wallenberg's syndrome, cerebral hemorrhage, epidural hematoma, subdural

hematoma, subarachnoid hemorrhage, cerebral infarction, cerebral ischemia (including transient), subclavian steal syndrome, periventricular leukomalacia, vascular headache, cluster headache, migraine, and vertebrobasilar insufficiency.

Embolisms include air embolisms, amniotic fluid embolisms, cholesterol  
5 embolisms, blue toe syndrome, fat embolisms, pulmonary embolisms, and thromboembolisms. Thrombosis include coronary thrombosis, hepatic vein thrombosis, retinal vein occlusion, carotid artery thrombosis, sinus thrombosis, Wallenberg's syndrome, and thrombophlebitis.

Ischemia includes cerebral ischemia, ischemic colitis, compartment  
10 syndromes, anterior compartment syndrome, myocardial ischemia, reperfusion injuries, and peripheral limb ischemia. Vasculitis includes aortitis, arteritis, Behcet's Syndrome, Churg-Strauss Syndrome, mucocutaneous lymph node syndrome, thromboangiitis obliterans, hypersensitivity vasculitis, Schoenlein-Henoch purpura, allergic cutaneous vasculitis, and Wegener's granulomatosis.

15 Polynucleotides or polypeptides, or agonists or antagonists of the invention, are especially effective for the treatment of critical limb ischemia and coronary disease.

Polypeptides may be administered using any method known in the art, including, but not limited to, direct needle injection at the delivery site, intravenous  
20 injection, topical administration, catheter infusion, biolistic injectors, particle accelerators, gelfoam sponge depots, other commercially available depot materials, osmotic pumps, oral or suppositorial solid pharmaceutical formulations, decanting or topical applications during surgery, aerosol delivery. Such methods are known in the art. Polypeptides of the invention may be administered as part of a *Therapeutic*,  
25 described in more detail below. Methods of delivering polynucleotides of the invention are described in more detail herein.

### **Anti-Angiogenesis Activity**

The naturally occurring balance between endogenous stimulators and  
30 inhibitors of angiogenesis is one in which inhibitory influences predominate. Rastinejad *et al.*, *Cell* 56:345-355 (1989). In those rare instances in which neovascularization occurs under normal physiological conditions, such as wound

healing, organ regeneration, embryonic development, and female reproductive processes, angiogenesis is stringently regulated and spatially and temporally delimited. Under conditions of pathological angiogenesis such as that characterizing solid tumor growth, these regulatory controls fail. Unregulated angiogenesis becomes pathologic and sustains progression of many neoplastic and non-neoplastic diseases. A number of serious diseases are dominated by abnormal neovascularization including solid tumor growth and metastases, arthritis, some types of eye diseases, disorders, and/or conditions, and psoriasis. See, e.g., reviews by Moses *et al.*, *Biotech.* 9:630-634 (1991); Folkman *et al.*, *N. Engl. J. Med.*, 333:1757-1763 (1995); Auerbach *et al.*, *J. Microvasc. Res.* 29:401-411 (1985); Folkman, *Advances in Cancer Research*, eds. Klein and Weinhouse, Academic Press, New York, pp. 175-203 (1985); Patz, *Am. J. Ophthalmol.* 94:715-743 (1982); and Folkman *et al.*, *Science* 221:719-725 (1983). In a number of pathological conditions, the process of angiogenesis contributes to the disease state. For example, significant data have accumulated which suggest that the growth of solid tumors is dependent on angiogenesis. Folkman and Klagsbrun, *Science* 235:442-447 (1987).

The present invention provides for treatment of diseases, disorders, and/or conditions associated with neovascularization by administration of the polynucleotides and/or polypeptides of the invention, as well as agonists or antagonists of the present invention. Malignant and metastatic conditions which can be treated with the polynucleotides and polypeptides, or agonists or antagonists of the invention include, but are not limited to, malignancies, solid tumors, and cancers described herein and otherwise known in the art (for a review of such disorders, see Fishman *et al.*, *Medicine*, 2d Ed., J. B. Lippincott Co., Philadelphia (1985)). Thus, the present invention provides a method of treating, preventing, and/or diagnosing an angiogenesis-related disease and/or disorder, comprising administering to an individual in need thereof a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist of the invention. For example, polynucleotides, polypeptides, antagonists and/or agonists may be utilized in a variety of additional methods in order to therapeutically treat or prevent a cancer or tumor. Cancers which may be treated, prevented, and/or diagnosed with polynucleotides, polypeptides, antagonists and/or agonists include, but are not limited to solid tumors,

including prostate, lung, breast, ovarian, stomach, pancreas, larynx, esophagus, testes, liver, parotid, biliary tract, colon, rectum, cervix, uterus, endometrium, kidney, bladder, thyroid cancer; primary tumors and metastases; melanomas; glioblastoma; Kaposi's sarcoma; leiomyosarcoma; non- small cell lung cancer; colorectal cancer; advanced malignancies; and blood born tumors such as leukemias. For example, polynucleotides, polypeptides, antagonists and/or agonists may be delivered topically, in order to treat or prevent cancers such as skin cancer, head and neck tumors, breast tumors, and Kaposi's sarcoma.

Within yet other aspects, polynucleotides, polypeptides, antagonists and/or agonists may be utilized to treat superficial forms of bladder cancer by, for example, intravesical administration. Polynucleotides, polypeptides, antagonists and/or agonists may be delivered directly into the tumor, or near the tumor site, via injection or a catheter. Of course, as the artisan of ordinary skill will appreciate, the appropriate mode of administration will vary according to the cancer to be treated. Other modes of delivery are discussed herein.

Polynucleotides, polypeptides, antagonists and/or agonists may be useful in treating, preventing, and/or diagnosing other diseases, disorders, and/or conditions, besides cancers, which involve angiogenesis. These diseases, disorders, and/or conditions include, but are not limited to: benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas; arteriosclerotic plaques; ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, uveitis and Pterygia (abnormal blood vessel growth) of the eye; rheumatoid arthritis; psoriasis; delayed wound healing; endometriosis; vasculogenesis; granulations; hypertrophic scars (keloids); nonunion fractures; scleroderma; trachoma; vascular adhesions; myocardial angiogenesis; coronary collaterals; cerebral collaterals; arteriovenous malformations; ischemic limb angiogenesis; Osler-Webber Syndrome; plaque neovascularization; telangiectasia; hemophilic joints; angiofibroma; fibromuscular dysplasia; wound granulation; Crohn's disease; and atherosclerosis.

For example, within one aspect of the present invention methods are provided for treating, preventing, and/or diagnosing hypertrophic scars and keloids, comprising

the step of administering a polynucleotide, polypeptide, antagonist and/or agonist of the invention to a hypertrophic scar or keloid.

Within one embodiment of the present invention polynucleotides, polypeptides, antagonists and/or agonists are directly injected into a hypertrophic scar or keloid, in order to prevent the progression of these lesions. This therapy is of particular value in the prophylactic treatment of conditions which are known to result in the development of hypertrophic scars and keloids (e.g., burns), and is preferably initiated after the proliferative phase has had time to progress (approximately 14 days after the initial injury), but before hypertrophic scar or keloid development. As noted above, the present invention also provides methods for treating, preventing, and/or diagnosing neovascular diseases of the eye, including for example, corneal neovascularization, neovascular glaucoma, proliferative diabetic retinopathy, retrolental fibroplasia and macular degeneration.

Moreover, Ocular diseases, disorders, and/or conditions associated with neovascularization which can be treated, prevented, and/or diagnosed with the polynucleotides and polypeptides of the present invention (including agonists and/or antagonists) include, but are not limited to: neovascular glaucoma, diabetic retinopathy, retinoblastoma, retrolental fibroplasia, uveitis, retinopathy of prematurity macular degeneration, corneal graft neovascularization, as well as other eye inflammatory diseases, ocular tumors and diseases associated with choroidal or iris neovascularization. See, e.g., reviews by Waltman *et al.*, *Am. J. Ophthalm.* 85:704-710 (1978) and Gartner *et al.*, *Surv. Ophthalm.* 22:291-312 (1978).

Thus, within one aspect of the present invention methods are provided for treating or preventing neovascular diseases of the eye such as corneal neovascularization (including corneal graft neovascularization), comprising the step of administering to a patient a therapeutically effective amount of a compound (as described above) to the cornea, such that the formation of blood vessels is inhibited. Briefly, the cornea is a tissue which normally lacks blood vessels. In certain pathological conditions however, capillaries may extend into the cornea from the pericorneal vascular plexus of the limbus. When the cornea becomes vascularized, it also becomes clouded, resulting in a decline in the patient's visual acuity. Visual loss may become complete if the cornea completely opacitates. A wide variety of



diseases, disorders, and/or conditions can result in corneal neovascularization, including for example, corneal infections (e.g., trachoma, herpes simplex keratitis, leishmaniasis and onchocerciasis), immunological processes (e.g., graft rejection and Stevens-Johnson's syndrome), alkali burns, trauma, inflammation (of any cause),  
5 toxic and nutritional deficiency states, and as a complication of wearing contact lenses.

Within particularly preferred embodiments of the invention, may be prepared for topical administration in saline (combined with any of the preservatives and antimicrobial agents commonly used in ocular preparations), and administered in  
10 eyedrop form. The solution or suspension may be prepared in its pure form and administered several times daily. Alternatively, anti-angiogenic compositions, prepared as described above, may also be administered directly to the cornea. Within preferred embodiments, the anti-angiogenic composition is prepared with a muco-adhesive polymer which binds to cornea. Within further embodiments, the anti-  
15 angiogenic factors or anti-angiogenic compositions may be utilized as an adjunct to conventional steroid therapy. Topical therapy may also be useful prophylactically in corneal lesions which are known to have a high probability of inducing an angiogenic response (such as chemical burns). In these instances the treatment, likely in combination with steroids, may be instituted immediately to help prevent subsequent  
20 complications.

Within other embodiments, the compounds described above may be injected directly into the corneal stroma by an ophthalmologist under microscopic guidance. The preferred site of injection may vary with the morphology of the individual lesion, but the goal of the administration would be to place the composition at the advancing  
25 front of the vasculature (i.e., interspersed between the blood vessels and the normal cornea). In most cases this would involve perilimbic corneal injection to "protect" the cornea from the advancing blood vessels. This method may also be utilized shortly after a corneal insult in order to prophylactically prevent corneal neovascularization. In this situation the material could be injected in the perilimbic cornea interspersed  
30 between the corneal lesion and its undesired potential limbic blood supply. Such methods may also be utilized in a similar fashion to prevent capillary invasion of transplanted corneas. In a sustained-release form injections might only be required 2-

3 times per year. A steroid could also be added to the injection solution to reduce inflammation resulting from the injection itself.

Within another aspect of the present invention, methods are provided for treating or preventing neovascular glaucoma, comprising the step of administering to  
5 a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eye, such that the formation of blood vessels is inhibited. In one embodiment, the compound may be administered topically to the eye in order to treat or prevent early forms of neovascular glaucoma. Within other  
10 embodiments, the compound may be implanted by injection into the region of the anterior chamber angle. Within other embodiments, the compound may also be placed in any location such that the compound is continuously released into the aqueous humor. Within another aspect of the present invention, methods are provided for treating or preventing proliferative diabetic retinopathy, comprising the step of  
15 administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eyes, such that the formation of blood vessels is inhibited.

Within particularly preferred embodiments of the invention, proliferative diabetic retinopathy may be treated by injection into the aqueous humor or the vitreous, in order to increase the local concentration of the polynucleotide,  
20 polypeptide, antagonist and/or agonist in the retina. Preferably, this treatment should be initiated prior to the acquisition of severe disease requiring photocoagulation.

Within another aspect of the present invention, methods are provided for treating or preventing retrolental fibroplasia, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist  
25 and/or agonist to the eye, such that the formation of blood vessels is inhibited. The compound may be administered topically, via intravitreal injection and/or via intraocular implants.

Additionally, diseases, disorders, and/or conditions which can be treated, prevented, and/or diagnosed with the polynucleotides, polypeptides, agonists and/or  
30 agonists include, but are not limited to, hemangioma, arthritis, psoriasis, angiofibroma, atherosclerotic plaques, delayed wound healing, granulations, hemophilic joints, hypertrophic scars, nonunion fractures, Osler-Weber syndrome,

pyogenic granuloma, scleroderma, trachoma, and vascular adhesions.

Moreover, diseases, disorders, and/or conditions and/or states, which can be treated, prevented, and/or diagnosed with the the polynucleotides, polypeptides, agonists and/or agonists include, but are not limited to, solid tumors, blood born  
5 tumors such as leukemias, tumor metastasis, Kaposi's sarcoma, benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas, rheumatoid arthritis, psoriasis, ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, and  
10 uivietis, delayed wound healing, endometriosis, vascluogenesis, granulations, hypertrophic scars (keloids), nonunion fractures, scleroderma, trachoma, vascular adhesions, myocardial angiogenesis, coronary collaterals, cerebral collaterals, arteriovenous malformations, ischemic limb angiogenesis, Osler-Webber Syndrome, plaque neovascularization, telangiectasia, hemophiliac joints, angiofibroma  
15 fibromuscular dysplasia, wound granulation, Crohn's disease, atherosclerosis, birth control agent by preventing vascularization required for embryo implantation controlling menstruation, diseases that have angiogenesis as a pathologic consequence such as cat scratch disease (*Rochela minalia quintosa*), ulcers (*Helicobacter pylori*), Bartonellosis and bacillary angiomatosis.

20 In one aspect of the birth control method, an amount of the compound sufficient to block embryo implantation is administered before or after intercourse and fertilization have occurred, thus providing an effective method of birth control, possibly a "morning after" method. Polynucleotides, polypeptides, agonists and/or agonists may also be used in controlling menstruation or administered as either a  
25 peritoneal lavage fluid or for peritoneal implantation in the treatment of endometriosis.

Polynucleotides, polypeptides, agonists and/or agonists of the present invention may be incorporated into surgical sutures in order to prevent stitch granulomas.

30 Polynucleotides, polypeptides, agonists and/or agonists may be utilized in a wide variety of surgical procedures. For example, within one aspect of the present invention a compositions (in the form of, for example, a spray or film) may be utilized

to coat or spray an area prior to removal of a tumor, in order to isolate normal surrounding tissues from malignant tissue, and/or to prevent the spread of disease to surrounding tissues. Within other aspects of the present invention, compositions (e.g., in the form of a spray) may be delivered via endoscopic procedures in order to coat tumors, or inhibit angiogenesis in a desired locale. Within yet other aspects of the present invention, surgical meshes which have been coated with anti-angiogenic compositions of the present invention may be utilized in any procedure wherein a surgical mesh might be utilized. For example, within one embodiment of the invention a surgical mesh laden with an anti-angiogenic composition may be utilized during abdominal cancer resection surgery (e.g., subsequent to colon resection) in order to provide support to the structure, and to release an amount of the anti-angiogenic factor.

Within further aspects of the present invention, methods are provided for treating tumor excision sites, comprising administering a polynucleotide, polypeptide, agonist and/or antagonist to the resection margins of a tumor subsequent to excision, such that the local recurrence of cancer and the formation of new blood vessels at the site is inhibited. Within one embodiment of the invention, the anti-angiogenic compound is administered directly to the tumor excision site (e.g., applied by swabbing, brushing or otherwise coating the resection margins of the tumor with the anti-angiogenic compound). Alternatively, the anti-angiogenic compounds may be incorporated into known surgical pastes prior to administration. Within particularly preferred embodiments of the invention, the anti-angiogenic compounds are applied after hepatic resections for malignancy, and after neurosurgical operations.

Within one aspect of the present invention, polynucleotides, polypeptides, agonists and/or antagonists may be administered to the resection margin of a wide variety of tumors, including for example, breast, colon, brain and hepatic tumors. For example, within one embodiment of the invention, anti-angiogenic compounds may be administered to the site of a neurological tumor subsequent to excision, such that the formation of new blood vessels at the site are inhibited.

The polynucleotides, polypeptides, agonists and/or antagonists of the present invention may also be administered along with other anti-angiogenic factors. Representative examples of other anti-angiogenic factors include: Anti-Invasive

Factor, retinoic acid and derivatives thereof, paclitaxel, Suramin, Tissue Inhibitor of Metalloproteinase-1, Tissue Inhibitor of Metalloproteinase-2, Plasminogen Activator Inhibitor-1, Plasminogen Activator Inhibitor-2, and various forms of the lighter "d group" transition metals.

5           Lighter "d group" transition metals include, for example, vanadium, molybdenum, tungsten, titanium, niobium, and tantalum species. Such transition metal species may form transition metal complexes. Suitable complexes of the above-mentioned transition metal species include oxo transition metal complexes.

10           Representative examples of vanadium complexes include oxo vanadium complexes such as vanadate and vanadyl complexes. Suitable vanadate complexes include metavanadate and orthovanadate complexes such as, for example, ammonium metavanadate, sodium metavanadate, and sodium orthovanadate. Suitable vanadyl complexes include, for example, vanadyl acetylacetonate and vanadyl sulfate including vanadyl sulfate hydrates such as vanadyl sulfate mono- and trihydrates.

15           Representative examples of tungsten and molybdenum complexes also include oxo complexes. Suitable oxo tungsten complexes include tungstate and tungsten oxide complexes. Suitable tungstate complexes include ammonium tungstate, calcium tungstate, sodium tungstate dihydrate, and tungstic acid. Suitable tungsten oxides include tungsten (IV) oxide and tungsten (VI) oxide. Suitable oxo  
20           molybdenum complexes include molybdate, molybdenum oxide, and molybdenyl complexes. Suitable molybdate complexes include ammonium molybdate and its hydrates, sodium molybdate and its hydrates, and potassium molybdate and its hydrates. Suitable molybdenum oxides include molybdenum (VI) oxide, molybdenum (VI) oxide, and molybdic acid. Suitable molybdenyl complexes include, for example,  
25           molybdenyl acetylacetonate. Other suitable tungsten and molybdenum complexes include hydroxo derivatives derived from, for example, glycerol, tartaric acid, and sugars.

          A wide variety of other anti-angiogenic factors may also be utilized within the context of the present invention. Representative examples include platelet factor 4;  
30           protamine sulphate; sulphated chitin derivatives (prepared from queen crab shells), (Murata et al., Cancer Res. 51:22-26, 1991); Sulphated Polysaccharide Peptidoglycan Complex (SP- PG) (the function of this compound may be enhanced by the presence

of steroids such as estrogen, and tamoxifen citrate); Staurosporine; modulators of matrix metabolism, including for example, proline analogs, cishydroxyproline, d,L-3,4-dehydroproline, Thiaproline, alpha,alpha-dipyridyl, aminopropionitrile fumarate; 4-propyl-5-(4-pyridinyl)-2(3H)-oxazolone; Methotrexate; Mitoxantrone; Heparin; Interferons; 2 Macroglobulin-serum; ChIMP-3 (Pavloff et al., J. Bio. Chem. 267:17321-17326, 1992); Chymostatin (Tomkinson et al., Biochem J. 286:475-480, 1992); Cyclodextrin Tetradesulfate; Eponemycin; Camptothecin; Fumagillin (Ingber et al., Nature 348:555-557, 1990); Gold Sodium Thiomalate ("GST"; Matsubara and Ziff, J. Clin. Invest. 79:1440-1446, 1987); anticollagenase-serum; alpha2-antiplasmin (Holmes et al., J. Biol. Chem. 262(4):1659-1664, 1987); Bisantrene (National Cancer Institute); Lobenzarit disodium (N-(2)-carboxyphenyl-4-chloroanthronilic acid disodium or "CCA"; Takeuchi et al., Agents Actions 36:312-316, 1992); Thalidomide; Angostatic steroid; AGM-1470; carboxyaminolimidazole; and metalloproteinase inhibitors such as BB94.

15

### **Diseases at the Cellular Level**

Diseases associated with increased cell survival or the inhibition of apoptosis that could be treated, prevented, and/or diagnosed by the polynucleotides or polypeptides and/or antagonists or agonists of the invention, include cancers (such as follicular lymphomas, carcinomas with p53 mutations, and hormone-dependent tumors, including, but not limited to colon cancer, cardiac tumors, pancreatic cancer, melanoma, retinoblastoma, glioblastoma, lung cancer, intestinal cancer, testicular cancer, stomach cancer, neuroblastoma, myxoma, myoma, lymphoma, endothelioma, osteoblastoma, osteoclastoma, osteosarcoma, chondrosarcoma, adenoma, breast cancer, prostate cancer, Kaposi's sarcoma and ovarian cancer); autoimmune diseases, disorders, and/or conditions (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) and viral infections (such as herpes viruses, pox viruses and adenoviruses), inflammation, graft v. host disease, acute graft rejection, and chronic graft rejection. In preferred embodiments, the polynucleotides or polypeptides, and/or

30

agonists or antagonists of the invention are used to inhibit growth, progression, and/or metasis of cancers, in particular those listed above.

Additional diseases or conditions associated with increased cell survival that could be treated, prevented or diagnosed by the polynucleotides or polypeptides, or agonists or antagonists of the invention, include, but are not limited to, progression, and/or metastases of malignancies and related disorders such as leukemia (including acute leukemias (e.g., acute lymphocytic leukemia, acute myelocytic leukemia (including myeloblastic, promyelocytic, myelomonocytic, monocytic, and erythroleukemia)) and chronic leukemias (e.g., chronic myelocytic (granulocytic) leukemia and chronic lymphocytic leukemia)), polycythemia vera, lymphomas (e.g., Hodgkin's disease and non-Hodgkin's disease), multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease, and solid tumors including, but not limited to, sarcomas and carcinomas such as fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, menangioma, melanoma, neuroblastoma, and retinoblastoma.

Diseases associated with increased apoptosis that could be treated, prevented, and/or diagnosed by the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, include AIDS; neurodegenerative diseases, disorders, and/or conditions (such as Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, Retinitis pigmentosa, Cerebellar degeneration and brain tumor or prior associated disease); autoimmune diseases, disorders, and/or conditions (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis,

Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) myelodysplastic syndromes (such as aplastic anemia), graft v. host disease, ischemic injury (such as that caused by myocardial infarction, stroke and reperfusion injury), liver injury (e.g.,  
5 hepatitis related liver injury, ischemia/reperfusion injury, cholestasis (bile duct injury) and liver cancer); toxin-induced liver disease (such as that caused by alcohol), septic shock, cachexia and anorexia.

### **Wound Healing and Epithelial Cell Proliferation**

10 In accordance with yet a further aspect of the present invention, there is provided a process for utilizing the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, for therapeutic purposes, for example, to stimulate epithelial cell proliferation and basal keratinocytes for the purpose of wound healing, and to stimulate hair follicle production and healing of dermal wounds.  
15 Polynucleotides or polypeptides, as well as agonists or antagonists of the invention, may be clinically useful in stimulating wound healing including surgical wounds, excisional wounds, deep wounds involving damage of the dermis and epidermis, eye tissue wounds, dental tissue wounds, oral cavity wounds, diabetic ulcers, dermal ulcers, cubitus ulcers, arterial ulcers, venous stasis ulcers, burns resulting from heat  
20 exposure or chemicals, and other abnormal wound healing conditions such as uremia, malnutrition, vitamin deficiencies and complications associated with systemic treatment with steroids, radiation therapy and antineoplastic drugs and antimetabolites. Polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to promote dermal reestablishment subsequent to dermal  
25 loss

The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to increase the adherence of skin grafts to a wound bed and to stimulate re-epithelialization from the wound bed. The following are a non-exhaustive list of grafts that polynucleotides or polypeptides, agonists or antagonists  
30 of the invention, could be used to increase adherence to a wound bed: autografts, artificial skin, allografts, autodermic graft, autoepidermic grafts, avacular grafts, Blair-Brown grafts, bone graft, brephoplastic grafts, cutis graft, delayed graft, dermic graft,



epidermic graft, fascia graft, full thickness graft, heterologous graft, xenograft, homologous graft, hyperplastic graft, lamellar graft, mesh graft, mucosal graft, Ollier-Thiersch graft, omentum graft, patch graft, pedicle graft, penetrating graft, split skin graft, thick split graft. The polynucleotides or polypeptides, and/or agonists or  
5 antagonists of the invention, can be used to promote skin strength and to improve the appearance of aged skin.

It is believed that the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, will also produce changes in hepatocyte proliferation, and epithelial cell proliferation in the lung, breast, pancreas, stomach, small intestine,  
10 and large intestine. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could promote proliferation of epithelial cells such as sebocytes, hair follicles, hepatocytes, type II pneumocytes, mucin-producing goblet cells, and other epithelial cells and their progenitors contained within the skin, lung, liver, and gastrointestinal tract. The polynucleotides or polypeptides, and/or agonists  
15 or antagonists of the invention, may promote proliferation of endothelial cells, keratinocytes, and basal keratinocytes.

The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could also be used to reduce the side effects of gut toxicity that result from radiation, chemotherapy treatments or viral infections. The polynucleotides or  
20 polypeptides, and/or agonists or antagonists of the invention, may have a cytoprotective effect on the small intestine mucosa. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, may also stimulate healing of mucositis (mouth ulcers) that result from chemotherapy and viral infections.

25 The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could further be used in full regeneration of skin in full and partial thickness skin defects, including burns, (i.e., repopulation of hair follicles, sweat glands, and sebaceous glands), treatment of other skin defects such as psoriasis. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could  
30 be used to treat epidermolysis bullosa, a defect in adherence of the epidermis to the underlying dermis which results in frequent, open and painful blisters by accelerating reepithelialization of these lesions. The polynucleotides or polypeptides, and/or

agonists or antagonists of the invention, could also be used to treat gastric and duodenal ulcers and help heal by scar formation of the mucosal lining and regeneration of glandular mucosa and duodenal mucosal lining more rapidly. Inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, are diseases which result in destruction of the mucosal surface of the small or large intestine, respectively. Thus, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to promote the resurfacing of the mucosal surface to aid more rapid healing and to prevent progression of inflammatory bowel disease. Treatment with the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, is expected to have a significant effect on the production of mucus throughout the gastrointestinal tract and could be used to protect the intestinal mucosa from injurious substances that are ingested or following surgery. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to treat diseases associated with the under expression of the polynucleotides of the invention.

Moreover, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to prevent and heal damage to the lungs due to various pathological states. A growth factor such as the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, which could stimulate proliferation and differentiation and promote the repair of alveoli and bronchiolar epithelium to prevent or treat acute or chronic lung damage. For example, emphysema, which results in the progressive loss of alveoli, and inhalation injuries, i.e., resulting from smoke inhalation and burns, that cause necrosis of the bronchiolar epithelium and alveoli could be effectively treated, prevented, and/or diagnosed using the polynucleotides or polypeptides, and/or agonists or antagonists of the invention. Also, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to stimulate the proliferation of and differentiation of type II pneumocytes, which may help treat or prevent disease such as hyaline membrane diseases, such as infant respiratory distress syndrome and bronchopulmonary dysplasia, in premature infants.

The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could stimulate the proliferation and differentiation of hepatocytes and,

thus, could be used to alleviate or treat liver diseases and pathologies such as fulminant liver failure caused by cirrhosis, liver damage caused by viral hepatitis and toxic substances (i.e., acetaminophen, carbon tetrachloride and other hepatotoxins known in the art).

5           In addition, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used treat or prevent the onset of diabetes mellitus. In patients with newly diagnosed Types I and II diabetes, where some islet cell function remains, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to maintain the islet function so as to alleviate, delay or  
10       prevent permanent manifestation of the disease. Also, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used as an auxiliary in islet cell transplantation to improve or promote islet cell function.

#### 15       Neurological Diseases

Nervous system diseases, disorders, and/or conditions, which can be treated, prevented, and/or diagnosed with the compositions of the invention (e.g., polypeptides, polynucleotides, and/or agonists or antagonists), include, but are not limited to, nervous system injuries, and diseases, disorders, and/or conditions which  
20       result in either a disconnection of axons, a diminution or degeneration of neurons, or demyelination. Nervous system lesions which may be treated, prevented, and/or diagnosed in a patient (including human and non-human mammalian patients) according to the invention, include but are not limited to, the following lesions of either the central (including spinal cord, brain) or peripheral nervous systems: (1)  
25       ischemic lesions, in which a lack of oxygen in a portion of the nervous system results in neuronal injury or death, including cerebral infarction or ischemia, or spinal cord infarction or ischemia; (2) traumatic lesions, including lesions caused by physical injury or associated with surgery, for example, lesions which sever a portion of the nervous system, or compression injuries; (3) malignant lesions, in which a portion of  
30       the nervous system is destroyed or injured by malignant tissue which is either a nervous system associated malignancy or a malignancy derived from non-nervous system tissue; (4) infectious lesions, in which a portion of the nervous system is

destroyed or injured as a result of infection, for example, by an abscess or associated with infection by human immunodeficiency virus, herpes zoster, or herpes simplex virus or with Lyme disease, tuberculosis, syphilis; (5) degenerative lesions, in which a portion of the nervous system is destroyed or injured as a result of a degenerative process including but not limited to degeneration associated with Parkinson's disease, Alzheimer's disease, Huntington's chorea, or amyotrophic lateral sclerosis (ALS); (6) lesions associated with nutritional diseases, disorders, and/or conditions, in which a portion of the nervous system is destroyed or injured by a nutritional disorder or disorder of metabolism including but not limited to, vitamin B12 deficiency, folic acid deficiency, Wernicke disease, tobacco-alcohol amblyopia, Marchiafava-Bignami disease (primary degeneration of the corpus callosum), and alcoholic cerebellar degeneration; (7) neurological lesions associated with systemic diseases including, but not limited to, diabetes (diabetic neuropathy, Bell's palsy), systemic lupus erythematosus, carcinoma, or sarcoidosis; (8) lesions caused by toxic substances including alcohol, lead, or particular neurotoxins; and (9) demyelinated lesions in which a portion of the nervous system is destroyed or injured by a demyelinating disease including, but not limited to, multiple sclerosis, human immunodeficiency virus-associated myelopathy, transverse myelopathy or various etiologies, progressive multifocal leukoencephalopathy, and central pontine myelinolysis.

20 In a preferred embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to protect neural cells from the damaging effects of cerebral hypoxia. According to this embodiment, the compositions of the invention are used to treat, prevent, and/or diagnose neural cell injury associated with cerebral hypoxia. In one aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose neural cell injury associated with cerebral ischemia. In another aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose neural cell injury associated with cerebral infarction. In another aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose or prevent neural cell injury associated with a stroke. In a further aspect of this embodiment, the polypeptides, polynucleotides, or agonists

or antagonists of the invention are used to treat, prevent, and/or diagnose neural cell injury associated with a heart attack.

The compositions of the invention which are useful for treating or preventing a nervous system disorder may be selected by testing for biological activity in promoting the survival or differentiation of neurons. For example, and not by way of limitation, compositions of the invention which elicit any of the following effects may be useful according to the invention: (1) increased survival time of neurons in culture; (2) increased sprouting of neurons in culture or *in vivo*; (3) increased production of a neuron-associated molecule in culture or *in vivo*, e.g., choline acetyltransferase or acetylcholinesterase with respect to motor neurons; or (4) decreased symptoms of neuron dysfunction *in vivo*. Such effects may be measured by any method known in the art. In preferred, non-limiting embodiments, increased survival of neurons may routinely be measured using a method set forth herein or otherwise known in the art, such as, for example, the method set forth in Arakawa et al. (J. Neurosci. 10:3507-3515 (1990)); increased sprouting of neurons may be detected by methods known in the art, such as, for example, the methods set forth in Pestronk et al. (Exp. Neurol. 70:65-82 (1980)) or Brown et al. (Ann. Rev. Neurosci. 4:17-42 (1981)); increased production of neuron-associated molecules may be measured by bioassay, enzymatic assay, antibody binding, Northern blot assay, etc., using techniques known in the art and depending on the molecule to be measured; and motor neuron dysfunction may be measured by assessing the physical manifestation of motor neuron disorder, e.g., weakness, motor neuron conduction velocity, or functional disability.

In specific embodiments, motor neuron diseases, disorders, and/or conditions that may be treated, prevented, and/or diagnosed according to the invention include, but are not limited to, diseases, disorders, and/or conditions such as infarction, infection, exposure to toxin, trauma, surgical damage, degenerative disease or malignancy that may affect motor neurons as well as other components of the nervous system, as well as diseases, disorders, and/or conditions that selectively affect neurons such as amyotrophic lateral sclerosis, and including, but not limited to, progressive spinal muscular atrophy, progressive bulbar palsy, primary lateral sclerosis, infantile and juvenile muscular atrophy, progressive bulbar paralysis of childhood (Fazio-

Londe syndrome), poliomyelitis and the post polio syndrome, and Hereditary Motorsensory Neuropathy (Charcot-Marie-Tooth Disease).

Further, polypeptides or polynucleotides of the invention may play a role in neuronal survival; synapse formation; conductance; neural differentiation, etc. Thus, compositions of the invention (including polynucleotides, polypeptides, and agonists or antagonists) may be used to diagnose and/or treat or prevent diseases or disorders associated with these roles, including, but not limited to, learning and/or cognition disorders. The compositions of the invention may also be useful in the treatment or prevention of neurodegenerative disease states and/or behavioural disorders. Such neurodegenerative disease states and/or behavioral disorders include, but are not limited to, Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, compositions of the invention may also play a role in the treatment, prevention and/or detection of developmental disorders associated with the developing embryo, or sexually-linked disorders.

Additionally, polypeptides, polynucleotides and/or agonists or antagonists of the invention, may be useful in protecting neural cells from diseases, damage, disorders, or injury, associated with cerebrovascular disorders including, but not limited to, carotid artery diseases (e.g., carotid artery thrombosis, carotid stenosis, or Moyamoya Disease), cerebral amyloid angiopathy, cerebral aneurysm, cerebral anoxia, cerebral arteriosclerosis, cerebral arteriovenous malformations, cerebral artery diseases, cerebral embolism and thrombosis (e.g., carotid artery thrombosis, sinus thrombosis, or Wallenberg's Syndrome), cerebral hemorrhage (e.g., epidural or subdural hematoma, or subarachnoid hemorrhage), cerebral infarction, cerebral ischemia (e.g., transient cerebral ischemia, Subclavian Steal Syndrome, or vertebrobasilar insufficiency), vascular dementia (e.g., multi-infarct), leukomalacia, periventricular, and vascular headache (e.g., cluster headache or migraines).

In accordance with yet a further aspect of the present invention, there is provided a process for utilizing polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, for therapeutic purposes, for example, to

stimulate neurological cell proliferation and/or differentiation. Therefore, polynucleotides, polypeptides, agonists and/or antagonists of the invention may be used to treat and/or detect neurologic diseases. Moreover, polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used as a marker or  
5 detector of a particular nervous system disease or disorder.

Examples of neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include brain diseases, such as metabolic brain diseases which includes phenylketonuria such as maternal phenylketonuria, pyruvate carboxylase deficiency,  
10 pyruvate dehydrogenase complex deficiency, Wernicke's Encephalopathy, brain edema, brain neoplasms such as cerebellar neoplasms which include infratentorial neoplasms, cerebral ventricle neoplasms such as choroid plexus neoplasms, hypothalamic neoplasms, supratentorial neoplasms, canavan disease, cerebellar diseases such as cerebellar ataxia which include spinocerebellar degeneration such as  
15 ataxia telangiectasia, cerebellar dyssynergia, Friederich's Ataxia, Machado-Joseph Disease, olivopontocerebellar atrophy, cerebellar neoplasms such as infratentorial neoplasms, diffuse cerebral sclerosis such as encephalitis periaxialis, globoid cell leukodystrophy, metachromatic leukodystrophy and subacute sclerosing panencephalitis.

20 Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include cerebrovascular disorders (such as carotid artery diseases which include carotid artery thrombosis, carotid stenosis and Moyamoya Disease), cerebral amyloid angiopathy, cerebral aneurysm, cerebral anoxia, cerebral arteriosclerosis, cerebral  
25 arteriovenous malformations, cerebral artery diseases, cerebral embolism and thrombosis such as carotid artery thrombosis, sinus thrombosis and Wallenberg's Syndrome, cerebral hemorrhage such as epidural hematoma, subdural hematoma and subarachnoid hemorrhage, cerebral infarction, cerebral ischemia such as transient cerebral ischemia, Subclavian Steal Syndrome and vertebrobasilar insufficiency,  
30 vascular dementia such as multi-infarct dementia, periventricular leukomalacia, vascular headache such as cluster headache and migraine.

Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include dementia such as AIDS Dementia Complex, presenile dementia such as Alzheimer's Disease and Creutzfeldt-Jakob Syndrome, senile dementia such as Alzheimer's Disease and progressive supranuclear palsy, vascular dementia such as multi-infarct dementia, encephalitis which include encephalitis periaxialis, viral encephalitis such as epidemic encephalitis, Japanese Encephalitis, St. Louis Encephalitis, tick-borne encephalitis and West Nile Fever, acute disseminated encephalomyelitis, meningoencephalitis such as uveomeningoencephalitic syndrome, Postencephalitic Parkinson Disease and subacute sclerosing panencephalitis, encephalomalacia such as periventricular leukomalacia, epilepsy such as generalized epilepsy which includes infantile spasms, absence epilepsy, myoclonic epilepsy which includes MERRF Syndrome, tonic-clonic epilepsy, partial epilepsy such as complex partial epilepsy, frontal lobe epilepsy and temporal lobe epilepsy, post-traumatic epilepsy, status epilepticus such as Epilepsia Partialis Continua, and Hallervorden-Spatz Syndrome.

Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include hydrocephalus such as Dandy-Walker Syndrome and normal pressure hydrocephalus, hypothalamic diseases such as hypothalamic neoplasms, cerebral malaria, narcolepsy which includes cataplexy, bulbar poliomyelitis, cerebri pseudotumor, Rett Syndrome, Reye's Syndrome, thalamic diseases, cerebral toxoplasmosis, intracranial tuberculoma and Zellweger Syndrome, central nervous system infections such as AIDS Dementia Complex, Brain Abscess, subdural empyema, encephalomyelitis such as Equine Encephalomyelitis, Venezuelan Equine Encephalomyelitis, Necrotizing Hemorrhagic Encephalomyelitis, Visna, and cerebral malaria.

Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include meningitis such as arachnoiditis, aseptic meningitis such as viral meningitis which includes lymphocytic choriomeningitis, Bacterial meningitis which includes Haemophilus Meningitis, Listeria Meningitis, Meningococcal Meningitis such as



Waterhouse-Friderichsen Syndrome, Pneumococcal Meningitis and meningeal tuberculosis, fungal meningitis such as Cryptococcal Meningitis, subdural effusion, meningoencephalitis such as uvemeningoencephalitic syndrome, myelitis such as transverse myelitis, neurosyphilis such as tabes dorsalis, poliomyelitis which includes  
5 bulbar poliomyelitis and postpoliomyelitis syndrome, prion diseases (such as Creutzfeldt-Jakob Syndrome, Bovine Spongiform Encephalopathy, Gerstmann-Straussler Syndrome, Kuru, Scrapie), and cerebral toxoplasmosis.

Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention  
10 include central nervous system neoplasms such as brain neoplasms that include cerebellar neoplasms such as infratentorial neoplasms, cerebral ventricle neoplasms such as choroid plexus neoplasms, hypothalamic neoplasms and supratentorial neoplasms, meningeal neoplasms, spinal cord neoplasms which include epidural neoplasms, demyelinating diseases such as Canavan Diseases, diffuse cerebral  
15 sclerolitis which includes adrenoleukodystrophy, encephalitis periaxialis, globoid cell leukodystrophy, diffuse cerebral sclerosis such as metachromatic leukodystrophy, allergic encephalomyelitis, necrotizing hemorrhagic encephalomyelitis, progressive multifocal leukoencephalopathy, multiple sclerosis, central pontine myelinolysis, transverse myelitis, neuromyelitis optica, Scrapie, Swayback, Chronic Fatigue  
20 Syndrome, Visna, High Pressure Nervous Syndrome, Meningism, spinal cord diseases such as amyotonia congenita, amyotrophic lateral sclerosis, spinal muscular atrophy such as Werdnig-Hoffmann Disease, spinal cord compression, spinal cord neoplasms such as epidural neoplasms, syringomyelia, Tabes Dorsalis, Stiff-Man Syndrome, mental retardation such as Angelman Syndrome, Cri-du-Chat Syndrome, De Lange's  
25 Syndrome, Down Syndrome, Gangliosidoses such as gangliosidoses G(M1), Sandhoff Disease, Tay-Sachs Disease, Hartnup Disease, homocystinuria, Laurence-Moon-Biedl Syndrome, Lesch-Nyhan Syndrome, Maple Syrup Urine Disease, mucopolipidosis such as fucosidosis, neuronal ceroid-lipofuscinosis, oculocerebrorenal syndrome, phenylketonuria such as maternal phenylketonuria, Prader-Willi Syndrome, Rett  
30 Syndrome, Rubinstein-Taybi Syndrome, Tuberous Sclerosis, WAGR Syndrome, nervous system abnormalities such as holoprosencephaly, neural tube defects such as anencephaly which includes hydrangencephaly, Arnold-Chairi Deformity,

encephalocele, meningocele, meningomyelocele, spinal dysraphism such as spina bifida cystica and spina bifida occulta.

Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention  
5 include hereditary motor and sensory neuropathies which include Charcot-Marie Disease, Hereditary optic atrophy, Refsum's Disease, hereditary spastic paraplegia, Werdnig-Hoffmann Disease, Hereditary Sensory and Autonomic Neuropathies such as Congenital Analgesia and Familial Dysautonomia, Neurologic manifestations (such as agnosia that include Gerstmann's Syndrome, Amnesia such as retrograde amnesia,  
10 apraxia, neurogenic bladder, cataplexy, communicative disorders such as hearing disorders that includes deafness, partial hearing loss, loudness recruitment and tinnitus, language disorders such as aphasia which include agraphia, anomia, broca aphasia, and Wernicke Aphasia, Dyslexia such as Acquired Dyslexia, language development disorders, speech disorders such as aphasia which includes anomia,  
15 broca aphasia and Wernicke Aphasia, articulation disorders, communicative disorders such as speech disorders which include dysarthria, echolalia, mutism and stuttering, voice disorders such as aphonia and hoarseness, decerebrate state, delirium, fasciculation, hallucinations, meningism, movement disorders such as angelman syndrome, ataxia, athetosis, chorea, dystonia, hypokinesia, muscle hypotonia,  
20 myoclonus, tic, torticollis and tremor, muscle hypertonia such as muscle rigidity such as stiff-man syndrome, muscle spasticity, paralysis such as facial paralysis which includes Herpes Zoster Oticus, Gastroparesis, Hemiplegia, ophthalmoplegia such as diplopia, Duane's Syndrome, Horner's Syndrome, Chronic progressive external ophthalmoplegia such as Kearns Syndrome, Bulbar Paralysis, Tropical Spastic  
25 Paraparesis, Paraplegia such as Brown-Sequard Syndrome, quadriplegia, respiratory paralysis and vocal cord paralysis, paresis, phantom limb, taste disorders such as ageusia and dysgeusia, vision disorders such as amblyopia, blindness, color vision defects, diplopia, hemianopsia, scotoma and subnormal vision, sleep disorders such as hypersomnia which includes Kleine-Levin Syndrome, insomnia, and somnambulism,  
30 spasm such as trismus, unconsciousness such as coma, persistent vegetative state and syncope and vertigo, neuromuscular diseases such as amyotonia congenita, amyotrophic lateral sclerosis, Lambert-Eaton Myasthenic Syndrome, motor neuron

disease, muscular atrophy such as spinal muscular atrophy, Charcot-Marie Disease and Werdnig-Hoffmann Disease, Postpoliomyelitis Syndrome, Muscular Dystrophy, Myasthenia Gravis, Myotonia Atrophica, Myotonia Confenita, Nemaline Myopathy, Familial Periodic Paralysis, Multiplex Paramyoclonus, Tropical Spastic Paraparesis  
5 and Stiff-Man Syndrome, peripheral nervous system diseases such as acrodynia, amyloid neuropathies, autonomic nervous system diseases such as Adie's Syndrome, Barre-Lieou Syndrome, Familial Dysautonomia, Horner's Syndrome, Reflex Sympathetic Dystrophy and Shy-Drager Syndrome, Cranial Nerve Diseases such as Acoustic Nerve Diseases such as Acoustic Neuroma which includes  
10 Neurofibromatosis 2, Facial Nerve Diseases such as Facial Neuralgia, Melkersson-Rosenthal Syndrome, ocular motility disorders which includes amblyopia, nystagmus, oculomotor nerve paralysis, ophthalmoplegia such as Duane's Syndrome, Horner's Syndrome, Chronic Progressive External Ophthalmoplegia which includes Kearns Syndrome, Strabismus such as Esotropia and Exotropia, Oculomotor Nerve Paralysis,  
15 Optic Nerve Diseases such as Optic Atrophy which includes Hereditary Optic Atrophy, Optic Disk Drusen, Optic Neuritis such as Neuromyelitis Optica, Papilledema, Trigeminal Neuralgia, Vocal Cord Paralysis, Demyelinating Diseases such as Neuromyelitis Optica and Swayback, and Diabetic neuropathies such as diabetic foot.

20 Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include nerve compression syndromes such as carpal tunnel syndrome, tarsal tunnel syndrome, thoracic outlet syndrome such as cervical rib syndrome, ulnar nerve compression syndrome, neuralgia such as causalgia, cervico-brachial neuralgia, facial  
25 neuralgia and trigeminal neuralgia, neuritis such as experimental allergic neuritis, optic neuritis, polyneuritis, polyradiculoneuritis and radiculities such as polyradiculitis, hereditary motor and sensory neuropathies such as Charcot-Marie Disease, Hereditary Optic Atrophy, Refsum's Disease, Hereditary Spastic Paraplegia and Werdnig-Hoffmann Disease, Hereditary Sensory and Autonomic Neuropathies  
30 which include Congenital Analgesia and Familial Dysautonomia, POEMS Syndrome, Sciatica, Gustatory Sweating and Tetany).

**Infectious Disease**

A polypeptide or polynucleotide and/or agonist or antagonist of the present invention can be used to treat, prevent, and/or diagnose infectious agents. For example, by increasing the immune response, particularly increasing the proliferation and differentiation of B and/or T cells, infectious diseases may be treated, prevented, and/or diagnosed. The immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, polypeptide or polynucleotide and/or agonist or antagonist of the present invention may also directly inhibit the infectious agent, without necessarily eliciting an immune response.

Viruses are one example of an infectious agent that can cause disease or symptoms that can be treated, prevented, and/or diagnosed by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention. Examples of viruses, include, but are not limited to Examples of viruses, include, but are not limited to the following DNA and RNA viruses and viral families: Arbovirus, Adenoviridae, Arenaviridae, Arterivirus, Bimaviridae, Bunyaviridae, Caliciviridae, Circoviridae, Coronaviridae, Dengue, EBV, HIV, Flaviviridae, Hepadnaviridae (Hepatitis), Herpesviridae (such as, Cytomegalovirus, Herpes Simplex, Herpes Zoster), Mononegavirus (e.g., Paramyxoviridae, Morbillivirus, Rhabdoviridae), Orthomyxoviridae (e.g., Influenza A, Influenza B, and parainfluenza), Papiloma virus, Papovaviridae, Parvoviridae, Picornaviridae, Poxviridae (such as Smallpox or Vaccinia), Reoviridae (e.g., Rotavirus), Retroviridae (HTLV-I, HTLV-II, Lentivirus), and Togaviridae (e.g., Rubivirus). Viruses falling within these families can cause a variety of diseases or symptoms, including, but not limited to: arthritis, bronchiolitis, respiratory syncytial virus, encephalitis, eye infections (e.g., conjunctivitis, keratitis), chronic fatigue syndrome, hepatitis (A, B, C, E, Chronic Active, Delta), Japanese B encephalitis, Junin, Chikungunya, Rift Valley fever, yellow fever, meningitis, opportunistic infections (e.g., AIDS), pneumonia, Burkitt's Lymphoma, chickenpox, hemorrhagic fever, Measles, Mumps, Parainfluenza, Rabies, the common cold, Polio, leukemia, Rubella, sexually transmitted diseases, skin diseases (e.g., Kaposi's, warts), and viremia. polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used to treat, prevent, and/or diagnose any of these symptoms or

diseases. In specific embodiments, polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose: meningitis, Dengue, EBV, and/or hepatitis (e.g., hepatitis B). In an additional specific embodiment polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat patients nonresponsive to one or more other commercially available hepatitis vaccines. In a further specific embodiment polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose AIDS.

Similarly, bacterial or fungal agents that can cause disease or symptoms and that can be treated, prevented, and/or diagnosed by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention include, but not limited to, include, but not limited to, the following Gram-Negative and Gram-positive bacteria and bacterial families and fungi: Actinomycetales (e.g., *Corynebacterium*, *Mycobacterium*, *Nocardia*), *Cryptococcus neoformans*, Aspergillosis, Bacillaceae (e.g., Anthrax, *Clostridium*), Bacteroidaceae, Blastomycosis, *Bordetella*, *Borrelia* (e.g., *Borrelia burgdorferi*), Brucellosis, Candidiasis, *Campylobacter*, Coccidioidomycosis, Cryptococcosis, Dermatocycoses, *E. coli* (e.g., Enterotoxigenic *E. coli* and Enterohemorrhagic *E. coli*), Enterobacteriaceae (*Klebsiella*, *Salmonella* (e.g., *Salmonella typhi*, and *Salmonella paratyphi*), *Serratia*, *Yersinia*), *Erysipelothrix*, *Helicobacter*, Legionellosis, Leptospirosis, *Listeria*, Mycoplasmatales, *Mycobacterium leprae*, *Vibrio cholerae*, Neisseriaceae (e.g., *Acinetobacter*, Gonorrhea, Meningococcal), *Meisseria meningitidis*, Pasteurellacea Infections (e.g., *Actinobacillus*, *Haemophilus* (e.g., *Haemophilus influenza* type B), *Pasteurella*, *Pseudomonas*, Rickettsiaceae, Chlamydiaceae, Syphilis, *Shigella* spp., Staphylococcal, Meningiococcal, Pneumococcal and Streptococcal (e.g., *Streptococcus pneumoniae* and Group B Streptococcus). These bacterial or fungal families can cause the following diseases or symptoms, including, but not limited to: bacteremia, endocarditis, eye infections (conjunctivitis, tuberculosis, uveitis), gingivitis, opportunistic infections (e.g., AIDS related infections), paronychia, prosthesis-related infections, Reiter's Disease, respiratory tract infections, such as Whooping Cough or Empyema, sepsis, Lyme Disease, Cat-Scratch Disease, Dysentery, Paratyphoid Fever, food poisoning, Typhoid, pneumonia, Gonorrhea,

meningitis (e.g., meningitis types A and B), Chlamydia, Syphilis, Diphtheria, Leprosy, Paratuberculosis, Tuberculosis, Lupus, Botulism, gangrene, tetanus, impetigo, Rheumatic Fever, Scarlet Fever, sexually transmitted diseases, skin diseases (e.g., cellulitis, dermatocycoses), toxemia, urinary tract infections, wound infections.

- 5 Polynucleotides or polypeptides, agonists or antagonists of the invention, can be used to treat, prevent, and/or diagnose any of these symptoms or diseases. In specific embodiments, polynucleotides, polypeptides, agonists or antagonists of the invention are used to treat, prevent, and/or diagnose: tetanus, Diphtheria, botulism, and/or meningitis type B.

- 10 Moreover, parasitic agents causing disease or symptoms that can be treated, prevented, and/or diagnosed by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention include, but not limited to, the following families or class: Amebiasis, Babesiosis, Coccidiosis, Cryptosporidiosis, Dientamoebiasis, Dourine, Ectoparasitic, Giardiasis, Helminthiasis, Leishmaniasis, Theileriasis, 15 Toxoplasmosis, Trypanosomiasis, and Trichomonas and Sporozoans (e.g., Plasmodium virax, Plasmodium falciparum, Plasmodium malariae and Plasmodium ovale). These parasites can cause a variety of diseases or symptoms, including, but not limited to: Scabies, Trombiculiasis, eye infections, intestinal disease (e.g., dysentery, giardiasis), liver disease, lung disease, opportunistic infections (e.g., AIDS 20 related), malaria, pregnancy complications, and toxoplasmosis. polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used to treat, prevent, and/or diagnose any of these symptoms or diseases. In specific embodiments, polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose malaria.

- 25 Preferably, treatment or prevention using a polypeptide or polynucleotide and/or agonist or antagonist of the present invention could either be by administering an effective amount of a polypeptide to the patient, or by removing cells from the patient, supplying the cells with a polynucleotide of the present invention, and returning the engineered cells to the patient (ex vivo therapy). Moreover, the 30 polypeptide or polynucleotide of the present invention can be used as an antigen in a vaccine to raise an immune response against infectious disease.

**Regeneration**

A polynucleotide or polypeptide and/or agonist or antagonist of the present invention can be used to differentiate, proliferate, and attract cells, leading to the regeneration of tissues. (See, Science 276:59-87 (1997).) The regeneration of tissues  
5 could be used to repair, replace, or protect tissue damaged by congenital defects, trauma (wounds, burns, incisions, or ulcers), age, disease (e.g. osteoporosis, osteoarthritis, periodontal disease, liver failure), surgery, including cosmetic plastic surgery, fibrosis, reperfusion injury, or systemic cytokine damage.

Tissues that could be regenerated using the present invention include organs  
10 (e.g., pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac), vasculature (including vascular and lymphatics), nervous, hematopoietic, and skeletal (bone, cartilage, tendon, and ligament) tissue. Preferably, regeneration occurs without or decreased scarring. Regeneration also may include angiogenesis.

Moreover, a polynucleotide or polypeptide and/or agonist or antagonist of the  
15 present invention may increase regeneration of tissues difficult to heal. For example, increased tendon/ligament regeneration would quicken recovery time after damage.

A polynucleotide or polypeptide and/or agonist or antagonist of the present invention could also be used prophylactically in an effort to avoid damage. Specific diseases that could be treated, prevented, and/or diagnosed include of tendinitis, carpal tunnel  
20 syndrome, and other tendon or ligament defects. A further example of tissue regeneration of non-healing wounds includes pressure ulcers, ulcers associated with vascular insufficiency, surgical, and traumatic wounds.

Similarly, nerve and brain tissue could also be regenerated by using a  
polynucleotide or polypeptide and/or agonist or antagonist of the present invention to  
25 proliferate and differentiate nerve cells. Diseases that could be treated, prevented, and/or diagnosed using this method include central and peripheral nervous system diseases, neuropathies, or mechanical and traumatic diseases, disorders, and/or conditions (e.g., spinal cord disorders, head trauma, cerebrovascular disease, and stroke). Specifically, diseases associated with peripheral nerve injuries, peripheral  
30 neuropathy (e.g., resulting from chemotherapy or other medical therapies), localized neuropathies, and central nervous system diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-

Drager syndrome), could all be treated, prevented, and/or diagnosed using the polynucleotide or polypeptide and/or agonist or antagonist of the present invention.

### **Chemotaxis**

5           A polynucleotide or polypeptide and/or agonist or antagonist of the present invention may have chemotaxis activity. A chemotactic molecule attracts or mobilizes cells (e.g., monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells) to a particular site in the body, such as inflammation, infection, or site of hyperproliferation. The mobilized cells can then  
10   fight off and/or heal the particular trauma or abnormality.

          A polynucleotide or polypeptide and/or agonist or antagonist of the present invention may increase chemotactic activity of particular cells. These chemotactic molecules can then be used to treat, prevent, and/or diagnose inflammation, infection, hyperproliferative diseases, disorders, and/or conditions, or any immune system  
15   disorder by increasing the number of cells targeted to a particular location in the body. For example, chemotactic molecules can be used to treat, prevent, and/or diagnose wounds and other trauma to tissues by attracting immune cells to the injured location. Chemotactic molecules of the present invention can also attract fibroblasts, which can be used to treat, prevent, and/or diagnose wounds.

20           It is also contemplated that a polynucleotide or polypeptide and/or agonist or antagonist of the present invention may inhibit chemotactic activity. These molecules could also be used to treat, prevent, and/or diagnose diseases, disorders, and/or conditions. Thus, a polynucleotide or polypeptide and/or agonist or antagonist of the present invention could be used as an inhibitor of chemotaxis.

25

### **Binding Activity**

          A polypeptide of the present invention may be used to screen for molecules that bind to the polypeptide or for molecules to which the polypeptide binds. The binding of the polypeptide and the molecule may activate (agonist), increase, inhibit  
30   (antagonist), or decrease activity of the polypeptide or the molecule bound. Examples of such molecules include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.



Preferably, the molecule is closely related to the natural ligand of the polypeptide, e.g., a fragment of the ligand, or a natural substrate, a ligand, a structural or functional mimetic. (See, Coligan et al., Current Protocols in Immunology 1(2):Chapter 5 (1991).) Similarly, the molecule can be closely related to the natural  
5 receptor to which the polypeptide binds, or at least, a fragment of the receptor capable of being bound by the polypeptide (e.g., active site). In either case, the molecule can be rationally designed using known techniques.

Preferably, the screening for these molecules involves producing appropriate cells which express the polypeptide, either as a secreted protein or on the cell  
10 membrane. Preferred cells include cells from mammals, yeast, *Drosophila*, or *E. coli*. Cells expressing the polypeptide (or cell membrane containing the expressed polypeptide) are then preferably contacted with a test compound potentially containing the molecule to observe binding, stimulation, or inhibition of activity of either the polypeptide or the molecule.

15 The assay may simply test binding of a candidate compound to the polypeptide, wherein binding is detected by a label, or in an assay involving competition with a labeled competitor. Further, the assay may test whether the candidate compound results in a signal generated by binding to the polypeptide.

Alternatively, the assay can be carried out using cell-free preparations,  
20 polypeptide/molecule affixed to a solid support, chemical libraries, or natural product mixtures. The assay may also simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide, measuring polypeptide/molecule activity or binding, and comparing the polypeptide/molecule activity or binding to a standard.

25 Preferably, an ELISA assay can measure polypeptide level or activity in a sample (e.g., biological sample) using a monoclonal or polyclonal antibody. The antibody can measure polypeptide level or activity by either binding, directly or indirectly, to the polypeptide or by competing with the polypeptide for a substrate.

Additionally, the receptor to which a polypeptide of the invention binds can be  
30 identified by numerous methods known to those of skill in the art, for example, ligand panning and FACS sorting (Coligan, et al., Current Protocols in Immun., 1(2), Chapter 5, (1991)). For example, expression cloning is employed wherein

polyadenylated RNA is prepared from a cell responsive to the polypeptides, for example, NIH3T3 cells which are known to contain multiple receptors for the FGF family proteins, and SC-3 cells, and a cDNA library created from this RNA is divided into pools and used to transfect COS cells or other cells that are not responsive to the polypeptides. Transfected cells which are grown on glass slides are exposed to the polypeptide of the present invention, after they have been labelled. The polypeptides can be labeled by a variety of means including iodination or inclusion of a recognition site for a site-specific protein kinase.

Following fixation and incubation, the slides are subjected to autoradiographic analysis. Positive pools are identified and sub-pools are prepared and re-transfected using an iterative sub-pooling and re-screening process, eventually yielding a single clones that encodes the putative receptor.

As an alternative approach for receptor identification, the labeled polypeptides can be photoaffinity linked with cell membrane or extract preparations that express the receptor molecule. Cross-linked material is resolved by PAGE analysis and exposed to X-ray film. The labeled complex containing the receptors of the polypeptides can be excised, resolved into peptide fragments, and subjected to protein microsequencing. The amino acid sequence obtained from microsequencing would be used to design a set of degenerate oligonucleotide probes to screen a cDNA library to identify the genes encoding the putative receptors.

Moreover, the techniques of gene-shuffling, motif-shuffling, exon-shuffling, and/or codon-shuffling (collectively referred to as "DNA shuffling") may be employed to modulate the activities of polypeptides of the invention thereby effectively generating agonists and antagonists of polypeptides of the invention. See generally, U.S. Patent Nos. 5,605,793, 5,811,238, 5,830,721, 5,834,252, and 5,837,458, and Patten, P. A., et al., *Curr. Opinion Biotechnol.* 8:724-33 (1997); Harayama, S. *Trends Biotechnol.* 16(2):76-82 (1998); Hansson, L. O., et al., *J. Mol. Biol.* 287:265-76 (1999); and Lorenzo, M. M. and Blasco, R. *Biotechniques* 24(2):308-13 (1998) (each of these patents and publications are hereby incorporated by reference). In one embodiment, alteration of polynucleotides and corresponding polypeptides of the invention may be achieved by DNA shuffling. DNA shuffling involves the assembly of two or more DNA segments into a desired polynucleotide

sequence of the invention molecule by homologous, or site-specific, recombination. In another embodiment, polynucleotides and corresponding polypeptides of the invention may be altered by being subjected to random mutagenesis by error-prone PCR, random nucleotide insertion or other methods prior to recombination. In  
5 another embodiment, one or more components, motifs, sections, parts, domains, fragments, etc., of the polypeptides of the invention may be recombined with one or more components, motifs, sections, parts, domains, fragments, etc. of one or more heterologous molecules. In preferred embodiments, the heterologous molecules are family members. In further preferred embodiments, the heterologous molecule is a  
10 growth factor such as, for example, platelet-derived growth factor (PDGF), insulin-like growth factor (IGF-I), transforming growth factor (TGF)-alpha, epidermal growth factor (EGF), fibroblast growth factor (FGF), TGF-beta, bone morphogenetic protein (BMP)-2, BMP-4, BMP-5, BMP-6, BMP-7, activins A and B, decapentaplegic(dpp), 60A, OP-2, dorsalin, growth differentiation factors (GDFs),  
15 nodal, MIS, inhibin-alpha, TGF-beta1, TGF-beta2, TGF-beta3, TGF-beta5, and glial-derived neurotrophic factor (GDNF).

Other preferred fragments are biologically active fragments of the polypeptides of the invention. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide. The  
20 biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity.

Additionally, this invention provides a method of screening compounds to identify those which modulate the action of the polypeptide of the present invention. An example of such an assay comprises combining a mammalian fibroblast cell, a the  
25 polypeptide of the present invention, the compound to be screened and 3[H] thymidine under cell culture conditions where the fibroblast cell would normally proliferate. A control assay may be performed in the absence of the compound to be screened and compared to the amount of fibroblast proliferation in the presence of the compound to determine if the compound stimulates proliferation by determining the  
30 uptake of 3[H] thymidine in each case. The amount of fibroblast cell proliferation is measured by liquid scintillation chromatography which measures the incorporation of

3[H] thymidine. Both agonist and antagonist compounds may be identified by this procedure.

In another method, a mammalian cell or membrane preparation expressing a receptor for a polypeptide of the present invention is incubated with a labeled polypeptide of the present invention in the presence of the compound. The ability of the compound to enhance or block this interaction could then be measured. Alternatively, the response of a known second messenger system following interaction of a compound to be screened and the receptor is measured and the ability of the compound to bind to the receptor and elicit a second messenger response is measured to determine if the compound is a potential agonist or antagonist. Such second messenger systems include but are not limited to, cAMP guanylate cyclase, ion channels or phosphoinositide hydrolysis.

All of these above assays can be used as diagnostic or prognostic markers. The molecules discovered using these assays can be used to treat, prevent, and/or diagnose disease or to bring about a particular result in a patient (e.g., blood vessel growth) by activating or inhibiting the polypeptide/molecule. Moreover, the assays can discover agents which may inhibit or enhance the production of the polypeptides of the invention from suitably manipulated cells or tissues. Therefore, the invention includes a method of identifying compounds which bind to the polypeptides of the invention comprising the steps of: (a) incubating a candidate binding compound with the polypeptide; and (b) determining if binding has occurred. Moreover, the invention includes a method of identifying agonists/antagonists comprising the steps of: (a) incubating a candidate compound with the polypeptide, (b) assaying a biological activity, and (b) determining if a biological activity of the polypeptide has been altered.

Also, one could identify molecules bind a polypeptide of the invention experimentally by using the beta-pleated sheet regions contained in the polypeptide sequence of the protein. Accordingly, specific embodiments of the invention are directed to polynucleotides encoding polypeptides which comprise, or alternatively consist of, the amino acid sequence of each beta pleated sheet regions in a disclosed polypeptide sequence. Additional embodiments of the invention are directed to polynucleotides encoding polypeptides which comprise, or alternatively consist of,

any combination or all of contained in the polypeptide sequences of the invention. Additional preferred embodiments of the invention are directed to polypeptides which comprise, or alternatively consist of, the amino acid sequence of each of the beta pleated sheet regions in one of the polypeptide sequences of the invention. Additional  
5       embodiments of the invention are directed to polypeptides which comprise, or alternatively consist of, any combination or all of the beta pleated sheet regions in one of the polypeptide sequences of the invention.

### **Targeted Delivery**

10               In another embodiment, the invention provides a method of delivering compositions to targeted cells expressing a receptor for a polypeptide of the invention, or cells expressing a cell bound form of a polypeptide of the invention.

As discussed herein, polypeptides or antibodies of the invention may be associated with heterologous polypeptides, heterologous nucleic acids, toxins, or  
15       prodrugs via hydrophobic, hydrophilic, ionic and/or covalent interactions. In one embodiment, the invention provides a method for the specific delivery of compositions of the invention to cells by administering polypeptides of the invention (including antibodies) that are associated with heterologous polypeptides or nucleic acids. In one example, the invention provides a method for delivering a therapeutic  
20       protein into the targeted cell. In another example, the invention provides a method for delivering a single stranded nucleic acid (e.g., antisense or ribozymes) or double stranded nucleic acid (e.g., DNA that can integrate into the cell's genome or replicate episomally and that can be transcribed) into the targeted cell.

In another embodiment, the invention provides a method for the specific  
25       destruction of cells (e.g., the destruction of tumor cells) by administering polypeptides of the invention (e.g., polypeptides of the invention or antibodies of the invention) in association with toxins or cytotoxic prodrugs.

By "toxin" is meant compounds that bind and activate endogenous cytotoxic effector systems, radioisotopes, holotoxins, modified toxins, catalytic subunits of  
30       toxins, or any molecules or enzymes not normally present in or on the surface of a cell that under defined conditions cause the cell's death. Toxins that may be used according to the methods of the invention include, but are not limited to, radioisotopes

known in the art, compounds such as, for example, antibodies (or complement fixing containing portions thereof) that bind an inherent or induced endogenous cytotoxic effector system, thymidine kinase, endonuclease, RNase, alpha toxin, ricin, abrin, *Pseudomonas* exotoxin A, diphtheria toxin, saporin, momordin, gelonin, pokeweed antiviral protein, alpha-sarcin and cholera toxin. By "cytotoxic prodrug" is meant a non-toxic compound that is converted by an enzyme, normally present in the cell, into a cytotoxic compound. Cytotoxic prodrugs that may be used according to the methods of the invention include, but are not limited to, glutamyl derivatives of benzoic acid mustard alkylating agent, phosphate derivatives of etoposide or mitomycin C, cytosine arabinoside, daunorubisin, and phenoxyacetamide derivatives of doxorubicin.

### **Drug Screening**

Further contemplated is the use of the polypeptides of the present invention, or the polynucleotides encoding these polypeptides, to screen for molecules which modify the activities of the polypeptides of the present invention. Such a method would include contacting the polypeptide of the present invention with a selected compound(s) suspected of having antagonist or agonist activity, and assaying the activity of these polypeptides following binding.

This invention is particularly useful for screening therapeutic compounds by using the polypeptides of the present invention, or binding fragments thereof, in any of a variety of drug screening techniques. The polypeptide or fragment employed in such a test may be affixed to a solid support, expressed on a cell surface, free in solution, or located intracellularly. One method of drug screening utilizes eukaryotic or prokaryotic host cells which are stably transformed with recombinant nucleic acids expressing the polypeptide or fragment. Drugs are screened against such transformed cells in competitive binding assays. One may measure, for example, the formulation of complexes between the agent being tested and a polypeptide of the present invention.

Thus, the present invention provides methods of screening for drugs or any other agents which affect activities mediated by the polypeptides of the present invention. These methods comprise contacting such an agent with a polypeptide of the

present invention or a fragment thereof and assaying for the presence of a complex between the agent and the polypeptide or a fragment thereof, by methods well known in the art. In such a competitive binding assay, the agents to screen are typically labeled. Following incubation, free agent is separated from that present in bound  
5 form, and the amount of free or uncomplexed label is a measure of the ability of a particular agent to bind to the polypeptides of the present invention.

Another technique for drug screening provides high throughput screening for compounds having suitable binding affinity to the polypeptides of the present invention, and is described in great detail in European Patent Application 84/03564,  
10 published on September 13, 1984, which is incorporated herein by reference herein. Briefly stated, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The peptide test compounds are reacted with polypeptides of the present invention and washed. Bound polypeptides are then detected by methods well known in the art.  
15 Purified polypeptides are coated directly onto plates for use in the aforementioned drug screening techniques. In addition, non-neutralizing antibodies may be used to capture the peptide and immobilize it on the solid support.

This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of binding polypeptides of the present  
20 invention specifically compete with a test compound for binding to the polypeptides or fragments thereof. In this manner, the antibodies are used to detect the presence of any peptide which shares one or more antigenic epitopes with a polypeptide of the invention.

### 25 **Polypeptides of the Invention Binding Peptides and Other Molecules**

The invention also encompasses screening methods for identifying polypeptides and nonpolypeptides that bind polypeptides of the invention, and the polypeptide of the invention binding molecules identified thereby. These binding molecules are useful, for example, as agonists and antagonists of the polypeptides of  
30 the invention. Such agonists and antagonists can be used, in accordance with the invention, in the therapeutic embodiments described in detail, below.

This method comprises the steps of:

- a. contacting a polypeptide of the invention with a plurality of molecules; and
- b. identifying a molecule that binds the polypeptide of the invention.

The step of contacting the polypeptide of the invention with the plurality of molecules may be effected in a number of ways. For example, one may contemplate  
5 immobilizing the polypeptide of the invention on a solid support and bringing a solution of the plurality of molecules in contact with the immobilized polypeptide of the invention. Such a procedure would be akin to an affinity chromatographic process, with the affinity matrix being comprised of the immobilized polypeptide of the invention. The molecules having a selective affinity for the polypeptide of the  
10 invention can then be purified by affinity selection. The nature of the solid support, process for attachment of the polypeptide of the invention to the solid support, solvent, and conditions of the affinity isolation or selection are largely conventional and well known to those of ordinary skill in the art.

Alternatively, one may also separate a plurality of polypeptides into  
15 substantially separate fractions comprising a subset of or individual polypeptides. For instance, one can separate the plurality of polypeptides by gel electrophoresis, column chromatography, or like method known to those of ordinary skill for the separation of polypeptides. The individual polypeptides can also be produced by a transformed host cell in such a way as to be expressed on or about its outer surface (e.g., a recombinant  
20 phage). Individual isolates can then be "probed" by the polypeptide of the invention, optionally in the presence of an inducer should one be required for expression, to determine if any selective affinity interaction takes place between the polypeptide of the invention and the individual clone. Prior to contacting the polypeptide of the invention with each fraction comprising individual polypeptides, the polypeptides  
25 could first be transferred to a solid support for additional convenience. Such a solid support may simply be a piece of filter membrane, such as one made of nitrocellulose or nylon. In this manner, positive clones could be identified from a collection of transformed host cells of an expression library, which harbor a DNA construct encoding a polypeptide having a selective affinity for a polypeptide of the invention.  
30 Furthermore, the amino acid sequence of the polypeptide having a selective affinity for the polypeptide of the invention can be determined directly by conventional means or the coding sequence of the DNA encoding the polypeptide can frequently be



determined more conveniently. The primary sequence can then be deduced from the corresponding DNA sequence. If the amino acid sequence is to be determined from the polypeptide itself, one may use microsequencing techniques. The sequencing technique may include mass spectroscopy.

5           In certain situations, it may be desirable to wash away any unbound polypeptide of the invention, or alternatively, unbound polypeptides, from a mixture of the polypeptide of the invention and the plurality of polypeptides prior to attempting to determine or to detect the presence of a selective affinity interaction. Such a wash step may be particularly desirable when the polypeptide of the invention  
10   or the plurality of polypeptides is bound to a solid support.

          The plurality of molecules provided according to this method may be provided by way of diversity libraries, such as random or combinatorial peptide or nonpeptide libraries which can be screened for molecules that specifically bind to a polypeptide of the invention. Many libraries are known in the art that can be used, e.g., chemically  
15   synthesized libraries, recombinant (e.g., phage display libraries), and in vitro translation-based libraries. Examples of chemically synthesized libraries are described in Fodor et al., 1991, *Science* 251:767-773; Houghten et al., 1991, *Nature* 354:84-86; Lam et al., 1991, *Nature* 354:82-84; Medynski, 1994, *Bio/Technology* 12:709-710; Gallop et al., 1994, *J. Medicinal Chemistry* 37(9):1233-1251; Ohlmeyer  
20   et al., 1993, *Proc. Natl. Acad. Sci. USA* 90:10922-10926; Erb et al., 1994, *Proc. Natl. Acad. Sci. USA* 91:11422-11426; Houghten et al., 1992, *Biotechniques* 13:412; Jayawickreme et al., 1994, *Proc. Natl. Acad. Sci. USA* 91:1614-1618; Salmon et al., 1993, *Proc. Natl. Acad. Sci. USA* 90:11708-11712; PCT Publication No. WO 93/20242; and Brenner and Lerner, 1992, *Proc. Natl. Acad. Sci. USA* 89:5381-5383.

25           Examples of phage display libraries are described in Scott and Smith, 1990, *Science* 249:386-390; Devlin et al., 1990, *Science*, 249:404-406; Christian, R. B., et al., 1992, *J. Mol. Biol.* 227:711-718; Lenstra, 1992, *J. Immunol. Meth.* 152:149-157; Kay et al., 1993, *Gene* 128:59-65; and PCT Publication No. WO 94/18318 dated Aug. 18, 1994.

30           In vitro translation-based libraries include but are not limited to those described in PCT Publication No. WO 91/05058 dated Apr. 18, 1991; and Mattheakis et al., 1994, *Proc. Natl. Acad. Sci. USA* 91:9022-9026.

By way of examples of nonpeptide libraries, a benzodiazepine library (see e.g., Bunin et al., 1994, Proc. Natl. Acad. Sci. USA 91:4708-4712) can be adapted for use. Peptoid libraries (Simon et al., 1992, Proc. Natl. Acad. Sci. USA 89:9367-9371) can also be used. Another example of a library that can be used, in which the amide  
5 functionalities in peptides have been permethylated to generate a chemically transformed combinatorial library, is described by Ostresh et al. (1994, Proc. Natl. Acad. Sci. USA 91:11138-11142).

The variety of non-peptide libraries that are useful in the present invention is great. For example, Ecker and Crooke, 1995, Bio/Technology 13:351-360 list  
10 benzodiazepines, hydantoins, piperazinediones, biphenyls, sugar analogs, beta-mercaptoketones, arylacetic acids, acylpiperidines, benzopyrans, cubanes, xanthines, aminimides, and oxazolones as among the chemical species that form the basis of various libraries.

Non-peptide libraries can be classified broadly into two types: decorated  
15 monomers and oligomers. Decorated monomer libraries employ a relatively simple scaffold structure upon which a variety functional groups is added. Often the scaffold will be a molecule with a known useful pharmacological activity. For example, the scaffold might be the benzodiazepine structure.

Non-peptide oligomer libraries utilize a large number of monomers that are  
20 assembled together in ways that create new shapes that depend on the order of the monomers. Among the monomer units that have been used are carbamates, pyrrolinones, and morpholinos. Peptoids, peptide-like oligomers in which the side chain is attached to the alpha amino group rather than the alpha carbon, form the basis of another version of non-peptide oligomer libraries. The first non-peptide oligomer  
25 libraries utilized a single type of monomer and thus contained a repeating backbone. Recent libraries have utilized more than one monomer, giving the libraries added flexibility.

Screening the libraries can be accomplished by any of a variety of commonly known methods. See, e.g., the following references, which disclose screening of  
30 peptide libraries: Parmley and Smith, 1989, Adv. Exp. Med. Biol. 251:215-218; Scott and Smith, 1990, Science 249:386-390; Fowlkes et al., 1992; BioTechniques 13:422-427; Oldenburg et al., 1992, Proc. Natl. Acad. Sci. USA 89:5393-5397; Yu et al.,

1994, Cell 76:933-945; Staudt et al., 1988, Science 241:577-580; Bock et al., 1992, Nature 355:564-566; Tuerk et al., 1992, Proc. Natl. Acad. Sci. USA 89:6988-6992; Ellington et al., 1992, Nature 355:850-852; U.S. Pat. No. 5,096,815, U.S. Pat. No. 5,223,409, and U.S. Pat. No. 5,198,346, all to Ladner et al.; Rebar and Pabo, 1993, Science 263:671-673; and CT Publication No. WO 94/18318.

In a specific embodiment, screening to identify a molecule that binds a polypeptide of the invention can be carried out by contacting the library members with a polypeptide of the invention immobilized on a solid phase and harvesting those library members that bind to the polypeptide of the invention. Examples of such screening methods, termed "panning" techniques are described by way of example in Parnley and Smith, 1988, Gene 73:305-318; Fowlkes et al., 1992, BioTechniques 13:422-427; PCT Publication No. WO 94/18318; and in references cited herein.

In another embodiment, the two-hybrid system for selecting interacting proteins in yeast (Fields and Song, 1989, Nature 340:245-246; Chien et al., 1991, Proc. Natl. Acad. Sci. USA 88:9578-9582) can be used to identify molecules that specifically bind to a polypeptide of the invention.

Where the polypeptide of the invention binding molecule is a polypeptide, the polypeptide can be conveniently selected from any peptide library, including random peptide libraries, combinatorial peptide libraries, or biased peptide libraries. The term "biased" is used herein to mean that the method of generating the library is manipulated so as to restrict one or more parameters that govern the diversity of the resulting collection of molecules, in this case peptides.

Thus, a truly random peptide library would generate a collection of peptides in which the probability of finding a particular amino acid at a given position of the peptide is the same for all 20 amino acids. A bias can be introduced into the library, however, by specifying, for example, that a lysine occur every fifth amino acid or that positions 4, 8, and 9 of a decapeptide library be fixed to include only arginine. Clearly, many types of biases can be contemplated, and the present invention is not restricted to any particular bias. Furthermore, the present invention contemplates specific types of peptide libraries, such as phage displayed peptide libraries and those that utilize a DNA construct comprising a lambda phage vector with a DNA insert.

As mentioned above, in the case of a polypeptide of the invention binding

molecule that is a polypeptide, the polypeptide may have about 6 to less than about 60 amino acid residues, preferably about 6 to about 10 amino acid residues, and most preferably, about 6 to about 22 amino acids. In another embodiment, a polypeptide of the invention binding polypeptide has in the range of 15-100 amino acids, or 20-50 amino acids.

The selected polypeptide of the invention binding polypeptide can be obtained by chemical synthesis or recombinant expression.

#### **Antisense And Ribozyme (Antagonists)**

In specific embodiments, antagonists according to the present invention are nucleic acids corresponding to the sequences contained in SEQ ID NO:X, or the complementary strand thereof, and/or to nucleotide sequences contained a deposited clone. In one embodiment, antisense sequence is generated internally by the organism, in another embodiment, the antisense sequence is separately administered (see, for example, O'Connor, Neurochem., 56:560 (1991). Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988). Antisense technology can be used to control gene expression through antisense DNA or RNA, or through triple-helix formation. Antisense techniques are discussed for example, in Okano, Neurochem., 56:560 (1991); Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988). Triple helix formation is discussed in, for instance, Lee et al., Nucleic Acids Research, 6:3073 (1979); Cooney et al., Science, 241:456 (1988); and Dervan et al., Science, 251:1300 (1991). The methods are based on binding of a polynucleotide to a complementary DNA or RNA.

For example, the use of c-myc and c-myb antisense RNA constructs to inhibit the growth of the non-lymphocytic leukemia cell line HL-60 and other cell lines was previously described. (Wickstrom et al. (1988); Anfossi et al. (1989)). These experiments were performed in vitro by incubating cells with the oligoribonucleotide. A similar procedure for in vivo use is described in WO 91/15580. Briefly, a pair of oligonucleotides for a given antisense RNA is produced as follows: A sequence complimentary to the first 15 bases of the open reading frame is flanked by an EcoRI site on the 5' end and a HindIII site on the 3' end. Next, the pair of oligonucleotides is

heated at 90°C for one minute and then annealed in 2X ligation buffer (20mM TRIS HCl pH 7.5, 10mM MgCl<sub>2</sub>, 10mM dithiothreitol (DTT) and 0.2 mM ATP) and then ligated to the EcoR1/Hind III site of the retroviral vector PMV7 (WO 91/15580).

For example, the 5' coding portion of a polynucleotide that encodes the mature  
5 polypeptide of the present invention may be used to design an antisense RNA  
oligonucleotide of from about 10 to 40 base pairs in length. A DNA oligonucleotide  
is designed to be complementary to a region of the gene involved in transcription  
thereby preventing transcription and the production of the receptor. The antisense  
RNA oligonucleotide hybridizes to the mRNA in vivo and blocks translation of the  
10 mRNA molecule into receptor polypeptide.

In one embodiment, the antisense nucleic acid of the invention is produced  
intracellularly by transcription from an exogenous sequence. For example, a vector or  
a portion thereof, is transcribed, producing an antisense nucleic acid (RNA) of the  
invention. Such a vector would contain a sequence encoding the antisense nucleic  
15 acid of the invention. Such a vector can remain episomal or become chromosomally  
integrated, as long as it can be transcribed to produce the desired antisense RNA.  
Such vectors can be constructed by recombinant DNA technology methods standard  
in the art. Vectors can be plasmid, viral, or others known in the art, used for  
replication and expression in vertebrate cells. Expression of the sequence encoding a  
20 polypeptide of the invention, or fragments thereof, can be by any promoter known in  
the art to act in vertebrate, preferably human cells. Such promoters can be inducible  
or constitutive. Such promoters include, but are not limited to, the SV40 early  
promoter region (Bernoist and Chambon, Nature, 29:304-310 (1981), the promoter  
contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto et al.,  
25 Cell, 22:787-797 (1980), the herpes thymidine promoter (Wagner et al., Proc. Natl.  
Acad. Sci. U.S.A., 78:1441-1445 (1981), the regulatory sequences of the  
metallothionein gene (Brinster et al., Nature, 296:39-42 (1982)), etc.

The antisense nucleic acids of the invention comprise a sequence  
complementary to at least a portion of an RNA transcript of a gene of interest.  
30 However, absolute complementarity, although preferred, is not required. A sequence  
"complementary to at least a portion of an RNA," referred to herein, means a  
sequence having sufficient complementarity to be able to hybridize with the RNA,

forming a stable duplex; in the case of double stranded antisense nucleic acids of the invention, a single strand of the duplex DNA may thus be tested, or triplex formation may be assayed. The ability to hybridize will depend on both the degree of complementarity and the length of the antisense nucleic acid. Generally, the larger the hybridizing nucleic acid, the more base mismatches with a RNA sequence of the invention it may contain and still form a stable duplex (or triplex as the case may be). One skilled in the art can ascertain a tolerable degree of mismatch by use of standard procedures to determine the melting point of the hybridized complex.

Oligonucleotides that are complementary to the 5' end of the message, *e.g.*, the 5' untranslated sequence up to and including the AUG initiation codon, should work most efficiently at inhibiting translation. However, sequences complementary to the 3' untranslated sequences of mRNAs have been shown to be effective at inhibiting translation of mRNAs as well. See generally, Wagner, R., *Nature*, 372:333-335 (1994). Thus, oligonucleotides complementary to either the 5' - or 3' - non- translated, non-coding regions of a polynucleotide sequence of the invention could be used in an antisense approach to inhibit translation of endogenous mRNA. Oligonucleotides complementary to the 5' untranslated region of the mRNA should include the complement of the AUG start codon. Antisense oligonucleotides complementary to mRNA coding regions are less efficient inhibitors of translation but could be used in accordance with the invention. Whether designed to hybridize to the 5' -, 3' - or coding region of mRNA, antisense nucleic acids should be at least six nucleotides in length, and are preferably oligonucleotides ranging from 6 to about 50 nucleotides in length. In specific aspects the oligonucleotide is at least 10 nucleotides, at least 17 nucleotides, at least 25 nucleotides or at least 50 nucleotides.

The polynucleotides of the invention can be DNA or RNA or chimeric mixtures or derivatives or modified versions thereof, single-stranded or double-stranded. The oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone, for example, to improve stability of the molecule, hybridization, etc. The oligonucleotide may include other appended groups such as peptides (*e.g.*, for targeting host cell receptors *in vivo*), or agents facilitating transport across the cell membrane (see, *e.g.*, Letsinger et al., *Proc. Natl. Acad. Sci. U.S.A.* 86:6553-6556 (1989); Lemaitre et al., *Proc. Natl. Acad. Sci.*, 84:648-652 (1987); PCT Publication

NO: WO88/09810, published December 15, 1988) or the blood-brain barrier (see, e.g., PCT Publication NO: WO89/10134, published April 25, 1988), hybridization-triggered cleavage agents. (See, e.g., Krol et al., BioTechniques, 6:958-976 (1988)) or intercalating agents. (See, e.g., Zon, Pharm. Res., 5:539-549 (1988)). To this end,  
5 the oligonucleotide may be conjugated to another molecule, e.g., a peptide, hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent, etc.

The antisense oligonucleotide may comprise at least one modified base moiety which is selected from the group including, but not limited to, 5-fluorouracil,  
10 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xantine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine,  
15 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil,  
20 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine.

The antisense oligonucleotide may also comprise at least one modified sugar moiety selected from the group including, but not limited to, arabinose,  
25 2-fluoroarabinose, xylulose, and hexose.

In yet another embodiment, the antisense oligonucleotide comprises at least one modified phosphate backbone selected from the group including, but not limited to, a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl  
30 phosphotriester, and a formacetal or analog thereof.

In yet another embodiment, the antisense oligonucleotide is an a-anomeric oligonucleotide. An a-anomeric oligonucleotide forms specific double-stranded

hybrids with complementary RNA in which, contrary to the usual b-units, the strands run parallel to each other (Gautier et al., Nucl. Acids Res., 15:6625-6641 (1987)).

The oligonucleotide is a 2'-O-methylribonucleotide (Inoue et al., Nucl. Acids Res., 15:6131-6148 (1987)), or a chimeric RNA-DNA analogue (Inoue et al., FEBS Lett. 5 215:327-330 (1987)).

Polynucleotides of the invention may be synthesized by standard methods known in the art, e.g. by use of an automated DNA synthesizer (such as are commercially available from Biosearch, Applied Biosystems, etc.). As examples, phosphorothioate oligonucleotides may be synthesized by the method of Stein et al. 10 (Nucl. Acids Res., 16:3209 (1988)), methylphosphonate oligonucleotides can be prepared by use of controlled pore glass polymer supports (Sarin et al., Proc. Natl. Acad. Sci. U.S.A., 85:7448-7451 (1988)), etc.

While antisense nucleotides complementary to the coding region sequence of the invention could be used, those complementary to the transcribed untranslated 15 region are most preferred.

Potential antagonists according to the invention also include catalytic RNA, or a ribozyme (See, e.g., PCT International Publication WO 90/11364, published October 4, 1990; Sarver et al, Science, 247:1222-1225 (1990). While ribozymes that cleave mRNA at site specific recognition sequences can be used to destroy mRNAs 20 corresponding to the polynucleotides of the invention, the use of hammerhead ribozymes is preferred. Hammerhead ribozymes cleave mRNAs at locations dictated by flanking regions that form complementary base pairs with the target mRNA. The sole requirement is that the target mRNA have the following sequence of two bases: 5' -UG-3' . The construction and production of hammerhead ribozymes is well 25 known in the art and is described more fully in Haseloff and Gerlach, Nature, 334:585-591 (1988). There are numerous potential hammerhead ribozyme cleavage sites within each nucleotide sequence disclosed in the sequence listing. Preferably, the ribozyme is engineered so that the cleavage recognition site is located near the 5' end of the mRNA corresponding to the polynucleotides of the invention; i.e., to 30 increase efficiency and minimize the intracellular accumulation of non-functional mRNA transcripts.



As in the antisense approach, the ribozymes of the invention can be composed of modified oligonucleotides (e.g. for improved stability, targeting, etc.) and should be delivered to cells which express the polynucleotides of the invention in vivo. DNA constructs encoding the ribozyme may be introduced into the cell in the same  
5 manner as described above for the introduction of antisense encoding DNA. A preferred method of delivery involves using a DNA construct "encoding" the ribozyme under the control of a strong constitutive promoter, such as, for example, pol III or pol II promoter, so that transfected cells will produce sufficient quantities of the ribozyme to destroy endogenous messages and inhibit translation. Since  
10 ribozymes unlike antisense molecules, are catalytic, a lower intracellular concentration is required for efficiency.

Antagonist/agonist compounds may be employed to inhibit the cell growth and proliferation effects of the polypeptides of the present invention on neoplastic cells and tissues, i.e. stimulation of angiogenesis of tumors, and, therefore, retard or  
15 prevent abnormal cellular growth and proliferation, for example, in tumor formation or growth.

The antagonist/agonist may also be employed to prevent hyper-vascular diseases, and prevent the proliferation of epithelial lens cells after extracapsular cataract surgery. Prevention of the mitogenic activity of the polypeptides of the  
20 present invention may also be desirous in cases such as restenosis after balloon angioplasty.

The antagonist/agonist may also be employed to prevent the growth of scar tissue during wound healing.

The antagonist/agonist may also be employed to treat, prevent, and/or  
25 diagnose the diseases described herein.

Thus, the invention provides a method of treating or preventing diseases, disorders, and/or conditions, including but not limited to the diseases, disorders, and/or conditions listed throughout this application, associated with overexpression of a polynucleotide of the present invention by administering to a patient (a) an antisense  
30 molecule directed to the polynucleotide of the present invention, and/or (b) a ribozyme directed to the polynucleotide of the present invention.

invention, and/or (b) a ribozyme directed to the polynucleotide of the present invention

### **Other Activities**

5           The polypeptide of the present invention, as a result of the ability to stimulate vascular endothelial cell growth, may be employed in treatment for stimulating re-vascularization of ischemic tissues due to various disease conditions such as thrombosis, arteriosclerosis, and other cardiovascular conditions. These polypeptide may also be employed to stimulate angiogenesis and limb regeneration, as discussed  
10   above.

          The polypeptide may also be employed for treating wounds due to injuries, burns, post-operative tissue repair, and ulcers since they are mitogenic to various cells of different origins, such as fibroblast cells and skeletal muscle cells, and therefore, facilitate the repair or replacement of damaged or diseased tissue.

15           The polypeptide of the present invention may also be employed stimulate neuronal growth and to treat, prevent, and/or diagnose neuronal damage which occurs in certain neuronal disorders or neuro-degenerative conditions such as Alzheimer's disease, Parkinson's disease, and AIDS-related complex. The polypeptide of the invention may have the ability to stimulate chondrocyte growth, therefore, they may  
20   be employed to enhance bone and periodontal regeneration and aid in tissue transplants or bone grafts.

          The polypeptide of the present invention may be also be employed to prevent skin aging due to sunburn by stimulating keratinocyte growth.

25           The polypeptide of the invention may also be employed for preventing hair loss, since FGF family members activate hair-forming cells and promotes melanocyte growth. Along the same lines, the polypeptides of the present invention may be employed to stimulate growth and differentiation of hematopoietic cells and bone marrow cells when used in combination with other cytokines.

30           The polypeptide of the invention may also be employed to maintain organs before transplantation or for supporting cell culture of primary tissues.

          The polypeptide of the present invention may also be employed for inducing tissue of mesodermal origin to differentiate in early embryos.

The polypeptide or polynucleotides and/or agonist or antagonists of the present invention may also increase or decrease the differentiation or proliferation of embryonic stem cells, besides, as discussed above, hematopoietic lineage.

5        The polypeptide or polynucleotides and/or agonist or antagonists of the present invention may also be used to modulate mammalian characteristics, such as body height, weight, hair color, eye color, skin, percentage of adipose tissue, pigmentation, size, and shape (e.g., cosmetic surgery). Similarly, polypeptides or polynucleotides and/or agonist or antagonists of the present invention may be used to  
10       modulate mammalian metabolism affecting catabolism, anabolism, processing, utilization, and storage of energy.

Polypeptide or polynucleotides and/or agonist or antagonists of the present invention may be used to change a mammal's mental state or physical state by influencing biorhythms, cardiac rhythms, depression (including depressive diseases,  
15       disorders, and/or conditions), tendency for violence, tolerance for pain, reproductive capabilities (preferably by Activin or Inhibin-like activity), hormonal or endocrine levels, appetite, libido, memory, stress, or other cognitive qualities.

Polypeptide or polynucleotides and/or agonist or antagonists of the present invention may also be used as a food additive or preservative, such as to increase or  
20       decrease storage capabilities, fat content, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional components.

### **Other Preferred Embodiments**

Other preferred embodiments of the claimed invention include an isolated  
25       nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 50 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1.

Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of  
30       positions beginning with the nucleotide at about the position of the 5' Nucleotide of

the Clone Sequence and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the Start Codon and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Similarly preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the First Amino Acid of the Signal Peptide and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 150 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

Further preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 500 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

A further preferred embodiment is a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the nucleotide sequence of SEQ ID NO:X beginning with the nucleotide at about the position of the 5' Nucleotide of the First Amino Acid of the Signal Peptide and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence of SEQ ID NO:X.

Also preferred is an isolated nucleic acid molecule which hybridizes under stringent hybridization conditions to a nucleic acid molecule, wherein said nucleic acid molecule which hybridizes does not hybridize under stringent hybridization

conditions to a nucleic acid molecule having a nucleotide sequence consisting of only A residues or of only T residues.

Also preferred is a composition of matter comprising a DNA molecule which comprises a human cDNA clone identified by a cDNA Clone Identifier in Table 1,  
5 which DNA molecule is contained in the material deposited with the American Type Culture Collection and given the ATCC Deposit Number shown in Table 1 for said cDNA Clone Identifier.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous  
10 nucleotides in the nucleotide sequence of a human cDNA clone identified by a cDNA Clone Identifier in Table 1, which DNA molecule is contained in the deposit given the ATCC Deposit Number shown in Table 1.

Also preferred is an isolated nucleic acid molecule, wherein said sequence of at least 50 contiguous nucleotides is included in the nucleotide sequence of the  
15 complete open reading frame sequence encoded by said human cDNA clone.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 150 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is an isolated nucleic acid molecule  
20 comprising a nucleotide sequence which is at least 95% identical to sequence of at least 500 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete  
25 nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is a method for detecting in a biological sample a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X  
30 wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table

1; which method comprises a step of comparing a nucleotide sequence of at least one nucleic acid molecule in said sample with a sequence selected from said group and determining whether the sequence of said nucleic acid molecule in said sample is at least 95% identical to said selected sequence.

5 Also preferred is the above method wherein said step of comparing sequences comprises determining the extent of nucleic acid hybridization between nucleic acid molecules in said sample and a nucleic acid molecule comprising said sequence selected from said group. Similarly, also preferred is the above method wherein said step of comparing sequences is performed by comparing the nucleotide sequence  
10 determined from a nucleic acid molecule in said sample with said sequence selected from said group. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

A further preferred embodiment is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting nucleic  
15 acid molecules in said sample, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained  
20 in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

The method for identifying the species, tissue or cell type of a biological sample can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least  
25 one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted protein identified in Table 1, which method comprises a step of detecting in a  
30 biological sample obtained from said subject nucleic acid molecules, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a

nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

5           The method for diagnosing a pathological condition can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

10           Also preferred is a composition of matter comprising isolated nucleic acid molecules wherein the nucleotide sequences of said nucleic acid molecules comprise a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID  
15 NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

20           Also preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1.

          Also preferred is a polypeptide, wherein said sequence of contiguous amino acids is included in the amino acid sequence of SEQ ID NO:Y in the range of  
25 positions beginning with the residue at about the position of the First Amino Acid of the Secreted Portion and ending with the residue at about the Last Amino Acid of the Open Reading Frame as set forth for SEQ ID NO:Y in Table 1.

          Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the  
30 amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid  
5 sequence at least 95% identical to the complete amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the complete amino acid sequence of a secreted protein encoded by a human  
10 cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is a polypeptide wherein said sequence of contiguous amino acids is included in the amino acid sequence of a secreted portion of the secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in  
15 Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human cDNA  
20 clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human  
25 cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1  
30 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.



Further preferred is an isolated antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as  
5 defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is a method for detecting in a biological sample a  
10 polypeptide comprising an amino acid sequence which is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained  
15 in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1; which method comprises a step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group and determining whether the sequence of said polypeptide molecule in said sample is at least 90% identical to said sequence of at least 10 contiguous amino acids.

20 Also preferred is the above method wherein said step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group comprises determining the extent of specific binding of polypeptides in said sample to an antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at  
25 least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

30 Also preferred is the above method wherein said step of comparing sequences is performed by comparing the amino acid sequence determined from a polypeptide molecule in said sample with said sequence selected from said group.

Also preferred is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting polypeptide molecules in said sample, if any, comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is the above method for identifying the species, tissue or cell type of a biological sample, which method comprises a step of detecting polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the above group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted protein identified in Table 1, which method comprises a step of detecting in a biological sample obtained from said subject polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

In any of these methods, the step of detecting said polypeptide molecules includes using an antibody.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a nucleotide sequence encoding a polypeptide wherein said polypeptide comprises an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence

selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number  
5 shown for said cDNA clone in Table 1.

Also preferred is an isolated nucleic acid molecule, wherein said nucleotide sequence encoding a polypeptide has been optimized for expression of said polypeptide in a prokaryotic host.

Also preferred is an isolated nucleic acid molecule, wherein said polypeptide  
10 comprises an amino acid sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

15 Further preferred is a method of making a recombinant vector comprising inserting any of the above isolated nucleic acid molecule into a vector. Also preferred is the recombinant vector produced by this method. Also preferred is a method of making a recombinant host cell comprising introducing the vector into a host cell, as well as the recombinant host cell produced by this method.

20 Also preferred is a method of making an isolated polypeptide comprising culturing this recombinant host cell under conditions such that said polypeptide is expressed and recovering said polypeptide. Also preferred is this method of making an isolated polypeptide, wherein said recombinant host cell is a eukaryotic cell and said polypeptide is a secreted portion of a human secreted protein comprising an  
25 amino acid sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y beginning with the residue at the position of the First Amino Acid of the Secreted Portion of SEQ ID NO:Y wherein Y is an integer set forth in Table 1 and said position of the First Amino Acid of the Secreted Portion of SEQ ID NO:Y is defined in Table 1; and an amino acid sequence of a secreted portion of a protein  
30 encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1. The isolated polypeptide produced by this method is also preferred.

Also preferred is a method of treatment of an individual in need of an increased level of a secreted protein activity, which method comprises administering to such an individual a pharmaceutical composition comprising an amount of an isolated polypeptide, polynucleotide, or antibody of the claimed invention effective to  
 5 increase the level of said protein activity in said individual.

The above-recited applications have uses in a wide variety of hosts. Such hosts include, but are not limited to, human, murine, rabbit, goat, guinea pig, camel, horse, mouse, rat, hamster, pig, micro-pig, chicken, goat, cow, sheep, dog, cat, non-human primate, and human. In specific embodiments, the host is a mouse, rabbit,  
 10 goat, guinea pig, chicken, rat, hamster, pig, sheep, dog or cat. In preferred embodiments, the host is a mammal. In most preferred embodiments, the host is a human.

In specific embodiments of the invention, for each "Contig ID" listed in the fourth column of Table 7, preferably excluded are one or more polynucleotides  
 15 comprising, or alternatively consisting of, a nucleotide sequence referenced in the fifth column of Table 7 and described by the general formula of a-b, whereas a and b are uniquely determined for the corresponding SEQ ID NO:X referred to in column 3 of Table 7. Further specific embodiments are directed to polynucleotide sequences excluding one, two, three, four, or more of the specific polynucleotide sequences  
 20 referred to in the fifth column of Table 7. In no way is this listing meant to encompass all of the sequences which may be excluded by the general formula, it is just a representative example. All references available through these accessions are hereby incorporated by reference in their entirety.

TABLE 7

Gene No.	cDNA Clone ID	NT SEQ ID NO: X	Contig ID	Public Accession Numbers
1	HDPPA04	11	904765	AI990290, AI798762, AA044757, AW105205, AW197379, AA039608, AA247117, AA303575, AA036918, AA247128, AI214428, AW449368, AA044631, AI762460, and AF142780.
1	HDPPA04	32	905419	AI990290, AI798762, AA044757, AW105205, AW197379, AA039608,

				AA303575, AA036918, AA247117, AI214428, AW449368, AA247128, AA044631, AI762460, AI432644, AI431337, AI623302, AI432662, AI431248, AI431328, AI432649, AI431254, AI431243, AI432665, AI431347, AI432653, AI431230, AI432654, AI431354, AI432655, AI431310, AI431312, AI431330, AW081103, AI432651, AI432647, AI432677, AI432661, AI432675, AI492519, AI431241, AI432658, AI431357, AI432676, AI431351, AI432673, AI431345, AI431353, AW128900, AI432672, AI432674, AI431346, AI431255, AI431340, AW128846, AI432664, AI432650, AI791349, AI431307, AI431316, AW128897, AI492520, AI431751, AI492509, AI432643, AI432657, AI492510, AI432666, AW129223, AI431247, AI431308, AW128884, Y17793, and AF064854.
1	HDPPA04	33	905418	AA247128 and AA247117.
2	HOHBY44	12	873264	AI037867, AW368603, AW151676, AW383192, AI753734, AI754387, AW044602, AW383224, AI041650, AW383194, AI750595, AW383164, AI884505, W52686, AW069006, AI750594, AA600082, AW078795, AI753050, AI802788, AW190902, AI750578, AI041803, AI621183, AI750577, AW383125, AA599801, AW087935, N31127, W51909, AI087351, AA071381, W47324, W48619, AA670070, W48852, N35377, AI752124, AI090390, W42791, W47325, N28395, N28453, AI085102, AI678451, AA545734, W42884, AA373348, AI302125, AI910477, H80042, AA071138, AA669811, AW361415, AW069430, AA788723, AW069485, AI940729, AI754608, AA376403, AA373673, H99469, AA373544, AI888605, AA373014, AI940705, AA373975, N27040, C01826, AA373298, AA112124, AA084001, AI940795, AA372833, AW005943, AW239511, AI521673, AW138508, AI932934, AA373557, AA344024, W25447, AI537571, C01953, AI476777, AF110137, Y10019, AB032372, AF045800, AF108189, and AF045801.
2	HOHBY44	34	873263	AW069165, AI968107, AW069264, AI754660, AA912445, AI754594, N21113, AA703927, AA543066, AW130486, AI814434, AI924946, AW069841, AW173667, AI753523, AI753558, AA789056, AI753482, AW068940, AI022286, AI753593, AI753469, AA669866, AI753255, AW008360, AI949111, AW069588, AI754028, AI679005, AI677772, AI754354, AI589279, AI888455, AI752878, AI753002, AA836970, N20040, W19275, AI968546, AA788723, AW016646, AI440410, AI752123, AI801326, AI610424, AI753621, AI446171, AI753087, AI453455,

				AA599863, AI802571, AI537325, AA669978, AI811571, AI753506, AI309543, AA670062, AI623845, AI075634, AA729459, H80043, AI921732, AA329219, AA577421, AA668620, C01795, AI919521, AA600003, AA653400, AI445339, AI802573, AW130343, AA373014, C01953, AA600104, AI090390, AI302125, AI087351, AW069006, AI754608, AA071381, W51909, W47325, W42791, AW069430, AI085102, AW005943, AA670070, AW069485, AA600082, AI753734, AI041803, AW138508, AI932934, AI754387, AI750577, AI750594, and AF110137.
2	HOHBY44	35	785886	AW082079, N35762, N42296, AI081481, AW009605, AI949111, W19275, AW130343, AA600104, AI445339, AA653400, AA600003, AA577421, AI919521, AI075634, AA729459, AI623845, AI309543, AI811571, AI537325, AI802571, AA599863, AI453455, AI446171, AI610424, AI753087, AI440410, AI753621, AI801326, N20040, AI679005, AI589279, AI677772, AI752878, AI754354, AI754028, AW069588, AW008360, AI753255, AA669866, AI753506, AI753593, AW068940, AI753482, AI753558, AI753523, AW173667, AW069841, AI924946, AI814434, AW130486, AA543066, AA703927, AI754594, AI754660, AW069264, N21113, AI968107, AW069165, AA912445, AA668620, AA836970, AA669978, AI968546, AI888455, AI753469, AA789056, AW016646, AI022286, C01795, and AF110137.
3	HOHBL42	13	1020664	H95505 and L20314.
3	HOHBL42	36	863123	H95505.
3	HOHBL42	38	834714	L20314.
4	HRABV43	14	1024909	AA740749, AA844682, AA977690, AA864844, AI801095, AI206056, AA488673, AA815296, AI742443, AI932302, AA180508, AI833279, AI859081, AA157888, AA179837, AW192608, AA532678, AA479341, AA946767, AA804256, AA401011, AI982686, AI096855, AA187599, N69435, AI342048, AI745007, AI831165, AA088238, W22883, R92180, AA769339, AI377067, AI143620, AW075726, AA620478, H81204, AA479449, H97641, AA973113, AA400972, AI082108, AA808322, T79180, AA326358, AA856779, AA157576, AW204418, AA907790, AA493191, H81203, AA455438, AA486056, AW206126, AA969911, AI364159, AI475423, H43700, R00938, AA720606, T77234, AW135686, R92284, AI672889, AI656432, R70152, H41249, T85995, AA984380, R86741, AA088288, R02180, T98954, R71371, AI915388, AI383063, R85065, T77448, T79264, T80896, T32391, T10419, R05703, AI270644, AA506839, AI290031,

				AI459837, AA894596, AA974600, T99869, T90967, R05702, AA312338, AA582695, R87108, R08118, T98910, AA335307, AA187391, N84682, T80825, R08119, R00566, R00671, N46204, AA362528, AI696531, AI652607, AA342282, AW237396, AA593124, W03260, T77927, H90040, T97899, AA341243, AA748184, W60591, AI695823, AA502058, AI040466, AA768593, AI147277, AI674501, AA211074, AA453417, AA723863, AI673001, AW008534, AI590725, C00030, AI919118, AA476751, AA782496, AI360894, AI308970, AI356725, AI800701, AI281134, AI027052, AW162438, AI421854, AI521004, AA834980, AI885897, H93566, AA975309, AI339377, AW149528, AA227152, AI580862, AW162508, AW149834, N27209, AA199737, AA873471, AW000752, AI862036, AI061193, AI348286, AW073221, AI049653, T32729, N69257, AW117999, AI371126, AI190452, AA046621, AI816144, AA069829, H54017, AA223575, AA593953, AW134905, W48701, AA533599, AA815362, AI355030, AI807069, AI346194, AI272101, AW183008, AA587783, AA703690, AA134981, AW103418, AI589847, AA401916, AA652228, T70319, AA054221, AW195167, AI676031, AA001439, R67338, R67057, AA577283, T57926, AI434272, W51922, W51921, R83286, AI688408, AA205942, AA557254, AI189237, R80210, and U39400.
4	HRABV43	39	883826	AA740749, T77234, T85995, T79264, N84682, AA157576, and AA768593.
4	HRABV43	40	902457	AA844682, AA977690, AA864844, AA488673, AA815296, AI206056, AI801095, AI932302, AI742443, AA180508, AI833279, AI859081, AA157888, AA179837, AW192608, AA532678, AA479341, AA946767, AI982686, AA401011, AI831165, AI096855, AA187599, N69435, AI342048, AI745007, W22883, AA088238, R92180, AA804256, AI377067, AI143620, AA769339, H81204, AA620478, AA479449, H97641, AA973113, AA400972, AW075726, AA808322, AI082108, T79180, AA326358, AA856779, AA493191, H81203, AA907790, AA455438, AW204418, AA486056, AA969911, AI364159, AI475423, H43700, AW206126, R00938, AA720606, R92284, AI672889, AA157576, R70152, AI656432, H41249, AA984380, R86741, AW135686, AA088288, R02180, T98954, R71371, AI915388, R85065, T77448, T80896, T32391, R05703, T10419, AI383063, AA506839, AI290031, AI459837, AA894596, AI270644, T99869, AA974600, R05702, T90967,

				AA582695, AA312338, R87108, R08118, T98910, AA335307, AA187391, R08119, T80825, R00566, R00671, N46204, AA362528, AI696531, AI652607, AA342282, AW237396, AA593124, W03260, T77927, H90040, T97899, AA748184, AA341243, W60591, AI695823, AA502058, AI040466, AI147277, AI674501, AA211074, AA453417, AA723863, AI673001, AW008534, AI590725, C00030, AA476751, AA782496, AI360894, AI308970, AI356725, AI800701, AI281134, AI027052, AW162438, AI421854, AI521004, AI919118, AA834980, H93566, AI885897, AA975309, AI339377, AW149528, AI580862, AA227152, AW162508, AW149834, N27209, AA199737, AA873471, AW000752, AI862036, AI061193, AI348286, AW073221, AI049653, T32729, N69257, AW117999, AI371126, AI190452, AA046621, AI816144, AA069829, H54017, AA223575, AA593953, AW134905, W48701, AA533599, AA815362, AI355030, AI272101, AI346194, AW183008, AA587783, AA703690, AA134981, AI589847, AW103418, AA401916, AI807069, AA652228, T70319, AA054221, AW195167, AI676031, AA001439, R67338, W51922, W51921, R67057, AA577283, T57926, AI434272, R83286, AI688408, AA205942, AA557254, AI189237, R80210, and U39400.
5	HDPRH52	15	906430	AW297778, AA704347, AI693619, and AL133353.
5	HDPRH52	41	905416	AA316209, N35618, AA121285, AI394711, R19007, R44077, AI687282, and AL133353.
6	HDTEK44	16	1025421	AW263031, AI825947, AI674408, AI949058, AI686114, AW236450, AI131456, AI921750, AI499386, AI744116, H17702, AA968971, AI202380, AI612728, AW151821, AA612626, AI568798, AI678940, AI868979, and AW084407.
6	HDTEK44	42	890972	AW392275, H20592, AA658220, AI583172, AA888002, H20504, AW392670, AL119457, AL119497, AW363220, AW384394, U46351, AL119443, U46347, U46346, Z99396, AW372827, AL119319, U46349, AL119444, U46350, AL119324, AL119484, AL119363, AL119391, AL119335, AL042965, AL119355, U46341, AL119483, AL119341, AL119439, AL119396, AL119511, AL119522, AL119418, AL119464, AB026436, AR054110, A81671, AR069079, AR060234, and AR066494.
6	HDTEK44	43	904770	AW263031, AI825947, AI949058, AI686114, AI674408, AW236450, AI131456, AI921750, AI499386, AI744116, H17702, AW392275, AA968971, AI202380, H20592, AI612728, AW151821, AA612626, AA658220, AI583172, AA888002, AI568798, AI678940, AI868979, H20504, and AW084407.



6	HDTEK44	44	902431	AW263031, AI825947, AI949058, AI686114, AI674408, AW236450, AI131456, AI499386, AI921750, AI744116, H17702, AA968971, AI202380, AI612728, AW151821, AA612626, AI568798, AI678940, AI868979, and AW084407.
7	HOHBP82	17	906794	AI739417, N44813, and A91748.
7	HOHBP82	45	906796	A91748.
7	HOHBP82	46	906795	AI269759, W44508, M79074, AI218914, AA969620, W44507, AA905017, and A91748.
7	HOHBP82	47	902318	AA150056, W44507, AA152178, AA037745, AA039255, AA247807, AA247955, AI218914, AI269759, W44508, AA969620, and A91748.
8	HWBAD01	49	610491	R17760, AC004231, Z77249, AC005632, AC004000, AC005189, AC005755, AL022067, AC005041, AC007298, AC004832, Z93241, U95742, AC007216, AC002306, AC006057, AC007371, AC005752, Z95152, and AL031295.
9	HWABE12	19	815536	AA524063, AI751102, AA978352, AI800962, AI125904, AI148136, AW021017, AI817327, AI090472, AA864640, AA910568, AA129538, AI347257, AA994194, AA055492, AA055493, AI186179, T59947, AI127212, AW367523, T71365, AW276864, W78183, W58529, AI183851, T50338, AW367579, H17402, AA171811, T51546, AA194069, AA352426, AW376869, AW377057, AW377030, AW117263, AW377059, AA399164, AI541412, AW339825, AA411205, AA194185, AA452074, AA311049, T71528, AI420299, AW367570, AI770095, AI126814, and AI751103.
9	HWABE12	50	815537	AI420299, AI126814, AI185173, AI125904, AI800962, AI148136, W58417, AA994194, AA978352, T50338, AA055493, T51546, AI817327, AI090472, AA910568, AI186179, AI127212, T71365, W58529, AI347257, AI183851, AA524063, AA194069, AA864640, AI751102, AA352426, H17402, T59947, AA830076, AA451878, W72641, AA744611, AA855081, AW117263, AI081422, AA399164, AA224273, AW339825, AA411205, AA171696, AI123489, AW021017, AA744609, AA279075, AI160983, AA744606, W78183, AA677361, AA055492, AW276864, AA136501, AA745601, AI142596, AW193618, AI055938, AW367523, AA129538, W77930, AW367579, AW241440, AW241497, AA452074, AI699697, AI698785, AA860754, F04664, F03954, AA487085, AA364006, AA009855, AA364988, AA296614, T39853, AA366269, T39843, AC002040, AC002468, AC005873, Z93241, AC005828, AC000120, Z98884,

				AC004106, AC005350, and AC005479.
9	HWABE12	51	694670	W72641, AI126814, AI185173, W58417, AI420299, AA744611, AI081422, AA830076, AA855081, AA171696, AA451878, W77930, AA224273, AI123489, AA744609, AA677361, AI160983, AA744606, AA279075, AA136501, AA745601, AI142596, AI055938, AW193618, AW241440, AW241497, AI698785, AI699697, AA860754, N95156, AI653333, AI933953, AI201780, D19771, W70320, AA887563, AI368873, AA127570, AI982547, AA364006, AA856842, AC002352, AC002040, AC020663, AC005350, AF053356, AC004678, AC005231, AC005412, AC011311, U47924, AC004686, AC004893, AF030453, AC000120, AL096701, AC005088, AC004966, AC005399, AC005512, AC002468, AL031729, AL117344, AL008726, AP000313, Z98884, AL022336, AC007731, D87022, AC005500, AP000553, AP000226, AC005873, AP000087, AP000050, AF001550, AP000117, AC005057, AC002385, AC004106, AC004851, AC005952, AF196971, AP000194, AC005944, AP000555, AL035465, AP000691, and AC003684.
10	HHEPJ23	20	1043435	T50625, R09009, R20490, R45313, R45313, H18236, H20422, H41102, H46766, R87981, R88024, R88944, H50900, N30260, N41983, N74323, N91758, W05230, W05562, W23596, W24176, W31111, W67681, W67680, AA034395, AA034396, AA044434, AA044605, AA161369, AA593612, AA595237, AA602781, AA632450, AA576151, AA566019, AA744132, AA808389, AA864841, AA877754, AA948357, AA706278, AA844058, AA844324, AA994658, AI027455, AI051083, AI041576, AI083966, AI268158, AI345057, AI347726, AI363264, AI199583, AI199634, AI564878, AI419579, AI571744, AI424352, AI126459, AI191262, AI199798, AI208380, AI312683, AI332581, AI760697, AI798543, AI817558, AI830412, AI871292, AI970628, AW003596, AW006710, AW083202, AW191061, and AW470476.
10	HHEPJ23	52	879858	AI126459, AI815708, R47401, AW392670, AI138849, AL119443, AA463298, AW384394, AW363220, U46349, AL119341, AW372827, U46351, AL119497, AL119319, AL119457, AL119324, U46341, Z99396, AL119444, AL119396, AL119355, AL119484, AL119363, AL119391, AL119483, U46350, U46347, U46346, AL134902, AL119418, AL119335, AL119439, AL119522, AL134525, AL119496, AL119401, AL134518, AL119399, AL037205, U46345, AL134538, AL134536,

				AL042450, AL042614, AL042970, AL042965, AL042975, AL042544, AL043019, AL042984, AL042542, AL042995, AL043029, AL042551, AL043003, AL119464, AL119488, AB026436, AR054110, A81671, AR066494, AR060234, and AR069079.
11	HWBAR14	53	845408	AF109303 and AI911903.
11	HWBAR14	54	873239	AA364356.
11	HWBAR14	55	762339	AA631143, AI703348, AA579486, AI969820, AA640153, AA225106, AI587483, AA631024, AI468280, AI911903, AI696721, N95796, AA492342, AI472447, W24907, AA652651, AA552457, AA579735, AA570251, AA652452, AA579320, AI984307, AA579319, AI432644, AI623302, AI431307, AI431316, AI431238, AI432666, AI431328, AI432657, AI431318, AI431347, AI432661, AI432653, AI431231, AI431230, AI431257, AI432654, AI432655, AI431310, AI431312, AW081103, AI432650, AI432677, AI431350, AI431323, AI431354, AI791349, AL045494, AI431353, AI431235, AI431247, AI431321, AI431315, AI431246, AI492519, AI432643, AI432675, AI431337, AI432651, AI432647, AW129223, AI432674, AI431330, AI431308, AI431243, AL042729, AI431248, AI431314, AL042931, AI492510, AI432649, AI432672, AI432665, AI432659, Y17793, and AF019249.
12	HDPPN86	22	1037893	AI821271, AI313180, W22478, AI002815, AA680243, AL037632, AI076616, AW406162, AI732120, AA484962, AI110760, AI313166, AA381195, AI364780, AA722372, AL044000, AL041706, AL040921, AI817516, AI565581, AI284640, AI963600, AI608771, AL048626, AW440545, AI204304, AW317075, AA836811, AW088224, AA634072, AI350211, AW193265, AI133164, AL046409, AA491814, N94311, AI431303, AI963720, AW276817, AI613280, AA601355, AW080939, AA599480, AI924251, AA469451, F36273, AI289067, AL119691, AI061334, AL045053, AI471481, AI305766, AL138265, AI679294, AA205915, AI754955, AW265385, AW419262, AL046205, AW276827, AI345654, AW327868, AI334443, AW269488, AW276435, AI270117, AI085719, AI890348, AI281881, AW193432, AL138455, AI341664, AI110688, AI149478, AW245747, AI754658, AI375710, AA587604, AI688846, AW406755, AW438643, AA581903, AI619997, AW407578, AA682912, AW029038, AI053623, AI801600, AI610159, AW023672, AI307608, AA610491, AA491284, AW303196, AW274349, AI679871, AA613345, AW021583, AW103758, AI792287, AA652764, AI537506, AW301350,

				AI053672, AA526787, AL041690, AL037683, AI355206, AI281697, AI358571, AW407632, AW088202, AL042853, AW004911, AI110770, AW265170, AI379719, AA502104, AW102811, AI192631, AI761471, AW088846, AI799642, AI679782, AA743907, AI754253, AA649642, AW073470, AI805363, AI696962, AL118991, AI469172, AA713815, AW339568, AI344844, AI887483, AL044940, AI064864, AW162049, AA284179, AI590958, AI929531, AI469968, AA714453, AI262909, AI298710, AI801482, AI754336, AL048925, AA490183, AI339850, AI434695, AI471543, AI921476, AI254316, AA720702, AI962050, AI340453, AI017024, AA806796, AW148792, AW265009, AA938105, AW338086, AA631507, AW265393, C75026, AI590689, AA513141, AI635818, AI358229, AI357551, AI434706, AA394271, W79504, AI246796, AI951863, AW022379, AW410400, AI049634, AW408717, AA654771, AI457397, AI918421, AI567674, AI561060, AI561255, AI919265, AI866856, AI053790, AI888752, AI669453, AA669840, AI499938, AL137737, AC005280, AC004263, AC005484, AF088219, AC004134, AC005288, AC005911, U47924, AC004859, AL035587, AL022724, AP000359, AC005324, AC005257, AC003009, AC005011, AL049759, AE000658, AC005670, AC007204, AC006251, AL139054, AC004821, AC003006, AC004678, AL117351, AC000118, U85195, Z93023, AC006211, AF196779, AL049776, AL133448, AC004675, AC005771, AC005234, AC000075, AC005488, AC004997, AC004876, AC005844, AL023575, AP000553, AC004596, AL031597, AB023049, AL121658, AC006064, AC005664, AF001549, AL121603, AC007052, AC007011, U95742, AL035422, AC004686, AF196971, AL132642, AC004638, AC007227, AC005585, AC003007, AC002314, AC005632, AP000302, AL078477, AL022328, AC003070, AC007298, AC003085, AC005696, AC005839, AD000092, AC005682, AP000513, Z98200, AC005668, AL096791, AC002470, AC005755, Z99129, AL035683, AC006128, AC008039, AC004019, AC008079, AC005330, AL031255, U78027, AC003111, AC004975, AC005377, AC005520, AC005081, AP000474, AL034420, AC006487, AP000555, AC007666, AC006468, AC006480, AC005399, AC006132, AC006312, AL035450, AC006130, AL133500, U91326, AL021939, AL035458, AL109985, Z82901, AC002549, Z85986,
--	--	--	--	---

				AC004841, AC005231, AC005900, AC008101, AL020995, AP000114, AP000046, AF010238, AP000351, AL132992, AC005200, AC007207, AP000512, AC005071, AC005608, AP000298, Z95114, AL031073, AC005821, AL035659, AC006449, AC005778, D87009, AC006137, AC003957, AL136295, AJ003147, AC005562, AC007308, AL132987, AC004894, AL078593, AC006277, AR036572, U91328, AC002402, AL121653, AJ010598, AL024507, AJ010770, AC004257, AC009516, AC005971, AL035400, AC005808, AF095725, AC009247, AC007216, AF123462, AF039907, AC005701, AC005846, AL034582, AF002223, AC005695, AL023284, AL117344, Z99716, AC005747, AC000026, AL022400, AL031295, AC004858, U63721, AC002316, AC006285, AC005242, AP000049, AL121591, AL049643, AC005785, AC005261, AC000066, AC003982, AC007842, AL023879, AC004253, AC002477, AL133238, Z83820, AC006014, AC002542, AL035425, AP000090, AP000044, AC005412, AC005177, AL049829, AL049779, AC007919, AC002059, AC005740, AC002350, AP000311, AL022721, Z83826, AF111169, AL021578, AC006511, AC007536, AP000556, AC006538, AP000558, Z98051, AC004887, AC005041, AC004752, AC004797, AC007043, AC004690, AL033392, AC002395, AC005089, AC007785, AC007151, AC005531, AL009181, AC005913, AC004862, AC005996, AL021878, AC005304, AL008726, AC005754, AC007688, AL050332, L48038, AC004682, AL117352, AC006530, AC002468, AC005005, AC005250, AC005666, and AC004985.
12	HDPPN86	56	895711	AI313180, W22478, AI002815, AA484962, AA381195, AA634072, AA350454, AA332295, AA360806, AI033197, AI821271, AA663922, AA769467, and AL137737.
13	HDPIW06	23	1018873	T71144, T81645, AA812058, AA604645, AA302937, N38979, AI915081, AL043351, AA610588, AI524453, AI280535, AA557945, AI984168, AA309156, AW272815, AA579276, AA703818, AA761606, AA761714, AW020150, AI453155, AA659324, R93341, AL044489, AA479751, AA368616, AI097051, AA347232, AA904275, AI797998, AI754064, AI521525, AI697239, H94269, AW272606, AI697242, AA877992, AI926102, AA847504, AA608729, AA664163, AA523293, T05604, AA367672, AI267320, N54538, AI573009, AF134726, AL034417, AP000503, AC007386, AF129756, AJ133269, AF196779, AB029025, Z95116, AL022316,

				AL022098, AC005369, AP000010, AC005081, AL023807, Z83820, AP000152, AC002990, AP000555, AL049749, AC005224, Z95114, AP000356, AC002106, AC004963, AC005049, AP000353, AC005015, AC005696, AC006064, AC004383, AC004079, AC004983, AL008729, AC002544, M63796, AC016830, AC004491, AC007066, AC007151, AL023656, AC008018, AL022721, AC005088, AC006449, AJ003147, AF030453, AC004962, U91318, AC004593, Z99716, AL050318, AP000049, AC004816, AC007263, AC004584, AP000311, AC006482, AC004216, AC007226, AL031577, AC007685, AC016027, AC003108, AC002558, AC003682, AL023575, AL008718, AL021393, AL035667, AC004084, AF109907, AC005014, AB023048, AL049776, AC002301, AC007666, AC002549, AC002300, AF111168, AC004685, AL009181, AL022320, AC005280, Z84480, AL121658, AL034429, AF053356, AP000045, AL035413, AC005821, AL049553, AL035683, AC004510, AC007684, AL031666, AL133163, AP000696, AC003006, AC007371, AC000052, AC006071, AC007216, AC005562, AC007784, Z95326, AL049745, AC004678, AC007021, Z93242, AP000269, U91321, AC004056, AP000697, AC008101, AF111169, AL049835, AC002476, Z83732, AC007308, AC004408, AC003035, AC006285, AC006450, AC005243, AL009031, AC007546, AP000085, AC004129, AL033504, U91322, AP000103, AC004228, AL031120, Y14768, AC004671, AC004686, AC005519, AC007227, AL035072, Z82184, AL080243, AL109827, AL035091, Z93017, AC004821, AC005412, AL031311, AC006479, AL021154, AC003101, AL035071, AC005060, AC004975, AC005482, AP000067, AL030997, AC002553, U95742, AP000505, AC015853, Z95115, AC005996, AC006536, U80017, AL078463, AP000113, AC005332, AL031846, AC002425, AC007637, AC002394, AL117694, AF165926, AL133396, AL122023, AC005702, AB001523, AC005914, AC004099, AC004131, Z97054, AC007686, AL139054, AC007051, AL133246, AF047825, AC005358, AC005529, AL034371, U52112, AP000511, AL008723, Z83826, AL022396, AC007919, AC004019, AL022238, AC005722, AC004217, AC004832, AC000026, AL031230, AC004882, AC003684, AC005899, AC012384, AL049843, Z97876, AC004858, AC007436, AL133382,
--	--	--	--	---

				AC007917, AF196969, AC007172, D88268, AC006537, AC007707, AC002326, AC005102, AC002039, Z99943, AL049697, Z98036, AC005288, Z98941, AC007324, AC004854, AC006961, AP000068, U80460, AL109865, AC003982, AL050348, AC003071, AC002492, AC006211, AL008582, AF088219, AP000300, AL031602, AL031393, AC009263, AC008055, and AL008710.
13	HDPIW06	58	902388	AB029025.
13	HDPIW06	60	531470	T71144, AW182499, AA678404, AC005081, AL078638, AF030453, AC005088, AL022721, AC005488, AC005486, AC005482, AC005015, AC005339, AF053356, AL096791, Z98036, AC002120, AC006101, AC003078, AC007663, AC006549, AC007488, AC004985, U73634, AL035413, AC002132, AC002288, L78833, AL034429, AC003065, AF134726, AL031577, AC006312, AL122023, AC005033, AF121781, AL022320, AC002996, AL135745, AC006208, AC005183, AC004228, AC004130, AC004253, AL022336, AC000025, AF001548, AC005822, AC005527, AL031677, AC007993, AL009181, AC002477, AL021391, AC006544, AC008119, AL034554, AF129756, AC005531, AC005899, AC004453, AC004841, AC005529, AC004983, AC000026, AC002551, AC004129, AC002452, AC005011, AC003109, AB004907, AC007386, AL049776, AC003969, AL009183, and AC006487.
14	HWBCH13	63	815535	AI056866, W90205, W90079, Z80900, AC003964, AC006197, AL121877, AC003009, and AC007312.
15	HOHCJ90	25	890046	AW372170, AA604346, AW068358, AA738473, AA913567, AA665740, AI799350, AI382075, AI142471, AW071731, AI818200, N92765, AW054966, AI869237, AI690475, AW135129, AA846091, AA678907, AA233833, AA934769, AA233799, T18597, Z33559, AI557262, Z32887, D59751, AI535660, AI557864, AI525316, AI541205, AI525500, AI525556, AI541356, C14210, D59436, AI540903, AI526078, AI541365, AI535639, AI536138, AI557084, D50992, R29657, AI557533, AI557809, AI541034, AI557852, AI557731, AI557317, AI541075, AI557602, D59458, AA585325, AI557264, AI557155, D57491, AI525302, AI525856, AI541346, AI557082, AI557808, AI546829, R45895, AI541321, AI540974, C15406, AA585098, AI525852, C15069, AA585101, C14228, Z32822, AI536150, D53161, AI526169, AI557810, AI547196, D61185, AI557238, AI546971, R28892, AI526112,

				<p> DS1433, D54850, AI541517, Z28355,  AI525168, AI526016, AI526158, AI541353,  AI557718, R28967, AA585430, AA585439,  AI536070, D60765, D60844, AI557740,  D54897, AI557041, AI546831, AI541013,  R28735, R29445, AI557408, AI525656,  AI526140, AA585155, AI541450, AI541492,  AI526187, AI541336, AI557039, AI547250,  AJ239433, AI525568, AA585378, AI541535,  R28965, AI526205, AI541422, AA585329,  C16294, C16315, AI526024, AI547189,  AI526146, AI541383, AI557312, Z33585,  AA170832, AI526191, Z36724, AI557758,  AI557727, AI547137, AI546999, AI525114,  H65400, AA585356, AI546875, AI557279,  AI526109, AI540928, AI557763, AI557258,  D55233, AI525339, AI547039, AI541027,  AI557734, D30843, AI541307, AI541374,  AI541515, AI557807, D61254, D53447,  C16292, C15120, C15762, D52835, AI541510,  R28895, AI547140, AA585389, AI525757,  AI547202, AI525076, AI541362, D53472,  AI547158, C16300, AI557787, AI525653,  AI546945, AI525431, AI546891, AI525878,  AI526117, AI541402, AI546996, AI541423,  D78224, AI525320, AI547138, AI557241,  AI557543, AI557785, AI541516, AI524890,  AI526176, AI525661, AA585434, AI526026,  AA585453, AI546855, AJ239466, AI524891,  AI540967, AI524904, U87306, Z30183,  A62298, AR050070, A82595, A82593,  AF006072, U94592, Y09813, AR031358,  AR017826, AR031365, AR062871, A25909,  AR038855, X82834, A62300, AF213384,  X82786, U45328, AF135243, A85395,  A70872, A70869, A85476, AB005666,  AR037157, L36913, AJ131952, U87250, and  AR025466. </p>
15	HOHCJ90	64	862934	<p> AI760912, AI817827, AI144009, AA127855,  AI819433, AI815208, AI683865, AA127885,  AW197055, AW300678, AI344433,  AI765641, AI318050, AI471973, Z44946,  AA295252, F07655, AI370426, R72446,  N57522, AA897641, AI985778, R38024,  AA873508, AA426097, AA852480, H61346,  AA953288, C02345, Z40698, F05244, T78309,  D60961, AI250054, H62373, AA330282,  AA911800, AI249948, AI674798, AI141688,  AI962233, AI222384, N55399, F01499,  F03905, N47672, AW050435, and AL049370. </p>
16	HWBCM79	26	839427	<p> AL042756, AL133668, AW303196,  AW301350, AI345550, AL046746, AL045709,  AI445914, AW271904, AW274349,  AI364180, AI590458, AA457249, AL079734,  AI590499, AI272052, AA714690, F23327,  AA176917, AA664521, AW019964, F17700,  AL134330, AI061313, AA837715, AI521049, </p>



				AL042853, AA608520, AI635819, AA115725, AA665330, AI973173, AI285615, AI783911, AI084012, F26719, F31654, AI872227, AL120976, AA191418, AI753365, AA535937, AL048616, F29541, AW074060, AW075132, AL119838, AA077776, AL119405, AA744001, AA630517, AA879053, AW419389, AW193493, AA516207, AI561116, AI049986, AW090028, N85991, N83375, AA834821, AA745356, AW271917, AL050318, AF029308, U66061, U89335, AC009516, AC000353, AC007242, AC005696, AC002430, AC007993, AC007384, AC002070, AL022312, AC007358, AL034429, AC004032, AC003025, AC007011, AC008372, AC005231, AC005972, AC005358, AC007707, Z99716, AF139813, AL034420, AL109613, U91318, AC005105, AL031733, AC007486, AL031737, Z98949, AC007385, AL022721, AL049829, AC005678, AF061032, AC005920, AC003104, AC005081, AC004966, AC006449, AC002492, AL035398, AP000557, AC002425, AL020995, AC010202, AC006530, Z86090, AL050309, AC005015, AC004383, AC002115, AL031985, AL031228, AL035703, AC007225, AF196779, AF117829, AL049709, AC004984, AL031662, AC004828, AL034424, AC004687, AL109984, Z82194, AL031685, AC004913, AL023803, AL021154, AC002394, AC004003, AC004477, AC003957, AC007880, AC006111, AC005356, AC004552, AC006063, AC006013, AC004812, AC000111, AC005412, Z92545, AC004228, AC019014, AC002544, AL122020, AC002477, Z98941, U78027, AC005261, AC004230, AC006017, AC011625, AC002554, M89651, U91321, AC005355, AL021977, AF134726, AL022316, AC006112, AC005552, AC007686, AL133485, AC005781, AL122023, AC003663, AL035422, AL031782, AC007363, AL035072, AP000014, AL031729, AL096763, AL035251, AL049569, AC007151, AC006285, AC005829, AC005189, AL136295, AC007161, AC007263, Z83844, AC006241, AL080317, AC005224, AL132857, AL031734, AF111168, AC005146, AF001549, AC003015, AL022400, AL132712, AC006071, AF095901, AP000558, AP000345, Z99755, AC007298, AC002352, AC005703, AC002302, AC006509, AC004859, AF129756, AL049759, Z97876, AF111169, AL035458, AP000128, AP000206, AC006948, AC005191, AL035455, U91326, AC002553, AP000043, AP000518, AC005722, AF107885,
--	--	--	--	---

				AC006120, AL121825, AC002476, U95743, AF001550, AL031279, AC005753, AF047825, AC003982, AC004887, Z83840, AC005242, AC004955, U95739, AL109623, Z99916, AC003992, AC003692, AC002316, AC005014, AC006965, AC006116, AF181897, AC004526, AP000247, AC000039, AL033530, AL035681, AC004883, AL050312, AP000248, AL008635, AC007193, Z70289, AL031054, AC004814, AC006571, Z93020, AL034548, AL022327, AC016025, AP000208, AP000130, AC007649, AC002303, AL035683, AP000245, AC007096, AL031674, AC018769, AC007688, AC006023, Z98750, AC016831, AC005069, AC002289, AC005284, AC002558, AC005567, AL021328, AC004865, AC003969, U91319, Y14768, AC006059, AF053356, AL035086, AC009946, AC005070, AL049692, AC007073, AC005670, AC005921, AC002331, and AC004821.
17	HWBDM62	27	906779	AI284640, AW303196, AW301350, AL046409, AA680243, AI963720, AL138265, AW274349, AI270117, AI281881, AW265385, AA587604, AW419262, AI732120, AL044940, AI133164, AA526787, AI431303, AI754658, AI754955, AI761097, AW193265, AW276827, AL037683, AI350211, AI679782, AL138455, AI341548, AA490183, AI801591, AI298710, AW439558, AL042753, AI345654, AW088846, AL134972, AI110770, AL079645, AI473943, AI434695, AI471481, AI610159, AW021583, AW072587, AA126051, AA126035, AL120687, AI919265, AA587256, AW270270, AW162049, AI929531, AI564185, AW438643, AL119391, AI733755, AA977743, F36273, AI619997, AA584195, AL040921, AI567674, AA470969, R17793, AW304584, AW088202, AW073470, AI289067, AI368745, AL040130, AI345681, AI345675, AA713815, AL038785, AI718446, AA621858, AW338086, AL119691, AI962050, AI061334, AI732764, AW406755, AI312309, AI471487, AI379719, AI110760, AA469451, AA488746, AI339850, AI688846, AI148277, AA682912, AW167372, AW088616, AI192631, AI457397, AI537955, AI814735, AW407578, AI559705, AL048925, AA649642, AL044858, AW193432, AW302013, AI653886, AA074130, AI623898, AW103758, AI798473, AW340844, AA491814, AI859742, AA719292, AI365988, AI375710, AI340453, AW162489, AA584581, AW166815, AI358229, AA719805, AW406447, AI281697, AA523843, AA502155, AW157005, AA482711,

				AW327868, AI358343, AI568678, AI745325, AI254615, AA584201, AL135405, AI871722, AW148792, AA581903, AI291268, AI267818, AI291124, AI144055, AW274346, AI286356, AA179944, AA446657, AA178953, AA192740, W79504, AI570261, AW410400, AI064864, AI368256, AI499938, AI303008, AA483771, AI674873, N29941, AI355224, AI951889, AA758934, AA652764, AI287485, AL041412, AI499503, AI110688, AA657835, AI143242, AI587583, AW023672, AA579063, AA177061, C06303, AI028510, AI635274, AW339568, AI587565, AA521323, F29989, AA629992, AP000330, AP000125, AP000057, AP000172, Z98742, AC007043, AC009069, AC003692, AP000365, AP000501, U66059, AF001550, Z98749, AC005839, AL022163, AC007226, AC005632, AC004263, AF015156, AC005815, U18398, AL050341, AC005019, AL132992, U18399, U18391, AC006057, AC006292, AC002477, AC016025, AC016830, U18395, AL022721, L44140, AF015149, AL050320, X55926, AC005755, U18394, AC005245, X54181, I51997, AL031280, AL121603, AL049757, AL049869, AF029308, AL049829, AC002492, AC005393, X54180, AC007541, AC005694, AF196969, U63630, AF015151, AC002045, AC005018, AL031650, AC006128, U95742, AC004992, AC004987, AC005562, D83989, Z73965, AC004593, AD000092, AC009516, AC006285, AF077058, AC007382, AC005250, S43650, AC004982, Z49816, AC005939, AC002377, AP000244, AC007227, AL008710, AP000204, AP000126, AB003151, AC004033, AC004948, AC004765, AL031003, AC004797, AC007319, Z98046, Z81314, AL080242, AP000156, AC006960, AL031311, AC008372, AL078644, AC006501, AL049544, X54176, AC005387, AC002430, AC006251, AC006130, AC004993, AL031767, Z84487, AC006208, AC007384, AL034351, AC004650, AC006205, AC004814, AC005360, AL021808, AC004024, AF015147, AC004019, AL133355, U18387, AC003957, AL008735, AC005529, AL008718, AC008064, AP000014, AL049748, AC005324, AL096712, AC006277, AP000431, Y18000, AC003048, X60459, AC002565, AC007666, AC006045, AL023575, AP000044, AP000112, AL034384, AC004963, AC005251, AC005777, AC005912, Z97200, AC006017, AC008079, AC005666, U12584, AC004381, AC002310, Z86061, AC000052, Z75744, AL031283, AL022328, AC006050, AC005331, AC006048, AC000353, Z93930,
--	--	--	--	---

				AC005190, AC010077, AL035455, AL133485, AC004940, X54178, AL035451, AC005740, AC007216, AC007875, AL031319, D84394, AL132799, AL035681, AC003982, AC005154, U07563, AP000297, AL021453, AL133494, AL133399, AC004638, AF015148, AL035072, AL031709, AP000504, AC004890, AC008009, AL031281, AC005209, AC008101, AC005284, AL096776, AC004825, AL034343, X55927, X55925, AC003003, AC000114, X55923, AL035683, Y10196, AL031848, AL024498, AL008728, AF129756, AL031257, AC007676, U91323, AL022322, AP000338, AC005998, AC002984, AC007228, AC008173, AP000495, AL022400, X88791, AL031053, U67231, AC005156, AC006153, AC004686, AL034417, AL031054, D87675, X55924, AC006071, AC005914, AC006480, AL035422, AL133246, AC005859, AL033392, AP000216, U57006, AL049760, AC005089, AC005091, Z93241, AC006511, U57009, AC006213, AC004887, and AC005808.
17	HWBDM62	65	902316	AP000330, AP000125, AP000057, and AP000172.
17	HWBDM62	66	895690	AI761097, AP000172, AP000057, AP000125, and AP000330.
17	HWBDM62	67	734124	AI431347, AW081103, AW128900, AC002544, X99832, AC002425, and Y17793.
18	HWBCV72	28	882920	AC006518.
18	HWBCV72	68	905783	AW266498, AL037695, and AC006518.
18	HWBCV72	69	905767	Z33596, AI284640, AA610491, AI344844, AI200051, AA720702, AI471481, AA630030, AA771811, T07451, AA525824, AA670468, AA554319, AA494099, N62433, AA908422, AA813902, AI049940, N26685, AI801591, AA346454, AA348017, AW272925, H15679, R43331, AI669453, AC006518, D83989, X75335, AC005839, AF042090, AF077058, X55922, AC006539, AC003047, AC005887, AL031904, AL009181, AC006211, AF064863, AC006057, AC005531, AC007630, AC005736, AC006261, U67827, AP000567, AC005519, AC007227, AC004463, U95742, AC005516, AC005520, AC002379, AL023879, Z32774, AC007216, AC005785, AC005373, AC005082, AC006277, AL049776, AF196779, AP000088, AC003962, AC005081, AC005037, AL021546, AL133371, AC004966, AL031848, AC002091, AC006241, AC007043, AC002059, AC004534, AL034371, AL022326, M89651, AC004485, AC006312, AL109984, AC004019, AC012380, AC006600, AC006538, AP000114, AC008033, AL132712, AC005180, AC009330, AC002369, AL021939,

				AC004812, AP000303, AC005523, Z98304, AL031281, AL049869, AF165926, AC004990, U07000, AC002509, AP001137, AC005411, AC004884, AF045555, AC000052, AC006051, AC008079, AC005011, AC004184, AC004858, AL135744, AP000046, and AC003104.
18	HWBCV72	70	869177	AA206019, AA650210, AI018503, AI380539, AI223829, AI934781, AA311371, AA430231, AI978828, AI916761, AA654703, AW139620, W55873, AA659588, AI752482, AI093053, AW207120, AA659723, AW204025, H92450, AA654949, R05745, AW075995, AA644273, AI418805, AA627128, H92449, D61582, AA375163, AA994023, AI201537, AW293550, AA077918, AA102222, AA045668, AA010326, AA376452, AL135481, AA077049, AI739469, AI051657, AI870944, W56301, AI383697, AI383695, AA598926, AA317114, AA586345, AW058408, AA077082, AA102223, AI091799, AA045669, T51787, AW361959, AA214166, W27535, AW370222, AA209520, and D16938.
19	HMTAL77	29	855227	AW248271, AA351119, and AL137682.
19	HMTAL77	71	855226	AA351119, T75083, AA338164, AW248271, AA356283, AA829052, AA873659, AF114124, and AL137682.
20	HHEPG23	30	1034541	AA732566, AI432371, AI394417, AI313180, AI367073, AI821271, W22478, AI521279, AI025957, AA612859, AW062389, AA485239, AI002815, AW183741, AW081769, AA769467, AI868573, AI076616, AL037632, AA680243, AA722372, AI732120, AW406162, AL040921, AA484962, AI110760, AI313166, AI364780, AL041706, AL044000, AI817516, AI924251, AI284640, AI963600, AW407632, AA634072, AI565581, AI608771, AL048626, AA836811, AW440545, AW088224, AW245747, AI204304, AW317075, AI350211, AI305766, AI133164, AW193265, AL138265, AL046409, N94311, AW276817, AA491814, AL045053, AI431303, AI963720, AI334443, AA601355, AI613280, AI679294, AI110688, AW080939, AA599480, AL042853, AL044940, F36273, AA350454, AL119691, AA469451, AI289067, AA610491, AW303196, AA604333, AI061334, AA205915, AI754955, AA353281, AI471481, AL042420, AW301350, AW265385, AW419262, AW276827, AI679871, AI345654, AW327868, AW406755, AW269488, AW276435, AI270117, AI064864, AI085719, AI890348, AL046205, AI281881, AW193432, AL138455, AI341664, AA587604, AL044858, AI754658, AI375710, AI688846, AW029038,

				<p> AW438643, AI149478, AA581903, AI619997,  AW407578, AA682912, AW023672,  AI801600, AI792287, AA526787, AI307608,  AW265170, AA652764, AW102811,  AI471603, AA491284, AI888752, AW274349,  AA743907, AA613345, AW021583,  AA502104, AA665330, AI610159, AA468022,  AL037683, AA482711, AW088202,  AI110770, AI499503, AI537506, AW103758,  AI053672, AL041690, AA846935, AI355206,  AI799642, AI679782, AI281697, AI358571,  AW004911, AA284179, N24538, AI379719,  AA649642, AI192631, AA713815, AI761471,  AI887483, AW088846, AW248847,  AI249997, AA470969, AW162049, AI754253,  AI929531, AW073470, AI805363, AI305547,  AI696962, AI469172, AI754336, AW339568,  AI344844, AI339850, AI471543, AI962050,  AI590958, AI469968, AA714453, AL079645,  AI262909, AW304584, AW062724,  AI801482, AL048925, AA490183, AA938105,  AW265393, AI434695, AI921476, AI254316,  AA720702, AI340453, AI017024, AL137737,  AC005280, AC004263, AC005911,  AC005484, AC005288, AL035587, AF088219,  AC004134, U47924, AC004859, AP000359,  AL022724, AC005257, AE000658, AL117351,  AL139054, AC005324, AC005844,  AC005670, AC003009, AC000118,  AL049776, AC006211, AL023575,  AC005585, Z93023, U85195, AC004821,  AC005234, AL121603, AC007227,  AC005682, AC007204, AL035422,  AC005488, AC004997, AC006251,  AC005696, AP000553, AC004675, AF196779,  AC003007, AL031597, AC002314,  AC000075, AL121658, AC005632,  AC005839, AC006965, AF001549, AL133448,  Z99129, AP000513, AC004638, AC003085,  AC004854, AC004876, AL022721,  AB023049, AL034420, AC008101,  AL049759, AC004686, AL021939, U78027,  AC008079, AC002470, AP000302, Z98200,  AC005231, AC007216, AL132642,  AL132992, U95742, AL035450, AL022328,  AL078477, AD000092, AC006312,  AC005011, AC007011, AL080243,  AC004841, AC009247, AC004678,  AC006128, AC005664, AC007052,  AC005081, AC003006, AP000512, AF196971,  AC007207, AJ010598, Z82901, AC004257,  AC008039, AC003957, AP000351,  AC006449, AJ003147, AC006064, AC006137,  AC006480, AC006130, AC004894,  AC005377, AC005755, AC004019,  AL023284, Z85986, AL035458, AP000049,  AC004975, AL024507, AC005005, </p>
--	--	--	--	--

				AC005200, AC005520, AF010238, AC002402, AC005900, AL133500, AC003982, AL096791, AC009516, D87009, AP000555, AP000114, AP000046, AC002549, AL035683, U91326, AP000311, AC004858, AL035400, AC003070, Z98051, AL136295, AC006277, AL034582, AC005771, AL031255, AC002477, AL117344, AC005913, AL031650, AC007043, AC005747, AP000556, AL050332, AP000090, AC007785, AC006468, AC005089, AC000066, AL031073, AF123462, AC004690, Z97195, AC004253, AL050318, AC006001, AC007308, AJ010770, AC005177, AL035425, AC006111, AL049779, AC005041, AL109985, AC005399, AC007676, AC007298, AC005608, AC007666, AC005193, AC004985, AL008726, AL132987, AC004596, AC002301, AL121653, AL035659, AF111169, AC002120, AC006132, AC005778, AP000298, AC005330, AC007919, AC004862, AL008725, AP000158, Z95114, Z83826, AL023494, AC006017, AC005531, AC005071, AP000349, AC006285, AL021878, AF095725, AC007387, AC004797, AC005859, AC005291, U66059, AP000558, AC006511, AC006960, AL049845, AC008018, AC005668, L48038, AC006487, AC005695, AC007064, AC002468, AC005242, AL021578, AL022400, AL117352, AL050341, AC006538, AL022323, AF109907, AC002347, AC003111, AP000044, Z83820, AL109758, AC005218, AC004990, AC000026, AC007536, AC005019, AC005785, AL023879, AL020995, AL121591, AF039907, Z94056, AL009181, AC005996, AL031320, AL035398, Z99716, and AL133238.
20	HHEPG23	72	884590	AI821271.
20	HHEPG23	73	902169	AA732566, AI432371, AI394417, AI367073, AI521279, AI025957, AA612859, AW062389, AA485239, AW183741, AW081769, AA769467, AI868573, AA353281, N24538, AI313180, AW206261, AA484962, AA381195, AA829326, T29199, AA362689, AA362688, AA362690, AA360806, AI033197, AI002815, AL044652, AL137737, A49045, AF019049, I66487, A94048, A94061, AR035224, AR067734, I07209, I09252, I09251, I07249, AR068508, I09270, I09268, I09269, AR068510, AR068509, A63954, A49701, A29109, A32111, I66495, AR068550, A23373, AR068551, I66494, E01324, I08638, A94046, A94054, I09267, I58322, I58323, I66498, I66497, I66496, I66486, A27169, A27170, A39929, A83151, AR038307,

				AR038321, I91969, AR067731, AR067732, I12325, M68882, AR051537, AR051524, AR051528, AR051547, Y17793, and A42964.
21	HWBAR88	31	836469	AA334103, AI654920, AW418882, AI949038, AI093540, AA703125, AI076049, AI356640, AI359681, AI160128, AI422536, and AB020316.



Having generally described the invention, the same will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended as limiting.

5

### Examples

#### Example 1: Isolation of a Selected cDNA Clone From the Deposited Sample

Each cDNA clone in a cited ATCC deposit is contained in a plasmid vector.

10 Table 1 identifies the vectors used to construct the cDNA library from which each clone was isolated. In many cases, the vector used to construct the library is a phage vector from which a plasmid has been excised. The table immediately below correlates the related plasmid for each phage vector used in constructing the cDNA library. For example, where a particular clone is identified in Table 1 as being

15 isolated in the vector "Lambda Zap," the corresponding deposited clone is in "pBluescript."

	<u>Vector Used to Construct Library</u>	<u>Corresponding Deposited</u>
	<u>Plasmid</u>	
	Lambda Zap	pBluescript (pBS)
20	Uni-Zap XR	pBluescript (pBS)
	Zap Express	pBK
	lafmid BA	plafmid BA
	pSport1	pSport1
	pCMVSPORT 2.0	pCMVSPORT 2.0
25	pCMVSPORT 3.0	pCMVSPORT 3.0
	pCR <sup>®</sup> 2.1	pCR <sup>®</sup> 2.1

Vectors Lambda Zap (U.S. Patent Nos. 5,128,256 and 5,286,636), Uni-Zap XR (U.S. Patent Nos. 5,128, 256 and 5,286,636), Zap Express (U.S. Patent Nos. 5,128,256 and 5,286,636), pBluescript (pBS) (Short, J. M. et al., Nucleic Acids Res.

30 16:7583-7600 (1988); Alting-Mees, M. A. and Short, J. M., Nucleic Acids Res. 17:9494 (1989)) and pBK (Alting-Mees, M. A. et al., Strategies 5:58-61 (1992)) are commercially available from Stratagene Cloning Systems, Inc., 11011 N. Torrey

Pines Road, La Jolla, CA, 92037. pBS contains an ampicillin resistance gene and pBK contains a neomycin resistance gene. Both can be transformed into E. coli strain XL-1 Blue, also available from Stratagene. pBS comes in 4 forms SK+, SK-, KS+ and KS-. The S and K refers to the orientation of the polylinker to the T7 and T3 primer sequences which flank the polylinker region ("S" is for SacI and "K" is for KpnI which are the first sites on each respective end of the linker). "+" or "-" refer to the orientation of the fl origin of replication ("ori"), such that in one orientation, single stranded rescue initiated from the fl ori generates sense strand DNA and in the other, antisense.

10            Vectors pSport1, pCMVSPORT 2.0 and pCMVSPORT 3.0, were obtained from Life Technologies, Inc., P. O. Box 6009, Gaithersburg, MD 20897. All Sport vectors contain an ampicillin resistance gene and may be transformed into E. coli strain DH10B, also available from Life Technologies. (See, for instance, Gruber, C. E., et al., Focus 15:59 (1993).) Vector lafmid BA (Bento Soares, Columbia University, 15 NY) contains an ampicillin resistance gene and can be transformed into E. coli strain XL-1 Blue. Vector pCR<sup>®</sup>2.1, which is available from Invitrogen, 1600 Faraday Avenue, Carlsbad, CA 92008, contains an ampicillin resistance gene and may be transformed into E. coli strain DH10B, available from Life Technologies. (See, for instance, Clark, J. M., Nuc. Acids Res. 16:9677-9686 (1988) and Mead, D. et al., 20 Bio/Technology 9: (1991).) Preferably, a polynucleotide of the present invention does not comprise the phage vector sequences identified for the particular clone in Table 1, as well as the corresponding plasmid vector sequences designated above.

          The deposited material in the sample assigned the ATCC Deposit Number cited in Table 1 for any given cDNA clone also may contain one or more additional 25 plasmids, each comprising a cDNA clone different from that given clone. Thus, deposits sharing the same ATCC Deposit Number contain at least a plasmid for each cDNA clone identified in Table 1. Typically, each ATCC deposit sample cited in Table 1 comprises a mixture of approximately equal amounts (by weight) of about 50 plasmid DNAs, each containing a different cDNA clone; but such a deposit sample 30 may include plasmids for more or less than 50 cDNA clones, up to about 500 cDNA clones.

Two approaches can be used to isolate a particular clone from the deposited sample of plasmid DNAs cited for that clone in Table 1. First, a plasmid is directly isolated by screening the clones using a polynucleotide probe corresponding to SEQ ID NO:X.

- 5            Particularly, a specific polynucleotide with 30-40 nucleotides is synthesized using an Applied Biosystems DNA synthesizer according to the sequence reported. The oligonucleotide is labeled, for instance, with  $^{32}\text{P}$ - $\gamma$ -ATP using T4 polynucleotide kinase and purified according to routine methods. (E.g., Maniatis et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Press, Cold Spring, NY (1982).)
- 10        The plasmid mixture is transformed into a suitable host, as indicated above (such as XL-1 Blue (Stratagene)) using techniques known to those of skill in the art, such as those provided by the vector supplier or in related publications or patents cited above. The transformants are plated on 1.5% agar plates (containing the appropriate selection agent, e.g., ampicillin) to a density of about 150 transformants (colonies) per plate.
- 15        These plates are screened using Nylon membranes according to routine methods for bacterial colony screening (e.g., Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd Edit., (1989), Cold Spring Harbor Laboratory Press, pages 1.93 to 1.104), or other techniques known to those of skill in the art.

- Alternatively, two primers of 17-20 nucleotides derived from both ends of the
- 20        SEQ ID NO:X (i.e., within the region of SEQ ID NO:X bounded by the 5' NT and the 3' NT of the clone defined in Table 1) are synthesized and used to amplify the desired cDNA using the deposited cDNA plasmid as a template. The polymerase chain reaction is carried out under routine conditions, for instance, in 25  $\mu\text{l}$  of reaction mixture with 0.5  $\mu\text{g}$  of the above cDNA template. A convenient reaction mixture is
- 25        1.5-5 mM  $\text{MgCl}_2$ , 0.01% (w/v) gelatin, 20  $\mu\text{M}$  each of dATP, dCTP, dGTP, dTTP, 25 pmol of each primer and 0.25 Unit of Taq polymerase. Thirty five cycles of PCR (denaturation at 94 degree C for 1 min; annealing at 55 degree C for 1 min; elongation at 72 degree C for 1 min) are performed with a Perkin-Elmer Cetus automated thermal cycler. The amplified product is analyzed by agarose gel electrophoresis and
- 30        the DNA band with expected molecular weight is excised and purified. The PCR product is verified to be the selected sequence by subcloning and sequencing the DNA product.

Several methods are available for the identification of the 5' or 3' non-coding portions of a gene which may not be present in the deposited clone. These methods include but are not limited to, filter probing, clone enrichment using specific probes, and protocols similar or identical to 5' and 3' "RACE" protocols which are well known in the art. For instance, a method similar to 5' RACE is available for generating the missing 5' end of a desired full-length transcript. (Fromont-Racine et al., Nucleic Acids Res. 21(7):1683-1684 (1993).)

Briefly, a specific RNA oligonucleotide is ligated to the 5' ends of a population of RNA presumably containing full-length gene RNA transcripts. A primer set containing a primer specific to the ligated RNA oligonucleotide and a primer specific to a known sequence of the gene of interest is used to PCR amplify the 5' portion of the desired full-length gene. This amplified product may then be sequenced and used to generate the full length gene.

This above method starts with total RNA isolated from the desired source, although poly-A+ RNA can be used. The RNA preparation can then be treated with phosphatase if necessary to eliminate 5' phosphate groups on degraded or damaged RNA which may interfere with the later RNA ligase step. The phosphatase should then be inactivated and the RNA treated with tobacco acid pyrophosphatase in order to remove the cap structure present at the 5' ends of messenger RNAs. This reaction leaves a 5' phosphate group at the 5' end of the cap cleaved RNA which can then be ligated to an RNA oligonucleotide using T4 RNA ligase.

This modified RNA preparation is used as a template for first strand cDNA synthesis using a gene specific oligonucleotide. The first strand synthesis reaction is used as a template for PCR amplification of the desired 5' end using a primer specific to the ligated RNA oligonucleotide and a primer specific to the known sequence of the gene of interest. The resultant product is then sequenced and analyzed to confirm that the 5' end sequence belongs to the desired gene.

#### **Example 2: Isolation of Genomic Clones Corresponding to a Polynucleotide**

A human genomic P1 library (Genomic Systems, Inc.) is screened by PCR using primers selected for the cDNA sequence corresponding to SEQ ID NO:X., according to the method described in Example 1. (See also, Sambrook.)

**Example 3: Tissue Distribution of Polypeptide**

Tissue distribution of mRNA expression of polynucleotides of the present invention is determined using protocols for Northern blot analysis, described by, among others, Sambrook et al. For example, a cDNA probe produced by the method described in Example 1 is labeled with  $P^{32}$  using the rediprime™ DNA labeling system (Amersham Life Science), according to manufacturer's instructions. After labeling, the probe is purified using CHROMA SPIN-100™ column (Clontech Laboratories, Inc.), according to manufacturer's protocol number PT1200-1. The purified labeled probe is then used to examine various human tissues for mRNA expression.

Multiple Tissue Northern (MTN) blots containing various human tissues (H) or human immune system tissues (IM) (Clontech) are examined with the labeled probe using ExpressHyb™ hybridization solution (Clontech) according to manufacturer's protocol number PT1190-1. Following hybridization and washing, the blots are mounted and exposed to film at -70 degree C overnight, and the films developed according to standard procedures.

**Example 4: Chromosomal Mapping of the Polynucleotides**

An oligonucleotide primer set is designed according to the sequence at the 5' end of SEQ ID NO:X. This primer preferably spans about 100 nucleotides. This primer set is then used in a polymerase chain reaction under the following set of conditions : 30 seconds, 95 degree C; 1 minute, 56 degree C; 1 minute, 70 degree C. This cycle is repeated 32 times followed by one 5 minute cycle at 70 degree C. Human, mouse, and hamster DNA is used as template in addition to a somatic cell hybrid panel containing individual chromosomes or chromosome fragments (Bios, Inc). The reactions is analyzed on either 8% polyacrylamide gels or 3.5 % agarose gels. Chromosome mapping is determined by the presence of an approximately 100 bp PCR fragment in the particular somatic cell hybrid.

**Example 5: Bacterial Expression of a Polypeptide**

A polynucleotide encoding a polypeptide of the present invention is amplified using PCR oligonucleotide primers corresponding to the 5' and 3' ends of the DNA sequence, as outlined in Example 1, to synthesize insertion fragments. The primers used to amplify the cDNA insert should preferably contain restriction sites, such as BamHI and XbaI, at the 5' end of the primers in order to clone the amplified product into the expression vector. For example, BamHI and XbaI correspond to the restriction enzyme sites on the bacterial expression vector pQE-9. (Qiagen, Inc., Chatsworth, CA). This plasmid vector encodes antibiotic resistance (Amp<sup>r</sup>), a bacterial origin of replication (ori), an IPTG-regulatable promoter/operator (P/O), a ribosome binding site (RBS), a 6-histidine tag (6-His), and restriction enzyme cloning sites.

The pQE-9 vector is digested with BamHI and XbaI and the amplified fragment is ligated into the pQE-9 vector maintaining the reading frame initiated at the bacterial RBS. The ligation mixture is then used to transform the E. coli strain M15/rep4 (Qiagen, Inc.) which contains multiple copies of the plasmid pREP4, which expresses the lacI repressor and also confers kanamycin resistance (Kan<sup>r</sup>). Transformants are identified by their ability to grow on LB plates and ampicillin/kanamycin resistant colonies are selected. Plasmid DNA is isolated and confirmed by restriction analysis.

Clones containing the desired constructs are grown overnight (O/N) in liquid culture in LB media supplemented with both Amp (100 ug/ml) and Kan (25 ug/ml). The O/N culture is used to inoculate a large culture at a ratio of 1:100 to 1:250. The cells are grown to an optical density 600 (O.D.<sup>600</sup>) of between 0.4 and 0.6. IPTG (Isopropyl-B-D-thiogalacto pyranoside) is then added to a final concentration of 1 mM. IPTG induces by inactivating the lacI repressor, clearing the P/O leading to increased gene expression.

Cells are grown for an extra 3 to 4 hours. Cells are then harvested by centrifugation (20 mins at 6000Xg). The cell pellet is solubilized in the chaotropic agent 6 Molar Guanidine HCl by stirring for 3-4 hours at 4 degree C. The cell debris is removed by centrifugation, and the supernatant containing the polypeptide is loaded onto a nickel-nitrilo-tri-acetic acid ("Ni-NTA") affinity resin column (available from QIAGEN, Inc., *supra*). Proteins with a 6 x His tag bind to the Ni-NTA resin with

high affinity and can be purified in a simple one-step procedure (for details see: The QIAexpressionist (1995) QIAGEN, Inc., *supra*).

Briefly, the supernatant is loaded onto the column in 6 M guanidine-HCl, pH 8, the column is first washed with 10 volumes of 6 M guanidine-HCl, pH 8, then  
5 washed with 10 volumes of 6 M guanidine-HCl pH 6, and finally the polypeptide is eluted with 6 M guanidine-HCl, pH 5.

The purified protein is then renatured by dialyzing it against phosphate-buffered saline (PBS) or 50 mM Na-acetate, pH 6 buffer plus 200 mM NaCl. Alternatively, the protein can be successfully refolded while immobilized on the Ni-  
10 NTA column. The recommended conditions are as follows: renature using a linear 6M-1M urea gradient in 500 mM NaCl, 20% glycerol, 20 mM Tris/HCl pH 7.4, containing protease inhibitors. The renaturation should be performed over a period of 1.5 hours or more. After renaturation the proteins are eluted by the addition of 250 mM imidazole. Imidazole is removed by a final dialyzing step against PBS or 50  
15 mM sodium acetate pH 6 buffer plus 200 mM NaCl. The purified protein is stored at 4 degree C or frozen at -80 degree C.

In addition to the above expression vector, the present invention further includes an expression vector comprising phage operator and promoter elements operatively linked to a polynucleotide of the present invention, called pHE4a. (ATCC  
20 Accession Number 209645, deposited on February 25, 1998.) This vector contains: 1) a neomycinphosphotransferase gene as a selection marker, 2) an E. coli origin of replication, 3) a T5 phage promoter sequence, 4) two lac operator sequences, 5) a Shine-Delgarno sequence, and 6) the lactose operon repressor gene (lacIq). The origin of replication (oriC) is derived from pUC19 (LTI, Gaithersburg, MD). The  
25 promoter sequence and operator sequences are made synthetically.

DNA can be inserted into the pHEa by restricting the vector with NdeI and XbaI, BamHI, XhoI, or Asp718, running the restricted product on a gel, and isolating the larger fragment (the stuffer fragment should be about 310 base pairs). The DNA insert is generated according to the PCR protocol described in Example 1, using PCR  
30 primers having restriction sites for NdeI (5' primer) and XbaI, BamHI, XhoI, or Asp718 (3' primer). The PCR insert is gel purified and restricted with compatible enzymes. The insert and vector are ligated according to standard protocols.

The engineered vector could easily be substituted in the above protocol to express protein in a bacterial system.

**Example 6: Purification of a Polypeptide from an Inclusion Body**

5       The following alternative method can be used to purify a polypeptide expressed in *E. coli* when it is present in the form of inclusion bodies. Unless otherwise specified, all of the following steps are conducted at 4-10 degree C.

      Upon completion of the production phase of the *E. coli* fermentation, the cell culture is cooled to 4-10 degree C and the cells harvested by continuous  
10   centrifugation at 15,000 rpm (Heraeus Sepatech). On the basis of the expected yield of protein per unit weight of cell paste and the amount of purified protein required, an appropriate amount of cell paste, by weight, is suspended in a buffer solution containing 100 mM Tris, 50 mM EDTA, pH 7.4. The cells are dispersed to a homogeneous suspension using a high shear mixer.

15       The cells are then lysed by passing the solution through a microfluidizer (Microfluidics, Corp. or APV Gaulin, Inc.) twice at 4000-6000 psi. The homogenate is then mixed with NaCl solution to a final concentration of 0.5 M NaCl, followed by centrifugation at 7000 xg for 15 min. The resultant pellet is washed again using 0.5M NaCl, 100 mM Tris, 50 mM EDTA, pH 7.4.

20       The resulting washed inclusion bodies are solubilized with 1.5 M guanidine hydrochloride (GuHCl) for 2-4 hours. After 7000 xg centrifugation for 15 min., the pellet is discarded and the polypeptide containing supernatant is incubated at 4 degree C overnight to allow further GuHCl extraction.

      Following high speed centrifugation (30,000 xg) to remove insoluble particles,  
25   the GuHCl solubilized protein is refolded by quickly mixing the GuHCl extract with 20 volumes of buffer containing 50 mM sodium, pH 4.5, 150 mM NaCl, 2 mM EDTA by vigorous stirring. The refolded diluted protein solution is kept at 4 degree C without mixing for 12 hours prior to further purification steps.

      To clarify the refolded polypeptide solution, a previously prepared tangential  
30   filtration unit equipped with 0.16 um membrane filter with appropriate surface area (e.g., Filtron), equilibrated with 40 mM sodium acetate, pH 6.0 is employed. The filtered sample is loaded onto a cation exchange resin (e.g., Poros HS-50, Perseptive



Biosystems). The column is washed with 40 mM sodium acetate, pH 6.0 and eluted with 250 mM, 500 mM, 1000 mM, and 1500 mM NaCl in the same buffer, in a stepwise manner. The absorbance at 280 nm of the effluent is continuously monitored. Fractions are collected and further analyzed by SDS-PAGE.

5 Fractions containing the polypeptide are then pooled and mixed with 4 volumes of water. The diluted sample is then loaded onto a previously prepared set of tandem columns of strong anion (Poros HQ-50, Perseptive Biosystems) and weak anion (Poros CM-20, Perseptive Biosystems) exchange resins. The columns are equilibrated with 40 mM sodium acetate, pH 6.0. Both columns are washed with 40  
10 mM sodium acetate, pH 6.0, 200 mM NaCl. The CM-20 column is then eluted using a 10 column volume linear gradient ranging from 0.2 M NaCl, 50 mM sodium acetate, pH 6.0 to 1.0 M NaCl, 50 mM sodium acetate, pH 6.5. Fractions are collected under constant  $A_{280}$  monitoring of the effluent. Fractions containing the polypeptide (determined, for instance, by 16% SDS-PAGE) are then pooled.

15 The resultant polypeptide should exhibit greater than 95% purity after the above refolding and purification steps. No major contaminant bands should be observed from Commassie blue stained 16% SDS-PAGE gel when 5 ug of purified protein is loaded. The purified protein can also be tested for endotoxin/LPS contamination, and typically the LPS content is less than 0.1 ng/ml according to LAL  
20 assays.

#### **Example 7: Cloning and Expression of a Polypeptide in a Baculovirus Expression System**

In this example, the plasmid shuttle vector pA2 is used to insert a  
25 polynucleotide into a baculovirus to express a polypeptide. This expression vector contains the strong polyhedrin promoter of the *Autographa californica* nuclear polyhedrosis virus (AcMNPV) followed by convenient restriction sites such as BamHI, Xba I and Asp718. The polyadenylation site of the simian virus 40 ("SV40") is used for efficient polyadenylation. For easy selection of recombinant virus, the  
30 plasmid contains the beta-galactosidase gene from *E. coli* under control of a weak *Drosophila* promoter in the same orientation, followed by the polyadenylation signal of the polyhedrin gene. The inserted genes are flanked on both sides by viral

sequences for cell-mediated homologous recombination with wild-type viral DNA to generate a viable virus that express the cloned polynucleotide.

Many other baculovirus vectors can be used in place of the vector above, such as pAc373, pVL941, and pAcIM1, as one skilled in the art would readily appreciate, as long as the construct provides appropriately located signals for transcription, translation, secretion and the like, including a signal peptide and an in-frame AUG as required. Such vectors are described, for instance, in Luckow et al., *Virology* 170:31-39 (1989).

Specifically, the cDNA sequence contained in the deposited clone, including the AUG initiation codon and the naturally associated leader sequence identified in Table 1, is amplified using the PCR protocol described in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the pA2 vector does not need a second signal peptide. Alternatively, the vector can be modified (pA2 GP) to include a baculovirus leader sequence, using the standard methods described in Summers et al., "A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures," Texas Agricultural Experimental Station Bulletin No. 1555 (1987).

The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("GeneClean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

The plasmid is digested with the corresponding restriction enzymes and optionally, can be dephosphorylated using calf intestinal phosphatase, using routine procedures known in the art. The DNA is then isolated from a 1% agarose gel using a commercially available kit ("GeneClean" BIO 101 Inc., La Jolla, Ca.).

The fragment and the dephosphorylated plasmid are ligated together with T4 DNA ligase. *E. coli* HB101 or other suitable *E. coli* hosts such as XL-1 Blue (Stratagene Cloning Systems, La Jolla, CA) cells are transformed with the ligation mixture and spread on culture plates. Bacteria containing the plasmid are identified by digesting DNA from individual colonies and analyzing the digestion product by gel electrophoresis. The sequence of the cloned fragment is confirmed by DNA sequencing.

Five ug of a plasmid containing the polynucleotide is co-transfected with 1.0 ug of a commercially available linearized baculovirus DNA ("BaculoGold™ baculovirus DNA", Pharmingen, San Diego, CA), using the lipofection method described by Felgner et al., Proc. Natl. Acad. Sci. USA 84:7413-7417 (1987). One ug  
5 of BaculoGold™ virus DNA and 5 ug of the plasmid are mixed in a sterile well of a microtiter plate containing 50 ul of serum-free Grace's medium (Life Technologies Inc., Gaithersburg, MD). Afterwards, 10 ul Lipofectin plus 90 ul Grace's medium are added, mixed and incubated for 15 minutes at room temperature. Then the transfection mixture is added drop-wise to Sf9 insect cells (ATCC CRL 1711) seeded  
10 in a 35 mm tissue culture plate with 1 ml Grace's medium without serum. The plate is then incubated for 5 hours at 27 degrees C. The transfection solution is then removed from the plate and 1 ml of Grace's insect medium supplemented with 10% fetal calf serum is added. Cultivation is then continued at 27 degrees C for four days.

After four days the supernatant is collected and a plaque assay is performed,  
15 as described by Summers and Smith, *supra*. An agarose gel with "Blue Gal" (Life Technologies Inc., Gaithersburg) is used to allow easy identification and isolation of gal-expressing clones, which produce blue-stained plaques. (A detailed description of a "plaque assay" of this type can also be found in the user's guide for insect cell culture and baculovirology distributed by Life Technologies Inc., Gaithersburg, page  
20 9-10.) After appropriate incubation, blue stained plaques are picked with the tip of a micropipettor (e.g., Eppendorf). The agar containing the recombinant viruses is then resuspended in a microcentrifuge tube containing 200 ul of Grace's medium and the suspension containing the recombinant baculovirus is used to infect Sf9 cells seeded in 35 mm dishes. Four days later the supernatants of these culture dishes are  
25 harvested and then they are stored at 4 degree C.

To verify the expression of the polypeptide, Sf9 cells are grown in Grace's medium supplemented with 10% heat-inactivated FBS. The cells are infected with the recombinant baculovirus containing the polynucleotide at a multiplicity of infection ("MOI") of about 2. If radiolabeled proteins are desired, 6 hours later the  
30 medium is removed and is replaced with SF900 II medium minus methionine and cysteine (available from Life Technologies Inc., Rockville, MD). After 42 hours, 5 uCi of <sup>35</sup>S-methionine and 5 uCi <sup>35</sup>S-cysteine (available from Amersham) are added.

The cells are further incubated for 16 hours and then are harvested by centrifugation. The proteins in the supernatant as well as the intracellular proteins are analyzed by SDS-PAGE followed by autoradiography (if radiolabeled).

Microsequencing of the amino acid sequence of the amino terminus of  
5 purified protein may be used to determine the amino terminal sequence of the produced protein.

#### **Example 8: Expression of a Polypeptide in Mammalian Cells**

The polypeptide of the present invention can be expressed in a mammalian cell. A typical mammalian expression vector contains a promoter element, which  
10 mediates the initiation of transcription of mRNA, a protein coding sequence, and signals required for the termination of transcription and polyadenylation of the transcript. Additional elements include enhancers, Kozak sequences and intervening sequences flanked by donor and acceptor sites for RNA splicing. Highly efficient transcription is achieved with the early and late promoters from SV40, the long  
15 terminal repeats (LTRs) from Retroviruses, e.g., RSV, HTLVI, HIVI and the early promoter of the cytomegalovirus (CMV). However, cellular elements can also be used (e.g., the human actin promoter).

Suitable expression vectors for use in practicing the present invention include, for example, vectors such as pSVL and pMSG (Pharmacia, Uppsala, Sweden),  
20 pRSVcat (ATCC 37152), pSV2dhfr (ATCC 37146), pBC12MI (ATCC 67109), pCMVSPORT 2.0, and pCMVSPORT 3.0. Mammalian host cells that could be used include, human Hela, 293, H9 and Jurkat cells, mouse NIH3T3 and C127 cells, Cos 1, Cos 7 and CV1, quail QC1-3 cells, mouse L cells and Chinese hamster ovary (CHO) cells.

25 Alternatively, the polypeptide can be expressed in stable cell lines containing the polynucleotide integrated into a chromosome. The co-transfection with a selectable marker such as dhfr, gpt, neomycin, hygromycin allows the identification and isolation of the transfected cells.

The transfected gene can also be amplified to express large amounts of the  
30 encoded protein. The DHFR (dihydrofolate reductase) marker is useful in developing cell lines that carry several hundred or even several thousand copies of the gene of

interest. (See, e.g., Alt, F. W., et al., J. Biol. Chem. 253:1357-1370 (1978); Hamlin, J. L. and Ma, C., Biochem. et Biophys. Acta, 1097:107-143 (1990); Page, M. J. and Sydenham, M. A., Biotechnology 9:64-68 (1991).) Another useful selection marker is the enzyme glutamine synthase (GS) (Murphy et al., Biochem J. 227:277-279 (1991); Bebbington et al., Bio/Technology 10:169-175 (1992). Using these markers, the mammalian cells are grown in selective medium and the cells with the highest resistance are selected. These cell lines contain the amplified gene(s) integrated into a chromosome. Chinese hamster ovary (CHO) and NSO cells are often used for the production of proteins.

Derivatives of the plasmid pSV2-dhfr (ATCC Accession No. 37146), the expression vectors pC4 (ATCC Accession No. 209646) and pC6 (ATCC Accession No.209647) contain the strong promoter (LTR) of the Rous Sarcoma Virus (Cullen et al., Molecular and Cellular Biology, 438-447 (March, 1985)) plus a fragment of the CMV-enhancer (Boshart et al., Cell 41:521-530 (1985).) Multiple cloning sites, e.g., with the restriction enzyme cleavage sites BamHI, XbaI and Asp718, facilitate the cloning of the gene of interest. The vectors also contain the 3' intron, the polyadenylation and termination signal of the rat preproinsulin gene, and the mouse DHFR gene under control of the SV40 early promoter.

Specifically, the plasmid pC6, for example, is digested with appropriate restriction enzymes and then dephosphorylated using calf intestinal phosphates by procedures known in the art. The vector is then isolated from a 1% agarose gel.

A polynucleotide of the present invention is amplified according to the protocol outlined in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the vector does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("GeneClean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

The amplified fragment is then digested with the same restriction enzyme and purified on a 1% agarose gel. The isolated fragment and the dephosphorylated vector

are then ligated with T4 DNA ligase. *E. coli* HB101 or XL-1 Blue cells are then transformed and bacteria are identified that contain the fragment inserted into plasmid pC6 using, for instance, restriction enzyme analysis.

Chinese hamster ovary cells lacking an active DHFR gene is used for transfection. Five  $\mu$ g of the expression plasmid pC6 a pC4 is cotransfected with 0.5  $\mu$ g of the plasmid pSVneo using lipofectin (Felgner et al., *supra*). The plasmid pSV2-neo contains a dominant selectable marker, the *neo* gene from Tn5 encoding an enzyme that confers resistance to a group of antibiotics including G418. The cells are seeded in alpha minus MEM supplemented with 1 mg/ml G418. After 2 days, the cells are trypsinized and seeded in hybridoma cloning plates (Greiner, Germany) in alpha minus MEM supplemented with 10, 25, or 50 ng/ml of methotrexate plus 1 mg/ml G418. After about 10-14 days single clones are trypsinized and then seeded in 6-well petri dishes or 10 ml flasks using different concentrations of methotrexate (50 nM, 100 nM, 200 nM, 400 nM, 800 nM). Clones growing at the highest concentrations of methotrexate are then transferred to new 6-well plates containing even higher concentrations of methotrexate (1  $\mu$ M, 2  $\mu$ M, 5  $\mu$ M, 10 mM, 20 mM). The same procedure is repeated until clones are obtained which grow at a concentration of 100 - 200  $\mu$ M. Expression of the desired gene product is analyzed, for instance, by SDS-PAGE and Western blot or by reversed phase HPLC analysis.

20

#### **Example 9: Protein Fusions**

The polypeptides of the present invention are preferably fused to other proteins. These fusion proteins can be used for a variety of applications. For example, fusion of the present polypeptides to His-tag, HA-tag, protein A, IgG domains, and maltose binding protein facilitates purification. (See Example 5; see also EP A 394,827; Traunecker, et al., Nature 331:84-86 (1988).) Similarly, fusion to IgG-1, IgG-3, and albumin increases the halflife time in vivo. Nuclear localization signals fused to the polypeptides of the present invention can target the protein to a specific subcellular localization, while covalent heterodimer or homodimers can increase or decrease the activity of a fusion protein. Fusion proteins can also create chimeric molecules having more than one function. Finally, fusion proteins can increase solubility and/or stability of the fused protein compared to the non-fused

30

protein. All of the types of fusion proteins described above can be made by modifying the following protocol, which outlines the fusion of a polypeptide to an IgG molecule, or the protocol described in Example 5.

Briefly, the human Fc portion of the IgG molecule can be PCR amplified, using primers that span the 5' and 3' ends of the sequence described below. These primers also should have convenient restriction enzyme sites that will facilitate cloning into an expression vector, preferably a mammalian expression vector.

For example, if pC4 (Accession No. 209646) is used, the human Fc portion can be ligated into the BamHI cloning site. Note that the 3' BamHI site should be destroyed. Next, the vector containing the human Fc portion is re-restricted with BamHI, linearizing the vector, and a polynucleotide of the present invention, isolated by the PCR protocol described in Example 1, is ligated into this BamHI site. Note that the polynucleotide is cloned without a stop codon, otherwise a fusion protein will not be produced.

If the naturally occurring signal sequence is used to produce the secreted protein, pC4 does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

Human IgG Fc region:

```
GGGATCCGGAGCCCAAATCTTCTGACAAACTCACACATGCCCACCGTGC
CCAGCACCTGAATTCGAGGGTGCACCGTCAGTCTTCCTCTTCCCCCAAAA
CCCAAGGACACCCTCATGATCTCCCGGACTCCTGAGGTCACATGCGTGGT
GGTGGACGTAAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGG
ACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTA
CAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACT
GGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCA
ACCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAAC
CACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAG
GTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCAAGCGACATCGCCGT
GGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACACTACAAGACCACGCCT
CCCGTGCTGGACTCCGACGGCTCCTTCTTCTCTACAGCAAGCTCACCGTG
```

GACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCA  
TGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGG  
GTAAATGAGTGCGACGGCCGCGACTCTAGAGGAT (SEQ ID NO:1)

5 **Example 10: Production of an Antibody from a Polypeptide**

The antibodies of the present invention can be prepared by a variety of methods. (See, Current Protocols, Chapter 2.) As one example of such methods, cells expressing a polypeptide of the present invention is administered to an animal to induce the production of sera containing polyclonal antibodies. In a preferred method, a preparation of the secreted protein is prepared and purified to render it substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity.

In the most preferred method, the antibodies of the present invention are monoclonal antibodies (or protein binding fragments thereof). Such monoclonal antibodies can be prepared using hybridoma technology. (Köhler et al., Nature 256:495 (1975); Köhler et al., Eur. J. Immunol. 6:511 (1976); Köhler et al., Eur. J. Immunol. 6:292 (1976); Hammerling et al., in: Monoclonal Antibodies and T-Cell Hybridomas, Elsevier, N.Y., pp. 563-681 (1981).) In general, such procedures involve immunizing an animal (preferably a mouse) with polypeptide or, more preferably, with a secreted polypeptide-expressing cell. Such cells may be cultured in any suitable tissue culture medium; however, it is preferable to culture cells in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56 degrees C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100 ug/ml of streptomycin.

25 The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands et al. (Gastroenterology 80:225-232 (1981).) The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the polypeptide.



Alternatively, additional antibodies capable of binding to the polypeptide can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the protein-specific antibody can be blocked by the polypeptide. Such antibodies comprise anti-idiotypic antibodies to the protein-specific antibody and can be used to immunize an animal to induce formation of further protein-specific antibodies.

It will be appreciated that Fab and F(ab')<sub>2</sub> and other fragments of the antibodies of the present invention may be used according to the methods disclosed herein. Such fragments are typically produced by proteolytic cleavage, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')<sub>2</sub> fragments). Alternatively, secreted protein-binding fragments can be produced through the application of recombinant DNA technology or through synthetic chemistry.

For in vivo use of antibodies in humans, it may be preferable to use "humanized" chimeric monoclonal antibodies. Such antibodies can be produced using genetic constructs derived from hybridoma cells producing the monoclonal antibodies described above. Methods for producing chimeric antibodies are known in the art. (See, for review, Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Cabilly et al., U.S. Patent No. 4,816,567; Taniguchi et al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson et al., WO 8702671; Boulianne et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268 (1985).)

### **Example 11: Production Of Secreted Protein For High-Throughput Screening**

#### **Assays**

The following protocol produces a supernatant containing a polypeptide to be tested. This supernatant can then be used in the Screening Assays described herein.

First, dilute Poly-D-Lysine (644 587 Boehringer-Mannheim) stock solution (1mg/ml in PBS) 1:20 in PBS (w/o calcium or magnesium 17-516F Biowhittaker) for a working solution of 50ug/ml. Add 200 ul of this solution to each well (24 well plates) and incubate at RT for 20 minutes. Be sure to distribute the solution over each well (note: a 12-channel pipetter may be used with tips on every other channel). Aspirate off the Poly-D-Lysine solution and rinse with 1ml PBS (Phosphate Buffered Saline). The PBS should remain in the well until just prior to plating the cells and plates may be poly-lysine coated in advance for up to two weeks.

Plate 293T cells (do not carry cells past P+20) at  $2 \times 10^5$  cells/well in .5ml DMEM(Dulbecco's Modified Eagle Medium)(with 4.5 G/L glucose and L-glutamine (12-604F Biowhittaker))/10% heat inactivated FBS(14-503F Biowhittaker)/1x Penstrep(17-602E Biowhittaker). Let the cells grow overnight.

The next day, mix together in a sterile solution basin: 300 ul Lipofectamine (18324-012 Gibco/BRL) and 5ml Optimem I (31985070 Gibco/BRL)/96-well plate. With a small volume multi-channel pipetter, aliquot approximately 2ug of an expression vector containing a polynucleotide insert, produced by the methods described in Examples 8 or 9, into an appropriately labeled 96-well round bottom plate. With a multi-channel pipetter, add 50ul of the Lipofectamine/Optimem I mixture to each well. Pipette up and down gently to mix. Incubate at RT 15-45 minutes. After about 20 minutes, use a multi-channel pipetter to add 150ul Optimem I to each well. As a control, one plate of vector DNA lacking an insert should be transfected with each set of transfections.

Preferably, the transfection should be performed by tag-teaming the following tasks. By tag-teaming, hands on time is cut in half, and the cells do not spend too much time on PBS. First, person A aspirates off the media from four 24-well plates of cells, and then person B rinses each well with .5-1ml PBS. Person A then aspirates off PBS rinse, and person B, using a 12-channel pipetter with tips on every other channel, adds the 200ul of DNA/Lipofectamine/Optimem I complex to the odd wells first, then to the even wells, to each row on the 24-well plates. Incubate at 37 degrees C for 6 hours.

While cells are incubating, prepare appropriate media, either 1%BSA in DMEM with 1x penstrep, or CHO-5 media (116.6 mg/L of CaCl<sub>2</sub> (anhyd); 0.00130

mg/L  $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ ; 0.050 mg/L of  $\text{Fe}(\text{NO}_3)_3 \cdot 9\text{H}_2\text{O}$ ; 0.417 mg/L of  $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$ ;  
 311.80 mg/L of KCl; 28.64 mg/L of  $\text{MgCl}_2$ ; 48.84 mg/L of  $\text{MgSO}_4$ ; 6995.50 mg/L of  
 NaCl; 2400.0 mg/L of  $\text{NaHCO}_3$ ; 62.50 mg/L of  $\text{NaH}_2\text{PO}_4 \cdot \text{H}_2\text{O}$ ; 71.02 mg/L of  
 $\text{Na}_2\text{HPO}_4$ ; .4320 mg/L of  $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$ ; .002 mg/L of Arachidonic Acid ; 1.022 mg/L  
 5 of Cholesterol; .070 mg/L of DL-alpha-Tocopherol-Acetate; 0.0520 mg/L of Linoleic  
 Acid; 0.010 mg/L of Linolenic Acid; 0.010 mg/L of Myristic Acid; 0.010 mg/L of  
 Oleic Acid; 0.010 mg/L of Palmitric Acid; 0.010 mg/L of Palmitic Acid; 100 mg/L of  
 Pluronic F-68; 0.010 mg/L of Stearic Acid; 2.20 mg/L of Tween 80; 4551 mg/L of D-  
 Glucose; 130.85 mg/ml of L- Alanine; 147.50 mg/ml of L-Arginine-HCL; 7.50 mg/ml  
 10 of L-Asparagine- $\text{H}_2\text{O}$ ; 6.65 mg/ml of L-Aspartic Acid; 29.56 mg/ml of L-Cystine-  
 2HCL- $\text{H}_2\text{O}$ ; 31.29 mg/ml of L-Cystine-2HCL; 7.35 mg/ml of L-Glutamic Acid; 365.0  
 mg/ml of L-Glutamine; 18.75 mg/ml of Glycine; 52.48 mg/ml of L-Histidine-HCL-  
 $\text{H}_2\text{O}$ ; 106.97 mg/ml of L-Isoleucine; 111.45 mg/ml of L-Leucine; 163.75 mg/ml of L-  
 Lysine HCL; 32.34 mg/ml of L-Methionine; 68.48 mg/ml of L-Phenylalanine; 40.0  
 15 mg/ml of L-Proline; 26.25 mg/ml of L-Serine; 101.05 mg/ml of L-Threonine; 19.22  
 mg/ml of L-Tryptophan; 91.79 mg/ml of L-Tyrosine-2Na- $2\text{H}_2\text{O}$ ; 99.65 mg/ml of L-  
 Valine; 0.0035 mg/L of Biotin; 3.24 mg/L of D-Ca Pantothenate; 11.78 mg/L of  
 Choline Chloride; 4.65 mg/L of Folic Acid; 15.60 mg/L of i-Inositol; 3.02 mg/L of  
 Niacinamide; 3.00 mg/L of Pyridoxal HCL; 0.031 mg/L of Pyridoxine HCL; 0.319  
 20 mg/L of Riboflavin; 3.17 mg/L of Thiamine HCL; 0.365 mg/L of Thymidine; and  
 0.680 mg/L of Vitamin B<sub>12</sub>; 25 mM of HEPES Buffer; 2.39 mg/L of Na  
 Hypoxanthine; 0.105 mg/L of Lipoic Acid; 0.081 mg/L of Sodium Putrescine-2HCL;  
 55.0 mg/L of Sodium Pyruvate; 0.0067 mg/L of Sodium Selenite; 20uM of  
 Ethanolamine; 0.122 mg/L of Ferric Citrate; 41.70 mg/L of Methyl-B-Cyclodextrin  
 25 complexed with Linoleic Acid; 33.33 mg/L of Methyl-B-Cyclodextrin complexed  
 with Oleic Acid; and 10 mg/L of Methyl-B-Cyclodextrin complexed with Retinal)  
 with 2mm glutamine and 1x penstrep. (BSA (81-068-3 Bayer) 100gm dissolved in 1L  
 DMEM for a 10% BSA stock solution). Filter the media and collect 50 ul for  
 endotoxin assay in 15ml polystyrene conical.

30 The transfection reaction is terminated, preferably by tag-teaming, at the end  
 of the incubation period. Person A aspirates off the transfection media, while person

B adds 1.5ml appropriate media to each well. Incubate at 37 degrees C for 45 or 72 hours depending on the media used: 1%BSA for 45 hours or CHO-5 for 72 hours.

On day four, using a 300ul multichannel pipetter, aliquot 600ul in one 1ml deep well plate and the remaining supernatant into a 2ml deep well. The supernatants  
5 from each well can then be used in the assays described in Examples 13-20.

It is specifically understood that when activity is obtained in any of the assays described below using a supernatant, the activity originates from either the polypeptide directly (e.g., as a secreted protein) or by the polypeptide inducing expression of other proteins, which are then secreted into the supernatant. Thus, the  
10 invention further provides a method of identifying the protein in the supernatant characterized by an activity in a particular assay.

#### **Example 12: Construction of GAS Reporter Construct**

One signal transduction pathway involved in the differentiation and  
15 proliferation of cells is called the Jaks-STATs pathway. Activated proteins in the Jaks-STATs pathway bind to gamma activation site "GAS" elements or interferon-sensitive responsive element ("ISRE"), located in the promoter of many genes. The binding of a protein to these elements alter the expression of the associated gene.

GAS and ISRE elements are recognized by a class of transcription factors  
20 called Signal Transducers and Activators of Transcription, or "STATs." There are six members of the STATs family. Stat1 and Stat3 are present in many cell types, as is Stat2 (as response to IFN-alpha is widespread). Stat4 is more restricted and is not in many cell types though it has been found in T helper class I, cells after treatment with IL-12. Stat5 was originally called mammary growth factor, but has been found at  
25 higher concentrations in other cells including myeloid cells. It can be activated in tissue culture cells by many cytokines.

The STATs are activated to translocate from the cytoplasm to the nucleus upon tyrosine phosphorylation by a set of kinases known as the Janus Kinase ("Jaks") family. Jaks represent a distinct family of soluble tyrosine kinases and include Tyk2,  
30 Jak1, Jak2, and Jak3. These kinases display significant sequence similarity and are generally catalytically inactive in resting cells.

The Jaks are activated by a wide range of receptors summarized in the Table below. (Adapted from review by Schidler and Darnell, *Ann. Rev. Biochem.* 64:621-51 (1995).) A cytokine receptor family, capable of activating Jaks, is divided into two groups: (a) Class 1 includes receptors for IL-2, IL-3, IL-4, IL-6, IL-7, IL-9, IL-11, IL-12, IL-15, Epo, PRL, GH, G-CSF, GM-CSF, LIF, CNTF, and thrombopoietin; and (b) Class 2 includes IFN- $\alpha$ , IFN- $\gamma$ , and IL-10. The Class 1 receptors share a conserved cysteine motif (a set of four conserved cysteines and one tryptophan) and a WSXWS motif (a membrane proximal region encoding Trp-Ser-Xxx-Trp-Ser (SEQ ID NO:2)).

Thus, on binding of a ligand to a receptor, Jaks are activated, which in turn activate STATs, which then translocate and bind to GAS elements. This entire process is encompassed in the Jaks-STATs signal transduction pathway.

Therefore, activation of the Jaks-STATs pathway, reflected by the binding of the GAS or the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells. For example, growth factors and cytokines are known to activate the Jaks-STATs pathway. (See Table below.) Thus, by using GAS elements linked to reporter molecules, activators of the Jaks-STATs pathway can be identified.

<u>Ligand</u>	<u>tyk2</u>	<u>JAKs</u>		<u>Jak3</u>	<u>STATS</u>	<u>GAS(elements) or ISRE</u>
		<u>Jak1</u>	<u>Jak2</u>			
<u>IFN family</u>						
IFN-a/B	+	+	-	-	1,2,3	ISRE
IFN-g		+	+	-	1	GAS (IRF1>Lys6>IFP)
Il-10	+	?	?	-	1,3	
<u>gp130 family</u>						
IL-6 (Pleiotrophic)	+	+	+	?	1,3	GAS (IRF1>Lys6>IFP)
Il-11(Pleiotrophic)	?	+	?	?	1,3	
OnM(Pleiotrophic)	?	+	+	?	1,3	
LIF(Pleiotrophic)	?	+	+	?	1,3	
CNTF(Pleiotrophic)	-/+	+	+	?	1,3	
G-CSF(Pleiotrophic)	?	+	?	?	1,3	
IL-12(Pleiotrophic)	+	-	+	+	1,3	
<u>g-C family</u>						
IL-2 (lymphocytes)	-	+	-	+	1,3,5	GAS
IL-4 (lymph/myeloid)	-	+	-	+	6	GAS (IRF1 = IFP >>Ly6)(IgH)
IL-7 (lymphocytes)	-	+	-	+	5	GAS
IL-9 (lymphocytes)	-	+	-	+	5	GAS
IL-13 (lymphocyte)	-	+	?	?	6	GAS
IL-15	?	+	?	+	5	GAS
<u>gp140 family</u>						
IL-3 (myeloid)	-	-	+	-	5	GAS (IRF1>IFP>>Ly6)
IL-5 (myeloid)	-	-	+	-	5	GAS
GM-CSF (myeloid)	-	-	+	-	5	GAS
<u>Growth hormone family</u>						
GH	?	-	+	-	5	
PRL	?	+/-	+	-	1,3,5	
EPO	?	-	+	-	5	GAS(B-CAS>IRF1=IFP>>Ly6)
<u>Receptor Tyrosine Kinases</u>						
EGF	?	+	+	-	1,3	GAS (IRF1)
PDGF	?	+	+	-	1,3	
CSF-1	?	+	+	-	1,3	GAS (not IRF1)

To construct a synthetic GAS containing promoter element, which is used in the Biological Assays described in Examples 13-14, a PCR based strategy is employed to generate a GAS-SV40 promoter sequence. The 5' primer contains four tandem copies of the GAS binding site found in the IRF1 promoter and previously demonstrated to bind STATs upon induction with a range of cytokines (Rothman et al., Immunity 1:457-468 (1994).), although other GAS or ISRE elements can be used instead. The 5' primer also contains 18bp of sequence complementary to the SV40 early promoter sequence and is flanked with an XhoI site. The sequence of the 5' primer is:

5' :GCGCCTCGAGATTTCCTCCGAAATCTAGATTTCCTCCGAAATGATTTCCTCCGAAATGATTTCCTCCGAAATATCTGCCATCTCAATTAG:3' (SEQ ID NO:3)

The downstream primer is complementary to the SV40 promoter and is flanked with a Hind III site: 5':GCGGCAAGCTTTTTGCAAAGCCTAGGC:3' (SEQ ID NO:4)

PCR amplification is performed using the SV40 promoter template present in the B-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI/Hind III and subcloned into BLSK2-. (Stratagene.) Sequencing with forward and reverse primers confirms that the insert contains the following sequence:

5':CTCGAGATTTCCTCCGAAATCTAGATTTCCTCCGAAATGATTTCCTCCGAAATGATTTCCTCCGAAATATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTT:3' (SEQ ID NO:5)

With this GAS promoter element linked to the SV40 promoter, a GAS:SEAP2 reporter construct is next engineered. Here, the reporter molecule is a secreted alkaline phosphatase, or "SEAP." Clearly, however, any reporter molecule can be instead of SEAP, in this or in any of the other Examples. Well known reporter molecules that can be used instead of SEAP include chloramphenicol acetyltransferase (CAT), luciferase, alkaline phosphatase, B-galactosidase, green fluorescent protein (GFP), or any protein detectable by an antibody.

The above sequence confirmed synthetic GAS-SV40 promoter element is subcloned into the pSEAP-Promoter vector obtained from Clontech using HindIII and XhoI, effectively replacing the SV40 promoter with the amplified GAS:SV40 promoter element, to create the GAS-SEAP vector. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

Thus, in order to generate mammalian stable cell lines expressing the GAS-SEAP reporter, the GAS-SEAP cassette is removed from the GAS-SEAP vector using SalI and NotI, and inserted into a backbone vector containing the neomycin resistance gene, such as pGFP-1 (Clontech), using these restriction sites in the multiple cloning site, to create the GAS-SEAP/Neo vector. Once this vector is transfected into mammalian cells, this vector can then be used as a reporter molecule for GAS binding as described in Examples 13-14.

Other constructs can be made using the above description and replacing GAS with a different promoter sequence. For example, construction of reporter molecules containing NFK-B and EGR promoter sequences are described in Examples 15 and 16. However, many other promoters can be substituted using the protocols described in these Examples. For instance, SRE, IL-2, NFAT, or Osteocalcin promoters can be substituted, alone or in combination (e.g., GAS/NF-KB/EGR, GAS/NF-KB, IL-2/NFAT, or NF-KB/GAS). Similarly, other cell lines can be used to test reporter construct activity, such as HELA (epithelial), HUVEC (endothelial), Reh (B-cell), Saos-2 (osteoblast), HUVAC (aortic), or Cardiomyocyte.

### **Example 13: High-Throughput Screening Assay for T-cell Activity.**

The following protocol is used to assess T-cell activity by identifying factors, and determining whether supernate containing a polypeptide of the invention proliferates and/or differentiates T-cells. T-cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The T-cell used in this assay is Jurkat T-cells (ATCC Accession No. TIB-152), although Molt-3 cells (ATCC Accession No. CRL-1552) and Molt-4 cells (ATCC Accession No. CRL-1582) cells can also be used.



Jurkat T-cells are lymphoblastic CD4+ Th1 helper cells. In order to generate stable cell lines, approximately 2 million Jurkat cells are transfected with the GAS-SEAP/neo vector using DMRIE-C (Life Technologies)(transfection procedure described below). The transfected cells are seeded to a density of approximately 20,000 cells per well and transfectants resistant to 1 mg/ml gentamicin selected. Resistant colonies are expanded and then tested for their response to increasing concentrations of interferon gamma. The dose response of a selected clone is demonstrated.

Specifically, the following protocol will yield sufficient cells for 75 wells containing 200 ul of cells. Thus, it is either scaled up, or performed in multiple to generate sufficient cells for multiple 96 well plates. Jurkat cells are maintained in RPMI + 10% serum with 1% Pen-Strep. Combine 2.5 mls of OPTI-MEM (Life Technologies) with 10 ug of plasmid DNA in a T25 flask. Add 2.5 ml OPTI-MEM containing 50 ul of DMRIE-C and incubate at room temperature for 15-45 mins.

During the incubation period, count cell concentration, spin down the required number of cells ( $10^7$  per transfection), and resuspend in OPTI-MEM to a final concentration of  $10^7$  cells/ml. Then add 1ml of  $1 \times 10^7$  cells in OPTI-MEM to T25 flask and incubate at 37 degrees C for 6 hrs. After the incubation, add 10 ml of RPMI + 15% serum.

The Jurkat:GAS-SEAP stable reporter lines are maintained in RPMI + 10% serum, 1 mg/ml Gentamicin, and 1% Pen-Strep. These cells are treated with supernatants containing polypeptides of the invention and/or induced polypeptides of the invention as produced by the protocol described in Example 11.

On the day of treatment with the supernatant, the cells should be washed and resuspended in fresh RPMI + 10% serum to a density of 500,000 cells per ml. The exact number of cells required will depend on the number of supernatants being screened. For one 96 well plate, approximately 10 million cells (for 10 plates, 100 million cells) are required.

Transfer the cells to a triangular reservoir boat, in order to dispense the cells into a 96 well dish, using a 12 channel pipette. Using a 12 channel pipette, transfer 200 ul of cells into each well (therefore adding 100,000 cells per well).

After all the plates have been seeded, 50 ul of the supernatants are transferred directly from the 96 well plate containing the supernatants into each well using a 12 channel pipette. In addition, a dose of exogenous interferon gamma (0.1, 1.0, 10 ng) is added to wells H9, H10, and H11 to serve as additional positive controls for the  
5 assay.

The 96 well dishes containing Jurkat cells treated with supernatants are placed in an incubator for 48 hrs (note: this time is variable between 48-72 hrs). 35 ul samples from each well are then transferred to an opaque 96 well plate using a 12 channel pipette. The opaque plates should be covered (using sellophene covers) and  
10 stored at -20 degrees C until SEAP assays are performed according to Example 17. The plates containing the remaining treated cells are placed at 4 degrees C and serve as a source of material for repeating the assay on a specific well if desired.

As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate Jurkat T cells. Over 30 fold induction is typically observed in the  
15 positive control wells.

The above protocol may be used in the generation of both transient, as well as, stable transfected cells, which would be apparent to those of skill in the art.

#### **Example 14: High-Throughput Screening Assay Identifying Myeloid Activity**

20 The following protocol is used to assess myeloid activity by determining whether polypeptides of the invention proliferates and/or differentiates myeloid cells. Myeloid cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The myeloid cell used in this assay is  
25 U937, a pre-monocyte cell line, although TF-1, HL60, or KG1 can be used.

To transiently transfect U937 cells with the GAS/SEAP/Neo construct produced in Example 12, a DEAE-Dextran method (Kharbanda et. al., 1994, Cell Growth & Differentiation, 5:259-265) is used. First, harvest  $2 \times 10^7$  U937 cells and wash with PBS. The U937 cells are usually grown in RPMI 1640 medium containing  
30 10% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 mg/ml streptomycin.

Next, suspend the cells in 1 ml of 20 mM Tris-HCl (pH 7.4) buffer containing 0.5 mg/ml DEAE-Dextran, 8 ug GAS-SEAP2 plasmid DNA, 140 mM NaCl, 5 mM KCl, 375 uM Na<sub>2</sub>HPO<sub>4</sub>·7H<sub>2</sub>O, 1 mM MgCl<sub>2</sub>, and 675 uM CaCl<sub>2</sub>. Incubate at 37 degrees C for 45 min.

- 5 Wash the cells with RPMI 1640 medium containing 10% FBS and then resuspend in 10 ml complete medium and incubate at 37 degrees C for 36 hr.

The GAS-SEAP/U937 stable cells are obtained by growing the cells in 400 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 400 ug/ml G418 for couple of passages.

- 10 These cells are tested by harvesting  $1 \times 10^8$  cells (this is enough for ten 96-well plates assay) and wash with PBS. Suspend the cells in 200 ml above described growth medium, with a final density of  $5 \times 10^5$  cells/ml. Plate 200 ul cells per well in the 96-well plate (or  $1 \times 10^5$  cells/well).

- Add 50 ul of the supernatant prepared by the protocol described in Example 11. Incubate at 37 degrees C for 48 to 72 hr. As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate U937 cells. Over 30 fold induction is typically observed in the positive control wells. SEAP assay the supernatant according to the protocol described in Example 17.

20 **Example 15: High-Throughput Screening Assay Identifying Neuronal Activity.**

- When cells undergo differentiation and proliferation, a group of genes are activated through many different signal transduction pathways. One of these genes, EGR1 (early growth response gene 1), is induced in various tissues and cell types upon activation. The promoter of EGR1 is responsible for such induction. Using the EGR1 promoter linked to reporter molecules, activation of cells can be assessed.

- 25 Particularly, the following protocol is used to assess neuronal activity in PC12 cell lines. PC12 cells (rat phenochromocytoma cells) are known to proliferate and/or differentiate by activation with a number of mitogens, such as TPA (tetradecanoyl phorbol acetate), NGF (nerve growth factor), and EGF (epidermal growth factor).

- 30 The EGR1 gene expression is activated during this treatment. Thus, by stably transfecting PC12 cells with a construct containing an EGR promoter linked to SEAP reporter, activation of PC12 cells can be assessed.

The EGR/SEAP reporter construct can be assembled by the following protocol. The EGR-1 promoter sequence (-633 to +1)(Sakamoto K et al., Oncogene 6:867-871 (1991)) can be PCR amplified from human genomic DNA using the following primers:

- 5            5' GCGCTCGAGGGATGACAGCGATAGAACCCCGG -3' (SEQ ID NO:6)  
             5' GCGAAGCTTCGCGACTCCCCGGATCCGCCTC-3' (SEQ ID NO:7)

Using the GAS:SEAP/Neo vector produced in Example 12, EGR1 amplified product can then be inserted into this vector. Linearize the GAS:SEAP/Neo vector using restriction enzymes XhoI/HindIII, removing the GAS/SV40 stuffer. Restrict the  
10 EGR1 amplified product with these same enzymes. Ligate the vector and the EGR1 promoter.

To prepare 96 well-plates for cell culture, two mls of a coating solution (1:30 dilution of collagen type I (Upstate Biotech Inc. Cat#08-115) in 30% ethanol (filter sterilized)) is added per one 10 cm plate or 50 ml per well of the 96-well plate, and  
15 allowed to air dry for 2 hr.

PC12 cells are routinely grown in RPMI-1640 medium (Bio Whittaker) containing 10% horse serum (JRH BIOSCIENCES, Cat. # 12449-78P), 5% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 ug/ml streptomycin on a precoated 10 cm tissue culture dish. One to four split is  
20 done every three to four days. Cells are removed from the plates by scraping and resuspended with pipetting up and down for more than 15 times.

Transfect the EGR/SEAP/Neo construct into PC12 using the Lipofectamine protocol described in Example 11. EGR-SEAP/PC12 stable cells are obtained by growing the cells in 300 ug/ml G418. The G418-free medium is used for routine  
25 growth but every one to two months, the cells should be re-grown in 300 ug/ml G418 for couple of passages.

To assay for neuronal activity, a 10 cm plate with cells around 70 to 80% confluent is screened by removing the old medium. Wash the cells once with PBS (Phosphate buffered saline). Then starve the cells in low serum medium (RPMI-1640  
30 containing 1% horse serum and 0.5% FBS with antibiotics) overnight.

The next morning, remove the medium and wash the cells with PBS. Scrape off the cells from the plate, suspend the cells well in 2 ml low serum medium. Count

the cell number and add more low serum medium to reach final cell density as  $5 \times 10^5$  cells/ml.

Add 200 ul of the cell suspension to each well of 96-well plate (equivalent to  $1 \times 10^5$  cells/well). Add 50 ul supernatant produced by Example 11, 37°C for 48 to 72 hr. As a positive control, a growth factor known to activate PC12 cells through EGR can be used, such as 50 ng/ul of Neuronal Growth Factor (NGF). Over fifty-fold induction of SEAP is typically seen in the positive control wells. SEAP assay the supernatant according to Example 17.

#### 10 **Example 16: High-Throughput Screening Assay for T-cell Activity**

NF-KB (Nuclear Factor KB) is a transcription factor activated by a wide variety of agents including the inflammatory cytokines IL-1 and TNF, CD30 and CD40, lymphotoxin-alpha and lymphotoxin-beta, by exposure to LPS or thrombin, and by expression of certain viral gene products. As a transcription factor, NF-KB regulates the expression of genes involved in immune cell activation, control of apoptosis (NF- KB appears to shield cells from apoptosis), B and T-cell development, anti-viral and antimicrobial responses, and multiple stress responses.

In non-stimulated conditions, NF- KB is retained in the cytoplasm with I-KB (Inhibitor KB). However, upon stimulation, I- KB is phosphorylated and degraded, causing NF- KB to shuttle to the nucleus, thereby activating transcription of target genes. Target genes activated by NF- KB include IL-2, IL-6, GM-CSF, ICAM-1 and class 1 MHC.

Due to its central role and ability to respond to a range of stimuli, reporter constructs utilizing the NF-KB promoter element are used to screen the supernatants produced in Example 11. Activators or inhibitors of NF-KB would be useful in treating diseases. For example, inhibitors of NF-KB could be used to treat those diseases related to the acute or chronic activation of NF-KB, such as rheumatoid arthritis.

To construct a vector containing the NF-KB promoter element, a PCR based strategy is employed. The upstream primer contains four tandem copies of the NF-KB binding site (GGGGACTTCCCC) (SEQ ID NO:8), 18 bp of sequence

complementary to the 5' end of the SV40 early promoter sequence, and is flanked with an XhoI site:

5':GCGGCCTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGAC  
TTTCCATCCTGCCATCTCAATTAG:3' (SEQ ID NO:9)

- 5 The downstream primer is complementary to the 3' end of the SV40 promoter and is flanked with a Hind III site:

5':GCGGCAAGCTTTTTGCAAAGCCTAGGC:3' (SEQ ID NO:4)

- 10 PCR amplification is performed using the SV40 promoter template present in the pB-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI and Hind III and subcloned into BLSK2-. (Stratagene) Sequencing with the T7 and T3 primers confirms the insert contains the following sequence:

- 15 5':CTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGACTTTCC  
ATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCC  
ATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGA  
CTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTA  
TTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAA  
GCTT:3' (SEQ ID NO:10)

20

Next, replace the SV40 minimal promoter element present in the pSEAP2-promoter plasmid (Clontech) with this NF-KB/SV40 fragment using XhoI and HindIII. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

- 25 In order to generate stable mammalian cell lines, the NF-KB/SV40/SEAP cassette is removed from the above NF-KB/SEAP vector using restriction enzymes SalI and NotI, and inserted into a vector containing neomycin resistance. Particularly, the NF-KB/SV40/SEAP cassette was inserted into pGFP-1 (Clontech), replacing the GFP gene, after restricting pGFP-1 with SalI and NotI.

- 30 Once NF-KB/SV40/SEAP/Neo vector is created, stable Jurkat T-cells are created and maintained according to the protocol described in Example 13. Similarly, the method for assaying supernatants with these stable Jurkat T-cells is also described

in Example 13. As a positive control, exogenous TNF alpha (0.1, 1, 10 ng) is added to wells H9, H10, and H11, with a 5-10 fold activation typically observed.

**Example 17: Assay for SEAP Activity**

5 As a reporter molecule for the assays described in Examples 13-16, SEAP activity is assayed using the Tropix Phospho-light Kit (Cat. BP-400) according to the following general procedure. The Tropix Phospho-light Kit supplies the Dilution, Assay, and Reaction Buffers used below.

10 Prime a dispenser with the 2.5x Dilution Buffer and dispense 15 ul of 2.5x dilution buffer into Optiplates containing 35 ul of a supernatant. Seal the plates with a plastic sealer and incubate at 65 degree C for 30 min. Separate the Optiplates to avoid uneven heating.

Cool the samples to room temperature for 15 minutes. Empty the dispenser and prime with the Assay Buffer. Add 50 ml Assay Buffer and incubate at room temperature 5 min. Empty the dispenser and prime with the Reaction Buffer (see the table below). Add 50 ul Reaction Buffer and incubate at room temperature for 20 minutes. Since the intensity of the chemiluminescent signal is time dependent, and it takes about 10 minutes to read 5 plates on luminometer, one should treat 5 plates at each time and start the second set 10 minutes later.

20 Read the relative light unit in the luminometer. Set H12 as blank, and print the results. An increase in chemiluminescence indicates reporter activity.

**Reaction Buffer Formulation:**

# of plates	Rxn buffer diluent (ml)	CSPD (ml)
10	60	3
11	65	3.25
12	70	3.5
13	75	3.75
14	80	4
15	85	4.25
16	90	4.5
17	95	4.75
18	100	5
19	105	5.25
20	110	5.5
21	115	5.75
22	120	6
23	125	6.25
24	130	6.5

25	135	6.75
26	140	7
27	145	7.25
28	150	7.5
29	155	7.75
30	160	8
31	165	8.25
32	170	8.5
33	175	8.75
34	180	9
35	185	9.25
36	190	9.5
37	195	9.75
38	200	10
39	205	10.25
40	210	10.5
41	215	10.75
42	220	11
43	225	11.25
44	230	11.5
45	235	11.75
46	240	12
47	245	12.25
48	250	12.5
49	255	12.75
50	260	13

**Example 18: High-Throughput Screening Assay Identifying Changes in Small Molecule Concentration and Membrane Permeability**

Binding of a ligand to a receptor is known to alter intracellular levels of small molecules, such as calcium, potassium, sodium, and pH, as well as alter membrane potential. These alterations can be measured in an assay to identify supernatants which bind to receptors of a particular cell. Although the following protocol describes an assay for calcium, this protocol can easily be modified to detect changes in potassium, sodium, pH, membrane potential, or any other small molecule which is detectable by a fluorescent probe.

The following assay uses Fluorometric Imaging Plate Reader ("FLIPR") to measure changes in fluorescent molecules (Molecular Probes) that bind small molecules. Clearly, any fluorescent molecule detecting a small molecule can be used instead of the calcium fluorescent molecule, fluo-4 (Molecular Probes, Inc.; catalog no. F-14202), used here.

For adherent cells, seed the cells at 10,000 -20,000 cells/well in a Co-star black 96-well plate with clear bottom. The plate is incubated in a CO<sub>2</sub> incubator for



20 hours. The adherent cells are washed two times in Biotek washer with 200 ul of HBSS (Hank's Balanced Salt Solution) leaving 100 ul of buffer after the final wash.

A stock solution of 1 mg/ml fluo-4 is made in 10% pluronic acid DMSO. To load the cells with fluo-4, 50 ul of 12 ug/ml fluo-4 is added to each well. The plate is incubated at 37 degrees C in a CO<sub>2</sub> incubator for 60 min. The plate is washed four times in the Biotek washer with HBSS leaving 100 ul of buffer.

For non-adherent cells, the cells are spun down from culture media. Cells are re-suspended to  $2-5 \times 10^6$  cells/ml with HBSS in a 50-ml conical tube. 4 ul of 1 mg/ml fluo-4 solution in 10% pluronic acid DMSO is added to each ml of cell suspension. The tube is then placed in a 37 degrees C water bath for 30-60 min. The cells are washed twice with HBSS, resuspended to  $1 \times 10^6$  cells/ml, and dispensed into a microplate, 100 ul/well. The plate is centrifuged at 1000 rpm for 5 min. The plate is then washed once in Denley CellWash with 200 ul, followed by an aspiration step to 100 ul final volume.

For a non-cell based assay, each well contains a fluorescent molecule, such as fluo-4. The supernatant is added to the well, and a change in fluorescence is detected.

To measure the fluorescence of intracellular calcium, the FLIPR is set for the following parameters: (1) System gain is 300-800 mW; (2) Exposure time is 0.4 second; (3) Camera F/stop is F/2; (4) Excitation is 488 nm; (5) Emission is 530 nm; and (6) Sample addition is 50 ul. Increased emission at 530 nm indicates an extracellular signaling event which has resulted in an increase in the intracellular Ca<sup>++</sup> concentration.

#### **Example 19: High-Throughput Screening Assay Identifying Tyrosine Kinase Activity**

The Protein Tyrosine Kinases (PTK) represent a diverse group of transmembrane and cytoplasmic kinases. Within the Receptor Protein Tyrosine Kinase (RPTK) group are receptors for a range of mitogenic and metabolic growth factors including the PDGF, FGF, EGF, NGF, HGF and Insulin receptor subfamilies. In addition there are a large family of RPTKs for which the corresponding ligand is

unknown. Ligands for RPTKs include mainly secreted small proteins, but also membrane-bound and extracellular matrix proteins.

Activation of RPTK by ligands involves ligand-mediated receptor dimerization, resulting in transphosphorylation of the receptor subunits and activation of the cytoplasmic tyrosine kinases. The cytoplasmic tyrosine kinases include receptor associated tyrosine kinases of the src-family (e.g., src, yes, lck, lyn, fyn) and non-receptor linked and cytosolic protein tyrosine kinases, such as the Jak family, members of which mediate signal transduction triggered by the cytokine superfamily of receptors (e.g., the Interleukins, Interferons, GM-CSF, and Leptin).

Because of the wide range of known factors capable of stimulating tyrosine kinase activity, the identification of novel human secreted proteins capable of activating tyrosine kinase signal transduction pathways are of interest. Therefore, the following protocol is designed to identify those novel human secreted proteins capable of activating the tyrosine kinase signal transduction pathways.

Seed target cells (e.g., primary keratinocytes) at a density of approximately 25,000 cells per well in a 96 well Loprodyne Silent Screen Plates purchased from Nalge Nunc (Naperville, IL). The plates are sterilized with two 30 minute rinses with 100% ethanol, rinsed with water and dried overnight. Some plates are coated for 2 hr with 100 ml of cell culture grade type I collagen (50 mg/ml), gelatin (2%) or polylysine (50 mg/ml), all of which can be purchased from Sigma Chemicals (St. Louis, MO) or 10% Matrigel purchased from Becton Dickinson (Bedford, MA), or calf serum, rinsed with PBS and stored at 4 degree C. Cell growth on these plates is assayed by seeding 5,000 cells/well in growth medium and indirect quantitation of cell number through use of alamarBlue as described by the manufacturer Alamar Biosciences, Inc. (Sacramento, CA) after 48 hr. Falcon plate covers #3071 from Becton Dickinson (Bedford, MA) are used to cover the Loprodyne Silent Screen Plates. Falcon Microtest III cell culture plates can also be used in some proliferation experiments.

To prepare extracts, A431 cells are seeded onto the nylon membranes of Loprodyne plates (20,000/200ml/well) and cultured overnight in complete medium. Cells are quiesced by incubation in serum-free basal medium for 24 hr. After 5-20 minutes treatment with EGF (60ng/ml) or 50 ul of the supernatant produced in

Example 11, the medium was removed and 100 ml of extraction buffer ((20 mM HEPES pH 7.5, 0.15 M NaCl, 1% Triton X-100, 0.1% SDS, 2 mM Na<sub>3</sub>VO<sub>4</sub>, 2 mM Na<sub>4</sub>P<sub>2</sub>O<sub>7</sub> and a cocktail of protease inhibitors (# 1836170) obtained from Boehringer Mannheim (Indianapolis, IN) is added to each well and the plate is  
5 shaken on a rotating shaker for 5 minutes at 4 degrees C. The plate is then placed in a vacuum transfer manifold and the extract filtered through the 0.45 mm membrane bottoms of each well using house vacuum. Extracts are collected in a 96-well catch/assay plate in the bottom of the vacuum manifold and immediately placed on ice. To obtain extracts clarified by centrifugation, the content of each well, after  
10 detergent solubilization for 5 minutes, is removed and centrifuged for 15 minutes at 4 degrees C at 16,000 x g.

Test the filtered extracts for levels of tyrosine kinase activity. Although many methods of detecting tyrosine kinase activity are known, one method is described here.

15 Generally, the tyrosine kinase activity of a supernatant is evaluated by determining its ability to phosphorylate a tyrosine residue on a specific substrate (a biotinylated peptide). Biotinylated peptides that can be used for this purpose include PSK1 (corresponding to amino acids 6-20 of the cell division kinase cdc2-p34) and PSK2 (corresponding to amino acids 1-17 of gastrin). Both peptides are substrates for  
20 a range of tyrosine kinases and are available from Boehringer Mannheim.

The tyrosine kinase reaction is set up by adding the following components in order. First, add 10ul of 5uM Biotinylated Peptide, then 10ul ATP/Mg<sub>2</sub><sup>+</sup> (5mM ATP/50mM MgCl<sub>2</sub>), then 10ul of 5x Assay Buffer (40mM imidazole hydrochloride, pH7.3, 40 mM beta-glycerophosphate, 1mM EGTA, 100mM MgCl<sub>2</sub>, 5 mM MnCl<sub>2</sub>,  
25 0.5 mg/ml BSA), then 5ul of Sodium Vanadate(1mM), and then 5ul of water. Mix the components gently and preincubate the reaction mix at 30 degrees C for 2 min. Initial the reaction by adding 10ul of the control enzyme or the filtered supernatant.

The tyrosine kinase assay reaction is then terminated by adding 10 ul of 120mM EDTA and place the reactions on ice.

30 Tyrosine kinase activity is determined by transferring 50 ul aliquot of reaction mixture to a microtiter plate (MTP) module and incubating at 37 degrees C for 20

min. This allows the streptavidin coated 96 well plate to associate with the biotinylated peptide. Wash the MTP module with 300ul/well of PBS four times. Next add 75 ul of anti-phosphotyrosine antibody conjugated to horse radish peroxidase(anti-P-Tyr-POD(0.5u/ml)) to each well and incubate at 37 degrees C for  
5 one hour. Wash the well as above.

Next add 100ul of peroxidase substrate solution (Boehringer Mannheim) and incubate at room temperature for at least 5 mins (up to 30 min). Measure the absorbance of the sample at 405 nm by using ELISA reader. The level of bound peroxidase activity is quantitated using an ELISA reader and reflects the level of  
10 tyrosine kinase activity.

### **Example 20: High-Throughput Screening Assay Identifying Phosphorylation**

#### **Activity**

As a potential alternative and/or compliment to the assay of protein tyrosine  
15 kinase activity described in Example 19, an assay which detects activation (phosphorylation) of major intracellular signal transduction intermediates can also be used. For example, as described below one particular assay can detect tyrosine phosphorylation of the Erk-1 and Erk-2 kinases. However, phosphorylation of other molecules, such as Raf, JNK, p38 MAP, Map kinase kinase (MEK), MEK kinase,  
20 Src, Muscle specific kinase (MuSK), IRAK, Tec, and Janus, as well as any other phosphoserine, phosphotyrosine, or phosphothreonine molecule, can be detected by substituting these molecules for Erk-1 or Erk-2 in the following assay.

Specifically, assay plates are made by coating the wells of a 96-well ELISA plate with 0.1ml of protein G (1ug/ml) for 2 hr at room temp, (RT). The plates are  
25 then rinsed with PBS and blocked with 3% BSA/PBS for 1 hr at RT. The protein G plates are then treated with 2 commercial monoclonal antibodies (100ng/well) against Erk-1and Erk-2 (1 hr at RT) (Santa Cruz Biotechnology). (To detect other molecules, this step can easily be modified by substituting a monoclonal antibody detecting any of the above described molecules.) After 3-5 rinses with PBS, the plates are stored at  
30 4 degrees C until use.

A431 cells are seeded at 20,000/well in a 96-well Loprodyne filterplate and

cultured overnight in growth medium. The cells are then starved for 48 hr in basal medium (DMEM) and then treated with EGF (6ng/well) or 50 ul of the supernatants obtained in Example 11 for 5-20 minutes. The cells are then solubilized and extracts filtered directly into the assay plate.

5           After incubation with the extract for 1 hr at RT, the wells are again rinsed. As a positive control, a commercial preparation of MAP kinase (10ng/well) is used in place of A431 extract. Plates are then treated with a commercial polyclonal (rabbit) antibody (1ug/ml) which specifically recognizes the phosphorylated epitope of the Erk-1 and Erk-2 kinases (1 hr at RT). This antibody is biotinylated by standard  
10       procedures. The bound polyclonal antibody is then quantitated by successive incubations with Europium-streptavidin and Europium fluorescence enhancing reagent in the Wallac DELFIA instrument (time-resolved fluorescence). An increased fluorescent signal over background indicates a phosphorylation.

15       **Example 21: Method of Determining Alterations in a Gene Corresponding to a Polynucleotide**

          RNA isolated from entire families or individual patients presenting with a phenotype of interest (such as a disease) is be isolated. cDNA is then generated from these RNA samples using protocols known in the art. (See, Sambrook.) The cDNA  
20       is then used as a template for PCR, employing primers surrounding regions of interest in SEQ ID NO:X. Suggested PCR conditions consist of 35 cycles at 95 degrees C for 30 seconds; 60-120 seconds at 52-58 degrees C; and 60-120 seconds at 70 degrees C, using buffer solutions described in Sidransky et al., Science 252:706 (1991).

          PCR products are then sequenced using primers labeled at their 5' end with T4  
25       polynucleotide kinase, employing SequiTherm Polymerase. (Epicentre Technologies). The intron-exon borders of selected exons is also determined and genomic PCR products analyzed to confirm the results. PCR products harboring suspected mutations is then cloned and sequenced to validate the results of the direct sequencing.

30       PCR products is cloned into T-tailed vectors as described in Holton et al., Nucleic Acids Research, 19:1156 (1991) and sequenced with T7 polymerase (United

States Biochemical). Affected individuals are identified by mutations not present in unaffected individuals.

Genomic rearrangements are also observed as a method of determining alterations in a gene corresponding to a polynucleotide. Genomic clones isolated according to Example 2 are nick-translated with digoxigenindeoxy-uridine 5'-triphosphate (Boehringer Mannheim), and FISH performed as described in Johnson et al., Methods Cell Biol. 35:73-99 (1991). Hybridization with the labeled probe is carried out using a vast excess of human cot-1 DNA for specific hybridization to the corresponding genomic locus.

Chromosomes are counterstained with 4,6-diamino-2-phenylidole and propidium iodide, producing a combination of C- and R-bands. Aligned images for precise mapping are obtained using a triple-band filter set (Chroma Technology, Brattleboro, VT) in combination with a cooled charge-coupled device camera (Photometrics, Tucson, AZ) and variable excitation wavelength filters. (Johnson et al., Genet. Anal. Tech. Appl., 8:75 (1991).) Image collection, analysis and chromosomal fractional length measurements are performed using the ISee Graphical Program System. (Inovision Corporation, Durham, NC.) Chromosome alterations of the genomic region hybridized by the probe are identified as insertions, deletions, and translocations. These alterations are used as a diagnostic marker for an associated disease.

**Example 22: Method of Detecting Abnormal Levels of a Polypeptide in a Biological Sample**

A polypeptide of the present invention can be detected in a biological sample, and if an increased or decreased level of the polypeptide is detected, this polypeptide is a marker for a particular phenotype. Methods of detection are numerous, and thus, it is understood that one skilled in the art can modify the following assay to fit their particular needs.

For example, antibody-sandwich ELISAs are used to detect polypeptides in a sample, preferably a biological sample. Wells of a microtiter plate are coated with specific antibodies, at a final concentration of 0.2 to 10 ug/ml. The antibodies are either monoclonal or polyclonal and are produced by the method described in

Example 10. The wells are blocked so that non-specific binding of the polypeptide to the well is reduced.

The coated wells are then incubated for > 2 hours at RT with a sample containing the polypeptide. Preferably, serial dilutions of the sample should be used to validate results. The plates are then washed three times with deionized or distilled water to remove unbounded polypeptide.

Next, 50 ul of specific antibody-alkaline phosphatase conjugate, at a concentration of 25-400 ng, is added and incubated for 2 hours at room temperature. The plates are again washed three times with deionized or distilled water to remove unbounded conjugate.

Add 75 ul of 4-methylumbelliferyl phosphate (MUP) or p-nitrophenyl phosphate (NPP) substrate solution to each well and incubate 1 hour at room temperature. Measure the reaction by a microtiter plate reader. Prepare a standard curve, using serial dilutions of a control sample, and plot polypeptide concentration on the X-axis (log scale) and fluorescence or absorbance of the Y-axis (linear scale). Interpolate the concentration of the polypeptide in the sample using the standard curve.

### **Example 23: Formulation**

The invention also provides methods of treatment and/or prevention diseases, disorders, and/or conditions (such as, for example, any one or more of the diseases or disorders disclosed herein) by administration to a subject of an effective amount of a Therapeutic. By therapeutic is meant a polynucleotides or polypeptides of the invention (including fragments and variants), agonists or antagonists thereof, and/or antibodies thereto, in combination with a pharmaceutically acceptable carrier type (e.g., a sterile carrier).

The Therapeutic will be formulated and dosed in a fashion consistent with good medical practice, taking into account the clinical condition of the individual patient (especially the side effects of treatment with the Therapeutic alone), the site of delivery, the method of administration, the scheduling of administration, and other factors known to practitioners. The "effective amount" for purposes herein is thus determined by such considerations.

As a general proposition, the total pharmaceutically effective amount of the Therapeutic administered parenterally per dose will be in the range of about 1 ug/kg/day to 10 mg/kg/day of patient body weight, although, as noted above, this will be subject to therapeutic discretion. More preferably, this dose is at least 0.01 mg/kg/day, and most preferably for humans between about 0.01 and 1 mg/kg/day for the hormone. If given continuously, the Therapeutic is typically administered at a dose rate of about 1 ug/kg/hour to about 50 ug/kg/hour, either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump. An intravenous bag solution may also be employed. The length of treatment needed to observe changes and the interval following treatment for responses to occur appears to vary depending on the desired effect.

Therapeutics can be administered orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), buccally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

Therapeutics of the invention are also suitably administered by sustained-release systems. Suitable examples of sustained-release Therapeutics are administered orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), buccally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

Therapeutics of the invention are also suitably administered by sustained-release systems. Suitable examples of sustained-release Therapeutics include suitable polymeric materials (such as, for example, semi-permeable polymer matrices in the form of shaped articles, e.g., films, or microcapsules), suitable hydrophobic materials



(for example as an emulsion in an acceptable oil) or ion exchange resins, and sparingly soluble derivatives (such as, for example, a sparingly soluble salt).

Sustained-release matrices include polylactides (U.S. Pat. No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman et al.,  
5 Biopolymers 22:547-556 (1983)), poly (2- hydroxyethyl methacrylate) (Langer et al., J. Biomed. Mater. Res. 15:167-277 (1981), and Langer, Chem. Tech. 12:98-105 (1982)), ethylene vinyl acetate (Langer et al., Id.) or poly-D- (-)-3-hydroxybutyric acid (EP 133,988).

Sustained-release Therapeutics also include liposomally entrapped  
10 Therapeutics of the invention (*see generally*, Langer, *Science* 249:1527-1533 (1990); Treat et al., in *Liposomes in the Therapy of Infectious Disease and Cancer*, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 317 -327 and 353-365 (1989)). Liposomes containing the Therapeutic are prepared by methods known per se: DE 3,218,121; Epstein et al., Proc. Natl. Acad. Sci. (USA) 82:3688-3692 (1985); Hwang  
15 et al., Proc. Natl. Acad. Sci.(USA) 77:4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese Pat. Appl. 83-118008; U.S. Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324. Ordinarily, the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the  
20 optimal Therapeutic.

In yet an additional embodiment, the Therapeutics of the invention are delivered by way of a pump (*see* Langer, *supra*; Sefton, CRC Crit. Ref. Biomed. Eng. 14:201 (1987); Buchwald et al., Surgery 88:507 (1980); Saudek et al., N. Engl. J. Med. 321:574 (1989)).

25 Other controlled release systems are discussed in the review by Langer (*Science* 249:1527-1533 (1990)).

For parenteral administration, in one embodiment, the Therapeutic is formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically  
30 acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation.

For example, the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to the Therapeutic.

Generally, the formulations are prepared by contacting the Therapeutic uniformly and intimately with liquid carriers or finely divided solid carriers or both.

5 Then, if necessary, the product is shaped into the desired formulation. Preferably the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes.

10 The carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability. Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten  
15 residues) polypeptides, e.g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, manose, or dextrans; chelating agents such as EDTA; sugar  
20 alcohols such as mannitol or sorbitol; counterions such as sodium; and/or nonionic surfactants such as polysorbates, poloxamers, or PEG.

The Therapeutic is typically formulated in such vehicles at a concentration of about 0.1 mg/ml to 100 mg/ml, preferably 1-10 mg/ml, at a pH of about 3 to 8. It will be understood that the use of certain of the foregoing excipients, carriers, or  
25 stabilizers will result in the formation of polypeptide salts.

Any pharmaceutical used for therapeutic administration can be sterile. Sterility is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 micron membranes). Therapeutics generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a  
30 stopper pierceable by a hypodermic injection needle.

Therapeutics ordinarily will be stored in unit or multi-dose containers, for example, sealed ampoules or vials, as an aqueous solution or as a lyophilized

formulation for reconstitution. As an example of a lyophilized formulation, 10-ml vials are filled with 5 ml of sterile-filtered 1% (w/v) aqueous Therapeutic solution, and the resulting mixture is lyophilized. The infusion solution is prepared by reconstituting the lyophilized Therapeutic using bacteriostatic Water-for-Injection.

5       The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the Therapeutics of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use  
10 or sale for human administration. In addition, the Therapeutics may be employed in conjunction with other therapeutic compounds.

      The Therapeutics of the invention may be administered alone or in combination with adjuvants. Adjuvants that may be administered with the Therapeutics of the invention include, but are not limited to, alum, alum plus  
15 deoxycholate (ImmunoAg), MTP-PE (Biocine Corp.), QS21 (Genentech, Inc.), BCG, and MPL. In a specific embodiment, Therapeutics of the invention are administered in combination with alum. In another specific embodiment, Therapeutics of the invention are administered in combination with QS-21. Further adjuvants that may be administered with the Therapeutics of the invention include, but are not limited to,  
20 Monophosphoryl lipid immunomodulator, AdjuVax 100a, QS-21, QS-18, CRL1005, Aluminum salts, MF-59, and Virosomal adjuvant technology. Vaccines that may be administered with the Therapeutics of the invention include, but are not limited to, vaccines directed toward protection against MMR (measles, mumps, rubella), polio, varicella, tetanus/diphtheria, hepatitis A, hepatitis B, haemophilus influenzae B,  
25 whooping cough, pneumonia, influenza, Lyme's Disease, rotavirus, cholera, yellow fever, Japanese encephalitis, poliomyelitis, rabies, typhoid fever, and pertussis. Combinations may be administered either concomitantly, e.g., as an admixture, separately but simultaneously or concurrently; or sequentially. This includes presentations in which the combined agents are administered together as a therapeutic  
30 mixture, and also procedures in which the combined agents are administered separately but simultaneously, e.g., as through separate intravenous lines into the same individual. Administration "in combination" further includes the separate

administration of one of the compounds or agents given first, followed by the second.

The Therapeutics of the invention may be administered alone or in combination with other therapeutic agents. Therapeutic agents that may be administered in combination with the Therapeutics of the invention, include but not limited to, other members of the TNF family, chemotherapeutic agents, antibiotics, 5 steroidal and non-steroidal anti-inflammatories, conventional immunotherapeutic agents, cytokines and/or growth factors. Combinations may be administered either concomitantly, e.g., as an admixture, separately but simultaneously or concurrently; or sequentially. This includes presentations in which the combined agents are administered together as a therapeutic mixture, and also procedures in which the 10 combined agents are administered separately but simultaneously, e.g., as through separate intravenous lines into the same individual. Administration "in combination" further includes the separate administration of one of the compounds or agents given first, followed by the second.

15 In one embodiment, the Therapeutics of the invention are administered in combination with members of the TNF family. TNF, TNF-related or TNF-like molecules that may be administered with the Therapeutics of the invention include, but are not limited to, soluble forms of TNF-alpha, lymphotoxin-alpha (LT-alpha, also known as TNF-beta), LT-beta (found in complex heterotrimer LT-alpha2-beta), 20 OPG, FasL, CD27L, CD30L, CD40L, 4-1BBL, DcR3, OX40L, TNF-gamma (International Publication No. WO 96/14328), AIM-I (International Publication No. WO 97/33899), endokine-alpha (International Publication No. WO 98/07880), TR6 (International Publication No. WO 98/30694), OPG, and neutrokin-alpha (International Publication No. WO 98/18921, OX40, and nerve growth factor (NGF), 25 and soluble forms of Fas, CD30, CD27, CD40 and 4-1BB, TR2 (International Publication No. WO 96/34095), DR3 (International Publication No. WO 97/33904), DR4 (International Publication No. WO 98/32856), TR5 (International Publication No. WO 98/30693), TR6 (International Publication No. WO 98/30694), TR7 (International Publication No. WO 98/41629), TRANK, TR9 (International Publication No. WO 98/56892), TR10 (International Publication No. WO 98/54202), 30 312C2 (International Publication No. WO 98/06842), and TR12, and soluble forms CD154, CD70, and CD153.

In certain embodiments, Therapeutics of the invention are administered in combination with antiretroviral agents, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and/or protease inhibitors. Nucleoside reverse transcriptase inhibitors that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, RETROVIR™ (zidovudine/AZT), VIDEX™ (didanosine/ddI), HIVID™ (zalcitabine/ddC), ZERIT™ (stavudine/d4T), EPIVIR™ (lamivudine/3TC), and COMBIVIR™ (zidovudine/lamivudine). Non-nucleoside reverse transcriptase inhibitors that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, VIRAMUNE™ (nevirapine), RESCRIPTOR™ (delavirdine), and SUSTIVA™ (efavirenz). Protease inhibitors that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, CRIXIVAN™ (indinavir), NORVIR™ (ritonavir), INVIRASE™ (saquinavir), and VIRACEPT™ (nelfinavir). In a specific embodiment, antiretroviral agents, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and/or protease inhibitors may be used in any combination with Therapeutics of the invention to treat AIDS and/or to prevent or treat HIV infection.

In other embodiments, Therapeutics of the invention may be administered in combination with anti-opportunistic infection agents. Anti-opportunistic agents that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, TRIMETHOPRIM-SULFAMETHOXAZOLE™, DAPSONE™, PENTAMIDINE™, ATOVAQUONE™, ISONIAZID™, RIFAMPIN™, PYRAZINAMIDE™, ETHAMBUTOL™, RIFABUTIN™, CLARITHROMYCIN™, AZITHROMYCIN™, GANCICLOVIR™, FOSCARNET™, CIDOFOVIR™, FLUCONAZOLE™, ITRACONAZOLE™, KETOCONAZOLE™, ACYCLOVIR™, FAMCICOLVIR™, PYRIMETHAMINE™, LEUCOVORIN™, NEUPOGEN™ (filgrastim/G-CSF), and LEUKINE™ (sargramostim/GM-CSF). In a specific embodiment, Therapeutics of the invention are used in any combination with TRIMETHOPRIM-SULFAMETHOXAZOLE™, DAPSONE™, PENTAMIDINE™, and/or ATOVAQUONE™ to prophylactically treat or prevent an opportunistic *Pneumocystis carinii* pneumonia infection. In

another specific embodiment, Therapeutics of the invention are used in any combination with ISONIAZID™, RIFAMPIN™, PYRAZINAMIDE™, and/or ETHAMBUTOL™ to prophylactically treat or prevent an opportunistic *Mycobacterium avium* complex infection. In another specific embodiment, Therapeutics of the invention are used in any combination with RIFABUTIN™, CLARITHROMYCIN™, and/or AZITHROMYCIN™ to prophylactically treat or prevent an opportunistic *Mycobacterium tuberculosis* infection. In another specific embodiment, Therapeutics of the invention are used in any combination with GANCICLOVIR™, FOSCARNET™, and/or CIDOFOVIR™ to prophylactically treat or prevent an opportunistic cytomegalovirus infection. In another specific embodiment, Therapeutics of the invention are used in any combination with FLUCONAZOLE™, ITRACONAZOLE™, and/or KETOCONAZOLE™ to prophylactically treat or prevent an opportunistic fungal infection. In another specific embodiment, Therapeutics of the invention are used in any combination with ACYCLOVIR™ and/or FAMCICOLVIR™ to prophylactically treat or prevent an opportunistic herpes simplex virus type I and/or type II infection. In another specific embodiment, Therapeutics of the invention are used in any combination with PYRIMETHAMINE™ and/or LEUCOVORIN™ to prophylactically treat or prevent an opportunistic *Toxoplasma gondii* infection. In another specific embodiment, Therapeutics of the invention are used in any combination with LEUCOVORIN™ and/or NEUPOGEN™ to prophylactically treat or prevent an opportunistic bacterial infection.

In a further embodiment, the Therapeutics of the invention are administered in combination with an antiviral agent. Antiviral agents that may be administered with the Therapeutics of the invention include, but are not limited to, acyclovir, ribavirin, amantadine, and remantidine.

In a further embodiment, the Therapeutics of the invention are administered in combination with an antibiotic agent. Antibiotic agents that may be administered with the Therapeutics of the invention include, but are not limited to, amoxicillin, beta-lactamases, aminoglycosides, beta-lactam (glycopeptide), beta-lactamases, Clindamycin, chloramphenicol, cephalosporins, ciprofloxacin, ciprofloxacin,

erythromycin, fluoroquinolones, macrolides, metronidazole, penicillins, quinolones, rifampin, streptomycin, sulfonamide, tetracyclines, trimethoprim, trimethoprim-sulfamthoxazole, and vancomycin.

Conventional nonspecific immunosuppressive agents, that may be administered in combination with the Therapeutics of the invention include, but are not limited to, steroids, cyclosporine, cyclosporine analogs, cyclophosphamide methylprednisone, prednisone, azathioprine, FK-506, 15-deoxyspergualin, and other immunosuppressive agents that act by suppressing the function of responding T cells.

In specific embodiments, Therapeutics of the invention are administered in combination with immunosuppressants. Immunosuppressants preparations that may be administered with the Therapeutics of the invention include, but are not limited to, ORTHOCLONE™ (OKT3), SANDIMMUNE™/NEORAL™/SANGDYA™ (cyclosporin), PROGRAF™ (tacrolimus), CELLCEPT™ (mycophenolate), Azathioprine, glucocorticosteroids, and RAPAMUNE™ (sirolimus). In a specific embodiment, immunosuppressants may be used to prevent rejection of organ or bone marrow transplantation.

In an additional embodiment, Therapeutics of the invention are administered alone or in combination with one or more intravenous immune globulin preparations. Intravenous immune globulin preparations that may be administered with the Therapeutics of the invention include, but not limited to, GAMMAR™, IVEEGAM™, SANDOGLOBULIN™, GAMMAGARD S/D™, and GAMIMUNE™. In a specific embodiment, Therapeutics of the invention are administered in combination with intravenous immune globulin preparations in transplantation therapy (e.g., bone marrow transplant).

In an additional embodiment, the Therapeutics of the invention are administered alone or in combination with an anti-inflammatory agent. Anti-inflammatory agents that may be administered with the Therapeutics of the invention include, but are not limited to, glucocorticoids and the nonsteroidal anti-inflammatories, aminoarylcarboxylic acid derivatives, arylacetic acid derivatives, arylbutyric acid derivatives, arylcarboxylic acids, arylpropionic acid derivatives, pyrazoles, pyrazolones, salicylic acid derivatives, thiazinecarboxamides, e-

acetamidocaproic acid, S-adenosylmethionine, 3-amino-4-hydroxybutyric acid, amixetrine, bendazac, benzydamine, bucolome, difenpiramide, ditazol, emorfazone, guaiazulene, nabumetone, nimesulide, orgotein, oxaceprol, paranyline, perisoxal, pifoxime, proquazone, proxazole, and tenidap.

5 In another embodiment, compositions of the invention are administered in combination with a chemotherapeutic agent. Chemotherapeutic agents that may be administered with the Therapeutics of the invention include, but are not limited to, antibiotic derivatives (e.g., doxorubicin, bleomycin, daunorubicin, and dactinomycin); antiestrogens (e.g., tamoxifen); antimetabolites (e.g., fluorouracil, 5-  
10 FU, methotrexate, floxuridine, interferon alpha-2b, glutamic acid, plicamycin, mercaptopurine, and 6-thioguanine); cytotoxic agents (e.g., carmustine, BCNU, lomustine, CCNU, cytosine arabinoside, cyclophosphamide, estramustine, hydroxyurea, procarbazine, mitomycin, busulfan, cis-platin, and vincristine sulfate); hormones (e.g., medroxyprogesterone, estramustine phosphate sodium, ethinyl  
15 estradiol, estradiol, megestrol acetate, methyltestosterone, diethylstilbestrol diphosphate, chlorotrianisene, and testolactone); nitrogen mustard derivatives (e.g., mephalen, chorambucil, mechlorethamine (nitrogen mustard) and thiotepa); steroids and combinations (e.g., bethamethasone sodium phosphate); and others (e.g., dicarbazine, asparaginase, mitotane, vincristine sulfate, vinblastine sulfate, and  
20 etoposide).

In a specific embodiment, Therapeutics of the invention are administered in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or any combination of the components of CHOP. In another embodiment, Therapeutics of the invention are administered in combination with  
25 Rituximab. In a further embodiment, Therapeutics of the invention are administered with Rituxmab and CHOP, or Rituxmab and any combination of the components of CHOP.

In an additional embodiment, the Therapeutics of the invention are administered in combination with cytokines. Cytokines that may be administered  
30 with the Therapeutics of the invention include, but are not limited to, IL2, IL3, IL4, IL5, IL6, IL7, IL10, IL12, IL13, IL15, anti-CD40, CD40L, IFN-gamma and TNF-alpha. In another embodiment, Therapeutics of the invention may be administered



with any interleukin, including, but not limited to, IL-1alpha, IL-1beta, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, and IL-21.

In an additional embodiment, the Therapeutics of the invention are administered in combination with angiogenic proteins. Angiogenic proteins that may be administered with the Therapeutics of the invention include, but are not limited to, Glioma Derived Growth Factor (GDGF), as disclosed in European Patent Number EP-399816; Platelet Derived Growth Factor-A (PDGF-A), as disclosed in European Patent Number EP-682110; Platelet Derived Growth Factor-B (PDGF-B), as disclosed in European Patent Number EP-282317; Placental Growth Factor (PlGF), as disclosed in International Publication Number WO 92/06194; Placental Growth Factor-2 (PlGF-2), as disclosed in Hauser et al., Growth Factors, 4:259-268 (1993); Vascular Endothelial Growth Factor (VEGF), as disclosed in International Publication Number WO 90/13649; Vascular Endothelial Growth Factor-A (VEGF-A), as disclosed in European Patent Number EP-506477; Vascular Endothelial Growth Factor-2 (VEGF-2), as disclosed in International Publication Number WO 96/39515; Vascular Endothelial Growth Factor B (VEGF-3); Vascular Endothelial Growth Factor B-186 (VEGF-B186), as disclosed in International Publication Number WO 96/26736; Vascular Endothelial Growth Factor-D (VEGF-D), as disclosed in International Publication Number WO 98/02543; Vascular Endothelial Growth Factor-D (VEGF-D), as disclosed in International Publication Number WO 98/07832; and Vascular Endothelial Growth Factor-E (VEGF-E), as disclosed in German Patent Number DE19639601. The above mentioned references are incorporated herein by reference herein.

In an additional embodiment, the Therapeutics of the invention are administered in combination with hematopoietic growth factors. Hematopoietic growth factors that may be administered with the Therapeutics of the invention include, but are not limited to, LEUKINE™ (SARGRAMOSTIM™) and NEUPOGEN™ (FILGRASTIM™).

In an additional embodiment, the Therapeutics of the invention are administered in combination with Fibroblast Growth Factors. Fibroblast Growth Factors that may be administered with the Therapeutics of the invention include, but

are not limited to, FGF-1, FGF-2, FGF-3, FGF-4, FGF-5, FGF-6, FGF-7, FGF-8, FGF-9, FGF-10, FGF-11, FGF-12, FGF-13, FGF-14, and FGF-15.

In additional embodiments, the Therapeutics of the invention are administered in combination with other therapeutic or prophylactic regimens, such as, for example,  
5 radiation therapy.

**Example 24: Method of Treating Decreased Levels of the Polypeptide**

The present invention relates to a method for treating an individual in need of an increased level of a polypeptide of the invention in the body comprising  
10 administering to such an individual a composition comprising a therapeutically effective amount of an agonist of the invention (including polypeptides of the invention). Moreover, it will be appreciated that conditions caused by a decrease in the standard or normal expression level of a secreted protein in an individual can be treated by administering the polypeptide of the present invention, preferably in the  
15 secreted form. Thus, the invention also provides a method of treatment of an individual in need of an increased level of the polypeptide comprising administering to such an individual a Therapeutic comprising an amount of the polypeptide to increase the activity level of the polypeptide in such an individual.

For example, a patient with decreased levels of a polypeptide receives a daily  
20 dose 0.1-100 ug/kg of the polypeptide for six consecutive days. Preferably, the polypeptide is in the secreted form. The exact details of the dosing scheme, based on administration and formulation, are provided in Example 23.

**Example 25: Method of Treating Increased Levels of the Polypeptide**

25 The present invention also relates to a method of treating an individual in need of a decreased level of a polypeptide of the invention in the body comprising administering to such an individual a composition comprising a therapeutically effective amount of an antagonist of the invention (including polypeptides and antibodies of the invention).

30 In one example, antisense technology is used to inhibit production of a polypeptide of the present invention. This technology is one example of a method of

decreasing levels of a polypeptide, preferably a secreted form, due to a variety of etiologies, such as cancer. For example, a patient diagnosed with abnormally increased levels of a polypeptide is administered intravenously antisense polynucleotides at 0.5, 1.0, 1.5, 2.0 and 3.0 mg/kg day for 21 days. This treatment is repeated after a 7-day rest period if the treatment was well tolerated. The formulation of the antisense polynucleotide is provided in Example 23.

**Example 26: Method of Treatment Using Gene Therapy-Ex Vivo**

One method of gene therapy transplants fibroblasts, which are capable of expressing a polypeptide, onto a patient. Generally, fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in tissue-culture medium and separated into small pieces. Small chunks of the tissue are placed on a wet surface of a tissue culture flask, approximately ten pieces are placed in each flask. The flask is turned upside down, closed tight and left at room temperature over night. After 24 hours at room temperature, the flask is inverted and the chunks of tissue remain fixed to the bottom of the flask and fresh media (e.g., Ham's F12 media, with 10% FBS, penicillin and streptomycin) is added. The flasks are then incubated at 37 degree C for approximately one week.

At this time, fresh media is added and subsequently changed every several days. After an additional two weeks in culture, a monolayer of fibroblasts emerge. The monolayer is trypsinized and scaled into larger flasks.

pMV-7 (Kirschmeier, P.T. et al., DNA, 7:219-25 (1988)), flanked by the long terminal repeats of the Moloney murine sarcoma virus, is digested with EcoRI and HindIII and subsequently treated with calf intestinal phosphatase. The linear vector is fractionated on agarose gel and purified, using glass beads.

The cDNA encoding a polypeptide of the present invention can be amplified using PCR primers which correspond to the 5' and 3' end sequences respectively as set forth in Example 1 using primers and having appropriate restriction sites and initiation/stop codons, if necessary. Preferably, the 5' primer contains an EcoRI site and the 3' primer includes a HindIII site. Equal quantities of the Moloney murine sarcoma virus linear backbone and the amplified EcoRI and HindIII fragment are added together, in the presence of T4 DNA ligase. The resulting mixture is

maintained under conditions appropriate for ligation of the two fragments. The ligation mixture is then used to transform bacteria HB101, which are then plated onto agar containing kanamycin for the purpose of confirming that the vector has the gene of interest properly inserted.

5           The amphotropic pA317 or GP+am12 packaging cells are grown in tissue culture to confluent density in Dulbecco's Modified Eagles Medium (DMEM) with 10% calf serum (CS), penicillin and streptomycin. The MSV vector containing the gene is then added to the media and the packaging cells transduced with the vector. The packaging cells now produce infectious viral particles containing the gene (the  
10       packaging cells are now referred to as producer cells).

          Fresh media is added to the transduced producer cells, and subsequently, the media is harvested from a 10 cm plate of confluent producer cells. The spent media, containing the infectious viral particles, is filtered through a millipore filter to remove detached producer cells and this media is then used to infect fibroblast cells. Media is  
15       removed from a sub-confluent plate of fibroblasts and quickly replaced with the media from the producer cells. This media is removed and replaced with fresh media. If the titer of virus is high, then virtually all fibroblasts will be infected and no selection is required. If the titer is very low, then it is necessary to use a retroviral vector that has a selectable marker, such as neo or his. Once the fibroblasts have been  
20       efficiently infected, the fibroblasts are analyzed to determine whether protein is produced.

          The engineered fibroblasts are then transplanted onto the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads.

25       **Example 27: Gene Therapy Using Endogenous Genes Corresponding To Polynucleotides of the Invention**

          Another method of gene therapy according to the present invention involves operably associating the endogenous polynucleotide sequence of the invention with a promoter via homologous recombination as described, for example, in U.S. Patent  
30       NO: 5,641,670, issued June 24, 1997; International Publication NO: WO 96/29411, published September 26, 1996; International Publication NO: WO 94/12650, published August 4, 1994; Koller et al., *Proc. Natl. Acad. Sci. USA*, 86:8932-8935

(1989); and Zijlstra et al., *Nature*, 342:435-438 (1989). This method involves the activation of a gene which is present in the target cells, but which is not expressed in the cells, or is expressed at a lower level than desired.

Polynucleotide constructs are made which contain a promoter and targeting  
5 sequences, which are homologous to the 5' non-coding sequence of endogenous  
polynucleotide sequence, flanking the promoter. The targeting sequence will be  
sufficiently near the 5' end of the polynucleotide sequence so the promoter will be  
operably linked to the endogenous sequence upon homologous recombination. The  
promoter and the targeting sequences can be amplified using PCR. Preferably, the  
10 amplified promoter contains distinct restriction enzyme sites on the 5' and 3' ends.  
Preferably, the 3' end of the first targeting sequence contains the same restriction  
enzyme site as the 5' end of the amplified promoter and the 5' end of the second  
targeting sequence contains the same restriction site as the 3' end of the amplified  
promoter.

15 The amplified promoter and the amplified targeting sequences are digested  
with the appropriate restriction enzymes and subsequently treated with calf intestinal  
phosphatase. The digested promoter and digested targeting sequences are added  
together in the presence of T4 DNA ligase. The resulting mixture is maintained under  
conditions appropriate for ligation of the two fragments. The construct is size  
20 fractionated on an agarose gel then purified by phenol extraction and ethanol  
precipitation.

In this Example, the polynucleotide constructs are administered as naked  
polynucleotides via electroporation. However, the polynucleotide constructs may also  
be administered with transfection-facilitating agents, such as liposomes, viral  
25 sequences, viral particles, precipitating agents, etc. Such methods of delivery are  
known in the art.

Once the cells are transfected, homologous recombination will take place  
which results in the promoter being operably linked to the endogenous polynucleotide  
sequence. This results in the expression of polynucleotide corresponding to the  
30 polynucleotide in the cell. Expression may be detected by immunological staining, or  
any other method known in the art.

Fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in DMEM + 10% fetal calf serum. Exponentially growing or early stationary phase fibroblasts are trypsinized and rinsed from the plastic surface with nutrient medium. An aliquot of the cell suspension is removed for counting, and the remaining  
5 cells are subjected to centrifugation. The supernatant is aspirated and the pellet is resuspended in 5 ml of electroporation buffer (20 mM HEPES pH 7.3, 137 mM NaCl, 5 mM KCl, 0.7 mM Na<sub>2</sub> HPO<sub>4</sub>, 6 mM dextrose). The cells are recentrifuged, the supernatant aspirated, and the cells resuspended in electroporation buffer containing 1 mg/ml acetylated bovine serum albumin. The final cell suspension contains  
10 approximately  $3 \times 10^6$  cells/ml. Electroporation should be performed immediately following resuspension.

Plasmid DNA is prepared according to standard techniques. For example, to construct a plasmid for targeting to the locus corresponding to the polynucleotide of the invention, plasmid pUC18 (MBI Fermentas, Amherst, NY) is digested with  
15 HindIII. The CMV promoter is amplified by PCR with an XbaI site on the 5' end and a BamHI site on the 3' end. Two non-coding sequences are amplified via PCR: one non-coding sequence (fragment 1) is amplified with a HindIII site at the 5' end and an Xba site at the 3' end; the other non-coding sequence (fragment 2) is amplified with a BamHI site at the 5' end and a HindIII site at the 3' end. The CMV promoter and the  
20 fragments (1 and 2) are digested with the appropriate enzymes (CMV promoter - XbaI and BamHI; fragment 1 - XbaI; fragment 2 - BamHI) and ligated together. The resulting ligation product is digested with HindIII, and ligated with the HindIII-digested pUC18 plasmid.

Plasmid DNA is added to a sterile cuvette with a 0.4 cm electrode gap  
25 (Bio-Rad). The final DNA concentration is generally at least 120 µg/ml. 0.5 ml of the cell suspension (containing approximately  $1.5 \times 10^6$  cells) is then added to the cuvette, and the cell suspension and DNA solutions are gently mixed. Electroporation is performed with a Gene-Pulser apparatus (Bio-Rad). Capacitance and voltage are set at 960 µF and 250-300 V, respectively. As voltage increases, cell survival decreases, but  
30 the percentage of surviving cells that stably incorporate the introduced DNA into their genome increases dramatically. Given these parameters, a pulse time of approximately 14-20 mSec should be observed.

Electroporated cells are maintained at room temperature for approximately 5 min, and the contents of the cuvette are then gently removed with a sterile transfer pipette. The cells are added directly to 10 ml of prewarmed nutrient media (DMEM with 15% calf serum) in a 10 cm dish and incubated at 37 degree C. The following  
5 day, the media is aspirated and replaced with 10 ml of fresh media and incubated for a further 16-24 hours.

The engineered fibroblasts are then injected into the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads. The fibroblasts now produce the protein product. The fibroblasts can then be introduced into a  
10 patient as described above.

#### **Example 28: Method of Treatment Using Gene Therapy - In Vivo**

Another aspect of the present invention is using *in vivo* gene therapy methods to treat disorders, diseases and conditions. The gene therapy method relates to the  
15 introduction of naked nucleic acid (DNA, RNA, and antisense DNA or RNA) sequences into an animal to increase or decrease the expression of the polypeptide. The polynucleotide of the present invention may be operatively linked to a promoter or any other genetic elements necessary for the expression of the polypeptide by the target tissue. Such gene therapy and delivery techniques and methods are known in  
20 the art, see, for example, WO90/11092, WO98/11779; U.S. Patent NO. 5693622, 5705151, 5580859; Tabata et al., Cardiovasc. Res. 35(3):470-479 (1997); Chao et al., Pharmacol. Res. 35(6):517-522 (1997); Wolff, Neuromuscul. Disord. 7(5):314-318 (1997); Schwartz et al., Gene Ther. 3(5):405-411 (1996); Tsurumi et al., Circulation 94(12):3281-3290 (1996) (incorporated herein by reference).

25 The polynucleotide constructs may be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver, intestine and the like). The polynucleotide constructs can be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

30 The term "naked" polynucleotide, DNA or RNA, refers to sequences that are free from any delivery vehicle that acts to assist, promote, or facilitate entry into the cell, including viral sequences, viral particles, liposome formulations, lipofectin or

precipitating agents and the like. However, the polynucleotides of the present invention may also be delivered in liposome formulations (such as those taught in Felgner P.L. et al. (1995) Ann. NY Acad. Sci. 772:126-139 and Abdallah B. et al. (1995) Biol. Cell 85(1):1-7) which can be prepared by methods well known to those skilled in the art.

The polynucleotide vector constructs used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Any strong promoter known to those skilled in the art can be used for driving the expression of DNA. Unlike other gene therapies techniques, one major advantage of introducing naked nucleic acid sequences into target cells is the transitory nature of the polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

The polynucleotide construct can be delivered to the interstitial space of tissues within the an animal, including of muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and connective tissue. Interstitial space of the tissues comprises the intercellular fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely differentiated cells, such as, for example, stem cells of blood or skin fibroblasts. *In vivo* muscle cells are particularly competent in their ability to take up and express polynucleotides.

For the naked polynucleotide injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05 g/kg body weight to about 50 mg/kg



body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence  
5 can readily be determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration. The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation particularly for delivery to lungs or bronchial tissues, throat or  
10 mucous membranes of the nose. In addition, naked polynucleotide constructs can be delivered to arteries during angioplasty by the catheter used in the procedure.

The dose response effects of injected polynucleotide in muscle *in vivo* is determined as follows. Suitable template DNA for production of mRNA coding for polypeptide of the present invention is prepared in accordance with a standard  
15 recombinant DNA methodology. The template DNA, which may be either circular or linear, is either used as naked DNA or complexed with liposomes. The quadriceps muscles of mice are then injected with various amounts of the template DNA.

Five to six week old female and male Balb/C mice are anesthetized by intraperitoneal injection with 0.3 ml of 2.5% Avertin. A 1.5 cm incision is made on  
20 the anterior thigh, and the quadriceps muscle is directly visualized. The template DNA is injected in 0.1 ml of carrier in a 1 cc syringe through a 27 gauge needle over one minute, approximately 0.5 cm from the distal insertion site of the muscle into the knee and about 0.2 cm deep. A suture is placed over the injection site for future localization, and the skin is closed with stainless steel clips.

25 After an appropriate incubation time (e.g., 7 days) muscle extracts are prepared by excising the entire quadriceps. Every fifth 15 um cross-section of the individual quadriceps muscles is histochemically stained for protein expression. A time course for protein expression may be done in a similar fashion except that quadriceps from different mice are harvested at different times. Persistence of DNA  
30 in muscle following injection may be determined by Southern blot analysis after preparing total cellular DNA and HIRT supernatants from injected and control mice. The results of the above experimentation in mice can be use to extrapolate proper

dosages and other treatment parameters in humans and other animals using naked DNA.

**Example 29: Transgenic Animals.**

5           The polypeptides of the invention can also be expressed in transgenic animals. Animals of any species, including, but not limited to, mice, rats, rabbits, hamsters, guinea pigs, pigs, micro-pigs, goats, sheep, cows and non-human primates, *e.g.*, baboons, monkeys, and chimpanzees may be used to generate transgenic animals. In a specific embodiment, techniques described herein or otherwise known in the art, are  
10       used to express polypeptides of the invention in humans, as part of a gene therapy protocol.

          Any technique known in the art may be used to introduce the transgene (*i.e.*, polynucleotides of the invention) into animals to produce the founder lines of transgenic animals. Such techniques include, but are not limited to, pronuclear  
15       microinjection (Paterson et al., Appl. Microbiol. Biotechnol. 40:691-698 (1994); Carver et al., Biotechnology (NY) 11:1263-1270 (1993); Wright et al., Biotechnology (NY) 9:830-834 (1991); and Hoppe et al., U.S. Pat. No. 4,873,191 (1989)); retrovirus mediated gene transfer into germ lines (Van der Putten et al., Proc. Natl. Acad. Sci., USA 82:6148-6152 (1985)), blastocysts or embryos; gene targeting in embryonic  
20       stem cells (Thompson et al., Cell 56:313-321 (1989)); electroporation of cells or embryos (Lo, 1983, Mol Cell. Biol. 3:1803-1814 (1983)); introduction of the polynucleotides of the invention using a gene gun (see, *e.g.*, Ulmer et al., Science 259:1745 (1993); introducing nucleic acid constructs into embryonic pluripotent stem cells and transferring the stem cells back into the blastocyst; and sperm-  
25       mediated gene transfer (Lavitrano et al., Cell 57:717-723 (1989); etc. For a review of such techniques, see Gordon, "Transgenic Animals," Intl. Rev. Cytol. 115:171-229 (1989), which is incorporated by reference herein in its entirety.

          Any technique known in the art may be used to produce transgenic clones containing polynucleotides of the invention, for example, nuclear transfer into  
30       enucleated oocytes of nuclei from cultured embryonic, fetal, or adult cells induced to quiescence (Campell et al., Nature 380:64-66 (1996); Wilmut et al., Nature 385:810-813 (1997)).

The present invention provides for transgenic animals that carry the transgene in all their cells, as well as animals which carry the transgene in some, but not all their cells, *i.e.*, mosaic animals or chimeric. The transgene may be integrated as a single transgene or as multiple copies such as in concatamers, *e.g.*, head-to-head tandems or head-to-tail tandems. The transgene may also be selectively introduced into and activated in a particular cell type by following, for example, the teaching of Lasko et al. (Lasko et al., Proc. Natl. Acad. Sci. USA 89:6232-6236 (1992)). The regulatory sequences required for such a cell-type specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art. When it is desired that the polynucleotide transgene be integrated into the chromosomal site of the endogenous gene, gene targeting is preferred. Briefly, when such a technique is to be utilized, vectors containing some nucleotide sequences homologous to the endogenous gene are designed for the purpose of integrating, via homologous recombination with chromosomal sequences, into and disrupting the function of the nucleotide sequence of the endogenous gene. The transgene may also be selectively introduced into a particular cell type, thus inactivating the endogenous gene in only that cell type, by following, for example, the teaching of Gu et al. (Gu et al., Science 265:103-106 (1994)). The regulatory sequences required for such a cell-type specific inactivation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.

Once transgenic animals have been generated, the expression of the recombinant gene may be assayed utilizing standard techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to verify that integration of the transgene has taken place. The level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques which include, but are not limited to, Northern blot analysis of tissue samples obtained from the animal, *in situ* hybridization analysis, and reverse transcriptase-PCR (rt-PCR). Samples of transgenic gene-expressing tissue may also be evaluated immunocytochemically or immunohistochemically using antibodies specific for the transgene product.

Once the founder animals are produced, they may be bred, inbred, outbred, or crossbred to produce colonies of the particular animal. Examples of such breeding

strategies include, but are not limited to: outbreeding of founder animals with more than one integration site in order to establish separate lines; inbreeding of separate lines in order to produce compound transgenics that express the transgene at higher levels because of the effects of additive expression of each transgene; crossing of  
5 heterozygous transgenic animals to produce animals homozygous for a given integration site in order to both augment expression and eliminate the need for screening of animals by DNA analysis; crossing of separate homozygous lines to produce compound heterozygous or homozygous lines; and breeding to place the transgene on a distinct background that is appropriate for an experimental model of  
10 interest.

Transgenic animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying diseases, disorders, and/or conditions associated with aberrant expression, and in screening for compounds effective in  
15 ameliorating such diseases, disorders, and/or conditions.

### **Example 30: Knock-Out Animals.**

Endogenous gene expression can also be reduced by inactivating or "knocking out" the gene and/or its promoter using targeted homologous recombination. (*E.g.*,  
20 see Smithies et al., Nature 317:230-234 (1985); Thomas & Capecchi, Cell 51:503-512 (1987); Thompson et al., Cell 5:313-321 (1989); each of which is incorporated by reference herein in its entirety). For example, a mutant, non-functional polynucleotide of the invention (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous polynucleotide sequence (either the coding  
25 regions or regulatory regions of the gene) can be used, with or without a selectable marker and/or a negative selectable marker, to transfect cells that express polypeptides of the invention *in vivo*. In another embodiment, techniques known in the art are used to generate knockouts in cells that contain, but do not express the gene of interest. Insertion of the DNA construct, via targeted homologous recombination,  
30 results in inactivation of the targeted gene. Such approaches are particularly suited in research and agricultural fields where modifications to embryonic stem cells can be used to generate animal offspring with an inactive targeted gene (*e.g.*, see Thomas &

Capecchi 1987 and Thompson 1989, *supra*). However this approach can be routinely adapted for use in humans provided the recombinant DNA constructs are directly administered or targeted to the required site *in vivo* using appropriate viral vectors that will be apparent to those of skill in the art.

5           In further embodiments of the invention, cells that are genetically engineered to express the polypeptides of the invention, or alternatively, that are genetically engineered not to express the polypeptides of the invention (e.g., knockouts) are administered to a patient *in vivo*. Such cells may be obtained from the patient (i.e., animal, including human) or an MHC compatible donor and can include, but are not  
10   limited to fibroblasts, bone marrow cells, blood cells (e.g., lymphocytes), adipocytes, muscle cells, endothelial cells etc. The cells are genetically engineered *in vitro* using recombinant DNA techniques to introduce the coding sequence of polypeptides of the invention into the cells, or alternatively, to disrupt the coding sequence and/or endogenous regulatory sequence associated with the polypeptides of the invention,  
15   e.g., by transduction (using viral vectors, and preferably vectors that integrate the transgene into the cell genome) or transfection procedures, including, but not limited to, the use of plasmids, cosmids, YACs, naked DNA, electroporation, liposomes, etc. The coding sequence of the polypeptides of the invention can be placed under the control of a strong constitutive or inducible promoter or promoter/enhancer to achieve  
20   expression, and preferably secretion, of the polypeptides of the invention. The engineered cells which express and preferably secrete the polypeptides of the invention can be introduced into the patient systemically, e.g., in the circulation, or intraperitoneally.

          Alternatively, the cells can be incorporated into a matrix and implanted in the  
25   body, e.g., genetically engineered fibroblasts can be implanted as part of a skin graft; genetically engineered endothelial cells can be implanted as part of a lymphatic or vascular graft. (See, for example, Anderson et al. U.S. Patent No. 5,399,349; and Mulligan & Wilson, U.S. Patent No. 5,460,959 each of which is incorporated by reference herein in its entirety).

30           When the cells to be administered are non-autologous or non-MHC compatible cells, they can be administered using well known techniques which prevent the development of a host immune response against the introduced cells. For

example, the cells may be introduced in an encapsulated form which, while allowing for an exchange of components with the immediate extracellular environment, does not allow the introduced cells to be recognized by the host immune system.

Transgenic and "knock-out" animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying diseases, disorders, and/or conditions associated with aberrant expression, and in screening for compounds effective in ameliorating such diseases, disorders, and/or conditions.

### 10 **Example 31: Production of an Antibody**

#### a) Hybridoma Technology

The antibodies of the present invention can be prepared by a variety of methods. (See, Current Protocols, Chapter 2.) As one example of such methods, cells expressing polypeptide(s) of the invention are administered to an animal to induce the production of sera containing polyclonal antibodies. In a preferred method, a preparation of polypeptide(s) of the invention is prepared and purified to render it substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity.

Monoclonal antibodies specific for polypeptide(s) of the invention are prepared using hybridoma technology. (Kohler et al., Nature 256:495 (1975); Kohler et al., Eur. J. Immunol. 6:511 (1976); Kohler et al., Eur. J. Immunol. 6:292 (1976); Hammerling et al., in: Monoclonal Antibodies and T-Cell Hybridomas, Elsevier, N.Y., pp. 563-681 (1981)). In general, an animal (preferably a mouse) is immunized with polypeptide(s) of the invention, or, more preferably, with a secreted polypeptide-expressing cell. Such polypeptide-expressing cells are cultured in any suitable tissue culture medium, preferably in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56°C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100 µg/ml of streptomycin.

The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line

(SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands et al. (Gastroenterology 80:225-232 (1981)). The hybridoma cells obtained through such a selection are then assayed to identify clones which  
5 secrete antibodies capable of binding the polypeptide(s) of the invention.

Alternatively, additional antibodies capable of binding polypeptide(s) of the invention can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In  
10 accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the polypeptide(s) of the invention protein-specific antibody can be blocked by polypeptide(s) of the invention.  
15 Such antibodies comprise anti-idiotypic antibodies to the polypeptide(s) of the invention protein-specific antibody and are used to immunize an animal to induce formation of further polypeptide(s) of the invention protein-specific antibodies.

For in vivo use of antibodies in humans, an antibody is "humanized". Such antibodies can be produced using genetic constructs derived from hybridoma cells  
20 producing the monoclonal antibodies described above. Methods for producing chimeric and humanized antibodies are known in the art and are discussed herein. (See, for review, Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Cabilly et al., U.S. Patent No. 4,816,567; Taniguchi et al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson et al., WO  
25 8702671; Boulianne et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268 (1985).)

#### b) Isolation Of Antibody Fragments Directed

polypeptide(s) of the invention From A Library Of scFvs

30 Naturally occurring V-genes isolated from human PBLs are constructed into a library of antibody fragments which contain reactivities against polypeptide(s) of the

invention to which the donor may or may not have been exposed (see e.g., U.S. Patent 5,885,793 incorporated herein by reference in its entirety).

Rescue of the Library. A library of scFvs is constructed from the RNA of human PBLs as described in PCT publication WO 92/01047. To rescue phage displaying antibody fragments, approximately 10<sup>9</sup> E. coli harboring the phagemid are used to inoculate 50 ml of 2xTY containing 1% glucose and 100 µg/ml of ampicillin (2xTY-AMP-GLU) and grown to an O.D. of 0.8 with shaking. Five ml of this culture is used to inoculate 50 ml of 2xTY-AMP-GLU, 2 x 10<sup>8</sup> TU of delta gene 3 helper (M13 delta gene III, see PCT publication WO 92/01047) are added and the culture incubated at 37°C for 45 minutes without shaking and then at 37°C for 45 minutes with shaking. The culture is centrifuged at 4000 r.p.m. for 10 min. and the pellet resuspended in 2 liters of 2xTY containing 100 µg/ml ampicillin and 50 µg/ml kanamycin and grown overnight. Phage are prepared as described in PCT publication WO 92/01047.

M13 delta gene III is prepared as follows: M13 delta gene III helper phage does not encode gene III protein, hence the phage(mid) displaying antibody fragments have a greater avidity of binding to antigen. Infectious M13 delta gene III particles are made by growing the helper phage in cells harboring a pUC19 derivative supplying the wild type gene III protein during phage morphogenesis. The culture is incubated for 1 hour at 37° C without shaking and then for a further hour at 37°C with shaking. Cells are spun down (IEC-Centra 8,400 r.p.m. for 10 min), resuspended in 300 ml 2xTY broth containing 100 µg ampicillin/ml and 25 µg kanamycin/ml (2xTY-AMP-KAN) and grown overnight, shaking at 37°C. Phage particles are purified and concentrated from the culture medium by two PEG-precipitations (Sambrook et al., 1990), resuspended in 2 ml PBS and passed through a 0.45 µm filter (Minisart NML; Sartorius) to give a final concentration of approximately 10<sup>13</sup> transducing units/ml (ampicillin-resistant clones).

Panning of the Library. Immunotubes (Nunc) are coated overnight in PBS with 4 ml of either 100 µg/ml or 10 µg/ml of a polypeptide of the present invention. Tubes are blocked with 2% Marvel-PBS for 2 hours at 37°C and then washed 3 times in PBS. Approximately 10<sup>13</sup> TU of phage is applied to the tube and incubated for 30 minutes at room temperature tumbling on an over and under turntable and then left to



stand for another 1.5 hours. Tubes are washed 10 times with PBS 0.1% Tween-20 and 10 times with PBS. Phage are eluted by adding 1 ml of 100 mM triethylamine and rotating 15 minutes on an under and over turntable after which the solution is immediately neutralized with 0.5 ml of 1.0M Tris-HCl, pH 7.4. Phage are then used to infect 10 ml of mid-log E. coli TG1 by incubating eluted phage with bacteria for 30 minutes at 37°C. The E. coli are then plated on TYE plates containing 1% glucose and 100 µg/ml ampicillin. The resulting bacterial library is then rescued with delta gene 3 helper phage as described above to prepare phage for a subsequent round of selection. This process is then repeated for a total of 4 rounds of affinity purification with tube-washing increased to 20 times with PBS, 0.1% Tween-20 and 20 times with PBS for rounds 3 and 4.

Characterization of Binders. Eluted phage from the 3rd and 4th rounds of selection are used to infect E. coli HB 2151 and soluble scFv is produced (Marks, et al., 1991) from single colonies for assay. ELISAs are performed with microtitre plates coated with either 10 pg/ml of the polypeptide of the present invention in 50 mM bicarbonate pH 9.6. Clones positive in ELISA are further characterized by PCR fingerprinting (see, e.g., PCT publication WO 92/01047) and then by sequencing. These ELISA positive clones may also be further characterized by techniques known in the art, such as, for example, epitope mapping, binding affinity, receptor signal transduction, ability to block or competitively inhibit antibody/antigen binding, and competitive agonistic or antagonistic activity.

### **Example 32: Assays Detecting Stimulation or Inhibition of B cell Proliferation and Differentiation**

Generation of functional humoral immune responses requires both soluble and cognate signaling between B-lineage cells and their microenvironment. Signals may impart a positive stimulus that allows a B-lineage cell to continue its programmed development, or a negative stimulus that instructs the cell to arrest its current developmental pathway. To date, numerous stimulatory and inhibitory signals have been found to influence B cell responsiveness including IL-2, IL-4, IL-5, IL-6, IL-7, IL10, IL-13, IL-14 and IL-15. Interestingly, these signals are by themselves weak effectors but can,

in combination with various co-stimulatory proteins, induce activation, proliferation, differentiation, homing, tolerance and death among B cell populations.

One of the best studied classes of B-cell co-stimulatory proteins is the TNF-superfamily. Within this family CD40, CD27, and CD30 along with their respective  
5 ligands CD154, CD70, and CD153 have been found to regulate a variety of immune responses. Assays which allow for the detection and/or observation of the proliferation and differentiation of these B-cell populations and their precursors are valuable tools in determining the effects various proteins may have on these B-cell populations in terms of proliferation and differentiation. Listed below are two assays designed to allow for the  
10 detection of the differentiation, proliferation, or inhibition of B-cell populations and their precursors.

In Vitro Assay- Purified polypeptides of the invention, or truncated forms thereof, is assessed for its ability to induce activation, proliferation, differentiation or inhibition and/or death in B-cell populations and their precursors. The activity of the  
15 polypeptides of the invention on purified human tonsillar B cells, measured qualitatively over the dose range from 0.1 to 10,000 ng/mL, is assessed in a standard B-lymphocyte co-stimulation assay in which purified tonsillar B cells are cultured in the presence of either formalin-fixed *Staphylococcus aureus* Cowan I (SAC) or immobilized anti-human IgM antibody as the priming agent. Second signals such as  
20 IL-2 and IL-15 synergize with SAC and IgM crosslinking to elicit B cell proliferation as measured by tritiated-thymidine incorporation. Novel synergizing agents can be readily identified using this assay. The assay involves isolating human tonsillar B cells by magnetic bead (MACS) depletion of CD3-positive cells. The resulting cell population is greater than 95% B cells as assessed by expression of CD45R(B220).

25 Various dilutions of each sample are placed into individual wells of a 96-well plate to which are added  $10^5$  B-cells suspended in culture medium (RPMI 1640 containing 10% FBS,  $5 \times 10^{-5}$ M 2ME, 100U/ml penicillin, 10ug/ml streptomycin, and  $10^{-5}$  dilution of SAC) in a total volume of 150ul. Proliferation or inhibition is quantitated by a 20h pulse (1uCi/well) with 3H-thymidine (6.7 Ci/mM) beginning 72h post factor addition. The  
30 positive and negative controls are IL2 and medium respectively.

In Vivo Assay- BALB/c mice are injected (i.p.) twice per day with buffer only, or 2 mg/Kg of a polypeptide of the invention, or truncated forms thereof. Mice

receive this treatment for 4 consecutive days, at which time they are sacrificed and various tissues and serum collected for analyses. Comparison of H&E sections from normal spleens and spleens treated with polypeptides of the invention identify the results of the activity of the polypeptides on spleen cells, such as the diffusion of peri-  
5 arterial lymphatic sheaths, and/or significant increases in the nucleated cellularity of the red pulp regions, which may indicate the activation of the differentiation and proliferation of B-cell populations. Immunohistochemical studies using a B cell marker, anti-CD45R(B220), are used to determine whether any physiological changes to splenic cells, such as splenic disorganization, are due to increased B-cell  
10 representation within loosely defined B-cell zones that infiltrate established T-cell regions.

Flow cytometric analyses of the spleens from mice treated with polypeptide is used to indicate whether the polypeptide specifically increases the proportion of ThB+, CD45R(B220)dull B cells over that which is observed in control mice.

15 Likewise, a predicted consequence of increased mature B-cell representation in vivo is a relative increase in serum Ig titers. Accordingly, serum IgM and IgA levels are compared between buffer and polypeptide-treated mice.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to  
20 test the activity of polynucleotides of the invention (e.g., gene therapy), agonists, and/or antagonists of polynucleotides or polypeptides of the invention.

### **Example 33: T Cell Proliferation Assay**

#### **Proliferation assay for Resting PBLs.**

25 A CD3-induced proliferation assay is performed on PBMCs and is measured by the uptake of <sup>3</sup>H-thymidine. The assay is performed as follows. Ninety-six well plates are coated with 100 microliters per well of mAb to CD3 (HIT3a, Pharmingen) or isotype-matched control mAb (B33.1) overnight at 4 °C (1 microgram/ml in .05M bicarbonate buffer, pH 9.5), then wash three times with PBS. PBMC are isolated by F/H gradient centrifugation from human peripheral  
30 blood and added to quadruplicate wells (5 x 10<sup>4</sup>/well) of mAb coated plates in RPMI containing 10% FCS and P/S in the presence of varying concentrations of TNF Delta and/or TNF Epsilon protein (total volume 200 microliters). Relevant protein buffer and medium alone are controls.

After 48 hr. culture at 37 °C, plates are spun for 2 min. at 1000 rpm and 100 microliters of supernatant is removed and stored -20 °C for measurement of IL-2 (or other cytokines) if effect on proliferation is observed. Wells are supplemented with 100 microliters of medium containing 0.5 microcuries of <sup>3</sup>H-thymidine and cultured at 37 °C for 18-24 hr. Wells are harvested and incorporation of <sup>3</sup>H-thymidine used as a measure of proliferation. Anti-CD3 alone is the positive control for proliferation. IL-2 (100 U/ml) is also used as a control which enhances proliferation. Control antibody which does not induce proliferation of T cells is used as the negative controls for the effects of TNF Delta and/or TNF Epsilon proteins.

Alternatively, a proliferation assay on resting PBL (peripheral blood lymphocytes) is measured by the up-take of <sup>3</sup>H-thymidine. The assay is performed as follows. PBMC are isolated by Ficoll (LSM, ICN Biotechnologies, Aurora, Ohio) gradient centrifugation from human peripheral blood, and are cultured overnight in 10% (Fetal Calf Serum, Biofluids, Rockville, MD)/RPMI (Gibco BRL, Gaithersburg, MD). This overnight incubation period allows the adherent cells to attach to the plastic, which results in a lower background in the assay as there are fewer cells that can act as antigen presenting cells or that might be producing growth factors. The following day the non-adherent cells are collected, washed and used in the proliferation assay. The assay is performed in a 96 well plate using 2 x 10<sup>4</sup> cells/well in a final volume of 200 microliters. The supernatants (e.g., CHO or 293T supernatants) expressing the protein of interest are tested at a 30% final dilution, therefore 60ul are added to 140ul of 10% FCS/RPMI containing the cells. Control supernatants are used at the same final dilution and express the following proteins: vector (negative control), IL-2 (\*), IFN $\gamma$ , TNF $\alpha$ , IL-10 and TR2. In addition to the control supernatants, recombinant human IL-2 (R & D Systems, Minneapolis, MN) at a final concentration of 100ng/ml is also used. After 24 hours of culture, each well is pulsed with 1uCi of <sup>3</sup>H-thymidine (Nen, Boston, MA). Cells are then harvested 20 hours following pulsing and incorporation of <sup>3</sup>H-thymidine is used as a measure of proliferation. Results are expressed as an average of triplicate samples plus or minus standard error.

(\*) The amount of the control cytokines IL-2, IFN $\gamma$ , TNF $\alpha$  and IL-10 produced in each transfection varies between 300pg to 5ng/ml.

**Costimulation assay.**

A costimulation assay on resting PBL (peripheral blood lymphocytes) is performed in the presence of immobilized antibodies to CD3 and CD28. The use of antibodies specific for the invariant regions of CD3 mimic the induction of T cell activation that would occur through stimulation of the T cell receptor by an antigen. Cross-linking of the TCR (first signal) in the absence of a costimulatory signal (second signal) causes very low induction of proliferation and will eventually result in a state of "anergy", which is characterized by the absence of growth and inability to produce cytokines. The addition of a costimulatory signal such as an antibody to CD28, which mimics the action of the costimulatory molecule. B7-1 expressed on activated APCs, results in enhancement of T cell responses including cell survival and production of IL-2. Therefore this type of assay allows to detect both positive and negative effects caused by addition of supernatants expressing the proteins of interest on T cell proliferation.

The assay is performed as follows. Ninety-six well plates are coated with 100ng/ml anti-CD3 and 5ug/ml anti-CD28 (Pharmingen, San Diego, CA) in a final volume of 100ul and incubated overnight at 4C. Plates are washed twice with PBS before use. PBMC are isolated by Ficoll (LSM, ICN Biotechnologies, Aurora, Ohio) gradient centrifugation from human peripheral blood, and are cultured overnight in 10% FCS(Fetal Calf Serum, Biofluids, Rockville, MD)/RPMI (Gibco BRL, Gaithersburg, MD). This overnight incubation period allows the adherent cells to attach to the plastic, which results in a lower background in the assay as there are fewer cells that can act as antigen presenting cells or that might be producing growth factors. The following day the non adherent cells are collected, washed and used in the proliferation assay. The assay is performed in a 96 well plate using  $2 \times 10^4$  cells/well in a final volume of 200ul. The supernatants (e.g., CHO or 293T supernatants) expressing the protein of interest are tested at a 30% final dilution, therefore 60ul are added to 140ul of 10% FCS/RPMI containing the cells. Control supernatants are used at the same final dilution and express the following proteins: vector only (negative control), IL-2, IFN $\gamma$ , TNF $\alpha$ , IL-10 and TR2. In addition to the control supernatants recombinant human IL-2 (R & D Systems, Minneapolis, MN) at a final concentration of 10ng/ml is also used. After 24 hours of culture, each well is

pulsed with 1uCi of  $^3\text{H}$ -thymidine (Nen, Boston, MA). Cells are then harvested 20 hours following pulsing and incorporation of  $^3\text{H}$ -thymidine is used as a measure of proliferation. Results are expressed as an average of triplicate samples plus or minus standard error.

#### 5 **Costimulation assay: IFN $\gamma$ and IL-2 ELISA**

The assay is performed as follows. Twenty-four well plates are coated with either 300ng/ml or 600ng/ml anti-CD3 and 5ug/ml anti-CD28 (Pharmingen, San Diego, CA) in a final volume of 500ul and incubated overnight at 4C. Plates are washed twice with PBS before use. PBMC are isolated by Ficoll (LSM, ICN Biotechnologies, Aurora, Ohio) gradient centrifugation from human peripheral blood, and are cultured overnight in 10% FCS(Fetal Calf Serum, Biofluids, Rockville, MD)/RPMI (Gibco BRL, Gaithersburg, MD). This overnight incubation period allows the adherent cells to attach to the plastic, which results in a lower background in the assay as there are fewer cells that can act as antigen presenting cells or that might be producing growth factors. The following day the non adherent cells are collected, washed and used in the costimulation assay. The assay is performed in the pre-coated twenty-four well plate using  $1 \times 10^5$  cells/well in a final volume of 900ul. The supernatants (293T supernatants) expressing the protein of interest are tested at a 30% final dilution, therefore 300ul are added to 600ul of 10% FCS/RPMI containing the cells. Control supernatants are used at the same final dilution and express the following proteins: vector only(negative control), IL-2, IFN $\gamma$ , IL-12 and IL-18. In addition to the control supernatants recombinant human IL-2 (all cytokines were purchased from R & D Systems, Minneapolis, MN) at a final concentration of 10ng/ml, IL-12 at a final concentration of 1ng/ml and IL-18 at a final concentration of 50ng/ml are also used. Controls and unknown samples are tested in duplicate. Supernatant samples (250ul) are collected 2 days and 5 days after the beginning of the assay. ELISAs to test for IFN $\gamma$  and IL-2 secretion are performed using kits purchased from R & D Systems, (Minneapolis, MN). Results are expressed as an average of duplicate samples plus or minus standard error.

30

#### **Proliferation assay for preactivated-resting T cells.**

A proliferation assay on preactivated-resting T cells is performed on cells that are previously activated with the lectin phytohemagglutinin (PHA). Lectins are polymeric plant proteins that can bind to residues on T cell surface glycoproteins including the TCR and act as polyclonal activators. PBLs treated with PHA and then  
5 cultured in the presence of low doses of IL-2 resemble effector T cells. These cells are generally more sensitive to further activation induced by growth factors such as IL-2. This is due to the expression of high affinity IL-2 receptors that allows this population to respond to amounts of IL-2 that are 100 fold lower than what would have an effect on a naïve T cell. Therefore the use of this type of cells might enable  
10 to detect the effect of very low doses of an unknown growth factor, that would not be sufficient to induce proliferation on resting (naïve ) T cells.

The assay is performed as follows. PBMC are isolated by F/H gradient centrifugation from human peripheral blood, and are cultured in 10% FCS (Fetal Calf Serum, Biofluids, Rockville, MD)/RPMI (Gibco BRL, Gaithersburg, MD) in the  
15 presence of 2 µg/ml PHA (Sigma, Saint Louis, MO) for three days. The cells are then washed in PBS and cultured in 10% FCS/RPMI in the presence of 5 ng/ml of human recombinant IL-2 (R & D Systems, Minneapolis, MN) for 3 days. The cells are washed and rested in starvation medium (1% FCS/RPMI) for 16 hours prior to the beginning of the proliferation assay. An aliquot of the cells is analyzed by FACS to  
20 determine the percentage of T cells (CD3 positive cells) present; this usually ranges between 93-97% depending on the donor. The assay is performed in a 96 well plate using  $2 \times 10^4$  cells/well in a final volume of 200 µl. The supernatants (e.g., CHO or 293T supernatants) expressing the protein of interest are tested at a 30% final dilution, therefore 60 µl are added to 140 µl of 10% FCS/RPMI containing the cells. Control  
25 supernatants are used at the same final dilution and express the following proteins: vector (negative control), IL-2, IFN $\gamma$ , TNF $\alpha$ , IL-10 and TR2. In addition to the control supernatants recombinant human IL-2 at a final concentration of 10 ng/ml is also used. After 24 hours of culture, each well is pulsed with 1 µCi of  $^3\text{H}$ -thymidine (Nen, Boston, MA). Cells are then harvested 20 hours following pulsing  
30 and incorporation of  $^3\text{H}$ -thymidine is used as a measure of proliferation. Results are expressed as an average of triplicate samples plus or minus standard error.

The studies described in this example test activity of polypeptides of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides of the invention (e.g., gene therapy), agonists, and/or antagonists of polynucleotides or polypeptides of the invention.

5

**Example 34: Effect of Polypeptides of the Invention on the Expression of MHC Class II, Costimulatory and Adhesion Molecules and Cell Differentiation of Monocytes and Monocyte-Derived Human Dendritic Cells**

10 Dendritic cells are generated by the expansion of proliferating precursors found in the peripheral blood: adherent PBMC or elutriated monocytic fractions are cultured for 7-10 days with GM-CSF (50 ng/ml) and IL-4 (20 ng/ml). These dendritic cells have the characteristic phenotype of immature cells (expression of CD1, CD80, CD86, CD40 and MHC class II antigens). Treatment with activating factors, such as TNF- $\alpha$ , causes a rapid  
15 change in surface phenotype (increased expression of MHC class I and II, costimulatory and adhesion molecules, downregulation of FC $\gamma$ RII, upregulation of CD83). These changes correlate with increased antigen-presenting capacity and with functional maturation of the dendritic cells.

FACS analysis of surface antigens is performed as follows. Cells are treated 1-3  
20 days with increasing concentrations of polypeptides of the invention or LPS (positive control), washed with PBS containing 1% BSA and 0.02 mM sodium azide, and then incubated with 1:20 dilution of appropriate FITC- or PE-labeled monoclonal antibodies for 30 minutes at 4 degrees C. After an additional wash, the labeled cells are analyzed by flow cytometry on a FACScan (Becton Dickinson).

25

Effect on the production of cytokines. Cytokines generated by dendritic cells, in particular IL-12, are important in the initiation of T-cell dependent immune responses. IL-12 strongly influences the development of Th1 helper T-cell immune response, and induces cytotoxic T and NK cell function. An ELISA is used to  
30 measure the IL-12 release as follows. Dendritic cells ( $10^6$ /ml) are treated with increasing concentrations of polypeptides of the invention for 24 hours. LPS (100 ng/ml) is added to the cell culture as positive control. Supernatants from the cell



cultures are then collected and analyzed for IL-12 content using commercial ELISA kit (e.g., R & D Systems (Minneapolis, MN)). The standard protocols provided with the kits are used.

5           Effect on the expression of MHC Class II, costimulatory and adhesion molecules. Three major families of cell surface antigens can be identified on monocytes: adhesion molecules, molecules involved in antigen presentation, and Fc receptor. Modulation of the expression of MHC class II antigens and other costimulatory molecules, such as B7 and ICAM-1, may result in changes in the  
10 antigen presenting capacity of monocytes and ability to induce T cell activation. Increase expression of Fc receptors may correlate with improved monocyte cytotoxic activity, cytokine release and phagocytosis.

FACS analysis is used to examine the surface antigens as follows. Monocytes are treated 1-5 days with increasing concentrations of polypeptides of the invention or  
15 LPS (positive control), washed with PBS containing 1% BSA and 0.02 mM sodium azide, and then incubated with 1:20 dilution of appropriate FITC- or PE-labeled monoclonal antibodies for 30 minutes at 4 degreesC. After an additional wash, the labeled cells are analyzed by flow cytometry on a FACScan (Becton Dickinson).

20           Monocyte activation and/or increased survival. Assays for molecules that activate (or alternatively, inactivate) monocytes and/or increase monocyte survival (or alternatively, decrease monocyte survival) are known in the art and may routinely be applied to determine whether a molecule of the invention functions as an inhibitor or activator of monocytes. Polypeptides, agonists, or antagonists of the invention can be  
25 screened using the three assays described below. For each of these assays, Peripheral blood mononuclear cells (PBMC) are purified from single donor leukopacks (American Red Cross, Baltimore, MD) by centrifugation through a Histopaque gradient (Sigma). Monocytes are isolated from PBMC by counterflow centrifugal elutriation.

30

Monocyte Survival Assay. Human peripheral blood monocytes progressively lose viability when cultured in absence of serum or other stimuli. Their death results

from internally regulated process (apoptosis). Addition to the culture of activating factors, such as TNF-alpha dramatically improves cell survival and prevents DNA fragmentation. Propidium iodide (PI) staining is used to measure apoptosis as follows. Monocytes are cultured for 48 hours in polypropylene tubes in serum-free medium (positive control), in the presence of 100 ng/ml TNF-alpha (negative control), and in the presence of varying concentrations of the compound to be tested. Cells are suspended at a concentration of  $2 \times 10^6$ /ml in PBS containing PI at a final concentration of 5  $\mu$ g/ml, and then incubated at room temperature for 5 minutes before FACSscan analysis. PI uptake has been demonstrated to correlate with DNA fragmentation in this experimental paradigm.

Effect on cytokine release. An important function of monocytes/macrophages is their regulatory activity on other cellular populations of the immune system through the release of cytokines after stimulation. An ELISA to measure cytokine release is performed as follows. Human monocytes are incubated at a density of  $5 \times 10^5$  cells/ml with increasing concentrations of the a polypeptide of the invention and under the same conditions, but in the absence of the polypeptide. For IL-12 production, the cells are primed overnight with IFN (100 U/ml) in presence of a polypeptide of the invention. LPS (10 ng/ml) is then added. Conditioned media are collected after 24h and kept frozen until use. Measurement of TNF-alpha, IL-10, MCP-1 and IL-8 is then performed using a commercially available ELISA kit (e.g, R & D Systems (Minneapolis, MN)) and applying the standard protocols provided with the kit.

Oxidative burst. Purified monocytes are plated in 96-w plate at  $2 \times 10^5$  cell/well. Increasing concentrations of polypeptides of the invention are added to the wells in a total volume of 0.2 ml culture medium (RPMI 1640 + 10% FCS, glutamine and antibiotics). After 3 days incubation, the plates are centrifuged and the medium is removed from the wells. To the macrophage monolayers, 0.2 ml per well of phenol red solution (140 mM NaCl, 10 mM potassium phosphate buffer pH 7.0, 5.5 mM dextrose, 0.56 mM phenol red and 19 U/ml of HRPO) is added, together with the stimulant (200 nM PMA). The plates are incubated at 37°C for 2 hours and the reaction is stopped by adding 20  $\mu$ l 1N NaOH per well. The absorbance is read at 610

nm. To calculate the amount of H<sub>2</sub>O<sub>2</sub> produced by the macrophages, a standard curve of a H<sub>2</sub>O<sub>2</sub> solution of known molarity is performed for each experiment.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polypeptides, polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

### **Example 35: Biological Effects of Polypeptides of the Invention**

#### **Astrocyte and Neuronal Assays:**

Recombinant polypeptides of the invention, expressed in *Escherichia coli* and purified as described above, can be tested for activity in promoting the survival, neurite outgrowth, or phenotypic differentiation of cortical neuronal cells and for inducing the proliferation of glial fibrillary acidic protein immunopositive cells, astrocytes. The selection of cortical cells for the bioassay is based on the prevalent expression of FGF-1 and FGF-2 in cortical structures and on the previously reported enhancement of cortical neuronal survival resulting from FGF-2 treatment. A thymidine incorporation assay, for example, can be used to elucidate a polypeptide of the invention's activity on these cells.

Moreover, previous reports describing the biological effects of FGF-2 (basic FGF) on cortical or hippocampal neurons *in vitro* have demonstrated increases in both neuron survival and neurite outgrowth (Walicke et al., "Fibroblast growth factor promotes survival of dissociated hippocampal neurons and enhances neurite extension." *Proc. Natl. Acad. Sci. USA* 83:3012-3016. (1986), assay herein incorporated by reference in its entirety). However, reports from experiments done on PC-12 cells suggest that these two responses are not necessarily synonymous and may depend on not only which FGF is being tested but also on which receptor(s) are expressed on the target cells. Using the primary cortical neuronal culture paradigm, the ability of a polypeptide of the invention to induce neurite outgrowth can be compared to the response achieved with FGF-2 using, for example, a thymidine incorporation assay.

**Fibroblast and endothelial cell assays**

Human lung fibroblasts are obtained from Clonetics (San Diego, CA) and maintained in growth media from Clonetics. Dermal microvascular endothelial cells are obtained from Cell Applications (San Diego, CA). For proliferation assays, the human lung fibroblasts and dermal microvascular endothelial cells can be cultured at 5,000 cells/well in a 96-well plate for one day in growth medium. The cells are then incubated for one day in 0.1% BSA basal medium. After replacing the medium with fresh 0.1% BSA medium, the cells are incubated with the test proteins for 3 days. Alamar Blue (Alamar Biosciences, Sacramento, CA) is added to each well to a final concentration of 10%. The cells are incubated for 4 hr. Cell viability is measured by reading in a CytoFluor fluorescence reader. For the PGE<sub>2</sub> assays, the human lung fibroblasts are cultured at 5,000 cells/well in a 96-well plate for one day. After a medium change to 0.1% BSA basal medium, the cells are incubated with FGF-2 or polypeptides of the invention with or without IL-1 $\alpha$  for 24 hours. The supernatants are collected and assayed for PGE<sub>2</sub> by EIA kit (Cayman, Ann Arbor, MI). For the IL-6 assays, the human lung fibroblasts are cultured at 5,000 cells/well in a 96-well plate for one day. After a medium change to 0.1% BSA basal medium, the cells are incubated with FGF-2 or with or without polypeptides of the invention IL-1 $\alpha$  for 24 hours. The supernatants are collected and assayed for IL-6 by ELISA kit (Endogen, Cambridge, MA).

Human lung fibroblasts are cultured with FGF-2 or polypeptides of the invention for 3 days in basal medium before the addition of Alamar Blue to assess effects on growth of the fibroblasts. FGF-2 should show a stimulation at 10 - 2500 ng/ml which can be used to compare stimulation with polypeptides of the invention.

#### Parkinson Models.

The loss of motor function in Parkinson's disease is attributed to a deficiency of striatal dopamine resulting from the degeneration of the nigrostriatal dopaminergic projection neurons. An animal model for Parkinson's that has been extensively characterized involves the systemic administration of 1-methyl-4 phenyl 1,2,3,6-tetrahydropyridine (MPTP). In the CNS, MPTP is taken-up by astrocytes and catabolized by monoamine oxidase B to 1-methyl-4-phenyl pyridine (MPP<sup>+</sup>) and released.

Subsequently, MPP<sup>+</sup> is actively accumulated in dopaminergic neurons by the high-affinity reuptake transporter for dopamine. MPP<sup>+</sup> is then concentrated in mitochondria by the electrochemical gradient and selectively inhibits nicotinamide adenine disphosphate: ubiquinone oxidoreductionase (complex I), thereby interfering with electron transport and  
5 eventually generating oxygen radicals.

It has been demonstrated in tissue culture paradigms that FGF-2 (basic FGF) has trophic activity towards nigral dopaminergic neurons (Ferrari et al., Dev. Biol. 1989). Recently, Dr. Unsicker's group has demonstrated that administering FGF-2 in gel foam implants in the striatum results in the near complete protection of nigral dopaminergic  
10 neurons from the toxicity associated with MPTP exposure (Otto and Unsicker, J. Neuroscience, 1990).

Based on the data with FGF-2, polypeptides of the invention can be evaluated to determine whether it has an action similar to that of FGF-2 in enhancing dopaminergic neuronal survival *in vitro* and it can also be tested *in vivo* for protection of dopaminergic  
15 neurons in the striatum from the damage associated with MPTP treatment. The potential effect of a polypeptide of the invention is first examined *in vitro* in a dopaminergic neuronal cell culture paradigm. The cultures are prepared by dissecting the midbrain floor plate from gestation day 14 Wistar rat embryos. The tissue is dissociated with trypsin and seeded at a density of 200,000 cells/cm<sup>2</sup> on polyorthinine-laminin coated glass coverslips.  
20 The cells are maintained in Dulbecco's Modified Eagle's medium and F12 medium containing hormonal supplements (N1). The cultures are fixed with paraformaldehyde after 8 days *in vitro* and are processed for tyrosine hydroxylase, a specific marker for dopaminergic neurons, immunohistochemical staining. Dissociated cell cultures are prepared from embryonic rats. The culture medium is changed every third day and the  
25 factors are also added at that time.

Since the dopaminergic neurons are isolated from animals at gestation day 14, a developmental time which is past the stage when the dopaminergic precursor cells are proliferating, an increase in the number of tyrosine hydroxylase immunopositive neurons would represent an increase in the number of dopaminergic neurons surviving *in vitro*.  
30 Therefore, if a polypeptide of the invention acts to prolong the survival of dopaminergic neurons, it would suggest that the polypeptide may be involved in Parkinson's Disease.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

5

**Example 36: The Effect of Polypeptides of the Invention on the Growth of Vascular Endothelial Cells**

On day 1, human umbilical vein endothelial cells (HUVEC) are seeded at  $2.5 \times 10^4$  cells/35 mm dish density in M199 medium containing 4% fetal bovine serum (FBS), 16 units/ml heparin, and 50 units/ml endothelial cell growth supplements (ECGS, Biotechnology, Inc.). On day 2, the medium is replaced with M199 containing 10% FBS, 8 units/ml heparin. A polypeptide having the amino acid sequence of SEQ ID NO:Y, and positive controls, such as VEGF and basic FGF (bFGF) are added, at varying concentrations. On days 4 and 6, the medium is replaced. On day 8, cell number is determined with a Coulter Counter.

An increase in the number of HUVEC cells indicates that the polypeptide of the invention may proliferate vascular endothelial cells.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 37: Stimulatory Effect of Polypeptides of the Invention on the Proliferation of Vascular Endothelial Cells**

For evaluation of mitogenic activity of growth factors, the colorimetric MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulphophenyl)2H-tetrazolium) assay with the electron coupling reagent PMS (phenazine methosulfate) was performed (CellTiter 96 AQ, Promega). Cells are seeded in a 96-well plate (5,000 cells/well) in 0.1 mL serum-supplemented medium and are allowed to attach overnight. After serum-starvation for 12 hours in 0.5% FBS, conditions (bFGF, VEGF<sub>165</sub> or a

polypeptide of the invention in 0.5% FBS) with or without Heparin (8 U/ml) are added to wells for 48 hours. 20 mg of MTS/PMS mixture (1:0.05) are added per well and allowed to incubate for 1 hour at 37°C before measuring the absorbance at 490 nm in an ELISA plate reader. Background absorbance from control wells (some media, no cells) is subtracted, and seven wells are performed in parallel for each condition. See, Leak *et al.* *In Vitro Cell. Dev. Biol.* 30A:512-518 (1994).

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 38: Inhibition of PDGF-induced Vascular Smooth Muscle Cell Proliferation Stimulatory Effect**

HAoSMC proliferation can be measured, for example, by BrdUrd incorporation. Briefly, subconfluent, quiescent cells grown on the 4-chamber slides are transfected with CRP or FITC-labeled AT2-3LP. Then, the cells are pulsed with 10% calf serum and 6 mg/ml BrdUrd. After 24 h, immunocytochemistry is performed by using BrdUrd Staining Kit (Zymed Laboratories). In brief, the cells are incubated with the biotinylated mouse anti-BrdUrd antibody at 4 degrees C for 2 h after being exposed to denaturing solution and then incubated with the streptavidin-peroxidase and diaminobenzidine. After counterstaining with hematoxylin, the cells are mounted for microscopic examination, and the BrdUrd-positive cells are counted. The BrdUrd index is calculated as a percent of the BrdUrd-positive cells to the total cell number. In addition, the simultaneous detection of the BrdUrd staining (nucleus) and the FITC uptake (cytoplasm) is performed for individual cells by the concomitant use of bright field illumination and dark field-UV fluorescent illumination. See, Hayashida et al., *J. Biol. Chem.* 6:271(36):21985-21992 (1996).

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 39: Stimulation of Endothelial Migration**

This example will be used to explore the possibility that a polypeptide of the invention may stimulate lymphatic endothelial cell migration.

Endothelial cell migration assays are performed using a 48 well microchemotaxis chamber (Neuroprobe Inc., Cabin John, MD; Falk, W., et al., J. Immunological Methods 1980;33:239-247). Polyvinylpyrrolidone-free polycarbonate filters with a pore size of 8  $\mu$ m (Nucleopore Corp. Cambridge, MA) are coated with 0.1% gelatin for at least 6 hours at room temperature and dried under sterile air. Test substances are diluted to appropriate concentrations in M199 supplemented with 0.25% bovine serum albumin (BSA), and 25  $\mu$ l of the final dilution is placed in the lower chamber of the modified Boyden apparatus. Subconfluent, early passage (2-6) HUVEC or BMEC cultures are washed and trypsinized for the minimum time required to achieve cell detachment. After placing the filter between lower and upper chamber,  $2.5 \times 10^5$  cells suspended in 50  $\mu$ l M199 containing 1% FBS are seeded in the upper compartment. The apparatus is then incubated for 5 hours at 37°C in a humidified chamber with 5% CO<sub>2</sub> to allow cell migration. After the incubation period, the filter is removed and the upper side of the filter with the non-migrated cells is scraped with a rubber policeman. The filters are fixed with methanol and stained with a Giemsa solution (Diff-Quick, Baxter, McGraw Park, IL). Migration is quantified by counting cells of three random high-power fields (40x) in each well, and all groups are performed in quadruplicate.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 40: Stimulation of Nitric Oxide Production by Endothelial Cells**


Nitric oxide released by the vascular endothelium is believed to be a mediator of vascular endothelium relaxation. Thus, activity of a polypeptide of the invention can be



assayed by determining nitric oxide production by endothelial cells in response to the polypeptide.

Nitric oxide is measured in 96-well plates of confluent microvascular endothelial cells after 24 hours starvation and a subsequent 4 hr exposure to various levels of a positive control (such as VEGF-1) and the polypeptide of the invention. Nitric oxide in the medium is determined by use of the Griess reagent to measure total nitrite after reduction of nitric oxide-derived nitrate by nitrate reductase. The effect of the polypeptide of the invention on nitric oxide release is examined on HUVEC.

Briefly, NO release from cultured HUVEC monolayer is measured with a NO-specific polarographic electrode connected to a NO meter (Iso-NO, World Precision Instruments Inc.) (1049). Calibration of the NO elements is performed according to the following equation:



The standard calibration curve is obtained by adding graded concentrations of KNO<sub>2</sub> (0, 5, 10, 25, 50, 100, 250, and 500 nmol/L) into the calibration solution containing KI and H<sub>2</sub>SO<sub>4</sub>. The specificity of the Iso-NO electrode to NO is previously determined by measurement of NO from authentic NO gas (1050). The culture medium is removed and HUVECs are washed twice with Dulbecco's phosphate buffered saline. The cells are then bathed in 5 ml of filtered Krebs-Henseleit solution in 6-well plates, and the cell plates are kept on a slide warmer (Lab Line Instruments Inc.) To maintain the temperature at 37°C. The NO sensor probe is inserted vertically into the wells, keeping the tip of the electrode 2 mm under the surface of the solution, before addition of the different conditions. S-nitroso acetyl penicillamin (SNAP) is used as a positive control. The amount of released NO is expressed as picomoles per 1x10<sup>6</sup> endothelial cells. All values reported are means of four to six measurements in each group (number of cell culture wells). See, Leak *et al. Biochem. and Biophys. Res. Comm.* 217:96-105 (1995).

The studies described in this example tested activity of polypeptides of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 41: Effect of Polypeptides of the Invention on Cord Formation in Angiogenesis**

Another step in angiogenesis is cord formation, marked by differentiation of endothelial cells. This bioassay measures the ability of microvascular endothelial cells to form capillary-like structures (hollow structures) when cultured *in vitro*.

CADMEC (microvascular endothelial cells) are purchased from Cell Applications, Inc. as proliferating (passage 2) cells and are cultured in Cell Applications' CADMEC Growth Medium and used at passage 5. For the *in vitro* angiogenesis assay, the wells of a 48-well cell culture plate are coated with Cell Applications' Attachment Factor Medium (200 µl/well) for 30 min. at 37°C. CADMEC are seeded onto the coated wells at 7,500 cells/well and cultured overnight in Growth Medium. The Growth Medium is then replaced with 300 µg Cell Applications' Chord Formation Medium containing control buffer or a polypeptide of the invention (0.1 to 100 ng/ml) and the cells are cultured for an additional 48 hr. The numbers and lengths of the capillary-like chords are quantitated through use of the Boeckeler VIA-170 video image analyzer. All assays are done in triplicate.

Commercial (R&D) VEGF (50 ng/ml) is used as a positive control. b-esteradiol (1 ng/ml) is used as a negative control. The appropriate buffer (without protein) is also utilized as a control.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 42: Angiogenic Effect on Chick Chorioallantoic Membrane**

Chick chorioallantoic membrane (CAM) is a well-established system to examine angiogenesis. Blood vessel formation on CAM is easily visible and quantifiable. The ability of polypeptides of the invention to stimulate angiogenesis in CAM can be examined.

Fertilized eggs of the White Leghorn chick (*Gallus gallus*) and the Japanese quail (*Coturnix coturnix*) are incubated at 37.8°C and 80% humidity. Differentiated CAM of 16-day-old chick and 13-day-old quail embryos is studied with the following methods.

On Day 4 of development, a window is made into the egg shell of chick eggs. The embryos are checked for normal development and the eggs sealed with cellotape. They are further incubated until Day 13. Thermanox coverslips (Nunc, Naperville, IL) are cut into disks of about 5 mm in diameter. Sterile and salt-free growth factors are dissolved in distilled water and about 3.3 mg/ 5 ml are pipetted on the disks. After air-drying, the inverted disks are applied on CAM. After 3 days, the specimens are fixed in 3% glutaraldehyde and 2% formaldehyde and rinsed in 0.12 M sodium cacodylate buffer. They are photographed with a stereo microscope [Wild M8] and embedded for semi- and ultrathin sectioning as described above. Controls are performed with carrier disks alone.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

#### **Example 43: Angiogenesis Assay Using a Matrigel Implant in Mouse**

*In vivo* angiogenesis assay of a polypeptide of the invention measures the ability of an existing capillary network to form new vessels in an implanted capsule of murine extracellular matrix material (Matrigel). The protein is mixed with the liquid Matrigel at 4 degree C and the mixture is then injected subcutaneously in mice where it solidifies. After 7 days, the solid "plug" of Matrigel is removed and examined for the presence of new blood vessels. Matrigel is purchased from Becton Dickinson Labware/Collaborative Biomedical Products.

When thawed at 4 degree C the Matrigel material is a liquid. The Matrigel is mixed with a polypeptide of the invention at 150 ng/ml at 4 degrees C and drawn into cold 3 ml syringes. Female C57Bl/6 mice approximately 8 weeks old are injected with the mixture of Matrigel and experimental protein at 2 sites at the midventral aspect of the abdomen (0.5 ml/site). After 7 days, the mice are sacrificed by cervical dislocation, the

Matrigel plugs are removed and cleaned (i.e., all clinging membranes and fibrous tissue is removed). Replicate whole plugs are fixed in neutral buffered 10% formaldehyde, embedded in paraffin and used to produce sections for histological examination after staining with Masson's Trichrome. Cross sections from 3 different regions of each plug  
5 are processed. Selected sections are stained for the presence of vWF. The positive control for this assay is bovine basic FGF (150 ng/ml). Matrigel alone is used to determine basal levels of angiogenesis.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to  
10 test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

#### **Example 44: Rescue of Ischemia in Rabbit Lower Limb Model**

15 To study the in vivo effects of polynucleotides and polypeptides of the invention on ischemia, a rabbit hindlimb ischemia model is created by surgical removal of one femoral arteries as described previously (Takeshita *et al.*, *Am J. Pathol* 147:1649-1660 (1995)). The excision of the femoral artery results in retrograde propagation of thrombus and occlusion of the external iliac artery. Consequently, blood flow to the ischemic limb  
20 is dependent upon collateral vessels originating from the internal iliac artery (Takeshita *et al.* *Am J. Pathol* 147:1649-1660 (1995)). An interval of 10 days is allowed for post-operative recovery of rabbits and development of endogenous collateral vessels. At 10 day post-operatively (day 0), after performing a baseline angiogram, the internal iliac artery of the ischemic limb is transfected with 500 mg naked expression plasmid  
25 containing a polynucleotide of the invention by arterial gene transfer technology using a hydrogel-coated balloon catheter as described (Riessen *et al.* *Hum Gene Ther.* 4:749-758 (1993); Leclerc *et al.* *J. Clin. Invest.* 90: 936-944 (1992)). When a polypeptide of the invention is used in the treatment, a single bolus of 500 mg polypeptide of the invention or control is delivered into the internal iliac artery of the ischemic limb over a period of 1  
30 min. through an infusion catheter. On day 30, various parameters are measured in these rabbits: (a) BP ratio - The blood pressure ratio of systolic pressure of the ischemic limb to that of normal limb; (b) Blood Flow and Flow Reserve - Resting FL: the blood flow

during undilated condition and Max FL: the blood flow during fully dilated condition (also an indirect measure of the blood vessel amount) and Flow Reserve is reflected by the ratio of max FL: resting FL; (c) Angiographic Score - This is measured by the angiogram of collateral vessels. A score is determined by the percentage of circles in an overlaying grid that with crossing opacified arteries divided by the total number in the rabbit thigh; (d) Capillary density - The number of collateral capillaries determined in light microscopic sections taken from hindlimbs.

The studies described in this example tested activity of polynucleotides and polypeptides of the invention. However, one skilled in the art could easily modify the exemplified studies to test the agonists, and/or antagonists of the invention.

#### **Example 45: Effect of Polypeptides of the Invention on Vasodilation**

Since dilation of vascular endothelium is important in reducing blood pressure, the ability of polypeptides of the invention to affect the blood pressure in spontaneously hypertensive rats (SHR) is examined. Increasing doses (0, 10, 30, 100, 300, and 900 mg/kg) of the polypeptides of the invention are administered to 13-14 week old spontaneously hypertensive rats (SHR). Data are expressed as the mean +/- SEM. Statistical analysis are performed with a paired t-test and statistical significance is defined as  $p < 0.05$  vs. the response to buffer alone.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

#### **Example 46: Rat Ischemic Skin Flap Model**

The evaluation parameters include skin blood flow, skin temperature, and factor VIII immunohistochemistry or endothelial alkaline phosphatase reaction. Expression of polypeptides of the invention, during the skin ischemia, is studied using in situ hybridization.

The study in this model is divided into three parts as follows:

- a) Ischemic skin
- b) Ischemic skin wounds
- c) Normal wounds

The experimental protocol includes:

- 5 a) Raising a 3x4 cm, single pedicle full-thickness random skin flap (myocutaneous flap over the lower back of the animal).
- b) An excisional wounding (4-6 mm in diameter) in the ischemic skin (skin-flap).
- c) Topical treatment with a polypeptide of the invention of the excisional wounds (day 0, 1, 2, 3, 4 post-wounding) at the following various dosage ranges: 1mg to 100 mg.
- 10 d) Harvesting the wound tissues at day 3, 5, 7, 10, 14 and 21 post-wounding for histological, immunohistochemical, and in situ studies.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the  
15 invention.

#### **Example 47: Peripheral Arterial Disease Model**

Angiogenic therapy using a polypeptide of the invention is a novel therapeutic  
20 strategy to obtain restoration of blood flow around the ischemia in case of peripheral arterial diseases. The experimental protocol includes:

- a) One side of the femoral artery is ligated to create ischemic muscle of the hindlimb, the other side of hindlimb serves as a control.
- b) a polypeptide of the invention, in a dosage range of 20 mg - 500 mg, is  
25 delivered intravenously and/or intramuscularly 3 times (perhaps more) per week for 2-3 weeks.
- c) The ischemic muscle tissue is collected after ligation of the femoral artery at 1, 2, and 3 weeks for the analysis of expression of a polypeptide of the invention and histology. Biopsy is also performed on the other side of normal muscle of the  
30 contralateral hindlimb.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to

test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 48: Ischemic Myocardial Disease Model**

5

A polypeptide of the invention is evaluated as a potent mitogen capable of stimulating the development of collateral vessels, and restructuring new vessels after coronary artery occlusion. Alteration of expression of the polypeptide is investigated in situ. The experimental protocol includes:

10       a) The heart is exposed through a left-side thoracotomy in the rat. Immediately, the left coronary artery is occluded with a thin suture (6-0) and the thorax is closed.

      b) a polypeptide of the invention, in a dosage range of 20 mg - 500 mg, is delivered intravenously and/or intramuscularly 3 times (perhaps more) per week for 2-4 weeks.

15       c) Thirty days after the surgery, the heart is removed and cross-sectioned for morphometric and in situ analyzes.

      The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the  
20   invention.

**Example 49: Rat Corneal Wound Healing Model**

      This animal model shows the effect of a polypeptide of the invention on  
25   neovascularization. The experimental protocol includes:

      a)     Making a 1-1.5 mm long incision from the center of cornea into the stromal layer.

      b)     Inserting a spatula below the lip of the incision facing the outer corner of the eye.

30       c)     Making a pocket (its base is 1-1.5 mm from the edge of the eye).

      d) Positioning a pellet, containing 50ng- 5ug of a polypeptide of the invention, within the pocket.

e) Treatment with a polypeptide of the invention can also be applied topically to the corneal wounds in a dosage range of 20mg - 500mg (daily treatment for five days).

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

#### **Example 50: Diabetic Mouse and Glucocorticoid-Impaired Wound Healing Models**

##### ***A. Diabetic db+/db+ Mouse Model.***

To demonstrate that a polypeptide of the invention accelerates the healing process, the genetically diabetic mouse model of wound healing is used. The full thickness wound healing model in the db+/db+ mouse is a well characterized, clinically relevant and reproducible model of impaired wound healing. Healing of the diabetic wound is dependent on formation of granulation tissue and re-epithelialization rather than contraction (Gartner, M.H. *et al.*, *J. Surg. Res.* 52:389 (1992); Greenhalgh, D.G. *et al.*, *Am. J. Pathol.* 136:1235 (1990)).

The diabetic animals have many of the characteristic features observed in Type II diabetes mellitus. Homozygous (db+/db+) mice are obese in comparison to their normal heterozygous (db+/-) littermates. Mutant diabetic (db+/db+) mice have a single autosomal recessive mutation on chromosome 4 (db+) (Coleman *et al.* *Proc. Natl. Acad. Sci. USA* 77:283-293 (1982)). Animals show polyphagia, polydipsia and polyuria. Mutant diabetic mice (db+/db+) have elevated blood glucose, increased or normal insulin levels, and suppressed cell-mediated immunity (Mandel *et al.*, *J. Immunol.* 120:1375 (1978); Debray-Sachs, M. *et al.*, *Clin. Exp. Immunol.* 51(1):1-7 (1983); Leiter *et al.*, *Am. J. of Pathol.* 114:46-55 (1985)). Peripheral neuropathy, myocardial complications, and microvascular lesions, basement membrane thickening and glomerular filtration abnormalities have been described in these animals (Norido, F. *et al.*, *Exp. Neurol.* 83(2):221-232 (1984); Robertson *et al.*, *Diabetes* 29(1):60-67 (1980); Giacomelli *et al.*, *Lab Invest.* 40(4):460-473 (1979); Coleman, D.L., *Diabetes* 31 (Suppl):1-6 (1982)). These



homozygous diabetic mice develop hyperglycemia that is resistant to insulin analogous to human type II diabetes (Mandel *et al.*, *J. Immunol.* 120:1375-1377 (1978)).

The characteristics observed in these animals suggests that healing in this model may be similar to the healing observed in human diabetes (Greenhalgh, *et al.*, *Am. J. of Pathol.* 136:1235-1246 (1990)).

Genetically diabetic female C57BL/KsJ (db+/db+) mice and their non-diabetic (db+/+m) heterozygous littermates are used in this study (Jackson Laboratories). The animals are purchased at 6 weeks of age and are 8 weeks old at the beginning of the study. Animals are individually housed and received food and water ad libitum. All manipulations are performed using aseptic techniques. The experiments are conducted according to the rules and guidelines of Human Genome Sciences, Inc. Institutional Animal Care and Use Committee and the Guidelines for the Care and Use of Laboratory Animals.

Wounding protocol is performed according to previously reported methods (Tsuboi, R. and Rifkin, D.B., *J. Exp. Med.* 172:245-251 (1990)). Briefly, on the day of wounding, animals are anesthetized with an intraperitoneal injection of Avertin (0.01 mg/mL), 2,2,2-tribromoethanol and 2-methyl-2-butanol dissolved in deionized water. The dorsal region of the animal is shaved and the skin washed with 70% ethanol solution and iodine. The surgical area is dried with sterile gauze prior to wounding. An 8 mm full-thickness wound is then created using a Keyes tissue punch. Immediately following wounding, the surrounding skin is gently stretched to eliminate wound expansion. The wounds are left open for the duration of the experiment. Application of the treatment is given topically for 5 consecutive days commencing on the day of wounding. Prior to treatment, wounds are gently cleansed with sterile saline and gauze sponges.

Wounds are visually examined and photographed at a fixed distance at the day of surgery and at two day intervals thereafter. Wound closure is determined by daily measurement on days 1-5 and on day 8. Wounds are measured horizontally and vertically using a calibrated Jameson caliper. Wounds are considered healed if granulation tissue is no longer visible and the wound is covered by a continuous epithelium.

A polypeptide of the invention is administered using at a range different doses, from 4mg to 500mg per wound per day for 8 days in vehicle. Vehicle control groups received 50mL of vehicle solution.

Animals are euthanized on day 8 with an intraperitoneal injection of sodium pentobarbital (300mg/kg). The wounds and surrounding skin are then harvested for histology and immunohistochemistry. Tissue specimens are placed in 10% neutral buffered formalin in tissue cassettes between biopsy sponges for further processing.

- 5        Three groups of 10 animals each (5 diabetic and 5 non-diabetic controls) are evaluated: 1) Vehicle placebo control, 2) untreated group, and 3) treated group.

Wound closure is analyzed by measuring the area in the vertical and horizontal axis and obtaining the total square area of the wound. Contraction is then estimated by establishing the differences between the initial wound area (day 0) and that of post  
10 treatment (day 8). The wound area on day 1 is 64mm<sup>2</sup>, the corresponding size of the dermal punch. Calculations are made using the following formula:

$$[\text{Open area on day 8}] - [\text{Open area on day 1}] / [\text{Open area on day 1}]$$

- 15        Specimens are fixed in 10% buffered formalin and paraffin embedded blocks are sectioned perpendicular to the wound surface (5mm) and cut using a Reichert-Jung microtome. Routine hematoxylin-eosin (H&E) staining is performed on cross-sections of bisected wounds. Histologic examination of the wounds are used to assess whether the healing process and the morphologic appearance of the repaired skin is altered by  
20 treatment with a polypeptide of the invention. This assessment included verification of the presence of cell accumulation, inflammatory cells, capillaries, fibroblasts, re-epithelialization and epidermal maturity (Greenhalgh, D.G. *et al.*, *Am. J. Pathol.* 136:1235 (1990)). A calibrated lens micrometer is used by a blinded observer.

- 25        Tissue sections are also stained immunohistochemically with a polyclonal rabbit anti-human keratin antibody using ABC Elite detection system. Human skin is used as a positive tissue control while non-immune IgG is used as a negative control. Keratinocyte growth is determined by evaluating the extent of reepithelialization of the wound using a calibrated lens micrometer.

- 30        Proliferating cell nuclear antigen/cyclin (PCNA) in skin specimens is demonstrated by using anti-PCNA antibody (1:50) with an ABC Elite detection system. Human colon cancer can serve as a positive tissue control and human brain tissue can be used as a negative tissue control. Each specimen includes a section with omission of the primary

antibody and substitution with non-immune mouse IgG. Ranking of these sections is based on the extent of proliferation on a scale of 0-8, the lower side of the scale reflecting slight proliferation to the higher side reflecting intense proliferation.

Experimental data are analyzed using an unpaired t test. A p value of < 0.05 is  
5 considered significant.

### ***B. Steroid Impaired Rat Model***

The inhibition of wound healing by steroids has been well documented in various *in vitro* and *in vivo* systems (Wahl, Glucocorticoids and Wound healing. In: Anti-  
10 Inflammatory Steroid Action: Basic and Clinical Aspects. 280-302 (1989); Wahlet *et al.*, *J. Immunol.* 115: 476-481 (1975); Werb *et al.*, *J. Exp. Med.* 147:1684-1694 (1978)). Glucocorticoids retard wound healing by inhibiting angiogenesis, decreasing vascular permeability (Ebert *et al.*, *An. Intern. Med.* 37:701-705 (1952)), fibroblast proliferation, and collagen synthesis (Beck *et al.*, *Growth Factors.* 5: 295-304 (1991); Haynes *et al.*,  
15 *J. Clin. Invest.* 61: 703-797 (1978)) and producing a transient reduction of circulating monocytes (Haynes *et al.*, *J. Clin. Invest.* 61: 703-797 (1978); Wahl, "Glucocorticoids and wound healing", In: Antiinflammatory Steroid Action: Basic and Clinical Aspects, Academic Press, New York, pp. 280-302 (1989)). The systemic administration of steroids to impaired wound healing is a well establish phenomenon in rats (Beck *et al.*, *Growth*  
20 *Factors.* 5: 295-304 (1991); Haynes *et al.*, *J. Clin. Invest.* 61: 703-797 (1978); Wahl, "Glucocorticoids and wound healing", In: Antiinflammatory Steroid Action: Basic and Clinical Aspects, Academic Press, New York, pp. 280-302 (1989); Pierce *et al.*, *Proc. Natl. Acad. Sci. USA* 86: 2229-2233 (1989)).

To demonstrate that a polypeptide of the invention can accelerate the healing  
25 process, the effects of multiple topical applications of the polypeptide on full thickness excisional skin wounds in rats in which healing has been impaired by the systemic administration of methylprednisolone is assessed.

Young adult male Sprague Dawley rats weighing 250-300 g (Charles River Laboratories) are used in this example. The animals are purchased at 8 weeks of age and  
30 are 9 weeks old at the beginning of the study. The healing response of rats is impaired by the systemic administration of methylprednisolone (17mg/kg/rat intramuscularly) at the time of wounding. Animals are individually housed and received food and water *ad*

*libitum*. All manipulations are performed using aseptic techniques. This study is conducted according to the rules and guidelines of Human Genome Sciences, Inc. Institutional Animal Care and Use Committee and the Guidelines for the Care and Use of Laboratory Animals.

5           The wounding protocol is followed according to section A, above. On the day of wounding, animals are anesthetized with an intramuscular injection of ketamine (50 mg/kg) and xylazine (5 mg/kg). The dorsal region of the animal is shaved and the skin washed with 70% ethanol and iodine solutions. The surgical area is dried with sterile gauze prior to wounding. An 8 mm full-thickness wound is created using a Keyes tissue  
10       punch. The wounds are left open for the duration of the experiment. Applications of the testing materials are given topically once a day for 7 consecutive days commencing on the day of wounding and subsequent to methylprednisolone administration. Prior to treatment, wounds are gently cleansed with sterile saline and gauze sponges.

          Wounds are visually examined and photographed at a fixed distance at the day of  
15       wounding and at the end of treatment. Wound closure is determined by daily measurement on days 1-5 and on day 8. Wounds are measured horizontally and vertically using a calibrated Jameson caliper. Wounds are considered healed if granulation tissue is no longer visible and the wound is covered by a continuous epithelium.

          The polypeptide of the invention is administered using at a range different doses,  
20       from 4mg to 500mg per wound per day for 8 days in vehicle. Vehicle control groups received 50mL of vehicle solution.

          Animals are euthanized on day 8 with an intraperitoneal injection of sodium pentobarbital (300mg/kg). The wounds and surrounding skin are then harvested for histology. Tissue specimens are placed in 10% neutral buffered formalin in tissue  
25       cassettes between biopsy sponges for further processing.

          Four groups of 10 animals each (5 with methylprednisolone and 5 without glucocorticoid) are evaluated: 1) Untreated group 2) Vehicle placebo control 3) treated groups.

          Wound closure is analyzed by measuring the area in the vertical and horizontal  
30       axis and obtaining the total area of the wound. Closure is then estimated by establishing the differences between the initial wound area (day 0) and that of post treatment (day 8).

The wound area on day 1 is 64mm<sup>2</sup>, the corresponding size of the dermal punch. Calculations are made using the following formula:

$$[\text{Open area on day 8}] - [\text{Open area on day 1}] / [\text{Open area on day 1}]$$

5

Specimens are fixed in 10% buffered formalin and paraffin embedded blocks are sectioned perpendicular to the wound surface (5mm) and cut using an Olympus microtome. Routine hematoxylin-eosin (H&E) staining is performed on cross-sections of bisected wounds. Histologic examination of the wounds allows assessment of whether the healing process and the morphologic appearance of the repaired skin is improved by treatment with a polypeptide of the invention. A calibrated lens micrometer is used by a blinded observer to determine the distance of the wound gap.

Experimental data are analyzed using an unpaired t test. A p value of < 0.05 is considered significant.

15 The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

#### 20 **Example 51: Lymphadema Animal Model**

or The purpose of this experimental approach is to create an appropriate and consistent lymphedema model for testing the therapeutic effects of a polypeptide of the invention in lymphangiogenesis and re-establishment of the lymphatic circulatory system in the rat hind limb. Effectiveness is measured by swelling volume of the affected limb, quantification of the amount of lymphatic vasculature, total blood plasma protein, and histopathology. Acute lymphedema is observed for 7-10 days. Perhaps more importantly, the chronic progress of the edema is followed for up to 3-4 weeks.

30 Prior to beginning surgery, blood sample is drawn for protein concentration analysis. Male rats weighing approximately ~350g are dosed with Pentobarbital. Subsequently, the right legs are shaved from knee to hip. The shaved area is swabbed with gauze soaked in 70% EtOH. Blood is drawn for serum total protein testing.

Circumference and volumetric measurements are made prior to injecting dye into paws after marking 2 measurement levels (0.5 cm above heel, at mid-pt of dorsal paw). The intradermal dorsum of both right and left paws are injected with 0.05 ml of 1% Evan's Blue. Circumference and volumetric measurements are then made following injection of  
5 dye into paws.

Using the knee joint as a landmark, a mid-leg inguinal incision is made circumferentially allowing the femoral vessels to be located. Forceps and hemostats are used to dissect and separate the skin flaps. After locating the femoral vessels, the lymphatic vessel that runs along side and underneath the vessel(s) is located. The main  
10 lymphatic vessels in this area are then electrically coagulated suture ligated.

Using a microscope, muscles in back of the leg (near the semitendinosus and adductors) are bluntly dissected. The popliteal lymph node is then located. The 2 proximal and 2 distal lymphatic vessels and distal blood supply of the popliteal node are then and ligated by suturing. The popliteal lymph node, and any accompanying adipose  
15 tissue, is then removed by cutting connective tissues.

Care is taken to control any mild bleeding resulting from this procedure. After lymphatics are occluded, the skin flaps are sealed by using liquid skin (Vetbond) (AJ Buck). The separated skin edges are sealed to the underlying muscle tissue while leaving a gap of ~0.5 cm around the leg. Skin also may be anchored by suturing to underlying  
20 muscle when necessary.

To avoid infection, animals are housed individually with mesh (no bedding). Recovering animals are checked daily through the optimal edematous peak, which typically occurred by day 5-7. The plateau edematous peak are then observed. To evaluate the intensity of the lymphedema, the circumference and volumes of 2 designated  
25 places on each paw before operation and daily for 7 days are measured. The effect plasma proteins on lymphedema is determined and whether protein analysis is a useful testing perimeter is also investigated. The weights of both control and edematous limbs are evaluated at 2 places. Analysis is performed in a blind manner.

Circumference Measurements: Under brief gas anesthetic to prevent limb  
30 movement, a cloth tape is used to measure limb circumference. Measurements are done at the ankle bone and dorsal paw by 2 different people then those 2 readings are averaged. Readings are taken from both control and edematous limbs.

Volumetric Measurements: On the day of surgery, animals are anesthetized with Pentobarbital and are tested prior to surgery. For daily volumetrics animals are under brief halothane anesthetic (rapid immobilization and quick recovery), both legs are shaved and equally marked using waterproof marker on legs. Legs are first dipped in water, then  
5 dipped into instrument to each marked level then measured by Buxco edema software(Chen/Victor). Data is recorded by one person, while the other is dipping the limb to marked area.

Blood-plasma protein measurements: Blood is drawn, spun, and serum separated prior to surgery and then at conclusion for total protein and Ca<sup>2+</sup> comparison.

10 Limb Weight Comparison: After drawing blood, the animal is prepared for tissue collection. The limbs are amputated using a quillitine, then both experimental and control legs are cut at the ligature and weighed. A second weighing is done as the tibio-cacaneal joint is disarticulated and the foot is weighed.

Histological Preparations: The transverse muscle located behind the knee  
15 (popliteal) area is dissected and arranged in a metal mold, filled with freezeGel, dipped into cold methylbutane, placed into labeled sample bags at - 80EC until sectioning. Upon sectioning, the muscle is observed under fluorescent microscopy for lymphatics..

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to  
20 test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 52: Suppression of TNF alpha-induced adhesion molecule expression  
by a Polypeptide of the Invention**

25 The recruitment of lymphocytes to areas of inflammation and angiogenesis involves specific receptor-ligand interactions between cell surface adhesion molecules (CAMs) on lymphocytes and the vascular endothelium. The adhesion process, in both normal and pathological settings, follows a multi-step cascade that involves intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and  
30 endothelial leukocyte adhesion molecule-1 (E-selectin) expression on endothelial cells (EC). The expression of these molecules and others on the vascular endothelium determines the efficiency with which leukocytes may adhere to the local vasculature and

extravasate into the local tissue during the development of an inflammatory response. The local concentration of cytokines and growth factor participate in the modulation of the expression of these CAMs.

5 Tumor necrosis factor alpha (TNF- $\alpha$ ), a potent proinflammatory cytokine, is a stimulator of all three CAMs on endothelial cells and may be involved in a wide variety of inflammatory responses, often resulting in a pathological outcome.

The potential of a polypeptide of the invention to mediate a suppression of TNF- $\alpha$  induced CAM expression can be examined. A modified ELISA assay which uses ECs as a solid phase absorbent is employed to measure the amount of CAM expression on TNF- $\alpha$  treated ECs when co-stimulated with a member of the FGF family of proteins.

To perform the experiment, human umbilical vein endothelial cell (HUVEC) cultures are obtained from pooled cord harvests and maintained in growth medium (EGM-2; Clonetics, San Diego, CA) supplemented with 10% FCS and 1% penicillin/streptomycin in a 37 degree C humidified incubator containing 5% CO<sub>2</sub>.

15 HUVECs are seeded in 96-well plates at concentrations of  $1 \times 10^4$  cells/well in EGM medium at 37 degree C for 18-24 hrs or until confluent. The monolayers are subsequently washed 3 times with a serum-free solution of RPMI-1640 supplemented with 100 U/ml penicillin and 100 mg/ml streptomycin, and treated with a given cytokine and/or growth factor(s) for 24 h at 37 degree C. Following incubation, the cells are then evaluated for

20 CAM expression.

Human Umbilical Vein Endothelial cells (HUVECs) are grown in a standard 96 well plate to confluence. Growth medium is removed from the cells and replaced with 90  $\mu$ l of 199 Medium (10% FBS). Samples for testing and positive or negative controls are added to the plate in triplicate (in 10  $\mu$ l volumes). Plates are incubated at 37 degree C for

25 either 5 h (selectin and integrin expression) or 24 h (integrin expression only). Plates are aspirated to remove medium and 100  $\mu$ l of 0.1% paraformaldehyde-PBS(with Ca<sup>++</sup> and Mg<sup>++</sup>) is added to each well. Plates are held at 4°C for 30 min.

Fixative is then removed from the wells and wells are washed 1X with PBS(+Ca,Mg)+0.5% BSA and drained. Do not allow the wells to dry. Add 10  $\mu$ l of

30 diluted primary antibody to the test and control wells. Anti-ICAM-1-Biotin, Anti-VCAM-1-Biotin and Anti-E-selectin-Biotin are used at a concentration of 10  $\mu$ g/ml (1:10 dilution



of 0.1 mg/ml stock antibody). Cells are incubated at 37°C for 30 min. in a humidified environment. Wells are washed X3 with PBS(+Ca,Mg)+0.5% BSA.

Then add 20 µl of diluted ExtrAvidin-Alkaline Phosphatase (1:5,000 dilution) to each well and incubated at 37°C for 30 min. Wells are washed X3 with

5 PBS(+Ca,Mg)+0.5% BSA. 1 tablet of p-Nitrophenol Phosphate pNPP is dissolved in 5 ml of glycine buffer (pH 10.4). 100 µl of pNPP substrate in glycine buffer is added to each test well. Standard wells in triplicate are prepared from the working dilution of the ExtrAvidin-Alkaline Phosphatase in glycine buffer:  $1:5,000 (10^0) > 10^{-0.5} > 10^{-1} > 10^{-1.5}$ . 5 µl of each dilution is added to triplicate wells and the resulting AP content in each well is

10 5.50 ng, 1.74 ng, 0.55 ng, 0.18 ng. 100 µl of pNPP reagent must then be added to each of the standard wells. The plate must be incubated at 37°C for 4h. A volume of 50 µl of 3M NaOH is added to all wells. The results are quantified on a plate reader at 405 nm. The background subtraction option is used on blank wells filled with glycine buffer only. The template is set up to indicate the concentration of AP-conjugate in each standard well [

15 5.50 ng; 1.74 ng; 0.55 ng; 0.18 ng]. Results are indicated as amount of bound AP-conjugate in each sample.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the

20 invention.

### **Example 53: Assay for the Stimulation of Bone Marrow CD34+ Cell**

#### **Proliferation**

This assay is based on the ability of human CD34+ to proliferate in the

25 presence of hematopoietic growth factors and evaluates the ability of isolated polypeptides expressed in mammalian cells to stimulate proliferation of CD34+ cells.

It has been previously shown that most mature precursors will respond to only a single signal. More immature precursors require at least two signals to respond. Therefore, to test the effect of polypeptides on hematopoietic activity of a wide range

30 of progenitor cells, the assay contains a given polypeptide in the presence or absence of other hematopoietic growth factors. Isolated cells are cultured for 5 days in the presence of Stem Cell Factor (SCF) in combination with tested sample. SCF alone

has a very limited effect on the proliferation of bone marrow (BM) cells, acting in such conditions only as a "survival" factor. However, combined with any factor exhibiting stimulatory effect on these cells (e.g., IL-3), SCF will cause a synergistic effect. Therefore, if the tested polypeptide has a stimulatory effect on a hematopoietic progenitors, such activity can be easily detected. Since normal BM cells have a low level of cycling cells, it is likely that any inhibitory effect of a given polypeptide, or agonists or antagonists thereof, might not be detected. Accordingly, assays for an inhibitory effect on progenitors is preferably tested in cells that are first subjected to *in vitro* stimulation with SCF+IL+3, and then contacted with the compound that is being evaluated for inhibition of such induced proliferation.

Briefly, CD34+ cells are isolated using methods known in the art. The cells are thawed and resuspended in medium (QBSF 60 serum-free medium with 1% L-glutamine (500ml) Quality Biological, Inc., Gaithersburg, MD Cat# 160-204-101). After several gentle centrifugation steps at 200 x g, cells are allowed to rest for one hour. The cell count is adjusted to  $2.5 \times 10^5$  cells/ml. During this time, 100  $\mu$ l of sterile water is added to the peripheral wells of a 96-well plate. The cytokines that can be tested with a given polypeptide in this assay is rhSCF (R&D Systems, Minneapolis, MN, Cat# 255-SC) at 50 ng/ml alone and in combination with rhSCF and rhIL-3 (R&D Systems, Minneapolis, MN, Cat# 203-ML) at 30 ng/ml. After one hour, 10  $\mu$ l of prepared cytokines, 50  $\mu$ l SID (supernatants at 1:2 dilution = 50  $\mu$ l) and 20  $\mu$ l of diluted cells are added to the media which is already present in the wells to allow for a final total volume of 100  $\mu$ l. The plates are then placed in a 37°C/5% CO<sub>2</sub> incubator for five days.

Eighteen hours before the assay is harvested, 0.5  $\mu$ Ci/well of [3H] Thymidine is added in a 10  $\mu$ l volume to each well to determine the proliferation rate. The experiment is terminated by harvesting the cells from each 96-well plate to a filtermat using the Tomtec Harvester 96. After harvesting, the filtermats are dried, trimmed and placed into OmniFilter assemblies consisting of one OmniFilter plate and one OmniFilter Tray. 60  $\mu$ l Microscint is added to each well and the plate sealed with TopSeal-A press-on sealing film. A bar code 15 sticker is affixed to the first plate for counting. The sealed plates is then loaded and the level of radioactivity determined

via the Packard Top Count and the printed data collected for analysis. The level of radioactivity reflects the amount of cell proliferation.

The studies described in this example test the activity of a given polypeptide to stimulate bone marrow CD34+ cell proliferation. One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), antibodies, agonists, and/or antagonists and fragments and variants thereof. As a nonlimiting example, potential antagonists tested in this assay would be expected to inhibit cell proliferation in the presence of cytokines and/or to increase the inhibition of cell proliferation in the presence of cytokines and a given polypeptide. In contrast, potential agonists tested in this assay would be expected to enhance cell proliferation and/or to decrease the inhibition of cell proliferation in the presence of cytokines and a given polypeptide.

The ability of a gene to stimulate the proliferation of bone marrow CD34+ cells indicates that polynucleotides and polypeptides corresponding to the gene are useful for the diagnosis and treatment of disorders affecting the immune system and hematopoiesis. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections above, and elsewhere herein.

**Example 54: Assay for Extracellular Matrix Enhanced Cell Response (EMECCR)**

The objective of the Extracellular Matrix Enhanced Cell Response (EMECCR) assay is to identify gene products (e.g., isolated polypeptides) that act on the hematopoietic stem cells in the context of the extracellular matrix (ECM) induced signal.

Cells respond to the regulatory factors in the context of signal(s) received from the surrounding microenvironment. For example, fibroblasts, and endothelial and epithelial stem cells fail to replicate in the absence of signals from the ECM. Hematopoietic stem cells can undergo self-renewal in the bone marrow, but not in *in vitro* suspension culture. The ability of stem cells to undergo self-renewal *in vitro* is dependent upon their interaction with the stromal cells and the ECM protein fibronectin (fn). Adhesion of cells to fn is mediated by the  $\alpha_5\beta_1$  and  $\alpha_4\beta_1$  integrin receptors, which are expressed by human and mouse hematopoietic stem cells. The factor(s) which integrate with the ECM environment and responsible for stimulating

stem cell self-renewal has not yet been identified. Discovery of such factors should be of great interest in gene therapy and bone marrow transplant applications

Briefly, polystyrene, non tissue culture treated, 96-well plates are coated with  
fn fragment at a coating concentration of  $0.2 \mu\text{g}/\text{cm}^2$ . Mouse bone marrow cells are  
5 plated (1,000 cells/well ) in 0.2 ml of serum-free medium. Cells cultured in the  
presence of IL-3 ( 5 ng/ml ) + SCF ( 50 ng/ml ) would serve as the positive control,  
conditions under which little self-renewal but pronounced differentiation of the stem  
cells is to be expected. Gene products are tested with appropriate negative controls in  
the presence and absence of SCF(5.0 ng/ml), where test factor supernates represent  
10 10% of the total assay volume. The plated cells are then allowed to grow by  
incubating in a low oxygen environment ( 5%  $\text{CO}_2$ , 7%  $\text{O}_2$ , and 88%  $\text{N}_2$  ) tissue  
culture incubator for 7 days. The number of proliferating cells within the wells is  
then quantitated by measuring thymidine incorporation into cellular DNA.  
Verification of the positive hits in the assay will require phenotypic characterization  
15 of the cells, which can be accomplished by scaling up of the culture system and using  
appropriate antibody reagents against cell surface antigens and FACScan.

One skilled in the art could easily modify the exemplified studies to test the  
activity of polynucleotides (e.g., gene therapy), antibodies, agonists, and/or  
antagonists and fragments and variants thereof.

20 If a particular gene product is found to be a stimulator of hematopoietic  
progenitors, polynucleotides and polypeptides corresponding to the gene may be  
useful for the diagnosis and treatment of disorders affecting the immune system and  
hematopoiesis. Representative uses are described in the "Immune Activity" and  
"Infectious Disease" sections above, and elsewhere herein. The gene product may  
25 also be useful in the expansion of stem cells and committed progenitors of various  
blood lineages, and in the differentiation and/or proliferation of various cell types.

Additionally, the polynucleotides and/or polypeptides of the gene of interest  
and/or agonists and/or antagonists thereof, may also be employed to inhibit the  
proliferation and differentiation of hematopoietic cells and therefore may be  
30 employed to protect bone marrow stem cells from chemotherapeutic agents during  
chemotherapy. This antiproliferative effect may allow administration of higher doses

of chemotherapeutic agents and, therefore, more effective chemotherapeutic treatment.

Moreover, polynucleotides and polypeptides corresponding to the gene of interest may also be useful for the treatment and diagnosis of hematopoietic related disorders such as, for example, anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include bone marrow cell ex-vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia.

#### **Example 55: Human Dermal Fibroblast and Aortic Smooth Muscle Cell Proliferation**

The polypeptide of interest is added to cultures of normal human dermal fibroblasts (NHDF) and human aortic smooth muscle cells (AoSMC) and two co-assays are performed with each sample. The first assay examines the effect of the polypeptide of interest on the proliferation of normal human dermal fibroblasts (NHDF) or aortic smooth muscle cells (AoSMC). Aberrant growth of fibroblasts or smooth muscle cells is a part of several pathological processes, including fibrosis, and restenosis. The second assay examines IL6 production by both NHDF and SMC. IL6 production is an indication of functional activation. Activated cells will have increased production of a number of cytokines and other factors, which can result in a proinflammatory or immunomodulatory outcome. Assays are run with and without co-TNF $\alpha$  stimulation, in order to check for costimulatory or inhibitory activity.

Briefly, on day 1, 96-well black plates are set up with 1000 cells/well (NHDF) or 2000 cells/well (AoSMC) in 100  $\mu$ l culture media. NHDF culture media contains: Clonetics FB basal media, 1mg/ml hFGF, 5mg/ml insulin, 50mg/ml gentamycin, 2%FBS, while AoSMC culture media contains Clonetics SM basal media, 0.5  $\mu$ g/ml hEGF, 5mg/ml insulin, 1 $\mu$ g/ml hFGF, 50mg/ml gentamycin, 50  $\mu$ g/ml Amphotericin B, 5%FBS. After incubation @ 37°C for at least 4-5 hours culture media is aspirated and replaced with growth arrest media. Growth arrest media for NHDF contains fibroblast basal media, 50mg/ml gentamycin, 2% FBS, while growth arrest media for

AoSMC contains SM basal media, 50mg/ml gentamycin, 50µg/ml Amphotericin B, 0.4% FBS. Incubate at 37C until day 2.

On day 2, serial dilutions and templates of the polypeptide of interest are designed which should always include media controls and known-protein controls.

- 5 For both stimulation and inhibition experiments, proteins are diluted in growth arrest media. For inhibition experiments, TNFα is added to a final concentration of 2ng/ml (NHDF) or 5ng/ml (AoSMC). Then add 1/3 vol media containing controls or supernatants and incubate at 37C/5% CO<sub>2</sub> until day 5.

10 Transfer 60µl from each well to another labeled 96-well plate, cover with a plate-sealer, and store at 4C until Day 6 (for IL6 ELISA). To the remaining 100 µl in the cell culture plate, aseptically add Alamar Blue in an amount equal to 10% of the culture volume (10µl). Return plates to incubator for 3 to 4 hours. Then measure fluorescence with excitation at 530nm and emission at 590nm using the CytoFluor. This yields the growth stimulation/inhibition data.

- 15 On day 5, the IL6 ELISA is performed by coating a 96 well plate with 50-100 µl/well of Anti-Human IL6 Monoclonal antibody diluted in PBS, pH 7.4, incubate ON at room temperature.

On day 6, empty the plates into the sink and blot on paper towels. Prepare Assay Buffer containing PBS with 4% BSA. Block the plates with 200 µl/well of  
20 Pierce Super Block blocking buffer in PBS for 1-2 hr and then wash plates with wash buffer (PBS, 0.05% Tween-20). Blot plates on paper towels. Then add 50 µl/well of diluted Anti-Human IL-6 Monoclonal, Biotin-labeled antibody at 0.50 mg/ml. Make dilutions of IL-6 stock in media (30, 10, 3, 1, 0.3, 0 ng/ml). Add duplicate samples to top row of plate. Cover the plates and incubate for 2 hours at RT on shaker.

- 25 Wash plates with wash buffer and blot on paper towels. Dilute EU-labeled Streptavidin 1:1000 in Assay buffer, and add 100 µl/well. Cover the plate and incubate 1 h at RT. Wash plates with wash buffer. Blot on paper towels.

Add 100 µl/well of Enhancement Solution. Shake for 5 minutes. Read the plate on the Wallac DELFIA Fluorometer. Readings from triplicate samples in each  
30 assay were tabulated and averaged.

A positive result in this assay suggests AoSMC cell proliferation and that the gene product of interest may be involved in dermal fibroblast proliferation and/or

smooth muscle cell proliferation. A positive result also suggests many potential uses of polypeptides, polynucleotides, agonists and/or antagonists of the gene/gene product of interest. For example, inflammation and immune responses, wound healing, and angiogenesis, as detailed throughout this specification. Particularly, polypeptides of the gene product and polynucleotides of the gene may be used in wound healing and dermal regeneration, as well as the promotion of vasculogenesis, both of the blood vessels and lymphatics. The growth of vessels can be used in the treatment of, for example, cardiovascular diseases. Additionally, antagonists of polypeptides of the gene product and polynucleotides of the gene may be useful in treating diseases, disorders, and/or conditions which involve angiogenesis by acting as an anti-vascular (e.g., anti-angiogenesis). These diseases, disorders, and/or conditions are known in the art and/or are described herein, such as, for example, malignancies, solid tumors, benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas; arteriosclerotic plaques; ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, uveitis and Pterygia (abnormal blood vessel growth) of the eye; rheumatoid arthritis; psoriasis; delayed wound healing; endometriosis; vasculogenesis; granulations; hypertrophic scars (keloids); nonunion fractures; scleroderma; trachoma; vascular adhesions; myocardial angiogenesis; coronary collaterals; cerebral collaterals; arteriovenous malformations; ischemic limb angiogenesis; Osler-Webber Syndrome; plaque neovascularization; telangiectasia; hemophilic joints; angiofibroma; fibromuscular dysplasia; wound granulation; Crohn's disease; and atherosclerosis. Moreover, antagonists of polypeptides of the gene product and polynucleotides of the gene may be useful in treating anti-hyperproliferative diseases and/or anti-inflammatory known in the art and/or described herein.

One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), antibodies, agonists, and/or antagonists and fragments and variants thereof.

**Example 56: Cellular Adhesion Molecule (CAM) Expression on Endothelial Cells**

The recruitment of lymphocytes to areas of inflammation and angiogenesis involves specific receptor-ligand interactions between cell surface adhesion molecules (CAMs) on lymphocytes and the vascular endothelium. The adhesion process, in both normal and pathological settings, follows a multi-step cascade that involves intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and endothelial leukocyte adhesion molecule-1 (E-selectin) expression on endothelial cells (EC). The expression of these molecules and others on the vascular endothelium determines the efficiency with which leukocytes may adhere to the local vasculature and extravasate into the local tissue during the development of an inflammatory response. The local concentration of cytokines and growth factor participate in the modulation of the expression of these CAMs.

Briefly, endothelial cells (e.g., Human Umbilical Vein Endothelial cells (HUVECs)) are grown in a standard 96 well plate to confluence, growth medium is removed from the cells and replaced with 100  $\mu$ l of 199 Medium (10% fetal bovine serum (FBS)). Samples for testing and positive or negative controls are added to the plate in triplicate (in 10  $\mu$ l volumes). Plates are then incubated at 37°C for either 5 h (selectin and integrin expression) or 24 h (integrin expression only). Plates are aspirated to remove medium and 100  $\mu$ l of 0.1% paraformaldehyde-PBS(with Ca++ and Mg++) is added to each well. Plates are held at 4°C for 30 min. Fixative is removed from the wells and wells are washed 1X with PBS(+Ca,Mg) + 0.5% BSA and drained. 10  $\mu$ l of diluted primary antibody is added to the test and control wells. Anti-ICAM-1-Biotin, Anti-VCAM-1-Biotin and Anti-E-selectin-Biotin are used at a concentration of 10  $\mu$ g/ml (1:10 dilution of 0.1 mg/ml stock antibody). Cells are incubated at 37°C for 30 min. in a humidified environment. Wells are washed three times with PBS(+Ca,Mg) + 0.5% BSA. 20  $\mu$ l of diluted ExtrAvidin-Alkaline Phosphatase (1:5,000 dilution, referred to herein as the working dilution) are added to each well and incubated at 37°C for 30 min. Wells are washed three times with PBS(+Ca,Mg)+0.5% BSA. Dissolve 1 tablet of p-Nitrophenol Phosphate pNPP per 5 ml of glycine buffer (pH 10.4). 100  $\mu$ l of pNPP substrate in glycine buffer is added to each test well. Standard wells in triplicate are prepared from the working dilution of



the ExtrAvidin-Alkaline Phosphatase in glycine buffer: 1:5,000 ( $10^0$ ) >  $10^{-0.5}$  >  $10^{-1}$  >  $10^{-1.5}$ . 5  $\mu$ l of each dilution is added to triplicate wells and the resulting AP content in each well is 5.50 ng, 1.74 ng, 0.55 ng, 0.18 ng. 100  $\mu$ l of pNPN reagent is then added to each of the standard wells. The plate is incubated at 37°C for 4h. A volume of 50  $\mu$ l of 3M NaOH is added to all wells. The plate is read on a plate reader at 405 nm using the background subtraction option on blank wells filled with glycine buffer only. Additionally, the template is set up to indicate the concentration of AP-conjugate in each standard well [ 5.50 ng; 1.74 ng; 0.55 ng; 0.18 ng]. Results are indicated as amount of bound AP-conjugate in each sample.

10

#### **Example 57: Alamar Blue Endothelial Cells Proliferation Assay**

This assay may be used to quantitatively determine protein mediated inhibition of bFGF-induced proliferation of Bovine Lymphatic Endothelial Cells (LECs), Bovine Aortic Endothelial Cells (BAECs) or Human Microvascular Uterine Myometrial Cells (UTMECs). This assay incorporates a fluorometric growth indicator based on detection of metabolic activity. A standard Alamar Blue Proliferation Assay is prepared in EGM-2MV with 10 ng /ml of bFGF added as a source of endothelial cell stimulation. This assay may be used with a variety of endothelial cells with slight changes in growth medium and cell concentration. Dilutions of the protein batches to be tested are diluted as appropriate. Serum-free medium (GIBCO SFM) without bFGF is used as a non-stimulated control and Angiostatin or TSP-1 are included as a known inhibitory controls.

Briefly, LEC, BAECs or UTMECs are seeded in growth media at a density of 5000 to 2000 cells/well in a 96 well plate and placed at 37-C overnight. After the overnight incubation of the cells, the growth media is removed and replaced with GIBCO EC-SFM. The cells are treated with the appropriate dilutions of the protein of interest or control protein sample(s) (prepared in SFM ) in triplicate wells with additional bFGF to a concentration of 10 ng/ ml. Once the cells have been treated with the samples, the plate(s) is/are placed back in the 37° C incubator for three days. After three days 10 ml of stock alamar blue (Biosource Cat# DAL1100) is added to each well and the plate(s) is/are placed back in the 37°C incubator for four hours. The

plate(s) are then read at 530nm excitation and 590nm emission using the CytoFluor fluorescence reader. Direct output is recorded in relative fluorescence units.

Alamar blue is an oxidation-reduction indicator that both fluoresces and changes color in response to chemical reduction of growth medium resulting from cell growth. As cells grow in culture, innate metabolic activity results in a chemical reduction of the immediate surrounding environment. Reduction related to growth causes the indicator to change from oxidized (non-fluorescent blue) form to reduced (fluorescent red) form. i.e. stimulated proliferation will produce a stronger signal and inhibited proliferation will produce a weaker signal and the total signal is proportional to the total number of cells as well as their metabolic activity. The background level of activity is observed with the starvation medium alone. This is compared to the output observed from the positive control samples (bFGF in growth medium) and protein dilutions.

#### 15 **Example 58: Detection of Inhibition of a Mixed Lymphocyte Reaction**

This assay can be used to detect and evaluate inhibition of a Mixed Lymphocyte Reaction (MLR) by gene products (e.g., isolated polypeptides). Inhibition of a MLR may be due to a direct effect on cell proliferation and viability, modulation of costimulatory molecules on interacting cells, modulation of adhesiveness between lymphocytes and accessory cells, or modulation of cytokine production by accessory cells. Multiple cells may be targeted by these polypeptides since the peripheral blood mononuclear fraction used in this assay includes T, B and natural killer lymphocytes, as well as monocytes and dendritic cells.

Polypeptides of interest found to inhibit the MLR may find application in diseases associated with lymphocyte and monocyte activation or proliferation. These include, but are not limited to, diseases such as asthma, arthritis, diabetes, inflammatory skin conditions, psoriasis, eczema, systemic lupus erythematosus, multiple sclerosis, glomerulonephritis, inflammatory bowel disease, crohn's disease, ulcerative colitis, arteriosclerosis, cirrhosis, graft vs. host disease, host vs. graft disease, hepatitis, leukemia and lymphoma.

Briefly, PBMCs from human donors are purified by density gradient centrifugation using Lymphocyte Separation Medium (LSM<sup>®</sup>, density 1.0770 g/ml,

Organon Teknika Corporation, West Chester, PA). PBMCs from two donors are adjusted to  $2 \times 10^6$  cells/ml in RPMI-1640 (Life Technologies, Grand Island, NY) supplemented with 10% FCS and 2 mM glutamine. PBMCs from a third donor is adjusted to  $2 \times 10^5$  cells/ml. Fifty microliters of PBMCs from each donor is added to  
5 wells of a 96-well round bottom microtiter plate. Dilutions of test materials (50  $\mu$ l) is added in triplicate to microtiter wells. Test samples (of the protein of interest) are added for final dilution of 1:4; rhuIL-2 (R&D Systems, Minneapolis, MN, catalog number 202-IL) is added to a final concentration of 1  $\mu$ g/ml; anti-CD4 mAb (R&D Systems, clone 34930.11, catalog number MAB379) is added to a final concentration  
10 of 10  $\mu$ g/ml. Cells are cultured for 7-8 days at 37°C in 5% CO<sub>2</sub>, and 1  $\mu$ C of [<sup>3</sup>H] thymidine is added to wells for the last 16 hrs of culture. Cells are harvested and thymidine incorporation determined using a Packard TopCount. Data is expressed as the mean and standard deviation of triplicate determinations.

Samples of the protein of interest are screened in separate experiments and  
15 compared to the negative control treatment, anti-CD4 mAb, which inhibits proliferation of lymphocytes and the positive control treatment, IL-2 (either as recombinant material or supernatant), which enhances proliferation of lymphocytes.

One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), antibodies, agonists, and/or  
20 antagonists and fragments and variants thereof.

It will be clear that the invention may be practiced otherwise than as particularly described in the foregoing description and examples. Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, are within the scope of the appended claims.

25 The entire disclosure of each document cited (including patents, patent applications, journal articles, abstracts, laboratory manuals, books, or other disclosures) in the Background of the Invention, Detailed Description, and Examples is hereby incorporated herein by reference. Further, the hard copy of the sequence listing submitted herewith and the corresponding computer readable form are both  
30 incorporated herein by reference in their entirety. Additionally, the contents of U.S. Provisional Applications Nos. 60/164,835 and 60/221,142 are all hereby incorporated by reference in their entirety.

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13 bis)

<b>A.</b> The indications made below relate to the microorganism referred to in the description on page <u>42</u> , line <u>N/A</u>	
<b>B. IDENTIFICATION OF DEPOSIT</b> <span style="float: right;">Further deposits are identified on an additional sheet <input type="checkbox"/></span>	
Name of depositary institution <u>American Type Culture Collection</u>	
Address of depositary institution <i>(including postal code and country)</i> <u>10801 University Boulevard</u> <u>Manassas, Virginia 20110-2209</u> <u>United States of America</u>	
Date of deposit <u>26 October 1999</u>	Accession Number <u>PTA-867</u>
<b>C. ADDITIONAL INDICATIONS</b> <i>(leave blank if not applicable)</i> <span style="float: right;">This information is continued on an additional sheet <input type="checkbox"/></span>	
<b>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE</b> <i>(if the indications are not for all designated States)</i>	
Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC). <div style="text-align: right;">Continued on the Attached Pages 2 &amp; 3</div>	
<b>E. SEPARATE FURNISHING OF INDICATIONS</b> <i>(leave blank if not applicable)</i>	
The indications listed below will be submitted to the International Bureau later <i>(specify the general nature of the indications e.g., "Accession Number of Deposit")</i>	

<p style="text-align: center;">For receiving Office use only</p> <p><input type="checkbox"/> This sheet was received with the international application</p> <p>Authorized officer</p>	<p style="text-align: center;">For International Bureau use only</p> <p><input type="checkbox"/> This sheet was received by the International Bureau on:</p> <p>Authorized officer</p>
---	--

**ATCC Deposit No. PTA-867****Page No. 2****CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

**NORWAY**

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

**AUSTRALIA**

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

**FINLAND**

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

**UNITED KINGDOM**

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

**ATCC Deposit No.: PTA-867****Page No. 3****DENMARK**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

**SWEDEN**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

**NETHERLANDS**

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

*What Is Claimed Is:*

1. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:
  - (a) a polynucleotide fragment of SEQ ID NO:X or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
  - (b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:Y or a polypeptide fragment encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
  - (c) a polynucleotide encoding a polypeptide domain of SEQ ID NO:Y or a polypeptide domain encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
  - (d) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:Y or a polypeptide epitope encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
  - (e) a polynucleotide encoding a polypeptide of SEQ ID NO:Y or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X, having biological activity;
  - (f) a polynucleotide which is a variant of SEQ ID NO:X;
  - (g) a polynucleotide which is an allelic variant of SEQ ID NO:X;
  - (h) a polynucleotide which encodes a species homologue of the SEQ ID NO:Y;
  - (i) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.

2. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding a secreted protein.
- 5 3. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding the sequence identified as SEQ ID NO:Y or the polypeptide encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.
- 10 4. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises the entire nucleotide sequence of SEQ ID NO:X or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.
- 15 5. The isolated nucleic acid molecule of claim 2, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.
6. The isolated nucleic acid molecule of claim 3, wherein the nucleotide  
20 sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.
7. A recombinant vector comprising the isolated nucleic acid molecule of claim 1.
- 25 8. A method of making a recombinant host cell comprising the isolated nucleic acid molecule of claim 1.
9. A recombinant host cell produced by the method of claim 8.
- 30 10. The recombinant host cell of claim 9 comprising vector sequences.



11. An isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of:

(a) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

5 (b) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z, having biological activity;

(c) a polypeptide domain of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

10 (d) a polypeptide epitope of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(e) a secreted form of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(f) a full length protein of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

15 (g) a variant of SEQ ID NO:Y;

(h) an allelic variant of SEQ ID NO:Y; or

(i) a species homologue of the SEQ ID NO:Y.

12. The isolated polypeptide of claim 11, wherein the secreted form or the full length protein comprises sequential amino acid deletions from either the C-terminus or the N-terminus.

13. An isolated antibody that binds specifically to the isolated polypeptide of claim 11.

25 14. A recombinant host cell that expresses the isolated polypeptide of claim 11.

15. A method of making an isolated polypeptide comprising:

30 (a) culturing the recombinant host cell of claim 14 under conditions such that said polypeptide is expressed; and

(b) recovering said polypeptide.

16. The polypeptide produced by claim 15.

17. A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount  
5 of the polypeptide of claim 11 or the polynucleotide of claim 1.

18. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

(a) determining the presence or absence of a mutation in the polynucleotide of  
10 claim 1; and

(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation.

19. A method of diagnosing a pathological condition or a susceptibility to  
15 a pathological condition in a subject comprising:

(a) determining the presence or amount of expression of the polypeptide of claim 11 in a biological sample; and

(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.  
20

20. A method for identifying a binding partner to the polypeptide of claim 11 comprising:

(a) contacting the polypeptide of claim 11 with a binding partner; and

(b) determining whether the binding partner effects an activity of the  
25 polypeptide.

21. The gene corresponding to the cDNA sequence of SEQ ID NO:Y.

22. A method of identifying an activity in a biological assay, wherein the  
30 method comprises:

(a) expressing SEQ ID NO:X in a cell;

(b) isolating the supernatant;

- (c) detecting an activity in a biological assay; and
- (d) identifying the protein in the supernatant having the activity.

23. The product produced by the method of claim 20.

<110> Human Genome Sciences, Inc.

<120> 21 Human Secreted Proteins

<130> PS711PCT

<140> Unassigned

<141> 2000-11-08

<150> 60/164,835

<151> 1999-11-12

<150> 60/221,142

<151> 2000-07-27

<160> 157

<170> PatentIn Ver. 2.0

<210> 1

<211> 733

<212> DNA

<213> Homo sapiens

<400> 1

gggatccgga	gccc aaatct	tctgacaaaa	ctcacacatg	cccaccgtgc	ccagcacctg	60
aattcgaggg	tgcaccgtca	gtcttcctct	tcccccaaa	acccaaggac	accctcatga	120
tctcccgga	tcctgaggtc	acatgcgtgg	tggtggacgt	aagccacgaa	gacctgagg	180
tcaagttcaa	ctggtacgtg	gacggcgtgg	aggtgcataa	tgccaagaca	aagccgcggg	240
aggagcagta	caacagcacg	taccgtgtgg	tcagcgtcct	caccgtcctg	caccaggact	300
ggctgaatgg	caaggagtac	aagtgaagg	tctccaacaa	agccctccca	accccatcg	360
agaaaacat	ctccaaagcc	aaagggcagc	cccgagaacc	acaggtgtac	accctgcccc	420
catcccgga	tgagctgacc	aagaaccagg	tcagcctgac	ctgcctgggc	aaaggcttct	480
atccaagcga	catcgccgtg	gagtgggaga	gcaatgggca	gccggagaac	aactacaaga	540
ccacgcctcc	cgtgctggac	tccgacggct	ccttcttctc	ctacagcaag	ctcaccgtgg	600
acaagagcag	gtggcagcag	gggaacgtct	tctcatgctc	cgtgatgcat	gaggctctgc	660
acaaccacta	cacgcagaag	agcctctccc	tgtctccggg	taaataagtg	cgacggccgc	720
gactctagag	gat					733

<210> 2

<211> 5

<212> PRT

<213> Homo sapiens

<220>

<221> Site

<222> (3)

<223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 2

Trp Ser Xaa Trp Ser

1

5

<210> 3

<211> 86

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 3

gcgccctcgag atttccccga aatctagatt tccccgaaat gatttccccg aaatgatttc	60
cccgaaatat ctgccatctc aattag	86

&lt;210&gt; 4

&lt;211&gt; 27

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 4

gcggcaagct ttttgcaaag cctaggc	27
-------------------------------	----

&lt;210&gt; 5

&lt;211&gt; 271

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 5

ctcgagattt ccccgaaatc tagatttccc cgaaatgatt tccccgaaat gatttccccg	60
aaatatctgc catctcaatt agtcagcaac catagtcccc cccctaactc cgcccatccc	120
gcccctaact ccgcccagtt ccgcccattc tccgccccat ggctgactaa ttttttttat	180
ttatgcagag gccgaggccg cctcggcctc tgagctattc cagaagtagt gaggaggctt	240
ttttggaggc ctaggctttt gcaaaaagct t	271

&lt;210&gt; 6

&lt;211&gt; 32

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 6

gcgctcgagg gatgacagcg atagaacccc gg	32
-------------------------------------	----

&lt;210&gt; 7

&lt;211&gt; 31

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 7

gcgaagcttc gcgactcccc ggatccgcct c	31
------------------------------------	----

&lt;210&gt; 8

&lt;211&gt; 12

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 8

ggggactttc cc	12
---------------	----

&lt;210&gt; 9

<211> 73  
 <212> DNA  
 <213> Homo sapiens

<400> 9  
 gcggcctcga ggggactttc ccggggactt tccggggact ttccgggact ttccatcctg 60  
 ccattctcaat tag 73

<210> 10  
 <211> 256  
 <212> DNA  
 <213> Homo sapiens

<400> 10  
 ctcgagggga ctttcccggg gactttccgg ggactttccg ggactttcca tctgccatct 60  
 caattagtca gcaaccatag tcccggccct aactccgccc atcccggccc taactccgcc 120  
 cagttccggc cattctccgc cccatggctg actaattttt tttatttatg cagaggccga 180  
 ggccgcctcg gcctctgagc tattccagaa gtagtgagga ggcttttttg gaggcctagg 240  
 cttttgcaaa aagctt 256

<210> 11  
 <211> 2406  
 <212> DNA  
 <213> Homo sapiens

<400> 11  
 ccacgcgtcc ggaatgaaca actttttcttc tcttgaatat atcttaacgc caaattttga 60  
 gtgctttttt gttacccatc ctcatatgtc ccagctggaa agaatcctgg gttggagcta 120  
 ctgcatgttg attgttttgt ttttcctttt ggctgttcat tttgggtggc actataagga 180  
 aatctaacac aaacagcaac tgttttttgt tgtttacttt tgcattctta cttgtggagc 240  
 tgtggcaagt cctcatatca aatacagaac atgatcttcc tctgctaatt gttgagcctg 300  
 gaattgacgc ttccaccagat agcagcttta ttcacagtga cagtcacctaa ggaactgtac 360  
 ataataagac atggcagcaa tgtgacctg gaatgcaact ttgacactgg aagtcattgtg 420  
 aaccttgagg caataacagc cagtttgcaa aagggtggaa atgatacatc cccacaccgt 480  
 gaaagagcca ctttgctgga ggagcagctg cccctagggg aggcctcggt ccacatacct 540  
 caagtccaag tgagggacga aggacagtac caatgcataa tcatctatgg ggtgcgctgg 600  
 gactacaagt acctgactct gaaagtcaaa gcttcctaca ggaaaataaa cactcacatc 660  
 ctaaaggttc cagaaacaga tgaggtagag ctccactgcc aggtacagg ttatcctctg 720  
 gcagaagtat cctggccaaa cgtcagcgtt cctgccaaca ccagccactc caggaccctc 780  
 gaaggcctct accaggtcac cagtgttctg cgcctaaagc caccctctgg cagaaacttc 840  
 agctgtgtgt tctggaatac tcacgtgagg gaacttactt tggccagcat tgaccttcaa 900  
 agtcagatgg aaccaggac ccatccaact tggctgcttc acattttcat cccctcctgc 960  
 atcattgctt tcattttcat agccacagtg atagccctaa gaaaacaact ctgtcaaaag 1020  
 ctgtattctt caaaagacac aacaaaaaga cctgtcacca caacaaagag ggaagtgaac 1080  
 agtgctgtga atctgaacct gtggtcttgg gagccagggt gacctgatat gacatctaaa 1140  
 gaagcttctg gactctgaac aagaattcgg tggcctgcag agcttgccat ttgactttt 1200  
 caaatgcctt tggatgacct agcactttta tctgaaacct gcaacaagac tagccaacac 1260  
 ctggccatga aacttgcccc ttcactgatc tggactcacc tctggagcct atggccttaa 1320  
 gcaagcacta ctgactttta cagaattacc ccactggatc ctggaccac agaattcctt 1380  
 caggatcctt cttgctgcca gactgaaagc aaaaggaatt atttcccctc aagttttcta 1440  
 agtgatttcc aaaagcagag gtgtgtggaa atttccagta acagaaacag atgggttgcc 1500  
 aatagagtta ttttttatct atagcttctt ctgggtacta gaagaggcta ttgagactat 1560  
 gagctcacag acagggtctc gcacaaactc aaatcataat tgacatgttt tatggattac 1620  
 tggaatcttg atagcataat gaagttgttc taattaacag agagcattta aatataact 1680  
 aagtgcacaa attgtggagt aaagtcacat agctctgttt ttgaggctta agtcacaaag 1740  
 catttgtttt aacctgtaat ggcaccatgt ttaatggtgg tttttttttt gaactacatc 1800

tttcctttaa	aaattattgg	tttcttttta	tttgttttta	ccttagaaat	caattatata	1860
cagtcaaaaa	tatttgatat	gctcacatcg	tgtatctgca	gcaatttcag	ataagtagct	1920
aaaatggcca	aagcccaaaa	ctaagcctcc	ttttctggcc	ctcaatatga	ctttaaattt	1980
gacttttcag	tgcctcagtt	tgcacatctg	taatacagca	atgctaagta	gtcaaggcct	2040
ttgataattg	gcactatgga	aatcctgcaa	gatcccacta	catatgtgtg	gagcagaagg	2100
gtaactcggc	tacagtaaca	gcttaatttt	gttaaatttg	ttctttatac	tgagagccatg	2160
aagctcagag	cattagctga	cccttgaact	attcaaattg	gcacattagc	tagtataaca	2220
gacttacata	ggtgggccta	aagcaagctc	cttaactgag	caaaatttgg	ggcttatgag	2280
aatgaaaggg	tgtgaaattg	actaacagac	aatcataca	tctcagtttc	tcaattctca	2340
tgtaaatcag	agaatgcctt	taaagaataa	aactcaattg	ttattcttca	aaaaaaaaaa	2400
aaaaaa						2406

&lt;210&gt; 12

&lt;211&gt; 3369

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 12

ggattcgcgg	ccgcgctcgga	ccttccgcgg	accgggcgac	ccagtgcacg	gccgccgcgt	60
cactctcggt	cccgcctgacc	ccgcgcgcag	ccccggcggc	tctggccgcg	gccgcactca	120
gcgccacgcg	tcgaaagcgc	aggccccgag	gacccgccgc	actgacagta	tgagccgcac	180
agcctacacg	gtgggagccc	tgtttctcct	cttggggacc	ctgctgccgg	ctgctgaagg	240
gaaaaagaaa	gggtcccaag	gtgccatccc	cccgccagac	aaggcccagc	acaatgactc	300
agagcagact	cagtcgcccc	agcagcctgg	ctccaggaac	cgggggaggc	gccaagggcg	360
gggcactgcc	atgcccgggg	aggagggtgt	ggagtccagc	caagaggccc	tgcatgtgac	420
ggagcgcaaa	tacctgaagc	gagactgggt	caaaaccag	ccgcttaagc	agaccatcca	480
cgaggaaggc	tgcaacagtc	gcaccatcat	caaccgcttc	tgttacggcc	agtgcaactc	540
tttctacatc	cccaggcaca	tccggaaggga	ggaagggttc	tttcagtcct	gctcctctgt	600
caagcccaag	aaattcacta	ccatgatggt	cacactcaac	tgccctgaac	tacagccacc	660
taccaagaag	aagagagtca	cacgtgtgaa	gcagtgtcgt	tgcatatcca	tcgatttgga	720
ttaagccaaa	tccagggtgca	cccagcatgt	cctaggaatg	cagmcccagg	aagtcccaga	780
cctaaaacaa	ccagattctt	acttggtcta	aacctagagg	ccagaagaac	ccccagctgc	840
ctcctggcag	gagcctgctt	gtgcgtagtt	cgtgtgcatg	agtgtggatg	ggtgcctgtg	900
ggtgttttta	gacaccagag	aaaacacagt	ctctgctaga	gagcactycc	tattttgtaa	960
acmtatctgc	tttaatgggg	atgtaccaga	aaccacctc	acccgggctc	acatctaaag	1020
gggcggggcc	gtgggtctgg	tctgactttg	tgtttttgtg	ccctcctggg	gaccagaatc	1080
tcctttcgga	atgaatgttc	atggaagagg	ctcctctgag	ggcaagagac	ctgttttagt	1140
gctgcattcg	acatggaaaa	gtccttttaa	cctgtgcttg	catcctcctt	tcctcctcct	1200
cctcacaatc	catctcttct	taagttgaya	gtgactatgt	cagtctaata	tcttgtttgc	1260
carggttctt	aaattaattc	acttaacat	gatgcaaatg	tttttcattt	tgtgaagacc	1320
ctccagactc	tgggagaggc	tgggtgtggc	aaggacaagc	aggatagtgg	agtgaagaag	1380
ggaggggtgga	gggtgaggcc	aatcagggtc	cagcaaaaag	cagtagggac	attgcagaag	1440
cttgaaaggc	caataccaga	acacaggctg	atgcttctga	gaaagtcttt	tcctagtatt	1500
taacagaacc	caagtgaaca	gaggagaaat	gagattgcca	gaaagtgatt	aactttggcc	1560
ggtgcaatct	gctcaaacct	aacaccaaac	tgaaaacata	aatactgacc	actcctatgt	1620
tcggacccaa	gcaagtttag	taaaccaaac	caactcctct	gctttgtccc	tcaggttgga	1680
aagagaggta	gtttagaact	ctctgcatag	gggtgggaat	taatcaaaaa	ckcagaggc	1740
tgaaattcct	aatacctttc	ctttatcgtg	gttatagtca	gtcattttcc	attccactat	1800
ttcccataat	gcttctgaga	gccactaact	tgattgataa	agatcctgcc	tctgctgagt	1860
gtacctgaca	gtagtctaag	atgagagagt	ttagggacta	ctctgtttta	gcaagagata	1920
ttttgggggt	ctttttgttt	taactattgt	caggagattg	ggctaaagag	aagacgacga	1980
gagtaaggaa	ataaagggaa	ttgcctctgg	ctagagagta	gttaggtgtt	aatactgggt	2040
agagatgtaa	gggatatgac	ctccctttct	ttatgtgtct	actgaggatc	tgaggggacc	2100
ctgttaggag	agcatagcat	catgatgtat	tagctgttca	tctgctactg	gttggttgga	2160
cataactatt	gtaactattc	agtattttact	ggtaggcact	gtcctctgat	taaacttggc	2220
ctactggcaa	tggctactta	ggattgatct	aagggccaaa	gtgcagggtg	ggtgaacttt	2280
attgtacttt	ggatttggtt	aacctgtttt	cttcaagcct	gaggttttat	atacaaaactc	2340

cctgaataact	ctttttgcct	tgtatcttct	cagcctccta	gccaaagtcct	atgtaatatg	2400
gaaaacaaac	actgcagact	tgagattcag	ttgccgatca	aggctctggc	attcagagaa	2460
cccttgcaac	tcgagaagct	gtttttatct	cgtttttggt	ttgatccagt	gctctcccat	2520
ctaacaacta	aacaggagcc	atttcaaggc	gggagatatt	ttaaaccacc	aaaatgttgg	2580
gtctgatttt	caaactttta	aactcactac	tgatgattct	cacgctaggc	gaatttgtcc	2640
aaacacatag	tgtgtgtgtt	ttgtatacac	tgtatgacct	caccccaaat	ctttgtattg	2700
tccacattct	ccaacaataa	agcacagagt	ggattttaatt	aagcacacaa	atgctaaggc	2760
agaattttga	gggtgggaga	gaagaaaagg	gaaagaagct	gaaaatgtaa	aaccacacca	2820
gggaggaaaa	atgacattca	gaaccagcaa	acactgaatt	tctcttggtg	ttttaactct	2880
gccacaagaa	tgcaatttcg	ttaayggaga	tgacttaagt	tggcagcagt	aatcttcttt	2940
taggagcttg	taccacagtc	ttgcacataa	gtgcagattt	ggctcaagta	aagagaattt	3000
cctcaacact	aacttcactg	ggataatcag	cagcgttaact	accctaaaag	catatcacta	3060
gccaaagagg	gaaatatctg	ttcttcttac	tgtgcctata	ttaagactag	tacaaatgtg	3120
gtgtgtcttc	caactttcat	tgaaaatgcc	atatctatac	catattttat	tcgagtcact	3180
gatgatgtaa	tgatatattt	tttcattatt	atagtagaat	atttttatgg	caagatatatt	3240
gtggtcttga	tcatacctat	taaaataatg	ccaaacacca	aatatgaatt	ttatgatgta	3300
cactttgtgc	ttggcattaa	aagaaaaaaa	cacaaaaaaa	aaaaaaaaaa	gggcggccgc	3360
tgcgcgatc						3369

&lt;210&gt; 13

&lt;211&gt; 3258

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 13

gcggccgcgt	cgacgctggc	cgctgtgtag	ggctgggtgag	tggctggggc	tgtctgagcc	60
atgaacaact	tcaggggccac	catcctcttc	tgggcagcgg	cagcatgggc	taaatcaggc	120
aagccttcgg	gagagatgga	cgaagttgga	gttcaaaaat	gcaagaatgc	cttgaaacta	180
cctgtcctgg	aagtcctacc	tggagggggc	tgggacaatc	tgcggaatgt	ggacatggga	240
cgagttatgg	aattgactta	ctccaactgc	aggacaacag	aggatggaca	gtatatcatc	300
cctgatgaaa	tcttcaccat	tcccagaaa	cagagcaacc	tggagatgaa	ctcagaaatc	360
ctggaatcct	gggcaaatta	ccagagtagc	acctcctact	ccatcaacac	agaactctct	420
cttttttcca	aagtcaatgg	caagttttcc	actgagttcc	agaggatgaa	gacctccaa	480
gtgaaggacc	aagctataac	tacccgagtt	caggtaagaa	acctcgtcta	cacagtcaaa	540
atcaacccaa	ctttagagct	aagctcaggt	tttaggaagg	aactccttga	catctctgac	600
cgtctagaga	acaaccagac	gaggatggcc	acctacctgg	cagaactcct	ggtgtctaac	660
tatggcacc	acgtcaccac	cagtgtcgac	gctggggctg	ctcttattca	ggaggaccac	720
ctcagggcct	ccttcctcca	agacagccag	agcagtcgta	gtgccgtgac	cgctctgct	780
ggacttgcc	ttcaaaacac	cgtgaacttc	aaatttgagg	aaaactatac	ctcgcagaat	840
gtcctcacca	agagctacct	ctcaaaccga	accaactcca	gggtgcagag	cattggaggg	900
gttccttttt	accagggcat	cacctccag	gcctggcagc	agggtatcac	caaccacctg	960
gtggccatcg	accgctctgg	cctgccgctg	catctcttca	tcaaccccaa	catgctacct	1020
gacttgccag	gccccctggt	gaagaagggt	tcaaagacag	tggaaactgc	tgtgaagcgc	1080
tattatacat	tcaaacaccta	ccctggctgc	acagatctca	attctcccaa	cttcaatttt	1140
caggccaaca	cggatgatgg	ctcctgcgag	gggaaaatga	ccaacttctc	tttcgggtggg	1200
gtttatcagg	aatgcactca	gctctcaggg	aatagggatg	tctcctctg	ccaaaagttg	1260
gagcagaaga	atccactcac	tgggtgattt	tctgcccc	ctggctactc	cccggtgac	1320
ctgttatccc	agatccacga	ggagggttac	aaccacctgg	agtgtcatcg	aaagtgcact	1380
ctcctcgtct	tctgcaagac	cgtgtgtgaa	gatgtgttcc	agggtggcaa	agctgaattt	1440
agggtctttt	ggtgtgtggc	cagcagccaa	gtacctgaaa	actcaggact	gctttttggg	1500
ggcctcttca	gcagcaagag	cataaacccc	atgacaaatg	cacagtcatg	cccagccggc	1560
tactttccac	tgagactctt	tgaaaacctc	aagggtatgtg	tttctcagga	ctatgagttg	1620
ggaagcaggt	ttgcgggtccc	ctttggcggg	ttcttttagct	gcacagttgg	gaaccccttg	1680
gtagatcctg	ctatatccag	agatttaggg	gcaccgtctc	tgaaaaagtg	ccccgggggc	1740
ttcagccagc	accagccct	catcagcgat	ggatgccaa	tgtcctattg	cgtcaaatcc	1800
gggtcttca	caggaggggc	cctgccccct	gccaggctcc	cacctttcac	ccggccaccc	1860
ctcatgagtc	aggctgccac	caatactgtc	atagtgaacca	attctgagaa	tgcgagatcc	1920



tggattaaag	actcccagac	ccaccagtgg	aggctgggag	aaccgataga	gctgcggagg	1980
gccatgaatg	tcatccatgg	ggatggtgg	ggtctgtcag	gaggggctgc	agctgggggtc	2040
acagtggggg	taccacccat	tctggctgtt	gttatcacct	tggccatcta	cggcaccccg	2100
aagttcaaga	agaaagcata	tcaggcaatt	gaggaaaggc	agagtttggt	tccaggcact	2160
gcagcaactg	gagacaccac	ttaccaagag	caggggcaga	gtccagctta	aatctctccc	2220
cgaaaatgg	ttctctcatc	tccagtgtgg	tcattgctga	ccactctgtt	ttcctaagca	2280
ttgaaatggc	aagtgcaccc	aaaagtaggt	atattcgtga	cttcttggtt	aggtctctgg	2340
gccaggaaat	tcatactgtt	acatggataa	ggttgggatt	ggggagaggg	aacagttggg	2400
actagaagca	aaagtgatcc	tgggactaaa	ataggaagca	gatgtccttt	cccaatgtgt	2460
gttgctgtct	tcacctgaat	gcatttgtgt	aaaaatagcg	gagggacaat	gtgaacattt	2520
gtatttggaa	gctatgaatt	tactctgaag	tttgcagttg	tttccaattt	gtgagctcta	2580
agagtttctg	cctgtaagaa	ctactctcct	tttattttga	tttttaaaaa	actgtctgaa	2640
tttcacactc	ttagagcctg	gaagagccct	gaaaagacac	aagtcttgcc	tggctactgc	2700
tttttaactt	tgagggtctt	atgttgacag	actgttatct	cctctgggtg	acctcaaaca	2760
tctgaaaaga	aagatgttgc	ctgtgccaat	tccacttttt	ccagctgccc	cttgatgaac	2820
actcccttat	accagaccac	tcttggactt	ctgactgggtg	tcacaaagtc	ctcagaaaat	2880
atttttaagtt	atttttaagtt	attaaggaag	ggatgatttg	gagacaagga	gtaatgaaag	2940
atgggtaaaa	actggaaaag	attctgggtgc	taagtactac	cccttcatct	tccatggatg	3000
gtcattacct	ttcctgtcct	cctgttctat	gaacacacac	acacacacac	cccccccaca	3060
tttcaataag	tcttcattgt	tctgggtcct	tacctttcct	gtcctcctgt	tatatgaaca	3120
cacacacaca	cacacacaca	cacacgcaca	cacataccac	atttcaataa	gtcttcattg	3180
ttctgggtcc	ttacctttcc	tgtcctcctg	ttatatgaac	acacacacac	acacacacac	3240
acacacacgc	acggtcga					3258

&lt;210&gt; 14

&lt;211&gt; 3077

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 14

ccacgcgtcc	ggggagtgtt	gttaaccgga	ggggcagccg	cagtcgcgcg	gattgagcgg	60
gctcgcggcg	ctgggttcc	ggtctccggg	ccagggaat	gttccgcacg	gcagtgatga	120
tggcggccag	cctggcgctg	accggggctg	tgggtggctca	cgcctactac	ctcaaaccac	180
agttctaccc	cactgtgggtg	tacctgacca	agtcacagccc	cagcatggca	gtcctgtaca	240
tccaggccctt	tgtccttgct	ttccttcttg	gcaagggtgat	gggcaagggtg	ttctttgggc	300
aactgagggc	agcagagatg	gagcaccttc	tggaaacgttc	ctggtacgcc	gtcacagaga	360
cttgtctggc	cttcaccggtt	tttcgggatg	acttcagccc	ccgctttgtt	gcactcttca	420
ctcttcttct	cttcctcaaa	tgtttccact	ggctgggtga	ggaccgtgtg	gactttatgg	480
aacgcagccc	caacatctcc	tggctctttc	actgccgcac	tgtctctctt	atgttctctc	540
tgggcatcct	ggacttcttc	ttcgtcagcc	acgcctatca	cagcatcctg	accggtgggg	600
cctctgtgca	gctgggtgtt	ggctttgagt	atgccatcct	gatgacgatg	gtgctcacca	660
tcttcatcaa	gtatgtgctg	cactccgtgg	acctccagag	tgagaacccc	tgggacaaca	720
aggctgtgta	catgctctac	acagagctgt	ttacaggctt	catcaagggtt	ctgctgtaca	780
tggccttcat	gaccatcatg	atcaagggtg	acaccttccc	actctttgcc	atccggccca	840
tgtacctggc	catgagacag	ttcaagaaag	ctgtgacaga	tgccatcatg	tctcgccgag	900
ccatccgcaa	catgaacacc	ctgtatccag	atgccacccc	agaggagctc	caggcaatgg	960
acaatgtctg	catcatctgc	cgagaagaga	tggtgactgg	tgccaaagaga	ctgccctgca	1020
accacatttt	ccataccagc	tgcctgcgct	cctgggtcca	gcggcagcag	acctgccccca	1080
cctgccgtat	ggatgtcctt	cgtgcacgcg	tgccagcgca	gtcaccacca	cccccgagc	1140
ctgcggtatca	ggggccaccc	cctgcccccc	acccccacc	actcttgcc	cagcccccca	1200
acttccccca	gggcctcctg	cctccttttc	ctccaggcat	gttcccactg	tggcccccca	1260
tgggcccctt	tccacctgtc	ccgcctcccc	ccagctcagg	agaggctgtg	gtcctcccat	1320
ccaccagtgc	agcagccctt	tctcggccca	gtggagcagc	tacaaccaca	gctgctggca	1380
ccagtgtctac	tgtgtcttct	gccacagcat	ctggcccagg	ctctggtctt	gccccagagg	1440
ctggccctgc	ccctgggttc	cccttccctc	ctccctggat	gggtatgccc	ctgcctccac	1500
cctttgcctt	cccccaatg	cctgtgcccc	ctgcgggctt	tgtctgggtg	accccagagg	1560
agctacgagc	tctggagggc	catgagcggc	agcacctgga	ggcccggctg	cagagcctgc	1620

gtaacatcca	cacactgctg	gacgccgcca	tgctgcagat	caaccagtac	ctcaccgtgc	1680
tggcctcctt	ggggccccc	cggcctgcca	cttcagtcaa	ctccactgag	gagactgcca	1740
ctacagttgt	tgctgctgcc	tcctccacca	gcatccctag	ctcagaggcc	acgaccccaa	1800
ccccaggagc	ctccccacca	gcccctgaaa	tggaaggcc	tccagctcct	gagtcagtgg	1860
gcacagagga	gatgcctgag	gatggagagc	ccgatgcagc	agagctccgc	cggcgccgcc	1920
tgcagaagct	ggagtctcct	gttgcccact	gacactgccc	cagcccagcc	ccagcctctg	1980
ctcttttgag	cagccctcgc	tggaacatgt	cctgccacca	agtgccagct	ccctctctgt	2040
ctgcaccagg	gagtagtacc	cccagctctg	agaaagaggc	ggcatcccct	aggccaagtg	2100
gaaagaggct	gggggttccca	tttgactcca	gtcccaggca	gccatgggga	tctcgggtca	2160
gttccagcct	tcctctccaa	ctcttcagcc	ctgtgttctg	ctggggccat	gaaggcagaa	2220
ggtttagcct	ctgagaagcc	ctcttcttcc	cccacccctt	tccaggagaa	ggggctgccc	2280
ctccaagccc	tacttgtatg	tgcgagatca	cactgcagtg	ccgaacagta	ttagctcccg	2340
ttcccaagtg	tggaactccag	aggggctgga	ggcaagctat	gaacttgctc	gctggcccac	2400
ccctaagact	ggtacccatt	tccttttctt	accctgatct	cccagaagc	ctcttggtgt	2460
ggtggctgtg	ccccctatgc	cctgtggcat	ttctgcgtct	tactggcaac	cacacaactc	2520
agggaaagga	atgcctggga	gtgggggtgc	aggcgggcag	cactgaggga	ccctgccccg	2580
ccctccccc	caggcccctt	tcccctgcag	cttctcaagt	gagactgacc	tgtctcacc	2640
agcagccact	gcccagccgc	actccaggca	agggccagtg	cgctgctcc	tgaccactgc	2700
aatcccagcg	cccaagggaag	gccacttctc	aactggcaga	acttctgaag	tttagaattg	2760
gaattacttc	cttactagtg	tcttttggct	taaattttgt	cttttgaagt	tgaatgctta	2820
atcccgggaa	agaggaacag	gagtgccaga	ctcctgggtc	ttccagttta	gaaaaggctc	2880
tgtgccaaag	agggaccaca	ggagctggga	cctgcctgcc	cctgtctttt	ccccttggtt	2940
ttgtgttaca	agagttgttg	gagacagttt	cagatgatta	tttaatttgt	aaatattgta	3000
caaattttaa	tagcttaaat	tgtatatata	gccaaataaa	aacttgcat	aacaattaaa	3060
aaaaaaaaaa	aaaaaaaa					3077

<210> 15

<211> 1082

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (211)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1027)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1041)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1042)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1079)

<223> n equals a,t,g, or c

<400> 15

gtttccttgg	ggacgtggcg	ccgccgccgg	ccggggccctc	cttccggctg	ggcaagggggc	60
cgcgggggagc	agctcggggac	tgaaccgaga	ggtgccgaag	gaaccggcg	gccgcttgat	120
cccgcgtgcag	acgtaggaga	tgcctgggac	aaggaggcca	ccttctcagg	gcaaaagaaa	180
aagaaggtga	caggcgttga	gaccaccgaa	nggaacccat	ggctaggatc	agtttttccct	240
acctctgccc	agcctcctgg	tacttcactg	tgcccacagt	gagtcattt	ctccgtcagc	300
gggtggcatt	cctgggactc	ttcttcata	cctgtctcct	tttacttatg	ttaatcatag	360
actttcgaca	ttggagtgt	tcattaccac	gagataggca	atacgaaagg	tatttggtc	420
gagtagggga	gcttgaagct	actgacactg	aagacccaaa	tctgaattat	ggacttgktg	480
ttgactgtgg	cagcagtggt	tcccggattt	ttgkttattt	ctggccaaga	cataatggga	540
acccccatga	cttgctggac	atcaaacaga	tgagagaccg	caacagccaa	ccagtgggta	600
aaaaaatcaa	gccaggaatc	tctgcaatgg	cagacactcc	agaacatgcc	agtgattacc	660
ttcgtcctct	gctgagcttt	gctgctgctc	atgtgcctgt	gaagaagcac	aaggagaccc	720
ctctttacat	cctctgcaca	gcaggcatga	ggcttctccc	tgagaggaag	cagttggcta	780
tcttggtga	cctagtga	gatttaccac	tggagtgtga	cttctcttt	tcacagtctc	840
aagcagaagt	gatctctggg	aagcaggaag	gggtttatgc	atggattgga	atcaactttg	900
ttttgsgaag	attcgaccac	gaggatgaat	cagatgctga	ggctaccag	gaattggcag	960
caggacggag	aaggacagta	gggatactgg	atatgggagg	agccyctcyc	caaattgctt	1020
atgaagntcc	tacctttccc	nnaaaaaaaaa	ccccccccc	ttttccctt	ttggggggna	1080
ta						1082

&lt;210&gt; 16

&lt;211&gt; 2070

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 16

ttttggtttt	tttttttttt	tttttttttc	catctttgaa	gtcctttatt	cccagcagtt	60
cacatcagtt	actcattgag	ctgggggttcg	tcatattaac	caagaattca	ttcatctttc	120
ttttgatatt	gtaatcttgt	cctcatctcc	acaactgagt	tggggcctga	gggggttaag	180
agttctcact	ccatcacagg	aggcaagggg	tacccttggtg	aaccagactt	caactcctgg	240
aagtcttggt	cagttcatag	gcaaataatct	ttgcaagttt	agtatgagac	agcccaacgg	300
ttaaataaat	aagacacagt	gccatgggtc	taggcatttg	gagagggaaa	aggcacatta	360
cacagattcc	cctggagaaa	atacaggcca	ttctcatctt	ctcaacatgc	attttcccac	420
tcttcagtga	cttttaatat	tatcccctgg	tctatgagaa	accataaccc	acgtgctact	480
gaatacattt	ttattttccc	ttcatgacat	agacttggtt	ccaagtatat	tttattttcc	540
tcccttatgc	ctacaagaca	tccaattttg	ttcagggtccc	ttttaatggc	acttaataaa	600
tatacattct	gagacctggc	agaacaggct	gtcccctttc	acactgcctt	taaagcgctt	660
gtttgaacta	gctagtgcag	agctcagggt	gggcacgtcc	tagcttacag	ctcwtggcca	720
tctctggcac	caggtctatc	tgtccaatac	tttgtgtcta	gggtagaggt	ccctaaccct	780
ggctgcacat	tgggaagcacc	tgggaagcct	tctgaattcc	tgaggcccga	gccacaccct	840
aaaccaattt	catcagaatc	tctgggtggg	acggagcctg	gattctgcca	gttgaaacct	900
gccatggtaa	cttcagtga	cagctacact	gagaactcct	gagctacaat	tctagcacac	960
agtaggcctt	cggtaggtat	ctgtggaacc	cacgagtggg	tttctattt	cattatctgt	1020
tcccctatgc	tctctatttt	tatcagaaat	ctgagcagga	aagagcagag	agaatgagtc	1080
aagagcatcc	tctcaagtga	attcgctgct	gagaaaggaa	ccgtagggt	tgcatttctc	1140
ttgtgtcatg	cagtcttcat	gctttaacag	gccagagga	ggcaagtatt	agactgacac	1200
agacatgtat	atattttctta	aaagcccttc	aaaaaccaga	gctcactgct	taggcactat	1260
ggttataaca	cagacatgtt	cttggaagca	tatctaaact	acctcctgtt	tgacacacat	1320
tctaacttgg	gttggttaca	aactttgtca	gttggttaaga	tcacacttgg	tcacattttc	1380
ccattttctgt	gaatcttgca	acttatcttt	gcccagagca	acagcctaga	catgaccacc	1440
ccaagcaggg	actgcactgc	acccaacatt	gccccagcag	gtcagtcctc	cttgaacagg	1500
aactgttttt	gaggggctcc	aattttccagg	ttctagaatg	gggtggctca	cttaccaagt	1560
taaagaggct	ggctacatag	aatgcagtat	tgagaagccc	cccaaggtag	atcctgggtt	1620
acaggaaaga	aagctatact	gatgaacaag	gtttgctgcc	acaggcatgg	gcgtggggga	1680
gggcagcatg	ccgggggcca	ccccgagatc	actgctgtca	tttacatttg	tatcacactt	1740
cacagtttac	agggagctct	gcatgcttag	ccccatgtca	ttctcagcac	aacctgtga	1800
gtgaggtcct	tctggatggg	aacactgaag	ttgtgtccta	catctaaggt	cccacagcca	1860

attgcatcac	atccacggct	gcctccagga	cctcaggggc	cacctgaaac	cactgggggt	1920
tccccctggc	tcccccttcta	accagaaaca	ggaaagcaag	ccattcccta	acctccccac	1980
ccaccaggcc	ttatcacgc	cttcccagag	tttcctctat	gatttgcata	cccctttgtt	2040
ccctagtcct	gagaacacag	cagagcttcc				2070

<210> 17  
 <211> 2055  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (2014)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (2016)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (2038)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (2045)  
 <223> n equals a,t,g, or c

<400> 17						60
gacgatgcct	gcttgaattt	cctggcagct	aagggaataa	acatccaggg	gctgtctgca	120
gaagagatca	ggaatggaaa	cctcaaggcc	attctaggcc	tcttcttcag	cctctcccg	180
tacaagcagc	agcagcagca	gccccagaag	cagcacctct	cctcacctct	gccgcccgcc	240
gtatcccagg	tggccggggc	ccccctccag	tgccaggctg	gcacccctca	gcagcagggtg	300
ccagtcactc	cccaagcccc	gtgccagcct	caccagccag	caccacatca	gcagtcaaaa	360
gcacaagctg	aaatgcagtc	cagagccttt	ggcaagttca	gcctcctccc	accccggaat	420
gagtgacaat	gcacctgctt	ccttggagag	cggcagcagc	tccacccta	ctaattgcag	480
tacctcctcg	gccatcccg	agcccggtgc	agccaccaag	ccttggcgca	gcaaatecct	540
cagcgtgaag	cacagtgcc	cggatccat	gctctcggtc	aagcctcctg	ggcctgaggc	600
ccccaggccc	acacctgaag	ccatgaagcc	ggcccccaac	aatcagaagt	ccatgctgga	660
aaagctgaaa	cttttcaaca	gtaaagggg	ctcaaaggca	ggtgaggggc	cgggggtccc	720
ggacacaagc	tgtgagcggc	tggagactct	gcccagcttc	gaagagagcg	aggagctgga	780
ggccgcccag	cgcagtctca	ccaccgtggg	ccctgcttcc	agcagcccca	agattgcact	840
caagggcatt	gcccagagga	cttttagccg	ggcactgacc	aacaagaaga	gttctctgaa	900
aggcaatgag	aaagagaagg	agaaacaaca	gcgggagaag	gataaggaga	aaagcaagga	960
ccttgccaag	agagcctctg	tgacggagag	gctggacctc	aaggaggagc	caaaagaaga	1020
ccccagtgga	gcagctgtgc	ccgagatgcc	aaaaaagtcc	tccaagattg	ccagcttcat	1080
ccccaaaggg	gggaagctca	acagtgccaa	gaaggagccc	atggccccctt	cccacagtgg	1140
aataccaaaa	ccaggaatga	agagcatgcc	cgggaaatcc	ccaagtgcc	cagcgccctc	1200
caaggaaggg	gagcggagcc	ggagtgggaa	gctgagctca	ggactcccc	agcagaagcc	1260
ccagctggac	ggcagacact	ccagttcctc	ttccagcctg	gcgtcctcag	aaggaaaagg	1320
cccaggagg	accaccctga	accacagcat	cagcagccag	actgtcagt	ggtctgtcgg	1380
gaccaccag	accacaggaa	gcaataccgt	cagtgttcag	ctacctcagc	cccagcagca	1440
atacaaccat	cccaacactg	ccacggttgc	acctttcttg	tacaggtctc	agacggacac	1500
tgaagggaat	gstacygscg	agtcaagctc	aacaggtgtg	agcgtggagc	ccagscactt	1560
yccaagactg	gacagcctgc	tctggaagaa	ctcactgggg	aagatcctga	ggctcggcgg	

ctgcggacag	tgaagaacat	cgctgatctg	cggcagaatt	tggaggaaac	catgtccagt	1620
ttaaggggaa	ctcagggttac	acacagcaca	ttggaaacca	cgtttgacac	caatgtcacc	1680
acggagatga	gtggccgtag	catactcagc	ttgacagggg	ggcccacacc	tctgtcctgg	1740
agactgggcc	agtccagccc	tcggctccaa	gcaggagacg	ccccctcaat	gggcaatggg	1800
tatccccctc	gagccaacgc	cagcaggttc	atcaacactg	agtcaggtcg	ctatgtgtac	1860
tccgccccctc	tgagaaggca	gctggcctcc	cggggcagta	gtgtctgcc	tgtggacgtc	1920
ttagacaagg	caggagatga	gatggacctg	gaaggcatca	gcatggacgc	ccccgggtca	1980
tgagcgatgg	ggatgtaact	gagcaagaac	attntngacc	gatgacaatt	atcaaagncg	2040
gggcntacca	ttgta					2055

<210> 18  
 <211> 829  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (758)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (767)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (793)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (810)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (814)  
 <223> n equals a,t,g, or c

<400> 18						
gacaggggtg	agccaccgcc	ccaggcctct	ttcggcactg	ccctcaacca	catgggcctc	60
actgttcttc	cggcgtagcc	agactttccc	catctcagcg	ccttcccacc	ggtcctgtgt	120
ttccatggcc	tttccccggg	taggggcctt	tcttttccta	gcttcgctca	gttcctgtgt	180
acattgtcgc	ctcctcgcag	aagccgtctc	tggccgttcc	gtatcgctag	cgccctctat	240
cattcgctag	cagctcacc	ggctctgttt	ttcttcattg	cacttctcgt	tatgtgccgt	300
tctcttataa	atgtttttgt	ctttatccct	cccatagaag	acacctccat	gaaaggccag	360
ggctttccga	ggttcttttc	ctctgtgggt	cctagaagag	ggcctggcac	atagccggcc	420
ttggctagct	ttttgcgtaa	atgtgaagg	atccaccttc	ctcccttata	agaggtagca	480
gtacctcctg	ttaccagcag	agggcaccac	cgtacagcac	ttggggggccg	cagggatcct	540
gctgggatgg	gagggtattta	aaaagcccac	aggcctctcc	tcccataatg	tgggcgctcc	600
cacagctggg	accggaagca	ggaaggggccc	ctgcgcta	ctgccctggc	agcagcgarc	660
tggaagcccc	tgggtgcata	atccggtgtg	ctctggtgcc	caaagtcggg	aatacctcam	720
tgggtggcttg	gaaaaaaccc	tgagcagtga	tgcttctnga	caattanaac	ctgttcgggg	780
gtcttaaaat	ganggaatga	catgagctgn	attntcgtta	agcgttttg		829

<210> 19  
 <211> 1056  
 <212> DNA  
 <213> Homo sapiens

```

<400> 19
gggtctaaaca tttyaggaat atctgctaaa gtccctatgt agatcctctt gagctacccc      60
ttgattaact agttctcctc ggtatctata taataactac ctttgtatth ttattgtgat      120
atatcaaaaa ttagcattta ggagcatgga agaagtagca ttcattggtht taaaaatagt      180
tttgcccttht ttgaagtctc tgtggctcca tgtttactta ctagcagtgc tgtggcctag      240
actggcttht atgatatact ttgggtccag gttatttcag attgttgatg gtgcttagcc      300
tctgagaggt agtttttagat attaacctat ttaatgtaat aatgtaatga aaagtttttag      360
tactaaaaata agtgtatgac cccacacatta attccattac aaaattactt tatcaaaaac      420
aaattagcta gaaaaaaaat tacatcttat gttttcttat atagataaag agaggcctgt      480
ccagtcttht gaaaacatcaa gagatacttc accctcaagt gggttcagcag tttcttcac      540
aaaggtgtta gacaaaccca gtaggctaac tgaaaaggaa cttgctgagg ctgcaagcaa      600
gtgggctgct gaaaagctag agaaatcaga tgaaagtaac ttgcctgaaa tttctgagta      660
tgaggcggga tccacagcac cattgtttac tgaccagcca gaggaacctg agtcaaacac      720
aacacatggg atagaattat ttgaagatag tcagctaacc actcgctcta aagcaatagc      780
atcaaaaacc aaagagattg aacaggthta ccgacaagac tgtgaaactt tcgggatggg      840
ggtgaaaatg ctgattgaaa aagatccttc attagaaaag tctatacagt ttgcattgag      900
gcagaattta catgaaatag gtgagcgggtg tgttgagaaa ctcaagcatt tcattgcaga      960
gtatgatact tccactcaag attttgagga gcctthtttag atthttctgc tcaggctaaa     1020
aaaaaaaaaa acagthttcta aaaattthtt ttcctg

```

<210> 20  
 <211> 3143  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (1396)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1442)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (3099)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (3132)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (3143)  
 <223> n equals a,t,g, or c

```

<400> 20
gcccagtaaa agctactagg tgacactata gaaggtagc ctgcaggtag cgggtccggaa      60

```

ttccccgggtc	gacccacgcg	tccggtagct	cagctgcatt	tgcacctgga	acccgcgctc	120
tcgcccaccc	tgtctagcc	ctggcctgtg	gctgggacct	ccagcataaa	ccggatgctc	180
tgcccagctc	tgggcccatt	tctgctgttt	ctgctcagtt	caacctgat	ggcttccttt	240
atgggtgaca	ctccatgtca	cccaggcgaa	ctgtcagcct	ttggagtggc	acccagtagg	300
gtctttactt	ccagtttctt	gttcacagtc	ttcactcctt	catacccctc	actccctggg	360
taacatcggg	ccaccagtaa	tgctggttcc	tagctctgca	acaccatgca	cgggtgtagta	420
gctaagagca	gagctttcgg	gtgtgaagta	cctgagtaca	gttccctgct	tcccctgtgt	480
gtgcctggaa	cagagtaaac	actcaggaag	cgttacccac	tgtgcccatt	cccagagatg	540
caaaagggtga	ggctctccgtt	ttgccatcta	tacaatagag	ataataaagg	ctatcccact	600
cttaatgtgt	gccagtttct	gtcctaggca	ttttgtagat	gtgtgagctt	atttagtgct	660
ttcttattat	tatttttggg	gatggctctca	ctgtgtggct	caggctgcag	tgcagcctct	720
gcctcccagg	cttaagcaat	cctcccacct	cagcctttca	agtagctgag	accacaggcg	780
tgtaccaccc	acccatggct	aattttttat	tttttatttt	ttattgtttg	tttgtttgtt	840
ttgagacaga	atctcactct	gtcaccacag	ctggagtgca	gtggcatgat	cttggcgcac	900
tgcaacctct	gcctcccggg	ttcaagtgat	tctcctgctt	cagcctcccg	agtagctggg	960
attacagggtg	cctgccacca	cgtctggcta	atttttgtat	ttttagtaga	gacgagggtt	1020
caccatgttg	gccaggctgg	tctcgagctc	ctaacctcag	gtgatccacc	tgcctcagcc	1080
tcccaaagtg	ctgggattac	aggcctgagc	cactgcgccc	agccagcctg	ttgtttttgt	1140
ttttgttttg	agacaagagt	ctcactctat	cgctcaggct	ggagtgcagt	ggcatgatct	1200
tggctcactg	tagcctccac	cttcagatt	caagcaattc	tcctgcctca	gcctcccagag	1260
tagctgggat	tacagacata	caccacaacg	cccggtcaat	gktggtttgk	ttgkttgktt	1320
gtgacggagt	tttgctcttg	ktgcccaggc	tggartgcag	tggcacaatc	tyagctyact	1380
gcaacctcca	tctccnggg	tcaagcgatt	ctcctgcttc	agcctcccca	gtagctggga	1440
tnacagggtg	cgcgccacct	gccgggctaa	ttttttatat	ttttagtaga	gatgggggtt	1500
cactgtgttg	gtccaggctg	tcttgaactc	ctgacctcag	gtgatccacc	ccaccttggc	1560
ctcccaaagt	gctgggatta	caggtgagag	ccaccgtgct	tagccctttt	aaaaatgttt	1620
aaaaattatt	atttagtcct	ttcaatgacc	ctaaggtagg	aactgttata	tccattttgc	1680
aggtgagaac	accaaggccc	agggaagata	tatcacattt	gaaccagat	tcagatttga	1740
atccagggtg	cctggctgct	gagtgcattg	tttgagtcac	tcctgtccc	ccagcttctt	1800
ctgttccatc	actctgggtt	attttctctc	ttgaagttaa	cagggattga	tactatcctg	1860
tgtttcattt	gcttggttag	cacctgtctg	ctctcaccta	gaatgttagc	tctctaaggg	1920
cagggactgt	atcctgccac	attggcccac	gtctggagag	cctgtggcac	atgggtggata	1980
caccatggat	ttgttgaaat	aaggcgcccc	ctgcaagcca	ggccctcacc	ctggcttctg	2040
gctgtggggc	caggggtgtc	ctgggagcac	aaccctagct	gaattcctgc	ctgccctccc	2100
ctccaggccg	agtgtactac	ttcaaccaca	tcactaacgc	cagccagtgg	gagcggccca	2160
gcggcaacag	cagcagtgg	ggcaaaaacg	ggcaggggga	gcctgccagg	gtccgctgct	2220
cgcacctgct	ggtgaagcac	agccagtcac	ggcgccctc	gtcctggcgg	caggagaaga	2280
tcacccgga	caaggaggag	gccttgagc	tgatcaacgg	ctacatccag	aagatcaagt	2340
cgggagagga	ggactttgag	tctctggcct	cacagttcag	cgactgcagc	tcagccaagg	2400
ccaggggaga	cctgggtgcc	ttcagcagag	gtcagatgca	gaagccattt	gaagacgcct	2460
cgtttgcgct	cgggacggg	gagatgagcg	ggcccggtgt	cacggattcc	ggcatccaca	2520
tcctcctccg	cactgagtga	gggtggggag	cccaggcctg	gcctcggggc	agggcagggc	2580
ggctaggccg	gccagctccc	ccttgcccgc	cagccagtgg	ccgaaccccc	cactccctgc	2640
caccgtcaca	cagtatttat	tgttcccaca	atggctggga	gggggcccct	ccagattggg	2700
ggccctgggg	tccccactcc	ctgtccatcc	ccagttgggg	ctgcgaccgc	cagatttctc	2760
cttaaggaat	tgacttcagc	aggggtggga	ggctcccaga	cccagggcag	tgtggtggga	2820
ggggtgttcc	aaagagaagg	cctgggtcagc	agagccgccc	cgtgtcccc	caggtgtctg	2880
aggcagactc	gagggccgaa	ttgtttctag	ttaggccacg	ctcctctgtt	cagtcgcaaa	2940
ggtgaacact	catgcggccc	agccatgggc	cctctgagca	actgtgcagc	accctttcac	3000
ccccaattaa	acccagaacc	actaaaaaaaa	aaaaaaaaaaaa	aaaaaaaaaaaa	aaaaaaaaaaaa	3060
aaaaaaaaaaaa	aaaaaaaaaaaa	aaaaaaaaaaaa	aaaaagggng	gccgttttaa	aggatccctc	3120
gaggggcca	antttacgcg	tgn				3143

&lt;210&gt; 21

&lt;211&gt; 3878

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

<220>  
 <221> SITE  
 <222> (36)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (61)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (210)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (271)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (2410)  
 <223> n equals a,t,g, or c

<400> 21									
tccctagggt	tgcgccctttt	gaataagtat	cacttnttag	ttgctccatg	cctcagtttg				60
ncatctgaaa	atgggggcat	ctgtaatgcc	tgtgttatga	ggagtaaatt	acaagcatcc				120
ctgtaagacg	tagcacagt	togagtacgg	aatgttattt	ccatccttct	cacggagctt				180
ggttcccttt	ccccatgccc	tttacttgtn	ccagccattg	actcatacta	cttcccttct				240
tgcaggcatt	ggtccagtgc	tgggcctggg	ntgtgtcccg	ctcctaggct	cagccagtga				300
ccactggcgw	ggacgctatg	gccgcccggg	gcccttcac	tgggcactgt	ccttgggcat				360
cctgctgagc	ctctttctca	tcccaagggc	cggttggtta	gcagggtgct	tgtgcccggg				420
tcccaggccc	ctggagctgg	cactgctcat	cctgggcgtg	gggctgctgg	acttctgtgg				480
ccagggtgtg	ttcactccac	tggaggccct	gctctctgac	ctcttcgggg	acccggacca				540
ctgtcgccag	gcctactctg	tctatgcctt	catgatcagt	cctggggggt	gcctgggcta				600
cctcctgcct	gccattgact	gggacaccag	tgccctggcc	ccctacctgg	gcacccagga				660
ggagtgcctc	tttgccctgc	tcaccctcat	cttccctacc	tgcgtagcag	ccacactgct				720
ggtggctgag	gaggcagcgc	tgggccccac	cgagccagca	gaagggtgtg	cgccccctc				780
cttgctgccc	cactgctgtc	catgccgggc	ccgcttggtt	ttccggaacc	tgggcgcctt				840
gcttccccgg	ctgcaccagc	tgtgctgccg	catgccccgc	accctgcgcc	ggctcttcgt				900
ggctgagctg	tgcagctgga	tggcactcat	gaccttcacg	ctgttttaca	cggatttcgt				960
gggcgagggg	ctgtaccagg	gcgtgcccag	agctgagccg	ggcaccgagg	cccggagaca				1020
ctatgatgaa	ggtaaggcct	tggcagccag	cagaggctgg	tgtgggagcc	gcccaccaga				1080
gacgacactc	ggggctgtgt	ctgggctggg	gcctctccat	cctggccccg	acttctctgt				1140
caggaaaagt	gggatggacc	ccatctgcat	acacggcttc	tcatgggtgt	ggaacatctc				1200
tgcctgcggg	ttcaggaagg	cctctggctg	ctctaggagt	ctgatcagag	tcgttgcccc				1260
agtttgacag	aaggaaaggc	ggagcttatt	caaagtctag	agggagtggg	ggagttaagg				1320
ctggatttca	gatctgcctg	gttccagccg	cagtgtgccc	tctgctcccc	caacgacttt				1380
ccaaataatc	tcaccagcgc	cttccagctc	aggcgtccca	gaagcgtctt	gaagcctatg				1440
gccagctgtc	tttgtgttcc	ctctcaccgc	cctgtcccca	cagctgagac	tcccaggaaa				1500
ccttcagact	accttcctct	gccttcagca	aggggcgttg	cccacattct	ctgagggtca				1560
gtggaagaac	ctagactccc	attgctagag	gtagaaaagg	gaagggtgct	ggggagcagg				1620
gctggtccac	agcaggctct	gtgcagcagg	tacctgtggg	tccgccttct	catctccctg				1680
agactgctcc	gacccttccc	tcccaggctc	tgtctgatgg	ccccctcccc	tctgcaggcg				1740
ttcggtggg	cagcctgggg	ctgttcctgc	agtgcgccat	ctccctgggc	ttctctctgg				1800
tcatggaccg	gctggtgcag	cgattcggca	ctcgagcagt	ctatttggcc	agtgtggcag				1860



ctttccctgt	ggctgccggt	gccacatgcc	tgtcccacag	tgtggccgtg	gtgacagctt	1920
cagccgccct	caccgggttc	accttctcag	ccctgcagat	cctgccctac	acactggcct	1980
ccctctacca	ccgggagaag	caggtgttcc	tgcccaaata	ccgaggggac	actggagggtg	2040
ctagcagtga	ggacagcctg	atgaccagct	tcttgccagg	ccctaagcct	ggagctccct	2100
tccctaattg	acacgtgggt	gctggaggca	gtggcctgct	cccacctcca	cccgcgtct	2160
gcggggcctc	tgctgtgat	gtctccgtac	gtgtgggtgt	gggtgagccc	accgaggcca	2220
gggtggttmm	gggccggggc	atctgcctgg	acctcgccat	cctggatagt	gccttctctgc	2280
tgtcccaggt	ggccccatcc	ctgtttatgg	gtccattgt	ccagctcagc	cagtctgtca	2340
ctgcctatat	ggtgtctgcc	gcaggcctgg	gtctggtcgc	catttacttt	gctacacagg	2400
tagtatattgn	caagagcgac	ttggcaaata	ctcagcgtag	aaacttccag	cmcattgggg	2460
tgragggcct	gcctcactgg	gtcccagctc	cctgctcctg	ttagcccat	ggggctgccg	2520
ggctggccgc	cagtttctgt	tgctgcaaaa	gtaatgtggc	tctctgctgc	cacctgtgc	2580
tgctgagggtg	cgtagctgca	cagctggggg	ctggggcgtc	cctctcctct	ctccccagtc	2640
tctagggctg	cctgactgga	ggccttccaa	gggggtttca	gtctggactt	atacaggag	2700
gccagaagg	ctccatgcac	tggaatgcgg	ggactctgca	ggtggattac	ccaggctcag	2760
ggttaacagc	tagcctccta	gttgagacac	acctagagaa	gggttttttg	gagctgaata	2820
aactcagtca	cctgggttcc	catctctaag	ccccttaacc	tgagcttcg	tttaatgtag	2880
ctcttgcatg	ggagtttcta	ggatgaaaca	ctcctccatg	ggatttgaac	atatgaaagt	2940
tatttgtagg	ggaagagtcc	tgaggggcaa	cacacaagaa	ccaggctccc	tcagcccaca	3000
gcactgtctt	tttgctgatc	cacccccctc	ttacctttta	tcaggatgtg	gcctgttgggt	3060
ccttctgttg	ccatcacaga	gacacaggca	tttaaatatt	taacttattt	atttaacaaa	3120
gtagaaggga	atccattgct	agcttttctg	tgttggtgtc	taatatttgg	gtaggggtggg	3180
ggatcccaa	caatcaggtc	ccctgagata	gctggctcatt	gggctgatca	ttgccagaat	3240
cttcttctcc	tgggggtctgg	cccccaaaa	tgctaacc	aggacctgg	aaattctact	3300
catcccaaat	gataattcca	aatgctgtta	cccaagggtta	gggtgttgaa	ggaaggtaga	3360
gggtggggct	tcagggtctca	acggcttccc	taaccacccc	tcttctcttg	gccagcctg	3420
gttcccccca	cttccactcc	cctctactct	ctctaggact	gggctgatga	aggcactgcc	3480
caaaatttcc	cctacccccca	actttccct	acccccaaact	tccccacca	gctccacaac	3540
cctgtttgga	gctactgcag	gaccagaagc	acaaagtgcg	gtttcccaag	cctttgtcca	3600
tctcagcccc	cagagtatat	ctgtgcttgg	ggaatctcac	acagaaactc	aggagcacc	3660
cctgcctgag	ctaagggagg	tcttatctct	caggggggggt	ttaagtgccg	tttgcaataa	3720
tgctgtctta	tttatttagc	ggggtgaata	ttttatactg	taagttagca	atcagagtat	3780
aatgtttatg	gtgacaaaat	taaaggcttt	cttatatgtt	taaaaaaaaa	aaaaaaaaaa	3840
aaaaaagggc	ggccgcctcta	gaggatccct	cgaggggc			3878

&lt;210&gt; 22

&lt;211&gt; 6297

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 22

ccacgcgtcc	ggtcagcttt	catctcgtcc	tatctttgtt	caggcaaact	tctctagttc	60
tgttttaata	ggcataattg	ttaggtctgt	tttttgaaat	cctctttttt	acattgttta	120
aagataatgc	cttggtataa	aagcctgctt	cacttttccc	tgtttttagt	tgttttctcc	180
acattggcag	taaagagcct	tggcgtccca	gtagcagcag	gttctccttt	ttgtattgtg	240
gatgttttgc	atttcatact	gttgtgaaga	gtggctttga	tcatacatgt	tgttggtata	300
tttgcccttt	tgctgggggt	gtgagaagaa	ccagagatga	gcagaggtag	accagtaga	360
cttcccagcc	tgacagcct	cccgggaaga	gcttccgtgt	tcagggtgctt	ggggccccac	420
cctaggagcc	tgactcacag	tcagagcagg	gtcccggctt	gtgttcagga	ttttgaaaca	480
tttgtaagggt	gattttgttg	tttctacacc	tttctcctca	tctttttttt	tttgtagtta	540
atcgttacta	ataacagaaa	agacattttt	ggcatggtaa	ttggcacaaa	gtgaataatt	600
gttgaataga	tgacttttga	ggctttcaaa	attcgagtgt	ccataaaatc	catccagagc	660
cacctgggtc	ctttttttga	accacttaac	gtaattctgg	aaaaccttga	ctgtgggtct	720
taagtttgggt	ggattgctgc	ttctcactgg	ctgacctttg	gaggtcgcac	atttcaggat	780
gtgattccac	ttaggtctca	tttcacctga	cactgcaatt	ctgtgccttc	agagggattt	840
gttattgcga	atgatgtgga	caacaagcgc	tgctacctgc	tcgtccatca	agccaagagg	900
ctgagcagcc	cctgcatcat	gggtgtcaac	catgatgcct	ccagcatacc	caggctccag	960

atagatgtgg	acggcaggaa	agagatcctc	ttctatgatc	gaatttttatg	tgatgtccct	1020
tgcagtggag	acggcactat	gagaaaaaac	attgatgttt	ggaaaaagtg	gaccacctta	1080
aatagcttgc	agctacatgg	cttacagctg	cggattgcaa	cacgcggggc	tgaacagctg	1140
gctgaagggtg	gaaggatggg	gtattccacg	tgttcactaa	accctattga	ggatgaagca	1200
gtcatagcat	ctttactgga	aaaaagtga	gggtgcttgg	agcttgctga	tgtgtcta	1260
gaactgccag	ggctgaagtg	gatgcctgga	atcacacagt	ggaaggtaac	ctttcctcga	1320
gaactttcat	tctaaagagt	aggtgcagca	tcactgaagt	agagtcaagt	ttcaaagcat	1380
tcacgtgtga	gtaacttgaa	taaatactac	atctgggtat	gccaattaga	atcaatttcg	1440
gagtgttatt	tcatgacaca	tttcatgaca	agtggcatgt	ttattcctgg	cagtggaaaa	1500
gttttttttt	ctccacgtac	agaaataaac	tcttttactc	tcattccctgt	aagggtagct	1560
ttgctttttt	tttttttttt	taaattgggc	cgggattcaa	gccttggttc	caatatgaag	1620
taattcatta	caatttttagg	ccagaaaacag	cctgaggctt	gtttaaaaag	aaaaaaacta	1680
tagggaaaa	gttattttat	aatgcttgtc	ctggttttta	gaataaatgt	atttcattct	1740
tgtttttaac	agaattttatg	tattaataat	ttggggattt	tctgtaaaga	ttgttttgtt	1800
ttgtcttggc	aaataatcct	cctatctttg	gagtgaatga	gaatcaccat	ttgtcacctt	1860
tgagagaatg	gatactcctg	ccctgtgatt	ttgttggtta	ttggatagt	ctagtaattc	1920
ggaatgtacc	ctgtggttct	gcaggtaatg	acgaaagatg	ggcagtgggt	tacagactgg	1980
gacgtgttct	ctcacagcag	acacaccacg	atccgacctt	ccatgttccc	tccgaaggac	2040
ccagaaaagc	tgcaggccat	gcacctggag	cgatgcctta	ggatattacc	ccatcatcag	2100
aatactggag	ggttttttgt	ggcagtattg	gtgaaaaaat	cttcaatgcc	gtggaataaa	2160
cgtcagccaa	aggtgagttt	ttctttttcc	aaaatgacat	aacatttgat	cttgtacatt	2220
taagacaaaa	actaaccgga	gttttagtaga	agtacagagg	aaagaggagc	ttcttgctgt	2280
gggcagcagg	agagctgacc	ctgaatgagg	gggaatttca	tttaaatatc	aagttttcca	2340
aaaagcagaa	atttctcata	ggtgataggt	aagtggagaa	gtcagtgttt	gggggaatgt	2400
attcctgcca	cactgtaaat	ccagttattt	aataaaaaatt	gaaaagacat	gaaagattgc	2460
tctgtggctc	tcaattggaa	gccccagggt	tctgtgctct	agttccttgt	gagtgggtca	2520
tttcaccaat	tacagatagc	agagctctgc	tgaccccaag	ccagcccggg	ttcaccttgg	2580
ctgcaaggaa	tgatgacggc	cttgtccaga	cctggctaga	aagatgcagc	ccggcctgtt	2640
tgctattgag	ctaaactgcc	tgtgtggttc	tttccaaggc	aggccaggaa	acagtgggtga	2700
aggagtgttg	ccctcatcct	aacacgcagt	cctttgtaat	gcgtgctgtc	tcacctgtat	2760
cacgccagca	ttattttatta	gttcataaat	cagccttcca	tgatgaaaga	acctggcctg	2820
gaatcaaagt	ctggaagtct	gtattttctt	aagatccatg	cttgaaaatt	aggacaaaaa	2880
acgcttagct	ttggagggaac	aaaaaggaaa	cagttccgca	aagagctcca	gcctttttct	2940
ggggcacggg	ttgtgcagtt	taacgttggg	acgtacagcc	tcagacgggc	aaagggggcg	3000
actgcacttc	tgccgccacc	agggtttttc	tgtcagggtta	gaaagtattt	cactttgagg	3060
ctaaaagtct	cacaagggtat	cttaacgctg	atggaatgtt	attttcatgg	aatcagtata	3120
agaaattata	ttgtaaagta	ttagatactt	tgcattcatt	catactaggt	ttcagtagct	3180
tgtgttttag	actttgcgct	tgtcacattt	taagtggtea	gtgaccacag	gcttgtggct	3240
gcccagctgc	agagcacagt	gcagtcacag	aggagcctgt	cttagagacg	cgtgctttag	3300
gttggcctgc	attagggctt	acattgatgt	ttctgacgtg	tttaacttta	catagaaagg	3360
ttttgacatt	ttttcaatta	gcccccttat	tatagtctta	cttttttagaa	caacttattg	3420
tcattttctc	gtttaaataa	tatgaatact	tctctctttc	tgttactatg	tcagtttctt	3480
attcacttag	ttcaacagat	ctagtgtctag	catggcctgt	gctgctgttg	gtcctactgg	3540
gaacgcaggg	agagtctcca	tggtcaggat	gccgtgttct	gttgtgtgtc	tgaggcctgt	3600
aagcacttgg	ctagaagtta	ggccagggaa	gctcacactg	accttggtat	ttgaagggtcc	3660
cagaatgagg	ttgttgaggg	agaacagaga	tggggagaaca	tgcccttggg	gctggactca	3720
acaagaaggc	ccctctgggg	gaagctgagg	ttggacagga	agggcgtgtg	ccctcactga	3780
cttgtctaca	ggcttggggg	tcattctgtt	tgggttttgc	ttttttacat	tatattaaca	3840
tggaaataaa	agggtgttcc	tgggatgctc	ccggcttctc	tgtctagtag	ctttgtggct	3900
ctgagtaaaa	tgaacttgcc	tgtgttgaaa	tatcctaatt	tttaaaactta	cttcataggg	3960
actgaggaat	tacgactttt	atcaattttg	tgacctgtta	aaatgttaaa	aaggacatgt	4020
atttttttaa	gatcttttaag	taaaacattt	tgtctattcc	caaagccaaa	tttaaaattat	4080
accatggccc	taattcagaa	gttcattctt	tggcagggtg	ttccttggtg	cctggggcac	4140
tctctctttc	tcccagttcc	tgtggcagtt	tgtccagggtg	cccaagaaca	attcataccc	4200
tcctttctcg	ttattttatat	acttgtcttt	ttgcccctgc	cgggtatttt	agaaatcgtg	4260
cttgggtgcac	tttgtgtcct	tcagtgtgcc	ttaccagag	cagatgcacg	ataagcattt	4320
ttacacgaga	acaagctggg	ggtgtaggcc	tctgctaagg	aacaggctgt	atatgctctt	4380
tgtgggatta	aggtagaatc	agctttaact	ccaaagaaac	tgtccatgaa	ttttgtttat	4440

aatagcaagt	agatttataaa	tgacactttg	aaaaaattct	gttgtctttc	tctacatata	4500
atgctgtaga	aaaatataac	tgatggattt	tgtgaacgtg	gtatttttaa	cttttcgtag	4560
cagcacaag	aatgctcctc	tttgtgtgtc	aatgaaattg	ttctttatga	cagcttcagg	4620
gtaaatctgc	agagaccaga	gaaagcacac	agctgagccc	tgcagatctc	acagaaggga	4680
aaccacaga	tccctctaag	ctggaaagtc	cgtcattcac	aggaactggg	gacacagaaa	4740
tagctcatgc	aactgaggat	ttagagaata	atggcagtaa	gaaagatggc	gtgtgtgggt	4800
aagaaaagt	gttatgtctt	gatctaatac	gctgggtgtc	tcacagtcct	tttggattaa	4860
atgggatccc	agagccactt	cttggtcggt	ttgagggggc	agtacatgtg	tggtatcagg	4920
cacatgcagt	gtgagggtg	gactctgtgg	aagccggaag	gtttcaacat	ctgccgcaaa	4980
ccgttccatg	ttgcacagaa	ctgacagaaa	ggaagaatgt	gcttttggtg	ttgaaggtta	5040
ccacacatta	cagattgatt	tgtctcatcc	tgattccctt	tttagtcctc	ctccatcaaa	5100
gaaaaatga	ttatttggat	ttaaagaaga	tccatttgta	tttattcctg	aagatgaccc	5160
attattttcca	cctattgagt	aaggattcag	cctttttaat	tattcattta	aagaaattta	5220
ctatagagta	tcaaatgtac	aactgatcac	atgtaaccat	tgttttgtat	gtagtctctg	5280
ctagcttttt	tttttttttt	aaccttttta	actgcatatt	agagcaggat	gaaacttttag	5340
aggttactca	atcttttaat	ttaaggagaa	agtaaacttt	tactttgtga	acatgataga	5400
taaaaaaaaa	ctggaccggg	cgcggtggct	cacggctgta	atcccagcac	tttgggaggc	5460
cgagacgggc	ggagcacgag	gtcaggagat	tgagaccatc	ctggctgaca	cggtgaaacc	5520
ccgtctctac	taaaaataca	aaaaaaatta	gccgggcgtg	gtggcgggca	cctgtagtcc	5580
cagctactct	ggaggctgag	gcaggagaat	ggcgtgaacc	tgggaggtgg	agcttgacgt	5640
gagccgagat	cgccgctg	cactccagcc	tggcgacag	agcgagactc	cgtctcaaaa	5700
aaaacaaaag	aaaactggac	tgtgattatg	aatctaaatt	agttgtgatc	ctgaacctaa	5760
attactcaat	tgagtatata	gacgagtagc	caaggttgct	tagttcagtt	tctgtagaag	5820
aatgaagag	cagcatgggt	gagggctaatt	tagggatgac	atagacagaa	tatagaggaa	5880
aagggttttag	gacaagtctg	acattcatct	gtttcttatt	cattgaattt	tagaatctat	5940
ttaccagggc	ggtcaccttac	tgtctttttt	aataactggg	cctttgcata	catttgtaaa	6000
agtctattaa	aaaataagtc	tcagccgggc	acatcccagc	acttggggag	gctgaggcag	6060
gcagatcatg	aggttaggag	tttgagacca	gtctgaccaa	tgtgggtgaaa	ccccgtcttt	6120
actaaaaata	caaaaaaaaa	ttaggtgtgg	tggcgtgcac	ctataatcac	agctgctcag	6180
gctgaggcag	gagaaccgct	tcaacccggg	aggcagaggt	tgcagtgagc	tgagactgcg	6240
ccactgcact	ccagcttggg	agacagagca	agactccata	tcaaaaaaaaa	aaaaaaa	6297

&lt;210&gt; 23

&lt;211&gt; 5257

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 23

ccacgcgtcc	gcattttaac	atctctaaat	caggatctgt	cttataatca	aaagtgcac	60
atattttaaca	gatggcgtgt	tttctttctt	agtagtacct	aaagtaatac	aacttaaaat	120
tgatggcatt	ttagattttaa	taaaatatgt	tcattttctt	gttcattttt	ggctctgggtga	180
ggctttggcc	ctgttgtgtg	gttatttatt	ttgtttatag	tatttgtaaa	caccagtgtt	240
ctcaagaggc	tcattcatca	atatttaact	gcaaatttgt	ttcccagtc	cagttttcta	300
taatgtaatc	cattttgtgg	gaaggggaag	ctaaaaatca	gtattttctgc	cagtattttc	360
tatatagatg	tcataaaaaca	aaaataccat	catgtattaa	tatttctaca	tgtgcaagac	420
agcactttga	attataaaac	ccaacttatt	cttttgcaat	gctaaactgg	ttgatcttca	480
aatcctacta	ccatgttggg	ggttcatata	gcaacaatgt	aaacacacac	atgtaccata	540
acctaaatat	aacaaaacag	accagttaac	tattctcact	catttaagtc	tcttgagggg	600
attcaagtca	gacttattga	tatatttaaaa	tattacaaaa	tccaaggtga	tgcataatttc	660
ctgcctaggg	ttttaaaaagt	gtgttttaac	ttaatattat	gttctttcag	aattgatata	720
tgactatctg	tcattagaaa	atgcccatct	aattatgagg	atttcaaaac	tactccatcc	780
tccaaagaaa	aatcacattt	ttgccactag	atgctattgt	aaaacctttt	agaaacttga	840
aagttttgtt	gttttaaaatt	tctttgtttt	taaagaattc	agtgatgggt	tccaccaatg	900
cattaacttt	aaataccttt	catttttgaga	ggcaaaattt	gatttatgga	taaaatatat	960
atacttatga	gagacgaata	aattcatagt	tctcgagaac	ccatggggat	attttatgag	1020
ttaataatgc	cttttctgaa	accaacttta	gcctttatct	taaaaccttt	taaaatttat	1080
gcaatatttc	atacacactt	taaaatttaa	ctttagcttt	ttacaagaaa	cttctaccaa	1140

aaaatgcaat	agtcattaac	ttgctctctt	taattatcaa	aatataatct	agctagtatt	1200
taatttaaca	ttttatztat	ttttactaag	taaattttgt	aatagcagga	taatttttga	1260
cttcattcta	gagtcaattg	gctcccagtg	aaagacaatg	taaaattaca	ttgattttgt	1320
tttccaatta	cagaagtaat	acatagtcac	tatagaacat	tttggaatat	ataaaatgta	1380
tgtaaagaga	aggaaaagtc	acccaaaact	taagcacatt	aaaaataatc	acaattaaca	1440
tttttgtatt	ttcttactat	ctttttttct	atatgtttat	gtataggcat	gtatataatc	1500
atatacatgt	aaacatcaaa	ctatgtatac	agttttacatt	tcctatcatt	agtaagtatt	1560
ttcacatata	attaactatt	attcaacatc	ttattttttc	atgattatat	tgcctttatg	1620
gacatgcagt	aattcattca	atcattcccc	aattatttga	tatttaagtt	gtttcaattt	1680
tttttactat	tataaattcc	atcaagcata	aaactgcacac	aattgaagta	ctactgagag	1740
agaggaacac	aagcattaga	gtaattactg	gaggtgccat	ggagatgaac	atgacagtga	1800
tgtaccaagt	ggattggaca	gtgaggttca	aatcacagag	acttcttagt	ggagaacaag	1860
gaagaaaggc	aaacctggag	tcccagccat	agaaacagaa	aggaaatgat	tgatatgaaa	1920
actagtatgt	tagaaactta	gaaggacttg	gcaaattgatg	aatattcatg	aggtatgagt	1980
caaagatcac	ttgaaagtgt	atgtgatggg	agaactgct	gccataaaca	gaaattgtca	2040
aatttggagg	agaaggccat	tgacctaga	ggtgaaaccg	aagctctgat	ggactctcac	2100
agctggagat	gaaaatacga	gttatacacg	gagaatgtaa	tggatgaatcc	atgggaataa	2160
ttgatataatt	tgagggtaat	tcagcacaa	tggaggaaaa	caggggtccag	ttgaaatctt	2220
tcagaatgac	ccatattttg	atgaaaagga	gtaagaacca	gtgagaaaag	agtagtctga	2280
aagtggggag	gagagggaaa	aggagagaat	gaattagaac	tccagtaata	gagattcact	2340
gggagccag	gaaggatgag	aactgcaggc	tcaaatccac	aatggtaagg	gccacaggca	2400
actatgccaa	gacaggccac	tgagaagtta	attgtaacct	ttaaagaacc	acaaaaagac	2460
ttcactgggtg	ttatgaccct	aagccagctt	gaacaagtag	gctatcaaga	acaagtaggt	2520
gatagccatg	attttgagct	tttgggtggtg	aaagaaaaga	aaatgtggga	tgtgctgcca	2580
aggcagtcac	aggaggtttg	gtgagatggt	gaaccgcacg	ggtgtcctgt	tctccataga	2640
atgtctcctt	ccaaccaatc	caggctctcg	ccatgaagct	gcctgggaag	tagaagaggg	2700
aattcatatg	gccaaccac	tttgttgacc	taaaaattac	tgcttaaaaa	ataattttta	2760
gaacttttaa	aggaatcatt	tattcaaggg	ggaaaaaat	ctctttttca	ggcaaccact	2820
gagaaaacgg	aaccgaatag	tcaagaggac	agaaatgatg	gtggaaaatc	aagaaaaggg	2880
aataatagaac	ttgcctcatc	aggtttgttt	cataagagac	tagtttttaag	gcaaatcatg	2940
gtaactgttt	aagatgtaat	ggaaatagtc	aagaattttt	cctactgagc	cacagaaaag	3000
tagtaattag	actccaggag	tgggtgcggtt	gtgctgccac	ctagaggctt	cctggggaag	3060
ttctgcccgt	atgggttaatg	ttgctgtgaa	aataggagcc	catgctcttt	cttaaagcta	3120
cccagtttta	ttttgttttt	taaaatattt	atccctataa	tcataaagaa	tactgtgttc	3180
ttccatataa	atcatgctaa	aaattgaggg	taggattttg	acacacagta	acagcaatag	3240
ataagcgaga	ggtcaaaaac	ataaaaatag	acgctgaaat	ggtaaagctc	acatatagtt	3300
aaaaatgaat	atagtgccat	gaatctggac	agttagtata	atatactgta	ttcgttggtt	3360
taggaagaag	accctgttcc	cgaaagtctt	gttccctcaat	atttttttgc	agccttatca	3420
atatgtttta	cactttttct	cttttgataa	acagtaaaaac	ctctcaccct	ctttcaatc	3480
caaattatta	ttttttataa	ggcctttctc	cagtgtttac	cacttgagaa	acataatttg	3540
tcaattacca	aattattttt	aggtaacatt	tttaaatata	ttaaatatca	cttaaaataa	3600
tagcattttac	tttttcaaac	tagattgtgc	cttcacattt	tgatatgccc	ccttaggtag	3660
tgacttttcc	accccttcta	aagtgaacct	aattcttctt	tatgtatcag	agaacacttt	3720
attttcattg	cattatatac	atatacccca	caatccgtaa	cacattccaa	ttaagaaatt	3780
ctgatgttaa	aatggagcat	tgaatacaaa	aaaaaggaag	catcagggtg	ctgctcattc	3840
actgggatag	aaactacctg	tagatgttct	cttatctagc	ccagctgtca	taattatata	3900
tttcgtgtca	gcattctgtt	ccatgtgggtg	ttattcagat	gtaaaccgtg	acccttacta	3960
aaaacttaag	ttcttcatag	tgtgggtata	ggacgtgatt	tgtgttgctt	gttgttcaat	4020
accatgaaag	agctttggga	attccagcat	cttaggctct	tttatatctc	tgagcacact	4080
gtcattcagc	ttatattgcc	aggacgggat	atggactgaa	tgtacttcat	ggcattgcag	4140
aataaatggg	cctatagata	tttgattttc	ttttccttct	gtacgtttct	ggatgtaact	4200
ccattgcaga	accacagcat	tttacaacaa	ctgtgactcg	atgcagcccc	accgtggcct	4260
ttgtggaatt	tccctccagc	ccccagctga	agaatgatgt	gtcggagaaa	aaagaccaga	4320
agaaaccaga	aatgaaatg	agtggaaagg	tggagttggg	gctgtcacia	aaggtgaagt	4380
gcagagtggg	ggaaagcggg	taaaccaca	agttaacatg	gccccatatt	acagctagct	4440
gctgctgtgg	cagttgtgaa	taatgaagat	ttatttctct	cctcatcttt	tttccatctc	4500
ttaatctgta	gtttttcttt	ttcgtgtgtg	tgtgtgtgtg	tgtgtgtgtg	tgtgtgatgg	4560
agttttgctc	ttgttgccca	ggctggaatg	cagcgggtgtg	atctctgctc	accacaactt	4620

ctacctcctg	ggttcaagtg	attctcctgc	cttaggctcc	cgagtagctg	ggattatagg	4680
cgtctgccac	cacgcccagc	taatttttat	atTTTTtagta	gagacggggt	ttcaccatgt	4740
tggccaggct	attctttgtg	gaaaagtgtg	atataagttc	taaagccttg	cagttagggt	4800
ttagtttgct	gtgtgtgttt	gcttatttgc	tttttaacct	gtcagcttac	tggctagtct	4860
ctctccaata	atcatctatt	tgttagcaat	ggtaattctg	atgccactgg	atttggataa	4920
caagaaacct	agaaaattat	tattctgata	taatagggtt	taaagtcttg	tttttattaa	4980
agtttcttcc	ttgttttagag	tctcatctca	ttcacattag	tttgatttgt	tttcagggtac	5040
agagtctaaa	aatattcatc	agttacacca	gttggttcgca	accttgatta	ctcttgggaa	5100
tttaaaaaat	aacaagctag	ctgggtgtgg	tggctcacaa	ctgtaatccc	agcactttgg	5160
gaggccaggg	caggaggatc	acttgagccc	aggagttcaa	gactagcctg	ggcaaccacg	5220
aaagtcttca	tctctaaaaa	aaaaaaaaaa	aaaaaaa			5257

&lt;210&gt; 24

&lt;211&gt; 464

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (404)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 24

ttcctgccgg	aattcggggc	ggaattcccg	ggtcgaccca	cgcgcccgca	tctgtcagggt	60
gctcccttgc	caatttgaga	catgtggctc	ccagcctggg	ctgccataga	aaccttctcc	120
acttgctcct	ctctctctct	ctccttccag	ccccgtggg	ctctggcctc	agagggatgt	180
gcagggtcct	atgtcaccac	ccacagggct	ctaggagccc	acctttggcc	tctctggtct	240
gaccagttcc	tggggaaagg	tctgggggtta	aggatccctt	tcatcaccca	tgcacaccag	300
tgatccaggt	tccacagatg	gacctgtgtt	ccagcagcac	tgcttgargc	atgttctagg	360
gatgcaaaac	tgaacagaaa	cacagagctg	ggkttgctct	tgancctcct	tmaamccagc	420
tttcaccctg	gttcttgcgt	gaagtgcagt	gtgtttgtat	acgt		464

&lt;210&gt; 25

&lt;211&gt; 1116

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (380)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1053)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1062)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1097)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1098)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 25

gggaagggga	gggccagata	ttccagctgc	ayaccacwct	ggcrgagaca	cctgctgget	60
ccctggacac	tctctgtctt	gcccctggca	scactgtcac	cacccagctg	ggaccttatg	120
ccttcaagat	cccactgtcc	atccgccaga	agatatgcaa	cagcctagat	gcccccaact	180
cacggggcaa	tgactggcgg	atgttagcac	agaagctctc	tatggaccgg	tacctgaatt	240
actttgccac	caaagcgagc	cccacgggtg	tgatcctgga	cctctgggaa	gctctgcagc	300
aggacgatgg	ggacctcaac	agcctggcga	gtgccttgga	ggagatgggc	aagagtgaga	360
tgctgggtgg	tggtggccacn	gacggggact	gctgagcctc	ctgggacagc	gggctggcag	420
ggactggcag	gaggcaggtg	cagggaggcc	tggggcagcc	tcctgatggg	gatgtttggc	480
ctctgcttcc	tcccagttca	cagccagagt	tgctctcctt	cctcctcttc	cccaaccccc	540
agaccatgac	cagccttaga	aaatccatgt	actctgttgt	tagaggggccc	agagttcctt	600
ctccaccccc	gctctctctc	tcttggcctg	agatctctgt	gcaggaacca	agatggggct	660
gaagcctctg	gaggcagttg	gttgggggcg	ggcaggcagg	aggccctccc	tccaccccc	720
caccctcagc	ccggcaactt	ctgggttccr	tgggttttag	ttccgttctt	cgttttcttc	780
ctccgttatt	gattttctct	ttctccctaa	gcccccttct	gcttccacgc	ccttttcttc	840
tttgaagagt	caagtacaat	tcagacaaac	tgctttctcc	tgtccaaaag	caaaaaggca	900
aaggaaagaa	agaaagcttc	agaccgctag	taaggctcaa	agaagaagaa	aaacacccaa	960
accacaaggg	aaaagaaaaa	cccagtttct	taggaaacgc	aaacgattta	ttatccagat	1020
tatttgata	agtccttttt	aagaaaaaaa	aanaaaaaaa	cncgaggggg	ggcccgggtac	1080
ccaattcgcc	ctatagnnag	tcgtattaca	attcac			1116

&lt;210&gt; 26

&lt;211&gt; 1563

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1449)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 26

actagttcta	gatcgcgagc	ggccgccectt	tttttttttt	tttgttcgtc	caagtgcact	60
ttccagtaca	cttaccatgt	tacgacttgt	ctcctctata	taaatgcgta	ggggttttag	120
ttaaagtcc	tttgaagtat	acttgaggag	ggtagaatcc	tgcccttcc	tccacataca	180
atgattatga	atcagaacca	caatttctag	gaacgcagct	gtatgccag	gaaaaaggaa	240
gagaagaaaa	cgaaacccag	gaggggcata	gtagctccaa	caggtaaagg	ggtgagagca	300
agaaagaagg	gttaaaagaa	atggtgcagc	ggacgtggaa	tagatacaat	accaagtgtc	360
aaccctgggtc	tttcattgtg	atggcaggag	aggaaatggc	atggggcgca	cgtctgtgga	420
taatgtgtya	gttattgttc	ttggcagcca	gtgagggcac	catgccacgc	ctgagagcgt	480
ctgcttggtg	agttacaagt	catcttttca	taagtcagtt	ttgttttgta	ttccccaaac	540
cctccagcag	tttctcagag	gaagagttct	tccacaaaaa	aatatttcat	aaatcctaga	600
ctcttccctc	attgtttcca	gccagcaagc	cctggagagc	tgctctcagg	ctcacttcag	660
ttcctgggtg	gggttacgtc	actgtttttc	agtagcgaa	tttctcagat	gggacacacc	720
caacctcaca	ggcaccagc	agttctcggg	tagcatgacc	caggetctac	tcaagaagtg	780
cggcccaatc	ccacaggctc	gcaactcaga	ctttctaaaga	atatgtccca	acaaatctca	840
gtaaaggggtc	tgagaattgk	ttatactctt	ttggctaatt	tttctataac	tgtgaaatta	900
tatcaaaatt	aaaacataa	aaacataaca	aatgcccaca	ataaacatag	tgcaattaag	960
agtgactgtt	caggctggga	gcggtggctc	acgcccgtaa	tcccaacact	ttgggaggcc	1020
aagggtgggtg	gatcacgagg	tcaggagttc	gagaccaacc	tggccaaacat	ggtgaaaccc	1080
catctctaca	aaaaatacaa	aaattagctt	agtgcaggcc	tgtggactat	gatttagaca	1140

tacttaggtc	taaaatcaca	cagctctgcc	acattctagc	tgcgtgacca	gaggcaagtt	1200
acttaacctc	tctgggcctc	agttttctca	ttactgtaaa	atgtgcaaaa	gaatatctac	1260
acaaccgtta	tgaagatata	atataagcca	ttattcaaca	actattttatt	gagtgcctat	1320
tgggtgccaag	cacttaaagc	tgtgagagac	agttgtggac	cccacctttc	tgccctttgct	1380
tggtgacag	cctagtttac	cttactcccc	accccagccc	cacaagaggt	ttttgggttt	1440
ttgkttggnt	tttttttttt	tttttttttt	tttttggtat	tacggatctc	tttaaaaaat	1500
aaagaccttt	taccaaaaaac	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaagggcggc	1560
cgc						1563

<210> 27  
 <211> 1528  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (895)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1424)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1502)  
 <223> n equals a,t,g, or c

<400> 27						
tatttaggtac	gcctgccggt	accgggtccgg	aattcccggg	tcgacccacg	cgctccggttt	60
atgaattcag	aaattctgct	cccagcaagc	agacctcact	atgattctct	atatttgcct	120
gcttctcaaa	atgtgggggt	gcagtttgcc	ctgcaacttc	agctttccat	tggacttaag	180
aaaagtcag	gatttttcagt	ttgttcagca	ttttttctta	taaaaacaag	agtgatgact	240
ctcaagctct	ttaaattttg	gaactgaaac	tagaagcaac	aggacattct	gacatgaatt	300
atttaaaagg	gtcattgttg	actctagaga	cattttaata	ttgctgcatc	aaaagataaa	360
agcattctcc	tttcttcttg	tgtgatata	gccgtgtaca	cctctgagct	caccactaac	420
ctcaactcta	ccttatccct	aacttcccat	ttcaaatgga	agggaatggg	gatcaaggag	480
tagaaggcct	gttttaccca	ttattgatga	ttaaaaagct	gaaaataacc	catcacaaaa	540
tggcctcagt	aaagtggctg	catcagacat	catttagcct	ggaaaaccag	tatgcataaa	600
ggctcawwt	taaatttttg	aatccagtg	tttttattta	ttattatttt	tttttttctg	660
agacggagtc	tggctctgtc	acctaggctg	gagtgacgtg	gcacgatctt	ggctcactgc	720
aagctccacc	tcctgggttc	atgccattct	cctgcctcag	cctcccaggt	ggctgggact	780
acaggcgccc	gccaccatgc	ccggctaatt	ttttgtattt	ttggtagaga	cagggtttca	840
ccgtgttggc	gaggatggtc	tcgatctcct	aacctcatga	tccacccgcc	tcggntcccc	900
aaagtgtctg	gattacaggt	atgagccact	gcgcccggcc	ctgaatccag	tattttttta	960
tagaaacatg	agttgggtga	gatactgagt	tcctgccttc	tcacatctaa	tcccaaattt	1020
ccaatctttg	gaaatttgcc	cctttaccat	ttaatctcct	gagcccagct	cctctccagc	1080
ctgaagagtg	tgtctgtcaa	gactgtagct	gtgaacaaaa	cactattact	tgagccttat	1140
cctggagcaa	atgtgtgtgg	tctcaccaat	gaacatcaga	taagtccctt	ggcatggatt	1200
tcttttcctt	tttagtaata	caatcataaa	ggttattcag	acttattgag	catttactat	1260
ggccagaaat	tgtgatactt	gctttccata	tagkttatct	cacttactyc	tattaccctt	1320
tgaagtcaga	attctaacta	tgaatcagag	aaaataagtg	acctgsctaa	ggcatccag	1380
ttggkttatg	gtgaaggcag	gatgcaaact	gaaattgctg	kganttgagt	cgggtctttc	1440
cctagtctcc	tcctctcaga	ggcagaacat	aagcatgtaa	tagataccac	taggggtctt	1500
gnttctacct	tgggaacagc	tgtttgca				1528

<210> 28  
 <211> 235  
 <212> DNA  
 <213> Homo sapiens

<400> 28	
gatacaacac cagcatttta aaaattttctt tttgtctgtt cagacatgat aactttttctg	60
cccatcatat tttccattct agtagtggtt acatttgtwa ttggaaattt tgctaattggc	120
ttcatagcgt tggtaaattc caccgagtgg gtgaagagac aaaagatctc ctttgctgac	180
caaattgtca ctgctctggc ggtctccaga gttggtttgc tctgggtgtt attat	235

<210> 29  
 <211> 569  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (196)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (503)  
 <223> n equals a,t,g, or c

<400> 29	
cgctgccctt cccctgggtc ccgcgagctc ggagggcccg gctggtgctg cgggggcccc	60
gggaggtacg gacctgggag gcgaggctcg tccggcgcta ggatcggect ccgcctccgg	120
gccgcttttag gtggctggtc tctgcctctc attccctctg ggggctcccc cgtgagaaaa	180
tctgtggcgg aggcantctt ggcccactct tayggwtcc yttattgtgg ggctcgctat	240
atggagaggg ggtctgtgtc aggagcttcc cctggagagg tttctgttar ggaccgtctt	300
tgggagtgat ctatctctgc tctctggggg ggatctttgt ctggagcttt tggggggctt	360
gtgtttggaa gtttgcttc ggggagatat ctgtctggga cctcttaggg tttctgtatc	420
tgagctttct cttttgtgtc tgtcagcca agggcagcaa aaagtatgtc ctttctgaag	480
ccttttttct cgtaggtttc ttnattcttt tctctcttgt cttatgttca ttttagccat	540
agacttgact ggagtttaga gggaattga	569

<210> 30  
 <211> 2767  
 <212> DNA  
 <213> Homo sapiens

<400> 30	
gcgtccggtt ctagatcgcg agcggccgccc cttttttttt ttttttgata tggagtcttg	60
ctctgtcttc caagctggag tgcagtggcg cagtctcagc tcaactgcaac ctctgcctcc	120
cgggttgaag cggttctcct gcctcagcct gtagtagctgt gattataggt gcacgccacc	180
acacctaat tttttttgta ttttttagtaa agacgggggtt tcaccacatt ggtcagactg	240
gtctcaaact cctaacctca tgatctgcct gcctcagcct cccaagtgc tgggatgtgc	300
ccggctgaga cttatttttt aatagacttt tacaaatgta tgcaaaggac cagttattaa	360
aaaagacagt aagtgaccgc cctggtaaat agattctaaa attcaatgaa taagaaacag	420
atgaatgtca gacttgctct aaaccctttt cctctatatt ctgtctatgt catcccta	480
tagccctcac ccattgtgct cttcattttt tctacagaaa ctgaactaga caacctggc	540
tactcgtcta tatactcaat tgagtaattt aggttcagga tcacaactaa tttagattca	600
taatcacagt ccagttttct tttgtttttt ttgagacgga gtctcgctct gtcgccagg	660



ctggagtgca	gcggcgcgat	ctcggtcac	tgcaagctcc	acctcccagg	ttcacgccat	720
tctcctgcct	cagcctccag	agtagctggg	actacagggtg	cccgccacca	cgccccgcta	780
atTTTTTTTg	tatTTTTtagt	agagacgggg	tttcaccgtg	tcagccagga	tggtctcaat	840
ctcctgacct	cgtgctccgc	ccgtctcggc	ctcccaaagt	gctgggatta	cagccgtgag	900
ccaccgcgcc	cggctccagtt	TTTTTTTatc	tatcatgttc	acaaagtaaa	agtttacttt	960
ctccttaaat	taaaagattg	agtaacctct	aaagtttcat	cctgctctaa	tatgcagtta	1020
aaaagggttaa	aaaaaaaaaa	aagctagaca	gaactacata	caaaacaatg	gttacatgtg	1080
atcagttgta	catttgatac	tctatagtaa	atTTCTTTaa	atgaataatt	aaaaaggctg	1140
aatccttact	caatagggtg	aaataatggg	tcatcttcag	gaataaatac	aaatggatct	1200
tctTTTaaatc	caaataactt	cattttcttt	gatggaggag	gaccacacac	gccatctttc	1260
ttactgccat	tattctctaa	atcctcagtt	gcatgagcta	tttctgtgtc	accagttcct	1320
gtgaatgacg	gactttccag	cttagaggga	tctgtgggtt	tcccttctgt	gagatctgca	1380
gggctcagct	gtgtgctttc	tctgggtctct	gcagatttac	cctgaagctt	tggctgacgt	1440
ttattccacg	gcattgaaga	TTTTTtcacc	aatactgcca	caaaaaaccc	tccagtatte	1500
tgatgatggg	gtaatatcct	aaggcatcgc	tccagggtgca	tggcctgcag	cttttctggg	1560
tccttcggag	ggaacatggt	aggctcggatc	tgggtgtgtc	tgctgtgagg	aacagcgtcc	1620
cagtctgtaa	accactgccc	atccttcgtc	attaccttcc	actgtgtgat	tccaggcatc	1680
cacttcagcc	ctggcagttc	attagacaca	tcagcaagct	ccaaagcacc	ttcacttttt	1740
tccagtaaag	atgctatgac	tgcttcatcc	tcaatagggt	ttagtgaaca	cgtggaatac	1800
accatccttc	caccttcagc	cagctgttca	gccccgcgtg	ttgcaatccg	cagctgtaag	1860
ccatgtagct	gcaagctatt	taagggtggc	cactTTTTtc	aaacatcaat	gttttttctc	1920
atagtgccgt	ctccactgca	agggacatca	cataaaattc	gatcatagaa	gaggatctct	1980
ttcctgccgt	ccacatctat	ctggagcctg	ggtatgctgg	aggcatcatg	gttgaccacc	2040
atgatgcagg	ggctgctcag	cctcttggct	tgatggacga	gcaggtagca	gcgcttgttg	2100
tccacatcat	tcgcaataac	aaatccctct	ggaaagggga	cattcatgtc	ggcatgtagc	2160
atTTcaatta	actgtgtggt	ctttgagcca	ggtgctgcac	acatatctaa	gatcttatga	2220
tgaggccgca	cgttgaggag	cagtgggtggg	atcatgctaa	cagcttcttg	acgactaata	2280
tttccagatt	ctgtttcact	aactagaaac	tgatgaaact	tttccaagtg	tggcgatttt	2340
ctcaagattt	ttcgacttaa	atTTgtgtgc	caggcaagtt	cttcaggata	ccaactcagt	2400
ggctgtggaa	cttcaacttt	ctgaccgtcc	acctccaggt	cctccaattc	cttaaaaatat	2460
ttgttcttta	agcaatggag	aatctctttt	gcgtggcttt	tgtaacacgt	aattcttaaa	2520
gtggccggga	gcggctccct	gagagcgtcc	atgaactggc	cccactcgcc	ctcgggcacg	2580
atccttgagct	cctggtagta	gtgctcgaac	agcttgttct	ccttgacgat	ctcggggtag	2640
cctccttccc	agcccgcctc	gccgcgcttt	ccaccaccct	cggcgccatc	ctccgcgtcc	2700
tccggccgct	gctgttgctg	gagccgccga	ccccgcgacc	gccgccccat	agcccacgcg	2760
gccgctc						2767

&lt;210&gt; 31

&lt;211&gt; 1051

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 31

gcgcggccct	ccccatgtgc	agccgggccag	ccgggctctc	ctcctcgcg	cggatgggtg	60
accttttct	ggcacgggca	ggctgtggga	ggcagcggag	caggcgatga	agaagaagca	120
gcagcatccc	ggcggcgggc	cggatccctg	gccccatggg	gcccctatgg	ggggcgcccc	180
tccgggcctg	ggcagctgga	agcgtcgggt	gcccctgctg	cctttcctgc	gcttctccct	240
cctctatcag	ctcagcgggg	gacccctcgc	cttctgctc	gacctgcggc	agtacttggg	300
aaattccact	tacttggatg	accatggacc	acctcctagt	aaggtagtac	ctttcccaag	360
ccagggtggtg	tacaacaggg	taggcaagtk	tgggagccgt	actgtggtct	tgttcttgag	420
aatcttgtcg	gagaagcacg	gatttaattt	ggtcacatca	gacattcaca	acaaaaccag	480
gcttactaaa	aatgaacaaa	tggaaactgat	taaaaatata	agtactgccg	aacaacccta	540
tttattcaact	cgacatgttc	atttctccta	cttctcaagg	tttgaggagg	accagcctgt	600
ctacatcaac	atcatttagag	accccgctca	ccggttctta	tccaactatt	ttttccgtcg	660
ctttggagac	tggagagggg	aacaaaatca	catgatccgc	acccccagca	tgaggcagga	720
ggagcgctac	ctggatatca	atgagtgtat	tcttgaaaac	tatcccagag	gctccaaccc	780
caggttatTT	tacatcatte	cgyacttkkg	tggacagcat	cccagatgca	gggagccctg	840

tgaatggggcc	cttgagagag	caaagctgaa	cgtgaatgaa	aacttcctgc	tcgtggggat	900
tcttgaagag	ttggaagatg	tgctgctgtt	actggaaaaga	tttttacctc	attacttcaa	960
ggsgtgctc	agtactacaa	agaccagag	cacaggaagc	ttggaaacat	gactgtgacg	1020
gtgaagaaga	ctgtccctc	tcctgaggct	g			1051

<210> 32  
 <211> 1675  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (1549)  
 <223> n equals a,t,g, or c

<400> 32						
gtacgacyca	ctatagggwg	agagctatga	cgtcgcgatgc	acgcgtaasc	ttggggcccct	60
cgagggatcc	tctagagcgg	ccgccctttt	tttttttttt	tttgaagaat	aacaattgag	120
ttttattctt	taaaggcatt	ctctgattta	catgagaatt	gagaaaactga	gatgtatgat	180
ttgtctgtta	gtcaatttca	caccctttca	ttctcataag	ccccaaattt	tgctcagtta	240
aggagcttgc	tttagggcca	cctatgtaag	tctgtttatac	tagctaattgt	gcccatttga	300
atagttcaag	ggtcagctaa	tgctctgagc	ttcatggctc	cagtataaag	aacaaattta	360
acaaaattaa	gctgttactg	tagccgagtt	accctttctgc	tccacacata	tgtagtggga	420
tcttgcagga	tttccatagt	gccaaattatc	aaaggccttg	actacttagc	attgctgtat	480
tacagatgtg	caaactgagg	cactgaaaag	tcaaatttaa	agtcataattg	agggccagaa	540
aaggaggctt	agtttggggc	tttggccatt	ttagctactt	atctgaaatt	gctgcagata	600
caacgtatga	gcataatcaa	tatttttgac	tgtatataat	tgattttctaa	ggtaaaaaaca	660
aataaaaaaga	aaccaataat	ttttaaagga	aagatgtagt	tcaaaaaaaaa	aaccaccatt	720
aaacatgggtg	ccattacagg	ttaaaacaaa	tgctttgtga	cttagacctc	aaaaacagag	780
cttgatgact	ttactccaca	atttgtgcac	ttagtgtata	tttaaattgct	ctctgttaat	840
tagaacaact	tcattatgct	atcaagattc	cagtaatcca	taaaacatgt	caattatgat	900
ttgagtttgt	gcgaagccct	gtctgtgagc	tcatagtctc	aatagcctct	tctagtacct	960
agaggaagct	atagataaaa	aataactcta	ttggcaaccc	atctgtttct	gttactggaa	1020
atttccacac	acctctgctt	ttggaaatca	cttagaaaac	ttgaggggaa	ataattcctt	1080
ttgctttcag	tctggcagca	agaaggatcc	tgaaggaatt	ctgtgggtcc	aggatccagt	1140
ggggtaattc	tgtaaagtgc	agtagtgctt	gcttaaagcc	ataggctcca	gaggtgagtc	1200
cagatcagtg	aaggggcaag	tttcatggcc	aggtgttggc	tagtcttggt	gcaggtttca	1260
gattaaagtg	ctgggtcatc	caaaggcatt	tgaaaagtgc	aaatggcaag	ctctgcaggc	1320
caccgaattc	ttgttcagag	tccagaagct	tcttttagatg	tcatatcagg	tcaccctggc	1380
tcccaagacc	acaggttcag	atagcactgt	tcacttcctt	ctttgttggtg	gtgacaggtc	1440
tttttgttgt	gtcttttgaa	gaatacagct	tttgacagag	ttgttttctt	agggctrtca	1500
ckgkggctat	gaaaatgaaa	gcaatgatgc	aggaggggat	gaaaatgtna	agcagccaag	1560
ttggatgggt	cctgggttcc	atctgacttt	gaagggtcaat	gctggccaaa	gtaagtcccc	1620
tcacgtgagt	attccagaac	acacagctga	agtttctgcc	aggggggtggc	tttag	1675

<210> 33  
 <211> 786  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (754)  
 <223> n equals a,t,g, or c

<220>

<221> SITE

<222> (778)

<223> n equals a,t,g, or c

<400> 33

ggaatgaaca	actttttcttc	tcttgaatat	atcttaacgc	caaattttga	gtgctttttt	60
gttaccatc	ctcatatgtc	ccagctggaa	agaatcctgg	gttggagcta	ctgcatgttg	120
attgttttgt	ttttcctttt	ggctgttcat	tttggtggct	actataagga	aatctaacac	180
aaacagcaac	tggtttttgt	tgtttacttt	tgcatcttta	cttgtggagc	tgtggcaagt	240
cctcatatca	aatacagaac	atgatcttcc	tcctgctaata	gttgagcctg	gaattgcagc	300
ttcaccagat	agcagcttta	ttcacagtga	cagtccttaa	ggaactgtac	ataatagagc	360
atggcagcaa	tgtgacctg	gaatgcaact	ttgacactgg	aagtcatgtg	aaccttggag	420
caataacagc	cagtttgcaa	aaggtggaaa	atgatacatc	cccacaccgt	gaaagagcca	480
ctttgctgga	ggagcagctg	cccctagggg	aggcctcggt	cccattmctc	aagtycaagt	540
gagggacgaa	ggacagtacc	aatgcataat	catctatggg	gtcgcctggg	actacaagta	600
cctgactctg	aaagtcaaag	cttcctacag	gaaaataaac	actcacatcc	taaagggtcc	660
agaacagat	gaggtagagc	tcacctgcc	ggctacaggt	tatcctctgg	cagaagtatc	720
ctggccaaac	gtcagcggtc	ctgccaaac	cagncactcc	aggaccctg	aaggcctnta	780
ccaggt						786

<210> 34

<211> 1063

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (23)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (27)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (30)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1032)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1055)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1056)

<223> n equals a,t,g, or c

<220>

<221> SITE

&lt;222&gt; (1062)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 34

ggtggggggg	tatgcccttt	cgntccnttn	aaatcgagtc	actgatsatg	taatgatata	60
ttttttcatt	attatagtag	aatattttta	tggcaagata	tttgtggtct	tgatcatacc	120
tattaaaata	atgccaaaca	ccaaatatga	attttatgat	gtacactttg	tgcttggcat	180
taaaagaaaa	aaacacacat	cctggaagtc	tgtaagttgt	tttttggtac	tgtaggtctt	240
caaagttaag	agtgttaagt	aaaaatctgg	aggagaggat	aatttccact	gtgtggaatg	300
tgaatagtta	aatgaaaagt	tatggttatt	taatgtaatt	attacttcaa	atcctttggt	360
cactgtgatt	tcaagcatgt	tttctttttc	tcctttatat	gactttctct	gagttgggca	420
aagaagaagc	tgacacaccg	tatgttggtt	gagtccttta	tctggtcagg	ggaaacaaaa	480
tcttgaccca	gctgaacatg	tcttcctgag	tcagtgcctg	aatcctttatt	ttttaaattg	540
aatgttcctt	aaagggttaac	atcttctaaag	caatattaag	aaagacttta	aatgtttatt	600
tgggaagactt	acgatgcatg	tatacaaacg	aatagcagat	aatgatgact	agttcacaca	660
taaagtcctt	ttaaggagaa	aatctaaaat	gaaaagtggg	taaacagaac	atctataagt	720
gatcagttta	tgcttaagag	tgaaagtagt	tctattgaca	ttcctcaaga	tatttaatat	780
caactgcatt	atgtattatg	tctgcttaaa	tcatttaaaa	acggcaaaga	attatataga	840
ctatgaggta	ccttgctgtg	taggaggatg	aaaggggagt	tgatagtctc	ataaaactaa	900
tttggttca	agtttcatga	atctgtaact	agaatttaat	tttcacccca	ataatgttct	960
atatagcctt	tgctaaagag	caactaataa	attaaaccta	ttctttcaaa	aaaaaaaaaa	1020
agggggggcc	cnttttaaa	gatccaagtt	taccnncccc	gng		1063

&lt;210&gt; 35

&lt;211&gt; 1178

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1138)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1176)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 35

gcggccgcgc	actagtgagc	tcgtcgaccc	gggaattcgc	ggccgcgctc	actggccttg	60
tattttttcta	atgggtgtgg	cttttctgag	aacactttct	ccttggtact	tgcttccatt	120
ctccccctcc	aagtccaaga	aggccatgac	aaaaagagag	gtggccaaga	ggctttgact	180
gaatgcttca	gatcttgggt	ycctgatgat	gcagctataa	tctcaggggt	gccttaatcg	240
ctagatgtga	acaatctagt	tagatctatt	tttagagtgc	tgtgttatgt	tcttaaaaga	300
acaaaccgat	aaaagttgct	cacagttttg	cataatgttt	aaggacccag	tgccacagta	360
agaccatata	agttcactgc	tttctascag	tgataatggg	acctacctca	ctgagctacc	420
gtgaagattg	agtgagaaac	aattcaaaga	aaatccttag	cacagtgtct	gggtgaacca	480
tcccatacat	arctgctggg	attttcatta	tcacagagc	acccatacct	aatagaaatc	540
ttgtattata	tatctaagta	gaaagggacc	tcagaaattg	acaagttcac	aattgcacac	600
caagggcagt	gacttactct	acttcacatc	cctattaaat	gatattctagc	ctgtggttta	660
atatttccaa	ggacaggagt	tcactatctt	ttaaagggtac	ctcatgggtat	tgccaatcac	720
tcttatcact	aggaagcttt	tccttctact	gagcccaaaa	tctttctcct	gcttttcccc	780
tggaaacccc	tgaaatgaag	ttattatcat	ttctgtgtga	tggtccttcc	atctcagggc	840
ctcccttata	acactctata	gttcttcttt	ctagttgtgc	tctaggggaag	aggctgggtac	900
ttccgattgc	agaccagctc	tcccttgcca	caacctgaag	tgctctacgg	aaatcaagca	960
gggtctgaaa	ggcctaggca	aaaggaataa	attccaccaa	agatcacagg	ctatccaatt	1020
ctcttttcta	cctcccttcc	catgataagt	gcatccctgc	tccacctctg	ccctaggaac	1080

actaccaaac	acaaacgcac	gctcacacac	acagaaagaa	taggtttaat	ttattagntg	1140
ctcttttagca	aaggctatat	agaacattat	tggggnga			1178

&lt;210&gt; 36

&lt;211&gt; 790

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 36

tgtgtgtgtg	tgtgtgtgtg	tgtgttcata	taacaggagg	acaggaaagg	taaggaccca	60
gaacaatgaa	gacttattga	aatgtggtat	gtgtgtgcbt	gtgtgtgtgt	gtgtgtgtrt	120
gtgtgttcac	ataacaggag	gacaggaaag	gtaaggaccc	agaacaatga	agacttattg	180
aaatgtgggg	ggggtgtgtg	tgtgtgtgtg	ttcatagaac	aggaggacag	gaaaggtaat	240
gaccatccat	ggaagatgaa	ggggtagtac	ttagcaccag	aatcttttcc	agtttttacc	300
catctttcat	tactccttgt	ctccaaatca	ycccttcctt	aataacttaa	aataacttaa	360
aatattttct	gaggacttga	tgacaccagt	cagaagtcca	agagtggctc	gggtataagg	420
agtgttcac	aaggggcagc	tggaaaaagt	ggaattggca	caggcaacat	ctttcttttc	480
agatgtttga	ggtcacccag	aggagataac	agtctgtcaa	catagagccc	tcaaagttaa	540
aaagcagtag	ccaggcaaga	cttgtgtcct	ttcagggctc	ttccaggctc	taagagtgtg	600
aaattcagac	agktttttaa	aaatcaaaat	aaaaggagag	tagttcttac	aggcagaaac	660
tcttagagct	cacaaattgg	aaacaactgc	aaacttcaga	gtaaattcat	agcttccaaa	720
tacaaatggt	cacattgtcc	ctccgctatt	tttacacaaa	tgcatcagc	tgaagacagc	780
aacacacatt						790

&lt;210&gt; 37

&lt;211&gt; 1203

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (9)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (10)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (13)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (106)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1160)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

<222> (1188)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1201)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1202)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1203)  
 <223> n equals a,t,g, or c

<400> 37  
 cggttccnn aanctgccag ttgggaaccc cctggtagat cctgctatat ccagagattt 60  
 agggcaccgt ctctgaaaaa gtgccccggg ggcttttcagc cagcanccag ccctcatcag 120  
 cgatgatgcc aagtgtccta ttgcgtcaaa tccgggctct tcmcagragg gtccctgccc 180  
 cctgccaggc tcccaccttt caccggccac ccctcatgag tcaggctgcc accaatactg 240  
 tcatagtac caattctgag aatgcgagat cctggattaa agactcccag acccaccagt 300  
 ggaggctggg agaaccgata gagctgcgga gggccatgaa tgcatccat ggggatggtg 360  
 gtggtctgtc aggaggggct gcagctgggg tcacagtggg ggtcaccacc attctggctg 420  
 ttgttatcac cttggccatc tacggcacc ggaagttcaa gaagaaagca tatcaggcaa 480  
 ttgaggaag gcagagtttg gttccaggca ctgcagcaac tggagacacc acttaccaag 540  
 agcaggggca gagtccagct taaatctctc cccgaaaatg gtttctctca tctccagtgt 600  
 ggtcattgct gaccactctg ttttcctaag cattgaaatg gcaagtgcaa ccaaagtag 660  
 gtatatctgt gacttcttgt ttaggtctct gggccaggaa attcactctg ttacatggat 720  
 aaggttggga ttggggagag ggaacagttg ggactagaag caaaagtgat tctgggacta 780  
 aaataggaag cagatgtcct ttcccaatgt gtgttgctgt cttcacctga atgcatttgt 840  
 gtaaaaatag cggagggaca atgtgaacat ttgtatttgg aagctatgaa tttactctga 900  
 agtttgcagt tgtttccaat ttgtgagctc taagagtttc tgcctgtaag aactactctc 960  
 cttttatattt gattttttaa aamctgtctg aatttcacac tcttagagcc tgggaagagcc 1020  
 ctgaaaagac acaagtcttg cctggctact gcttttwaac tttgagggct ctatgttgac 1080  
 agactgttat ctccctctgg tgacctcaaa catctraaaa raaagatgtt gcctgtgcca 1140  
 attccacttt ttccagctgn scttggctct aaccagagg agcataantt cccatccccg 1200  
 nnn 1203

<210> 38  
 <211> 804  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (801)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (802)  
 <223> n equals a,t,g, or c

<400> 38

gcggccgcgcg	actagtgagc	tcgtcgaccc	gggaattcgc	ggccgcgctcg	acgctggccg	60
ctgtgtaggg	ctggtgagtg	gctggggctg	tctgagccat	gaacaacttc	agggccacca	120
tcctcttctg	ggcagcggca	gcatgggcta	aatcaggcaa	gccttcggga	gagatggacg	180
aagttggagt	tcaaaaatgc	aagaatgcct	tgaaactacc	tgtcctggaa	gtcctacctg	240
gagggggctg	ggacaatctg	cggaatgtgg	acatgggacg	agttatggaa	ttgacttact	300
ccaactgcag	gacaacagag	gatggacagt	atatcatccc	tgatgaaatc	ttcaccattc	360
cccagaaaca	gagcaacctg	gagatgaact	cagaaatcct	ggaatcctgg	gcaaattacc	420
agagtagcac	ctcctactcc	atcaacacag	aactctctct	tttttccaaa	gtcaatggca	480
agttttccac	tgagttccag	aggatgaaga	ccctccaagt	gaaggaccaa	gctataacta	540
cccagattca	ggtaagaaac	ctcgkctaca	cagtcaaaat	caacccaact	ttagagctaa	600
gctcaggttt	taggaaggaa	ctccttgaca	tctctgaccg	tctagagAAC	aaccagacga	660
ggatggccac	ctacctggca	gaactcctgg	tgctcaacta	tggcaccac	gtcaccacca	720
gtgtcgacgc	tggggctgct	cttattcagg	aggaccacct	caagggtccc	ttcctccaag	780
acagccagag	caagtccgta	nntg				804

&lt;210&gt; 39

&lt;211&gt; 1602

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1599)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1602)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 39

ggggagtgtt	gttaaccgga	gggcagccgc	agtcgcgcgcg	attgagcggg	ctcgcggcgc	60
tgggttcctg	gtctccgggc	cagggcaatg	ttccgcacgg	cagtgatgat	ggcggccagc	120
ctggcgctga	ccggggctgt	ggtggctcac	gcctactacc	tcaaacacca	gttctacccc	180
actgtgggtg	acctgaccaa	gtccagcccc	agcatggcag	tcctgtacat	ccaggccttt	240
gtccttgtct	tccttctggg	caaggtgatg	ggcaaggtgt	tctttgggca	actgagggca	300
gcagagatgg	agcaccttct	ggaacgttcc	tggtagcccg	tcacagagac	ttgtctggcc	360
ttcaccgttt	ttcgggatga	cttcagcccc	cgctttgttg	cactcttcac	tcttcttctc	420
ttctcctctc	gtttccactg	gctggctgag	gaccgtgtgg	actttatgga	acgcagcccc	480
aacatctcct	ggctctttca	ctgccgcatt	gtctctctta	tgttctctct	gggcacccctg	540
gacttcctct	tcgtcagcca	cgctatcac	agcatcctga	cccgtagggc	ctctgtgcag	600
ctgggtgtttg	gctttgagta	tgccatcctg	atgacgatgg	tgctcaccat	cttcatcaag	660
tatgtgctgc	actccgtgga	cctccagagt	gagaaccctt	gggacaacaa	ggctgtgtac	720
atgctctaca	cagagctgtt	tacaggcttc	atcaaggttc	tgctgtacat	ggccttcacg	780
accatcatga	tcaagggtga	caccttcccc	ctctttgcca	tccggcccat	gtacctggcc	840
atgagacagt	tcaagaaagc	tgtgacagat	gccatcatgt	ctcgccgagc	catccgcaac	900
atgaacaccc	tgtatccaga	tgccaccccc	gaggagctcc	aggcaatgga	caatgtctgc	960
atcatctgcc	gagaagagat	ggtgactggg	gccaagagac	tgccctgcaa	ccacattttc	1020
cataccagct	gcctgcgctc	ctgggtccag	cggcagcaga	cctgccccac	ctgccgtatg	1080
gatgtccttc	gtgcacgcgt	gccagcgcag	tcaccaccac	ccccggagcc	tgcggatcag	1140
gggccacccc	ctgccccssa	ccccccacca	ctcttgcttc	agccccccaa	cttccccccag	1200
ggcctcctgc	ctcctttttc	tccaggcatg	ttcccactgt	ggccccccat	gggccccttt	1260
ccacctgtcc	cgccctcccc	cagctcagga	gaggctgtgg	ctcctccatc	caccagtgc	1320
gcagcccttt	ctcggccccc	tggagcagct	acaaccacag	ctgctggcac	cagtgtctact	1380
gctgcttctg	ccacagcctc	tggcccaggc	tctggctctg	ccccagaggc	tggccctgcc	1440
cctgggtttc	ccttccctcc	tccctggatg	ggtatgcccc	tgcctccacc	ctttgccttc	1500
cccccaatgc	ctgtgcccc	tgcgggcttt	gctgggctga	ccccagagga	gtacgagctc	1560

tggagggscatgagcggcag aactggaggc cgggtgcana an

1602

<210> 40  
 <211> 1789  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (1742)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1743)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1781)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1786)  
 <223> n equals a,t,g, or c

<400> 40							
gccgcagtcg	cgcggtattga	gcgggctcgc	ggcgctgggt	tcttggtctc	cgggccaggg		60
caatgttccg	cacggcagtg	atgatggcgg	ccagcatctg	gcccaggctc	tggytctgcc		120
ccaraggctg	gccctgcccc	tggtttcccc	ttccctcctc	cctggatggg	tatgccccctg		180
cctccaccct	ttgccttccc	cccaatgcct	gtgccccctg	cggstttgct	gggctgaccc		240
cagaggagct	acgagctctg	gagggccatg	agcggcagca	cctggaggcc	cggctgcaga		300
gcctgcgtaa	catccacaca	ctgctggacg	ccgccatgct	gcagatcaac	cagtacctca		360
ccgtgctggc	ctccttgggg	cccccccggc	ctgccacttc	agtcaactcc	actgaggaga		420
ctgccactac	agttgttgct	gctgcctcct	ccaccagcat	ccctagctca	gaggccacga		480
ccccaacccc	aggagcctcc	ccaccagccc	ctgaaatgga	aaggcctcca	gctcctgagt		540
cagtgggcac	agaggagatg	cctgaggatg	gagagcccga	tgcagcagag	ctccgcccggc		600
gccgcctgca	gaagctggag	tctcctgttg	cccactgaca	ctgccccagc	ccagccccag		660
cctctgctct	tttgagcagc	cctcgctgga	acatgtcctg	ccaccaagtg	ccagctccct		720
ctctgtctgc	accagggagt	agtaccccca	gctctgagaa	agaggcggca	tcccctaggc		780
caagtggaaa	gaggctgggg	ttcccatttg	actccagtcc	caggcagcca	tggggatctc		840
gggtcagttc	cagccttcct	ctccaaactct	tcagccctgt	gttctgctgg	ggccatgaag		900
gcagaagggt	tagcctctga	gaagccctct	tcttccccca	cccctttcca	ggagaagggg		960
ctgccccctc	aagccctact	tgtatgtgcg	gagtcacact	gcagtgccga	acagtattag		1020
ctccccgttc	caagtgtgga	ctccagaggg	gctggaggca	agctatgaac	ttgctcgctg		1080
gccccaccct	aagactggta	cccatttcct	tttcttacct	tgatctcccc	agaagcctct		1140
tgtgggtggg	gctgtgcccc	ctatgccctg	tggcatttct	gcgtcttact	ggcaaccaca		1200
caactcaggg	aaaggaatgc	ctgggagtg	gggtgcaggc	gggcagcact	gagggaccct		1260
gccccgcccc	tccccccagg	cccctttccc	ctgcagcttc	tcaagtgaga	ctgacctgtc		1320
tcaccagca	gccactgccc	agccgcactc	caggcaagg	ccagtgcgcc	tgctcctgac		1380
cactgcaatc	ccagcgcccc	aggaaggcca	cttctcaact	ggcagaactt	ctgaagttta		1440
gaattggaat	tacttcctta	ctagtgtctt	ttggcttaaa	ttttgtcttt	tgaagttgaa		1500
tgcttaatcc	cgggaaagag	gaacaggagt	gccagactcc	tggtctttcc	agtttagaaa		1560
aggctctgtg	ccaaggagg	accacaggag	ctgggacctg	cctgcccctg	tcttttcccc		1620
ttggttttgt	gttacaagag	ttgttgagga	cagtttcaga	tgattattta	atttgtaaat		1680
attgtacaaa	ttttaatagc	ttaaattgta	tatacagcca	aataaaaaact	tgcattaaca		1740



annaaaaaaaa aaaaaaggggg gggggcccttt taagaaccag nttaanaac

1789

<210> 41

<211> 2102

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (22)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (24)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (35)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (83)

<223> n equals a,t,g, or c

<400> 41

atcgactcgg	gagtttgccg	tntntgcaac	ctggntatga	agttcctacc	tcaacctctg	60
tccttcctgc	aaagcaggaa	gantctgtca	agatcctgct	ggctgagttc	aaggctgggc	120
tgtgatgtgc	aacacactga	acacgtgtac	agggtttatg	tcacaacttt	tctgggtttc	180
ggaggcaact	ttgcccggca	gcgctacgaa	gaccttggtc	tgaatgaaac	tcttaacaaa	240
aacagattgc	ttggtcagaa	gacaggtctg	agtcccgcga	atccatttct	ggatccctgc	300
ctgccagtgg	gactcacaga	tgtggtggag	aggaacagcc	aagtcttaca	tgtccgagga	360
agaggagact	gggtgtcttg	tggggcaatg	ctgagccccc	tgctggctcg	ctccaacacc	420
agccaggcct	cactcaatgg	catatatcaa	tcgcctattg	acttcaacaa	cagcgagttc	480
tacggcttct	ctgagttttt	ttattgtaca	gaggatgtgt	tgcgcatggg	tggccgctac	540
catggggcaa	catttgccaa	ggctgctcag	gattactgtg	gcatggcttg	gtcgggtacta	600
actcagagat	tcaagaatgg	cctcttttca	tcacatgcag	atgagcatcg	actcaaatat	660
cagtgtttta	aatcggcttg	gatgtaccaa	gtcttacatg	aaggattcca	ctttccctat	720
gactacccaa	acctgcggac	agcccagctg	gtgtatgacc	gagaggttca	gtggacgctg	780
ggagccattc	tatataaaaac	acgattctta	ccactcaggg	atcttcggca	ggaagggtgc	840
cgacaagccc	atggtagctg	gttccgtctc	tcctttgtat	acaaccacta	tctcttcttt	900
gcctgtatcc	tggtgggtgct	actggccatc	ttcctatacc	ttctgcggct	acgccgaatt	960
caccaccgac	aaacacgagc	ctcagctcca	ttggacttgc	tgtggcttga	agagggtggtg	1020
cccatgatgg	gagtacaggt	ggggccgtga	ggctggacca	ggactagaga	agcttgagca	1080
cccccgagtt	gctgctcatt	gaattcctcc	actttcttat	atagcctcag	atgctgtgat	1140
gtctgacctt	gtggatattt	gcccttgga	tttctacttt	actttctacc	gtaattcctt	1200
ctccgtaccc	aggctctctc	tgagagaagc	tataatttaa	tctgtgagga	actaaatgac	1260
aggagattgg	tgctaatacg	ggggaccaag	ctttgtccaa	gtgaagcagg	cttcgactcc	1320
ttctgagarg	tctggtgtgt	tcctagaatc	tcaccttttc	ttcccttgct	aaagcatgaa	1380
gtttggcatt	tggcacactg	gaagcctggt	tgaatgaaa	tttgtagcrt	ctgatacaaa	1440
gccagr gaca	ttctagcaag	tgacgasc	ccttctttct	ctgtaacaga	gatatcattt	1500
atgtggagat	ccacaacctt	taacagggat	ccaagatctt	tgacgttcaa	tcgaccacat	1560
aggaatttcc	aggcaccaaa	atgatataac	ttccttgctt	ccttgacaaa	gaagccatca	1620
tgggtgtgat	ccaagatccc	tgtcgtagt	ttgatgatgt	tagtacatga	ttttaaaggt	1680
tagaaccctt	tctaaatgaa	tggctctgtg	aagattttag	tatcttatct	gatgcctggg	1740

atgatgagga	tagaaaaattt	ttccattttt	atgtgcctca	caggctgttt	gggcattaat	1800
tttgcttttt	gagccttaag	tgtgttagta	ggatggagaa	actgtgatgg	ggactgggaa	1860
cctggatttg	tctgatttta	ggtcactgtt	ccctgggcct	gtttttgtga	gcccttacac	1920
aggaagatat	aaagagagtt	ctttcatttc	actgctaaaa	tcagtatgta	gtatggggaa	1980
tgtatttggg	ttgtttttta	agaaaagggg	aacagaatca	ggagagtggg	caaaggcaat	2040
aaaatcaaag	ttcttattaa	ttaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aagggcgggc	2100
gc						2102

&lt;210&gt; 42

&lt;211&gt; 1005

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1004)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 42

atgggaaatg	ctcttttgaa	ggtacgcccg	caggctcccg	tccggaattc	ccgggtcgac	60
ccacgcgtcc	ggccagaagc	agccatgaag	tgagcctgca	ggcaggccag	cctgtgacca	120
tcctggaggc	ccaggacaag	aaggggaacc	ctgagtggag	cctgggtggaa	gtgaatggac	180
agaggggtta	tgtgccttct	ggcttcttgg	ccagggtctg	gagcccagtt	ctgtggggct	240
ggagtctgcc	ctcttagggg	accctctttg	gagcctacat	tgccaaatga	tgggggaggg	300
ttagaggctc	tgaccctggg	gggaaaagaa	gcaaaggaaa	ggtggagggtg	gaagggaaga	360
ccaggccagg	gtgggtgaag	cacactcagg	aggcagccag	aagacatggg	cgggcctcgc	420
agagtgcctg	gtgtggtggg	ggcacaggag	gctccagcca	ggactgctca	ttatgtctgc	480
ataaagaact	cattccgacc	tggggtcaca	atgcacttgg	acagcaggtc	acagctgatt	540
ggccaggact	ctcgatagg	tatggccagt	cttagctgtg	cctgcatccg	ggcctgctg	600
tgggcgtggg	tcacacggga	taatgttacc	tgcgtgctgt	gtgggtgcag	gaagcgggtt	660
ctggaggagt	ccagaactgc	ctgggtcagac	agttcacttc	ctacacatgg	tatcaggaga	720
catcataacc	aatgagtcag	cttttatttc	tctatgctgg	aagctgagtt	tatcttgggc	780
agtgaccac	tgggagccct	ctcaagtggg	gaagccatgg	atttatcggg	gtagcagaga	840
ggttcccaag	actcttgact	ggtcctggga	gtgggtgtga	ccaagtcata	gttctggaat	900
gtgtgtaggc	aaattcagag	gctgttccag	ggaagagggg	attttgatac	tgtgttaggt	960
ggggtgtgtg	aggctgytgg	cagcagggtga	acagctactg	ctgng		1005

&lt;210&gt; 43

&lt;211&gt; 2988

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 43

cccacgcgtc	cggccagaag	cagccatgaa	gtgagcctgc	aggcaggcca	gcctgtgacc	60
atcctggagg	cccaggacaa	gaaggggaac	cctgagtggg	gcctgggtga	agtgaatgga	120
cagaggggtt	atgtgccttc	tggcttcttg	gccagggtct	ggagcccagt	tctgtggggc	180
tggagtctgc	cctcttaggg	taccctcttt	ggagcctaca	ttgccaaatg	atgggggagg	240
cttagaggct	ctgaccctgg	ggggaaaaga	agcaaaggaa	aggtggagggt	ggaagggaag	300
accaggccag	ggtgggtgaa	gcacactcag	gaggcagcca	gaagacatgg	gcgggcctcg	360
cagagtgcct	ggtgtggtgg	gggcacagga	ggctccagcc	aggactgctc	attatgtctg	420
cataaagaac	tcattccgac	ctgggggtcac	aatgcacttg	gacagcagggt	cacagctgat	480
tggccaggac	tctcgatagg	ttatggccag	tcttagctgt	gcctgcatcc	gggcctgcct	540
gtgggcgtgg	gtcacacggg	ataatgttac	ctgctgctg	tgtgggttga	ggaagcgggt	600
tctggaggag	tccagaactg	cctgggtcaga	cagttcactt	cctacacatg	gtatcaggag	660
acatcataac	caatgagtca	gcttttattt	ctctatgctg	gaagctgagt	ttatcttggg	720
cagtgaacca	ctgggagccc	tctcaagtgg	ggaagccatg	gatttatcgg	tgtagcagag	780

aggttcccaa	gactcttgac	tggtcctggg	agtgggtgtg	accaagtcac	agttctggaa	840
tgtgtgtagg	caaattcaga	ggctgttcca	gggaagaggg	gattttgata	ctgtgttagg	900
tggggtgtgt	gaggctgttg	gcagcaggtg	aacagctact	gctgtgttct	caggactagg	960
gaacaaaggg	gtatgcaaat	catagaggaa	actctgggaa	ggcgggtgata	aggcctgggtg	1020
ggtggggagg	ttagggaatg	gcttgctttc	ctgtttcttg	ttagaagggg	agccaggggg	1080
aacccccagt	ggtttcaggt	ggcccctgag	gtcctggagg	cagccgtgga	tgtgatgcaa	1140
ttggctgtgg	gaccttagat	gtaggacaca	acttcagtgt	tcccatccag	aaagacctca	1200
ctcacagggt	tgtgctgaga	atgacatggg	gctaagcatg	cagagctccc	tgtaaactgt	1260
gaagtgtgat	acaaatgtaa	atgacagcag	tgatctcggg	gtggcccccg	gcatgctgcc	1320
ctccccacg	cccatgcctg	tggcagcaaa	ccttgttcat	cagtatagct	ttctttcctg	1380
taaccacagga	tctaccttgg	ggggcttctc	aatactgcat	tctatgtagc	cagcctcttt	1440
aacttggtaa	gtgagccacc	ccattctaga	acctggaaat	tggagccctt	caaaaacagt	1500
tcctgttcaa	ggaggactga	cctgctgggg	caatgttggg	tgcagtgcag	tcctgtcttg	1560
gggtggtcat	gtctaggctg	ttgctctggg	caaagataag	ttgcaagatt	cacagaaatg	1620
ggaaaatgtg	accaagtgtg	atcttaacaa	ctgacaaagt	ttgtaaccaa	cccaagttag	1680
aatgtgtgtc	aaacaggagg	tagtttagat	atgcttccaa	gaacatgtct	gtgttataac	1740
catagtgcct	aagcagttag	ctctggtttt	tgaagggtct	ttaagaaata	tatacatgtc	1800
tgtgtcagtc	tataacttgc	ctcctctggg	cctgttaaag	catgaagact	gcatgacaca	1860
agagaaatgc	aagccctacg	gttcctttct	cagcagcgaa	ttcacttgag	aggatgtctt	1920
tgactcattc	tctctgctct	ttcctgctca	gatttctgat	aaaaatagag	agcatagggg	1980
aacagataat	gaaataggaa	accactcgt	gggttccaca	gatacctacc	gaaggcctac	2040
tgtgtgctag	aattgtagct	caggagtctt	cagtgtagct	gtcactgaa	gttaccatgg	2100
caggtttcaa	ctggcagaat	ccaggctccg	tcccacccag	agattctgat	gaaattgggt	2160
taggggtgtg	ctcgggcctc	aggaattcag	aaagcttccc	agggtgcttc	aatgtgcagc	2220
cagggttagg	gacctctacc	ctagacacaa	agtattggac	agatagacct	ggtgccagag	2280
atggccaaga	gctgtaagct	aggacgtgcc	ccacctgagc	tctgcactag	ctagtcca	2340
caggcgcttt	aaaggcagtg	tgaaagggga	cagcctgttc	tgccagggtc	cagaatgtat	2400
atttattaag	tgccattaaa	agggacctga	acaaaattgg	atgtcttgta	ggcataaggg	2460
aggaaaataa	aatatacttg	gaaccaagtc	tatgtcatga	agggaaaata	aaaatgtatt	2520
cagtagcacg	tgggttatgg	tttctcatag	accaggggat	aagattaaaa	gtcactgaag	2580
agtgggaaaa	tgcatgttga	gaagatgaga	atggcctgta	tttctccag	gggaatctgt	2640
gtaatgtgcc	tttccctct	ccaaatgcct	agaacctagg	cactgtgtct	tatttattta	2700
accgttgggc	tgtctcatac	taaacttgca	aagatatttg	cctatgaact	gaacaagact	2760
tccaggagtt	gaagtctggt	tcacaagggg	accccttgcc	tcctgtgatg	gagtgagaac	2820
tcttaaacc	ctcaggcccc	aactcagttg	tggagatgag	gacaagatta	caatatcaaa	2880
agaaagatga	atgaattctt	ggttaatatg	acgaaccca	gctcaatgag	taactgatgt	2940
gaactgctgg	gaataaagga	cttcaaagat	ggaaaaaaaa	aaaaaaaa		2988

&lt;210&gt; 44

&lt;211&gt; 2052

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 44

tttttttttt	tccatctttg	aagtccttta	ttcccagcag	ttcacatcag	ttactcattg	60
agctgggggt	cgtcataatta	accaagaatt	cattcatctt	tcttttgata	ttgtaatctt	120
gtcctcatct	ccacaactga	gttggggcct	gaggggttta	agagttctca	ctccatcaca	180
ggaggcaagg	ggtacccttg	tgaaccagac	ttcaactcct	ggaagtcttg	ttcagttcat	240
aggcaaatat	ctttgcaagt	ttagtatgag	acagcccaac	ggttaaataa	ataagacaca	300
gtgccatggt	tctaggcatt	tggagaggga	aaaggcacat	tacacagatt	cccctggaga	360
aaatacaggc	cattctcatc	ttctcaacat	gcattttccc	actcttcagt	gacttttaat	420
cttatcccct	ggtctatgag	aaaccataac	ccacgtgcta	ctgaatacat	ttttattttc	480
ccttcatgac	atagacttgg	ttccaagtat	attttatttt	cctcccttat	gcctacaaga	540
catccaattt	tgttcagggtc	ccttttaatg	gcacttaata	aatatacatt	ctgagacctg	600
gcagaacagg	ctgtccccct	tcacactgac	tttaaagcgc	ctgtttgaac	tagctagtgc	660
agagctcagg	tggggcacgt	cctagcttac	agctcwtggc	catctctggc	accaggctca	720
tctgtccaat	actttgtgtc	tagggtagag	gtccctaacc	ctggctgcac	attggaagca	780

cctgggaagc	tttctgaatt	cctgaggccc	gagccacacc	ctaaaccaat	ttcatcagaa	840
tctctgggtg	ggacggagcc	tggtattctgc	cagttgaaac	ctgccatggg	aacttcagtg	900
agcagctaca	ctgagaactc	ctgagctaca	attctagcac	acagtaggcc	ttcggtaggt	960
atctgtggaa	cccacgagtg	ggtttcctat	ttcattatct	gttcccctat	gctctctatt	1020
ttkatcagaa	atctgagcar	gaaagagcag	agagaatgag	tcaagagcat	cctctcaagt	1080
gaattcgctg	ctgagaaagg	aaccgtaggg	cttgcatttc	tcttgtgtca	tgcagtcttc	1140
atgctttaac	aggcccagag	gaggcaagtt	atagactgac	acagacatgt	atatatttct	1200
taaaagccct	tcaaaaacca	gagctcactg	cttaggcact	atggttataa	cacagacatg	1260
ttcttggaag	catatctaaa	ctacctcctg	tttgacacac	attctaactt	gggttggtta	1320
caaactttgt	cagttgttaa	gatcacactt	ggtcacattt	tcccatttct	gtgaatcttg	1380
caacttatct	ttgcccagag	caacagccta	gacatgacca	ccccaaagcag	ggactgcact	1440
gcacccaaca	ttgccccagc	aggtcagtc	tccttgaaca	ggaactgttt	ttgaggggct	1500
ccaattttcca	ggttctagaa	tggggtggct	cacttaccaa	gttaaagagg	ctggctacat	1560
agaatgcagt	attgagaagc	cccccaagg	agatcctggg	ttacaggaaa	gaaagctata	1620
ctgatgaaca	aggtttgctg	ccacaggcat	gggcgtgggg	gagggcagca	tgccgggggc	1680
caccccgaga	tactgtctgt	catttacatt	tgtatcacac	ttcacagttt	acagggagct	1740
ctgcatgctt	agccccatgt	cattctcagc	acaacctgt	gagtgaggtc	tttctggatg	1800
ggaacactga	agttgtgtcc	tacatctaag	gtcccacagc	caattgcatc	acatccacgg	1860
ctgctccag	gacctcagg	gccacctgaa	accactgggg	gttccccctg	gctccccctc	1920
taaccagaaa	caggaaagca	agccattccc	taacctcccc	acccaccagg	ccttatcacc	1980
gccttcccag	agtttcctct	atgatttgca	tacccctttg	ttccctagtc	ctgagaacac	2040
agcagagctt	tc					2052

&lt;210&gt; 45

&lt;211&gt; 617

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (600)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 45

gtaccggtcc	ggattcgcg	ccgcgtcgac	gatgcctgct	tgaatttcct	ggcagctaag	60
ggaataaaca	tccaggggct	gtctgcagaa	gagatcagga	atggaaacct	caaggccatt	120
ctaggcctct	tcttcagcct	ctcccagatac	aagcagcagc	agcagcagcc	ccagaagcag	180
cacctctcct	cacctctgcc	gcccgcctga	tcccagggtg	ccggggcccc	ctcccagtg	240
caggctggca	cccctcagca	gcaggtgcca	gtcactcccc	aagccccgtg	ccagcctcac	300
cagccagcac	catatcagca	gtcaaaaagca	caagctgaaa	tgcagtccag	agcctttggc	360
aagktcagcc	tyctcccacc	ccggaatgag	tgacaatgca	cctgcttcct	tggagagcgg	420
cagcagctyc	accctacta	awtgcagtac	ctyctcgggc	atyccgcarc	ccggtgcaag	480
caccaagcct	tggcgcaasa	aatcctyarc	gkgaacaca	agtggccacg	gtatccakct	540
yttcgggyaa	gcttctgggg	ctkaaggccc	caaggcccaa	accttgaaag	ccattgaaan	600
ccgggccccca	acaatta					617

&lt;210&gt; 46

&lt;211&gt; 558

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (390)

&lt;223&gt; n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (391)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (434)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (485)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (541)  
 <223> n equals a,t,g, or c

<400> 46  
 gaccctgcaa cgaaatacct ccctgggcct cggagacgct gacagctggg acgacagcag 60  
 ctccgtcagc agcggcatca gcgacacatc agacaacctc agcactgatg acatcaacac 120  
 cagctcctcc atcagctctt atgccaacac acctgcctyc tctcgaaaaa acctggatgt 180  
 gcagactgat gctgagaagc actcacaggt ggagaggaat tcctgtggtc tggatgatgt 240  
 gtcaagaaat cagacggagg ctcagacagc ggcatataaa tggagccagg ttycaagtgg 300  
 aggcggaatc cttctgatgt gtctgacgag tccgacaaaa gcacgtcggg caagaagaat 360  
 cctggcatct ccagacaggc tcatggcggn naggcatgac agctcaagtg ggcatcacca 420  
 tgccaaggac gaangcttca gcccggcagg cgcactgaag accccaggaa ctggaaaaac 480  
 agacnacgca aagggtgtctg agaaaggaaa ggggtttttc taaaggcttc caagtgaaag 540  
 nggttcccat caaatgca 558

<210> 47  
 <211> 1454  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (1)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (10)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (15)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (38)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (53)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1427)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1429)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1445)  
 <223> n equals a,t,g, or c

<400> 47  
 nacatttggn attcntaagc taatcttttt atttttgnaa ggggtgtcttt ctnagaaagg 60  
 cagccagagg cacagcacca acctttctga cagtgtgggtc ttcacactgt tagttctgac 120  
 aaagggagtc aaggagtcgt ccttgaggga ggcgatgagg ccagtggag aattgtggct 180  
 ggggaccctt ccactgctga gggagatgtc gatggactca cagctgggtg ggaggctgct 240  
 gacagactga aagcccaggc catccttgct aactgcgag gagctgctgg cgttggtgcc 300  
 ccaggtgagg ctggttgaag gggccgagtg ggctgagctg gggctggagg ctacgggaga 360  
 ctgggtgagg tccacattct tgctgtagag aggactgctg ctcccactgc tcaggacgcc 420  
 actgctgac ggggagtccta ggttaccttg ctgagtcag gtggcatgag gattggagat 480  
 gaccaccgaa tttttcatgt tttcagctgt ggcgatgggc acttgcttgg taggcttccc 540  
 accaaagagt ctgcgagtg tgggagaggc cacatctggg tacttggttc caggctggag 600  
 actggtctga gccggactgg acacaggctg ggctgccgga ttcactttca ccgagttaca 660  
 ggaagccaca ctctcgtkgt ctgatgagat gcctttctcc ttgtctgttt ggttgaccag 720  
 acctggtaga gagctgccta gggctgtttt ggaaggctcc ctgagtttg gactggcag 780  
 gcctgcggac ttgctgctaa tgttgaatc tatgctgctg gtgctagacc tgttcccagc 840  
 cccgttccgg ctggttgact tactgggctt cggcaaacct cggtagtgaa ggtttgtccg 900  
 ggagcttagg gctagatacc cgtcatcctg attctgagcc ccatccatac ttgacttccg 960  
 accagcagac cgactgacga gtgcagatga ctttgggatt ttgcccagtg tggtgacct 1020  
 gctggtgaca gtcaccccg cgtgctgtgat catggccagg ccggcgggcg aaccactctg 1080  
 cttcttgaac ccaaagctgt tggcattggc agtaggtgtc ctgagctgc tggggagggg 1140  
 ctttttggat tgcaccac tgctccggcc tgcactctgat ggggagcgct tcacctggga 1200  
 ggcttttagga gaaagccttc ctttctcaga cacccttgct tegtctgttt ttccagttcc 1260  
 tggggtcttc agtgcgcctg ccggggctga agccttcgtc cttggcatgg tgatgcccac 1320  
 ctgagctgtc atgcctcgcc gccatgagcc tgtaaggaaa atgacaggat tcttcttgcc 1380  
 cgacgtgctt ttgtcggact cgtcaggcrg gyagytgaaa ctaaacntng gaagtgtacc 1440  
 accgnctcac caac 1454

<210> 48  
 <211> 835  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (204)  
 <223> n equals a,t,g, or c

```

<220>
<221> SITE
<222> (781)
<223> n equals a,t,g, or c

<400> 48
ccgctcagag gaagagtggg tatgtctgct gctgccctcc gagagaacct gtgcacattc      60
ctgaagcccc tcctagctcc tgcaggccta gtttggtggg tggttaagct gggctcaaatt      120
acacatattc ccagtgtggc tttaggcggg ctttgtacat ctgctaagcc tcagttgctt      180
gtttgggaaa tggaatgata atancaatat ctcctttttg gtgtggctgt gactgtgggg      240
ctttaagagc acattccagg aggcagattg cccagccctg tctatctatg tggccttggg      300
ccagtcactt aagctgtccg ggcctcagtt tccttgtgta gaacgggaca gcgatatgac      360
ctmcctccct ragttgttgt raggatccag tgagttttta tgcataaagc acttaaagag      420
ttcctggcat raggtcagca ccatgtaagt gttggctatt rgccaatgtt tggagatcac      480
tttctctctg cttggctcct aataagctct tggtgaaagg tagttgttat ttttaacttc      540
ttcgttctcc ttcactgtct taattccac cttcatttag ccttgcaatt tcctttaaat      600
accttatctt ctcccctcgt ttgttgtcaa tctgctgcac taccaataaa ggcgtgcata      660
aattatattt gtcccatgtt tacattcata aaacatttcc catgcactcc tgtcccaacc      720
tcacagcaaa cgcgtgagcg agcagtgcag ctcatgtcat tgccctcatt ttgagagccc      780
nggacagggg gtgatctgtc cagaagcatc acctgctcag ggggtgtctcc aagcc          835

```

```

<210> 49
<211> 516
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> SITE
<222> (435)
<223> n equals a,t,g, or c

```

```

<220>
<221> SITE
<222> (510)
<223> n equals a,t,g, or c

```

```

<220>
<221> SITE
<222> (515)
<223> n equals a,t,g, or c

```

```

<400> 49
tttttttttt tttttttttt ggagacaggg tctcactttg tcacccagac tggagtgtag      60
tggcacaatc ttggctcaag ccattctccc acctcagcct catgagtagc tgggattaca      120
ggtgtgagcc accgcacctg accaacataa taataattct taacatatga tcaccatatg      180
ctgggagaac gccctcctac actcctgagc ctagccacgt tactctcaga agtaaggggtg      240
tatgtgccta gtccctggag ggggtgtgtg ctctgccctc tgcaagtgggc atcagagtgt      300
gtgggtgccc ccctgtgccc agggccacca gttcagtaac agagtgggccc gtgaaacagg      360
aggcatgggg atgtgggtgg agtgcagccc tggaatgaca cctgcagccc ccacgtgcac      420
cccgatttct cargntcctc ttcctcttcc ttgcggggccc tagcacagga ttcaagcagc      480
agagttttta gccctcccag tgtgaatgtg ttcana          516

```

```

<210> 50
<211> 534
<212> DNA
<213> Homo sapiens

```

<220>  
 <221> SITE  
 <222> (6)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (11)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (516)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (519)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (525)  
 <223> n equals a,t,g, or c

<400> 50	
ggggtncctc ngaggcaggc agatccttga ggccaggagt tagagactag cctggccaac	60
atgggtgaacc ccatctctac aaaaaataca aaaatttgaa tcaaacattt taaacagact	120
attttagatg tttattttaat actgaaatgt tgtcaactat cataaagtat ttctctgcat	180
cmcaaaaatt ccatatatta aggattttacm caatccagga aaaaaaattt ttagaaactg	240
tttttttttt ttttagcctg agcagaaaaa tctaaaaagg ctctccaaaa tcttgagtgg	300
aagtatcata ctctgcaatg aaatgcttga gttcttcaac acaccgctca cctatttcat	360
gtaaattctg cctcaatgca aactgtatag acttttctaa tgaaggatct ttttcaatca	420
gcattttcac caccatcccg aaagtttcac agtcttgtcg gtaaacctgt tcaatctctt	480
tggtttttga tgctattgct ttagagccgg aaaggnttng ggggnttttt ttaa	534

<210> 51  
 <211> 503  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (422)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (474)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (493)  
 <223> n equals a,t,g, or c



<400> 51  
 ttttctctaa gataccaaaag tatttcagttt attaggatag tacactttaa catattacaa 60  
 gttacaaagc ctaagaaaaa gcaagcaaca agtcaataaa atcacaaactc agaattctaa 120  
 catttttcaga tggatatatgt gttgggcagg gagcgggtggc cacgcctgta atctcaacac 180  
 tttgagagggc tgaggcaggc agatcacttg aggccaggag ttagagacta gcctggccaa 240  
 catggtgaac cccatctcta caaaaaatac aaaaatttga atcaaacatt ttaaacagac 300  
 tatttttagat gtttatttaa tactgaaatg ttgtcaacta tcataaagta tttctctgca 360  
 tcacaaaaat tccatatatt aaggatttac acaatccagg aaaaaaaatt tttagaaact 420  
 gntttttttt ttttttagcc tgagcagaaa aatctaaaaa ggctccccc gtgnccgaat 480  
 tccttggccc cgnngggccca att 503

<210> 52  
 <211> 607  
 <212> DNA  
 <213> Homo sapiens

<400> 52  
 gcccagtaaa agctactagg tgacactata gaaggtagcg ctgcaggtag cggtccggaa 60  
 ttcccgggtc gacccacgcg tccggtagct cagctgcatt tgcacctgga acccgcgctc 120  
 tcgcccaccc tgctctagcc ctggcctgtg gctgggacct ccagcataaa ccgatgctc 180  
 tgcccagctc tggggccatt tctgctgttt ctgctcagtt caaccctgat ggcttccttt 240  
 atgggtgaca ctccatgtca cccaggcgaa ctgtcagcct ttggagtggc acccagtagg 300  
 gtctttactt ccagtttctt gtccacagtc ttactcctt cataccctc actccctggg 360  
 taacatcggg ccaccagtaa tgctggttcc tagctctgca acaccatgca cgggtgtagta 420  
 gctaagagca gagctttcgg gtgtgaagta cctgagtaca gttcctgcct tcccctgtgt 480  
 gtgcctggaa cagagtaaac actcaggaag cgttaccac tgctgccatt cccagagatg 540  
 caaaaggtga ggtctccgtt ttgccatcta tacaatagag ataataaagg ctatccact 600  
 cttaatg 607

<210> 53  
 <211> 432  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (420)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (422)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (428)  
 <223> n equals a,t,g, or c

<400> 53  
 gggcggaacc agyctgcacg cgctggctcc ggggtgacagc cgcgcgcctc ggccaggatc 60  
 tgagtgatga gacgtgtccc cactgaggtg cccacagca gcaggtgttg agcatgggct 120  
 gagaagctgg accggcacca aagggtggc agaaatgggc gcctggctga ttcctaggca 180  
 gttggcggga gcaaggagga gagggccgagc cttctggagc agagccgaga cgaagcagtt 240  
 ctggagtgcc tgaacggccc cctgagccct acccgcttg cccactatgg tccagaggct 300  
 gtgggtgagc cgcctgctgc ggcaccggaa agcccagctc ttgctggtca acctgctaac 360

ctttggcctg gargtgtgtt tggccgcagg attcacctat gtgccgctct gctgtggaan 420  
tnggggtanaa ga 432

<210> 54  
<211> 794  
<212> DNA  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (5)  
<223> n equals a,t,g, or c

<220>  
<221> SITE  
<222> (760)  
<223> n equals a,t,g, or c

<220>  
<221> SITE  
<222> (769)  
<223> n equals a,t,g, or c

<400> 54  
ttcengaccc yggsetgmgg gggcacacca agagaaagaa gagaatacca mggacatacc 60  
ycagtcacct ctggatccct ggkctgcac agagcctggc tcataggaga cactggagaa 120  
atgctcctaa cctttggcta gcccttttat aatttatagc gattatctca tttaatgctt 180  
acaaccacca tttgaggtga tccattttac agagaaggaa gcagaggctt ttaagagggt 240  
aggtaagtct tagccaaagc caaatagcag ctgaacagta gagctgggac tccatcaagg 300  
tctcccagcc ggagcttgct cctaccctta ggacaagggg tggactcctg actctgcaga 360  
taaattctac aaaaagccaca gaaggcaagt agtaaccatt gtgtgacaac ccttcacccc 420  
caggaagagg gggccctgtg aggattgcag gctctggagt cacactgctt gttgaaacgc 480  
tgctctttac cctccctagg tctgcgcctt tgaataagta tcacktctta gttgctccat 540  
gcctcagttt gyccatctga aaatgggggc atctgtaatg cctgtgktat gaggagtaaa 600  
ttacagcaty cctgtgaaga cgtarcacag tgycgagtac ggaatggat ttcactcctt 660  
ctacggagct tgggtcccty cccttgccct tacttgccca gccattgayt catactactt 720  
ccttcttgca ggcattggtc cagtgtctggc ctggctgggn ccgttctang ctcagcagtg 780  
accatgcgtg gacg 794

<210> 55  
<211> 1019  
<212> DNA  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (962)  
<223> n equals a,t,g, or c

<400> 55  
gcccctcgag ggatcctcta gagcggccgc cctttttttt tttttttttt tttttttaac 60  
atataaaaa gcctttaatt ttgtcaccat aaacattata ctctgattgc tcacttacag 120  
tataaaatat tcccccgct aaataaataa gacgacatta ttgcaaacgg cacttaaacc 180  
ccccctgaga gataagacct cccttagctc aggcaggggg tgctcctgag tttctgtgtg 240  
agattcccca agcacagata tactctgggg gctgagatgg acaaaggctt gggaaaccgc 300  
actttgtgct tctggtcctg cagttagctcc aaacaggggt gtggagctgg tggggaaagt 360

tggtggtagg	ggaaagttag	gggtaggagg	aattttgggc	agtgccttca	tcagcccagt	420
cctagagaga	gtagagggga	gtggaagtgg	ggggaaccag	gctggggcaa	gagaagaggg	480
gtggttaggg	aagccgttga	gacctgaagc	cccaccctct	accttccttc	aacaccctaa	540
ccttggttaa	cagcatttgg	aattatcatt	tgggatgagt	agaatttcca	aggctcctggg	600
ttaggcattt	tggggggcca	gaccccagga	gaagaagatt	ctggcaatga	tcagcccaat	660
gaccagctat	ctcaggggac	ctgattgttg	gggatccccc	accctaccca	aattattagac	720
accaacacag	aaaagctagc	aatggattcc	cttctacttt	gytaaataaa	taagttaaata	780
atttaaattgc	ctgtgtctct	gtgatggcaa	cagaaggacc	aacaggccac	atcctgataa	840
aaggtaagag	gggggtggat	cagcaaaaag	acagtgtgtg	gggctsaggg	gacctgggttc	900
ttgtgtgttg	cccctcagga	ctcttcccta	caaataactt	tatatgttca	aatcccatgg	960
angagtcgct	tcatacctaga	aactcccatt	gcaagaacct	accattaaac	cgaagctgc	1019

&lt;210&gt; 56

&lt;211&gt; 2042

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (2001)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 56

ggtcagcttt	catctcgtcc	tatctttgtt	caggcaaaact	tctctagtcc	tgttttaata	60
ggcatatttg	ttaggtctgt	tttttgaaat	cctctttttt	acattgttta	aagataatgc	120
cttggtctaa	aagcctgctt	cacttttccc	tgttttttagt	tgttttctcc	acattggcag	180
taaagagcct	tggcgctcca	gtagcagcag	gttctccttt	ttgtattgtg	gatgttttgc	240
atttcatact	gttgtgaaga	gtggctttga	tcatacatgt	tgttggtata	tttgccyttt	300
tgtctgggggt	gtgagaagaa	ccagagatga	gcagaggtac	acccagtaga	cttcccagcc	360
tgcagagcct	cccgggaaga	gcttccgtgt	tcaggtgctt	ggggccccwc	cctaggagcc	420
tgwctcwcag	tcagagcwg	gtcccggctt	gygttcagga	ttttgaaaca	tttgtaagggt	480
gattttgttg	tttctacacc	tttctcctca	tctttttttt	ttttagtata	atcgttacta	540
ataacagaaa	agacattttt	ggcatggtaa	ttggcacaaa	gtgaataatt	gttgaataga	600
tgacttttga	ggcttttcaa	attcgagtgt	ccataaaaatc	catccagagc	cacctgggtc	660
ctttttttga	accacttaac	gtaattcttg	aaaaccttga	ctgtgggtct	taagtttggg	720
ggattgctgc	ttctcactgg	ctgacctttg	gaggtcgcat	atttcaggat	gtgattccac	780
ttaggctcca	tttcacctga	cactgcaatt	ctgtgccttc	agagggattt	gttattgcga	840
atgatgtgga	gaacaagcgc	tgctacctgc	tcgtccatca	agccaagagg	ctgagcagcc	900
cctgcatcat	ggtggtcaac	catgatgcct	ccagcatacc	caggctccag	atagatgtgg	960
acggcaggaa	agagatcctc	ttctatgata	gaattttatg	tgatgtccct	tgcagtggag	1020
acggcactat	gagaaaaaac	attgatgttt	ggaaaaagtg	gaccacctta	aatagcttgc	1080
agctacatgg	cttacagctg	cggattgcaa	cacgcggggc	tgaacagctg	gctgaagggtg	1140
gaaggatggg	gtattccacg	tgttcactaa	accctattga	ggatgaagca	gtcatagcat	1200
ctttactgga	aaaaagtga	ggtgcttttg	agcttgctga	tgtgtctaat	gaactgccag	1260
ggctgaagtg	gatgcctgga	atcacacagt	ggaaggtaat	gacgaaagat	gggcagtggg	1320
ttacagactg	ggacgctgtt	cctcacagca	gacacaccca	gatccgacct	accatgttcc	1380
ctccgaagga	cccagaaaag	ctgcaggcca	tgcacctgga	gcgatgcctt	aggatattac	1440
cccatcatca	gaatactgga	gggttttttg	tggcagttat	ggtgaaaaaa	tcttcaatgc	1500
cgtggaataa	acgtcagcca	aagcttcagg	gtaaatctgc	agagaccaga	gaaagcacac	1560
agctgagccc	tgcagatctc	acagaaggga	aaccacacaga	tccctctaag	ctggaaagtc	1620
cgtcattcac	aggaactggg	gacacagaaa	tagctcatgc	aactgaggat	ttagagaata	1680
atggcagtaa	gaaagatggc	gtgtgtgggc	ctcctccatc	aaagaaaatg	aagtattttg	1740
gatttaaaga	agatccattt	gtattttatt	ctgaagatga	cccattattt	ccacctattg	1800
tgaaggattt	cagccttttt	aattattcat	ttaaagaaat	ttactataga	gtatcaaattg	1860
ataactgat	cacatgtaac	cattgttttg	tatgtagttc	tgtctagctt	tttttttttt	1920
ttaacctttt	taactgcata	ttagagcagg	atgaaacttt	agaggttact	caatctttta	1980
atttaaggag	aaagttaaaca	nttactttgt	gaacatgata	gataaaaaaa	aactggaccg	2040

gg

2042

<210> 57  
 <211> 584  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (469)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (509)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (519)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (531)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (536)  
 <223> n equals a,t,g, or c

<400> 57									
gtaccggtcc	ggaattcccg	ggtcgaccca	cgcgtccgca	ttttaacatc	tctaaatcag				60
gatctgtctt	ataatcaaaa	gtgcatcata	tttaacagat	ggcgtgtttt	ctttcttagt				120
agtacctaaa	gtaatacaac	ttaaaattga	tggcatttta	gatttaataa	aatatgttca				180
tttcttttgt	catttttggt	ctgggtgaggc	tttggccctg	ttgtgtagtt	at ttat ttttg				240
tttatagtat	ttgtaaacac	cagtgttctc	aagaggetca	ttcatcaata	tttaactgca				300
aatttgtttc	ccagtctcag	ttttctataa	tgtaatccat	tgtggggaag	gggaagctaa				360
aaatcagtat	tcygccagta	tttyctatat	agawgtcata	aaaccaaaaa	taccatcatg				420
tattaatatt	cctacawggt	ggcaagacag	cactttggaa	ttataaaaanc	caacttaatt				480
cctttgccaa	tgccaaaact	gggttgganc	ttccaaaanc	ccactaccca	ngggttnggag				540
ggttcaataa	taggcctaac	caaatggtaa	aaccaccacc	acaa					584

<210> 58  
 <211> 684  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (173)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE

<222> (243)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (663)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (668)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (681)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (683)  
 <223> n equals a,t,g, or c

<400> 58  
 aaaaccccat acgggcagaa cttccccagg aagcctctag gtggcagcac aaccgcacca 60  
 ctcttgaggt ctaattacta cttttctgtg gctcagtagg aaaaattctt gactatttcc 120  
 attacatctt aaacagttac catgatttgc cttaaaacta gtctcttatg aancaaacct 180  
 gatgaggcaa gttctatatt cccttttctt gattttccac catcattctt gtcctcttga 240  
 ctnttcgggt ccgttttctc agtggttgcc tgaaaaagag atttttttcc cccttgaata 300  
 aatgattcct ttaaaagtgc taaaaattat tttttaagca gtaattttta ggtcaacaaa 360  
 gtggtttggc catatgaatt ccctcttcta cttcccaggc agcttcatgg cgagagcctg 420  
 gattggttgg aaggagacat tctatggaga acaggacacc catgcggttc accatctcmc 480  
 caaacctcct atgactgcct tggacgcaca tcccmcatth tcttttcttt caccacaaa 540  
 agtcaaaaat catggctatc acctacttgt tcttgatagc ctacttggtc aagctggctt 600  
 aaggtaataa caccagtga gttcttttgt ggttctttta aggttacaat taggttcgga 660  
 ggncaaantc aaggcagaag ngna 684

<210> 59  
 <211> 2070  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (108)  
 <223> n equals a,t,g, or c

<400> 59  
 catcccacct ttttctttt cttttcacca ccaaaagctc aaaattcatg gctatcacct 60  
 acttggttct tgatagcctt acttggtcaa gctggcttag ggtcatanca ccagtgaagt 120  
 ctttttgtgg ttctttaaaag gttacaatta cttctctcagt ggctgtctt ggcatagttg 180  
 cctgtggccc ttaccattgt ggatttgagc ctgcagttct catccttctt gggctcccag 240  
 tgaatctcta ttactggagt tctaattcat tctctcttct tccctctctt cccactttc 300  
 agactactct tttctcactg gttcttactc cttttcatca aaatatgggt cattctgaaa 360  
 gatttcaact ggaccctgtt ttcttccact tgtgctgaat taccctcaa tatatcaatt 420  
 attcccattg attcaccatt acattctccg tgtataactc gtattttcat ctccagctgt 480  
 gagagtccat cagagcttcg gtttcmctc tagggccaat ggccttctcc tccaaatttg 540

acaattttctg	tttatggcag	cagttcttcc	catcacataa	actttcaagt	gatctttgac	600
tcataacctca	tgaatattca	tcatttgcca	agtccttcta	agtttctaac	atactagttt	660
tcatatcaat	catttccctt	ctgtttctat	ggctgggact	ccagggttgc	ctttcttccct	720
tgttctccac	taagaagtct	ctgtgatttg	aacctcactg	tccaatccac	ttggtacatc	780
actgtcatgt	tcactctccat	ggcacctcca	gtaattactc	taatgcttgt	gttcctctct	840
ctcagtagta	cttcaattgt	gtcagtttta	tgcttgatgg	aattttataat	agtaaaaaaa	900
attgaaacaa	cttaaataatc	caataattgg	ggaatgattg	aatgaattac	tgcatgtcca	960
taaaggcaat	ataatcatga	aaaaataaga	tggtgaataa	tagttaatga	tatgtgaaaa	1020
tacttactaa	tgataggaaa	tgtaaactgt	atacatagww	tgatgtttac	atgtatatga	1080
ttatatacat	gcctatacat	aaacatatag	aaaaaaaagat	agtaagaaaa	tacaaaaatg	1140
ttaatgtga	ttatttttta	tgtgcttaag	ttttgggtga	cttttccttc	tctttacata	1200
cattttatat	attccaaaat	gttctataat	gactatgtat	tacttctgta	attggaaaaac	1260
aaaatcaatg	taatttttaca	ttgtctttca	ctgggagcca	attgactcta	gaatgaagtc	1320
caaaattatc	ctgctattac	aaaatttact	tagtaaaaaat	aaataaaaatg	ttaaattaaa	1380
tactagctag	attatatattt	gataattaaa	gagagcaagt	taatgactat	tgcattttttt	1440
ggtagaagtt	tcttgtaaaa	agctaaagtt	aaattytara	gtgtgtatga	aatattgcat	1500
aaattttaaa	aggttttaag	ataaaggcta	aagttggttt	cagaaaaggc	attatttaact	1560
cataaaatat	ccccatgggt	tctcgagaac	tatgaattta	ttcgtctctc	ataagtatat	1620
atattttatc	cataaatcaa	attttgccctc	tcaaaatgaa	aggtatttaa	agttaatgca	1680
ttggtggaaa	ccatcactga	attcttttaa	aacaaagaaa	ttttaaacia	caaaactttc	1740
aagtttctaa	aagggttttac	aatagcatct	agtggcaaaa	atgtgatttt	tctttggagg	1800
atggagtagt	tttgaaatcc	tcataattag	atgggcattt	tctaatagaca	gatagtcatg	1860
tatcaattct	gaaagaacat	aatattaagt	taaaacacac	ttttaaaacc	ctaggcagga	1920
aatatgcac	accttggtg	ttgtaatat	ttaatatatc	aataagtctg	acttgamycc	1980
ctgcaagaga	cttaaattgag	tgagaatagt	taactgggtct	gttttgttat	atttaggtta	2040
tggtacatgt	gtgtgtttac	attgtgggct				2070

&lt;210&gt; 60

&lt;211&gt; 427

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (384)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 60

ggccgccctt	tttttttttt	tttttttttt	agagatgaag	actttctggg	ttgccaggc	60
tagtcttgaa	ctcctgggct	caagtgatcc	tcttgccctg	gcctcccaaa	gtgctgggat	120
tacagttgtg	agccaccaca	cccagctagc	ttgttatttt	ttaaattccc	aagagtaatc	180
aagggtgcga	acaactggtg	taactgatga	atatttttag	actctgtacc	tgaaaacaaa	240
tcaaactaat	gtgaatgaga	tgagactcta	aacaagggaag	aaactttaat	aaaaacaaga	300
ctttaaaacc	tattatatca	ggaataataa	ttttctaggg	ttcctgttat	ccaaatccag	360
tggcatcaga	attaccaatt	gccnaacaaa	taggatgatt	atggagagag	actagccagt	420
aagctga						427

&lt;210&gt; 61

&lt;211&gt; 341

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (51)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (54)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 61

cctgatatct	cccagtatca	tgactcaaca	gtgccccaaa	gcaactcagc	nccnccgaaa	60
cctcacacat	ggatgtgact	cgccaccac	agtgacaggc	acagccaagt	ctgatttagg	120
aagatgtttt	caaagcagag	taactcgcaa	ctttcctgga	tcattctctaa	acaaaaaaca	180
aattagggaa	tcagttttgc	cacctgctga	aggtgaactc	gcaggtgaag	ccactctgaa	240
accttctcag	gtctgagagg	ctccagtgcc	ccaggagggc	atcccatctg	ccaggagggtg	300
cccagaagat	gctaagttgt	ctcaaagcca	agggcaaaag	g		341

&lt;210&gt; 62

&lt;211&gt; 804

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (20)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (74)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (795)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 62

ctgattggcc	acasscagtn	tggcgccctct	cagtgtcagc	aggcccaggt	ttctaagtat	60
agaccccatg	cagncccgtg	gctscctagta	aatccctgga	taccatttga	tacctaaactg	120
gccctgagct	gccggcttac	ccagcatggc	ctgtgacgcc	agcctctgcc	agctgctggg	180
ggagggggta	gcacgttgcc	caaaccctac	ctcaccctcc	actggagaga	atggagacca	240
gcagtctcct	gctaatagaca	tgactggatt	gtcacagact	gggagtgacc	tcagcactca	300
actggccctg	ctctccaatt	attatcagaa	agaataactt	aatcccacct	actggagAAC	360
atatctcctg	gtttgagaga	gacaggcaga	ggcagggagc	caatgatctc	tgatgctgtc	420
actctgctcc	tcatttctgc	atccccacct	gtgtgcaccc	atgctaacc	tgagacttgt	480
cggagctggg	actgggcac	tctcaagatg	gattgggcat	ctcctatgat	ggctctgggca	540
tccatgtctt	ccgttttttg	tttgtagttc	catattttgk	tcttttagaca	gaagctgggg	600
tgggcagtaa	ttccttgag	gcagtacgga	ctyccagccg	ggttcttcag	aactttgggg	660
tatgggcaga	gagagggg	gtttgcccct	ggctttgaga	caacttaaca	tcttctgggc	720
accttctggs	agatgggatg	ccttctgggg	cactggarcc	tttagacctg	araagggttc	780
aaarggcttw	actgnagtta	cctt				804

&lt;210&gt; 63

&lt;211&gt; 1081

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

<221> SITE  
 <222> (500)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (993)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1018)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1036)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1068)  
 <223> n equals a,t,g, or c

<400> 63  
 gcggccgccc tttttttttt tttttattca tctcctcctc acccatacca agtttcaagt 60  
 tctcaaagta actacattta ttattacaaa ctatttgcca gaacaatatg cctagggcctt 120  
 tgtatacatt attttatctt taatcaactc cgcaagtaga tggagttaag tccatcttac 180  
 tgaggctcag agacttcaca gcttaacaag tggctgagca gaattgaaac ccacgtgcgc 240  
 acgattccaa acctcctcca aatattccat gctgtccact tgtaaacctg gcaaagcctt 300  
 gggatacagc agctaccttt caggggaaat tatttttttc gaagtaaatt aatttctacc 360  
 tactttcaga aaatagaagt gaggtacaga aacagctgga ttggttacag ctcctttgcc 420  
 ttatttgaac aagattcgaa cagttggcta catttgattg gcacaagtgc agtctacagt 480  
 gtttttatac ctccacttgn tatagttcat gatatacaga aaaaccttta ggctgaactt 540  
 aaaatatcta aggaggtagc tctaggctaa acttgattta acacacttct ctgccttttt 600  
 actgaacaag aaacccaacg gcagcaatgg caatgctaaa cagaaaaccc ccgctttcct 660  
 cccttggtgt tggggaaagg ggcaggcaat ggaggggcac cagaacttct ggttttaaag 720  
 aaatctgaat ttttattttt aaatggctgg cttttacatg gtgataacta attcaaactt 780  
 gtgcaaacaa aacaaattat gtccatgagg aacatggggc ttccaggcct aagcgcgag 840  
 accccatggg aagaatctga tgccctccaa ggttaatctg atcagtgagt gacatctaaa 900  
 actttatttc tgtaggcaaa cgggggagga tgcaggcccc agtagcaagt acttcagggg 960  
 accaggcttt ctcaagtagg ggcccaccct ggnaacaaag ggcccaactt tccaactnta 1020  
 caactggctc tgaganccaa tggttaacta atcaagaaag gaaagctncc caggaccggt 1080  
 c 1081

<210> 64  
 <211> 2211  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (44)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE



<222> (60)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (78)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (81)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (113)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (126)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (199)  
 <223> n equals a,t,g, or c

<400> 64  
 tctaagtcc aaaaagctta agctttcccg gtgtcaagtc aagntttgca acggtggaan 60  
 cctttgaaag ccgggtgncc ntggcttggt ctttcataat gcccaggaag tgnagaagga 120  
 aggctnagaa agcttggttt cccaagcttc tgattctcca cagggcactt ctaataaccc 180  
 ttcttctcac ccaccccgnt acggttytkaa ragatytgaa awacmccttt ccagtgga 240  
 aggggttgcca ggggttgagg gacagcacat accaccccca cccaacctgt tcgagggggc 300  
 ctgcatggca cgggatgagt ccctgccctg tgcagctgcc tggcagtggtc tgggacaagg 360  
 atcttgagc cagcacagag gcctcttcaa aggcctctcc ctcttggcac tccaggcaag 420  
 gcagggtgccc gcttcccca cactccagg cagtgcacct agggcatgcc ccagcaggtc 480  
 tccgagcagc cactgggacc cgtctcagca catcctggcc tttgaaagtc tgatatactg 540  
 agaggagggc aggttttagg gccgcagttc cagccagcgt ccccgacctg gcttccctgc 600  
 catggactca gtagctcgtg gggcttctta ccaccacca gcccgcctgg ggtgcggcct 660  
 ggctgtgggc aaaggaggac ttgcctggag atttgagaga agattccttc taccagggtc 720  
 gctgaggggc caggcctgca tcaggggcta ggctctggct gggcccgag gctgagacta 780  
 aggccttcca ccctgggtgcc tccatgtgga tgctgcctca gacaaaggca gtgagccttc 840  
 cctgccaaaag tgcccatccc atgggctcgg cctcactggt cactgttagc ccatgaacac 900  
 gtgtgggcct cggtcacgtg gctttgaggg cagtctgacc aggctagacc acacgtgccg 960  
 tgacaggggg tgccattccc ctgcagggc ctaatgtgcc cacatgtagc ctggcagtc 1020  
 aaagaccaag aatcaacttg caaatctgcc attaaactgc tgtgcgactt caggcatatc 1080  
 actgccttct ctgggcttca gtgtcctttt catacctaga agtctgcggc ctgaggtctc 1140  
 ttgggttcag acacactgtt ctaggcttct gtagrggacc ttgtgatctg ccgtgcccct 1200  
 cctccctgtt cttttctgtc ctccccaccc caccctcaga agctgcttgc tctgccccca 1260  
 ggacaggagc ttgacggatg argtgagcc agccacccag gtgccatttc cagtctgact 1320  
 tccagaaatg tgcaccatgt cctagagcac agacccattg gctggagcct cctgggaggg 1380  
 ttcaaaccat cagctctatg agaaatgccc agaaaggctt tgccgactcc atccgtctgt 1440  
 ggaggtgccc tgccctccggg gtgggatggg tggtttctcc tccaattcag acccaagagg 1500  
 tagccccga gggcatgtac ctggtgggaa gcagctcagg tacccttggg ggttgccargg 1560  
 cccttaagca gtatttctct ctctctctctc tctggggtgc gtgtgtgcgt gcgctgtgc 1620  
 ttgcctatgc ttttctctgt gggcacatca ggatgcccct cggagagcat gtgcacgtgt 1680  
 cccacctga gcgagcgtgt gtgtgtgctc ctctgcgtcc caggtttgga cgtctaggg 1740

ttgggtgtgcc	tgtcttctgc	cctccctgag	cccacagggg	cagtcaatgt	atcttctacg	1800
tgccctctccc	tctgccttct	ctcacagtgc	ccccggctcc	agagctcagg	ggtagggggt	1860
ctcctgaggg	tgaggggat	ccttctcatc	tcctggaccc	tccagggcac	tctggctccct	1920
attccccagc	tcctaggcag	ctgagccggg	tccttaggg	gaggtgacca	ggagctttgg	1980
tgacgggagc	tcttggtggg	gcaaagggct	ggacccctgc	caggtctgtg	gacatgggta	2040
tatgcccggg	agaggggggt	gcagggcccc	agggatggcc	cccaatccca	cctctgttta	2100
ttctgtaaac	tgcaacctat	aaataacctt	tagcattcct	attgtaacaa	aattaatttt	2160
tatgaaataa	attatatattc	ctagtcta	aaaaaaaaa	aaaaaaaaa	a	2211

&lt;210&gt; 65

&lt;211&gt; 1236

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (5)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (7)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (69)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (71)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (843)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 65

aactncttta	agatactctc	cccttcggag	gtgagaataa	cgaaagtgtc	agtgagtaat	60
ccaatgtent	ncatttgctc	accagacaga	aagaccaaga	gttcacctct	cctgcctatt	120
agtcacagtgc	tcgggtggcc	catgagttca	tggtggccct	gtcagaccaa	agacagtaat	180
gaatattaaa	cccagaatgc	accatattat	caggcctttt	ttgtttttgt	tttctattag	240
taacacaggt	agaagaggaa	acaactaaaa	ccccaacatt	agaggctcac	catccccacc	300
ttctggccca	ccactggcaa	tgaacccaag	cacaggtcac	tgtggtctca	tgaagaaaaa	360
ctgatgtggg	gggtgggtgg	gcttcagggg	gttgactgcc	atcttccctc	ccagcacctg	420
aaaagctaa	ttatgggtgtg	aagtcagaaa	atgtggaatc	tgcaagcctg	tctttaaaaa	480
acaaaaaaac	tcatagaact	tggactttta	tcataaagat	cattttacca	aagcatattt	540
tttaaaggct	gtgaaatatt	atgcaacgtt	tgcatgggtt	aattatgagt	ttagaaaasc	600
ctagcacgac	tttttacta	cagtaaaaca	tgacggagca	tgaatcatgg	catagtactt	660
tatgcttagt	gtggcttttag	acatgggggt	agaggtgtga	ggctgtctac	acaacaaggc	720
gtgaattact	gtactgcagt	tcacaccccc	gggggcttta	tgacagttct	gaaacctctt	780
tkgtttgctt	ttaaaatgat	taaagtattg	gagtactata	tattcactta	gtaaatgtgt	840
gtntctagta	tatacgcatg	tcttatacaa	aatatctaag	tatatgattt	ttttttcact	900
tggagcaaaa	tacttgacgt	agcatgggga	tattgaaccg	tctgctattt	ctgtttgcct	960
ttagtcattg	gaaacactgt	tagctgtaa	attacacagg	agcttcagcc	aaggttgaac	1020

atattattttc	tgctgagttt	aaaatggacc	agctcctttt	gttccttgcc	agctccttaa	1080
atcctcctaaa	atgtggaata	aaatgaagac	ctttccttaa	tattagattt	caaagattcc	1140
aagttaaact	atgtgcctgg	gaactaccag	gtttttttaa	cttaaaaaat	cagttatttt	1200
cactcacaca	caaaaaaaaa	aaaaaagggc	ggccgc			1236

&lt;210&gt; 66

&lt;211&gt; 797

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (16)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (26)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (751)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (763)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (781)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 66

gggcaaatta	ggcagntaat	ctagcngtta	gcccagatac	agcccttggg	caccctagta	60
gctgtaactt	ccagaaggca	ggaaccttcc	attcactagt	gagtcctcaa	aacagtggcc	120
caagtgaagc	aaaaatgttt	gttgggaaat	akgagygaat	gammaagtaa	tttcatgaac	180
atatgaatga	ataaatgaat	gaagcaacac	ccagtatgat	gattaatgcc	acaggaagat	240
gcctttccaa	gcatcacaa	atcctgggat	cttcactgac	tgtaagtgcc	tgtggggcag	300
ggaccatggt	ggtcttattc	atcactctcc	tgccaggtaa	attagcacat	tcctggcaca	360
ctgtaaatgt	tcaataagct	tttgttcttt	tagatggatt	gacttatcag	aggcaactct	420
ttcaagaaca	agtagccctg	tgctctggag	aatgatttac	agtggttctc	ttcctcagcc	480
tggggccttt	tctggataac	tcccatcgta	ctctyctcta	cttcctcttc	ctagaataca	540
caaatttatt	attacaggca	ccactcttca	ccccacatct	gattcttccc	tgactctgct	600
taatgtacaa	gtaaagcaaa	gaaatactgt	gtaggaccta	ttggaattag	aatcctgctc	660
tgaccaccatt	ggaaaggatt	tagggatcac	ctyccttcgg	aggtgagaat	waagaaagtg	720
gcargtgagt	aatccaatgg	caccagttg	nttaaccaag	acngaaagac	ccaagaggtt	780
nccttttctg	gctaata					797

&lt;210&gt; 67

&lt;211&gt; 534

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

<220>  
 <221> SITE  
 <222> (77)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (471)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (475)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (499)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (510)  
 <223> n equals a,t,g, or c

<400> 67	
ccttcgtagg gacagagcta tgacgtcgca tgcacgcgta agcttgggcc cctcgaggga	60
tcctctagag cggccgncct tttttttttt tttttctctc tctttctctc tctctctctc	120
actctcacc caggctgcagt gccacagtta cagctcactg catacttgaa ctctctcagtt	180
caagaaatcc tcccacctca gcctcccaag tagctgggac tatagtgcac gacaccacac	240
gtggctaatt tttaaaattt tttttggtaa aggctgaac gaccacacc ggcaaaaaaa	300
taggttttat tacatagctc ataaatgacc attcaaaagt gctttgaaca atggcaatga	360
cgtcattctc atgggtggtaa ctcagaagg cgggccaaact tcattcacat gtacagtttg	420
agttctatgg gttgtcaaag ttcattgtcac tatgttaggg ctggccttta nagtngtact	480
tctcttaagt gtgggtgtnc caaagatatn tggaaaaaat actttgctag gatg	534

<210> 68  
 <211> 1096  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (33)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (47)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (57)  
 <223> n equals a,t,g, or c

<220>

<221> SITE  
 <222> (253)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (887)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (969)  
 <223> n equals a,t,g, or c

<400> 68  
 aggtttttaa aattcccatg gaaattgaaa ttnccaccat gggcttncaa taatttnttg 60  
 aggaatTTTT ggccatattt tgaataatct gccagttcca tatgaaaaac caaagaagag 120  
 tatgttattg gccaatgttc ttaagttttt caccacacac atacacacac atacatacat 180  
 ttttttagact aggttaaaga tttatctagg tatatgtttg gaaattattc atacacatac 240  
 attacagaaa acncagtaag aaatataaaa tgtttcatac accaccagtt tgttttctgc 300  
 tagaagacac acaatgcccc tcttctgaat ctatggagat gaaggcttct ctctttcac 360  
 ccagtacgtc atttgccaca aaactgaaag ataagtctgc tttagcttct tgtttcccca 420  
 aatcaggatg aacgggtggg ctgaagaaca gctgaatcca atagcttggc agaacaatgaa 480  
 gacaggtttg ttttccagat tcttaaaact ccaaactgat attattacag acacaaagta 540  
 aatggcacat aacaagagga aggagatcac agtttgcaaa acttttatgt ggaccttggg 600  
 actgggatct tgagatcctt tgccatggag gtgcattctc ttgagatggt tacacagaga 660  
 acagactaac agcagaaaag atatcagggt tacagtaaag ggtactaagt ttgctagcat 720  
 gggtacagtc gtatctgaaa ggtacattgc acgcctcaat ttgatcttcc aagtcattgt 780  
 tccttcatac tcttttgtcc atacaatstg attcatgttt accacaaaaa gataacaagc 840  
 caaratagc aaaggcccca acagcatcac cagaatgaca ctcttancts tcctctttaa 900  
 ggccaagaaa artaaggktg gagaaattgg caatcttgag caaataaaat atgctgaggc 960  
 tagtagcang ccagttgctg aaatggcccc gttactgccc agwtattata agcagtagtt 1020  
 cttatttcta cactacaaaa agctggattc aacacagttg aatmcaattt aataataccc 1080  
 ccagagcaaa ccaact 1096

<210> 69  
 <211> 1288  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (404)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1261)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1263)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE

&lt;222&gt; (1266)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 69

atcatggtct	tgattgctat	tatcgggttc	catacgcagt	tagaaacatc	atttcttcca	60
gcttttgaat	taaagaaaag	ctgtttttga	agttgagatc	tgatgtaa	tatttttagta	120
tttttttcta	aggcacttct	aagccctga	attgctaatt	ataycctcwt	ctyccwttta	180
caaaattcct	tctaaacttc	agwtaagaga	actcaawtct	tctcttttct	aaaaaaaaaa	240
amctatcmt	gtaaaaatag	atagaaatta	tggaaaataa	ttccagtga	mctttktggt	300
aaatgttaaa	atagtatcta	tgaaatctat	gtattaatta	tgggatgtgc	cttaccattg	360
taattttgtt	gtcagtgtat	aaagtgtttt	gacatattca	ttancaggaa	gttctattat	420
aagaaagaaa	tgtacagtct	tgttcacagc	taaattctat	atgactacat	taattcttgg	480
tgttatgaag	ttttaacaat	gttattttaa	gttattttaa	ccttaagata	aatcatcccc	540
acacctgatt	tatgtaattt	tttaatcata	tatcttcttc	agtacaatgt	aagaactgta	600
aagaaagaga	tcatgtctga	cttgctttct	gttgactccc	aggacctaga	acccagcacc	660
aagaatagat	ggccaaaaat	gatactttta	tgaacaaata	aatgggtggc	taaaatggat	720
aagttgatgt	ggtaaatcaa	tgaaaaggaa	actcatcaca	aaatctgcag	ttgcatgaat	780
tccctgttc	tgggtctcagg	ttgaggttkc	aggcttatcc	aagcagaatc	cttcctcaga	840
ggaaaagttt	ggctattcca	caatttttagg	ggaaatatca	cactagtgat	atatatagt	900
atatatagtc	acactatata	tatatatagt	gatatatagt	cttgatgcag	ctgtgtcagg	960
tgtctgaatt	ggagacaagg	taaaacatca	aaattagatg	gcaccttgga	aggctgaggc	1020
ggkcggtatca	cgagggtcagg	atatcgagac	catcccggtc	actatggtga	aaccccgctc	1080
ccactaaaaa	tacaaaaaaa	ttagctggga	gtggtggtgg	gcacctgtat	tcccagctac	1140
tcggaaggct	gtggccagag	aatggcggtga	acgtgggtgg	cagagcttgc	agtgaagccga	1200
gaccgcgcca	ctgcattcca	gcctgggcga	caaacaaaaa	aaaaaaaaaa	agggcggccg	1260
ntntanagga	tccctcgagg	ggcccaag				1288

&lt;210&gt; 70

&lt;211&gt; 3319

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 70

gtgacgccgg	ggcagggccg	gaaggagtgc	agcggctgcc	acggagctcg	tagctgcagc	60
tttgaggag	taagcggcgt	ggtagcgaag	gtcgccgaac	ccgcctggct	agccggcgag	120
ttgagtggcg	actcttttga	aacagatggt	caccatgttt	agatattagc	agtcccgtat	180
gtgcatgtct	gcatttgaaa	atggaagagg	gaaacaacaa	tgaagaggta	attcacttga	240
acaactttca	ctgccatcgg	ggacaagact	ttgtaatttt	cttctggaaa	acccagatta	300
tccaaagaga	gaagacagaa	tcattataaa	tcccagtagc	agtctgctgg	ccagccaaga	360
tgagacaaaag	ttgcctaaaa	taagactttt	ttgactattc	ttaattgact	cctcttgacc	420
agcactgctt	catccaagct	gctgacctcc	tcatggccga	cttcaaagt	ctcagtagtc	480
aggacatcaw	gtgggccctg	cacgagctca	aaggacacta	tgcaatcacc	cgaaaggcct	540
tktctgatgc	cattaaaaaa	tggcaggagc	trtcaccaga	aaccagtggg	aaaaggaaga	600
agagaaaaca	aatgaaccag	tattcttaca	ttgatttcaa	gtttgaacaa	ggtgacataa	660
aaatagaaaa	gaggatgttc	tttcttgaaa	ataagcgacg	acattgtagg	tcctatgacc	720
gacgtgctct	ccttcagct	gtgcaacaag	agcaggagtt	ctatgagcag	aaaatcaaag	780
agatggcaga	gcatgaagac	tttttgcttg	ccctacagat	gaatgaagaa	cagtatcaaa	840
aggatggcca	gctgattgag	tgtcgctgct	gctatgggga	atttccattc	gaggagctga	900
cgcattgcga	gatgctcact	tgttctgcaa	agagtgtctc	atcagatatg	cccaagaggc	960
agtctttggw	tctggaaaag	tggagctcag	ctgcatggaa	ggcagctgca	cgtgttcgtt	1020
cccaaccagt	gagctggaga	aggtgctccc	ccagaccatc	ctgtataagt	actatgagcg	1080
aaaagccgag	gaggagggtg	cggcagccta	cgccgacgag	cttgtcagg	gcccgtcctg	1140
tagctttccg	gctctgttgg	acagtgatgt	gaagagggtc	agctgtccta	atcctcactg	1200
ccgaaaggaa	acctgtagga	agtgtcaggg	actctggaaa	gaacataatg	gcctcacctg	1260
tgaagagctg	gctgaaaaag	acgacatcaa	gtaccgtacc	tctattgaag	aaaaaatgac	1320
tgctgccccg	attagaaaat	gccacaagt	tgggactggc	ctcatcaaat	ctgaaggctg	1380
caaccgcagt	tcttgccgct	gtggtgccca	gatgtgctac	ctctgtcgag	tttctattaa	1440

tggatatgac	catttctgcc	aacatccccg	ctcaccagga	gccccttgcc	aggagtgttc	1500
aagatgctct	ctctggaccg	atcccactga	agatgatgag	aagcttattg	aggaaatcca	1560
gaaggaggct	gaagaggaac	agaaaagaaa	gaatggagag	aacaccttca	aacgcattgg	1620
acccccgctg	gagaagcctg	tggagaaggt	gcagagggtg	gaggccctcc	cgaggcccggt	1680
tccgcagaac	ctgccacagc	cacagatgcc	accctatgcc	ttcgcgcacc	cacccttccc	1740
cctgcctccc	gtgcggcctg	tggtcaacaa	cttcccactc	aacatggggc	ctatcccagc	1800
cccgtacgtg	ccccctctgc	ccaacgtgcg	ggtcaactat	gacttcggtc	ccatccacat	1860
gcccctggag	cacaacctgc	ccatgcactt	tggccccag	ccgcggcatc	gcttctgatg	1920
gccccgaatc	cccattgagc	agcacaaagc	ccgtttgggg	taggagtgtg	gatggagaac	1980
cctcccccaa	ggctggtgtc	tgtaccattg	catcctaagt	cagcttgaag	ggtaggctgg	2040
ttttcttccc	acccctttcc	tagaagggtc	actgctcctg	gaagagtgga	cggatccata	2100
ataaagacgt	cccaaagtgt	ggagtctcga	gagagctgcg	atgtgaactg	cccctcscct	2160
cgcatccccc	aggccaccaa	cggcagtcct	tctgccttgt	ccatggcata	ggccatagac	2220
caggtccctg	ctgctcacac	ctgggcctct	cctcggagcc	gacccctggg	tagcaaggca	2280
gccgagagca	tctccctgga	ggggcccacg	gttggggcaa	gggcagaggg	ggctgcacct	2340
gcgggcctgg	gaagcattgc	tcagggtggg	gggctgggac	catggcccg	agaggcactg	2400
ccacagctgt	gagggccaag	atgctgtccc	cccatccaaa	acccgtgcgc	cactgcagtg	2460
agtgttgagg	gcacctctcc	tcccctctta	cacctactca	gatgaggcag	cagcagaccc	2520
atctcggggc	gggggttttg	ttctgttgcc	gcctaacttt	ctcactctcg	gtctctggaa	2580
agtcaggctg	agaaatcctt	tcccaggcca	ggcgcgtgcg	gtacactgga	tggttctgaa	2640
gctggcccat	tgaagagcc	tcttaaggca	gctgggacag	aggcctgggt	gccctgctgg	2700
gcagcccaac	tgctggggga	gacgtttcts	ccaccctggg	tgatgagcag	cttttcccc	2760
ctggctttct	gggggaggag	tgggcctcct	tagggagaca	ggtgaccctg	ggtgccaccc	2820
ctgcccctg	tgtgccccgg	gtgttctcag	tggttgctga	aggcaggtag	agggtgctgt	2880
ccagtatccc	ccatgtgaag	gtcacttccc	ttctcatgga	gtcagctgag	catcagctca	2940
gccctgccat	gtccccactc	accctcctcg	cctcctgtcc	ggccctgggt	ttctagcggg	3000
gcctgaggca	tcactctggc	ccattgacag	atgagaggtc	tgaagccttc	ctggccacag	3060
gcatcacttt	ctcctctctc	tcatgccctg	ccttgctcct	gtcgtgttgc	catgggggtc	3120
tgagaggctg	ggagttcaca	gacctcagac	acagctgagt	ccgacaacca	ttgggggtgg	3180
gctgcatcag	tctccggagt	ggccccccac	ctcctgaagc	agggcctggc	ccaccaagg	3240
tgctgggggc	aggcgggcac	cgtcattcgc	tgccattggc	ttctcagatg	tatttcaagg	3300
actaaagtgg	gctctaaga					3319

&lt;210&gt; 71

&lt;211&gt; 372

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (309)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 71

ggcacgagaa	gactggagcc	tttgcggcgg	cgctgcccct	cccctgggtc	ccgcgagctc	60
ggagggcccg	gctggtgctg	cgggggcccc	gggaggtacg	gacctgggag	gcgaggtctg	120
tccggcgcta	ggatcggcct	ccgcctccgg	gccgctttag	gttgaaacta	agcatgggga	180
agagctgcaa	ggtggtcgtg	tgtggccagg	cgtctgtggg	caaaacttca	atcctggagc	240
agcttctgta	tgggaacctat	gtagtgggtt	cggagatgat	cgagacgcag	gaggacatta	300
cgtgggctnc	attgagacag	accggggggg	gcgagagcag	gtgcgtttta	tgacaaccgg	360
gggctccgag	at					372

&lt;210&gt; 72

&lt;211&gt; 337

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (326)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 72

gtgcccggct	gaagacttat	ttttaataga	cttttacaaa	gtatgcaaag	gaccagttat	60
taaaaaagac	agtaagtac	cgccctggta	aatagattct	aaaattcaat	gaataagaaa	120
cagatgaatg	tcagacttgt	cctaaaccct	tttcctctat	attctgtcta	tgatcatcct	180
aattagccct	cacccatgct	gctcttcatt	tcttctacag	aaactgaact	agacaacctt	240
ggctactcgt	ctatatactc	aattgagtaa	tttaggttca	ggatcacaac	taatttagat	300
tcataatcac	agtccagttt	tcttngttt	ttttgtg			337

&lt;210&gt; 73

&lt;211&gt; 1415

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (64)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (117)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (119)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 73

ggttttttta	aagcaagtaa	accctctcca	attgtggtat	ggctgattat	gatcatgacc	60
cagnctgtga	ggactgaggg	gcctgaaatg	aagccttggg	actgtgaatc	taaaatncnc	120
aaccaattag	aatcactagc	tcctgtgtat	aatattttca	taaatcatac	tcagtaagca	180
aaactctcaa	gcagcaagca	tatgcagcta	gtttaacaca	ttatacactt	aaaaatttta	240
tattttacctt	agagctttta	atctctgtag	gtagtttgtc	caattatgtc	acaccacaga	300
agtaagggttc	cttcacaaaag	atcccaagct	agcagatctc	ccagtcacga	cgttgtaaaa	360
cgacggccag	tgccctagctt	ataatacgac	tcactatagg	gagagagcta	tgacgtcgca	420
tgcacgcgta	agcttggggc	cctcgaggga	tcctctagag	cggccgcgtg	ggctatgggg	480
cggcggtcgc	ggggctggcg	gctccagcaa	cagcagcggc	cggaggacgc	ggaggatggc	540
gccgagggtg	gtggaaagcg	cggcgaggcg	ggctgggaag	gaggctaccc	cgagatcgtc	600
aaggagaaca	agctgttcga	gcactactac	caggagctca	agatcgtgcc	cgagggcgag	660
tggggccagt	tcattggacgc	tctcaggag	cgcctcccg	ccactttaag	aattactggg	720
tacaaaagcc	acgcaaaaga	gattctccat	tgcttaaaaga	acaaatattt	taagggaattg	780
gaggacctgg	aggtggacgg	tcagaaagtt	gaagtccac	agccactgag	ttgggtatcct	840
gaagaacttg	cctggcacac	aaatttaagt	cgaaaaatct	tgagaaaatc	gccacacttg	900
gaaaagtttc	atcagtttct	agttagttaa	acagaatctg	gaaatattag	tcgtcaagaa	960
gctgttagca	tgatccacc	actgctcctc	aacgtgcggc	ctcatcataa	gatcttagat	1020
atgtgtgcag	cacctggctc	aaagaccaca	cagttaattg	aaatgctaca	tgccgacatg	1080
aatgtccctt	ttccagaggg	atgtgttatt	gcgaatgatg	tggaacaaca	gcgctgctac	1140
ctgctcgccc	atcaagccaa	gaggctgagc	agcccttgca	tcattggtgg	caaccatgat	1200
gcctccagca	taccagggct	ccagatagat	gtggacggca	ggaaagagat	cctcttctat	1260
gatsgatttt	atgtgatgtc	ccttgcagtg	gaacggcact	atgagaaara	acatgatggt	1320



tkgaaaaagt ggaccwccgg tgccgattct tggcctcggg ggcaagattc ctatgagtgg 1380  
 tgcgattaaa tccgtatcag tgcaaagcgg ttcct 1415

<210> 74

<211> 283

<212> PRT

<213> Homo sapiens

<400> 74

Met Ile Phe Leu Leu Leu Met Leu Ser Leu Glu Leu Gln Leu His Gln  
 1 5 10 15

Ile Ala Ala Leu Phe Thr Val Thr Val Pro Lys Glu Leu Tyr Ile Ile  
 20 25 30

Glu His Gly Ser Asn Val Thr Leu Glu Cys Asn Phe Asp Thr Gly Ser  
 35 40 45

His Val Asn Leu Gly Ala Ile Thr Ala Ser Leu Gln Lys Val Glu Asn  
 50 55 60

Asp Thr Ser Pro His Arg Glu Arg Ala Thr Leu Leu Glu Glu Gln Leu  
 65 70 75 80

Pro Leu Gly Lys Ala Ser Phe His Ile Pro Gln Val Gln Val Arg Asp  
 85 90 95

Glu Gly Gln Tyr Gln Cys Ile Ile Ile Tyr Gly Val Ala Trp Asp Tyr  
 100 105 110

Lys Tyr Leu Thr Leu Lys Val Lys Ala Ser Tyr Arg Lys Ile Asn Thr  
 115 120 125

His Ile Leu Lys Val Pro Glu Thr Asp Glu Val Glu Leu Thr Cys Gln  
 130 135 140

Ala Thr Gly Tyr Pro Leu Ala Glu Val Ser Trp Pro Asn Val Ser Val  
 145 150 155 160

Pro Ala Asn Thr Ser His Ser Arg Thr Pro Glu Gly Leu Tyr Gln Val  
 165 170 175

Thr Ser Val Leu Arg Leu Lys Pro Pro Pro Gly Arg Asn Phe Ser Cys  
 180 185 190

Val Phe Trp Asn Thr His Val Arg Glu Leu Thr Leu Ala Ser Ile Asp  
 195 200 205

Leu Gln Ser Gln Met Glu Pro Arg Thr His Pro Thr Trp Leu Leu His  
 210 215 220

Ile Phe Ile Pro Ser Cys Ile Ile Ala Phe Ile Phe Ile Ala Thr Val  
 225 230 235 240

Ile Ala Leu Arg Lys Gln Leu Cys Gln Lys Leu Tyr Ser Ser Lys Asp  
 245 250 255

55

Thr Thr Lys Arg Pro Val Thr Thr Thr Lys Arg Glu Val Asn Ser Ala  
 260 265 270

Val Asn Leu Asn Leu Trp Ser Trp Glu Pro Gly  
 275 280

<210> 75  
 <211> 184  
 <212> PRT  
 <213> Homo sapiens

<400> 75  
 Met Ser Arg Thr Ala Tyr Thr Val Gly Ala Leu Leu Leu Leu Leu Gly  
 1 5 10 15  
 Thr Leu Leu Pro Ala Ala Glu Gly Lys Lys Lys Gly Ser Gln Gly Ala  
 20 25 30  
 Ile Pro Pro Pro Asp Lys Ala Gln His Asn Asp Ser Glu Gln Thr Gln  
 35 40 45  
 Ser Pro Gln Gln Pro Gly Ser Arg Asn Arg Gly Arg Gly Gln Gly Arg  
 50 55 60  
 Gly Thr Ala Met Pro Gly Glu Glu Val Leu Glu Ser Ser Gln Glu Ala  
 65 70 75 80  
 Leu His Val Thr Glu Arg Lys Tyr Leu Lys Arg Asp Trp Cys Lys Thr  
 85 90 95  
 Gln Pro Leu Lys Gln Thr Ile His Glu Glu Gly Cys Asn Ser Arg Thr  
 100 105 110  
 Ile Ile Asn Arg Phe Cys Tyr Gly Gln Cys Asn Ser Phe Tyr Ile Pro  
 115 120 125  
 Arg His Ile Arg Lys Glu Glu Gly Ser Phe Gln Ser Cys Ser Phe Cys  
 130 135 140  
 Lys Pro Lys Lys Phe Thr Thr Met Met Val Thr Leu Asn Cys Pro Glu  
 145 150 155 160  
 Leu Gln Pro Pro Thr Lys Lys Lys Arg Val Thr Arg Val Lys Gln Cys  
 165 170 175  
 Arg Cys Ile Ser Ile Asp Leu Asp  
 180

<210> 76  
 <211> 716  
 <212> PRT  
 <213> Homo sapiens

<400> 76  
 Met Asn Asn Phe Arg Ala Thr Ile Leu Phe Trp Ala Ala Ala Ala Trp  
 1 5 10 15

Ala Lys Ser Gly Lys Pro Ser Gly Glu Met Asp Glu Val Gly Val Gln  
                     20                    25                    30  
 Lys Cys Lys Asn Ala Leu Lys Leu Pro Val Leu Glu Val Leu Pro Gly  
                     35                    40                    45  
 Gly Gly Trp Asp Asn Leu Arg Asn Val Asp Met Gly Arg Val Met Glu  
                     50                    55                    60  
 Leu Thr Tyr Ser Asn Cys Arg Thr Thr Glu Asp Gly Gln Tyr Ile Ile  
                     65                    70                    75                    80  
 Pro Asp Glu Ile Phe Thr Ile Pro Gln Lys Gln Ser Asn Leu Glu Met  
                     85                    90                    95  
 Asn Ser Glu Ile Leu Glu Ser Trp Ala Asn Tyr Gln Ser Ser Thr Ser  
                     100                    105                    110  
 Tyr Ser Ile Asn Thr Glu Leu Ser Leu Phe Ser Lys Val Asn Gly Lys  
                     115                    120                    125  
 Phe Ser Thr Glu Phe Gln Arg Met Lys Thr Leu Gln Val Lys Asp Gln  
                     130                    135                    140  
 Ala Ile Thr Thr Arg Val Gln Val Arg Asn Leu Val Tyr Thr Val Lys  
                     145                    150                    155                    160  
 Ile Asn Pro Thr Leu Glu Leu Ser Ser Gly Phe Arg Lys Glu Leu Leu  
                     165                    170                    175  
 Asp Ile Ser Asp Arg Leu Glu Asn Asn Gln Thr Arg Met Ala Thr Tyr  
                     180                    185                    190  
 Leu Ala Glu Leu Leu Val Leu Asn Tyr Gly Thr His Val Thr Thr Ser  
                     195                    200                    205  
 Val Asp Ala Gly Ala Ala Leu Ile Gln Glu Asp His Leu Arg Ala Ser  
                     210                    215                    220  
 Phe Leu Gln Asp Ser Gln Ser Ser Arg Ser Ala Val Thr Ala Ser Ala  
                     225                    230                    235                    240  
 Gly Leu Ala Phe Gln Asn Thr Val Asn Phe Lys Phe Glu Glu Asn Tyr  
                     245                    250                    255  
 Thr Ser Gln Asn Val Leu Thr Lys Ser Tyr Leu Ser Asn Arg Thr Asn  
                     260                    265                    270  
 Ser Arg Val Gln Ser Ile Gly Gly Val Pro Phe Tyr Pro Gly Ile Thr  
                     275                    280                    285  
 Leu Gln Ala Trp Gln Gln Gly Ile Thr Asn His Leu Val Ala Ile Asp  
                     290                    295                    300  
 Arg Ser Gly Leu Pro Leu His Phe Phe Ile Asn Pro Asn Met Leu Pro  
                     305                    310                    315                    320

Asp Leu Pro Gly Pro Leu Val Lys Lys Val Ser Lys Thr Val Glu Thr  
 325 330 335  
 Ala Val Lys Arg Tyr Tyr Thr Phe Asn Thr Tyr Pro Gly Cys Thr Asp  
 340 345 350  
 Leu Asn Ser Pro Asn Phe Asn Phe Gln Ala Asn Thr Asp Asp Gly Ser  
 355 360 365  
 Cys Glu Gly Lys Met Thr Asn Phe Ser Phe Gly Gly Val Tyr Gln Glu  
 370 375 380  
 Cys Thr Gln Leu Ser Gly Asn Arg Asp Val Leu Leu Cys Gln Lys Leu  
 385 390 395 400  
 Glu Gln Lys Asn Pro Leu Thr Gly Asp Phe Ser Cys Pro Ser Gly Tyr  
 405 410 415  
 Ser Pro Val His Leu Leu Ser Gln Ile His Glu Glu Gly Tyr Asn His  
 420 425 430  
 Leu Glu Cys His Arg Lys Cys Thr Leu Leu Val Phe Cys Lys Thr Val  
 435 440 445  
 Cys Glu Asp Val Phe Gln Val Ala Lys Ala Glu Phe Arg Ala Phe Trp  
 450 455 460  
 Cys Val Ala Ser Ser Gln Val Pro Glu Asn Ser Gly Leu Leu Phe Gly  
 465 470 475 480  
 Gly Leu Phe Ser Ser Lys Ser Ile Asn Pro Met Thr Asn Ala Gln Ser  
 485 490 495  
 Cys Pro Ala Gly Tyr Phe Pro Leu Arg Leu Phe Glu Asn Leu Lys Val  
 500 505 510  
 Cys Val Ser Gln Asp Tyr Glu Leu Gly Ser Arg Phe Ala Val Pro Phe  
 515 520 525  
 Gly Gly Phe Phe Ser Cys Thr Val Gly Asn Pro Leu Val Asp Pro Ala  
 530 535 540  
 Ile Ser Arg Asp Leu Gly Ala Pro Ser Leu Lys Lys Cys Pro Gly Gly  
 545 550 555 560  
 Phe Ser Gln His Pro Ala Leu Ile Ser Asp Gly Cys Gln Val Ser Tyr  
 565 570 575  
 Cys Val Lys Ser Gly Leu Phe Thr Gly Gly Ser Leu Pro Pro Ala Arg  
 580 585 590  
 Leu Pro Pro Phe Thr Arg Pro Pro Leu Met Ser Gln Ala Ala Thr Asn  
 595 600 605  
 Thr Val Ile Val Thr Asn Ser Glu Asn Ala Arg Ser Trp Ile Lys Asp  
 610 615 620  
 Ser Gln Thr His Gln Trp Arg Leu Gly Glu Pro Ile Glu Leu Arg Arg

58

625                                  630                                  635                                  640

Ala Met Asn Val Ile His Gly Asp Gly Gly Gly Leu Ser Gly Gly Ala  
    645                                  650                                  655

Ala Ala Gly Val Thr Val Gly Val Thr Thr Ile Leu Ala Val Val Ile  
    660                                  665                                  670

Thr Leu Ala Ile Tyr Gly Thr Arg Lys Phe Lys Lys Lys Ala Tyr Gln  
    675                                  680                                  685

Ala Ile Glu Glu Arg Gln Ser Leu Val Pro Gly Thr Ala Ala Thr Gly  
    690                                  695                                  700

Asp Thr Thr Tyr Gln Glu Gln Gly Gln Ser Pro Ala  
 705                                  710                                  715

&lt;210&gt; 77

&lt;211&gt; 617

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 77

Met Phe Arg Thr Ala Val Met Met Ala Ala Ser Leu Ala Leu Thr Gly  
   1                                  5                                  10                                  15

Ala Val Val Ala His Ala Tyr Tyr Leu Lys His Gln Phe Tyr Pro Thr  
    20                                  25                                  30

Val Val Tyr Leu Thr Lys Ser Ser Pro Ser Met Ala Val Leu Tyr Ile  
    35                                  40                                  45

Gln Ala Phe Val Leu Val Phe Leu Leu Gly Lys Val Met Gly Lys Val  
   50                                  55                                  60

Phe Phe Gly Gln Leu Arg Ala Ala Glu Met Glu His Leu Leu Glu Arg  
   65                                  70                                  75                                  80

Ser Trp Tyr Ala Val Thr Glu Thr Cys Leu Ala Phe Thr Val Phe Arg  
    85                                  90                                  95

Asp Asp Phe Ser Pro Arg Phe Val Ala Leu Phe Thr Leu Leu Leu Phe  
    100                                  105                                  110

Leu Lys Cys Phe His Trp Leu Ala Glu Asp Arg Val Asp Phe Met Glu  
    115                                  120                                  125

Arg Ser Pro Asn Ile Ser Trp Leu Phe His Cys Arg Ile Val Ser Leu  
   130                                  135                                  140

Met Phe Leu Leu Gly Ile Leu Asp Phe Leu Phe Val Ser His Ala Tyr  
   145                                  150                                  155                                  160

His Ser Ile Leu Thr Arg Gly Ala Ser Val Gln Leu Val Phe Gly Phe  
    165                                  170                                  175

Glu Tyr Ala Ile Leu Met Thr Met Val Leu Thr Ile Phe Ile Lys Tyr

180	185	190
Val Leu His Ser Val Asp Leu Gln Ser Glu Asn Pro Trp Asp Asn Lys		
195	200	205
Ala Val Tyr Met Leu Tyr Thr Glu Leu Phe Thr Gly Phe Ile Lys Val		
210	215	220
Leu Leu Tyr Met Ala Phe Met Thr Ile Met Ile Lys Val His Thr Phe		
225	230	235
Pro Leu Phe Ala Ile Arg Pro Met Tyr Leu Ala Met Arg Gln Phe Lys		
245	250	255
Lys Ala Val Thr Asp Ala Ile Met Ser Arg Arg Ala Ile Arg Asn Met		
260	265	270
Asn Thr Leu Tyr Pro Asp Ala Thr Pro Glu Glu Leu Gln Ala Met Asp		
275	280	285
Asn Val Cys Ile Ile Cys Arg Glu Glu Met Val Thr Gly Ala Lys Arg		
290	295	300
Leu Pro Cys Asn His Ile Phe His Thr Ser Cys Leu Arg Ser Trp Phe		
305	310	315
Gln Arg Gln Gln Thr Cys Pro Thr Cys Arg Met Asp Val Leu Arg Ala		
325	330	335
Ser Leu Pro Ala Gln Ser Pro Pro Pro Pro Glu Pro Ala Asp Gln Gly		
340	345	350
Pro Pro Pro Ala Pro His Pro Pro Pro Leu Leu Pro Gln Pro Pro Asn		
355	360	365
Phe Pro Gln Gly Leu Leu Pro Pro Phe Pro Pro Gly Met Phe Pro Leu		
370	375	380
Trp Pro Pro Met Gly Pro Phe Pro Pro Val Pro Pro Pro Pro Ser Ser		
385	390	395
Gly Glu Ala Val Ala Pro Pro Ser Thr Ser Ala Ala Ala Leu Ser Arg		
405	410	415
Pro Ser Gly Ala Ala Thr Thr Thr Ala Ala Gly Thr Ser Ala Thr Ala		
420	425	430
Ala Ser Ala Thr Ala Ser Gly Pro Gly Ser Gly Ser Ala Pro Glu Ala		
435	440	445
Gly Pro Ala Pro Gly Phe Pro Phe Pro Pro Pro Trp Met Gly Met Pro		
450	455	460
Leu Pro Pro Pro Phe Ala Phe Pro Pro Met Pro Val Pro Pro Ala Gly		
465	470	475
Phe Ala Gly Leu Thr Pro Glu Glu Leu Arg Ala Leu Glu Gly His Glu		
485	490	495

Arg Gln His Leu Glu Ala Arg Leu Gln Ser Leu Arg Asn Ile His Thr  
                   500                                  505                                  510  
 Leu Leu Asp Ala Ala Met Leu Gln Ile Asn Gln Tyr Leu Thr Val Leu  
                   515                                  520                                  525  
 Ala Ser Leu Gly Pro Pro Arg Pro Ala Thr Ser Val Asn Ser Thr Glu  
                   530                                  535                                  540  
 Glu Thr Ala Thr Thr Val Val Ala Ala Ala Ser Ser Thr Ser Ile Pro  
 545                                  550                                  555                                  560  
 Ser Ser Glu Ala Thr Thr Pro Thr Pro Gly Ala Ser Pro Pro Ala Pro  
                                   565                                  570                                  575  
 Glu Met Glu Arg Pro Pro Ala Pro Glu Ser Val Gly Thr Glu Glu Met  
                                   580                                  585                                  590  
 Pro Glu Asp Gly Glu Pro Asp Ala Ala Glu Leu Arg Arg Arg Arg Leu  
                   595                                  600                                  605  
 Gln Lys Leu Glu Ser Pro Val Ala His  
                   610                                  615

<210> 78

<211> 288

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (87)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (99)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (230)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (263)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (264)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

&lt;222&gt; (270)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (275)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 78

Met	Ala	Arg	Ile	Ser	Phe	Ser	Tyr	Leu	Cys	Pro	Ala	Ser	Trp	Tyr	Phe
1				5					10					15	

Thr	Val	Pro	Thr	Val	Ser	Pro	Phe	Leu	Arg	Gln	Arg	Val	Ala	Phe	Leu
			20					25					30		

Gly	Leu	Phe	Phe	Ile	Ser	Cys	Leu	Leu	Leu	Leu	Met	Leu	Ile	Ile	Asp
		35					40					45			

Phe	Arg	His	Trp	Ser	Ala	Ser	Leu	Pro	Arg	Asp	Arg	Gln	Tyr	Glu	Arg
	50					55					60				

Tyr	Leu	Ala	Arg	Val	Gly	Glu	Leu	Glu	Ala	Thr	Asp	Thr	Glu	Asp	Pro
65					70					75					80

Asn	Leu	Asn	Tyr	Gly	Leu	Xaa	Val	Asp	Cys	Gly	Ser	Ser	Gly	Ser	Arg
				85					90					95	

Ile	Phe	Xaa	Tyr	Phe	Trp	Pro	Arg	His	Asn	Gly	Asn	Pro	His	Asp	Leu
			100					105					110		

Leu	Asp	Ile	Lys	Gln	Met	Arg	Asp	Arg	Asn	Ser	Gln	Pro	Val	Val	Lys
		115					120					125			

Lys	Ile	Lys	Pro	Gly	Ile	Ser	Ala	Met	Ala	Asp	Thr	Pro	Glu	His	Ala
	130					135					140				

Ser	Asp	Tyr	Leu	Arg	Pro	Leu	Leu	Ser	Phe	Ala	Ala	Ala	His	Val	Pro
145					150					155					160

Val	Lys	Lys	His	Lys	Glu	Thr	Pro	Leu	Tyr	Ile	Leu	Cys	Thr	Ala	Gly
			165						170					175	

Met	Arg	Leu	Leu	Pro	Glu	Arg	Lys	Gln	Leu	Ala	Ile	Leu	Ala	Asp	Leu
		180						185					190		

Val	Lys	Asp	Leu	Pro	Leu	Glu	Phe	Asp	Phe	Leu	Phe	Ser	Gln	Ser	Gln
		195					200					205			

Ala	Glu	Val	Ile	Ser	Gly	Lys	Gln	Glu	Gly	Val	Tyr	Ala	Trp	Ile	Gly
	210					215					220				

Ile	Asn	Phe	Val	Leu	Xaa	Arg	Phe	Asp	His	Glu	Asp	Glu	Ser	Asp	Ala
225					230					235					240

Glu	Ala	Thr	Gln	Glu	Leu	Ala	Ala	Gly	Arg	Arg	Arg	Thr	Val	Gly	Ile
			245						250					255	

Leu	Asp	Met	Gly	Gly	Ala	Xaa	Xaa	Gln	Ile	Ala	Tyr	Glu	Xaa	Pro	Thr
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----



62

260	265	270
Phe Pro Xaa Lys Lys Thr Pro	Pro Leu Phe Pro Leu	Leu Gly Gly Ile
275	280	285

<210> 79  
 <211> 83  
 <212> PRT  
 <213> Homo sapiens

<400> 79  
 Gly His Val Leu Ala Tyr Ser Ser Trp Pro Ser Leu Ala Pro Gly Leu  
 1 5 10 15  
 Ser Val Gln Tyr Phe Val Ser Arg Val Glu Val Pro Asn Pro Gly Cys  
 20 25 30  
 Thr Leu Glu Ala Pro Gly Lys Leu Ser Glu Phe Leu Arg Pro Glu Pro  
 35 40 45  
 His Pro Lys Pro Ile Ser Ser Glu Ser Leu Gly Gly Thr Glu Pro Gly  
 50 55 60  
 Phe Cys Gln Leu Lys Pro Ala Met Val Thr Ser Val Ser Ser Tyr Thr  
 65 70 75 80  
 Glu Asn Ser

<210> 80  
 <211> 39  
 <212> PRT  
 <213> Homo sapiens

<400> 80  
 Met His Leu Leu Pro Trp Arg Ala Ala Ala Ala Pro Pro Leu Leu Ile  
 1 5 10 15  
 Ala Val Pro Pro Arg Pro Ser Arg Ser Pro Val Gln Pro Pro Ser Leu  
 20 25 30  
 Gly Ala Ala Asn Pro Ser Ala  
 35

<210> 81  
 <211> 41  
 <212> PRT  
 <213> Homo sapiens

<400> 81  
 Met Ala Phe Pro Arg Val Gly Ala Phe Leu Phe Leu Ala Ser Leu Ser  
 1 5 10 15

63

Ser Leu Leu His Cys Arg Leu Leu Ala Glu Ala Val Ser Gly Arg Ser  
20 25 30

Val Ser Leu Ala Pro Ser Ile Ile Arg  
35 40

<210> 82  
<211> 50  
<212> PRT  
<213> Homo sapiens

<400> 82  
Met Glu Glu Val Ala Phe Met Val Leu Lys Tyr Val Leu Pro Phe Leu  
1 5 10 15

Lys Ser Leu Trp Leu His Val Tyr Leu Leu Ala Val Leu Trp Pro Arg  
20 25 30

Leu Ala Ser Met Ile Ser Phe Gly Ser Arg Leu Phe Gln Ile Val Asp  
35 40 45

Gly Ala  
50

<210> 83  
<211> 62  
<212> PRT  
<213> Homo sapiens

<400> 83  
Met Leu Cys Pro Ala Leu Gly Pro Phe Leu Leu Phe Leu Leu Ser Ser  
1 5 10 15

Thr Leu Met Ala Ser Phe Met Gly Asp Thr Pro Cys His Pro Gly Glu  
20 25 30

Leu Ser Ala Phe Gly Val Ala Pro Ser Arg Val Phe Thr Ser Ser Phe  
35 40 45

Leu Phe Thr Val Phe Thr Pro Ser Tyr Pro Ser Leu Pro Gly  
50 55 60

<210> 84  
<211> 371  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (20)  
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 84  
Met Leu Phe Pro Ser Phe Ser Arg Ser Leu Val Pro Leu Pro His Ala

64

1	5	10	15
Leu Tyr Leu Xaa Gln Pro Leu Thr His Thr Thr Ser Leu Leu Ala Gly	20	25	30
Ile Gly Pro Val Leu Gly Leu Val Cys Val Pro Leu Leu Gly Ser Ala	35	40	45
Ser Asp His Trp Arg Gly Arg Tyr Gly Arg Arg Arg Pro Phe Ile Trp	50	55	60
Ala Leu Ser Leu Gly Ile Leu Leu Ser Leu Phe Leu Ile Pro Arg Ala	65	70	75
Gly Trp Leu Ala Gly Leu Leu Cys Pro Asp Pro Arg Pro Leu Glu Leu	85	90	95
Ala Leu Leu Ile Leu Gly Val Gly Leu Leu Asp Phe Cys Gly Gln Val	100	105	110
Cys Phe Thr Pro Leu Glu Ala Leu Leu Ser Asp Leu Phe Arg Asp Pro	115	120	125
Asp His Cys Arg Gln Ala Tyr Ser Val Tyr Ala Phe Met Ile Ser Leu	130	135	140
Gly Gly Cys Leu Gly Tyr Leu Leu Pro Ala Ile Asp Trp Asp Thr Ser	145	150	155
Ala Leu Ala Pro Tyr Leu Gly Thr Gln Glu Glu Cys Leu Phe Gly Leu	165	170	175
Leu Thr Leu Ile Phe Leu Thr Cys Val Ala Ala Thr Leu Leu Val Ala	180	185	190
Glu Glu Ala Ala Leu Gly Pro Thr Glu Pro Ala Glu Gly Leu Ser Ala	195	200	205
Pro Ser Leu Ser Pro His Cys Cys Pro Cys Arg Ala Arg Leu Ala Phe	210	215	220
Arg Asn Leu Gly Ala Leu Leu Pro Arg Leu His Gln Leu Cys Cys Arg	225	230	235
Met Pro Arg Thr Leu Arg Arg Leu Phe Val Ala Glu Leu Cys Ser Trp	245	250	255
Met Ala Leu Met Thr Phe Thr Leu Phe Tyr Thr Asp Phe Val Gly Glu	260	265	270
Gly Leu Tyr Gln Gly Val Pro Arg Ala Glu Pro Gly Thr Glu Ala Arg	275	280	285
Arg His Tyr Asp Glu Gly Lys Ala Leu Ala Ala Ser Arg Gly Trp Cys	290	295	300
Gly Ser Arg Pro Pro Glu Thr Thr Leu Gly Ala Val Ser Gly Leu Val	305	310	315
			320

Pro Leu His Pro Gly Pro Asp Phe Ser Val Arg Lys Val Gly Met Asp  
325 330 335

Pro Ile Cys Ile His Gly Phe Ser Trp Val Trp Asn Ile Ser Ala Cys  
340 345 350

Gly Phe Arg Lys Ala Ser Gly Cys Ser Arg Ser Leu Ile Arg Val Val  
355 360 365

Ala Pro Val  
370

<210> 85

<211> 46

<212> PRT

<213> Homo sapiens

<400> 85

Met Pro Trp Leu Lys Ser Leu Leu His Phe Ser Leu Phe Leu Val Val  
1 5 10 15

Phe Ser Thr Leu Ala Val Lys Ser Leu Gly Val Pro Val Ala Ala Gly  
20 25 30

Ser Pro Phe Cys Ile Val Asp Val Leu His Phe Ile Leu Leu  
35 40 45

<210> 86

<211> 53

<212> PRT

<213> Homo sapiens

<400> 86

Met Phe Ile Ser Leu Phe Ile Phe Gly Leu Val Arg Leu Trp Pro Cys  
1 5 10 15

Cys Val Val Ile Tyr Phe Val Tyr Ser Ile Cys Lys His Gln Cys Ser  
20 25 30

Gln Glu Ala His Ser Ser Ile Phe Asn Cys Lys Phe Val Ser Gln Ser  
35 40 45

Gln Phe Ser Ile Met  
50

<210> 87

<211> 73

<212> PRT

<213> Homo sapiens

<400> 87

Met Trp Leu Pro Ala Trp Ala Ala Ile Glu Thr Phe Ser Thr Cys Ser  
1 5 10 15

66

Ser Leu Ser Leu Ser Phe Gln Pro Arg Trp Ala Leu Ala Ser Glu Gly  
                   20                  25                  30

Cys Ala Gly Ser Tyr Val Thr Thr His Arg Ala Leu Gly Ala His Leu  
                   35                  40                  45

Trp Pro Leu Trp Ser Asp Gln Phe Leu Gly Lys Gly Leu Gly Leu Arg  
           50                  55                  60

Ile Pro Phe Ile Thr His Ala His Gln  
   65                  70

<210> 88  
 <211> 80  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (25)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 88  
 Met Gly Thr Ser Thr Ala Trp Arg Val Pro Trp Arg Arg Trp Ala Arg  
   1                  5                  10                  15

Val Arg Cys Trp Trp Leu Trp Pro Xaa Thr Gly Thr Ala Glu Pro Pro  
           20                  25                  30

Gly Thr Ala Gly Trp Gln Gly Leu Ala Gly Gly Arg Cys Arg Glu Ala  
           35                  40                  45

Trp Gly Ser Leu Leu Met Gly Met Phe Gly Leu Cys Phe Leu Pro Val  
   50                  55                  60

His Ser Gln Ser Cys Leu Ser Ser Ser Ser Ser Pro Thr Pro Arg Pro  
   65                  70                  75                  80

<210> 89  
 <211> 36  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (17)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 89  
 Met Ala Gly Glu Glu Met Ala Trp Gly Ala Arg Leu Trp Ile Met Cys  
   1                  5                  10                  15

Xaa Leu Leu Phe Leu Ala Ala Ser Glu Gly Ile Met Pro Arg Leu Arg

20 25 30

Ala Ser Ala Trp  
35

<210> 90  
<211> 40  
<212> PRT  
<213> Homo sapiens

<400> 90  
Met Ile Leu Tyr Ile Cys Leu Leu Leu Lys Ile Trp Gly Cys Ser Leu  
1 5 10 15  
Pro Cys Asn Phe Ser Phe Pro Leu Asp Leu Arg Lys Val Met Asp Phe  
20 25 30  
Gln Phe Val Gln His Phe Phe Leu  
35 40

<210> 91  
<211> 63  
<212> PRT  
<213> Homo sapiens

<400> 91  
Met Ile Thr Phe Leu Pro Ile Ile Phe Ser Ile Leu Val Val Val Thr  
1 5 10 15  
Phe Val Ile Gly Asn Phe Ala Asn Gly Phe Ile Ala Leu Val Asn Ser  
20 25 30  
Thr Glu Trp Val Lys Arg Gln Lys Ile Ser Phe Ala Asp Gln Ile Val  
35 40 45  
Thr Ala Leu Ala Val Ser Arg Val Gly Leu Leu Trp Val Leu Leu  
50 55 60

<210> 92  
<211> 86  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (2)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (25)  
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 92  
Ser Xaa Ile Val Gly Leu Ala Ile Trp Arg Gly Gly Leu Cys Gln Glu

68

1                      5                      10                      15  
 Leu Pro Leu Glu Arg Phe Leu Leu Xaa Thr Val Phe Gly Ser Asp Leu  
                             20                      25                      30  
 Ser Leu Leu Ser Gly Gly Asp Leu Cys Leu Glu Leu Leu Gly Gly Leu  
                             35                      40                      45  
 Cys Leu Glu Val Cys Leu Arg Gly Asp Ile Cys Leu Gly Pro Leu Arg  
                             50                      55                      60  
 Val Ser Val Ser Glu Leu Ser Leu Leu Cys Leu Ser Val Gln Gly Gln  
                             65                      70                      75                      80  
 Gln Lys Val Cys Pro Phe  
                             85

<210> 93  
 <211> 20  
 <212> PRT  
 <213> Homo sapiens

<400> 93  
 Met Asn Val Arg Leu Val Leu Asn Pro Phe Pro Leu Tyr Ser Val Tyr  
                             1                      5                      10                      15  
 Val Ile Pro Asn  
                             20

<210> 94  
 <211> 75  
 <212> PRT  
 <213> Homo sapiens

<400> 94  
 Met Gly Pro Leu Trp Gly Ala Pro Leu Arg Ala Trp Ala Ala Gly Ser  
                             1                      5                      10                      15  
 Val Gly Cys Pro Cys Cys Leu Ser Cys Ala Ser Pro Ser Ser Ile Ser  
                             20                      25                      30  
 Ser Ala Gly Asp Pro Leu Ala Ser Cys Ser Thr Cys Gly Ser Thr Trp  
                             35                      40                      45  
 Glu Ile Pro Leu Thr Trp Met Thr Met Asp His Leu Leu Val Arg Tyr  
                             50                      55                      60  
 Tyr Leu Ser Gln Ala Arg Trp Cys Thr Thr Gly  
                             65                      70                      75

<210> 95  
 <211> 23  
 <212> PRT  
 <213> Homo sapiens

69

&lt;400&gt; 95

Leu Phe Leu Leu Leu Glu Ile Ser Thr His Leu Cys Phe Trp Lys Ser  
 1 5 10 15

Leu Arg Lys Leu Glu Gly Lys  
 20

&lt;210&gt; 96

&lt;211&gt; 93

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (89)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (92)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 96

Met Ile Phe Leu Leu Leu Met Leu Ser Leu Glu Leu Gln Leu His Gln  
 1 5 10 15

Ile Ala Ala Leu Phe Thr Val Thr Val Pro Lys Glu Leu Tyr Ile Ile  
 20 25 30

Glu His Gly Ser Asn Val Thr Leu Glu Cys Asn Phe Asp Thr Gly Ser  
 35 40 45

His Val Asn Leu Gly Ala Ile Thr Ala Ser Leu Gln Lys Val Glu Asn  
 50 55 60

Asp Thr Ser Pro His Arg Glu Arg Ala Thr Leu Leu Glu Glu Gln Leu  
 65 70 75 80

Pro Leu Gly Lys Ala Ser Phe Pro Xaa Leu Lys Xaa Lys  
 85 90

&lt;210&gt; 97

&lt;211&gt; 77

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (8)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (9)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids



70

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (10)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (16)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 97

Leu	Gly	Gly	Tyr	Ala	Leu	Ser	Xaa	Xaa	Xaa	Asn	Arg	Val	Thr	Asp	Xaa
1				5					10					15	

Val	Met	Ile	Tyr	Phe	Phe	Ile	Ile	Ile	Val	Glu	Tyr	Phe	Tyr	Gly	Lys
			20					25						30	

Ile	Phe	Val	Val	Leu	Ile	Ile	Pro	Ile	Lys	Ile	Met	Pro	Asn	Thr	Lys
		35					40					45			

Tyr	Glu	Phe	Tyr	Asp	Val	His	Phe	Val	Leu	Gly	Ile	Lys	Arg	Lys	Lys
	50					55					60				

His	Thr	Ser	Trp	Lys	Ser	Val	Ser	Cys	Phe	Leu	Leu	Leu
65					70					75		

&lt;210&gt; 98

&lt;211&gt; 84

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 98

Thr	Tyr	Ser	Phe	Cys	Val	Cys	Glu	Arg	Ala	Phe	Val	Phe	Gly	Ser	Val
1				5					10					15	

Pro	Arg	Ala	Glu	Val	Glu	Gln	Gly	Cys	Thr	Tyr	His	Gly	Lys	Gly	Gly
			20					25					30		

Arg	Lys	Glu	Asn	Trp	Ile	Ala	Cys	Asp	Leu	Trp	Trp	Asn	Leu	Phe	Leu
		35					40					45			

Leu	Pro	Arg	Pro	Phe	Arg	Pro	Cys	Leu	Ile	Ser	Val	Gly	His	Phe	Arg
	50					55					60				

Leu	Trp	Gln	Gly	Arg	Ala	Gly	Leu	Gln	Ser	Glu	Val	Pro	Ala	Ser	Ser
65					70					75				80	

Leu Glu His Asn

&lt;210&gt; 99

&lt;211&gt; 61

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

71

&lt;221&gt; SITE

&lt;222&gt; (13)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 99

Met Trp Tyr Val Cys Ala Cys Val Cys Val Cys Val Xaa Val Cys Ser  
 1 5 10 15

Tyr Asn Arg Arg Thr Gly Lys Val Arg Thr Gln Asn Asn Glu Asp Leu  
 20 25 30

Leu Lys Cys Gly Gly Gly Val Cys Val Cys Val Phe Ile Glu Gln Glu  
 35 40 45

Asp Arg Lys Gly Asn Asp His Pro Trp Lys Met Lys Gly  
 50 55 60

&lt;210&gt; 100

&lt;211&gt; 11

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 100

Val Cys Cys Cys Leu His Leu Asn Ala Phe Val  
 1 5 10

&lt;210&gt; 101

&lt;211&gt; 66

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (9)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 101

Ser Trp Val Asp Phe Asp Cys Val Xaa Glu Val Ser Tyr Leu Asn Ser  
 1 5 10 15

Gly Ser Tyr Ser Leu Val Leu His Leu Glu Gly Leu His Pro Leu Glu  
 20 25 30

Leu Ser Gly Lys Leu Ala Ile Asp Phe Gly Lys Lys Arg Glu Phe Cys  
 35 40 45

Val Asp Gly Val Gly Gly Ala Thr Leu Val Ile Cys Pro Gly Phe Gln  
 50 55 60

Asp Phe  
 65

&lt;210&gt; 102

&lt;211&gt; 505

&lt;212&gt; PRT

<213> Homo sapiens

<220>

&lt;221&gt; SITE

<222> (358)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (494)

<223> Xaa equals any of the naturally occurring L-amino acids

$\langle 220 \rangle$

<221> SITE

<222> (504)

<223> Xaa equals any of the naturally occurring L-amino acids

 $\langle 220 \rangle$ 

&lt;221&gt; SITE

<222> (505)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 102

Met Phe Arg Thr Ala Val Met Met Ala Ala Ser Leu Ala Leu Thr Gly  
1 5 10 15

Ala Val Val Ala His Ala Tyr Tyr Leu Lys His Gln Phe Tyr Pro Thr  
20 25 30

Val Val Tyr Leu Thr Lys Ser Ser Pro Ser Met Ala Val Leu Tyr Ile  
35 40 45

Gln Ala Phe Val Leu Val Phe Leu Leu Gly Lys Val Met Gly Lys Val  
50 55 60

Phe Phe Gly Gln Leu Arg Ala Ala Glu Met Glu His Leu Leu Glu Arg  
65 70 75 80

Ser Trp Tyr Ala Val Thr Glu Thr Cys Leu Ala Phe Thr Val Phe Arg  
85 90 95

Asp Asp Phe Ser Pro Arg Phe Val Ala Leu Phe Thr Leu Leu Leu Phe  
100 105 110

Leu Lys Cys Phe His Trp Leu Ala Glu Asp Arg Val Asp Phe Met Glu  
115 120 125

Arg Ser Pro Asn Ile Ser Trp Leu Phe His Cys Arg Ile Val Ser Leu  
130 135 140

Met Phe Leu Leu Gly Ile Leu Asp Phe Leu Phe Val Ser His Ala Tyr  
145 150 155 160

His Ser Ile Leu Thr Arg Gly Ala Ser Val Gln Leu Val Phe Gly Phe  
165 170 175

Glu Tyr Ala Ile Leu Met Thr Met Val Leu Thr Ile Phe Ile Lys Tyr  
180 185 190

Val Leu His Ser Val Asp Leu Gln Ser Glu Asn Pro Trp Asp Asn Lys  
 195 200 205  
 Ala Val Tyr Met Leu Tyr Thr Glu Leu Phe Thr Gly Phe Ile Lys Val  
 210 215 220  
 Leu Leu Tyr Met Ala Phe Met Thr Ile Met Ile Lys Val His Thr Phe  
 225 230 235 240  
 Pro Leu Phe Ala Ile Arg Pro Met Tyr Leu Ala Met Arg Gln Phe Lys  
 245 250 255  
 Lys Ala Val Thr Asp Ala Ile Met Ser Arg Arg Ala Ile Arg Asn Met  
 260 265 270  
 Asn Thr Leu Tyr Pro Asp Ala Thr Pro Glu Glu Leu Gln Ala Met Asp  
 275 280 285  
 Asn Val Cys Ile Ile Cys Arg Glu Glu Met Val Thr Gly Ala Lys Arg  
 290 295 300  
 Leu Pro Cys Asn His Ile Phe His Thr Ser Cys Leu Arg Ser Trp Phe  
 305 310 315 320  
 Gln Arg Gln Gln Thr Cys Pro Thr Cys Arg Met Asp Val Leu Arg Ala  
 325 330 335  
 Ser Leu Pro Ala Gln Ser Pro Pro Pro Pro Glu Pro Ala Asp Gln Gly  
 340 345 350  
 Pro Pro Pro Ala Pro Xaa Pro Pro Pro Leu Leu Pro Gln Pro Pro Asn  
 355 360 365  
 Phe Pro Gln Gly Leu Leu Pro Pro Phe Pro Pro Gly Met Phe Pro Leu  
 370 375 380  
 Trp Pro Pro Met Gly Pro Phe Pro Pro Val Pro Pro Pro Pro Ser Ser  
 385 390 395 400  
 Gly Glu Ala Val Ala Pro Pro Ser Thr Ser Ala Ala Ala Leu Ser Arg  
 405 410 415  
 Pro Ser Gly Ala Ala Thr Thr Thr Ala Ala Gly Thr Ser Ala Thr Ala  
 420 425 430  
 Ala Ser Ala Thr Ala Ser Gly Pro Gly Ser Gly Ser Ala Pro Glu Ala  
 435 440 445  
 Gly Pro Ala Pro Gly Phe Pro Phe Pro Pro Pro Trp Met Gly Met Pro  
 450 455 460  
 Leu Pro Pro Pro Phe Ala Phe Pro Pro Met Pro Val Pro Pro Ala Gly  
 465 470 475 480  
 Phe Ala Gly Leu Thr Pro Glu Glu Tyr Glu Leu Trp Arg Xaa Met Ser  
 485 490 495

Gly Arg Thr Gly Gly Pro Val Xaa Xaa  
                   500                  505

<210> 103

<211> 191

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (18)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (21)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 103

Met Phe Arg Thr Ala Val Met Met Ala Ala Ser Ile Trp Pro Arg Leu  
   1                  5                  10                  15

Trp Xaa Cys Pro Xaa Gly Trp Pro Cys Pro Trp Phe Pro Leu Pro Ser  
                   20                  25                  30

Ser Leu Asp Gly Tyr Ala Pro Ala Ser Thr Leu Cys Leu Pro Pro Asn  
                   35                  40                  45

Ala Cys Ala Pro Cys Gly Phe Ala Gly Leu Thr Pro Glu Glu Leu Arg  
                   50                  55                  60

Ala Leu Glu Gly His Glu Arg Gln His Leu Glu Ala Arg Leu Gln Ser  
   65                  70                  75                  80

Leu Arg Asn Ile His Thr Leu Leu Asp Ala Ala Met Leu Gln Ile Asn  
                   85                  90                  95

Gln Tyr Leu Thr Val Leu Ala Ser Leu Gly Pro Pro Arg Pro Ala Thr  
                   100                  105                  110

Ser Val Asn Ser Thr Glu Glu Thr Ala Thr Thr Val Val Ala Ala Ala  
                   115                  120                  125

Ser Ser Thr Ser Ile Pro Ser Ser Glu Ala Thr Thr Pro Thr Pro Gly  
                   130                  135                  140

Ala Ser Pro Pro Ala Pro Glu Met Glu Arg Pro Pro Ala Pro Glu Ser  
   145                  150                  155                  160

Val Gly Thr Glu Glu Met Pro Glu Asp Gly Glu Pro Asp Ala Ala Glu  
                   165                  170                  175

Leu Arg Arg Arg Arg Leu Gln Lys Leu Glu Ser Pro Val Ala His  
                   180                  185                  190

<210> 104

```
<211> 33
<212> PRT
<213> Homo sapiens
```

```
<400> 104
Lys Ile Leu Val Ser Tyr Leu Met Pro Gly Met Met Arg Ile Glu Asn
  1             5             10             15
Phe Ser Ile Phe Met Cys Leu Thr Gly Cys Leu Gly Ile Asn Phe Ala
      20             25             30
Phe
```

```
<210> 105  
<211> 67  
<212> PRT  
<213> Homo sapiens
```

```

<400> 105
Met Asp Arg Gly Val Met Cys Leu Leu Ala Ser Trp Pro Gly Leu Gly
  1                               10                      15
Ala Gln Phe Cys Gly Ala Gly Val Cys Pro Leu Arg Val Pro Ser Leu
      20                               25                      30
Glu Pro Thr Leu Pro Asn Asp Gly Gly Gly Leu Glu Ala Leu Thr Leu
      35                               40                      45
Gly Gly Lys Glu Ala Lys Glu Arg Trp Arg Trp Lys Gly Arg Pro Gly
      50                               55                      60
Gln Gly Gly
      65

```

```
<210> 106
<211> 67
<212> PRT
<213> Homo sapiens
```

```

<400> 106
Met Asp Arg Gly Val Met Cys Leu Leu Ala Ser Trp Pro Gly Leu Gly
  1              5              10              15
Ala Gln Phe Cys Gly Ala Gly Val Cys Pro Leu Arg Val Pro Ser Leu
      20              25              30
Glu Pro Thr Leu Pro Asn Asp Gly Gly Gly Leu Glu Ala Leu Thr Leu
      35              40              45
Gly Gly Lys Glu Ala Lys Glu Arg Trp Arg Trp Lys Gly Arg Pro Gly
  50              55              60
Gln Gly Gly
  65

```

<210> 107  
<211> 83  
<212> PRT  
<213> Homo sapiens

<400> 107  
Gly His Val Leu Ala Tyr Ser Ser Trp Pro Ser Leu Ala Pro Gly Leu  
1 5 10 15  
Ser Val Gln Tyr Phe Val Ser Arg Val Glu Val Pro Asn Pro Gly Cys  
20 25 30  
Thr Leu Glu Ala Pro Gly Lys Leu Ser Glu Phe Leu Arg Pro Glu Pro  
35 40 45  
His Pro Lys Pro Ile Ser Ser Glu Ser Leu Gly Gly Thr Glu Pro Gly  
50 55 60  
Phe Cys Gln Leu Lys Pro Ala Met Val Thr Ser Val Ser Ser Tyr Thr  
65 70 75 80  
Glu Asn Ser

<210> 108  
<211> 63  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (12)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (16)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (20)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (23)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (25)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE

<222> (35)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (38)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (48)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (49)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 108

Met His Leu Leu Pro Trp Arg Ala Ala Ala Ala Xaa Pro Leu Leu Xaa  
1 5 10 15

Ala Val Pro Xaa Arg Ala Xaa Arg Xaa Pro Val Gln Ala Pro Ser Leu  
20 25 30

Gly Ala Xaa Asn Pro Xaa Arg Gly Thr Gln Val Ala Thr Val Ser Xaa  
35 40 45

Xaa Ser Gly Lys Leu Leu Gly Leu Lys Ala Pro Arg Pro Lys Pro  
50 55 60

<210> 109

<211> 9

<212> PRT

<213> Homo sapiens

<400> 109

Pro Ser Ala Ala Ala Ser Ala Thr Pro  
1 5

<210> 110

<211> 94

<212> PRT

<213> Homo sapiens

<400> 110

Leu Ala Val Ile Met Ala Arg Pro Ala Ala Glu Pro Leu Cys Phe Leu  
1 5 10 15

Asn Pro Lys Leu Leu Ala Leu Ala Val Gly Val Leu Glu Leu Leu Gly  
20 25 30

Arg Gly Phe Leu Asp Ser Ser Pro Leu Leu Arg Pro Ala Ser Asp Gly  
35 40 45

Glu Arg Phe Thr Trp Glu Ala Leu Gly Glu Ser Leu Pro Phe Ser Asp



78

50                                      55                                      60  
 Thr Phe Ala Ser Ser Val Phe Pro Val Pro Gly Val Phe Ser Ala Pro  
 65                                      70                                      75                                      80  
 Ala Gly Ala Glu Ala Phe Val Leu Gly Met Val Met Pro Thr  
                                     85                                      90

<210> 111  
 <211> 77  
 <212> PRT  
 <213> Homo sapiens

<400> 111  
 Phe Val Leu Leu His Cys Leu Asn Ser His Leu His Leu Ala Leu Gln  
 1                                      5                                      10                                      15  
 Phe Pro Leu Asn Thr Leu Ser Ser Pro Leu Val Cys Cys Gln Ser Ala  
                                     20                                      25                                      30  
 Ala Leu Pro Ile Lys Ala Cys Ile Asn Tyr Ile Cys Pro Met Phe Thr  
                                     35                                      40                                      45  
 Phe Ile Lys His Phe Pro Cys Thr Pro Val Pro Thr Ser Gln Gln Thr  
                                     50                                      55                                      60  
 Arg Glu Arg Ala Val Gln Leu Met Ser Leu Pro Ser Phe  
 65                                      70                                      75

<210> 112  
 <211> 87  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (1)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (26)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 112  
 Xaa His Ser His Trp Glu Gly Leu Lys Leu Cys Cys Leu Asn Pro Val  
 1                                      5                                      10                                      15  
 Leu Gly Pro Ala Arg Lys Arg Lys Arg Xaa Leu Arg Asn Arg Gly Ala  
                                     20                                      25                                      30  
 Arg Gly Gly Cys Arg Cys His Ser Arg Ala Ala Leu His Pro His Pro  
                                     35                                      40                                      45  
 His Ala Ser Cys Phe Thr Ala His Ser Val Thr Glu Leu Val Ala Leu  
                                     50                                      55                                      60

Gly Thr Gly Gly His Pro His Thr Leu Met Pro Thr Ala Glu Gly Arg  
 65 70 75 80

Ala Thr His Pro Ser Arg Asp  
 85

<210> 113  
 <211> 86  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (3)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (5)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (6)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 113  
 Lys Lys Xaa Pro Xaa Xaa Leu Ser Gly Ser Lys Ala Ile Ala Ser Lys  
 1 5 10 15

Thr Lys Glu Ile Glu Gln Val Tyr Arg Gln Asp Cys Glu Thr Phe Gly  
 20 25 30

Met Val Val Lys Met Leu Ile Glu Lys Asp Pro Ser Leu Glu Lys Ser  
 35 40 45

Ile Gln Phe Ala Leu Arg Gln Asn Leu His Glu Ile Gly Glu Arg Cys  
 50 55 60

Val Glu Glu Leu Lys His Phe Ile Ala Glu Tyr Asp Thr Ser Thr Gln  
 65 70 75 80

Asp Phe Gly Glu Pro Phe  
 85

<210> 114  
 <211> 53  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (4)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (10)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (27)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 114  
 Ile Gly Pro Xaa Gly Pro Arg Asn Ser Xaa Thr Gly Gly Ala Phe Leu  
   1                  5                  10                  15  
 Asp Phe Ser Ala Gln Ala Lys Lys Lys Lys Xaa Gln Phe Leu Lys Ile  
                   20                  25                  30  
 Phe Phe Pro Gly Leu Cys Lys Ser Leu Ile Tyr Gly Ile Phe Val Met  
           35                  40                  45  
 Gln Arg Asn Thr Leu  
       50

<210> 115  
 <211> 62  
 <212> PRT  
 <213> Homo sapiens

<400> 115  
 Met Leu Cys Pro Ala Leu Gly Pro Phe Leu Leu Phe Leu Leu Ser Ser  
   1                  5                  10                  15  
 Thr Leu Met Ala Ser Phe Met Gly Asp Thr Pro Cys His Pro Gly Glu  
           20                  25                  30  
 Leu Ser Ala Phe Gly Val Ala Pro Ser Arg Val Phe Thr Ser Ser Phe  
           35                  40                  45  
 Leu Phe Thr Val Phe Thr Pro Ser Tyr Pro Ser Leu Pro Gly  
       50                  55                  60

<210> 116  
 <211> 48  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (45)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (46)  
 <223> Xaa equals any of the naturally occurring L-amino acids

81

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (48)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 116

Met Val Gln Arg Leu Trp Val Ser Arg Leu Leu Arg His Arg Lys Ala  
 1 5 10 15

Gln Leu Leu Leu Val Asn Leu Leu Thr Phe Gly Leu Glu Val Cys Leu  
 20 25 30

Ala Ala Gly Phe Thr Tyr Val Pro Leu Cys Cys Gly Xaa Xaa Val Xaa  
 35 40 45

&lt;210&gt; 117

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 117

Ile Leu Gln Arg Arg Lys Gln Arg Leu Leu Arg Gly  
 1 5 10

&lt;210&gt; 118

&lt;211&gt; 129

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 118

Arg Lys Val Glu Gly Gly Ala Ser Gly Leu Asn Gly Phe Pro Asn His  
 1 5 10 15

Pro Ser Ser Leu Gly Pro Ala Trp Phe Pro Pro Leu Pro Leu Pro Ser  
 20 25 30

Thr Leu Ser Arg Thr Gly Leu Met Lys Ala Leu Pro Lys Ile Ser Pro  
 35 40 45

Thr Pro Asn Phe Pro Leu Pro Pro Thr Phe Pro Thr Ser Ser Thr Thr  
 50 55 60

Leu Phe Gly Ala Thr Ala Gly Pro Glu Ala Gln Ser Ala Val Ser Gln  
 65 70 75 80

Ala Phe Val His Leu Ser Pro Gln Ser Ile Ser Val Leu Gly Glu Ser  
 85 90 95

His Thr Glu Thr Gln Glu His Pro Leu Pro Glu Leu Arg Glu Val Leu  
 100 105 110

Ser Leu Arg Gly Gly Leu Ser Ala Val Cys Asn Asn Val Val Leu Phe  
 115 120 125

Ile

&lt;210&gt; 119

&lt;211&gt; 46

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 119

Met Pro Trp Leu Lys Ser Leu Leu His Phe Ser Leu Phe Leu Val Val  
 1 5 10 15

Phe Ser Thr Leu Ala Val Lys Ser Leu Gly Val Pro Val Ala Ala Gly  
 20 25 30

Ser Pro Phe Cys Ile Val Asp Val Leu His Phe Ile Leu Leu  
 35 40 45

&lt;210&gt; 120

&lt;211&gt; 53

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 120

Met Phe Ile Ser Leu Phe Ile Phe Gly Leu Val Arg Leu Trp Pro Cys  
 1 5 10 15

Cys Val Val Ile Tyr Phe Val Tyr Ser Ile Cys Lys His Gln Cys Ser  
 20 25 30

Gln Glu Ala His Ser Ser Ile Phe Asn Cys Lys Phe Val Ser Gln Ser  
 35 40 45

Gln Phe Ser Ile Met  
 50

&lt;210&gt; 121

&lt;211&gt; 4

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 121

Phe Leu Ser Ser  
 1

&lt;210&gt; 122

&lt;211&gt; 19

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 122

Leu Val Cys Phe Val Ile Phe Arg Leu Trp Tyr Met Cys Val Phe Thr  
 1 5 10 15

Leu Trp Ala

<210> 123  
 <211> 51  
 <212> PRT  
 <213> Homo sapiens

<400> 123  
 Gln Ala Ser Trp Val Trp Trp Leu Thr Thr Val Ile Pro Ala Leu Trp  
           1                  5                  10                  15  
 Glu Ala Arg Ala Gly Gly Ser Leu Glu Pro Arg Ser Ser Arg Leu Ala  
                   20                  25                  30  
 Trp Ala Thr Gln Lys Val Phe Ile Ser Lys Lys Lys Lys Lys Lys Lys  
                   35                  40                  45  
 Arg Ala Ala  
           50

<210> 124  
 <211> 5  
 <212> PRT  
 <213> Homo sapiens

<400> 124  
 Ser Phe Ala Thr Cys  
           1                  5

<210> 125  
 <211> 10  
 <212> PRT  
 <213> Homo sapiens

<400> 125  
 Trp Ala Ser Met Ser Ser Val Phe Gly Leu  
           1                  5                  10

<210> 126  
 <211> 57  
 <212> PRT  
 <213> Homo sapiens

<400> 126  
 Ile Ser Tyr His His Val Lys Ala Ser His Leu Lys Ile Lys Ile Gln  
           1                  5                  10                  15  
 Ile Ser Leu Lys Pro Glu Val Leu Val Pro Leu His Cys Leu Pro Leu  
                   20                  25                  30  
 Ser Pro Thr Pro Arg Glu Glu Ser Gly Gly Phe Leu Phe Ser Ile Ala  
                   35                  40                  45

Ile Ala Ala Val Gly Phe Leu Val Gln  
           50                          55

<210> 127

<211> 164

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (3)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (95)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 127

Arg Met Xaa Cys Ser Gln Pro Pro Arg Cys His Phe Gln Ser Asp Phe  
       1                          5                          10                          15

Gln Lys Cys Ala Pro Cys Pro Arg Ala Gln Thr His Trp Leu Glu Pro  
                           20                          25                          30

Pro Gly Arg Val Gln Thr Ile Ser Ser Met Arg Asn Ala Gln Lys Gly  
                           35                          40                          45

Phe Ala Asp Ser Ile Arg Leu Trp Arg Leu Pro Ala Ser Gly Val Gly  
       50                          55                          60

Trp Val Val Ser Pro Pro Ile Gln Thr Gln Glu Val Ala Pro Glu Gly  
       65                          70                          75                          80

Met Tyr Leu Val Gly Ser Ser Ser Gly Thr Leu Gly Gly Cys Xaa Ala  
                           85                          90                          95

Leu Thr Gln Tyr Phe Ser Leu Ser Pro Leu Trp Gly Ala Cys Val Arg  
                           100                          105                          110

Ala Arg Val Leu Ala Tyr Ala Phe Leu Cys Gly His Ile Arg Met Pro  
                           115                          120                          125

Leu Gly Glu His Val His Val Ser Pro Pro Glu Arg Ala Cys Val Cys  
       130                          135                          140

Ala Pro Leu Arg Pro Arg Phe Gly Arg Leu Gly Phe Gly Val Pro Val  
       145                          150                          155                          160

Phe Cys Pro Pro

<210> 128

<211> 2

<212> PRT

85

&lt;213&gt; Homo sapiens

&lt;400&gt; 128

Gly Cys

1

&lt;210&gt; 129

&lt;211&gt; 22

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 129

Leu Val Leu Phe Ile Thr Leu Leu Pro Gly Lys Leu Ala His Ser Trp  
1 5 10 15

His Thr Val Asn Val Gln  
20

&lt;210&gt; 130

&lt;211&gt; 53

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (35)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 130

Thr Glu Glu Phe Lys Tyr Ala Val Ser Cys Asn Cys Gly Thr Ala Ala  
1 5 10 15

Trp Val Arg Val Arg Glu Arg Glu Arg Lys Arg Glu Lys Lys Lys Lys  
20 25 30

Lys Arg Xaa Ala Ala Leu Glu Asp Pro Ser Arg Gly Pro Ser Leu Arg  
35 40 45

Val His Ala Thr Ser  
50

&lt;210&gt; 131

&lt;211&gt; 7

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 131

Thr Tyr Ile His Phe Leu Asp  
1 5

&lt;210&gt; 132

&lt;211&gt; 8

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens



&lt;400&gt; 132

Leu Thr Met Leu Phe Asn Val Ile

1 5

&lt;210&gt; 133

&lt;211&gt; 352

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 133

Val Ser Leu Leu Leu Trp Gly Ile Ser Ile Arg Gly Ala Asp Ala Cys

1 5 10 15

Ala Asp Ala His Leu Phe Cys Lys Glu Cys Leu Ile Arg Tyr Ala Gln

20 25 30

Glu Ala Val Phe Gly Ser Gly Lys Leu Glu Leu Ser Cys Met Glu Gly

35 40 45

Ser Cys Thr Cys Ser Phe Pro Thr Ser Glu Leu Glu Lys Val Leu Pro

50 55 60

Gln Thr Ile Leu Tyr Lys Tyr Tyr Glu Arg Lys Ala Glu Glu Glu Val

65 70 75 80

Ala Ala Ala Tyr Ala Asp Glu Leu Val Arg Cys Pro Ser Cys Ser Phe

85 90 95

Pro Ala Leu Leu Asp Ser Asp Val Lys Arg Phe Ser Cys Pro Asn Pro

100 105 110

His Cys Arg Lys Glu Thr Cys Arg Lys Cys Gln Gly Leu Trp Lys Glu

115 120 125

His Asn Gly Leu Thr Cys Glu Glu Leu Ala Glu Lys Asp Asp Ile Lys

130 135 140

Tyr Arg Thr Ser Ile Glu Glu Lys Met Thr Ala Ala Arg Ile Arg Lys

145 150 155 160

Cys His Lys Cys Gly Thr Gly Leu Ile Lys Ser Glu Gly Cys Asn Arg

165 170 175

Met Ser Cys Arg Cys Gly Ala Gln Met Cys Tyr Leu Cys Arg Val Ser

180 185 190

Ile Asn Gly Tyr Asp His Phe Cys Gln His Pro Arg Ser Pro Gly Ala

195 200 205

Pro Cys Gln Glu Cys Ser Arg Cys Ser Leu Trp Thr Asp Pro Thr Glu

210 215 220

Asp Asp Glu Lys Leu Ile Glu Glu Ile Gln Lys Glu Ala Glu Glu Glu

225 230 235 240

Gln Lys Arg Lys Asn Gly Glu Asn Thr Phe Lys Arg Ile Gly Pro Pro

87

245					250					255					
Leu	Glu	Lys	Pro	Val	Glu	Lys	Val	Gln	Arg	Val	Glu	Ala	Leu	Pro	Arg
			260					265					270		
Pro	Val	Pro	Gln	Asn	Leu	Pro	Gln	Pro	Gln	Met	Pro	Pro	Tyr	Ala	Phe
			275					280					285		
Ala	His	Pro	Pro	Phe	Pro	Leu	Pro	Pro	Val	Arg	Pro	Val	Phe	Asn	Asn
			290					295					300		
Phe	Pro	Leu	Asn	Met	Gly	Pro	Ile	Pro	Ala	Pro	Tyr	Val	Pro	Pro	Leu
			305					310					315		320
Pro	Asn	Val	Arg	Val	Asn	Tyr	Asp	Phe	Gly	Pro	Ile	His	Met	Pro	Leu
			325					330					335		
Glu	His	Asn	Leu	Pro	Met	His	Phe	Gly	Pro	Gln	Pro	Arg	His	Arg	Phe
			340					345					350		

&lt;210&gt; 134

&lt;211&gt; 7

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 134

Ser Phe Cys Met Gly Thr Met

1

5

&lt;210&gt; 135

&lt;211&gt; 20

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 135

Met Asn Val Arg Leu Val Leu Asn Pro Phe Pro Leu Tyr Ser Val Tyr

1

5

10

15

Val Ile Pro Asn

20

&lt;210&gt; 136

&lt;211&gt; 11

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 136

Leu Glu Ile Leu Val Val Lys Lys Leu Leu Ala

1

5

10

&lt;210&gt; 137

88

&lt;211&gt; 233

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 137

His Pro Val Ala Ala Leu Phe Thr Val Thr Ala Pro Lys Glu Val Tyr  
 1 5 10 15  
 Thr Val Asp Val Gly Ser Ser Val Ser Leu Glu Cys Asp Phe Asp Arg  
 20 25 30  
 Arg Glu Cys Thr Glu Leu Glu Gly Ile Arg Ala Ser Leu Gln Lys Val  
 35 40 45  
 Glu Asn Asp Thr Ser Leu Gln Ser Glu Arg Ala Thr Leu Leu Glu Glu  
 50 55 60  
 Gln Leu Pro Leu Gly Lys Ala Leu Phe His Ile Pro Ser Val Gln Val  
 65 70 75 80  
 Arg Asp Ser Gly Gln Tyr Arg Cys Leu Val Ile Cys Gly Ala Ala Trp  
 85 90 95  
 Asp Tyr Lys Tyr Leu Thr Val Lys Val Lys Ala Ser Tyr Met Arg Ile  
 100 105 110  
 Asp Thr Arg Ile Leu Glu Val Pro Gly Thr Gly Glu Val Gln Leu Thr  
 115 120 125  
 Cys Gln Ala Arg Gly Tyr Pro Leu Ala Glu Val Ser Trp Gln Asn Val  
 130 135 140  
 Ser Val Pro Ala Asn Thr Ser His Ile Arg Thr Pro Glu Gly Leu Tyr  
 145 150 155 160  
 Gln Val Thr Ser Val Leu Arg Leu Lys Pro Gln Pro Ser Arg Asn Phe  
 165 170 175  
 Ser Cys Met Phe Trp Asn Ala His Met Lys Glu Leu Thr Ser Ala Ile  
 180 185 190  
 Ile Asp Pro Leu Ser Arg Met Glu Pro Lys Val Pro Arg Thr Trp Pro  
 195 200 205  
 Leu His Val Phe Ile Pro Ala Cys Thr Ile Ala Leu Ile Phe Leu Ala  
 210 215 220  
 Ile Val Ile Ile Gln Arg Lys Arg Ile  
 225 230

&lt;210&gt; 138

&lt;211&gt; 233

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 138

His Gln Ile Ala Ala Leu Phe Thr Val Thr Val Pro Lys Glu Leu Tyr

89

[illegible]

```
<210> 139
<211> 184
<212> PRT
<213> Homo sapiens
```

```

<400> 139
Met Ser Arg Thr Ala Tyr Thr Val Gly Ala Leu Leu Leu Leu Leu Gly
  1                      5                      10                      15
Thr Leu Leu Pro Ala Ala Glu Gly Lys Lys Lys Gly Ser Gln Gly Ala
      20                      25                      30
Ile Pro Pro Pro Asp Lys Ala Gln His Asn Asp Ser Glu Gln Thr Gln

```

90

35                      40                      45  
 Ser Pro Gln Gln Pro Gly Ser Arg Asn Arg Gly Arg Gly Gln Gly Arg  
     50                      55                      60  
 Gly Thr Ala Met Pro Gly Glu Glu Val Leu Glu Ser Ser Gln Glu Ala  
     65                      70                      75                      80  
 Leu His Val Thr Glu Arg Lys Tyr Leu Lys Arg Asp Trp Cys Lys Thr  
                     85                      90                      95  
 Gln Pro Leu Lys Gln Thr Ile His Glu Glu Gly Cys Asn Ser Arg Thr  
                     100                      105                      110  
 Ile Ile Asn Arg Phe Cys Tyr Gly Gln Cys Asn Ser Phe Tyr Ile Pro  
                     115                      120                      125  
 Arg His Ile Arg Lys Glu Glu Gly Ser Phe Gln Ser Cys Ser Phe Cys  
     130                      135                      140  
 Lys Pro Lys Lys Phe Thr Thr Met Met Val Thr Leu Asn Cys Pro Glu  
     145                      150                      155                      160  
 Leu Gln Pro Pro Thr Lys Lys Lys Arg Val Thr Arg Val Lys Gln Cys  
                     165                      170                      175  
 Arg Cys Ile Ser Ile Asp Leu Asp  
                     180

&lt;210&gt; 140

&lt;211&gt; 330

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 140

Leu Met Ile Gly Gly Ser Cys Val Ala Thr Ala Ala Thr Ile Leu Asn  
     1                      5                      10                      15  
 Ala Phe Leu Ile Asn Lys Gln Phe Tyr Pro Ser Ile Val Tyr Leu Ser  
                     20                      25                      30  
 Lys Ser Asn Ala Ser Met Ala Val Ile Tyr Val Gln Gly Ile Val Leu  
                     35                      40                      45  
 Val Tyr Leu Met Phe Gln Leu Leu Lys Ser Ile Leu Phe Gly Asp Leu  
     50                      55                      60  
 Arg Ala Ala Glu Ala Glu His Leu Ser Glu Arg Thr Trp His Ala Val  
     65                      70                      75                      80  
 Leu Glu Thr Cys Leu Ala Phe Thr Val Phe Arg Asp Asp Phe Ser Ala  
                     85                      90                      95  
 Ile Phe Val Met Gln Phe Ile Gly Leu Leu Phe Ile Lys Cys Phe His  
                     100                      105                      110  
 Trp Leu Ala Asp Asp Arg Val Asp Met Met Glu Arg Ser Pro Val Ile

115	120	125
Thr Leu Arg Phe His Leu Arg Met Met Thr Val Leu Ala Ala Leu Gly		
130	135	140
Phe Ala Asp Ser Tyr Phe Val Ser Ser Ala Tyr Phe Thr Thr Ile Thr		
145	150	155 160
Arg Gly Ala Ser Ala Gln Ile Val Phe Gly Phe Glu Tyr Ala Ile Leu		
	165	170 175
Leu Ala Leu Val Leu His Val Thr Ile Lys Tyr Leu Leu His Met His		
	180	185 190
Asp Leu Arg Asn Pro Gln Ser Trp Asp Asn Lys Ala Val Tyr Leu Leu		
	195	200 205
Tyr Ala Glu Leu Phe Ile Asn Leu Ile Arg Cys Leu Leu Tyr Gly Phe		
	210	215 220
Phe Ala Val Val Met Leu Arg Val His Thr Phe Pro Leu Phe Ser Val		
225	230	235 240
Arg Pro Phe Tyr Gln Ser Val Arg Ala Leu His Lys Ala Phe Leu Asp		
	245	250 255
Val Ile Leu Ser Arg Arg Ala Ile Asn Ala Met Asn Ser Gln Phe Pro		
	260	265 270
Val Val Ser Ala Glu Asp Leu Ala Ala Met Asp Ala Thr Cys Ile Ile		
	275	280 285
Cys Arg Glu Glu Met Thr Val Asp Ala Ser Pro Lys Arg Leu Pro Cys		
	290	295 300
Ser His Val Phe His Ala His Cys Leu Arg Ser Trp Phe Gln Arg Gln		
305	310	315 320
Gln Thr Cys Pro Thr Cys Arg Thr Asp Ile		
	325	330
<210> 141		
<211> 328		
<212> PRT		
<213> Homo sapiens		
<400> 141		
Val Met Met Ala Ala Ser Leu Ala Leu Thr Gly Ala Val Val Ala His		
1	5	10 15
Ala Tyr Tyr Leu Lys His Gln Phe Tyr Pro Thr Val Val Tyr Leu Thr		
	20	25 30
Lys Ser Ser Pro Ser Met Ala Val Leu Tyr Ile Gln Ala Phe Val Leu		
	35	40 45
Val Phe Leu Leu Gly Lys Val Met Gly Lys Val Phe Phe Gly Gln Leu		

50	55	60
Arg Ala Ala Glu Met Glu His Leu Leu Glu Arg Ser Trp Tyr Ala Val 65 70 75 80		
Thr Glu Thr Cys Leu Ala Phe Thr Val Phe Arg Asp Asp Phe Ser Pro 85 90 95		
Arg Phe Val Ala Leu Phe Thr Leu Leu Leu Phe Leu Lys Cys Phe His 100 105 110		
Trp Leu Ala Glu Asp Arg Val Asp Phe Met Glu Arg Ser Pro Asn Ile 115 120 125		
Ser Trp Leu Phe His Cys Arg Ile Val Ser Leu Met Phe Leu Leu Gly 130 135 140		
Ile Leu Asp Phe Leu Phe Val Ser His Ala Tyr His Ser Ile Leu Thr 145 150 155 160		
Arg Gly Ala Ser Val Gln Leu Val Phe Gly Phe Glu Tyr Ala Ile Leu 165 170 175		
Met Thr Met Val Leu Thr Ile Phe Ile Lys Tyr Val Leu His Ser Val 180 185 190		
Asp Leu Gln Ser Glu Asn Pro Trp Asp Asn Lys Ala Val Tyr Met Leu 195 200 205		
Tyr Thr Glu Leu Phe Thr Gly Phe Ile Lys Val Leu Leu Tyr Met Ala 210 215 220		
Phe Met Thr Ile Met Ile Lys Val His Thr Phe Pro Leu Phe Ala Ile 225 230 235 240		
Arg Pro Met Tyr Leu Ala Met Arg Gln Phe Lys Lys Ala Val Thr Asp 245 250 255		
Ala Ile Met Ser Arg Arg Ala Ile Arg Asn Met Asn Thr Leu Tyr Pro 260 265 270		
Asp Ala Thr Pro Glu Glu Leu Gln Ala Met Asp Asn Val Cys Ile Ile 275 280 285		
Cys Arg Glu Glu Met Val Thr Gly Ala Lys Arg Leu Pro Cys Asn His 290 295 300		
Ile Phe His Thr Ser Cys Leu Arg Ser Trp Phe Gln Arg Gln Gln Thr 305 310 315 320		
Cys Pro Thr Cys Arg Met Asp Val 325		

&lt;210&gt; 142

&lt;211&gt; 283

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 142

```

Met Gly Arg Ile Gly Ile Ser Cys Leu Phe Pro Ala Ser Trp His Phe
 1           5           10           15

Ser Ile Ser Pro Val Gly Cys Pro Arg Ile Leu Asn Thr Asn Leu Arg
          20           25           30

Gln Ile Met Val Ile Ser Val Leu Ala Ala Ala Ala Val Ser Leu Leu
          35           40           45

Tyr Phe Ser Val Val Ile Ile Arg Asn Lys Tyr Gly Arg Leu Thr Arg
          50           55           60

Asp Lys Lys Phe Gln Arg Tyr Leu Ala Arg Val Thr Asp Ile Glu Ala
 65           70           75           80

Thr Asp Thr Asn Asn Pro Asn Val Asn Tyr Gly Ile Val Val Asp Cys
          85           90           95

Gly Ser Ser Gly Ser Arg Val Phe Val Tyr Cys Trp Pro Arg His Asn
          100          105          110

Gly Asn Pro His Asp Leu Leu Asp Ile Arg Gln Met Arg Asp Lys Asn
          115          120          125

Arg Lys Pro Val Val Met Lys Ile Lys Pro Gly Ile Ser Glu Phe Ala
          130          135          140

Thr Ser Pro Glu Lys Val Ser Asp Tyr Ile Ser Pro Leu Leu Asn Phe
          145          150          155          160

Ala Ala Glu His Val Pro Arg Ala Lys His Lys Glu Thr Pro Leu Tyr
          165          170          175

Ile Leu Cys Thr Ala Gly Met Arg Ile Leu Pro Glu Ser Gln Gln Lys
          180          185          190

Ala Ile Leu Glu Asp Leu Leu Thr Asp Ile Pro Val His Phe Asp Phe
          195          200          205

Leu Phe Ser Asp Ser His Ala Glu Val Ile Ser Gly Lys Gln Glu Gly
          210          215          220

Val Tyr Ala Trp Ile Gly Ile Asn Phe Val Leu Gly Arg Phe Glu His
          225          230          235          240

Ile Glu Asp Asp Asp Glu Ala Val Val Glu Val Asn Ile Pro Gly Ser
          245          250          255

Glu Ser Ser Glu Ala Ile Val Arg Lys Arg Thr Ala Gly Ile Leu Asp
          260          265          270

Met Gly Gly Val Ser Thr Gln Ile Ala Tyr Glu
          275          280

```

&lt;210&gt; 143



<211> 269  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (87)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (99)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (230)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (263)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (264)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 143

Met	Ala	Arg	Ile	Ser	Phe	Ser	Tyr	Leu	Cys	Pro	Ala	Ser	Trp	Tyr	Phe
1				5				10						15	

Thr	Val	Pro	Thr	Val	Ser	Pro	Phe	Leu	Arg	Gln	Arg	Val	Ala	Phe	Leu
			20					25					30		

Gly	Leu	Phe	Phe	Ile	Ser	Cys	Leu	Leu	Leu	Leu	Met	Leu	Ile	Ile	Asp
		35					40					45			

Phe	Arg	His	Trp	Ser	Ala	Ser	Leu	Pro	Arg	Asp	Arg	Gln	Tyr	Glu	Arg
	50					55					60				

Tyr	Leu	Ala	Arg	Val	Gly	Glu	Leu	Glu	Ala	Thr	Asp	Thr	Glu	Asp	Pro
65					70					75					80

Asn	Leu	Asn	Tyr	Gly	Leu	Xaa	Val	Asp	Cys	Gly	Ser	Ser	Gly	Ser	Arg
				85					90					95	

Ile	Phe	Xaa	Tyr	Phe	Trp	Pro	Arg	His	Asn	Gly	Asn	Pro	His	Asp	Leu
			100					105					110		

Leu	Asp	Ile	Lys	Gln	Met	Arg	Asp	Arg	Asn	Ser	Gln	Pro	Val	Val	Lys
		115					120					125			

Lys	Ile	Lys	Pro	Gly	Ile	Ser	Ala	Met	Ala	Asp	Thr	Pro	Glu	His	Ala
	130					135					140				

Ser	Asp	Tyr	Leu	Arg	Pro	Leu	Leu	Ser	Phe	Ala	Ala	Ala	His	Val	Pro
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

95

145                      150                      155                      160  
 Val Lys Lys His Lys Glu Thr Pro Leu Tyr Ile Leu Cys Thr Ala Gly  
                                  165                      170                      175  
 Met Arg Leu Leu Pro Glu Arg Lys Gln Leu Ala Ile Leu Ala Asp Leu  
                                  180                      185                      190  
 Val Lys Asp Leu Pro Leu Glu Phe Asp Phe Leu Phe Ser Gln Ser Gln  
                                  195                      200                      205  
 Ala Glu Val Ile Ser Gly Lys Gln Glu Gly Val Tyr Ala Trp Ile Gly  
                                  210                      215                      220  
 Ile Asn Phe Val Leu Xaa Arg Phe Asp His Glu Asp Glu Ser Asp Ala  
 225                                   230                      235                      240  
 Glu Ala Thr Gln Glu Leu Ala Ala Gly Arg Arg Arg Thr Val Gly Ile  
                                  245                      250                      255  
 Leu Asp Met Gly Gly Ala Xaa Xaa Gln Ile Ala Tyr Glu  
                                  260                      265

<210> 144  
 <211> 112  
 <212> PRT  
 <213> Homo sapiens

<400> 144  
 Met Ser Ser Gly Cys Leu Leu Ser Val Leu His Pro Pro Trp Pro Gly  
   1                                 5                                 10                                 15  
 Leu Pro Phe His Leu His Leu Ser Phe Ala Ser Phe Pro Pro Arg Val  
                                  20                                 25                                 30  
 Arg Ala Ser Lys Pro Pro Pro Ser Phe Gly Asn Val Gly Ser Lys Glu  
                                  35                                 40                                 45  
 Gly Thr Leu Arg Gly Gln Thr Pro Ala Pro Gln Asn Trp Ala Pro Ser  
                                  50                                 55                                 60  
 Pro Gly Gln Glu Ala Arg Arg His Ile Thr Pro Leu Ser Ile His Phe  
   65                                 70                                 75                                 80  
 His Gln Ala Pro Leu Arg Val Pro Leu Leu Val Leu Gly Leu Gln Asp  
                                  85                                 90                                 95  
 Gly His Arg Leu Ala Cys Leu Gln Ala His Phe Met Ala Ala Ser Gly  
                                  100                                 105                                 110

<210> 145  
 <211> 404  
 <212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (365)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (367)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (379)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 145

Met	Ser	Asp	Asn	Ala	Pro	Ala	Ser	Leu	Glu	Ser	Gly	Ser	Ser	Ser	Thr
1				5					10					15	

Pro	Thr	Asn	Cys	Ser	Thr	Ser	Ser	Ala	Ile	Pro	Gln	Pro	Gly	Ala	Ala
			20					25					30		

Thr	Lys	Pro	Trp	Arg	Ser	Lys	Ser	Leu	Ser	Val	Lys	His	Ser	Ala	Thr
		35					40					45			

Val	Ser	Met	Leu	Ser	Val	Lys	Pro	Pro	Gly	Pro	Glu	Ala	Pro	Arg	Pro
	50					55					60				

Thr	Pro	Glu	Ala	Met	Lys	Pro	Ala	Pro	Asn	Asn	Gln	Lys	Ser	Met	Leu
65					70					75					80

Glu	Lys	Leu	Lys	Leu	Phe	Asn	Ser	Lys	Gly	Gly	Ser	Lys	Ala	Gly	Glu
				85					90					95	

Gly	Pro	Gly	Ser	Arg	Asp	Thr	Ser	Cys	Glu	Arg	Leu	Glu	Thr	Leu	Pro
			100					105					110		

Ser	Phe	Glu	Glu	Ser	Glu	Glu	Leu	Glu	Ala	Ala	Ser	Arg	Met	Leu	Thr
		115					120					125			

Thr	Val	Gly	Pro	Ala	Ser	Ser	Ser	Pro	Lys	Ile	Ala	Leu	Lys	Gly	Ile
	130					135					140				

Ala	Gln	Arg	Thr	Phe	Ser	Arg	Ala	Leu	Thr	Asn	Lys	Lys	Ser	Ser	Leu
145					150					155					160

Lys	Gly	Asn	Glu	Lys	Glu	Lys	Glu	Lys	Gln	Gln	Arg	Glu	Lys	Asp	Lys
				165					170					175	

Glu	Lys	Ser	Lys	Asp	Leu	Ala	Lys	Arg	Ala	Ser	Val	Thr	Glu	Arg	Leu
			180					185					190		

Asp	Leu	Lys	Glu	Glu	Pro	Lys	Glu	Asp	Pro	Ser	Gly	Ala	Ala	Val	Pro
	195						200					205			

Glu Met Pro Lys Lys Ser Ser Lys Ile Ala Ser Phe Ile Pro Lys Gly

97

210                      215                      220  
 Gly Lys Leu Asn Ser Ala Lys Lys Glu Pro Met Ala Pro Ser His Ser  
 225                      230                      235                      240  
 Gly Ile Pro Lys Pro Gly Met Lys Ser Met Pro Gly Lys Ser Pro Ser  
                     245                      250                      255  
 Ala Pro Ala Pro Ser Lys Glu Gly Glu Arg Ser Arg Ser Gly Lys Leu  
                     260                      265                      270  
 Ser Ser Gly Leu Pro Gln Gln Lys Pro Gln Leu Asp Gly Arg His Ser  
                     275                      280                      285  
 Ser Ser Ser Ser Ser Leu Ala Ser Ser Glu Gly Lys Gly Pro Gly Gly  
                     290                      295                      300  
 Thr Thr Leu Asn His Ser Ile Ser Ser Gln Thr Val Ser Gly Ser Val  
 305                      310                      315                      320  
 Gly Thr Thr Gln Thr Thr Gly Ser Asn Thr Val Ser Val Gln Leu Pro  
                     325                      330                      335  
 Gln Pro Gln Gln Gln Tyr Asn His Pro Asn Thr Ala Thr Val Ala Pro  
                     340                      345                      350  
 Phe Leu Tyr Arg Ser Gln Thr Asp Thr Glu Gly Asn Xaa Thr Xaa Glu  
                     355                      360                      365  
 Ser Ser Ser Thr Gly Val Ser Val Glu Pro Xaa His Phe Pro Arg Leu  
                     370                      375                      380  
 Asp Ser Leu Leu Trp Lys Asn Ser Leu Gly Lys Ile Leu Arg Leu Gly  
 385                      390                      395                      400  
 Gly Cys Gly Gln

&lt;210&gt; 146

&lt;211&gt; 1020

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 146

Met Ser Asp Asn Ala Pro Ala Ser Leu Glu Ser Gly Ser Ser Ser Thr  
 1                      5                      10                      15  
 Pro Thr Asn Cys Ser Thr Ser Ser Ala Ile Pro Gln Pro Gly Ala Ala  
                     20                      25                      30  
 Thr Lys Pro Trp Arg Ser Lys Ser Leu Ser Val Lys His Ser Ala Thr  
                     35                      40                      45  
 Val Ser Met Leu Ser Val Lys Pro Pro Gly Pro Glu Ala Pro Arg Pro  
                     50                      55                      60  
 Thr Pro Glu Ala Met Lys Pro Ala Pro Asn Asn Gln Lys Ser Met Leu

65		70		75		80
Glu Lys Leu Lys Leu Phe Asn Ser Lys Gly Gly Ser Lys Ala Gly Glu						
	85		90		95	
Gly Pro Gly Ser Arg Asp Thr Ser Cys Glu Arg Leu Glu Thr Leu Pro						
	100		105		110	
Ser Phe Glu Glu Ser Glu Glu Leu Glu Ala Ala Ser Arg Met Leu Thr						
	115		120		125	
Thr Val Gly Pro Ala Ser Ser Ser Pro Lys Ile Ala Leu Lys Gly Ile						
	130		135		140	
Ala Gln Arg Thr Phe Ser Arg Ala Leu Thr Asn Lys Lys Ser Ser Leu						
	145		150		155	160
Lys Gly Asn Glu Lys Glu Lys Glu Lys Gln Gln Arg Glu Lys Asp Lys						
	165		170		175	
Glu Lys Ser Lys Asp Leu Ala Lys Arg Ala Ser Val Thr Glu Arg Leu						
	180		185		190	
Asp Leu Lys Glu Glu Pro Lys Glu Asp Pro Ser Gly Ala Ala Val Pro						
	195		200		205	
Glu Met Pro Lys Lys Ser Ser Lys Ile Ala Ser Phe Ile Pro Lys Gly						
	210		215		220	
Gly Lys Leu Asn Ser Ala Lys Lys Glu Pro Met Ala Pro Ser His Ser						
	225		230		235	240
Gly Ile Pro Lys Pro Gly Met Lys Ser Met Pro Gly Lys Ser Pro Ser						
	245		250		255	
Ala Pro Ala Pro Ser Lys Glu Gly Glu Arg Ser Arg Ser Gly Lys Leu						
	260		265		270	
Ser Ser Gly Leu Pro Gln Gln Lys Pro Gln Leu Asp Gly Arg His Ser						
	275		280		285	
Ser Ser Ser Ser Ser Leu Ala Ser Ser Glu Gly Lys Gly Pro Gly Gly						
	290		295		300	
Thr Thr Leu Asn His Ser Ile Ser Ser Gln Thr Val Ser Gly Ser Val						
	305		310		315	320
Gly Thr Thr Gln Thr Thr Gly Ser Asn Thr Val Ser Val Gln Leu Pro						
	325		330		335	
Gln Pro Gln Gln Gln Tyr Asn His Pro Asn Thr Ala Thr Val Ala Pro						
	340		345		350	
Phe Leu Tyr Arg Ser Gln Thr Asp Thr Glu Gly Asn Val Thr Ala Glu						
	355		360		365	
Ser Ser Ser Thr Gly Val Ser Val Glu Pro Ser His Phe Thr Lys Thr						
	370		375		380	

Gly Gln Pro Ala Leu Glu Glu Leu Thr Gly Glu Asp Pro Glu Ala Arg  
 385 390 395 400  
 Arg Leu Arg Thr Val Lys Asn Ile Ala Asp Leu Arg Gln Asn Leu Glu  
 405 410 415  
 Glu Thr Met Ser Ser Leu Arg Gly Thr Gln Val Thr His Ser Thr Leu  
 420 425 430  
 Glu Thr Thr Phe Asp Thr Asn Val Thr Thr Glu Met Ser Gly Arg Ser  
 435 440 445  
 Ile Leu Ser Leu Thr Gly Arg Pro Thr Pro Leu Ser Trp Arg Leu Gly  
 450 455 460  
 Gln Ser Ser Pro Arg Leu Gln Ala Gly Asp Ala Pro Ser Met Gly Asn  
 465 470 475 480  
 Gly Tyr Pro Pro Arg Ala Asn Ala Ser Arg Phe Ile Asn Thr Glu Ser  
 485 490 495  
 Gly Arg Tyr Val Tyr Ser Ala Pro Leu Arg Arg Gln Leu Ala Ser Arg  
 500 505 510  
 Gly Ser Ser Val Cys His Val Asp Val Leu Asp Lys Ala Gly Asp Glu  
 515 520 525  
 Met Asp Leu Glu Gly Ile Ser Met Asp Ala Pro Gly Tyr Met Ser Asp  
 530 535 540  
 Gly Asp Val Leu Ser Lys Asn Ile Arg Thr Asp Asp Ile Thr Ser Gly  
 545 550 555 560  
 Tyr Met Thr Asp Gly Gly Leu Gly Leu Tyr Thr Arg Arg Leu Asn Arg  
 565 570 575  
 Leu Pro Asp Gly Met Ala Val Val Arg Glu Thr Leu Gln Arg Asn Thr  
 580 585 590  
 Ser Leu Gly Leu Gly Asp Ala Asp Ser Trp Asp Asp Ser Ser Ser Val  
 595 600 605  
 Ser Ser Gly Ile Ser Asp Thr Ile Asp Asn Leu Ser Thr Asp Asp Ile  
 610 615 620  
 Asn Thr Ser Ser Ser Ile Ser Ser Tyr Ala Asn Thr Pro Ala Ser Ser  
 625 630 635 640  
 Arg Lys Asn Leu Asp Val Gln Thr Asp Ala Glu Lys His Ser Gln Val  
 645 650 655  
 Glu Arg Asn Ser Leu Trp Ser Gly Asp Asp Val Lys Lys Ser Asp Gly  
 660 665 670  
 Gly Ser Asp Ser Gly Ile Lys Met Glu Pro Gly Ser Lys Trp Arg Arg  
 675 680 685

100

Asn Pro Ser Asp Val Ser Asp Glu Ser Asp Lys Ser Thr Ser Gly Lys  
 690 695 700  
 Lys Asn Pro Val Ile Ser Gln Thr Gly Ser Trp Arg Arg Gly Met Thr  
 705 710 715 720  
 Ala Gln Val Gly Ile Thr Met Pro Arg Thr Lys Ala Ser Ala Pro Ala  
 725 730 735  
 Gly Ala Leu Lys Thr Pro Gly Thr Gly Lys Thr Asp Asp Ala Lys Val  
 740 745 750  
 Ser Glu Lys Gly Arg Leu Ser Pro Lys Ala Ser Gln Val Lys Arg Ser  
 755 760 765  
 Pro Ser Asp Ala Gly Arg Ser Ser Gly Asp Glu Ser Lys Lys Pro Leu  
 770 775 780  
 Pro Ser Ser Ser Arg Thr Pro Thr Ala Asn Ala Asn Ser Phe Gly Phe  
 785 790 795 800  
 Lys Lys Gln Ser Gly Ser Ala Ala Gly Leu Ala Met Ile Thr Ala Ser  
 805 810 815  
 Gly Val Thr Val Thr Ser Arg Ser Ala Thr Leu Gly Lys Ile Pro Lys  
 820 825 830  
 Ser Ser Ala Leu Val Ser Arg Ser Ala Gly Arg Lys Ser Ser Met Asp  
 835 840 845  
 Gly Ala His Asn Gln Asp Asp Gly Tyr Leu Ala Leu Ser Ser Arg Thr  
 850 855 860  
 Asn Leu Gln Tyr Arg Ser Leu Pro Arg Pro Ser Lys Ser Asn Ser Arg  
 865 870 875 880  
 Asn Gly Ala Gly Asn Arg Ser Ser Thr Ser Ser Ile Asp Ser Asn Ile  
 885 890 895  
 Ser Ser Lys Ser Ala Gly Leu Pro Val Pro Lys Leu Arg Glu Pro Ser  
 900 905 910  
 Lys Thr Ala Leu Gly Ser Ser Leu Pro Gly Leu Val Asn Gln Thr Asp  
 915 920 925  
 Lys Glu Lys Gly Ile Ser Ser Asp Asn Glu Ser Val Ala Ser Cys Asn  
 930 935 940  
 Ser Val Lys Val Asn Pro Ala Ala Gln Pro Val Ser Ser Pro Ala Gln  
 945 950 955 960  
 Thr Ser Leu Gln Pro Gly Ala Lys Tyr Pro Asp Val Ala Ser Pro Thr  
 965 970 975  
 Leu Arg Arg Leu Phe Gly Gly Lys Pro Thr Lys Gln Val Pro Ile Ala  
 980 985 990  
 Thr Ala Glu Asn Met Lys Asn Ser Val Val Ile Ser Asn Pro His Ala

995	1000	1005
Thr Met Thr Gln Gln Gly Arg Arg Gly Arg Glu Phe		
1010	1015	1020
<p>&lt;210&gt; 147            &lt;211&gt; 252            &lt;212&gt; PRT            &lt;213&gt; Homo sapiens</p> <p>&lt;220&gt;            &lt;221&gt; SITE            &lt;222&gt; (162)            &lt;223&gt; Xaa equals any of the naturally occurring L-amino acids</p> <p>&lt;220&gt;            &lt;221&gt; SITE            &lt;222&gt; (222)            &lt;223&gt; Xaa equals any of the naturally occurring L-amino acids</p> <p>&lt;220&gt;            &lt;221&gt; SITE            &lt;222&gt; (236)            &lt;223&gt; Xaa equals any of the naturally occurring L-amino acids</p> <p>&lt;220&gt;            &lt;221&gt; SITE            &lt;222&gt; (240)            &lt;223&gt; Xaa equals any of the naturally occurring L-amino acids</p> <p>&lt;400&gt; 147            Met Gly Ser Leu Gly Leu Phe Leu Gln Cys Ala Ile Ser Leu Val Phe              1                  5                  10                  15</p> <p>Ser Leu Val Met Asp Arg Leu Val Gln Arg Phe Gly Thr Arg Ala Val                      20                  25                  30</p> <p>Tyr Leu Ala Ser Val Ala Ala Phe Pro Val Ala Ala Gly Ala Thr Cys                  35                  40                  45</p> <p>Leu Ser His Ser Val Ala Val Val Thr Ala Ser Ala Ala Leu Thr Gly              50                  55                  60</p> <p>Phe Thr Phe Ser Ala Leu Gln Ile Leu Pro Tyr Thr Leu Ala Ser Leu             65                  70                  75                  80</p> <p>Tyr His Arg Glu Lys Gln Val Phe Leu Pro Lys Tyr Arg Gly Asp Thr                      85                  90                  95</p> <p>Gly Gly Ala Ser Ser Glu Asp Ser Leu Met Thr Ser Phe Leu Pro Gly                 100                 105                 110</p> <p>Pro Lys Pro Gly Ala Pro Phe Pro Asn Gly His Val Gly Ala Gly Gly             115                 120                 125</p> <p>Ser Gly Leu Leu Pro Pro Pro Pro Ala Leu Cys Gly Ala Ser Ala Cys             130                 135                 140</p>		



Asp Val Ser Val Arg Val Val Val Gly Glu Pro Thr Glu Ala Arg Val  
 145 150 155 160

Val Xaa Gly Arg Gly Ile Cys Leu Asp Leu Ala Ile Leu Asp Ser Ala  
 165 170 175

Phe Leu Leu Ser Gln Val Ala Pro Ser Leu Phe Met Gly Ser Ile Val  
 180 185 190

Gln Leu Ser Gln Ser Val Thr Ala Tyr Met Val Ser Ala Ala Gly Leu  
 195 200 205

Gly Leu Val Ala Ile Tyr Phe Ala Thr Gln Val Val Phe Xaa Lys Ser  
 210 215 220

Asp Leu Ala Asn Thr Gln Arg Arg Asn Phe Gln Xaa Ile Gly Val Xaa  
 225 230 235 240

Gly Leu Pro His Trp Val Pro Ala Pro Cys Ser Cys  
 245 250

<210> 148

<211> 272

<212> PRT

<213> Homo sapiens

<400> 148

Leu His Ala Ala Pro Glu Glu His Lys Ile Pro Pro Gly Phe Val Leu  
 1 5 10 15

Ala Asn Asp Val Asp Asn Asn Arg Cys Tyr Met Leu Val His Gln Ala  
 20 25 30

Lys Arg Leu Asn Ser Pro Cys Leu Leu Val Thr Asn His Asp Ser Ser  
 35 40 45

Val Phe Pro Asn Leu Val Thr Thr Lys Pro Asp Gly Ser Lys Ala Ile  
 50 55 60

Leu Lys Phe Asp Lys Ile Leu Cys Asp Val Pro Cys Ser Gly Asp Gly  
 65 70 75 80

Thr Leu Arg Lys Asn Pro Asp Ile Trp Leu Lys Trp Asn Leu Ala Gln  
 85 90 95

Ala Tyr Asn Leu His Gly Ile Gln Tyr Arg Ile Val Arg Arg Gly Ala  
 100 105 110

Glu Met Leu Glu Val Gly Gly Arg Leu Val Tyr Ser Thr Cys Ser Leu  
 115 120 125

Asn Pro Ile Glu Asn Glu Ala Val Leu Gln Arg Ile Ile Lys Asp Ala  
 130 135 140

Asp Gly Ala Leu Glu Leu Val Asp Ala Gly His Leu Val Pro Gly Leu  
 145 150 155 160

103

Lys Tyr Lys Pro Gly Met Thr Asp Trp Lys Leu Ala Thr Lys Glu Val  
                     165                    170                    175  
 Asp Gln Ile Phe Thr Arg Phe Glu Glu Val Pro Glu Ser Leu His Thr  
                     180                    185                    190  
 Ile Ile Arg Pro Gly Met Phe Pro Leu Pro Ala Asp Glu Met Ala Lys  
                     195                    200                    205  
 Ile Gly Leu Glu Lys Cys Leu Arg Val Leu Pro His Leu Gln Asp Ser  
                     210                    215                    220  
 Gly Gly Phe Phe Val Ala Val Leu Glu Lys Arg Arg Gln Leu Ser Phe  
                     225                    230                    235                    240  
 Glu Lys Asn Asp Val Val Glu Leu Val Lys Leu Asn Glu Thr Ala Lys  
                     245                    250                    255  
 Gln Pro Ala Ala Glu Pro Gln Val Asp Ala Asp Gly Lys Pro Ile Glu  
                     260                    265                    270

&lt;210&gt; 149

&lt;211&gt; 272

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (5)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 149

Leu His Phe Thr Xaa His Cys Asn Ser Val Pro Ser Glu Gly Phe Val  
   1                    5                    10                    15  
 Ile Ala Asn Asp Val Asp Asn Lys Arg Cys Tyr Leu Leu Val His Gln  
                     20                    25                    30  
 Ala Lys Arg Leu Ser Ser Pro Cys Ile Met Val Val Asn His Asp Ala  
                     35                    40                    45  
 Ser Ser Ile Pro Arg Leu Gln Ile Asp Val Asp Gly Arg Lys Glu Ile  
                     50                    55                    60  
 Leu Phe Tyr Asp Arg Ile Leu Cys Asp Val Pro Cys Ser Gly Asp Gly  
                     65                    70                    75                    80  
 Thr Met Arg Lys Asn Ile Asp Val Trp Lys Lys Trp Thr Thr Leu Asn  
                     85                    90                    95  
 Ser Leu Gln Leu His Gly Leu Gln Leu Arg Ile Ala Thr Arg Gly Ala  
                     100                    105                    110

104

Glu Gln Leu Ala Glu Gly Gly Arg Met Val Tyr Ser Thr Cys Ser Leu  
 115 120 125  
 Asn Pro Ile Glu Asp Glu Ala Val Ile Ala Ser Leu Leu Glu Lys Ser  
 130 135 140  
 Glu Gly Ala Leu Glu Leu Ala Asp Val Ser Asn Glu Leu Pro Gly Leu  
 145 150 155 160  
 Lys Trp Met Pro Gly Ile Thr Gln Trp Lys Val Met Thr Lys Asp Gly  
 165 170 175  
 Gln Trp Phe Thr Asp Trp Asp Ala Val Pro His Ser Arg His Thr Gln  
 180 185 190  
 Ile Arg Pro Thr Met Phe Pro Pro Lys Asp Pro Glu Lys Leu Gln Ala  
 195 200 205  
 Met His Leu Glu Arg Cys Leu Arg Ile Leu Pro His His Gln Asn Thr  
 210 215 220  
 Gly Gly Phe Phe Val Ala Val Leu Val Lys Lys Ser Ser Met Pro Trp  
 225 230 235 240  
 Asn Lys Arg Gln Pro Lys Leu Gln Gly Lys Ser Ala Glu Thr Arg Glu  
 245 250 255  
 Ser Thr Gln Leu Ser Pro Ala Asp Leu Thr Glu Gly Lys Pro Thr Asp  
 260 265 270

<210> 150  
 <211> 130  
 <212> PRT  
 <213> Homo sapiens

<400> 150  
 Glu Gly Glu Gly Gln Ile Phe Gln Leu His Thr Thr Leu Ala Glu Thr  
 1 5 10 15  
 Pro Ala Gly Ser Leu Asp Ala Leu Cys Ser Ala Pro Gly Asn Ala Ala  
 20 25 30  
 Thr Thr Gln Leu Gly Pro Tyr Ala Phe Lys Ile Pro Leu Ser Ile Arg  
 35 40 45  
 Gln Lys Ile Cys Asn Ser Leu Asp Ala Pro Asn Ser Arg Gly Asn Asp  
 50 55 60  
 Trp Arg Leu Leu Ala Gln Lys Leu Ser Met Asp Arg Tyr Leu Asn Tyr  
 65 70 75 80  
 Phe Ala Thr Lys Ala Ser Pro Thr Gly Val Ile Leu Asp Leu Trp Glu  
 85 90 95

105

Ala Arg Gln Gln Asp Asp Gly Asp Leu Asn Ser Leu Ala Ser Ala Leu  
                   100                  105                  110

Glu Glu Met Gly Lys Ser Glu Met Leu Val Ala Met Thr Thr Asp Gly  
                   115                  120                  125

Asp Cys  
       130

<210> 151  
 <211> 130  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (30)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 151  
 Glu Gly Glu Gly Gln Ile Phe Gln Leu His Thr Thr Leu Ala Glu Thr  
       1                  5                  10                  15

Pro Ala Gly Ser Leu Asp Thr Leu Cys Ser Ala Pro Gly Xaa Thr Val  
                   20                  25                  30

Thr Thr Gln Leu Gly Pro Tyr Ala Phe Lys Ile Pro Leu Ser Ile Arg  
                   35                  40                  45

Gln Lys Ile Cys Asn Ser Leu Asp Ala Pro Asn Ser Arg Gly Asn Asp  
                   50                  55                  60

Trp Arg Met Leu Ala Gln Lys Leu Ser Met Asp Arg Tyr Leu Asn Tyr  
       65                  70                  75                  80

Phe Ala Thr Lys Ala Ser Pro Thr Gly Val Ile Leu Asp Leu Trp Glu  
                   85                  90                  95

Ala Leu Gln Gln Asp Asp Gly Asp Leu Asn Ser Leu Ala Ser Ala Leu  
                   100                  105                  110

Glu Glu Met Gly Lys Ser Glu Met Leu Val Ala Val Ala Thr Asp Gly  
                   115                  120                  125

Asp Cys  
       130

<210> 152  
 <211> 130  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (30)  
 <223> Xaa equals any of the naturally occurring L-amino acids

106

&lt;400&gt; 152

Glu Gly Glu Gly Gln Ile Phe Gln Leu His Thr Thr Leu Ala Glu Thr  
 1 5 10 15

Pro Ala Gly Ser Leu Asp Thr Leu Cys Ser Ala Pro Gly Xaa Thr Val  
 20 25 30

Thr Thr Gln Leu Gly Pro Tyr Ala Phe Lys Ile Pro Leu Ser Ile Arg  
 35 40 45

Gln Lys Ile Cys Asn Ser Leu Asp Ala Pro Asn Ser Arg Gly Asn Asp  
 50 55 60

Trp Arg Met Leu Ala Gln Lys Leu Ser Met Asp Arg Tyr Leu Asn Tyr  
 65 70 75 80

Phe Ala Thr Lys Ala Ser Pro Thr Gly Val Ile Leu Asp Leu Trp Glu  
 85 90 95

Ala Leu Gln Gln Asp Asp Gly Asp Leu Asn Ser Leu Ala Ser Ala Leu  
 100 105 110

Glu Glu Met Gly Lys Ser Glu Met Leu Val Ala Val Ala Thr Asp Gly  
 115 120 125

Asp Cys  
 130

&lt;210&gt; 153

&lt;211&gt; 113

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (20)

&lt;223&gt; Xaa equals stop translation

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (67)

&lt;223&gt; Xaa equals stop translation

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (82)

&lt;223&gt; Xaa equals stop translation

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (90)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (106)

107

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 153

Val Phe Phe Ile Tyr Tyr Tyr Phe Phe Phe Ser Glu Thr Glu Ser Gly  
 1 5 10 15

Ser Val Thr Xaa Ala Gly Val Gln Trp His Asp Leu Gly Ser Leu Gln  
 20 25 30

Ala Pro Pro Pro Gly Phe Met Pro Phe Ser Cys Leu Ser Leu Pro Ser  
 35 40 45

Gly Trp Asp Tyr Arg Arg Pro Pro Pro Cys Pro Ala Asn Phe Leu Tyr  
 50 55 60

Phe Trp Xaa Arg Gln Gly Phe Thr Val Leu Ala Arg Met Val Ser Ile  
 65 70 75 80

Ser Xaa Pro His Asp Pro Pro Ala Ser Xaa Ser Gln Ser Ala Gly Ile  
 85 90 95

Thr Gly Met Ser His Cys Ala Arg Pro Xaa Ile Gln Tyr Phe Leu Ile  
 100 105 110

Glu

&lt;210&gt; 154

&lt;211&gt; 256

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (59)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (197)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (198)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (199)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 154

Leu Leu Pro Phe Leu Arg Phe Ser Leu Leu Tyr Gln Leu Ser Gly Gly  
 1 5 10 15

Pro Pro Arg Phe Leu Leu Asp Leu Arg Gln Tyr Leu Gly Asn Ser Thr

108

20					25					30					
Tyr	Leu	Asp	Asp	His	Gly	Pro	Pro	Pro	Ser	Lys	Val	Leu	Pro	Phe	Pro
		35					40					45			
Ser	Gln	Val	Val	Tyr	Asn	Arg	Val	Gly	Lys	Xaa	Gly	Ser	Arg	Thr	Val
	50					55					60				
Val	Leu	Leu	Leu	Arg	Ile	Leu	Ser	Glu	Lys	His	Gly	Phe	Asn	Leu	Val
	65					70					75				80
Thr	Ser	Asp	Ile	His	Asn	Lys	Thr	Arg	Leu	Thr	Lys	Asn	Glu	Gln	Met
				85					90					95	
Glu	Leu	Ile	Lys	Asn	Ile	Ser	Thr	Ala	Glu	Gln	Pro	Tyr	Leu	Phe	Thr
			100					105					110		
Arg	His	Val	His	Phe	Leu	Asn	Phe	Ser	Arg	Phe	Gly	Gly	Asp	Gln	Pro
		115					120					125			
Val	Tyr	Ile	Asn	Ile	Ile	Arg	Asp	Pro	Val	Asn	Arg	Phe	Leu	Ser	Asn
	130					135					140				
Tyr	Phe	Phe	Arg	Arg	Phe	Gly	Asp	Trp	Arg	Gly	Glu	Gln	Asn	His	Met
	145					150					155				160
Ile	Arg	Thr	Pro	Ser	Met	Arg	Gln	Glu	Glu	Arg	Tyr	Leu	Asp	Ile	Asn
				165					170					175	
Glu	Cys	Ile	Leu	Glu	Asn	Tyr	Pro	Glu	Cys	Ser	Asn	Pro	Arg	Leu	Phe
		180						185					190		
Tyr	Ile	Ile	Pro	Xaa	Xaa	Xaa	Gly	Gln	His	Pro	Arg	Cys	Arg	Glu	Pro
		195					200					205			
Gly	Glu	Trp	Ala	Leu	Glu	Arg	Ala	Lys	Leu	Asn	Val	Asn	Glu	Asn	Phe
	210					215					220				
Leu	Leu	Val	Gly	Ile	Leu	Glu	Glu	Leu	Glu	Asp	Val	Leu	Leu	Leu	Leu
	225					230					235				240
Glu	Arg	Phe	Leu	Pro	His	Tyr	Phe	Lys	Gly	Val	Leu	Ser	Thr	Thr	Lys
				245					250					255	

&lt;210&gt; 155

&lt;211&gt; 45

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 155

Met	Lys	Lys	Lys	Gln	Gln	His	Pro	Gly	Gly	Gly	Ala	Asp	Pro	Trp	Pro
1				5				10						15	

His Gly Ala Pro Met Gly Gly Ala Pro Pro Gly Leu Gly Ser Trp Lys

109

	20		25		30
Arg	Arg	Val	Pro	Leu	Leu
	35			40	
					45

&lt;210&gt; 156

&lt;211&gt; 31

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (3)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 156

Gln	Gly	Xaa	Ala	Gln	Tyr	Tyr	Lys	Asp	Pro	Glu	His	Arg	Lys	Leu	Gly
1				5					10					15	

Asn	Met	Thr	Val	Thr	Val	Lys	Lys	Thr	Val	Pro	Ser	Pro	Glu	Ala
			20					25					30	

&lt;210&gt; 157

&lt;211&gt; 301

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (95)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (233)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (234)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (235)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 157

Met	Lys	Lys	Lys	Gln	Gln	His	Pro	Gly	Gly	Gly	Ala	Asp	Pro	Trp	Pro
1				5					10					15	

His	Gly	Ala	Pro	Met	Gly	Gly	Ala	Pro	Pro	Gly	Leu	Gly	Ser	Trp	Lys
			20					25					30		

Arg	Arg	Val	Pro	Leu	Leu	Pro	Phe	Leu	Arg	Phe	Ser	Leu	Leu	Tyr	Gln
		35					40					45			



110

Leu Ser Gly Gly Pro Pro Arg Phe Leu Leu Asp Leu Arg Gln Tyr Leu  
 50 55 60  
 Gly Asn Ser Thr Tyr Leu Asp Asp His Gly Pro Pro Pro Ser Lys Val  
 65 70 75 80  
 Leu Pro Phe Pro Ser Gln Val Val Tyr Asn Arg Val Gly Lys Xaa Gly  
 85 90 95  
 Ser Arg Thr Val Val Leu Leu Leu Arg Ile Leu Ser Glu Lys His Gly  
 100 105 110  
 Phe Asn Leu Val Thr Ser Asp Ile His Asn Lys Thr Arg Leu Thr Lys  
 115 120 125  
 Asn Glu Gln Met Glu Leu Ile Lys Asn Ile Ser Thr Ala Glu Gln Pro  
 130 135 140  
 Tyr Leu Phe Thr Arg His Val His Phe Leu Asn Phe Ser Arg Phe Gly  
 145 150 155 160  
 Gly Asp Gln Pro Val Tyr Ile Asn Ile Ile Arg Asp Pro Val Asn Arg  
 165 170 175  
 Phe Leu Ser Asn Tyr Phe Phe Arg Arg Phe Gly Asp Trp Arg Gly Glu  
 180 185 190  
 Gln Asn His Met Ile Arg Thr Pro Ser Met Arg Gln Glu Glu Arg Tyr  
 195 200 205  
 Leu Asp Ile Asn Glu Cys Ile Leu Glu Asn Tyr Pro Glu Cys Ser Asn  
 210 215 220  
 Pro Arg Leu Phe Tyr Ile Ile Pro Xaa Xaa Xaa Gly Gln His Pro Arg  
 225 230 235 240  
 Cys Arg Glu Pro Gly Glu Trp Ala Leu Glu Arg Ala Lys Leu Asn Val  
 245 250 255  
 Asn Glu Asn Phe Leu Leu Val Gly Ile Leu Glu Glu Leu Glu Asp Val  
 260 265 270  
 Leu Leu Leu Leu Glu Arg Phe Leu Pro His Tyr Phe Lys Gly Val Leu  
 275 280 285  
 Ser Thr Thr Lys Thr Gln Ser Thr Gly Ser Leu Glu Thr  
 290 295 300

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US00/30654

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : Please See Extra Sheet.

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : Please See Extra Sheet.

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5,831,056 (JACOBS et al.) 03 November 1998, see entire document.	1-10, 21
X	Database GenBank (EST); Accession NO: AW105205; NCI-CGAP; tumor gene index; 20 October 1999; having 99.8% sequence identity with SEQ ID NO: 11; vector: pT7T3D-Pac; host cell: DH10B, (see alignment result 5).	1-10, 21
X	US 5,807,709 (JACOBS et al.), 15 September 1998, "Secreted proteins and polynucleotides encoding them"	1-10, 21

☐

Further documents are listed in the continuation of Box C.

☐

See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*G* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

08 JANUARY 2001

Date of mailing of the international search report

26 FEB 2001

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

RITA MITRA

Telephone No. (703) 308-0196

DELLA MAE COLLINS  
PARALEGAL SPECIALIST  
TECHNOLOGY CENTER 1000

**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
1-10, 14, 15 and 21, all in part.

Remark on Protest

☐  
☐

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

**A. CLASSIFICATION OF SUBJECT MATTER:**  
IPC (7):

C07H 21/04; C07H 21/02; C07K 5/00; C07K 14/00; C12Q 1/68; C12N 1/21; C12N 15/63; C12N 15/85, 15/86

**A. CLASSIFICATION OF SUBJECT MATTER:**  
US CL :

536/23.1, 23.5, 24.31; 530/300, 350; 435/6, 69.1, 252.3, 320.1, 325

**B. FIELDS SEARCHED**

Minimum documentation searched  
Classification System: U.S.

536/23.1, 23.5, 24.31; 530/300, 350; 435/6, 69.1, 252.3, 320.1, 325  
514/2, 12

**B. FIELDS SEARCHED**

Electronic data bases consulted (Name of data base and where practicable terms used):

WEST, STN (Database: Biosis, Embase, Medline, Scisearch, Lifesci, Caplus).

Search terms: secreted protein or peptide, butyrophilin\_like protein, polynucleotide, DNA, RNA, nucleic acid, oligonucleotide, dendritic cell, uterus, spleen, thymus, aorta, T-cell lymphoma, testis.

GenBank (Databases: GenEmbl, N\_Genseq\_36, Issued\_Patents, EST, A\_Genseq\_36, PIR\_65, SwissProt\_39, Sptrembl\_14)

**BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING**

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Groups 1-63, claim(s) 1-10, 14, 15 and 21, all in part, drawn to an isolated nucleic acid of SEQ ID NO X or a peptide of SEQ ID NO Y, wherein X and Y are values that correlate to those listed in Table 1, and correspond to one of the cDNA Clone IDs, respectively. For example,

If group 1 is elected, this correlates to Gene NO 1, cDNA clone ID HDPPA04 of Table 1, wherein X is 11 and Y is 74.

If group 2 is elected, this correlates to Gene NO 2, cDNA clone ID HOHBY44, wherein X is 12 and Y is 75.

Groups 64-126, claim(s) 11, 12, 16 and 23, all in part, each group directed to a peptide of SEQ ID NO; Y, wherein Y correlates to one of those listed in Table 1, and corresponds to one of the cDNA Clone IDs, respectively.

For examples,

If group 64 is elected, this correlates to Gene NO 1, cDNA clone ID HDPPA04 of Table 1, wherein Y is 74.

If group 65 is elected, this correlates to Gene NO 2, cDNA clone ID HOHBY44, wherein Y is 75.

Groups 127-189, claim 13, in part, drawn to an isolated antibody which binds to a protein with SEQ ID NO Y, wherein Y correlates to one of those listed in Table 1, and corresponds to one of the cDNA Clone IDs, respectively. For examples,

If group 127 is elected, this correlates to Gene NO 1, cDNA clone ID HDPPA04 of Table 1, wherein Y is 74.

If group 128 is elected, this correlates to Gene NO 2, cDNA clone ID HOHBY44, wherein Y is 75.

Groups 190-252, claim 17, in part, drawn to a method for preventing, treating or ameliorating an undefined medical condition by administering a polypeptide of SEQ ID NO Y, wherein Y correlates to one of those listed in Table 1, and corresponds to one of the cDNA Clone IDs, respectively. For examples,

If group 190 is elected, this correlates to Gene NO 1, cDNA clone ID HDPPA04 of Table 1, wherein Y is 74.

If group 191 is elected, this correlates to Gene NO 2, cDNA clone ID HOHBY44, wherein Y is 75.

Groups 253-315, claim 17, in part, drawn to a method for preventing, treating or ameliorating an undefined medical condition by administering a polynucleotide of SEQ ID NO X encoding a protein of SEQ ID NO Y, wherein X and Y correlate to one of those listed in Table 1, and corresponds to one of the cDNA Clone IDs, respectively. For examples,

If group 253 is elected, this correlates to Gene NO 1, cDNA clone ID HDPPA04 of Table 1, wherein Y is 74.

If group 254 is elected, this correlates to Gene NO 2, cDNA clone ID HOHBY44, wherein Y is 75.

Groups 316-378, claims 18 and 19, in part, drawn to a method of diagnosis of an undefined pathological condition by determining the presence or absence of a mutation in a polynucleotide of SEQ ID NO X, wherein X correlates to one of those listed in Table 1, and corresponds to one of the cDNA Clone IDs, respectively. For examples,

If group 316 is elected, this correlates to Gene NO 1, cDNA clone ID HDPPA04 of Table 1, wherein X is 11.

If group 317 is elected, this correlates to Gene NO 2, cDNA clone ID HOHBY44, wherein X is 12.

Groups 379-441, claim 20, in part, drawn to a method of identifying a binding partner to a polypeptide defined by SEQ ID NO Y, wherein Y correlates to one of those listed in Table 1, and corresponds to one of the cDNA Clone IDs, respectively. For examples,

If group 379 is elected, this correlates to Gene NO 1, cDNA clone ID HDPPA04 of Table 1, wherein Y is 74.

If group 380 is elected, this correlates to Gene NO 2, cDNA clone ID HOHBY44, wherein Y is 75.

Groups 442-504, claim 22, in part, drawn to a method of identifying an activity in a biological assay by identification of the protein in the supernatant wherein the cell expresses a polypeptide encoded by SEQ ID NO X, wherein X correlates to one of those listed in Table 1, and corresponds to one of the cDNA Clone IDs, respectively. For examples,

If group 442 is elected, this correlates to Gene NO 1, cDNA clone ID HDPPA04 of Table 1, wherein X is 11.

If group 443 is elected, this correlates to Gene NO 2, cDNA clone ID HOHBY44, wherein X is 12.

The inventions listed as Groups 1-504 do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The polynucleotides and polypeptides of each invention are unrelated, each to each other. The polynucleotide sequences encode structurally distinct polypeptides. Additionally the claimed methods produce different products and/or different results which are not coextensive and which do not share the same technical feature.